<SEC-DOCUMENT>0001641172-25-002426.txt : 20250402
<SEC-HEADER>0001641172-25-002426.hdr.sgml : 20250402
<ACCEPTANCE-DATETIME>20250402171957
ACCESSION NUMBER:		0001641172-25-002426
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250402
DATE AS OF CHANGE:		20250402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tevogen Bio Holdings Inc.
		CENTRAL INDEX KEY:			0001860871
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981597194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41002
		FILM NUMBER:		25806133

	BUSINESS ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		646-807-8832

	MAIL ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Semper Paratus Acquisition Corp
		DATE OF NAME CHANGE:	20210505
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:TVGN="http://tevogen.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_030_TVGN_tevogen.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001860871 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001860871</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2024-12-31" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0284" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0286" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0288" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0308" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0310" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0312" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0324" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0326" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0328" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0476" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0492" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:CashAcquiredInConnectionWithReverseRecapitalization" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:RepurchaseOfSeriesBPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="xdx2ixbrl0689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0707" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0974" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0976" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0978" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0980" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0982" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0984" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0986" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0988" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0990" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl0992" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1002" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="xdx2ixbrl1004" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1018" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1020" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1030" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1032" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1038" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="xdx2ixbrl1040" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl1176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1179" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl1182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl1185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl1188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="xdx2ixbrl1199" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1202" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="xdx2ixbrl1204" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_EarnoutSharesMember" id="xdx2ixbrl1208" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1226" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1239" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1242" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1244" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1247" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1248" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="TVGN:DeferredTaxAssetsFixedAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl1268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="xdx2ixbrl1271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tvgn-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SemperParatusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-14_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ComputerAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ComputerAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:PolarMultiStrategyMasterFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PerformanceBasedRSUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-26</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-21</xbrli:startDate>
        <xbrli:endDate>2024-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember69680781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember69680796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember69680906">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SponsorAdvisoryServicesFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:WifeOfChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:MehtaphoricConsultingIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:KRHPLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001860871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>TVGN:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001086" toRefs="Footnote001091"/>
  <ix:relationship fromRefs="Fact001088" toRefs="Footnote001092"/>
  <ix:relationship fromRefs="Fact001195" toRefs="Footnote001212"/>
  <ix:relationship fromRefs="Fact001196" toRefs="Footnote001212"/>
  <ix:relationship fromRefs="xdx2ixbrl1204" toRefs="Footnote001215"/>
  <ix:relationship fromRefs="Fact001205" toRefs="Footnote001215"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20240101__20241231_zFDcT64c1LJe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--DocumentAnnualReport_c20240101__20241231_z0xf5sbDSzab"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934&#160;</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_902_edei--DocumentPeriodEndDate_c20240101__20241231_zgnwRnUNBu46"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_903_edei--CurrentFiscalYearEndDate_c20240101__20241231_zwkxKLQxGuL6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90A_edei--DocumentFiscalYearFocus_c20240101__20241231_zIpxlLaBkiY3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--DocumentTransitionReport_c20240101__20241231_zj17ycBtLV5k"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <b><span id="xdx_901_edei--EntityFileNumber_c20240101__20241231_zjEBZcvsGQoh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityFileNumber">001-39269</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="logo_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20240101__20241231_znPXhL2Wbtuj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityRegistrantName">Tevogen
Bio Holdings Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zboc7Gvrg2Aa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20240101__20241231_zS70DkwxR0D6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">98-1597194</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<br/>
 incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<br/>
 Identification No.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20240101__20241231_zvAtcg0jz01j"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">15
    Independence Boulevard</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20240101__20241231_zuIH2446tmoh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite #410</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20240101__20241231_zb6gOM5ZBwqe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Warren</ix:nonNumeric></span>,
    <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20240101__20241231_zZZfR7wE1Zyg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000025" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20240101__20241231_zgXlqcbmsk5g"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">07059</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_90A_edei--CityAreaCode_c20240101__20241231_zGycbjdu0Yi1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:CityAreaCode">(877)</ix:nonNumeric></span> <span id="xdx_90B_edei--LocalPhoneNumber_c20240101__20241231_zp4w9b2ldop8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:LocalPhoneNumber">838-6434</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symbol(s)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zk1oZ66spG0g"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000029" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_zkXrnej8L4R2"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" id="Fact000030" name="dei:Security12bTitle">Warrants,
    each exercisable for one share of Common Stock for $11.50 per share</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zJrZfaC6iMm2"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000031" name="dei:TradingSymbol">TVGN</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_zd3S1RxHsbQa"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" id="Fact000032" name="dei:TradingSymbol">TVGNW</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zvxkdSwVlSpg"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_zSsQMwoxePi4"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: <b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;<span style="text-transform: uppercase">Yes
</span>&#9744; <span style="text-transform: uppercase"><span id="xdx_903_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_z2fNEUE1qMDd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. <span style="text-transform: uppercase">Yes
</span>&#9744; <span style="text-transform: uppercase"><span id="xdx_90A_edei--EntityVoluntaryFilers_c20240101__20241231_zNE50NohWvmg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000036" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></span> &#9746;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span style="text-transform: uppercase"><span id="xdx_90F_edei--EntityCurrentReportingStatus_c20240101__20241231_zNrgzbr2lzgc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span></span> &#9746; <span style="text-transform: uppercase">No
</span>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span style="text-transform: uppercase"><span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20240101__20241231_z2N7OTVA8ZKk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span></span> &#9746; <span style="text-transform: uppercase">No
</span>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20240101__20241231_z3pBuKHjSGNl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000039" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntitySmallBusiness_c20240101__20241231_zqOAZKixCEkf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000040" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20240101__20241231_zzDWpzjPrQD8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000041" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_907_edei--EntityExTransitionPeriod_c20240101__20241231_zSf4bYgikjXc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90E_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zlbHxYyK9kk1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90C_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_ztkNQ4egUrI3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <span style="text-transform: uppercase">Yes</span>&#160;&#9744;&#160;<span style="text-transform: uppercase">No
</span><span id="xdx_909_edei--EntityShellCompany_dbF_c20240101__20241231_zcsBVTN0Xg1a"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the common stock held by non-affiliates of the registrant, computed by reference to the price at which the
common stock was last sold on The Nasdaq Stock Market on June 28, 2024 (the last business day of the registrant&#8217;s most recently
completed second fiscal quarter), was $<span id="xdx_90B_edei--EntityPublicFloat_iI_pn5n6_c20240628_z2znNP7LIjA3"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-28" id="Fact000046" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">21.4</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of registrant&#8217;s common stock outstanding as of March 21, 2025 was <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20250321_zKxj0F69fOxb"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-21" id="Fact000047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">183,893,433</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zf9fY2le587g"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000048" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions
of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2025 Annual Meeting of Stockholders are incorporated
by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the
Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2024.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><a href="#g_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#g_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#g_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">78</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><a href="#g_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">80</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">80</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">80</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><a href="#g_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers, and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><a href="#g_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and Financial Statement Schedule</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; vertical-align: bottom; text-align: center">95</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#g_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#g_028">SIGNATURES</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">98</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) contains statements that constitute &#8220;forward-looking statements&#8221;
for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements that discuss future
events, hopes, expectations, beliefs, intentions, or strategies regarding the future, projections of results of operations or financial
condition, changes in the markets in which we compete, and trends in our business. In addition, any statements that refer to projections,
forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221;
&#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions
or their opposites may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements in this Annual Report may include, for example, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development of, potential benefits of, and patient access to our product candidates for the
                                            treatment of infectious diseases, cancer, and neurological disorders, including TVGN 489
                                            for the treatment of COVID-19 and Long COVID;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to develop additional product candidates, including through the use of our ExacTcell<sup>TM&#160;</sup>technology;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            anticipated benefits of ExacTcell;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding our future clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            manufacturing plans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to generate revenue in the future;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to manage, grow, and diversify our business and execute our business initiatives
                                            and strategy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
                                            regarding the healthcare and biopharmaceutical industries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential liquidity and trading of our securities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            future business, operations, and financial performance of our Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this Annual Report are based on management&#8217;s current expectations, assumptions, and beliefs
concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will
be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond
our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. <span style="color: #212529">These risks and uncertainties include, but are not limited to, the
factors set forth below in &#8220;Summary of Risk Factors.&#8221;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements should be considered in light of these factors and the factors described elsewhere in this Annual Report, including in the
sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations.&#8221; You should read these factors and the other cautionary statements made in this Annual Report as being applicable to
all related forward-looking statements wherever they appear in this Annual Report. It is not possible to predict or identity all such
risks. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires or unless stated otherwise, references to &#8220;Tevogen&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
&#8220;the Company&#8221; and &#8220;our Company&#8221; refer to Tevogen Bio Holdings Inc. and its consolidated subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
OF RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to a variety of risks and uncertainties, including risks that could have a material adverse effect on our business, financial
condition, results of operations, and cash flows. The following summary of the principal factors that make an investment in our securities
speculative or risky should not be relied upon as an exhaustive summary of the material risks facing us. You should read the following
summary together with the more detailed description of risks under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report
and the other information contained in this Annual Report before investing in our securities. Capitalized terms not otherwise defined
below have been defined elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Financial Position and Need for Additional Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history, no products approved for commercial sale, have never generated
                                            revenue from product sales, and have a history of significant losses.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are relying in part on an additional $8.0 million of grant funding that
we have not yet received to meet our liquidity needs.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will require substantial additional financing to achieve our business objectives.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Development, Regulatory Review, and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
                                            of cellular therapy product candidates is rigorous, complex, uncertain, and subject to change.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have limited experience designing and implementing preclinical and clinical trials, which
                                            are complex, expensive, time-consuming, difficult to design and implement, and involve uncertain
                                            outcomes.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to develop, receive regulatory approval for, and commercialize our product
                                            candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter substantial delays and disruptions in the development of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            FDA regulatory approval process is lengthy and time-consuming.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may never receive regenerative medicine advanced therapy designation for any product candidate,
                                            and this designation may not lead to a faster development or regulatory review or approval
                                            process.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business is highly dependent on our first product candidate, TVGN 489.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            from our clinical trials may change and are subject to audit, validation, and verification
                                            procedures.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
                                            results and results of earlier trials may not be predictive of future results.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            TVGN 489 proof-of-concept clinical trial results may be less reliable than results in larger
                                            clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in product candidate manufacturing or formulation may result in additional costs or delay.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
                                            is unproven and may not result in marketable products.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse
                                            or unacceptable side effects may be identified during development.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may encounter difficulties enrolling patients in our clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to suspend, repeat, or terminate our clinical trials if they are not conducted
                                            in accordance with regulatory requirements, the results are negative or inconclusive, or
                                            the trials are not well designed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not achieve our projected development goals in the time frames we announce and expect.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
                                            at government agencies could hinder or prevent product development and commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                            of product candidates in combination with other therapies presents additional regulatory
                                            risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail utilizing new and evolving technologies, such as artificial intelligence (&#8220;AI&#8221;),
                                            in our business.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Business Development and Commercialization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            commercial success depends upon attaining significant market acceptance of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulated
                                            biologics may be subject to biosimilar competition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            incidence and prevalence of target patient populations are based on estimates and third-party
                                            sources.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will face extensive ongoing regulatory requirements and regulatory review after regulatory
                                            approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to establish sales and marketing capabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                            to comply with or adapt to changes in data protection, privacy, and similar laws could materially
                                            and adversely harm our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
                                            use of AI could lead to liability, violation of data security and privacy laws, or reputational
                                            damage.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
                                            systems may fail or suffer security breaches.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coverage
                                            and reimbursement may be limited or unavailable in certain market segments.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
                                            reform may negatively impact our ability to sell our product candidates profitably.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could violate healthcare fraud and abuse, false claims, and health information privacy and
                                            security laws.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail to comply with environmental, health and safety laws and regulations.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Manufacturing and Reliance on Third Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            manufacture of cell therapies is subject to a multitude of manufacturing risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            efforts to establish manufacturing capabilities will involve time and expense and may not
                                            be successful.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            loss of suppliers or their inability to supply us with adequate materials could harm our
                                            business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not obtain marketing approval for or successfully commercialize product candidates as
                                            a result of failures by third parties.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to establish collaborations on commercially reasonable terms.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to obtain and maintain sufficient patent protection for our product candidates
                                            or ExacTcell.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            patent protection could be reduced or eliminated for non-compliance with patent agency requirements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to protect our intellectual property rights throughout the world.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in patent law could diminish the value of patents in general.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may become involved in lawsuits to protect or enforce our intellectual property.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
                                            patents covering our product candidates could be found invalid or unenforceable if challenged
                                            in court.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
                                            parties may initiate legal proceedings alleging that we are infringing their intellectual
                                            property rights.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
                                            may claim an ownership interest in our intellectual property and our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be unable to protect the confidentiality of our proprietary information.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to claims asserting that our agents have wrongfully used or disclosed alleged
                                            trade secrets.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            trademarks and trade names may be inadequately protected.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
                                            property rights do not necessarily address all potential threats.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are highly dependent on our key personnel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may face substantial competition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to grow the size of our organization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
                                            liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be limited in our ability to use our net operating loss carryforwards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Being a Public Company and Ownership of Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            price of our common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;),
                                            or warrants to purchase our Common Stock (the &#8220;Warrants&#8221;) may fluctuate significantly.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have previously failed to timely file certain periodic reports with the SEC and could fail
                                            to timely file such reports in the future.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not have the funds necessary to satisfy our future obligations under the terms of our
                                            outstanding preferred stock (the &#8220;Preferred Stock&#8221;).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            incur increased costs due to operating as a public company, and our management devotes substantial
                                            time to compliance initiatives and corporate governance practices.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may issue additional shares of our Common Stock or other equity securities without your approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            management team has limited experience managing a public company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysts
                                            may not publish research about us or may change their recommendation regarding our Common
                                            Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could become subject to securities litigation or stockholder activism.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to take write-downs or write-offs, restructuring and impairment or other
                                            charges.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could fail to maintain proper and effective internal control over financial reporting.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
                                            of a substantial number of our securities by existing securityholders could cause their price
                                            to fall.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            individuals have substantial control over us.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="g_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes (&#8220;CTLs&#8221;), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers,
and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability
and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative
business models and engagement across the development lifecycle and healthcare system. We believe the full potential of T cell therapies
remains largely untapped and aspire to be the first biotechnology company offering commercially attractive, economically viable, and
cost-effective personalized T cell therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our allogeneic, precision T cell technology, ExacTcell<sup>TM</sup>, represents a significant scientific breakthrough with the
potential to mainstream cell therapy with a new class of off-the-shelf &#8211; manufactured and stored for immediate use &#8211; T cell
therapies with diverse applications across virology, oncology, and other areas. ExacTcell is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen (&#8220;HLA&#8221;) restricted CTL therapies with proactively selected, precisely
defined targets. HLA molecules are proteins that play an important role in the immune system&#8217;s ability to recognize &#8220;self&#8221;
versus &#8220;foreign.&#8221; There are numerous HLA types that vary from person to person. CD8+ CTLs, also known as killer T cells,
are white blood cells that are part of the immune system and destroy infected, malignant, or otherwise damaged cells. We are focused
on using ExacTcell to develop allogeneic therapeutics, meaning therapeutics that are intended to be infused in patients other than the
original donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
therapies are based on carefully selected, naturally occurring CTLs that are designed to recognize targets of interest from the body&#8217;s
native T cell receptor pool, unlike genetically engineered T cell therapies. CD8+ CTLs in ExacTcell-based products target multiple and
distinct antigens, with the aim to circumvent the impact of mutations in viruses and cancer cells, which can render existing treatments
focused on a single target ineffective. ExacTcell is designed to maximize the immunologic specificity of our products in order to eliminate
malignant and virally infected cells while allowing healthy cells to remain intact. We believe this high degree of specificity has the
potential to significantly reduce the chances of cross-reactivity or adverse impact on healthy cells. Our confidence in ExacTcell is
reflected in our development pipeline, which has been carefully tailored to address the unmet needs of large patient populations grappling
with life-threatening viral diseases, cancers, and other disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised
and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease
(&#8220;Long COVID&#8221;). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production
plants. Elimination of infected cells is necessary to allow them to be replaced by healthy, uninfected counterparts. TVGN 489 consists
of CTLs designed to be active against multiple precise, well defined, and well characterized targets spread across the SARS-CoV-2 genome.
The product progressed from pre-discovery to the clinic in less than 18 months, and in January 2023, we completed the Phase 1 proof-of-concept
clinical trial of TVGN 489 for the treatment of ambulatory, high-risk adult COVID-19 patients. No dose-limiting toxicities or significant
treatment-related adverse events were observed in the treatment arm. Secondary endpoints showed a rapid reduction of viral load and that
infusion of TVGN 489 did not prevent the development of the patients&#8217; own T cell-related (cellular) or antibody-related (humoral)
anti-COVID-19 immunity. None of the patients reported progression of infection, reinfection, or the development of Long COVID during
the six-month follow-up period. These clinical observations were mirrored by laboratory evidence of the persistence of TVGN 489 cells
for at least six months after treatment. The results of the trial were published in&#160;<i>Blood Advances</i>&#160;in June 2024 following
peer review. We believe these findings validate our initiative to develop off-the-shelf T cell therapies for outpatient administration,
targeting diseases that affect large patient populations &#8211; for the very first time. We are planning a pivotal trial of TVGN 489
in COVID-19 patients with B cell malignancies, with studies of other highly vulnerable populations thereafter. TVGN 489 is also in preclinical
development for treatment and prevention of Long COVID based on evidence of a persistent viral reservoir in Long COVID patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, Tevogen Bio Inc (n/k/a Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;) completed the previously announced business combination
with Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), a special purpose acquisition company formed for the purpose
of effecting a merger, stock purchase, reorganization or similar acquisition or business combination with one or more businesses, pursuant
to which Tevogen Bio became a wholly owned subsidiary of Semper Paratus. In connection with the closing of that business combination,
Semper Paratus changed its name from &#8220;Semper Paratus Acquisition Corporation&#8221; to &#8220;Tevogen Bio Holdings Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our understanding of immunotherapy and our ExacTcell technology to discover, validate, and build a proprietary pipeline
of T cell therapies with diverse targets in infectious disease, cancer, and other disorders. The figure below details our pipeline of
product candidates and their targets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_002.jpg" alt=""/>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 clinical trials are designed
    in part to generate proof of concept data and safety-related data on tolerability and side effects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A pivotal trial is a trial designed to generate data
    sufficient to support the filing of an application for regulatory approval. A pivotal trial may not necessarily be denoted as a Phase
    3 clinical trial and instead may be a Phase 2 or Phase 2/3 clinical trial. We believe that Phase 2, Phase 2/3, or Phase 3 clinical
    trials may serve as pivotal trials for TVGN 489.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that the safety data from our completed
    Phase 1 clinical trial should be sufficient to serve as the basis for one or more later stage, potentially pivotal trials in acute
    SARS-CoV-2 patients with B-cell cancer immune suppression, other B cell immune suppressed acute SARS-CoV-2 patients with a B cell
    cancer indication, and for Long COVID prevention and treatment. We cannot be certain whether we will be permitted to move from a
    Phase 1 trial directly to a pivotal trial covering any specific target population until FDA reviews and concurs with or rejects our
    proposed plans, and FDA may require us to conduct further trials to generate additional safety and efficacy data prior to approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to have a positive impact on patients&#8217; health and treatment equity by developing and commercializing personalized cell
therapies to treat infectious disease, cancer, and other diseases. Our strategy is to target large patient populations for each pipeline
product. Key elements of our strategy to advance toward this goal include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advancing
    the clinical development of TVGN 489 for the treatment of COVID-19 and Long COVID</i></b>. We completed a Phase 1 proof-of-concept
    trial of TVGN 489 for the treatment of high-risk ambulatory adult COVID-19 patients in January 2023 and plan to launch a pivotal
    trial in COVID-19 patients with B cell malignancies. TVGN 489 is also in development for other highly vulnerable COVID-19 patients
    and sufferers of Long COVID. A Phase 2 treatment trial examining the safety and efficacy of TVGN 489 in individuals with Long COVID
    is currently under development. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leveraging our ExacTcell
    technology to develop therapies for additional indications</i></b>. In addition to TVGN 489, we are leveraging our ExacTcell technology
    to advance product candidates in virology, oncology, and other conditions. For example, early work is underway that leverages our
    expertise in the selection of viral peptide targets to be used preventatively in the form of a T cell vaccination. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing manufacturing
    capabilities, including through acquisitions</i></b>. We will need to develop manufacturing capabilities for clinical and, if approved,
    commercial supply of our cell therapy products. Our efforts to develop manufacturing capability are currently focused on acquiring
    a manufacturing and research and development facility, including through collaboration with a potential facility development partner.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forming strategic
    alliances and collaborating with partners to augment our capabilities</i></b>. We may pursue strategic alliances with other biopharmaceutical
    companies with well-established presences in the specialties we aim to target for our indications. This may include co-marketing,
    co-promotion, and co-development relationships, or a partnership with a diagnostics company to help improve availability of HLA testing
    (rapid testing in acute illnesses and prompt testing in more chronic conditions). We also intend to explore options to work with
    partners to augment the study and treatment of patients and the impact of our product candidates, including medical professionals,
    healthcare professional networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that positive data from studies and clinical trials can help pave the way for positive regulatory discussions, strategic partnerships,
and future label expansions, furthering our ability to meet our goal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ExacTcell Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ExacTcell technology and our therapies harness one of nature&#8217;s own approaches to eradicating cancer and other diseases: the cytotoxic
or killer T cell. We believe that our patented ExacTcell precision allogeneic T cell development technology has the potential to be a
broadly applicable approach for developing convenient and reasonably priced cellular immunotherapies for the treatment of acute viral
infections, long-term consequences of viral infections such as Long COVID, viral- and non-viral-induced cancers, and other disorders.
Although our initial product development has been in the area of infectious disease, we believe our technology also holds promise for
applications in cancers and autoimmune diseases, which would increase our total addressable market. We also believe that ExacTcell can
enable us to deliver products faster, at a greater scale, and at lower cost than future competing cell therapies, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
focuses on the selection and expansion of naturally occurring, genetically unmodified CD8+ CTLs to target multiple, distinct, preselected
antigens present only on virus-infected or malignant cells and to kill those cells. We believe that by relying on CD8+ CTLs, ExacTcell
has the potential to produce an entirely new class of drugs that could present numerous benefits over existing platforms. In contrast
to other approaches, ExacTcell enables a single, specific HLA molecule to be targeted in a clinical product and the specific target peptides
to be known with certainty and precision. HLA molecules are proteins present on the cell surface that play an important role in the immune
system&#8217;s ability to recognize &#8220;self&#8221; versus &#8220;foreign.&#8221; Specifically, HLA molecules present foreign antigens
to T cells for eradication. There are numerous HLA types that vary from person to person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Killer
T cells are white blood cells that play a vital role in the immune system&#8217;s defense against diseases, including viruses and cancer.
CTLs, including those developed with ExacTcell, express T cell receptors (&#8220;TCRs&#8221;), which are surface proteins that provide
each T cell with its unique immune specificity to recognize and react against specific foreign antigenic peptides of infected or malignant
cells. These foreign antigenic peptides are presented in conjunction with an HLA molecule. The CTLs destroy their infected or malignant
cell targets by inducing them to undergo apoptosis, or programmed cell death, by releasing cytolytic granules that produce pores in the
target cell&#8217;s membrane. CTLs also possess a protein that spans the entirety of the cell membrane, known as Cluster Differentiation
8 (which makes them CD8+), that aids in the reaction. CD8+ T cells work in conjunction with HLA-class I molecules, and CD4+ T cells work
in conjunction with HLA-class II molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
available cell-based immunotherapy approaches include genetically unmodified T cells applied to the treatment of viruses early after
transplant and genetically modified chimeric antigen receptor (&#8220;CAR&#8221;) T cells used to treat a selected subset of malignancies.
We believe that to date, cellular therapy has not been harnessed to its full potential for clinical application. We believe that our
proprietary approach will allow T cell products to be generated with a much higher target-specific CD8+ content and better-defined target
specificity than existing commercially available approaches. Contrasted with our approach, the genetically unmodified T cells used after
hematopoietic stem cell transplantation for the treatment of viral infections have used large viral proteins, pools of peptides, or infected
cells to stimulate CTLs. These broader targets may stimulate both CD4+ and CD8+ T cell responses, resulting in more heterogeneous T cell
products with little information regarding the specific peptide targets recognized by the T cells. By stimulating with only carefully
selected smaller peptides that are known to bind to a single HLA-class I molecule and to be recognized by CTLs, our approach elicits
a high degree of target-specific CD8+ responses, which we believe may result in improved outcomes as compared to these other approaches.
Knowing the specific peptide targets also allows rapid identification of the impact of mutations on our CTL products. Having multiple
targets within a product also blunts the impact of any one mutation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the targeted nature of the cells ExacTcell can produce, we also believe we may be able to avoid some of the unwanted corollary effects
observed in other T cell immunotherapies. For example, we believe products developed through ExacTcell could potentially avoid the high
incidence of adverse events, some life-threatening, such as cytokine release syndrome and neurotoxicity, that have been observed with
autologous and allogeneic CAR-T platforms. Data from our Phase 1 trial strongly supports this belief. Autologous cell therapies are derived
from a donor&#8217;s own cells, as contrasted with allogenic therapies such as ours, where cells are from third party donors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to select candidate peptides for ExacTcell products, we rely on computer-facilitated prediction of the ability of specific peptide
candidates to bind to specific HLA molecules. Once candidates are selected and used to stimulate T cells in the laboratory, we use tetramer
staining to assess whether T cells recognize the target peptides and assess cytotoxicity against individual peptide-pulsed and non-pulsed
targets. This allows us to rapidly and proactively select multiple, precise, candidate T cell targets and then quickly experimentally
confirm their effectiveness. <span style="color: #212529; background-color: white">Through our Tevogen.AI artificial intelligence initiative,
we are exploring ways to deploy artificial intelligence-powered target detection to accelerate our product development pace, either internally
or in collaboration with leading entities in the field of artificial intelligence, such as through our enrollment in the Microsoft for
Startups program and use of Microsoft Azure.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;As
illustrated in the figure below, we begin the ExacTcell process by collecting cells from a healthy donor. T cells from the donor are
exposed to the preselected targeted peptides and through a repetitive process of selection and expansion. CD8+ CTLs specific for the
targeted, antigenic peptides become the major cellular component of the final product. The expansion of the antigen specific CTLs is
extensive enough to produce over 100, and up to hundreds, of doses from a single donor. Those doses can then be used to treat hundreds
of patients who share the same HLA type.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ExacTcell
stands in contrast with both autologous and allogeneic CAR-T platforms, which target antigens present on both healthy and diseased cells
and require genetic modification of the T cells. In autologous CAR-T approaches, the quantity and health of desired T cells in patient
blood samples used to manufacture the CAR-T product have been among the largest obstacles for T cell therapies to date. Much of this
is due to the chemotherapy treatments the patients have already received. Some existing CAR-T therapies may take weeks to manufacture,
may require patients to receive pre-infusion lymphodepleting (<i>i.e.</i>, immunosuppressing) chemotherapy as part of a lengthy preparation
process, and be hospitalized in many cases during the CAR-T cell infusion or afterwards due to the frequency of side effects from the
therapy such as cytokine release syndrome. These treatments may also require lifelong monitoring for the development and treatment of
infections due to eradication of normal parts of the immune system along with the cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, FDA announced that it had &#8220;received reports of T-cell malignancies&#8221; in patients who received certain autologous
CAR T cell immunotherapies. In January 2024, FDA required a class-wide black box warning be added to the label of these CAR T products
regarding this risk. Currently approved autologous CAR-T platforms utilize the patient&#8217;s own T cells to manufacture their products.
These cells have previously been exposed to cancer therapy and are genetically altered and subsequently expanded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast, CTLs generated using the ExacTcell technology come from a healthy donor with a normal immune system. ExacTcell CTLs are not
genetically altered in the manufacturing process and although they expand during manufacture, this is the expected response of a T-lymphocyte
when encountering its target antigen. The genetic modifications necessary to make CAR-T cells, which may be associated with the recent
reports of T cell malignancies, are not utilized in the manufacture of our products made on the ExacTcell technology. Moreover, secondary
malignancies have not been described in the unmodified T cell products given to hundreds of post-transplant patients. Although products
from our ExacTcell technology are not designed to be genetically modified, they are still in the early stages of testing, and only limited
human and laboratory study data are available regarding the risk profiles of our products. Allogeneic CAR-T approaches are in early-stage
development, but concerns exist regarding side effects similar to autologous CAR-T, and additionally, the development of graft versus
host disease with allogeneic CAR-T products, both of which we believe will be of lower risk with our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_005.jpg" alt="" style="height: 243px; width: 660px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hundreds
of doses per donor can be obtained using the ExacTcell approach, which is expected to facilitate off-the-shelf use and the ability to
administer doses within hours of diagnosis when rapid therapeutic intervention is crucial. Use of TVGN 489, for example, is expected
to begin with a confirmatory COVID-19 test and rapid HLA typing for which results would be available in six to eight hours, allowing
selection of the proper product based on HLA type. After confirmation of HLA type, thawing takes minutes, and cells are infused within
ten minutes of thawing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convenience of &#8220;off-the-shelf&#8221; &#8211; manufactured and stored for immediate use &#8211; therapy has the potential to offer
timely and cost-efficient therapeutics by potentially eliminating the need for specialized medical facilities, unlike existing platforms.
By producing products in which the active CD8+ T cell components are present at high concentrations, we believe relatively small volumes
will be required, allowing our therapies to be easily and promptly delivered in the ambulatory setting as a very brief intravenous administration
such as in a physician&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working to further advance ExacTcell with a new, proprietary T cell receptor-engineered process, which we believe may substantially
increase the number of doses that can be produced from a single donor. Available technology can be used to allow us to interrogate over
a thousand individual T cells to determine which one kills peptide-pulsed targets fastest or kills the most in a given timeframe. This
highest performing T cell can then be isolated, and its T cell receptor sequenced, allowing us to make an artificial TCR gene that can
be introduced into CD8+ T cells collected from healthy donors. We believe this could allow at least a several-fold increase in the number
of desired CTLs as compared to our current approach. We expect efforts to produce second generation products based on this process may
begin shortly after and if initial regulatory approval of the first-generation product is obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
First Product Candidate</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical remaining
gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, who remain at substantial risk for poor outcomes,
with potential applications in both treatment and prevention of Long COVID. Treatment for these groups represents an area of unmet or
incompletely met need which we believe TVGN 489 can significantly address. We rapidly progressed TVGN 489 from pre-discovery to the clinic
in only 18 months. TVGN 489 cells are derived from healthy donors who recovered from a prior COVID-19 infection, and TVGN 489 is active
against multiple, precise targets spread across the SARS-CoV-2 genome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we completed a Phase 1 proof-of-concept trial of TVGN 489 for the treatment of ambulatory high-risk adult COVID-19 patients.
No dose-limiting toxicities or significant TVGN 489-related adverse events were observed in this trial at any of the four dosing levels
tested. Secondary endpoint analysis showed a rapid reduction in COVID-19 viral load and that the infusion of TVGN 489 did not prevent
the development of the patient&#8217;s own T cell-related (cellular) and antibody-related (humoral) anti-COVID-19 immunity. In addition,
none of the patients in the treatment arm reported progression of infection, reinfection, or the development of Long COVID during the
six-month follow-up period. The TVGN 489 in the Phase 1 trial was formulated to match patients expressing HLA-A*02:01, the most common
HLA type in the population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that TVGN 489 targets are less susceptible to viral mutations due to their small size than monoclonal antibody targets and less
susceptible to drug resistance than antivirals. As evidence of this, despite selection of T cell targets in 2020, more than 95% of the
targets for the HLA-A*02:01 TVGN 489 product targets have remained intact through the first quarter of 2025. In contrast, most monoclonal
antibodies were withdrawn from the market for lack of efficacy related to the lack of recognition of new variants, providing what we
believe to be evidence of decreased susceptibility of TVGN 489 to viral mutation. In addition, knowing the precise peptide targets of
our therapy helps allow rapid assessment regarding their preservation or loss as soon as new variants are sequenced. We check emerging
COVID-19 variants against TVGN 489 targets on an ongoing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19
Background </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19,
caused by the SARS-CoV-2 virus, has killed millions and infected hundreds of millions since its emergence in late 2019. Groups most at
risk for poor outcomes due to COVID-19 are immunocompromised individuals unable to mount an adequate immune response, such as those with
immune system cancers, immunodeficiency disorders, transplant recipients, patients with immune-mediated disorders requiring immunosuppressive
therapy, or high doses of corticosteroids, the elderly and the unvaccinated. Data shows that the majority of COVID-19 deaths occur in
people over the age of 65. The risk of severe illness from COVID-19 for an individual tends to escalate with an increase in their number
of underlying medical conditions. In addition to the acute impacts of infection, a significant portion of those who have been infected
by COVID-19 in the past develop more chronic and potentially debilitating symptoms afterwards, a condition termed Long COVID. Despite
the availability of vaccines and emergence of initial therapeutics, significant gaps and shortcomings in treatment remain both for vulnerable
patients experiencing an acute infection and for Long Covid sufferers for whom there are no treatment options approved for the indication
or its underlying causes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
other viruses that have RNA as their genetic material, SARS-CoV-2 is constantly evolving through random mutations. New mutations can
potentially increase or decrease infectiousness and virulence. In addition, mutations can increase the virus&#8217; ability to evade
adaptive immune responses from past SARS-CoV-2 infection or vaccination. New variants of the SARS-CoV-2 virus continue to emerge, and
many people continue to be adversely affected by COVID-19, particularly those at the highest risk and sufferers of Long COVID. Moreover,
a growing body of scientific data suggests new immune-evasive variants are more likely to arise in immunocompromised patients because
they are less able to eradicate the virus. The longer duration of infection within the host affords the virus more opportunity to mutate
so as to evade the immune system. The potential rise of immune-evasive variants in immunocompromised patients provides a public health
rationale for the treatment of immunocompromised patients in order to more rapidly and aggressively eliminate the virus and avoid generation
of new variants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
large number of Americans remain highly vulnerable to COVID-19 infection, including immunocompromised and elderly patients. For example,
the rate of hospitalization in cancer patients with COVID-19 infection remains high, specifically for those under active chemotherapy
or immunosuppression. There is therefore a high unmet need to have an effective treatment available for these populations. Classic herd
immunity leading to eradication of COVID-19 is unlikely, much as is the case for influenza, respiratory syncytial virus (RSV), and other
endemic respiratory viruses. This contrasts with smallpox, for example, where both natural infection and vaccination eliminated virus
transmission. SARS-CoV-2 infection and vaccination produce a steadily waning natural and vaccine-induced immunity, respectively, but
do not eliminate transmission. Although the number of daily reported cases and deaths has declined, the emergence of more transmissible
variants has led to spikes in cases and mortality, and variants are expected to continue to evolve over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current COVID-19 landscape is also characterized by continued vaccine hesitancy among a significant portion of the population, unequal
access to vaccines and treatment, lack of response in some immunocompromised and other high-risk groups, and breakthrough cases among
the vaccinated due in part to increased immune evasion by current and emerging variants and the relatively short duration of protection
by booster shots. We expect these circumstances to continue, which could adversely impact long-term community-level protective immunity.
In addition, we believe that the expiration of the U.S. federal Public Health Emergency and U.S. government funding for COVID-19 testing,
and treatment could lead to higher pricing for diagnostics and therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
two anti-viral agents, Nirmatrelvir with Ritonavir (Paxlovid) and Veklury (remdesivir), have been FDA-approved for the treatment of COVID-19.
While Paxlovid is indicated for treatment in individuals at high risk for viral progression, neither drug has been specifically authorized
for use in immunocompromised patients, creating a need for the development of novel therapies in this area. Both drugs also present challenges
for subsets of patients. Paxlovid is associated with many drug-drug interactions, resulting in the need to temporarily stop ongoing medications
or seek alternative therapy and thereby making it difficult for some patients to take. This is especially true for patients on multiple
medications, which is often true of high-risk patients requiring anti-COVID-19 treatment. Paxlovid is also known to be associated with
COVID-19 rebound, which has been calculated as high as 21% in ambulatory patients, according to a study published in the Annals of Internal
Medicine in November 2023. Although the rate of rebound in high-risk subgroups is less well-documented, we anticipate it may be as high
or higher in this group. Paxlovid also must be started within five days of symptom development to be effective. Remdesivir must be given
within seven days and is only available in intravenous form, requiring three daily infusions in a treatment center. Remdesivir has also
been associated with liver enzyme abnormalities and gastrointestinal side effects. Monoclonal antibodies to the viral spike protein were
introduced early in the pandemic for treatment of COVID-19 but typically have been rendered ineffective over time as the virus continues
to evolve. One prophylactic monoclonal antibody for COVID-19 prevention, Pemgarda (Pemivibart), has received emergency use authorization
for moderate to severely immune compromised patients. Whether this monoclonal antibody will remain more durable than other monoclonal
antibody remains to be seen, although resistance to the drug has already been observed in some variants. No therapies have been approved
to treat the underlying causes of the symptoms of Long COVID, and significant research is ongoing to determine why some patients fully
recover while others develop long-term complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Advantages of TVGN 489<i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the ongoing spread of COVID-19 and its effects and continued gaps in treatment, there is a clear need for alternatives to current therapeutic
options for COVID-19 We have shown that TVGN 489 is less susceptible to viral mutations than monoclonal antibodies and thus able to overcome
the increased immune evasion of current and emerging COVID-19 variants. We also believe TVGN 489 has the potential to be less susceptible
to drug resistance than antivirals. As contrasted with existing therapies, TVGN 489 is designed to recognize multiple specific target
peptides from distinct COVID-19 proteins, versus one or two targets typically derived only from the spike protein. Whereas other viral
therapies buy time for natural immunity to emerge and definitively control the virus, TVGN 489 provides natural immunity directly and
immediately to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<img src="form10-k_006.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489&#8217;s targets have also persisted in studied COVID-19 variants. We have observed TVGN 489&#8217;s targets to be generally retained,
in nearly all cases at greater than a 95% level of retention, in the genome of all of the isolates of SARS-CoV-2 variants that we have
studied to date. This is in significant contrast with the target loss of anti-spike monoclonal antibody therapies, which has led to the
withdrawal of emergency use authorizations (&#8220;EUAs&#8221;) that had been granted during the now-expired COVID-19 National Public
Health Emergency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
variants have demonstrated how this virus is able to escape our immune system through mutation. However, we believe our proprietary approach
to manufacturing TVGN 489 may allow us to monitor the sequences of emerging variants and, if necessary, to proactively adjust or fine
tune our products to ensure that they continue to recognize and treat current and future variants of this and other viruses. For example,
with our approach, if a product contains T cells that recognize and target seven different peptides and one is lost through mutation,
that peptide can be dropped from future product batches. Similarly, if the mutation generates a new peptide target, that target can be
added to future batches. However, making these types of changes to TVGN 489 may require additional regulatory approvals, and there is
no guarantee that we will receive such approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 is also designed to be fast acting, as the cells are fully mature and crafted to be primed to act as soon as they find their way
to infected cells. All patients in the interventional arm of our Phase 1 clinical trial noted improved symptoms within two to three days,
which is shorter than the average noted by patients in the observational arm, and 83% of patients in the interventional arm had negative
nasal swab polymerase chain reaction tests and there was a 99% viral load reduction in all patients within 14 days. The consistency of
the resolution was suggestive of a treatment effect and the rapidity of nasal swab COVID-19 resolution was shown in a population where
five individuals were on active immunosuppression for cancer (three with hematological malignancy, two with solid tumors) and one for
lupus at the time of COVID-19 infection. Moreover, a more recent study showed that the median time to SARS-CoV-2 nasal swab PCR negativity
was 72 days for patients with a hematologic malignancy highlighting the rapidity of response in the Tevogen phase I study. Two patients
on the trial went on to stem cell transplantation, an immunosuppressive procedure, within a month of treatment. Neither experienced COVID-19
reactivation, which we believe further attests to the rapid acting nature of this product. When immunocompromised patients get sick from
COVID-19, their current treatment regimens for existing conditions are often stopped. For oncology patients, this can be especially disruptive
or even harmful to the curative potential of their treatment. Given TVGN 489&#8217;s design and these results, we believe TVGN 489 may
allow immunocompromised patients to recover and be able to return to their pre-COVID-19 treatment regimen with minimal delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Production
of TVGN 489 and Mechanism of Action</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 cells are sourced from healthy donors who have recovered from a previous COVID-19 infection. These donor cells are subsequently expanded
by 600-fold or more by restimulating them toward specific peptide targets. This is accomplished by exposing them to antigen-presenting
cells and selectively isolating the T cells that recognize the specific targets. TVGN 489 is formulated to precisely target multiple
peptide targets spread across the SARS-CoV-2 genome, rather than focusing solely on the mutation-susceptible spike protein, which is
the primary target of most vaccines and monoclonal antibodies. Upon completion of the manufacturing process, the cells are frozen and
stored for future intravenous infusion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration
of TVGN 489 infuses the body with killer T cells that have been designed to attack COVID-19 infected cells. These highly purified, multi-target
CD8+ CTLs are intended to bind to and eliminate infected cells expressing the targeted peptides against which the CTLs were manufactured.
Peptides are presented in conjunction with the HLA molecule and the CTLs eradicate diseased cells expressing these viral or malignant
targets. To be clinically effective, a T cell therapy must be compatible with the patient&#8217;s specific HLA type. Therefore, a panel
of HLA-specific CTL products is necessary to broadly cover and treat the population. In our next clinical trial of TVGN 489, we expect
to treat patients with the six most common HLA types, which we believe would represent between 60% and 65% of the COVID-19 infected population.
We plan to continue expansion into additional HLA types until we are confident that between 90% and 95% of the population could be treated
based on our research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that once bound to infected cells, TVGN 489 cells then destroy the infected cells through formation of an immunological synapse
between the killer cell and target and the release of cytotoxic granules from TVGN 489 into the target. These both produce pores in the
target cell&#8217;s membrane and also trigger a process known as apoptosis, or programmed cell death, which is built into all our cells.
Then, once the infected cells die, new, healthy cells are able to grow in their place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_007.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discovery
and Preclinical Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approach to identifying CTL targets starts with computer-based prediction and then tests candidate peptides functionally with T cells.
We use a technique known as tetramer staining to assess whether T cells recognized these target peptides, assessed cytotoxicity against
individual peptide-pulsed and non-pulsed targets, and selected final peptides for use in TVGN 489 on that basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted multiple in-vitro studies of TVGN 489 in preparation for filing the IND with FDA and observed strong antiviral activity against
SARS-CoV-2 in these laboratory studies. In preclinical studies, we observed that TVGN 489 cells kill target cells that are exposed to
SARS-CoV-2 peptides, but not cells that are not exposed to those peptides. This is illustrated in the figure below, which shows the percentage
of cells killed over a four-hour period when targets were pulsed with the peptides and when they were not, with the x-axis showing the
lysis rates based on the ratio of CTLs to target cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" style="height: 246px; width: 400px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of appropriate COVID-19 peptide targets for additional HLA molecules remains ongoing, and we plan to continue this testing until we are
confident that between 90% and 95% of the COVID-19 infected population could be treated based on our research. We believe generating
these CTLs can provide treatment for SARS-CoV-2 or, with the appropriate targets, for other viral infections. Immunizing an individual
to these specific targets should form the basis of helping to prevent a subsequent infection through a T cell vaccine. Target identification
thus has the potential to assist with prevention as well as treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Development for COVID-19 Patients</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
permitted our IND for TVGN 489 to proceed in May 2021, and we began enrolling patients in the Phase 1 proof-of-concept trial of TVGN
489 for the treatment of high-risk ambulatory adult COVID-19 patients in October 2021. Patients in the trial were newly diagnosed with
COVID-19 and were deemed to be at high risk for complications due to the presence of one or more underlying medical conditions defined
as high risk by the Centers for Disease Control and Prevention, including among others cancer, hypertension, obesity, diabetes, cardiovascular
disease, and old age. The trial, which was conducted at Thomas Jefferson University Hospital in Philadelphia, was completed in January
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial included two arms, with 12 patients in the treatment, or interventional, arm and 18 patients in the observational arm. Assignment
to the interventional arm versus the observational arm was based on each patient&#8217;s HLA type. Patients expressing HLA-A*02:01, the
most common HLA type in the population, matched the CTLs and were enrolled in the interventional arm. Patients in the treatment arm had
been infected with either the delta variant or one of three omicron variants of COVID-19. Patients on the interventional arm had a higher
median number of comorbid conditions, a higher incidence of immune compromise, and a higher number of patients who were unvaccinated
or failed to respond to vaccination versus patients on the observational arm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
patient in the treatment arm received a single intravenous infusion of TVGN 489 within four days of diagnosis. Analysis of COVID-19 viral
load showed that the patients were early in their COVID-19 disease course. Patients were treated with TVGN 489 at one of four dose levels:
1 x 10<sup>5</sup>/kg; 3 x 10<sup>5</sup>/kg; 1 x 10<sup>6</sup>/kg; or 3 x 10<sup>6</sup>/kg. Patients treated on the first dosing level
had the high-risk delta variant of COVID-19. These dose levels were chosen based on data regarding antiviral T cell therapy in hematopoietic
transplant patients involving the administration of similar cell numbers. Three patients were enrolled at each dosing level with the
option to enroll three more if a significant side effect was observed. Each dose level concluded with three patients rather than six
and the treatment arm concluded with a total of 12 patients rather than 24, due to the absence of appreciable toxicities across all dose
levels. The comparative arm, which was designed to end enrollment when treatment arm enrollment was completed, concluded with 18 patients,
appreciably less than what would have occurred if the treatment group required additional enrollment. Observational arm patients received
standard of care treatment, including monoclonal antibodies. Interventional arm patients were monitored in the hospital for four days
before being discharged and then were observed daily at home for ten additional days and again at the one, two, three, and six-month
anniversary of the initial infusion. Observational arm patients were monitored at home over the same interval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoints of the trial, which were safety-related, were met. No dose-limiting toxicities or significant adverse events related
to TVGN 489, including acute infusion reactions, cytokine release syndrome, neurotoxicity, or instances of graft versus host disease,
were observed in any patient at any dose level of our Phase 1 trial of TVGN 489.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
endpoints showing a rapid reduction of COVID-19 viral load and showing that infusion of TVGN 489 did not prevent development of the patient&#8217;s
own T cell-related (cellular) and antibody-related (humoral) anti-COVID-19 immunity were also met. In other words, observations indicate
that TVGN 489 did not prevent the body from responding to the infection and generating its own CTLs and antibodies to COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
treatment arm patients reported returning to their baseline level of health without COVID-19 symptoms within 14 days of treatment. All
such patients also reported symptom improvement within two to three days of treatment, which corresponded with a decrease in the COVID-19
viral load on PCR testing in the majority of patients. None of the patients who participated in the trial reported progression of their
COVID-19 infection and none developed recurrent COVID-19 or Long COVID during the six-month follow-up period. These clinical observations
were mirrored by laboratory evidence of the persistence of infused TVGN 489 cells for at least six months after treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_009.jpg" alt=""/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persistence
of infused therapeutic cells remains a significant issue in the T cell therapy space, leading to challenges in controlling viral infections,
preventing viral recurrence, and managing cancer relapse. The shorter the CTLs persist in the recipient, the less opportunity they have
to perform their intended therapeutic tasks. Genetic differences between donor and recipient in allogeneic cell products and new genes
introduced into autologous products can be recognized by the patient&#8217;s immune system, which can encourage elimination of the administered
cells. This is one of the reasons why lymphodepleting therapy is commonly administered prior to CAR-T treatments. Maximizing the percentage
of CTLs in the products is also useful as the CTLs may receive re-stimulation from the virus infecting the patient and have a better
ability to protect themselves against elimination by the patient&#8217;s immune system. Most studies of genetically unmodified CTLs have
suggested that they are eliminated within weeks, with three months, in highly immune-suppressed hematopoietic blood and marrow transplant
(&#8220;HSCT&#8221;) patients, being the longest that they typically are reported to persist. The highly immune-suppressed nature of
the HSCT patient group is thought to allow for longer than typical persistence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our Phase 1 clinical trial for TVGN 489, following infusion, peripheral blood of five patients was collected at various timepoints throughout
the six-month follow-up period. These samples were sent to Adaptive Biotechnologies (&#8220;Adaptive&#8221;) to evaluate the persistence
of infused TVGN 489 in the patients following treatment, and Adaptive conducted analyses by sequencing protein chains of TCRs in the
samples. As seen in the figure below, Adaptive&#8217;s data showed persistence of T cells present in the TVGN 489 product but absent
from the recipients prior to administration of TVGN 489. This subset of CTLs was found in all samples tested, including at the final
study assessment at six months. The TCRs used to recognize TVGN 489&#8217;s peptides were also shown to be largely distinct from person
to person, making it highly unlikely that the cells from later timepoints derive from anything other than the product in these five different
patients. Taken together, we believe this data shows the persistence of TVGN 489 cells six months after administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN
489 COVID-19 Reactive CD8+ T Cells Detected Throughout the Six-Month Follow Up Period</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form10-k_010.jpg" alt=""/>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion
and persistence of allogeneic T cells has been associated with disease control in many settings. Whether the prolonged persistence of
the CTLs used in this study is of benefit in the treatment of COVID-19, Long COVID, or alternate future viral or oncologic targets for
these CTLs merits further examination. However, the evidence of their prolonged persistence provides us with encouragement for future
applications of the ExacTcell technology, particularly in oncology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe based on precedential industry examples, including in areas with high unmet needs or strong early phase clinical trial results,
that we may be able to commence pivotal trials of TVGN 489 on the basis of the results of our completed Phase 1 trial. A pivotal trial
is a trial designed to generate data sufficient to support the filing of an application for regulatory approval. Although the clinical
trial process usually includes three phases, a pivotal trial may not necessarily be denoted as a Phase 3 clinical trial and instead may
be a Phase 2 or Phase 2/3 clinical trial. We hope to begin a pivotal trial of TVGN 489 for the treatment of COVID-19 in select vulnerable
populations with humoral immune suppression due to B cell malignancy or the treatment thereof. Patients with hematological malignancies
continue to experience higher rates of hospitalization and death as compared to the general population and those with solid tumors. Increased
mortality, hospitalization, and incidence of Long COVID are higher in patients with B cell malignancies due to inadequate vaccination
response and the immunosuppressive consequences of treatment received for B cell cancers. While the major acute outcomes of patients
with hematological malignancies and COVID-19 have improved with increasing experience, for cancer patients who contract COVID-19, uninterrupted
treatment is critical, as delays can impact long-term outcomes. Whereas treatment arm patients in our Phase 1 proof-of-concept clinical
trial all had a single HLA type, we expect to treat patients in this pivotal trial who have any of the six most common HLA types, which
we believe would represent between 60% and 65% of the population. The primary endpoint of this trial is planned to be reduction in SARS-CoV-2
viral load and reduction in the delays of cancer treatment. Secondary endpoints include the incidence and duration of hospitalization,
intensive care unit admissions, hours on supplemental oxygen, mortality, COVID-19 recurrence, and Long COVID diagnosis. At this stage,
however, we cannot be certain whether we will be permitted to move from a Phase 1 trial directly to a pivotal trial until FDA reviews
and concurs with or rejects our proposed plans, and FDA may require us to conduct further trials to generate additional safety and efficacy
data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
development of TVGN 489 continues, we may also seek FDA&#8217;s RMAT designation for TVGN 489, which as explained in &#8220;Regulatory
Environment &#8211; Expedited Development and Review Programs&#8221; below, is intended to facilitate efficient development and expedited
review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Target Patient Populations and Indications for TVGN 489 </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the majority of younger and healthier adults with COVID-19 avoid poor outcomes after infection without treatment, there remain subsets
of the population (such as humorally suppressed patients with B cell malignancies, as described above) who are vulnerable to significant
complications from COVID-19 because of a weak immune system or suboptimal responses to vaccines. Treatment of these individuals is an
area of unmet need that we believe TVGN 489 therapy has the opportunity to fill. These target populations also include COVID-19 patients
with a non-B-cell cancer indication, elderly and infirm acute COVID-19 patients, and those with immune suppression due solid organ or
hematopoietic transplantation or autoimmunity or its treatment. Regardless of age or comorbidity, individuals with Long COVID represent
another critical area of unmet need. As noted above, these patients are among those with the greatest need for effective treatment. We
believe that the safety and the clinical benefit data from our completed Phase 1 clinical trial in ambulatory, high-risk adult patients
should be sufficient to serve as the basis for later-stage and potentially pivotal trials in these patient groups as well as for the
prevention of Long COVID. However, whether such trials may serve as pivotal trials, the phase of these trials, and the dose level to
be selected in each trial remains subject to discussions with and agreement by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
studies have detected persistent viral spike and nucleocapsid proteins in some Long COVID patients, suggesting a persistent viral reservoir
in those patients. If that is correct, we believe that TVGN 489 may circumvent Long COVID by preventing such a reservoir from being established
or by minimizing its size. No treated patients in our Phase 1 proof-of-concept trial developed Long COVID. We expect considerable additional
information on Long COVID prevention to be obtained from our planned acute COVID-19 treatment trials in which patients treated with TVGN
489 are expected to be compared to patients receiving standard of care treatment. We believe that the comparative data with respect to
patients in these trial arms going on to develop Long COVID should provide sufficient information to obviate a separate Phase 1 Long
COVID prevention trial, and that the significant unmet need for treatment in vulnerable patients as well as the efficacy data in preventing
Long COVID generated in these studies will lend further support for a streamlined development pathway. However, we cannot be certain
whether FDA will require us to conduct a separate prevention trial until FDA reviews and concurs with or rejects our proposed plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
studies have indicated that there is not an HLA class I-based predisposition to Long COVID. Therefore, it was not necessary for us to
undertake a genetic prediction study to determine optimal class I HLA types for CTL donor selection. Instead, a Phase 2 study is in development
that will examine the effect of treatment with TVGN 489 on specific categories of Long COVID sufferers such as those with fatigue or
brain fog based on the existence of a SARS-CoV-2 reservoir which may cause these symptoms. This protocol is in a very early stage of
development.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Discovery Programs, Product Candidates and Indications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to TVGN 489, we have several product candidates under early-stage development in virology, neurology, and oncology using our
ExacTcell technology. For example, investigative work is also underway to develop product candidates targeted at human papilloma virus
(&#8220;HPV&#8221;)-related diseases, including TVGN 920 in cervical cancer and TVGN 960 in oropharyngeal cancer, which is a type of
mouth and throat cancer. Cervical cancer and oropharyngeal cancer are both commonly caused by HPV. According to the WHO, HPV is responsible
for 99% of cervical cancers. Mouth and throat cancers are more diverse, but the WHO estimates that about 70% of oropharyngeal cancers
are due to HPV. Although a vaccine for HPV exists, the National Cancer Institute estimates that as of 2022, only 58.6% of adolescents
between the ages of 13 and 15 had received the recommended doses, estimated vaccination among older populations is lower, and the COVID
pandemic has shown that significant portions of the population will avoid vaccination. We believe that as with other viral infections,
the availability of both a preventative strategy and a treatment strategy is important to reduce incidence and impact of disease and
is investigating peptide candidates for HPV to further the development of TVGN 920 and TVGN 960. We are also beginning investigative
work to develop TVGN 116, a product candidate targeted at hepatitis B. We are also developing Epstein-Barr virus (&#8220;EBV&#8221;)
specific CTLs for potential use in multiple sclerosis (&#8220;MS&#8221;) and EBV-associated lymphomas. Our TVGN 601 is being developed
for MS, and our TVGN 930 is being developed for EBV-associated lymphomas. EBV is a common virus that infects over 90% of the world&#8217;s
adult population, according to the World Health Organization (the &#8220;WHO&#8221;), and is mainly transmitted through saliva, but also
through other body fluids such as blood and semen. EBV is the leading cause of infectious mononucleosis, and infects B-cells, a type
of immune cell. Recent studies have suggested a potential link between infection with EBV and later onset of inflammation that causes
MS, and EBV infection can lead to a variety of cancers and cancer-like disorders, including lymphomas, nasopharyngeal cancers, Post-Transplant
Lymphoproliferative Disorder, and others. Given the widespread nature of EBV and the serious health problems it can cause, investigative
work is underway to identify effective peptide targets for this virus to further the development of TVGN 601 and TVGN 930. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ExacTcell approach also presents a novel and highly specific technique to combating cancers with T cell therapy. Unlike
CAR-T or Bispecific T-cell Engager (BiTE) antibody approaches, which recruit a heterogeneous group of T cells to the tumor, our approach
would instead focus a highly purified population of CTLs on the tumor, which we believe may provide more potential to accomplish the
task of eradicating the cancer. Cancer cells may not always express an ideal T cell target on their own. However, it is possible to coat
a cancer cell with a well-recognized target peptide using monoclonal antibodies or liposomes. We believe this would allow our target
specific CTLs to then attack the cancer cells. We also believe that our approach has the potential to eventually bring the benefits of
cell therapies to first-line options in oncology, as well as to create products that may overcome current limitations of checkpoint inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
cells can lose their ability to fight viruses and tumors in prolonged infections and cancer in a state called T cell exhaustion that
is characterized by the presence of certain biomarkers. Expression of these markers, which include PD-1, PDL-1, and LAG-3, has been observed
to be low level to absent in TVGN 489 cells. Moreover, TVGN 489 cells are functionally tested after generation, and have been observed
to remain strongly cytolytic at very low ratios of CTLs to target cells, which shows that they are not displaying the functional limitations
associated with T cell exhaustion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
relied on a Clinical Trial Services and Materials Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our
Phase 1 proof-of-concept trial. However, we will need to develop manufacturing capabilities for clinical and, if approved, commercial
supply of our cell therapy products. Our efforts to develop manufacturing capability are currently focused on finding a manufacturing
and research and development facility, including through collaboration with a potential facility development partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Commercialization Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, we plan to globally commercialize TVGN 489 and our other product candidates aimed at serving a large patient population suffering
from infectious diseases, cancer, and other disorders. Our commercial and market access team has been diligently working alongside our
research and development team and external experts to better understand market dynamics, identify segments with high unmet needs, map
the patient journey, understand the competition within each segment, and identify opportunities for our product candidates. The same
team continues to offer input in portfolio planning and target prioritization for our research pipeline. We are also proactive in identifying
potential collaboration and service partners, including distribution partners for our sophisticated, cryopreserved cell therapy products
like TVGN 489. As part of our Company&#8217;s mission of patient centricity, we aim to collaborate with all stakeholders, including patients,
healthcare professionals, sales channel partners, public and private payers, and service providers. Essential commercial capabilities,
such as market analytics, pricing, and commercial operations functions, are continuously being developed as we progress toward the later-stage
development of TVGN 489.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the U.S. opportunity for our key pipeline products includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN 489: </b>Approximately 750,000
    patients with B cell hematologic cancer, 2,175,000 addressable patients with other cancers, including lung, breast, colon, pancreatic
    and liver, and 18 million addressable patients with Long COVID.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN 920: </b>Approximately 5.5 million patients
    with high-risk HPV infections, of which 200,000 are diagnosed with high grade dysplasia per year.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN 930: </b>Approximately 92,000 patients with
    the main EBV-associated lymphomas.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN 960: </b>Approximately 110,000 patients with
    HPV-related mouth and throat cancer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN 601: </b>Approximately 1 million patients with
    EBV-related multiple sclerosis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TVGN 116: </b>Approximately 500,000 to 1 million
    patients with high-risk chronic Hepatitis B for prevention of liver cancer. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Artificial
Intelligence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, we announced Tevogen.AI, a new early-stage initiative focused on harnessing the potential of artificial intelligence to
expedite drug development, optimize laboratory processes and clinical trials, unravel complex biological data, improve patient outcomes,
and pass on related savings to patients. We intend to assemble a team of research scientists, physicians, data scientists, and artificial
intelligence and machine learning engineers to help accomplish these goals by leveraging tools and techniques that might include large,
curated data sets, algorithmic models, pattern recognition, data analyses, automation, and artificial intelligence-powered software such
as chatbots. As an initial part of this initiative, we are specifically exploring ways to deploy artificial intelligence-powered target
detection to further accelerate our product development pace, either internally or in collaboration with leading entities in the field
of artificial intelligence. We also intend to explore the potential use of artificial intelligence to power tools that could anticipate
potential adverse reactions, efficacy concerns, and identify patients who would be most likely to respond to an investigational therapy.
The ability to search the human genome for specific peptide sequences might, for example, eliminate some peptide targets simplifying
the peptide screening/selection process. We have filed patents for algorithms to be trained against a curated dataset to predict immunologically
active HLA-peptide complexes and additionally to predict T cell receptor engagement tied to specific HLA-peptide complexes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its inception, Tevogen.AI has begun investigating individual viral isolates with a keen focus on target selection of peptides for our
pipeline of products. We continue curating a highly refined dataset across 14 isolates, with more targets planned, to train future machine
learning and predictive artificial intelligence foundational models. Further, we are investigating the human genome to understand immunologically
active HLA-peptide complexes related to our first patent filing. We intend to create an interface we call PredicTcell to take inputs
in the form of proteins and suggest a viable T cell receptor design to bind to the given protein. To aid this effort, we have entered
into agreements with leading artificial intelligence and technology companies. The collaborative nature of these agreements affords Tevogen.AI
access to experts and other resources to fulfill its mission of creating foundational algorithmic models of T cell interactions with
proteins. Tevogen.AI is also exploring how we can leverage datasets from partners and enrich them with internal insights to drive clinical
trial recruitment and monitoring to ensure efficacy of a given T cell product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
History and Team</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio was established in June 2020 as a Delaware corporation, and Semper Paratus was incorporated as a Cayman Islands exempted company
in April 2021. Our senior leadership team is composed of accomplished scientists and biopharmaceutical leaders. The team brings together
diverse experience across the entire life sciences spectrum, including biotechnology, pharmaceuticals, hospitals, public and private
insurance, education, and health policy. Additionally, our team holds substantial expertise in drug development, global product launches,
and commercialization and ensuring patient access across a range of therapeutic areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology industry, and in particular the cell therapy sector, are characterized by the rapid evolution of technologies and understanding
of disease etiology, and strong pursuit and defense of intellectual property. We believe that our approach, strategy, scientific development
capabilities, know-how, access to global experts, and experience provide us with competitive advantages. However, we expect future competition
in some of the indications we are targeting and from existing or emerging pharmaceutical and biotechnology companies as well as possibly
from governmental agencies, academic institutions, and public and private research institutions, among others. Some of our competitors,
either alone or through collaborations, have greater financial resources and expertise in research and development, conducting clinical
trials, manufacturing, obtaining regulatory approvals, and marketing approved products than we do. Smaller or early-stage companies may
also prove to be competitors, particularly through collaborative arrangements with large and established companies. Entities in the biotechnology
industry also compete with us in recruiting and retaining qualified scientific, clinical, and management personnel and may compete with
us in establishing clinical trial sites and enrolling patients in clinical trials as well as in acquiring technologies complementary
to, or necessary for, our programs. As a result, our competitors may discover, develop, license, or commercialize products before or
more successfully than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TVGN
489 is being developed to fill the critical gaps that exist in COVID-19 therapeutics for the immunocompromised, the high-risk elderly,
and Long COVID. Only one product has been FDA approved to date for treatment of COVID-19 in the immunocompromised population. This treatment
provides passive immunity in the form of high-titer COVID-19 convalescent plasma (&#8220;CCP&#8221;) treatment, available from the non-profit
blood donation center, OneBlood, serving the southeastern United States. Blood banks nationwide can request CCP from OneBlood, but it
is unclear how long it takes to transport the therapy. In one trial, CCP was administered to young (median age 43 years) patients with
few comorbidities other than multiple sclerosis or neuromyelitis optica, for which they were receiving anti-CD 20 therapy. Treated patients
with persistent symptoms before therapy had resolution of fever in seven days and the majority had reduction of viremia after CCP treatment.
In another trial of immune compromised patients with mild COVID-19 within seven days of infection, CCP did not prevent the evolution
of SARS-CoV-2 mutations in either the treated or untreated groups, and only two of 117 patients studied had B cell deficiency. While
the majority of patients had undergone solid organ transplantation, only one patient in the treatment group underwent allogeneic hematopoietic
stem cell transplant, and there were minimal differences in outcomes between CCP-treated and non-treated groups. The only significant
finding was a reduced rate of hospitalization in the CCP treatment group versus the non-treated group, with zero hospitalizations out
of 59 patients versus five out of 58. In both of these studies, CCP was dosed multiple times. This therapy is an FDA licensed treatment
through a blood donation center and is not marketed. We believe more data is needed regarding this therapy, especially in humorally suppressed
individuals, and that questions remain about widespread availability and effectiveness in specific subgroups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trial data of other approved treatments in immunocompromised patients is limited. The National Institutes of Health&#8217;s COVID-19
Treatment Guidelines Panel, a group of clinical experts that developed guidance on COVID-19 care (the &#8220;NIH Panel Guidelines&#8221;),
recommended prompt treatment of COVID-19 in non-hospitalized immunocompromised patients with antiviral drugs, but acknowledged the limitations
of these drugs and related research in such patients. Two antivirals are currently FDA-approved for COVID-19 treatment: Gilead Science&#8217;s
Veklury<sup>&#174;</sup>&#160;(Remdesivir) for the treatment of mild-to-moderate COVID-19 in hospitalized or non-hospitalized adults who
are at high risk for progression to severe COVID-19, and Pfizer&#8217;s Paxlovid (Nirmatrelvir/Ritonavir tablets) for the treatment of
mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19. The NIH Panel Guidelines highlight the limitation
of the insights that clinical trials conducted for Remdesivir and for Nirmatrelvir/Ritonavir tablets in broader populations can provide
with respect to immunocompromised patients, as each trial enrolled only limited numbers of such patients. For example, a retrospective
study examining the use of Nirmatrelvir/Ritonavir tablets in vulnerable individuals with COVID-19 included only 13.2% highly immunocompromised
and 10.6% moderately immunocompromised patients with cancer, with cancer type and type immunosuppressive medications not otherwise specified.
Although the NIH Panel Guidelines acknowledge observation in retrospective studies of &#8220;some potential benefits&#8221; of the use
of Paxlovid for patients with &#8220;various immunocompromising conditions,&#8221; they also note that because the pivotal trial of Nirmatrelvir/Ritonavir
tablets did not enroll many immunocompromised participants, &#8220;efficacy ... was not established for this population.&#8221; Based
on our target product profile, therefore, we anticipate that these products may not be direct competitors in our target patient population.
Moreover, we believe that TVGN 489&#8217;s anticipated single outpatient infusion may be easier to administer than Veklury&#8217;s multiple
infusions over a number of days. Additionally, Paxlovid requires daily doses, has a significant number of drug interaction issues, as
discussed in &#8220;COVID-19 Background&#8221; and noted by the NIH Panel Guidelines, and has experienced numerous patient reports of
disease relapse or rebound, which in each case we do not anticipate for TVGN 489 based on its design and our Phase 1 proof of concept
trial results. We do expect that these products may present direct competition in high-risk elderly patients, but we are initially targeting
immunocompromised indications. There remains no documented effective treatments for Long COVID, with a recent study showing no benefit
from the use of Paxlovid (Nirmatrelvir/Ritonavir tablets) in patients with Long COVID.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monoclonal
antibodies have also previously been considered promising as an effective therapeutic option for COVID-19, including in immunocompromised
patients, and several had been granted EUAs. Most of these treatments have had their EUAs revoked by FDA due to lack of efficacy stemming
from viral mutations. There are nonetheless ongoing efforts to develop additional anti-COVID monoclonal antibodies for treatment and
prevention of COVID-19 infection. For example, in March 2024, Invivyd received an EUA of its product, Pemgarda (pemivibart), a broadly
neutralizing monoclonal antibody used for COVID-19 prevention in immunocompromised individuals who have not either been exposed to or
developed active COVID infection. <span style="color: #242424">While recent press releases from Invivyd confirm continued activity of
Pemivibart against circulating strains of SARS-CoV-2, third-party research showed that inhibitory concentrations needed for neutralization
of the JN.1 sublineages increased for Pemivibart, and that activity was substantially adversely impacted by the currently highest circulating
variant at the time of the research.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pemivibart
and other monoclonal antibodies remain vulnerable to novel viral mutations. Antibodies, unlike T-cells, recognize intact molecules. Consequently,
even remote mutations, not directly where the antibodies bind, may alter how the target molecule folds and its overall shape and therefore
prevent antibody binding. T-cells, in contrast, recognize small peptide breakdown products of proteins and are only affected if the mutation
is directly within the target peptide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
broadly, known companies developing virus-specific T cell therapies include Atara Biotherapeutics (&#8220;Atara Bio&#8221;), whose Ebvallo
(tabelecleucel) has received approval in Europe for treating a rare hematologic cancer caused by EBV. AlloVir, Inc. (&#8220;AlloVir&#8221;)
is another company developing allogeneic T cell therapies for viral diseases. Neither Atara Bio nor AlloVir has an active development
program for the treatment of COVID-19. AlloVir conducted a Phase 1b trial of an allogeneic, partially HLA-matched product candidate in
COVID-19 and reported results of the trial in 2021 but has not continued clinical development. One patient in the trial experienced a
recurrence of the disease and died four weeks after treatment. Atara Bio paused development of its T cell therapy, ATA188, after announcing
in November 2023 that the Phase 2 trial of ATA188 targeting EBV-infected B cells and plasma cells in progressive forms of multiple sclerosis
failed to meet efficacy or biomarker endpoints. ATA188 targets only three latent EBV proteins, whereas our CTL peptide targets are selected
from all proteins expressed at the appropriate point in the viral life cycle, whether unique to that point in the viral life cycle or
not. This approach provides far more immunologic targets and thus more opportunities for viral control. In addition, ATA188 is generated
against targets restricted by several HLA alleles, which is likely to reduce the functional dose of drug targeting any one HLA allele,
as contrasted with CTLs developed with ExacTcell, which are generated against a single HLA specificity and therefore allow a more precise
understanding and control of dosage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will continue to face competition as new therapies enter the market and advanced technologies become available from
time to time. We expect that any treatments which we develop and commercialize will need to compete on, among other things, efficacy,
safety, convenience of administration and delivery, and price. Commercialization of any treatments we develop will be affected by the
level of competition from original and biosimilars products and the availability of reimbursement from government and other third-party
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize our proprietary cell products could be significantly and adversely affected if our competitors develop and commercialize
products that are more effective, have a better safety profile, are more convenient or are less expensive than our products. Our competitors
also may obtain relevant regulatory approvals for their products more rapidly than we may be able to obtain approval for ours, which
could result in our competitors obtaining a head start and establishing a frontrunner position before we are ready to commercialize.
If we are not able to compete effectively against our existing and potential competitors, our business, financial condition, results
of operations and growth prospects may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for our products and
methods, preserve the confidentiality of our trade secrets, operate without infringing, misappropriating, or otherwise violating the
valid, enforceable proprietary rights of others, and prevent others from infringing, misappropriating, or otherwise violating our proprietary
rights. We rely on a combination of patents, patent applications, trademarks, and trade secrets to establish and protect our intellectual
property rights. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products without the
right to do so may depend on the extent to which we have rights under valid and enforceable patents, trademarks or trade secrets that
cover these activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to build our intellectual property portfolio and seek to protect our proprietary position by, among other things, filing patent
applications. Our patent estate includes patents and patent applications with claims relating to our product candidates, methods of use,
and methods of preparing the product candidates. As of February 24, 2025, our U.S. intellectual property portfolio includes three U.S.
patents relating to TVGN 489 for the treatment of COVID-19, nine pending U.S. patent applications, including two patent applications
relating to the treatment of COVID-19, six relating to the treatment of other viruses or cancer, and one related to artificial intelligence-driven
T cell target identification and receptor engagement, as well as thirteen ex-U.S. patent applications, including applications in Australia,
Canada, Europe, Japan, Qatar, United Arab Emirates, and the Patent Cooperation Treaty (PCT) directed at viral specific T cells, methods
of treating and preventing viral infections, methods for developing CD3+CD+ cells against multiple viral epitopes for the treatment of
viral infections, and systems for predicting immunologically active peptides with machine learning models, which have anticipated expiration
dates through December 16, 2044.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our three issued utility patents, all of which will expire on December 9, 2040, are U.S. Patent No. 11,191,827 covering
methods of treating COVID-19 infection using COVID-19 peptide specific CTLs, U.S. Patent No. 11,207,401 covering COVID-19 peptide-specific
CTLs, and U.S. Patent No. 11,219,684 covering methods of manufacturing COVID-19 peptide specific CTLs. A pending utility patent application
in the United States directed at viral specific T cells and methods of treating and preventing viral infections has an anticipated expiration
of December 9, 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine strategy for claim scope for our patent applications on a case-by-case basis, taking into account advice of counsel and our
business model and needs. We file patents containing claims for protection of useful applications of our proprietary technologies and
any product candidates, including new applications or uses we discover for existing technologies and product candidates, based on our
assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as our pending and
issued patent claims, to ensure maximum coverage and value are obtained for our processes and compositions, given existing patent office
rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we own a registered trademark for &#8220;Tevogen Bio&#8221; (and design), and have applied for a registered trademark protection
for &#8220;ExacTcell&#8221; and &#8220;Tevogen.AI&#8221; (and logo) with the USPTO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to attract and retain highly qualified management and personnel. As of March 21, 2025, we had 18 full-time
and no part-time employees. We value a work culture that encourages employees, contractors, and vendors to contribute their unique and
diverse perspectives, to harness optimism and creativity, and to be ready to learn and develop solutions towards a common and greater
purpose of developing accessible immunotherapies. Our work culture is centered around four &#8220;CORE&#8221; values: Curiosity, Optimism,
Respect, and Equality. We believe it is essential and necessary that these values are instilled and maintained in each of our employees
to foster a collaborative culture. At our current size, ensuring this culture is primarily achieved through the recruitment process.
Talent recruitment at our current stage is setting the foundation for further company growth. When attracting talent, we ensure that
every job description mentions our core values, and the importance of these values in achieving our mission. Beyond evaluating experience,
job applicants are also evaluated based on their values and passions. We believe it is necessary that each employee represents our four
core values. As our employee numbers increase, we plan to create more defined programs to further enhance our company culture and retention
of personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Warren, New Jersey, and consist of 6,708 square feet dedicated to corporate, operational, and pre-commercial
activities under a lease that expires February 14, 2026. We also have two research and development facilities located in Philadelphia:
our 3,620 square foot research and development center under a lease that expires June 30, 2025; and a shared facility with laboratory
space dedicated to us that is focused on preclinical and pharmacodynamic activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate expansion of both our corporate office and research and development facilities and intend to facilitate both in-house clinical
and commercial manufacturing and are currently engaged in active discussions regarding such expansion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;),
and the Public Health Service Act (the &#8220;PHSA&#8221;), and other federal, state, and local statutes and regulations. Both the FDCA
and PHSA and their corresponding regulations govern, among other things, the research, development, clinical trials, testing, manufacturing,
quality control, safety, purity and potency (efficacy), labeling, packaging, storage, record keeping, distribution, reporting, marketing,
promotion, advertising, post-approval monitoring, and post-approval reporting involving biological products. Along with third-party contractors,
we will be required to navigate the various preclinical and clinical regulatory obligations and the commercial approval requirements
of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product
candidates. The processes for obtaining regulatory approvals in the United States, along with subsequent compliance with applicable laws
and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
policies may change and additional government regulations may be enacted that could prevent, delay, or present significant new challenges
and costs for further development or regulatory approval of any product candidates, product or manufacturing changes, additional disease
indications or label changes. We cannot predict the likelihood, nature or extent of government regulation that might arise from future
legislative or administrative action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Review
and Approval for Licensing Biologics in the United States </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, FDA regulates our current product candidates as biological products, or biologics, under the FDCA, the PHSA, and associated
implementing regulations. Biologics, like other drugs, are used for the diagnosis, cure, mitigation, treatment, or prevention of disease
in humans. In contrast to low molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics
are generally derived from living material (human, animal, or microorganism), are complex in structure, and thus are usually not fully
characterized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biologics
are also subject to other federal, state, and local statutes and regulations. The failure to comply with applicable statutory and regulatory
requirements at any time during the product development process, approval process, or after approval may subject a sponsor or applicant
to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by FDA,
FDA&#8217;s refusal to approve pending applications or supplemental applications, suspension or withdrawal of an approval, issuance of
warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, import detention,
injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties
brought by FDA, the Department of Justice (&#8220;DOJ&#8221;), and other governmental entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
applicant seeking approval to market and distribute a biologic in the United States must typically undertake the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            of non-clinical laboratory tests and studies performed in accordance with FDA&#8217;s Good
                                            Laboratory Practice (&#8220;GLP&#8221;) regulations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture,
                                            labeling and distribution of investigational drugs in compliance with FDA&#8217;s current
                                            Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to FDA of an Investigational New Drug application (&#8220;IND&#8221;), which must become
                                            effective before clinical trials may begin and must be updated annually and when significant
                                            changes are made;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            by an Investigational Review Board (&#8220;IRB&#8221;) for each clinical site before each
                                            clinical trial may be initiated;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s Good
                                            Clinical Practice (&#8220;GCP&#8221;) requirements to establish the safety, purity, and potency
                                            of the proposed biological product candidate for its intended purpose;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
                                            completion of all pivotal clinical trials, preparation of and submission to FDA of a Biologics
                                            License Application (&#8220;BLA&#8221;) requesting marketing approval, which includes providing
                                            sufficient evidence to establish the efficacy, safety, purity, and potency of the proposed
                                            biological product for its intended use, including from results of nonclinical testing and
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA advisory committee review, when appropriate, as may be requested by
                                            FDA to assist with its review;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of one or more FDA inspections of the manufacturing facility or facilities at
                                            which the proposed product, or certain components thereof, are produced to assess compliance
                                            with cGMP and data integrity requirements to assure that the facilities, methods, and controls
                                            are adequate to preserve the biological product&#8217;s identity, strength, quality, and
                                            purity and, if applicable, FDA&#8217;s Good Tissue practice (&#8220;GTP&#8221;) requirements
                                            for certain human cellular and tissue products;&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of FDA inspections of selected clinical investigation sites to assure compliance
                                            with GCP requirements and the integrity of the clinical data;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA sponsor GCP inspection, often conducted at the applicant&#8217;s headquarters
                                            facility;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of user fees (unless there is a waiver, exemption, or reduction) under the Prescription Drug
                                            User Fee Act (&#8220;PDUFA&#8221;) for the relevant year;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
                                            review and approval of the BLA to permit commercial marketing of the licensed biologic for
                                            particular indications for use in the United States; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                            with post-approval requirements, including the potential requirements to implement a Risk
                                            Evaluation and Mitigation Strategies (&#8220;REMS&#8221;), to report adverse events and biological
                                            product deviations, and to complete any post-approval studies such as confirmatory trials
                                            or pediatric studies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing
the testing, approval, manufacturing, and marketing of biological products regulated by FDA. In addition to new legislation, FDA regulations,
guidance documents, and policies are often revised or interpreted by the agency in ways that may significantly affect the regulation
of biological products in the United States. It is impossible to predict whether further legislative changes will be enacted or whether
FDA regulations, guidance, policies, or interpretations will change, and the effects of any such changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
and Clinical Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
an applicant can begin testing the potential product candidate in human subjects, the applicant must first conduct preclinical studies.
Preclinical studies may include laboratory evaluations of product chemistry, toxicity, and formulation, as well as in vitro and animal
studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic
use. Preclinical studies are subject to federal regulations and requirements, including GLP regulations, which govern the conduct of
animal studies designed to test a product&#8217;s safety. None of our preclinical studies to date have been animal studies. The results
of an applicant&#8217;s preclinical studies are submitted to FDA as part of an IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND is a request for authorization from FDA to administer an investigational new drug product to humans. An IND is an exemption from
the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in a clinical trial. Such authorization must be
secured prior to interstate shipment and administration of a biological drug that is not subject of an approved BLA. In support of an
IND, applicants must submit a protocol for each clinical trial, which details, among other things, the objectives of the trial, the parameters
to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made
for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30 days after receipt by FDA, unless
FDA raises safety concerns or questions about the proposed clinical trial within the 30-day time period. In such a case, FDA may place
the IND on clinical hold and the IND sponsor must resolve any of FDA&#8217;s outstanding concerns or questions before the clinical trial
can begin. Submission of an IND therefore may or may not result in regulatory authorization to begin a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also place a clinical hold or partial clinical hold on a clinical trial following commencement of the trial under an IND. A clinical
hold is an order issued by FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial
clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, under a partial clinical
hold, FDA may instruct a sponsor not to enroll any new patients into a study, but permit the previously enrolled patients to continue
in the study. No more than 30 days after imposition of a clinical hold or partial clinical hold, FDA will provide the sponsor a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume
after FDA has notified the sponsor that the investigation may proceed. FDA will base that determination on information provided by the
sponsor addressing the deficiencies previously cited or otherwise satisfying FDA that the investigation can proceed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical trial. If a sponsor chooses to conduct a foreign clinical study under an IND, all FDA IND requirements must be met unless
waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with GCP regulations
in order to use the study as support for an IND or application for marketing approval, including review and approval by an IRB and informed
consent from subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
an independent IRB for all sites participating in a clinical trial must review and approve the plan for any clinical trial and its informed
consent form before the clinical trial begins at each site, and must monitor the trial until completed. Regulatory authorities, the IRB,
or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to
an unacceptable health risk or that the trial is unlikely to meet its stated objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a DSMB.
DSMBs review unblinded study data at pre-specified times during the course of the study. If the DSMB determines that there is an unacceptable
safety risk for subjects or other grounds, such as no demonstration of efficacy, the DSMB can make a recommendation to the sponsor to
modify or stop the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
grounds for a sponsor&#8217;s decision to suspend or terminate a study may be made based on evolving business objectives or competitive
climate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of BLA approval, clinical trials are typically conducted in the following sequential phases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: The investigational product is initially introduced into a small group of healthy human
                                            subjects or patients with the target disease or condition. These trials are designed to test
                                            the safety, dosage tolerance, absorption, metabolism and distribution of the investigational
                                            product in humans and the side effects associated with increasing doses. These trials may
                                            also yield early evidence of effectiveness.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            2: The investigational product is administered to a slightly larger patient population with
                                            a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and
                                            dosing schedule and to identify possible adverse side effects and safety risks. Multiple
                                            Phase 2 clinical trials may be conducted to obtain information prior to beginning larger
                                            and more expensive Phase 3 clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            3: The investigational product is administered to an expanded patient population to further
                                            evaluate dosage, to provide statistically significant evidence of clinical efficacy and to
                                            further test for safety, generally at multiple geographically dispersed clinical trial sites.
                                            These clinical trials are intended to generate sufficient data to statistically demonstrate
                                            the efficacy and safety of the product, to establish the overall risk/benefit ratio of the
                                            investigational product, and to provide an adequate basis for product approval by FDA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
phases may overlap or be combined. In some cases, FDA may require, or companies may voluntarily pursue, additional clinical trials after
a product is approved to gain more information about the product, referred to as Phase 4 trials. Such post-approval trials are conducted
following initial approval, often to develop additional data and information relating to the use of the product in new indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to FDA. In addition, IND safety reports must
be submitted to FDA for any of the following: serious and unexpected suspected adverse reactions in study subjects; findings from epidemiological
studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an
IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important
increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor&#8217;s planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, FDA or
the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution,
or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the
drug has been associated with unexpected serious harm to patients. FDA will typically inspect one or more clinical sites to assure compliance
with GCP and the integrity of the clinical data submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported
outcomes (&#8220;PROs&#8221;), the process typically is an iterative one. FDA has issued guidance on the framework it uses to evaluate
PRO instruments. Although the agency may offer advice on optimizing PRO instruments during the clinical development process, FDA usually
reserves final judgment until it reviews the BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and
physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things,
must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging
must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable
deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BLA
Submission and Review</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit
a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results
of nonclinical studies and clinical trials; detailed information on the product&#8217;s chemistry, manufacture, controls; and proposed
labeling. Under the PDUFA, a BLA submission is subject to an application user fee, unless a waiver, reduction, or exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
will initially review the BLA for completeness before accepting it for filing. Under FDA&#8217;s procedures, the agency has 60 days from
its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines
that the application does not meet this initial threshold standard, FDA may refuse to file the application and request additional information,
in which case the application must be resubmitted with the requested information and review of the application delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the BLA is accepted for filing, FDA reviews the BLA to determine, among other things, whether a product is safe, pure, and potent and
if the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued
identity, strength, quality, safety, purity, and potency. To ensure cGMP, GLP, GCP, GTP, and other regulatory compliance, an applicant
must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production and quality control.
In addition, FDA expects that all data be reliable and accurate, and requires sponsors to implement meaningful and effective strategies
to manage data integrity risks. Data integrity is an important component of the sponsor&#8217;s responsibility to ensure the safety,
efficacy and quality of its product or products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
cellular products, FDA will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable.
GTPs are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture
of human cells, tissue, and cellular and tissue-based products (&#8220;HCT/Ps&#8221;), which are human cells or tissue intended for implantation,
transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based
products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations
also specify how HCT/P establishments must register and list their HCT/Ps with FDA and how they must evaluate donors through screening
and testing, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies
in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance goals and policies implemented by FDA under the PDUFA generally provide for FDA action on an original BLA within 10 months
of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances.
Furthermore, the review process is often significantly extended by FDA&#8217;s requests for additional information or clarification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.
Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate, and provide
a recommendation as to whether the application should be approved and, if so, under what conditions. FDA is not bound by the recommendations
of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will
be produced, FDA may issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial
marketing of the biologic with specific prescribing information for specific indications. A CRL will describe all of the deficiencies
that FDA has identified in the BLA, except that where FDA determines that the data supporting the application are inadequate to support
approval, FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed
labeling. If and when the deficiencies have been addressed to FDA&#8217;s satisfaction in a resubmission of the BLA, FDA will issue an
approval letter. In issuing the CRL, FDA may recommend actions that the applicant might take to place the BLA in condition for approval,
including requests for additional data, information, or clarification. FDA may delay or refuse approval of a BLA if applicable regulatory
criteria are not satisfied, and may require additional testing or information and/or require new clinical trials. Even with submission
of this additional information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the approval process, FDA will determine whether a REMS is necessary to help ensure the benefits outweigh the risks of the biologic.
A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued
access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to
assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If FDA concludes that
a REMS is needed, the BLA sponsor must submit a proposed REMS and FDA will not approve the BLA without a REMS that the agency has determined
is acceptable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings, or
precautions be included in the product labeling. FDA may also require that post-approval studies, including Phase 4 clinical trials,
be conducted to further assess the drug&#8217;s safety after approval. FDA may prevent or limit further marketing of a product based
on the results of post-market studies or surveillance programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include
official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution.
The manufacturer then typically must submit samples of each lot of product to FDA, together with a release protocol showing a summary
of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. FDA may also
perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, an approved BLA only allows the sponsor to market the biologic as approved, without modification. If, for example, a sponsor
modifies an approved T cell product to target different peptides or in our case to target another HLA type, the sponsor would be required
to either file a supplemental BLA with FDA or receive FDA approval for a comparability protocol in order to implement this change into
the final product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after
the product reaches the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences,
product sampling and distribution, and advertising and promotion of the product. After approval, many types of changes to the approved
product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements
and FDA review and approval, depending on the nature of the post-approval change. There also are continuing user fee requirements, under
which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party
contractors are required to register their facilities with FDA and certain state agencies. These facilities are subject to routine and
periodic unannounced inspections by FDA and certain state agencies for compliance with cGMP, post-marketing safety reporting and data
integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product.
FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of its oversight.
Requirements with respect to data integrity include, among other things, controls ensuring complete and secure data; activities documented
at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records
for accuracy, completeness, and compliance with established standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting
requirements upon the sponsor and any third-party manufacturers that the sponsor may use. Accordingly, manufacturers must continue to
expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance,
and other aspects of regulatory compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-approval studies to assess new safety risks; or imposition of distribution
or other restrictions under a REMS. Other potential consequences include, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of a product, complete withdrawal of the product from the
                                            market, or product recalls;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            warning or untitled letters, or holds on post-approval clinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            of FDA to approve pending applications or supplements to approved applications, or suspension
                                            or revocation of existing product approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention, or refusal of FDA to permit the import or export of products; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permanent
                                            injunctions and consent decrees, including the imposition of civil or criminal penalties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
strictly regulates the marketing, labeling, advertising, and promotion of prescription drug products placed on the market. A company
can make only those claims relating to safety and efficacy, purity and potency that are approved by FDA and in accordance with the provisions
of the approved labeling. FDA&#8217;s regulation includes, among other things, standards and regulations for direct-to-consumer advertising,
communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving
the Internet and social media. Promotional claims relating to a product&#8217;s safety or effectiveness are prohibited before the drug
is approved. After approval, a product generally may not be promoted for uses that are not approved by FDA, as reflected in the product&#8217;s
prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not
described in the drug&#8217;s labeling, known as off-label uses, because FDA does not regulate the practice of medicine. However, FDA
regulations impose rigorous restrictions on manufacturers&#8217; communications and prohibit the promotion of off-label uses. It may
be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication
regarding off-label information, such as distributing scientific or medical journal information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial
enforcement by FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services (&#8220;HHS&#8221;),
as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial
impact, including civil, administrative, and criminal fines, penalties, and agreements that materially restrict the manner in which a
company promotes or distributes products. The federal government has levied large civil, administrative, and criminal fines and penalties
against companies for alleged improper promotion, and has also requested that companies enter into Corporate Integrity Agreements and
Consent Decrees of Permanent Injunction under which specified promotional conduct is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;), which requires
manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification,
and licensing requirements. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the
distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution
and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful
from the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
offers a number of expedited development and review programs for qualifying product candidates. The fast-track program is intended to
expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for
fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential
to address unmet medical needs for the disease or condition. A product intended to treat a serious or life-threatening disease or condition
may also be eligible for breakthrough therapy designation to expedite its development and review. Any marketing application for a biologic
submitted to FDA for approval, including a product with a fast-track designation and/or breakthrough therapy designation, may be eligible
for other types of FDA programs intended to expedite FDA review and approval process, such as priority review and accelerated approval.
FDA also may grant accelerated approval to certain products studied for their safety and effectiveness in treating serious or life-threatening
diseases or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMAT designation, which we are currently planning to seek for some of our therapies, is intended to facilitate an efficient development
program for, and expedite review of, any drug that meets the following criteria: (1) the drug is a cell therapy, therapeutic tissue engineering
product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) the
drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical
evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough
therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development
plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be
eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical
benefit, or reliance upon data obtained from a meaningful number of sites (including through expansion to additional sites) so as to
remove any likelihood of site-specific or investigator-specific bias on the evidence of effectiveness. Once approved, when appropriate,
FDA can permit fulfillment of post-approval requirements for RMATs receiving accelerated approval through the submission of clinical
evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the
collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards
for approval but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Term Restoration and Marketing Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
approval, owners of relevant drug or biological product patents may apply for up to a five year term patent extension to restore a portion
of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial
marketing or use of a drug or biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration
Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as one-half of the product&#8217;s
testing phase, which is the time between the effective date of an IND and initial BLA submission, and all of the approval phase, which
is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if FDA determines that the
applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years from the date
of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must
apply for restoration within 60 days of approval, even if the product cannot be commercially marketed at that time. The USPTO, in consultation
with FDA, reviews and approves the application for patent term restoration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
patents that might expire during the BLA application phase, the patent owner may request an interim patent extension. An interim patent
extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval
patent extension is reduced by one year. The director of the USPTO must determine that approval of the product candidate covered by the
patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for
which a BLA has not been submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and Marketing Exclusivities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BPCIA created an abbreviated approval pathway for biological product candidates shown to be highly similar to or interchangeable with
an FDA licensed biological product. A biological product on which another biological product candidate&#8217;s BLA relies to establish
biosimilarity is known as a reference product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there
be no differences in conditions of use, route of administration, dosage form and strength, and no clinically meaningful differences between
the biological product candidate and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through
analytical trials, animal trials and at least one clinical trial, unless the Secretary of HHS waives a required element. A biosimilar
product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it
can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biological
product candidate and the reference biologic may be switched after one has been previously administered without increasing safety risks
or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often
more complex, structures of biologics, as well as the process by which such products are manufactured, pose significant hurdles to implementation
of the abbreviated approval pathway that are still being resolved by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for
a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biological product candidate
submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first
commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if
there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the
first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar&#8217;s application has been
approved if a patent lawsuit is ongoing within the 42 month period. At this time, it is unclear whether products deemed &#8220;interchangeable&#8221;
by FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Coverage,
Pricing, and Reimbursement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully commercialize any products for which we receive regulatory approval for commercial sale will depend, in part,
on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products, and significant
uncertainty exists as to the coverage and reimbursement status of any products for which may we obtain regulatory approval. In the United
States, third-party payors include federal and state health care programs, private managed care providers, health insurers and other
organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process
for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party
payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved
products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity, and
reviewing the cost-effectiveness of medical products, therapies, and services, in addition to questioning their safety and efficacy.
We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our
products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary
or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will
be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide
coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to
realize an appropriate return on our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has
increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Healthcare Laws and Compliance Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we currently do not have any commercialized products, our current and future business operations may be subject to additional healthcare
regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our
business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security,
price reporting and physician sunshine laws. Some of our pre-commercial activities are subject to some of these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer or a party acting
on its behalf to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration in cash or in kind
that is intended to induce or reward the referral of business, including the purchase, order, or lease of any item or service for which
payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly
interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on one hand and prescribers, purchasers, formulary managers and beneficiaries on the other.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions
and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases
or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements
of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback
Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts
and circumstances. Several courts have found that the Anti-Kickback Statute may be violated if any one purpose of an arrangement involving
remuneration is to induce referrals of federal healthcare program business. In addition, liability may be established without actual
knowledge of the statute or specific intent to violate it. Violations of this law are punishable by up to ten years in prison, and can
also result in criminal fines, civil money penalties and exclusion from participation in federal healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment of government funds or knowingly making, using, or causing to be made or used, a false record
or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing,
or concealing an obligation to pay money to the federal government. Persons and entities can be held liable under these laws if they
are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding
information to customers or promoting a product off-label. Many pharmaceutical and other healthcare companies have been investigated
and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged
improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal
programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe
our products; and inflating prices reported to private price publication services, which are used to set drug payment rates under government
healthcare programs. Penalties for federal civil False Claims Act violations may include up to three times the actual damages sustained
by the government, plus mandatory per claim civil penalties, and the potential for exclusion from participation in federal healthcare
programs. In addition, although the federal False Claims Act is a civil statute, False Claims Act violations may also implicate various
federal criminal statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare fraud provisions of The Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) prohibit knowingly and willfully
executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly
and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare
offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious
or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback
Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed
a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have analogous laws and regulations, such as: state anti-kickback and false claims laws that may apply to sales or marketing arrangements
and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; laws
that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to certain healthcare providers;
laws that require drug manufacturers to report information related to clinical trials or information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures; laws that restrict the ability of manufacturers to offer
co-pay support to patients for certain prescription drugs; and laws and local ordinances that require identification or licensing of
sales representatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations,
mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions,
as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption
of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security
standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive,
or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased
the civil and criminal penalties that may be imposed against covered entities and business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s
fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health
information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant
ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can
result in the imposition of significant civil and/or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Physician Payment Sunshine Act, implemented as the Open Payments Program, requires manufacturers of drugs, devices, biologics,
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain
exceptions) to report annually to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) information related to direct or
indirect payments and other transfers of value to physicians and teaching hospitals (and certain other practitioners as of 2022), as
well as ownership and investment interests held in the Company by physicians and their immediate family members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we intend to commercialize products that could be reimbursed under a federal health care program and other governmental healthcare programs,
we intend to develop a comprehensive compliance program that establishes internal control to facilitate adherence to the rules and program
requirements to which we will or may become subject. Although the development and implementation of compliance programs designed to establish
internal control and facilitate compliance can mitigate the risk of investigation, prosecution, and penalties assessed for violations
of these laws, the risks cannot be entirely eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject
to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual
damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from
participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to
operate our business and our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Care Reform</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval
activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers
and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has
been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the Affordable Care Act (&#8220;ACA&#8221;) substantially changed the way healthcare is financed by both the government and
private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA contains provisions that may reduce the profitability
of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed
care plans, mandatory discounts for certain Medicare Part D beneficiaries, and annual fees based on pharmaceutical companies&#8217; share
of sales to federal health care programs. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical
manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate. The ACA also expanded the universe of Medicaid utilization
subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging
the population potentially eligible for Medicaid drug benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial challenges to certain aspects of the ACA, as well as efforts by Congress to modify, and by agencies to alter the implementation
of, certain aspects of the ACA. For example, Congress eliminated the tax penalty for failure to comply with the ACA&#8217;s individual
mandate to carry health insurance. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA to increase from 50
percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D to close
the coverage gap in most Medicare drug plans, commonly referred to as the donut hole (this existing coverage gap program will be sunset
by the Inflation Reduction Act beginning in 2025 and replaced with a new manufacturer discount program).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that the ACA, as currently enacted or as may be amended in the future, as well as other healthcare reform measures, including
those that may be adopted in the future, may result in more rigorous coverage criteria, and less favorable payment methodologies, or
other downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement
or restriction on coverage under Medicare or other federal health care programs may result in a similar reduction or restriction by private
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. For example, the Inflation Reduction Act introduces
several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability
under the program which could negatively affect the profitability of our product candidates. The IRA sunsets the current Part D coverage
gap discount program starting in 2025 and replaces it with a new manufacturer discount program. Failure to pay a discount under this
new program will be subject to a civil monetary penalty. In addition, the IRA establishes a Medicare Part B inflation rebate scheme effective
January 2023 and a Medicare Part D inflation rebate scheme effective October 2022, under which, generally speaking, manufacturers will
owe rebates if the price of a Part B or Part D drug increases faster than the pace of inflation. Failure to timely pay a Part B or D
inflation rebate is subject to a civil monetary penalty. The IRA also creates a drug price negotiation program under which the prices
for Medicare units of certain high Medicare spend drugs and biologicals without generic or biosimilar competition will be capped by reference
to, among other things, a specified non-federal average manufacturer price starting in 2026. Failure to comply with requirements under
the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty. Congress continues to examine various
policy proposals that may result in pressure on the prices of prescription drugs with respect to the government health benefit programs
and otherwise. The IRA or other legislative changes could impact the market conditions for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, there has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their commercial
products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug product pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Privacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to federal, state, national and international laws and regulations governing the privacy and security of health-related
and other personal data we collect and maintain (e.g., Section 5 of the Federal Trade Commission Act (the &#8220;FTC Act&#8221;), the
California Consumer Privacy Act, as amended by the California Privacy Rights Act (the &#8220;CCPA&#8221;), and the European Union&#8217;s
(&#8220;EU&#8221;) General Data Protection Regulation). These laws and regulations are evolving and subject to interpretation and may
impose limitations on our activities or otherwise adversely affect our business. In addition, state laws govern the privacy and security
of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same
effect, thus complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection
and privacy laws and regulations, or if we were to experience a data breach involving personal data, we could be subject to government
enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government actions could lead to
unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments
or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments
in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other
remedies that harm our business, including orders that we modify or cease existing business practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a website at the following address: www.tevogen.com. The information on our website is not incorporated by reference in this
report. We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the
Securities and Exchange Commission (the &#8220;SEC&#8221;) in accordance with the&#160;Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;). These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. We make this information available on our website free of charge as soon as reasonably practicable after we electronically
file the information with, or furnish it to, the SEC. In addition, we routinely post on the &#8220;Investors&#8221; page of our website
news releases, announcements and other statements about our business and results of operations. We may use the &#8220;Investors&#8221;
page of our website as a means of disclosing material, non-public information and to comply with our disclosure obligations under&#160;Regulation
FD. Therefore, we encourage investors to monitor the &#8220;Investors&#8221; page of our website and review the information we post on
that page.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC at the following address: http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
About Our Executive Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
table below sets forth certain information concerning our executive officers serving as of the filing of this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
Report<span style="background-color: white">:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
    Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Ryan Saadi</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer, Chairperson and Director </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti Desai</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Neal Flomenberg</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529; background-color: white">Chief
    Scientific Officer and Global R&amp;D Lead</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sadiq Khan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Commercial
    Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Ryan Saadi</i></b> has served as our Chief Executive Officer and Chairperson since February  2024, and served as Chief Executive Officer
and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public
Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing
for CSL Behring, a biopharmaceutical company that manufactures plasma-derived and recombination therapeutic products, from September
2018 to October 2019. Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen from 2012 to
September 2018 and Worldwide Vice President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson &amp; Johnson&#8217;s
Cordis business from 2008 to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes &amp; Pricing for Genzyme and Global
Head, Health Outcomes and Market Access for Sanofi-Aventis&#8217; oncology, bone and arthritis product portfolio. From 2010 through 2019,
Dr. Saadi has also served as a Voting Member of the CMS Medicare Evidence Development &amp; Coverage Advisory Committee, which provides
independent guidance and expert advice to CMS on clinical topics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kirti
Desai</i></b> has served as our Chief Financial Officer since February  2024, and served as Chief Financial Officer of Tevogen Bio
beginning in June 2020. Mr. Desai previously served as President of Star Accounting Services Inc., an accounting firm providing accounting
and tax services to businesses and individuals, from January 2005 to December 2021. Mr. Desai is a certified public accountant. Mr. Desai
also serves as the Treasurer of Shrimad Rajchandra Mission Dharampur (USA) Inc., a community outreach and development nonprofit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Neal Flomenberg</i></b> has served as our Chief Scientific Officer and Global R&amp;D Lead since February  2024, and served as Chief
Scientific Officer and Global R&amp;D Lead of Tevogen Bio beginning in July 2022. Prior to joining Tevogen Bio, Dr. Flomenberg served
as professor and Chair of the Department of Medical Oncology at Sidney Kimmel Medical College of Thomas Jefferson University from 2008
to July 2022 and Deputy Director of Thomas Jefferson University&#8217;s Sidney Kimmel Cancer Center from 2015 to July 2022. Prior to
those positions, Dr. Flomenberg held a number of leadership roles in the academia, hospital, and research settings. Dr. Flomenberg&#8217;s
career has focused on blood cancers, particularly those requiring bone marrow or peripheral blood stem cell transplants, and he has authored
over 175 peer reviewed publications. At Jefferson, Dr. Flomenberg also maintained an active medical practice and was continually listed
in Philadelphia Magazine&#8217;s &#8220;Top Doctors in Philadelphia&#8221; for more than 15 years prior to joining Tevogen Bio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sadiq
Khan </i></b>has served as our Chief Commercial Officer since February  2024, and served as Chief Commercial Officer of Tevogen Bio
beginning in April 2022. Previously, Mr. Khan held several roles at the New Jersey Institute of Technology (&#8220;NJIT&#8221;), a public
research university, and its subsidiaries from 2014 to March 2022. Most recently, Mr. Khan served as Senior Director and then Executive
Director of Operations &amp; Business Planning at BioCentriq, a for-profit cell and gene therapy contract development and manufacturing
organization owned by New Jersey Innovation Institute (&#8220;NJII&#8221;), which was itself a non-profit subsidiary of NJIT, from September
2018 to March 2022. While at BioCentriq, Mr. Khan was part of the leadership team that prepared BioCentriq for its spin-off from NJII.
Mr. Khan held several roles at NJII from 2014 to February 2020, including Director of Business Development, Biopharma Innovation beginning
in 2018, where he worked to facilitate academic, government, and industry collaboration in the biopharmaceutical field. From 2008 to
March 2018, Mr. Khan also acted as Founder and Chief Strategist for Pharmique Health LLC, where he advised corporations on strategic
commercial planning and other matters. Previously, Mr. Khan co-founded Tegelix Therapeutics, a now-defunct pharmaceutical company, and
held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi-Aventis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_003"></span>Item
1A. Risk Factors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our shares of Common Stock or Warrants involves a high degree of risk. Before making an investment, you should carefully consider
the following risks and uncertainties, as well as general economic and business risks, and the other information contained in this Annual
Report. These risk factors are not exhaustive, and investors are encouraged to perform their own investigation with respect to our business,
financial condition and prospects. Our business, financial condition, results of operations, or prospects could be materially and adversely
affected if any of these risks occurs, and as a result, the market price of our Common Stock and Warrants could decline and you could
lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and no products approved for commercial sale and have never generated revenue from product sales. We
have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve
or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty immunotherapy company with a limited operating history. Investment in immunotherapy product development
entails substantial upfront capital expenditures and significant risk that product candidates will fail to prove safe or effective, gain
regulatory approval or become commercially viable. Since our founding in 2020, we have incurred significant net losses. We have funded
our operations to date primarily with proceeds from offerings of convertible notes and preferred stock and have devoted substantially
all of our efforts and financial resources to organizing and staffing our Company, conducting discovery, research, and development activities,
securing intellectual property rights related to our product candidates and ExacTcell technology, raising capital, and the business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that it could be years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses
and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from year to year. We anticipate
that our expenses will increase substantially if, and as, we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            to advance the development of TVGN 489 and our preclinical product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leverage
                                            our ExacTcell technology to advance additional product candidates into preclinical and clinical
                                            development;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            regulatory approvals for any product candidates that successfully complete clinical trials
                                            and potential commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            and expand our current cGMP manufacturing capacity, including to provide drug supply for
                                            future clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            our AI technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            additional clinical, quality control, regulatory, scientific, and administrative personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
                                            our operational, financial, and management systems and increase personnel, including to support
                                            our clinical development, manufacturing, and commercialization efforts and our operations
                                            as a public company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                            expand, and protect our intellectual property portfolio;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            a marketing, sales, distribution, and medical affairs infrastructure to commercialize any
                                            products for which we may obtain marketing approval and commercialize, whether on our own
                                            or jointly with a partner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
                                            or in-license other technologies or engage in strategic partnerships; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
                                            additional legal, accounting, or other expenses in operating our business.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated revenue. To become and remain profitable, we, whether on our own or jointly with a collaborator, must develop
and commercialize products with significant market potential. Our ability to generate revenue from product sales and achieve profitability
depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory
approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for some time,
if ever. Our ability to generate future revenue from product sales depends heavily on our, or our potential future collaborators&#8217;,
success in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing
                                            preclinical studies and clinical trials of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
                                            and obtaining marketing approvals for any product candidates that we or our collaborators
                                            develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
                                            authorization of investigational new drug applications INDs for future product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
                                            and developing new product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            cGMP supply of our product candidates for clinical trials and, if approved, commercial sales;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
                                            and commercializing products for which we obtain marketing approval by establishing a marketing,
                                            sales, distribution, and medical affairs infrastructure or, alternatively, collaborating
                                            with a commercialization partner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
                                            coverage and adequate reimbursement by hospitals and third-party payors, including governmental
                                            authorities, such as Medicare and Medicaid, private insurers, and managed care organizations,
                                            for product candidates, if approved, that we or our collaborators develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            market acceptance of product candidates, if approved, that we develop as viable treatment
                                            options;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
                                            any competing technological and market developments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
                                            favorable terms in any collaboration, licensing, or other arrangements into which we may
                                            enter and performing our obligations under such arrangements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining,
                                            protecting, and expanding our portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">defending
                                            against third-party interference or infringement claims, if any; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
                                            hiring, and retaining qualified personnel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough
to achieve profitability and may need to obtain additional funding to continue operations. If we do achieve profitability, we may not
be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease
the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business,
or continue our operations. A decline in the value of our Company could also cause you to lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are relying in part on an additional $8.0 million of grant funding that we have not yet received to meet our liquidity needs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary sources of funds to meet our near-term liquidity and capital requirements include cash on hand, amounts available under the
Loan Agreement, and an additional $8.0 million of grant funding we expect to receive in the second quarter of 2025 from KRHP LLC, a
New Jersey limited liability company (&#8220;KRHP&#8221;). In January 2025, we received a grant of $2.0 million from KRHP to further
our development of off-the-shelf, genetically unmodified precision T cell therapeutics to treat infectious diseases and cancers.
KRHP also committed to provide an additional $8.0 million of grant funding to the Company to be used towards the Company&#8217;s
ongoing operational expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying in part on the additional grant funding to help meet our liquidity needs. Even if we receive all of such proceeds, we will
still need additional capital to fully implement our business, operating, and development plans. At this time, we have not secured any
additional financing. There can be no assurance that additional capital will be available to us, or that, if available, it will be on
terms satisfactory to us. If we do not obtain additional capital on terms satisfactory to us, or at all, it may cause us to delay, curtail,
scale back or forgo some or all of our research and development or business operations, which could have a material adverse effect on
our business and financial results.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at
all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development,
commercialization efforts or other operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to spend substantial amounts of cash to continue the preclinical and clinical development of our current and future programs.
If we receive marketing approval for any product candidates, including TVGN 489, we will require significant additional amounts of cash
in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and
outcomes of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary
to successfully complete the development of and commercialize any product candidate we develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, timing, results, and costs of researching and developing TVGN 489 and our
                                            other product candidates, including product candidates developed with our ExacTcell technology,
                                            and of conducting preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of, and the costs involved in, obtaining marketing approval for TVGN 489 and any future
                                            product candidates we develop, if clinical trials are successful;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of manufacturing TVGN 489 and any future product candidates for preclinical studies
                                            and clinical trials and in preparation for marketing approval and commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of commercialization activities, including marketing, sales, and distribution costs,
                                            for TVGN 489 and any future product candidates we develop if any of these product candidates
                                            are approved for sale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to establish and maintain strategic collaborations, licensing, or other arrangements
                                            on favorable terms, if at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and
                                            enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing, receipt, and amount of sales of, or royalties on, our future products, if any; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            emergence of competing therapies and other developments in the markets we intend to address.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance
our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances,
and licensing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the terms of the Preferred Stock and our Loan Agreement may negatively impact our ability to raise additional capital through equity
or debt financings, due to the potential substantial dilution to our stockholders that could occur as a result of the conversion of our
convertible Preferred Stock or our issuance of shares under the Loan Agreement and due to the other terms of our Preferred Stock and
the Loan Agreement, or may negatively affect our ability to obtain favorable or acceptable terms in connection with any such financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if we raise additional capital through marketing, sales, and distribution arrangements or other collaborations, strategic alliances,
or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, future revenue
streams, research programs, or technologies or grant licenses on terms that may not be favorable to us. If we raise additional capital
through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of Common Stock or securities
convertible or exchangeable into Common Stock, your ownership interest will be diluted. If we raise additional capital through debt financing,
we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, engaging in acquisition, merger, or collaboration transactions,
selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends, or
other operating restrictions that could adversely impact our ability to conduct our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future debt financing or other financing of securities senior to our Common Stock will likely include financial and other covenants that
will restrict our flexibility. Any failure to comply with these covenants may cause an event of default and acceleration of the obligation
to pay the debt, which would have a material adverse effect on our business, prospects, financial condition, and results of operations
and we could lose our existing sources of funding and impair our ability to secure new sources of funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market
conditions. If we are unable to obtain additional financing on favorable terms when needed, we may be required to delay, limit, reduce,
or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Development, Regulatory Review, and Product Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory landscape that applies to cellular therapy product candidates is rigorous, complex, uncertain, and subject to change. Our
allogeneic T cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny,
delays in clinical development or delays in or our ability to achieve regulatory approval, if at all, and commercialization or payor
coverage and reimbursement of our product candidates, if approved.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our unique approach to T cell therapy. Because these programs, particularly our pipeline of allogeneic
T cell product candidates that are developed from donors, represent a novel approach to immunotherapy for the treatment of virus-infected
cells in order to produce T cell immunity, developing and commercializing our product candidates subjects us to a number of challenges,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            regulatory approval from FDA, which has relatively limited experience with regulating the
                                            development and commercialization of T cell immunotherapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            and deploying consistent and reliable processes for procuring blood from consenting third-party
                                            donors, isolating T cells from the blood of such donors, activating the isolated T cells
                                            against specific antigens, characterizing and storing the resulting activated T cells for
                                            future therapeutic use, selecting and delivering a sufficient supply and breadth of appropriate
                                            human leukocyte antigen-matched (&#8220;HLA-matched&#8221;) cells from among the available
                                            T cell lines, and finally infusing these activated T cells into patients to eliminate virus-infected
                                            cells in the patient and induce anti-disease benefit;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relying
                                            on healthcare provider site availability and accessibility to patients for receipt of T cell
                                            infusions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">utilizing
                                            these product candidates in combination with other therapies currently used to treat patients
                                            in our target population, which may increase the risk of adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">educating
                                            medical personnel regarding the potential side effect profile of each of our product candidates,
                                            particularly those that may be unique to our allogeneic T cell therapy product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">understanding
                                            and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately
                                            affect our ability to manufacture product in a reliable and consistent manner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            processes for the safe administration of these products, including long-term follow-up and
                                            registries, as applicable, for all patients who receive these product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            our product candidates to our specifications and in a timely manner to support our clinical
                                            trials and, if approved, commercialization;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sourcing
                                            clinical and, if approved by FDA, commercial supplies for the materials used to manufacture
                                            and process these product candidates that are free from viruses and other pathogens that
                                            may increase the risk of adverse side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            a manufacturing process and distribution network that can provide a stable supply with a
                                            cost of goods that allows for an attractive return on investment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            sales and marketing capabilities ahead of and after obtaining any regulatory approval to
                                            gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party
                                            payors and government authorities; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            therapies for types of diseases beyond those initially addressed by our current product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
developments in preclinical studies or clinical trials conducted by others in cellular therapy products may cause FDA and other regulatory
bodies to amend the requirements for approval of any product candidates we may develop or limit the use of products utilizing cellular
therapy technologies, either of which could harm our business. In addition, FDA&#8217;s clinical trial requirements and its criteria
for determining the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended
use and market of the potential products. The regulatory approval process for product candidates such as ours could be more expensive
and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we
are developing novel potential treatments for diseases in which in some cases there is relatively little clinical experience with new
endpoints and methodologies, there is heightened risk that FDA or other regulatory bodies may not consider the clinical trial endpoints
to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. Regulatory agencies
administering existing or future regulations or legislation may not allow production and marketing of products utilizing cellular therapy
technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation
could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that the manufacturing processes used in connection with our T cell immunotherapy product candidates will yield a sufficient
supply of satisfactory products that are safe, pure, and potent, scalable, or profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the
willingness of patients to participate in clinical trials, or if approved by FDA, of physicians to subscribe to the novel treatment mechanics.
FDA may ask for specific post-market requirements, such as establishment of a REMS, and additional information informing benefits or
risks of our products may emerge at any time prior to or after regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of any
current or future product candidate. We cannot predict the likelihood, nature or extent of government regulation that may arise from
future legislation or administrative action. If we are slow or unable to adapt to changes in existing requirements or to the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we
may have obtained. In addition, the regulatory landscape applicable to AI is immature and changes to existing regulations or new regulations
could impede our use of AI, which could impair our ability to achieve our goals for our AI initiative and result in an adverse effect
on our business, results of operations and financial condition. For example, FDA&#8217;s Center for Biologics Evaluation and Research,
in coordination with others in FDA, has recently developed a regulatory framework for the safe and responsible use of AI throughout the
biological product lifecycle, which is outlined in a draft guidance document issued by FDA. If and when finalized, this and other guidance
documents, as well as other new FDA regulations and requirements, could present substantial and increasing costs for our compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
an organization, we have limited experience designing and implementing preclinical and clinical trials, which is a complex, expensive,
and time-consuming process and involves uncertain outcomes, and we have never conducted pivotal clinical trials. We may fail to adequately
design a trial, which could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory
approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience designing and implementing preclinical and clinical trials, which is a complex, expensive, and time-consuming
process and involves uncertain outcomes. All of our product candidates are in preclinical or clinical development and their risk of failure
is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if
approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and
in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial
sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials
that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates
are subject to regulation as biological products, we will need to demonstrate that they are safe, pure, and potent for use in their target
indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for
its intended use. We cannot be certain of the timely completion or outcome of our preclinical studies and clinical trials and cannot
predict if FDA will accept our proposed clinical programs or if the outcome of our preclinical studies and clinical trials will ultimately
support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit
INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that such submission
will result in FDA allowing clinical trials to begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we may not successfully or cost-effectively design and implement preclinical and clinical trials that achieve our desired clinical endpoints
efficiently, or at all. A clinical trial that is not well designed may delay or prevent initiation or completion of the trial, can lead
to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on
the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product
successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or
more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could
lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. See &#8220;&#8212;&#160;<i>Risks
Related to Reliance on Manufacturing and Third Parties</i>.&#8221; If these third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize
TVGN 489 any future product candidates we develop, and our business could be materially harmed. We may require more time and incur greater
costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to successfully develop, receive regulatory approval for, and commercialize our product candidates, our business will be
harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our product candidates are still in preclinical and clinical development and, with the exception of TVGN 489, we are early in our
development efforts. FDA permitted our IND for TVGN 489 to proceed in May 2021, and we began enrolling subjects in October 2021. Each
of our programs and product candidates will require additional preclinical and/or clinical development, regulatory approval, obtaining
manufacturing supply, capacity, and expertise, building a commercial organization or successfully outsourcing commercialization, substantial
investment, and significant marketing efforts, before we generate any revenue from product sales. We do not have any products that are
approved for commercial sale, and we may never be able to develop or commercialize marketable products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenue from our product candidates, which could take years to develop, if it ever does, will depend heavily on the
successful development, regulatory approval, and eventual commercialization of our product candidates. The success of our product candidates
or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
                                            and successful completion of preclinical studies and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effective
                                            INDs submitted to FDA that allow commencement of our clinical trials for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficiency
                                            of our financial and other resources to complete the necessary preclinical studies and clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            development of, or making arrangements with third-party manufacturers for, our commercial
                                            manufacturing processes for our clinical trials and any of our product candidates that receive
                                            regulatory approval at an acceptable cost and on a timely basis;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            of timely marketing approvals from FDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
                                            commercial sales of products, if approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of the benefits and use of our products, if approved, by patients, the medical community,
                                            and third-party payors, for their approved indications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of adverse events or other safety issues experienced with our product
                                            candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability, perceived advantages, cost, safety, and efficacy of alternative therapies for
                                            any product candidate, and any indications for such product candidate, that we develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to produce any product candidates we develop on a commercial scale;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining patent, trademark and trade secret protection and regulatory exclusivity
                                            for our product candidates and otherwise protecting our rights in our intellectual property
                                            portfolio;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            compliance with regulatory requirements, including cGMP requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining coverage and adequate reimbursement by third-party payors, including government
                                            payors, for our products, if approved by FDA;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            a continued acceptable safety, tolerability and efficacy profile of the products following
                                            approval; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            and growing an organization of scientists and functional experts who can develop and commercialize
                                            our products and technology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not succeed with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or
an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not
receive marketing approvals for any product candidate we develop, we may not be able to continue our operations. Even if regulatory approvals
are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product
candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of
any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays and disruptions in completing the development of our product candidates that could impair our ability
to successfully commercialize our product candidates and may harm our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience delays in completing planned clinical trials for a variety of reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extensive research and development required because our product candidates are based on new
                                            technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of financial resources to commence and complete the planned trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
                                            agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;)
                                            and clinical trial sites, the terms of which can be subject to extensive negotiation and
                                            may vary significantly among different CROs and trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            or independent IRBs may not authorize us or our investigators to commence a clinical trial
                                            or conduct a clinical trial at a prospective trial site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
                                            suitable patients to participate in a trial or sufficient patients to complete a trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
                                            patients complete a trial or return for post-treatment follow-up;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trial sites deviating from trial protocol or dropping out of a trial, which may require that
                                            we add new clinical trial sites or investigators;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                            the necessary product for use in the clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trials of any product candidate may fail to show safety, purity, or potency, or may produce
                                            negative or inconclusive results, which may cause us to decide, or regulators to require
                                            us, to conduct additional nonclinical trials or clinical trials or which may cause us to
                                            decide to abandon product candidate development programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            of our product candidates could cause undesirable side effects that could result in significant
                                            negative consequences, including the inability to enter clinical development or receive regulatory
                                            approval; and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            from other clinical trial programs for similar indications and clinical trial patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinical trial may also be suspended or terminated by us, the IRB for the institutions in which such trials are being conducted, the
data and safety monitoring board (&#8220;DSMB&#8221;) for such trial, or by FDA due to a number of factors. Those factors could include
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by FDA, resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack
of adequate funding to continue the clinical trial. In addition, FDA may order the temporary or permanent discontinuation of our clinical
trials at any time if it believes that the clinical trials are not being conducted in accordance with applicable regulatory requirements
or that they present an unacceptable safety risk to the patients enrolled in our clinical trials, or that the applicable INDs do not
contain sufficient information to assess the risks to patients in the proposed trials. For example, in November 2020, FDA placed a clinical
hold on our IND for TVGN 489 for the treatment of patients with COVID-19 infection, requested certain information regarding the manufacture
of TVGN 489, and asked us to revise our sterility testing approach so that such testing is performed on the final drug product, as opposed
to testing before harvesting the cells for cryopreservation. In May 2021, FDA found that we sufficiently addressed all of these issues
and lifted the clinical hold, permitting us to initiate our Phase 1 trial, which we completed in January 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience regulatory delays or rejections as a result of many reasons. For example, we believe based on precedential industry examples,
including in areas with high unmet needs or strong early phase clinical trial results, that we may be able to commence pivotal trials
of TVGN 489 on the basis of the results of our completed Phase 1 trial. However, the clinical trial process usually includes three phases,
and our current plan to move TVGN 489 from its recently completed Phase 1 trial directly into pivotal trials may be rejected by FDA or
may be otherwise unfeasible. We may have to conduct additional Phase 1 testing or other Phase 2 trials, or may experience other delays,
prior to escalating TVGN 489 into a pivotal trial. At this stage, we cannot be certain whether we will be permitted to move from a Phase
1 trial directly to pivotal trials until FDA reviews and concurs with or rejects our proposed plans, and FDA may require us to conduct
further trials to generate additional safety and efficacy data. If regulatory inspectors conclude that we or our clinical trial sites
are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations
or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses
to be inadequate, or are dissatisfied with corrective actions, our clinical trials may be temporarily or permanently discontinued, we
or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve
our marketing applications or allow us to manufacture or market our products, we may face civil enforcement actions from FDA, and we
may be criminally prosecuted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects
for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our product development and approval process, and jeopardize our ability to commence
product sales and generate revenue. Significant clinical trial delays could also allow our competitors to bring products to market before
we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. In addition, many of the
factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of
regulatory approval of our product candidates or result in the development of our product candidates stopping early.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA regulatory approval process is lengthy and time-consuming and may lead to significant delays in the clinical development and regulatory
approval of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval from FDA is unpredictable but typically takes many years following the commencement of clinical trials
and depends upon numerous factors, including the substantial discretion of FDA. Any delay in obtaining FDA and/or other necessary regulatory
approvals in the United States for any investigational new drug and failure to receive such approvals would have an adverse effect on
the investigational new drug&#8217;s potential commercial success and on our business, prospects, financial condition, and results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not obtained regulatory approval for any product candidate. We have not previously submitted a BLA to FDA. It is possible that none
of our current or future product candidates will ever obtain regulatory approval from FDA. The novel nature of our product candidates
may create further challenges in obtaining regulatory approval. The regulatory approval pathway for our product candidates may be uncertain,
complex, expensive, and lengthy, and approval may not be obtained. In addition, factors outside our control, such as government shutdowns,
natural disasters, and public health emergencies, could disrupt business at FDA, which could result in delays of reviews, approvals and
communications with FDA related to our clinical trials and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may disagree with the design or implementation of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate to the satisfaction of FDA that a product candidate is safe,
                                            pure, and potent for its proposed indication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of clinical trials may not meet the level of statistical significance required by
                                            FDA for approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits
                                            outweigh its safety risks;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials of our product candidates may not be sufficient to support
                                            the submission of a BLA to FDA to obtain regulatory approval in the United States; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may find deficiencies with or fail to approve our manufacturing processes or facility or
                                            the manufacturing processes or facilities of third-party manufacturers with which we contract
                                            for clinical and commercial supplies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval
to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. Even if
we believe the data collected from current or future clinical trials of our product candidates are promising, such data may not be sufficient
to support approval by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approval, FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient
population, than we request; may grant approval contingent on the performance of costly post-approval clinical trials or other post-marketing
requirements; or may approve a product candidate with labeling that does not include the claims we believe are necessary or desirable
for the successful commercialization of such product candidates. Moreover, if we modify TVGN 489 and our other product candidates so
that they recognize and target new or more prevalent variants of COVID-19 and other viruses, we may have to either file a supplemental
BLA with FDA or receive FDA approval for a comparability protocol or obtain other regulatory approval. These requirements may be costly
and time-consuming and FDA ultimately may not approve of such changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
may also change its policies, promulgate additional regulations, revise existing regulations, or take other actions that may prevent
or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional
requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain
any marketing authorizations we may have obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may never receive regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation for TVGN 489 or any other product candidate,
and receiving this designation may not lead to a faster development or regulatory review or approval process, and will not increase the
likelihood that such product candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek RMAT designation from FDA for TVGN 489 for the treatment of COVID-19, or for our other product candidates. FDA may find that
TVGN 489 or our other product candidates do not meet the criteria for RMAT designation or may otherwise deny our requests for RMAT designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMAT
designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product
candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for
accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or
reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites post-approval, if appropriate.
RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the
submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence; through the collection
of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the
therapy. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), FDA is permitted to require that a post-approval confirmatory
study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated
approval. FDORA also requires sponsors to send updates to FDA on the status of such studies and FDA must promptly post this information
publicly. FDORA also gives FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited
basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to FDA, or if such post-approval studies
fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, FDA is empowered to take action, such as issuing fines, against
companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their
progress. In addition, for products being considered for accelerated approval, FDA generally requires, unless otherwise informed by the
agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval
be submitted to the agency for review during the pre-approval review period. There can be no assurance that FDA would allow any of the
product candidates we may develop to proceed on an accelerated approval pathway, and even if FDA did allow such pathway, there can be
no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted
on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify
clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval
does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RMAT
designation does not change the standards for product approval, and there is no assurance that any such designation or eligibility will
result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation.
Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is highly dependent on our first product candidate, TVGN 489, and we must conduct clinical testing before we can obtain regulatory
approval and begin commercialization of any of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and personnel resources and are placing significant focus on the development of TVGN 489, we may forgo or delay
pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current
and future research and development programs and other future product candidates for specific indications may not yield any commercially
viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future
product candidate, we may relinquish valuable rights to those future product candidates through collaboration, licensing, or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim
and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit, validation, and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim
data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as
patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation,
and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously
published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the
final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects
and may cause the trading price of our Common Stock to fluctuate significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
results of earlier preclinical and clinical trials may not be predictive of future clinical trial results. Initial positive results in
any of our clinical trials may not be indicative of results obtained when the trial is completed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
can occur at any time during the clinical trial process. Preclinical studies and early-stage clinical trials are primarily designed to
test safety, to study pharmacokinetics and pharmacodynamics, and to understand the side effects of product candidates at various doses
and schedules, and the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the
results of larger, later-stage controlled clinical trials. For example, our current or future product candidates may demonstrate different
chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological
systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological
properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical
trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Product
candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical
trials. Our sole clinical trial to date was conducted on a small number of patients in a single academic clinical site for a limited
number of indications. We will have to conduct larger, well-controlled trials in our proposed indications at multiple sites to verify
the results obtained to date and to support any regulatory submissions for further clinical development of our product candidates. Our
assumptions related to our product candidates, such as with respect to lack of toxicity, are based on an early limited clinical trial
and may prove to be incorrect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even
after achieving promising results in earlier, smaller clinical trials, and any such setbacks in our clinical development could have a
material adverse effect on our business and operating results. Moreover, clinical data are often susceptible to varying interpretations
and analyses that may delay, limit, or prevent regulatory approval. We do not know whether any later stage clinical trials of TVGN 489
or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication
for use sufficient to receive regulatory approval or market our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the number of patients in our proof-of-concept clinical trial of TVGN 489 was small, the results from this trial may be less reliable
than results achieved in larger clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
trial design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as
proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes,
such as our proof-of-concept clinical trial of TVGN 489, can be disproportionately influenced by the impact the product had on a few
individuals, which limits the ability to generalize the results across a broader community, thus making the study results less reliable
than studies with a larger number of patients and making it difficult to predict final results from preliminary results. Our proof-of-concept
clinical trial only tested TVGN 489 in the most common HLA type, and while we intend to treat patients with the six most common HLA types
in our next clinical trial of TVGN 489, our results in our proof-of-concept clinical trial may not be predictive of results in other
HLA types. As a result, there may be less certainty that TVGN 489 would achieve a statistically significant effect in any future clinical
trials. If we conduct any future clinical trials of TVGN 489, we may not achieve a statistically significant result. Similarly, if we
conduct a clinical trial of any other product candidate we develop with a small sample size, the results of any such trial may be less
reliable than results achieved in larger clinical trials and may provide less certainty of achieving statistically significant effects
in any future clinical trials. Such results could negatively impact our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA notification, or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or
the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, and jeopardize
our ability to commence sales and generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
approach to the discovery and development of product candidates using our ExacTcell technology is unproven and may not result in marketable
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our business depends in part upon our ability to develop and commercialize cell therapies based on our proprietary ExacTcell
technology. We have only conducted one Phase 1 trial based on a product developed using ExacTcell. Our approach to the development of
cell therapies using ExacTcell is novel. We may not continue to have access to effective HLA-typing diagnostics and may have difficulties
in obtaining or manufacturing significant quantities and breadth of single HLA-restricted cell lines to use in clinical trials or sufficient
to cover desired patient populations. We cannot assure the product candidates we develop with ExacTcell will be found to be safe and
effective in treating any disease so as to achieve marketing approval. If we uncover any previously unknown risks related to ExacTcell,
or if we experience unanticipated problems or delays in developing our ExacTcell product candidates, we may be unable to achieve our
strategy of building a broad pipeline of cell therapy product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse
or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory
approval and commercialization, increase our costs, or necessitate the abandonment or limitation of the development of some of our product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive
preclinical studies and clinical trials that our product candidates are safe, pure, and effective for use in each target indication,
and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy
of the product candidate studied for the target indication. The use of our current or future product candidates could be associated with
side effects or adverse events, which could vary in severity from minor reactions to death and in frequency from infrequent to prevalent.
In addition, if one or more of our product candidates or our T cell technology proves to be unsafe it would also materially harm our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side
effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse
events were not caused by the drug or administration process or related procedures, FDA could order us to cease further development of,
or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious
adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete
the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our
product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from
any of these product candidates may be delayed or eliminated. In addition, these side effects may not be appropriately recognized or
managed by the treating medical staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our current and future product candidates have undergone and will undergo extensive safety testing and, where applicable, under such
conditions discussed with FDA, not all adverse effects of drugs can be predicted or anticipated. Immunotherapy and its method of action
of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials
or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates
have been approved by FDA and the approved product has been marketed, resulting in the exposure of additional patients. If our product
candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their
development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe,
or more acceptable from a risk-benefit perspective. So far, we have not demonstrated that TVGN 489 or any other product candidate is
safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates
fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue
and our business will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct
additional preclinical studies regarding the safety and efficacy of our product candidates that we have not planned or anticipated. Such
findings could further result in FDA failing to provide marketing authorization for our product candidates or limiting the scope of the
approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found
to cause side effects that prevented further development of the product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such
products, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may withdraw approvals of such product;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            may require additional warnings on the labels such as a &#8220;black box&#8221; warning or
                                            a contraindication;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to create a medication guide outlining the risks of such side effects for
                                            distribution to patients or other requirements subject to a REMS;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            could be sued and held liable for harm caused to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to achieve or maintain third-party payor coverage and adequate reimbursement;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to recall a product or change the way such product is administered to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                            restrictions may be imposed on the marketing of the particular product or the manufacturing
                                            processes for the product or any component thereof; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reputation and physician or patient acceptance of our products may suffer.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of FDA in a timely
manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to
enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We
may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends
on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patient eligibility criteria defined in the protocol;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            nature and size of the patient population required for analysis of the trial&#8217;s primary
                                            endpoints and the process for identifying patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number and location of participating clinical sites or patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            design of the trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
                                            and patients&#8217; perceptions as to the potential advantages and risks of the product candidate
                                            being studied in relation to other available therapies, including any new products that may
                                            be approved for the indications we are investigating;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of competing commercially available therapies and other competing drug candidates&#8217;
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain patient informed consents for participation in our clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that patients enrolled in clinical trials will drop out of the trials before completion;
                                            and/or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">factors
                                            outside of our control, including as a result of business interruptions resulting from natural
                                            disasters and public health emergencies, such as the coronavirus.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons. A decrease in cases may reduce
the number of eligible candidates for trials testing COVID-19 therapeutics, such as TVGN 489. Additionally, as time passes, treating
COVID-19 is becoming a less critical issue in the eyes of the public, further limiting the potential patient population for COVID-19
therapeutics. Moreover, TVGN 489 may represent a departure from more commonly used methods for COVID-19 treatment, and potential patients
and their doctors may be inclined to use more conventional therapies for the treatment of COVID-19 rather than enroll in any future clinical
trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the study until its conclusion. In addition, our clinical trials may compete with existing therapies
and other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition
may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead
opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee that our clinical trials will progress
as planned or as scheduled. Delays from difficulties in patient enrollment in a clinical trial may result in increased costs or affect
the timing, outcome, or completion of the trial, which could delay or prevent our receipt of regulatory approval of the applicable product
candidate or to abandon the trial altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to suspend, repeat, or terminate our clinical trials if they are not conducted in accordance with regulatory requirements,
the results are negative or inconclusive, or the trials are not well designed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted in accordance with FDA&#8217;s GCP requirements. Clinical trials are subject to oversight by FDA and IRBs or
ethical committees at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product
candidates manufactured in accordance with applicable cGMP requirements. Clinical trials may be suspended by FDA, us, a DSMB, or by an
IRB with respect to a particular clinical trial site, for various reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the conduct of the clinical trials, including failure to conduct the clinical trial in
                                            accordance with regulatory requirements or study protocols;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the clinical trial operations or trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
                                            adverse side effects or the emergence of undue risks to study subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deficiencies
                                            in the trial design necessary to demonstrate efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            product candidate may not appear to offer benefits over current therapies; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            quality or stability of the product candidate may fall below acceptable standards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such suspension or delay may result in us failing to obtain regulatory approval for our product candidates, which would materially harm
our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may
be delayed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing, and other
product development goals, which we may refer to as milestones. These milestones may include the commencement or completion of preclinical
studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may announce the
expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual
timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, including
with respect to challenges related to enrollment, manufacturing, and our reliance on third parties to conduct, supervise or monitor some
or all aspects of our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at FDA and other government agencies, such as those that may be caused by funding shortages, could hinder their ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized
in a timely manner or at all, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
statutory, regulatory, and policy changes, FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees,
and other events that may otherwise affect FDA&#8217;s ability to perform routine functions. Average review times at the agency have
fluctuated in recent years as a result. Disruptions at FDA and other agencies may also increase the time necessary to meet with and provide
feedback to entities developing drug products, review and/or approve our submissions, conduct inspections, issue regulatory guidance,
or otherwise authorize our actions requiring regulatory approval, which would adversely affect our business. In addition, government
funding of FDA and other government agencies on which our operations may rely, including those that fund research and development activities,
is subject to the political process, which is inherently fluid and unpredictable. For example, the Trump Administration recently established
the Department of Government Efficiency, which implemented a federal government hiring freeze and large scale layoffs of current federal
employees, and also announced additional efforts to reduce federal government employee headcount and the size of the federal government.
The Trump Administration has also, for example, rescinded a previous executive order tasking the Center for Medicare and Medicaid Innovation
to consider new payment and healthcare models to limit drug spending and eliminated a previous executive order that directed HHS to establish
an artificial intelligence task force and develop a strategic plan.&#160;It is unclear how these executive actions or other potential
actions by the Trump Administration will impact the regulatory authorities that oversee our business. These budgetary pressures may reduce
FDA&#8217;s ability to perform its responsibilities. If a significant reduction in FDA&#8217;s workforce occurs, FDA&#8217;s budget is
significantly reduced, or there are other disruptions at FDA and other agencies, more time may be necessary for biological products,
or biologics, or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which could increase
our costs and would adversely affect our business. In addition, if a prolonged government shutdown occurs, it could significantly impact
the ability of FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
For example, over the last several years, the United States government has shut down several times and certain regulatory agencies, such
as FDA, have had to furlough critical FDA employees and stop critical activities. Additionally, Congress may introduce and ultimately
pass healthcare related legislation that could impact the drug approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may develop future product candidates in combination with other therapies, which exposes us to additional regulatory risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may develop future product candidates in combination with one or more currently approved therapies. These combinations may, among other
things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other
combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those
clinical trials or obtain marketing approval for the combination therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with
other existing therapies, we would continue to be subject to the risk that FDA or a comparable foreign regulatory authorities could revoke
approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing, or supply issues could
arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also evaluate future product candidates in combination with one or more other therapies that have not yet been approved for marketing
by FDA or comparable foreign regulatory authorities. We will not be able to market and sell TVGN 489 or any product candidate we develop
in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing,
or supply issues arise with, the biologics we choose to evaluate in combination with any product candidate we develop, we may be unable
to obtain approval of or market any such product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
use artificial intelligence in our business may require us to spend material resources and presents risks that could adversely impact
our business, including by posing security and other risks to our confidential and/or proprietary information.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use AI in and integrate AI into our business processes, and this innovation presents risks and challenges that could affect
its adoption, and therefore our business. If we enable or offer solutions that draw controversy due to perceived or actual negative societal
impact, we may experience brand or reputational harm, competitive harm or legal liability. The use of certain AI technology can give
rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement.
Additionally, we expect to see increasing government and supranational regulation related to AI use and ethics, which may also significantly
increase the burden and cost of research, development and compliance in this area. For example, the new Artificial Intelligence Act (the
&#8220;AI Act&#8221;) in the EU imposes significant obligations on providers and deployers of high-risk AI systems and encourages such
providers and deployers to account for specified ethical principles in the development and use of these systems. If we develop or use
AI systems that are governed by the AI Act or similar regulations, it may necessitate ensuring higher standards of data quality, transparency,
and human oversight, as well as adhering to specific and potentially burdensome and costly ethical, accountability, and administrative
requirements. The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our
products and services to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible
manner and to minimize any real or perceived unintended harmful impacts. Our vendors may also incorporate AI tools into their offerings,
and may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security.
Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities
involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could
damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and
adversely impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Business Development and Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients,
healthcare payors and the medical community, including hospitals and outpatient clinics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not
gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts,
including hospitals and outpatient clinics. Market acceptance of any of our product candidates for which we receive approval depends
on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            efficacy and safety of the product candidates as demonstrated in clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            clinical indications and patient populations for which the product candidate is approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            by physicians and patients of the drug as a safe and effective treatment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            administrative and logistical burden of treating patients, including the availability and
                                            accessibility of healthcare provider sites for administering infusions to patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            adoption of novel cellular therapies by physicians, hospitals, and third-party payors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential and perceived advantages of product candidates over alternative treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            safety of product candidates seen in a broader patient group, including its use outside the
                                            approved indications should physicians choose to prescribe for such uses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            restrictions on use together with other medications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
                                            product labeling or package insert requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of market introduction of our products as well as competitive products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development of manufacturing and distribution processes for our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost of treatment in relation to alternative treatments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of coverage and adequate reimbursement from, and our ability to negotiate pricing
                                            with, third-party payors, providers, and government authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience and ease of administration; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of our sales and marketing efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect the product candidates we develop will be regulated biologics and therefore they may be subject to biosimilar competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) created an abbreviated pathway for the approval of for biological
product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. Under the BPCIA, an application
for a biosimilar product cannot be approved by FDA until 12 years after the reference product was approved under a BLA. The law is complex
and is still being interpreted and implemented by FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
Although it is uncertain when processes intended to implement BPCIA may be fully adopted by FDA, any of these processes could have a
material adverse effect on the future commercial prospects for our biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should
qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened, potentially creating
the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted
for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not
yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Additionally, the increased likelihood
of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to these risks, and uncertainties
regarding patent protection, if one of our product candidates are approved for marketing, it is not possible to predict the length of
market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current
forms of regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues
from product sales of that product and thus our financial results and condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the approval of a biologic product that is a biosimilar to one of our products could have a material adverse impact on our
business as it may be significantly less costly to bring to market and may be priced significantly lower than our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
incidence and prevalence of the target patient population for TVGN 489 are based on estimates and third-party sources. If the market
opportunity for TVGN 489 or our other product candidates is smaller than we estimate or if any approval that we obtain is based on a
narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
we make estimates regarding the incidence and prevalence of target patient populations based on various third-party sources and internally
generated analysis. These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity
for TVGN 489 will depend on, among other things, acceptance of TVGN 489 by the medical community, patient access, drug pricing and reimbursement,
and the number of eligible patients with COVID-19, which may decrease. The number of patients in the addressable markets may turn out
to be lower than expected, patients may not be otherwise amenable to treatment with TVGN 489, or new patients may become increasingly
difficult to identify or gain access to or may not have the requisite HLA-typing to receive the drug, all of which may significantly
harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our product candidates receive regulatory approval, we will still face extensive ongoing regulatory requirements and continued regulatory
review, which may result in significant additional expense, and our products may still face future development and regulatory difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for a product candidate, it would be subject to ongoing requirements by FDA governing the manufacture,
materials and facilities, qualification testing, quality control, further development, labeling, packaging, storage, distribution, post-approval
clinical data, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety
and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports,
establishment registration and product listing, as well as continued compliance by us and/or our contract manufacturing organizations
(&#8220;CMOs&#8221;) and CROs for any post-approval clinical trials that we conduct. The safety profile of any product will continue
to be closely monitored by FDA after approval. If FDA become aware of new safety information after approval of any of our product candidates,
they may require labeling changes or establishment of a REMS, impose significant restrictions on a product&#8217;s indicated uses or
marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of cell therapies and their facilities are subject to initial and continual review and periodic inspections by
FDA for compliance with cGMP, GCP, GLP, GTP and other regulations. For certain commercial prescription biological products, manufacturers,
and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable
systems for product tracking and tracing and for notifying FDA of counterfeit, diverted, stolen, and intentionally adulterated products
or other products that are otherwise unfit for distribution in the United States. If we or a regulatory agency discover previously unknown
problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product
is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall
or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates, or the manufacturing facilities
for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
                                            warning letters or untitled letters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandate
                                            modifications to promotional materials or require us to provide corrective information to
                                            healthcare practitioners, or require other restrictions on the labeling or marketing of such
                                            products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to enter into a consent decree, which can include imposition of various fines, reimbursements
                                            for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend,
                                            withdraw, or modify regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                            or modify any ongoing clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
                                            to approve pending applications or supplements to applications filed by us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
                                            or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
                                            or detain products, refuse to permit the import or export of products, or require us to initiate
                                            a product recall.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of the foregoing may inhibit our ability to successfully commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by FDA, the FTC, the Department
of Justice, the Office of Inspector General of the Department of Health and Human Services, state attorneys general, members of the U.S.
Congress and the public. Violations, including actual or alleged promotion of our products for unapproved or off-label uses, are subject
to enforcement letters, inquiries and investigations, and potential civil and criminal sanctions by FDA. Any actual or alleged failure
to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective information to healthcare
practitioners, injunctions, or civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product
candidates, we may be unable to generate any revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are at an early stage of establishing an organization that will be responsible for the sale, marketing and distribution of cell therapy
products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to
market any products that may be approved by FDA, we must build our sales, marketing, managerial and other non-technical capabilities
or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate
training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of these products. We may be competing with many companies that currently have extensive and well-funded sales and marketing operations.
Without a sufficiently scaled, appropriately timed, and trained internal commercial organization or the support of a third party to perform
sales and marketing functions, we may be unable to compete successfully against these more established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes
in these laws could materially and adversely harm our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to federal and state data privacy and security laws and regulations, state data breach notification laws, state health information
and/or genetic privacy laws, and federal and state consumer protection and consumer privacy laws (such as Section 5 of the FTC Act, the
FTC Health Breach Notification Rule, and the CCPA)). Laws and expectations relating to privacy continue to evolve. Changes in these laws
may limit our data access, use, and disclosure, and may require increased expenditures. In addition, data protection, privacy and similar
laws protect more than patient information and, although they vary by jurisdiction, these laws can extend to employee information, business
contact information, provider information, and other information relating to identifiable individuals. For example, the CCPA requires
covered businesses to, among other things, provide disclosures to California consumers regarding the collection, use and disclosure of
such consumers&#8217; personal information and afford such consumers new rights with respect to their personal information, including
the right to opt out of certain sales of personal information. Comprehensive and sensitive data laws in a number of states have gone
into or will go into effect during the next few years. We believe that further increased regulation in additional jurisdictions is likely
in the area of data privacy. Any of the foregoing may have a material adverse effect on our ability to provide services to patients and,
in turn, our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with these laws may result in, among other things, civil and criminal liability, negative publicity, damage to our reputation,
and liability under contractual provisions. In addition, compliance with such laws may require increased costs to us or may dictate that
wet not offer certain types of services in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increasing
use of AI could give rise to liability, breaches of data security and privacy laws, or reputational damage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AI-based
solutions, including generative AI, are increasingly being used in the biopharmaceutical industry. There is a global trend towards more
regulation (e.g., the AI Act and AI laws passed in certain states) to ensure the ethical use, privacy, and security of AI and the data
that it processes. AI solutions that we may employ and rely upon may lead to the impermissible use or disclosure of confidential information
(including personal data and proprietary information) in contravention of our internal policies, data protection laws, other applicable
laws, or contractual requirements. The misuse of AI solutions may give rise to liability, lead to the loss of trade secrets or other
intellectual property, result in reputational harm, or lead to outcomes with unintended biases or other consequences. The misuse of AI
solutions could also result in unauthorized access and use of personal data of our employees, clinical trial participants, collaborators,
or other third parties. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial
condition and could adversely affect the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those used by our contractors or consultants, may fail, or suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and the systems of our contractors and consultants are vulnerable to damage from cyber-attacks and unauthorized
access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations.
For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Despite our efforts and given the ever-changing threat landscape,
the possibility of these events occurring cannot be eliminated entirely and there can be no assurance that any measures we take will
prevent cyber-attacks or unauthorized access that could adversely affect our business. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult
for us to sell our product candidates, if approved, profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors
including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others.
Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance. Third-party
payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend
upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is a covered
benefit under its health plan, safe, effective, and medically necessary, appropriate for the specific patient, cost-effective, and neither
experimental nor investigational.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement of a product from a government or other third-party payor is a time consuming and costly process that could
require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we
obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for
use in their facility or third-party payors may require co-payments that patients find unacceptably high. Separate reimbursement for
the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing
the treatment or procedure in which our product is used. Further, at least annually, CMS revises the reimbursement systems used to reimburse
health care providers, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions
of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs
may negatively impact payments from private third-party payers and reduce the willingness of physicians and providers to use our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage
for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
Because our product candidate may have a higher cost of goods than conventional therapies, and may require long-term follow-up evaluations,
the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant
uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and reimbursement for our product candidate. Moreover, payment methodologies
may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures
are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. We expect
to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare,
the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in
the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from
list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate
and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some
cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts
or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. Increased efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate
payment for our product candidate. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be
subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics
is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time
after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that
compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU member states allow companies
to fix their own prices for medicines but monitor and control company profits. In addition, in some countries, cross-border imports from
low-priced markets exert a commercial pressure on pricing within a country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other
third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue.
Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status
is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates
may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory
changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been heightened governmental scrutiny in the United States of pharmaceutical and biologics pricing practices in light of the
rising cost of prescription drugs and biologics. This scrutiny has resulted in various Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates
or additional pricing pressures. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors, which may adversely affect our future profitability. Individual states in the United States have also
become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure
and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Additionally, some individual
states have begun establishing Prescription Drug Affordability Boards to review high-cost drugs and, in some cases, set upper payment
limits. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial
condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly
using bidding procedures to determine what drug products and which suppliers will be included in their prescription drug and other healthcare
programs. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services
to contain or reduce costs of healthcare and/or impose price controls may adversely affect our business, financial condition, results
of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the
federal False Claims Act, and federal and state transparency laws and regulations. These laws may impact, among other things, our proposed
sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government
and the states in which we conduct our business. These laws, described in further detail in &#8220;<i>Regulatory Environment &#8211;
Healthcare Regulation &#8211; Other Healthcare Laws and Compliance Requirements</i>,&#8221; include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly
                                            and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly,
                                            to induce, or in return for, the purchase or recommendation of an item or service reimbursable
                                            under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal civil False Claims Act, which prohibits, among other things, individuals or entities
                                            from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment
                                            of government funds, or knowingly making, using or causing to be made or used, a false record
                                            or statement material to an obligation to pay money to the government or knowingly concealing
                                            or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money
                                            to the federal government;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            which created new federal criminal statutes that prohibit executing a scheme to defraud any
                                            healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act, and
                                            its implementing regulations, which imposes specified requirements relating to the privacy,
                                            security, and transmission of individually identifiable health information;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            U.S. federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices,
                                            biologics, and medical supplies for which payment is available under Medicare, Medicaid or
                                            the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually
                                            to the CMS information related to direct or indirect payments and other transfers of value
                                            to physicians and teaching hospitals (and certain other practitioners), as well as ownership
                                            and investment interests held in the Company by physicians and their immediate family members;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
                                            law equivalents of each of the above federal laws, such as anti-kickback and false claims
                                            laws that may apply to items or services reimbursed by any third-party payor, including governmental
                                            and private payors, laws that require manufacturers to comply with the pharmaceutical industry&#8217;s
                                            voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
                                            government, or otherwise restrict payments that may be made to healthcare providers and other
                                            potential referral sources, state laws that require drug manufacturers to report information
                                            related to payments and other transfers of value to physicians and other healthcare providers
                                            or marketing expenditures, and state laws governing the privacy and security of health information
                                            in specified circumstances, many of which differ from each other in significant ways and
                                            may not have the same scope or application, thus complicating compliance efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our collaborations with third parties, and our business generally, will comply with applicable United States and healthcare
laws and regulations will involve substantial costs. Governmental authorities could conclude that our business practices may not comply
with statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to violate any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs,
contractual damages, reputational harm, disgorgement or curtailment or restricting of our operations, any of which could substantially
disrupt our operations and diminish our profits and future earnings. If any of the physicians or other providers or entities with whom
we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs. The risk of our being found in violation of these laws is
increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions
are open to a variety of interpretations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers, physicians including clinical investigators, CROs and third-party payors are subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, transparency laws,
government price reporting and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial
partners, vendors, or other agents violate these laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
laws may impact, among other things, our clinical research programs as well as our proposed and future sales, marketing, and education
programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations
designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We
may also be subject to federal, state, and foreign laws governing the privacy and security of identifiable patient information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform.
Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare
providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. Because
of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that
some of our business activities, or our arrangements with physicians, could be subject to challenge under one or more of such laws. If
we or our employees, independent contractors, consultants, commercial partners, and vendors violate these laws, we may be subject to
investigations, enforcement actions and/or significant penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and
prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure
that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental
and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or
case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against
us, and we are not successful in defending themselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from
participation in federal healthcare programs, reputational harm, diminished profits and future earnings, additional reporting requirements
and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance
with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results
of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely
subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable
materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We cannot eliminate the
risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials,
we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs
associated with civil or criminal fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Manufacturing and Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
manufacture of cell therapies is subject to a multitude of manufacturing risks, any of which could substantially increase our costs and
limit supply of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing cell therapies is complex, highly regulated, subject to multiple risks, and requires significant expertise.
Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial
production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, shortages
of qualified personnel, and compliance with strictly enforced regulations. Cell therapy manufacturing facilities also require appropriate
commissioning and validation activities to demonstrate that they operate as designed. There are limited numbers of CMOs that operate
under cGMP regulations and that are capable of manufacturing cell therapies, and transferring manufacturing processes and know-how is
complex and may require utilization of new or different processes to meet the specific requirements of a given facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
therapy manufacturing is susceptible to product loss due to contamination, equipment failure, and vendor or operator error. The facilities
in which our product candidates will be made could also be adversely affected by pandemics, natural disasters, equipment failures, labor
shortages, power failures, supply chain problems, changes in laws and regulations, and numerous other factors. Even minor deviations
from normal manufacturing and distribution for any of our product candidates could result in reduced production yields, impact to product
quality, and other supply disruptions. Manufacturing cell therapies is susceptible to risks associated with the need to maintain aseptic
conditions throughout the manufacturing process. Contamination with pathogens or ingress of microbiological material may result in unusable
product and could also delay the manufacture of product candidates, resulting in delays in development. If contamination is discovered,
the facilities in which our product candidates are made may need to be closed for an extended period of time for investigation and remediation.
Because our cell therapy product candidates are manufactured from the cells of third-party donors, the manufacturing process is also
susceptible to insufficient quantity or inadequate quality of third-party donor material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
is also subject to FDA and comparable foreign regulation. For example, FDA will not approve a cellular product if the manufacturer is
not in compliance with cGMPs and GTPs, to the extent applicable. If we are unable to reliably produce products in accordance with specifications
acceptable to authorities, we may not obtain or maintain the approvals we need to commercialize our product candidates. Failure to comply
with manufacturing regulations may lead to regulatory enforcement actions against our third-party manufacturers or us that result in
fines and civil and criminal penalties, imprisonment, suspension, delay, or restriction of production, injunctions, delay or denial of
product approval, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications
warning the public about safety issues with the cell therapies, refusal to permit import or export, product seizure, detention, or recall,
lawsuits under the civil False Claims Act, or consent decrees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
efforts to establish manufacturing capabilities, either on our own or through a contract relationship, will involve significant time
and expense and may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing experience as an organization and with our contractors is limited. We relied on a Clinical Trial Services and Materials
Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our Phase 1 proof-of-concept trial. However, we will need
to establish manufacturing capabilities, either on our own or through a contract relationship, in order to meet our projected supply
needs for clinical and commercial materials to support our activities through regulatory approval and commercial manufacturing of our
product candidates, if approved. Our efforts to develop manufacturing capability are currently focused on acquiring existing manufacturing
facilities or constructing one or more new manufacturing facilities, including through collaboration with a potential facility development
partner. Securing a manufacturing facility will involve considerable time and expense, and may not be successful. In addition, we cannot
ensure that we can successfully manufacture our products in compliance with cGMP, GTP, and any other applicable laws, regulations, and
standards in sufficient quantities for clinical trials or for commercial sale. We have no prior experience in establishing a manufacturing
facility and we may encounter challenges given the complexity of manufacturing cell therapies. We must also compete for the small number
of individuals with expertise in cell therapy manufacturing. Even if we are able to establish manufacturing operations, given the complexities
of manufacturing cell therapy products, there is no assurance that we will be able to successfully produce sufficient amounts, or sufficient
quality, of TVGN 489 in order to move forward with our clinical development plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or
their inability to supply us with adequate materials could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence
on these suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited
control over pricing, availability, and quality and delivery schedules. We also face competition for supplies from other cell therapy
companies. Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable
terms or in a timely manner. Our negotiation leverage is limited, and we are likely to get lower priority than our competitors that are
larger than we are. In addition, the biotechnology market has recently experienced supply chain disruptions. We cannot be certain that
our suppliers will continue to provide us with the quantities of the raw materials that we require or satisfy our anticipated specifications
and quality requirements whether due to our size or otherwise. Any supply interruption in limited or sole sourced raw materials could
materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified.
We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Significant
changes in global economic conditions, and an increase in the costs of goods and services, including as a result of tariffs, could negatively
impact testing volumes, the demand for biopharma laboratory services, cash collections, profitability, and the availability and cost
of credit. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product
candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the third parties we rely on to help conduct our preclinical studies and clinical trials do not successfully carry out their contractual
duties, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize
TVGN 489 and any future product candidates we develop, and our business could be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
outsource some of the conduct and management of our clinical trials to third parties. Agreements with clinical investigators and medical
institutions for clinical testing and with other third parties for data management services and clinical trial management services place
substantial responsibilities on these parties that, if unmet, could result in delays in, or termination of, our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on universities, medical institutions, clinical investigators, contract laboratories and other third parties to conduct or help
us conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While
we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their
actual performance. The third parties with whom we contract play a significant role in the conduct of these studies and trials and the
subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts
with such third parties, we have limited ability to control the amount or timing of resources that they devote to our current or future
product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical
trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its
investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory
responsibilities. If any of our clinical trial sites fail to comply with GCP, we may be unable to use the data gathered at those sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Some
of our agreements may also be terminated by these third parties under certain other circumstances. If the third parties conducting our
preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant
business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced,
or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and GCP,
or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly,
or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated, or repeated. As a result,
we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial
results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may depend on third-party collaborators for the development and commercialization of certain of our current and future product candidates.
If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may form or seek strategic alliances, joint ventures, or collaborations, or enter into licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we
develop. Potential future collaborations involving our product candidates may pose the following risks to us:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may have significant discretion in determining the efforts and resources that they will apply
                                            to these collaborations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            could independently develop, or develop with third parties, products that compete directly
                                            or indirectly with our products or product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not properly enforce, maintain, or defend our intellectual property rights or may use
                                            our proprietary information in a way that gives rise to actual or threatened litigation or
                                            that could jeopardize or invalidate our intellectual property or proprietary information,
                                            exposing us to potential litigation or other intellectual property proceedings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may infringe the intellectual property rights of third parties, which may expose us to litigation
                                            and potential liability;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            may arise between a collaborator and us that cause the delay or termination of the research,
                                            development, or commercialization of the product candidate, or that result in costly litigation
                                            or arbitration that diverts management attention and resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            with marketing and distribution rights to one or more of our product candidates that achieve
                                            regulatory approval may not commit sufficient resources to the marketing and distribution
                                            of such products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            a present or future collaborator were to be involved in a business combination, the continued
                                            pursuit and emphasis on our product development or commercialization program under such collaboration
                                            could be delayed, diminished, or terminated; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
                                            agreements may restrict our right to independently pursue new product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into collaboration agreements and strategic partnerships or license our intellectual property, products, or businesses, we may
not be able to realize the expected benefit of such transactions if we are unable to successfully integrate them with our existing operations,
which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction
or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above and any delays
in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development
and commercialization of our product candidates, which would harm our business prospects, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event a present or future collaborator terminates their agreement with us, we would be prevented from receiving the benefits of any
such agreement, which could have a materially adverse effect on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have to alter our development and commercialization plans if we seek to establish collaborations and are not able to establish them
on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advancement of our product candidates and development programs and the potential commercialization of our current and future product
candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide
to collaborate with third parties with respect to development and potential commercialization. Any of these relationships may require
us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing
stockholders, or disrupt our management and business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether
we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s
resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of
factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval
by FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs
and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence
of uncertainty with respect to our ownership of technology and market conditions generally. The collaborator may also consider alternative
product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could
be more attractive than the one with us for our product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators.
Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been
a significant number of business combinations among large pharmaceutical and biotechnology companies that have resulted in a reduced
number of potential future collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have
to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program
or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which
may not be available to us on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain adequate patent protection for our product candidates or ExacTcell, our competitors could develop
and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our product candidates. We have sought, and intend to seek, to protect our proprietary position by filing patent applications
in the United States and abroad related to our product candidates and technology that are important to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial
value of our patent rights are highly uncertain. Our issued patents may not, and our pending and future patent applications may not result
in patents being issued that adequately protect our technology or product candidates or prevent others from commercializing similar or
alternative competitive technologies and product candidates. There is no assurance that all potentially relevant prior art relating to
our patents and patent applications is known to us or has been found. We may be unaware of prior art that could be used to invalidate
an issued patent or prevent a pending patent application from issuing as a patent. Because patent applications in the United States and
most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we
were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have
filed such patent applications, we may challenge their ownership, for example in a derivation proceeding before the U.S. Patent and Trademark
Office (the &#8220;USPTO&#8221;) to determine who has the right to the claimed subject matter in the applications. Similarly, if our
patent applications are challenged in a derivation proceeding, the USPTO may hold that a third party is entitled to certain patent ownership
rights instead of us. We may then be forced to seek a license from the third party that may not be available on commercially favorable
terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or
license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail
to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the
USPTO and various government patent agencies outside of the United States over the lifetime of our patents or applications and any patent
rights we own or may own in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural,
documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can
be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance
could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In
addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our patents in all countries
outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and,
further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as
that in the United States. These products may compete with our products and our patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition,
results of operations and prospects may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding
the prosecution of patent applications and the enforcement or defense of issued patents. After March 2013, under the Leahy-Smith America
Invents Act (the &#8220;America Invents Act&#8221;), the United States transitioned to a first inventor to file system in which, assuming
that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on
an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also included
a number of significant changes that affected the way patent applications are prosecuted and also may affect patent litigation. These
include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity
or ownership of a patent by USPTO administered post-grant proceedings, including post-grant review,&#160;<i>inter partes</i>&#160;review
and derivation proceedings. Additional changes in patent law could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our
business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events
has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material
adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property rights, or we may be required to defend against claims of infringement. Countering infringement
or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to
be negative, it could have a substantial adverse effect on the price of our Common Stock. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future marketing, sales, or distribution
activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater
financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop
the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce
our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages
or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop
or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issued
patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect
our trade secrets in court.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we initiate legal proceedings against a third party to enforce any patent that is issued covering one of our product candidates, the
defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the
United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, or
non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type
double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or
the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding
of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third
parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.
Such mechanisms include re-examination, post grant review,&#160;<i>inter partes</i>&#160;review and equivalent proceedings in foreign
jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they
no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We
cannot be certain that there is no invalidating prior art of which the patent examiner and we were unaware during prosecution. If a defendant
were to prevail on a legal assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection
on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents, including portions of our ExacTcell technology. However, trade secrets can be difficult to protect, and some courts
inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties.
We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods,
product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect
to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our product candidates and technology, including post grant review and&#160;<i>inter partes</i>&#160;review
before the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach
commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based
on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose
to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are
without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which
could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted
third-party patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license
from such third party to continue developing, manufacturing, and marketing our product candidates and technology. However, we may not
be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could
require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing,
and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including
treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right.
A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of
our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or
trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Others
may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have
a significant adverse effect on our prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we
cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example,
a third party may claim an ownership interest in one or more of our patents or other proprietary or intellectual property rights. A third
party could bring legal actions against us to seek monetary damages or enjoin clinical testing, manufacturing, or marketing of the affected
product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause
a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential
liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or
product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure
you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a
product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other
intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially
true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably
disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter
into confidentiality agreements with our employees, consultants, collaborators, and others upon the commencement of their relationships
with us. These agreements require that all confidential information developed by the individual or made known to the individual by us
during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements
with employees and consultants also provide that any inventions conceived by the individual in the course of rendering services to us
shall be our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have
or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we have these agreements may
not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third
parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained,
may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees,
consultants, or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and
those third parties as to the rights in related inventions. We also seek to preserve the integrity and confidentiality of our trade secrets
by other means, including maintaining physical security of our premises and physical and electronic security of our information technology
systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets
would impair our competitive position and may materially harm our business, financial condition, and results of operations. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade
secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop
our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent
discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate
a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees
to attempt to independently reverse engineer or otherwise duplicate our cell therapy technologies to replicate our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets
of their current or former employers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical
companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents
and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates,
are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending
claims of misappropriation and similar claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
registered trademarks or trade names may be challenged, circumvented, or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential
partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name
or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered
or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks
and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or
protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective
and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may be able to make products that are similar to our product candidates but that are not
                                            covered by the claims of the patents that we own or may own in the future;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
                                            or any partners or collaborators, might not have been the first to make the inventions covered
                                            by the issued patents or pending patent applications that we own or may own in the future;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
                                            or any partners or collaborators, might not have been the first to file patent applications
                                            covering certain of our or their inventions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies
                                            without infringing our owned or licensed intellectual property rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            is possible that our pending patent applications or those that we may own in the future will
                                            not lead to issued patents;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
                                            patents that we hold rights to may be held invalid or unenforceable, including as a result
                                            of legal challenges by our competitors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            competitors might conduct research and development activities in countries where we do not
                                            have patent rights and then use the information learned from such activities to develop competitive
                                            products for sale in our major commercial markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not develop additional proprietary technologies that are patentable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patents of others may have an adverse effect on our business; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may choose not to file a patent for certain trade secrets or know-how, and a third party
                                            may subsequently file a patent covering such intellectual property.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel,
we may not be able to successfully implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of
our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221;
employees, and we do not have &#8220;key person&#8221; insurance on them. The loss of the services of our Chief Executive Officer Ryan
Saadi, Chief Scientific Officer Neal Flomenberg, or one or more of our other executive officers or key employees could impede the achievement
of our research, development, and commercialization objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting
and retaining qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also
be critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract
and retain personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies and academic
institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing
approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of
certain executives, key employees, consultants, or advisors, may impede the progress of our research, development and commercialization
objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully
than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries, and in particular the immunotherapy sector, are characterized by the rapid evolution of
technologies and understanding of disease etiology, intense competition, and strong pursuit and defense of intellectual property. We
may face substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical and existing or emerging
biotechnology companies, governmental agencies, academic institutions, public and private research institutions, technology companies
active in the AI space, and others. Our commercial opportunities will be significantly impacted if our competitors develop and commercialize
products that are safer, more effective, have fewer side effects, are less expensive or obtain more significant acceptance in the market
than any product candidates that we develop. Additionally, our commercial opportunities will be significantly impacted if novel upstream
products or changes in treatment protocols reduce the overall incidence or prevalence of diseases in our current or future target population.
Competition could result in reduced sales and pricing pressure on our product candidates, if approved by FDA. In addition, significant
delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any
ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the approved or commonly used drugs and therapies for certain of our target diseases are well established and are widely accepted
by physicians, patients, and third-party payors. Some of these drugs are branded and subject to patent protection, and other drugs and
nutritional supplements are available on a generic basis. Insurers and other third-party payors may encourage the use of generic products
or specific branded products. If any of our product candidates are approved, although we expect they may be priced at a discount to existing
cell therapies, we also expect they will be priced at a significant premium over any competitive generic products. Absent differentiated
and compelling clinical evidence, pricing premiums may impede the adoption of our products over currently approved or commonly used therapies,
which may adversely impact our business. In addition, many companies are developing new therapeutics, and we cannot predict what the
standard of care will become as our products continue in clinical development. We anticipate that we could face intense and increasing
competition as new therapies enter the market and advanced technologies become available from time to time. We expect that any treatments
which we develop and commercialize will need to compete on, among other things, efficacy, safety, convenience of administration and delivery,
and price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors or potential competitors, either alone or through collaborations, have significantly greater market presence, financial
resources and expertise in research and development, preclinical studies, conducting clinical trials, manufacturing, obtaining regulatory
approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Smaller or early-stage
companies may also prove to be significant competitors, including through collaborative arrangements or mergers with large and established
companies. These third parties compete with us in establishing clinical trial sites and patient enrollment for clinical trials, as well
as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also face substantial competition for our AI initiatives and our computational approaches to drug discovery. Our competitors may have
significantly greater experience and expertise in using AI, algorithmic tool development, predictive analytics, and data science to expedite
drug development, optimize laboratory processes and clinical trials, unravel complex biological data, and improve patient outcomes than
we do, and significantly greater financial and other resources with which to do so. AI technologies are changing rapidly and we must
adapt and develop these technologies in a timely and effective manner at an acceptable cost in order to compete. There can be no assurance
that we will be able to develop, acquire, or integrate AI technologies, tools, and processes successfully or as quickly or cost-effectively
as our competitors, or that these technologies, tools, and processes will meet our needs or achieve our goals. In addition, if the technologies,
tools, or processes that we develop are incorrectly designed, do not operate properly, or are otherwise deficient, or if we do not have
the rights to use the data on which they rely, we may not achieve our goals for this initiative, our performance and reputation could
suffer or we could incur liability through the violation of laws, privacy rights, or contracts. Even with the successful use of AI, we
may fail to allocate resources efficiently, which could adversely impact our pipeline and ability to compete effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to attract and retain highly skilled personnel is critical to our operations and expansion. We also face competition for these
types of personnel from biotechnology and other companies and organizations, many of which have significantly larger operations and greater
financial, technical, human, and other resources than us. We may not be successful in attracting and retaining qualified personnel on
a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating
them into our operations, our business, prospects, financial condition, and results of operations will be materially adversely affected.
In such circumstances, we may be unable to conduct certain research and development programs, unable to adequately manage our clinical
trials and development of our product candidates, and unable to adequately address our management needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, these competitors may obtain regulatory approval of their products before we are able to, which could result
in our competitors obtaining a head start and establishing a frontrunner position before we are ready to commercialize and will limit
our ability to develop or commercialize our product candidates. Our ability to commercialize our proprietary cell products could also
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have a better safety profile,
are more convenient or are less expensive than our products. Our competitors also may be more successful than us in manufacturing and
marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover
the expenses of development and commercialization. If we are not able to compete effectively against our existing and potential competitors,
our business, financial condition, results of operations and growth prospects may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development plans and strategies develop, we expect to need additional managerial, operational, marketing, sales, financial and other
personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
                                            recruiting, integrating, maintaining, and motivating additional employees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
                                            our internal development efforts effectively, including the clinical and FDA review process
                                            for TVGN 489 and any future product candidates we develop, while complying with our contractual
                                            obligations to contractors and other third parties; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
                                            our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to advance development of and, if approved, commercialize TVGN 489 and any future product
candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert
a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing
these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants
will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are
unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised
for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain marketing approval of any
current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing
consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop and commercialize TVGN 489 and any future product
candidates we develop and, accordingly, may not achieve our research, development, and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater
risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our
trials, patients, healthcare providers or others using, administering, or selling our products. If we cannot successfully defend ourselves
against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
                                            demand for any product candidate we may develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
                                            of trial participants;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
                                            of clinical trial sites or entire trial programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
                                            to our reputation and significant negative media attention;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
                                            of investigations by regulators;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            time and costs to defend the related litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
                                            monetary awards to trial subjects or patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
                                            of management and scientific resources from our business operations; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability to commercialize any product candidates that we may develop.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we currently hold liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all
liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy
any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we
obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability insurance.
A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage,
could decrease our cash and adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income,
if any, until such unused losses expire. Limitations imposed by the applicable jurisdictions on our ability to utilize net operating
loss carryforwards could cause income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause
such net operating loss carryforwards to expire unused, in each case reducing or eliminating the benefit of such net operating loss carryforwards.
Furthermore, we may not be able to generate sufficient taxable income to utilize our net operating loss carryforwards before they expire.
If any of these events occur, we may not derive some or all of the expected benefits from our net operating loss carryforwards. In addition,
we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside
of our control. As a result, even if we earn net taxable income, our ability to use our net operating loss and tax credit carryforwards
may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Being a Public Company and Ownership of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our Common Stock and Warrants may fluctuate significantly and you could lose all or part of your investment as a result.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Common Stock and Warrants has been and is likely to continue to be volatile. The stock market in general, and the
market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating
performance or prospects of particular companies. As a result of this volatility, you could lose all or part of your investment. Many
factors may have a material adverse effect on the market price of our securities, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            commencement, enrollment, delay, or results of our ongoing or future clinical trials, or
                                            changes in the development status of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            decision to initiate, not to initiate, or to terminate a clinical trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
                                            serious safety concerns related to the use of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            delay in our regulatory filings for our product candidates and any adverse or perceived adverse
                                            development with respect to the applicable regulatory authority&#8217;s review of such filings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            actions, including failure to receive regulatory approval, with respect to our product candidates
                                            or our competitors&#8217; products or product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to commercialize our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to utilize AI technologies in the development of our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of competitive products or technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            by us or our competitors of significant acquisitions, strategic collaborations, joint ventures,
                                            collaborations, capital commitments, significant development milestones, or product approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to obtain new commercial partners;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to obtain adequate manufacturing capacity or product supply for any approved product
                                            or inability to do so at acceptable cost;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure to achieve expected product sales and profitability;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            or legal developments applicable to our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            level of expenses related to our product candidates or clinical development programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            lawsuits, including without limitation patent or stockholder litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of the incidence and development of COVID-19 on our business and product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            changes in our Board of Directors (the &#8220;Board&#8221;) or senior management;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated fluctuations in our cash position or operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in financial estimates or recommendations by securities analysts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
                                            in the valuation or financial results of companies perceived by investors to be comparable
                                            to us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inconsistent
                                            trading volume levels of our shares;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
                                            or expectation of additional financing efforts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of Common Stock by us, our executive officers or directors, or our stockholders;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
                                            and market conditions in the U.S. equity markets generally and in the biotechnology sector;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic, political and social conditions; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            events or factors, many of which are beyond our control, or unrelated to our operating performance
                                            or prospects.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or
disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations.
Broad market and industry factors may seriously affect the market price of our Common Stock and Warrants, regardless of actual operating
performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation
has often been brought against that company. Because of the potential volatility of our Common Stock and warrant price, we may become
the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s
attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including
those described in this &#8220;<i>Risk Factors</i>&#8221; section, could have a dramatic and material adverse impact on the market price
of our Common Stock following the business combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have previously failed to timely file certain periodic reports with the SEC. Potential future delays in the filing of our reports with
the SEC pose significant risks to our business, and could materially and adversely affect our financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 or our Form 10-Q for the quarterly
period ended March 31, 2024 and missed the initial deadline for the filing of our Form 10-Q for the quarterly period ended September
30, 2024 and our Form 10-K for the fiscal year ended December 31, 2024. While we are now current in our filing of periodic reports under the Exchange Act, there is no assurance that in the
future our reporting will always be timely. Our access to financing may be impaired by any untimely filing of our periodic reports.
For example, we will not be eligible to register the offer and sale of our securities using a short-form registration statement on
Form S-3 until we have timely filed all periodic reports required under the&#160;Exchange Act for a period of twelve calendar months
and any portion of a month immediately preceding the filing of such registration statement. In addition, in the event the filing of
our periodic reporting is delayed in the future, we may experience a material adverse effect on our ability to grow our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
failures to timely file periodic reports with the SEC could subject us to enforcement action by the SEC and stockholder lawsuits, and
result in the delisting of our Common Stock and Warrants from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), regulatory sanctions
from the SEC, or breach of covenants in any future credit facilities or of any preferred equity or debt securities that we may issue
in the future, any of which could have a material adverse impact on our operations, your investment in our Common Stock and Warrants,
and our ability to register with the SEC public offerings of our securities for our benefit or the benefit of our security holders. Additionally,
any potential failure to timely file future periodic reports could result in investors not receiving access to current or timely information
regarding our business and operations with which to make investment decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not have the funds necessary to satisfy our future obligations under the terms of our Preferred Stock and uncertainties with respect
to our obligations under the terms of our Preferred Stock could materially and adversely affect our ability to raise capital, our liquidity
position, our ability to operate our business and execute our business strategy, and the trading volatility and price of our securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainty
regarding our ability to satisfy our future obligations under the terms of our Preferred Stock could materially and adversely affect
our business. Our Series A Preferred Stock, which has an aggregate face value of $2.0 million, carries an annual 5% cumulative dividend,
increasing by 2% each year. The Series A Preferred Stock is callable if the volume weighted average price of the Common Stock for the
20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement
on file covering the underlying Common Stock. Our Series C Preferred Stock, which has an aggregate face value of $6.0 million, carries
an annual 7.5% cumulative dividend, compounded annually, payable in shares of Series C Preferred Stock, or at our election, in cash.
The Series C Preferred Stock is callable at any time after the fifth anniversary of the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have sufficient funds or be able to obtain financing from third parties to pay the dividends applicable to our Preferred Stock
or to redeem the Preferred Stock pursuant to our call rights, and the amount of dividend we may be required to pay on the Preferred Stock
is uncertain. These uncertainties could materially and adversely affect our ability to raise capital, our liquidity position, our ability
to operate our business and execute our business strategy, and the trading volatility and price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives
and corporate governance practices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities
rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure
and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other
personnel in connection with our efforts to comply with the requirements of being, a public company, and our management and other personnel
devote a substantial amount of time towards maintaining compliance with these requirements. These requirements contribute significantly
to our legal and financial compliance costs. These rules and regulations are often subject to varying interpretations, in many cases
due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional shares of our Common Stock or other equity securities without your approval, which would dilute your ownership interests
and may depress the market price of your shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue additional shares of our Common Stock or other equity securities of equal or senior rank in the future in connection with,
among other things, raising additional capital, future acquisitions, repayment of outstanding indebtedness, or award issuances under
the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, without stockholder approval, in a number of circumstances. The additional
shares or other securities convertible into or exchangeable for our public shares may be offered at price that may not be the same as
the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less
than the price per share paid by the investors in this offering, and investors purchasing shares or other securities in the future could
have rights superior to existing stockholders. The price per share at which the additional shares or securities convertible or exchangeable
into public shares, will be sold in future transactions may be higher or lower than the price per share paid by investors in this offering.
If any of the above should occur, our stockholders, including investors who purchased public shares in this offering, will experience
additional dilution, and any such issuances may result in downward pressure on the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional shares of Common Stock or other equity securities of equal or senior rank could have the following effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">your
                                            proportionate ownership interest in Tevogen will decrease;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            relative voting strength of each previously outstanding share of Common Stock may be diminished;
                                            or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            market price of your shares of Common Stock may decline.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;, and certain exemptions from disclosure requirements
available to us could make our securities less attractive to investors and may make it more difficult to compare our performance to the
performance of other public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an &#8220;emerging growth company&#8221; as defined in Section 2(a)(19) of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), as modified by the JOBS Act. As such, we are eligible for and intend to take advantage of certain exemptions from various
reporting requirements applicable to other public companies that are not emerging growth companies for as long as we continue to be an
emerging growth company, including, but not limited to, (a) not being required to comply with the auditor attestation requirements of
Section 404 of the Sarbanes-Oxley Act, (b) reduced disclosure obligations regarding executive compensation in our periodic reports and
proxy statements and (c) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information
they may deem important. We cannot predict whether investors will find our securities less attractive because we rely on these exemptions.
If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities
may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our
securities may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest of : (i) the last day of the fiscal year (a) following the fifth anniversary
of the closing of Semper Paratus&#8217; initial public offering, or December 31, 2026, (b) in which we have total annual gross revenue
of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common
equity that is held by non-affiliates exceeds $700 million as of the last business day of its most recently completed second fiscal quarter;
and (ii) the date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period.
In addition, the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition period and, therefore,
we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
This may make comparison of our financial statements with the financial statements of other companies who comply with public company
adoption dates difficult or impossible because of the potential differences in accounting standards used. Investors may find our Common
Stock less attractive because it will rely on these exemptions, which may result in a less active trading market for our Common Stock
and its price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we qualify as a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may
take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial
statements. We will remain a smaller reporting company and may take advantage of certain scaled disclosures available to smaller reporting
companies for so long as the market value of our voting and non-voting common equity held by non-affiliates is less than $250.0 million,
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently
completed fiscal year and the market value of our common equity held by non-affiliates is less than $700.0 million, measured on the last
business day of our second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison
of its financial statements with other public companies difficult or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management team has limited experience managing a public company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of our management team have limited experience managing a publicly traded company, interacting with public company investors, and complying
with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our
transition to being a public company that is subject to significant regulatory oversight and reporting obligations under the federal
securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents require significant
attention from our senior management and could divert their attention away from the day-to-day management of our business, which could
harm our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendation
regarding our Common Stock or if our results of operations do not meet their expectations, including projections in those reports that
differ from our actual results, our share price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Common Stock may be influenced by research and reports that industry or securities analysts may publish about
us or our business. We do not have any control over these analysts. We have limited analyst coverage and we may continue to have limited
analyst coverage in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities or industry analysts fail to commence coverage of us, the trading price of our Common Stock may be negatively impacted. In
the event securities or industry analysts initiate coverage, and one or more of these analysts cease coverage of us or fail to publish
reports on us regularly, we could lose visibility in the financial markets, which in turn could cause the price of our Common Stock or
trading volume to decline. Moreover, if one or more of the analysts who cover us publish negative reports, downgrade our stock, or if
our results of operations do not meet their expectations, the price of our Common Stock could decline. Securities research analysts may
establish and publish their own periodic projections for us. These projections may vary widely and may not accurately predict the results
we actually achieve. Our share price may decline if our actual results do not match the projections of these securities research analysts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations could be negatively affected we become subject to any securities litigation or stockholder activism, which could
cause us to incur significant expense, hinder execution of business and growth strategy and impact its stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has
often been brought against that company. Stockholder activism, which could take many forms or arise in a variety of situations, has been
increasing recently. Volatility in the stock price of our Common Stock or other reasons may in the future cause it to become the target
of securities litigation or stockholder activism. Securities litigation and stockholder activism, including potential proxy contests,
could result in substantial costs and divert management&#8217;s and Board&#8217;s attention and resources from our business. Additionally,
such securities litigation and stockholder activism could give rise to perceived uncertainties as to our future, adversely affect its
relationships with service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to
incur significant legal fees and other expenses related to any securities litigation and activist stockholder matters. Further, its stock
price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities
litigation and stockholder activism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative
effect on its financial condition, results of operations and the share price of our securities, which could cause you to lose some or
all of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be forced to write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in
our reporting losses. In addition, unexpected risks may arise and previously known risks may materialize in a manner not consistent with
prior risk analysis. If any of these risks materialize, this could have a material adverse effect on our financial condition and results
of operations and could contribute to negative market perceptions about our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified material weaknesses in our internal control over financial reporting. If we are unable to develop and maintain proper
and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired,
investors may lose confidence in our financial reporting and the trading price of our Common Stock may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has previously concluded that we had material weaknesses in our internal controls over financial reporting related to our
not maintaining a sufficient complement of personnel commensurate with its accounting and reporting requirements resulting in inadequate
segregation of duties over the preparation, review, and posting of manual journal entries to the general ledger and in not having a sufficient
risk assessment process to identify and analyze risks of misstatement due to error and/or fraud. A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material
misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we continue to evaluate steps to remediate these material weaknesses, the material weaknesses will not be considered remediated until
our plan has been fully implemented, the applicable controls are fully operational for a sufficient period of time, and we have concluded,
through testing, that the newly implemented and enhanced controls are operating effectively. At this time, we cannot predict the success
of such efforts or the outcome of future assessments of the remediation efforts. If the material weaknesses are not remediated, or if
we generally fail to establish and maintain effective internal controls appropriate for a public company, we may be unable to produce
timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which
could adversely impact our investors&#8217; confidence and our stock price. In addition, these remediation measures may be time consuming
and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent
or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial
statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic
reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our
stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the
future, will be sufficient to avoid potential future material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address these material weaknesses, we intend to hire additional accounting personnel with appropriate expertise in accounting and reporting
under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and SEC regulations in order to better align with segregation
of duties and perform appropriate risk assessment procedures to evaluate risks of material misstatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Our
independent registered public accounting firm is not required to provide an attestation report on the effectiveness of our internal control
over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material
weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Any failure to maintain internal
control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations
or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered
public accounting firm determines we have a material weakness in our internal control over financial reporting, investors may lose confidence
in the accuracy and completeness of our financial reports, the market price of our Common Stock could decline, and we could be subject
to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal
control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also
restrict our future access to the capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
significant portion of our total outstanding shares may be sold into the market in the near future. This could cause the market price
of our Common Stock to drop significantly, even if our business is doing well.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our Common Stock in the public market could occur at any time. In addition, until recently we had
a substantial number of restricted stock units. Sales, or the perception in the market that the holders of a large number of shares intend
to sell shares, could reduce the market price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
restrictions on resale end and any registration statements we file for the resale of such shares are available for use, the market price
of our Common Stock could decline if the holders of previously restricted shares sell them or are perceived by the market as intending
to sell them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
directors, executive officers, and principal stockholders, and Dr. Ryan Saadi in particular, have substantial control over our Company,
which could limit your ability to influence the outcome of key transactions, including a change of control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers, directors, and principal stockholders and their affiliates beneficially own approximately 90% of the outstanding
shares of Common Stock and our Chief Executive Officer, Dr. Ryan Saadi, beneficially owns approximately 70% of the outstanding shares
of Common Stock. As a result, these stockholders exercise a significant level of control over all matters requiring stockholder approval,
including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may also have
interests that differ from our investors and may vote in a way with which our investors disagree. In addition, under the Nasdaq rules,
a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221;
and need not comply with certain requirements, including the requirement that a majority of the board of directors consist of independent
directors and the requirements that our compensation and nominating and governance committees be composed entirely of independent directors.
We are not currently taking advantage of these exemptions. However, for so long as we qualify as a &#8220;controlled company,&#8221;
we maintain the option to rely on some or all of these exemptions. If we rely on these exemptions, we may not have a majority of independent
directors and our compensation and nominating and governance committees may not consist entirely of independent directors. Accordingly,
in the event we elect to rely on these exemptions in the future, our stockholders would not have the same protections afforded to stockholders
of companies that are subject to all of the corporate governance requirements of Nasdaq. This concentration of ownership may have the
effect of delaying, preventing or deterring a change of control, could deprive our stockholders of an opportunity to receive a premium
for their Common Stock as part of a sale, and might ultimately affect the market price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may redeem a warrant holder&#8217;s unexpired warrants prior to their exercise at a time that may be disadvantageous to such warrant
holder, thereby making its warrants worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the ability to redeem outstanding public warrants at any time after they become exercisable and prior to their expiration, at a
price of $0.01 per warrant, provided that the last reported sales price of Common Stock equals or exceeds $18.00 per share (as adjusted
for stock splits, stock capitalizations, reorganizations, recapitalizations and the like for certain issuances of public shares and equity-linked
securities for capital raising purposes in connection with the closing of its initial business combination) for any 20 trading days within
a 30 trading-day period ending on the third trading day prior to the date we send the notice of redemption to the warrant holders. We
may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable
state securities laws. Redemption of the outstanding warrants could force a warrant holder to: (i) exercise its warrants and pay the
exercise price at a time when it may be disadvantageous for such warrant holder to do so; (ii) sell its warrants at the then-current
market price when a warrant holder might otherwise wish to hold its warrants; or (iii) accept the nominal redemption price which, at
the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of a warrant holder&#8217;s
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their
warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_004"></span>Item
1B. Unresolved Staff Comments.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="g_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1C. Cybersecurity.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_980_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_iB_c20240101__20241231_gBFCRMPITB-JY_zUaj3vKypLv9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000055-01" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Program</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"><span id="xdx_C04_gBFCRMPITB-JY_zF9Im4NcBxv7"><ix:continuation continuedAt="ConU000055-02" id="ConU000055-01"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></ix:continuation></span></p>

<div id="xdx_C0D_gBFCRMPITB-JY_zogKJclPugPh"><ix:continuation continuedAt="ConU000055-03" id="ConU000055-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
security and availability of our information systems and the protection of the information we collect, create, process, and store are
important to our business. We have implemented a cybersecurity program that is designed to support both the effectiveness of our systems
and our preparedness for information security risks. This program includes a number of safeguards, such as: multi-factor authentication;
monitoring internal and cloud-based systems for threats; email filters; cybersecurity awareness training; limitation on the use of third-party
devices; conditional access rules; and regular evaluations of our cybersecurity program.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white; color: #212529"><span id="xdx_C05_gBFCRMPITB-JY_z6CsaXQUiaNj"><ix:continuation continuedAt="ConU000055-04" id="ConU000055-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white; color: #212529"></p>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white; color: #212529"><span id="xdx_C0B_gBFCRMPITB-JY_zZ5zrxeaosdk"><ix:continuation continuedAt="ConU000055-05" id="ConU000055-04"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></ix:continuation></span></p>

<div id="xdx_C0F_gBFCRMPITB-JY_zTpz4sN64Xl3"><ix:continuation continuedAt="ConU000055-06" id="ConU000055-05"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_i01_dbT_c20240101__20241231_zAHdpa5PWZpk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">We
use a risk-based approach with respect to our use and oversight of third-party service providers and vendors, tailoring processes according
to the nature and sensitivity of the data accessed, processed, or stored by such third-party service provider. We use numerous means
to assess cyber risks related to our third-party service providers, including for example use of a managed security service provider
(&#8220;MSSP&#8221;) that monitors cybersecurity events for our cloud systems. We also seek to include appropriate security terms in
our contracts where applicable as part of our oversight of third-party service providers.</ix:nonNumeric></span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span id="xdx_C09_gBFCRMPITB-JY_z8yk31iOXtad"><ix:continuation id="ConU000055-06"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-RIH_zPtH1QyU6snl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000060-01" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C0A_gBFCRBODOTB-RIH_zhdAYeZiytIe"><ix:continuation continuedAt="ConU000060-02" id="ConU000060-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></ix:continuation></span></p>

<div id="xdx_C0D_gBFCRBODOTB-RIH_ze7ANnjebqvj"><ix:continuation continuedAt="ConU000060-03" id="ConU000060-02"><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management
Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
controls and processes employed to assess, identify,&#160;and manage material risks from cybersecurity threats are implemented and overseen
by <span id="xdx_906_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_i01_dbT_c20240101__20241231_z2qwTKXXXNql" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000061" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">our Chief Information Officer (&#8220;CIO&#8221;). Our CIO has more than 20 years of information technology experience, including
seven years specializing in cybersecurity. Our CIO is responsible for assessing the impact of cybersecurity threats and incidents, assessing
whether and to what extent they can be contained and mitigated, containing and mitigating them, remediating incidents, and performing
post-incident analysis and program enhancements. In the event of a significant cybersecurity incident, our CIO would engage senior management
to inform them of the incident and related threats and response. We would also likely engage a third-party incident response vendor to
assist us in the event of a significant cybersecurity incident. Our Chief Executive Officer directly oversees our CIO and receives information
on cybersecurity risks from our CIO. Our CIO, in turn, is informed about risks from cybersecurity threats through dashboards, email alerts,
reporting from the MSSP, and regular review of our systems and information technology environment</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board
Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Board has overall responsibility for risk oversight, the Board delegated to the audit committee the responsibility for assisting
the Board with oversight and monitoring of matters relating to our risk assessment, risk management, and risk mitigation policies and
programs, including matters related to privacy, information technology,&#160;and cybersecurity, and for reviewing and discussing with
management our risk exposures related to these matters. In its oversight role, the Board is expected to specifically consider risks that
relate to our reputation and the general industry in which we operate, including with respect to privacy, information technology and
cybersecurity,&#160;and threats to technology infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CIO may report to and brief the Board and the audit committee on cybersecurity matters, including key risks, the potential impact of
those exposures on our business, financial results, operations, and reputation, as well as the programs and steps implemented by management
to monitor and mitigate risks<b><i>.</i></b> The reporting cadence and structure continues to develop.</span></p>

</div></ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span id="xdx_C0B_gBFCRBODOTB-RIH_zWEtIN27n5jc"><ix:continuation id="ConU000060-03"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></ix:continuation></span></p>

<p id="xdx_988_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-TOONT_zYFTS9XWgN5k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000065-01" escape="true" id="Fact000065" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C0A_gBFCRMPFAIAMT-TOONT_zzE5QFP3mi81"><ix:continuation continuedAt="ConU000065-02" id="ConU000065-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C06_gBFCRMPFAIAMT-TOONT_znUZsuRRMfJf"><ix:continuation continuedAt="ConU000065-03" id="ConU000065-02"><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management processes are integrated into our overall approach to risk management. Given the nature and size of our
Company, we do not have a dedicated enterprise risk function, but our executives regularly consider and evaluate risks to our Company.
As part of that risk management process, members of our executive team identify, assess,&#160;and evaluate risks impacting our operations,
including those risks related to cybersecurity, and raise them for discussion with other executives, and where it is determined to be
appropriate, issues are also raised to the Board for consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, <span id="xdx_901_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_dbT_c20240101__20241231_zgQ8dgrVqXk6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000066" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">we are <span id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zkXZL3j403Tc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000067" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no</ix:nonNumeric></span>t aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity
incidents, that have materially affected our business strategy, results of operations,&#160;or financial condition or are reasonably
likely to have such a material effect</ix:nonNumeric></span>. While we have implemented a cybersecurity program, the techniques used to infiltrate information
technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement security
measures adequate to prevent cybersecurity incidents or fully mitigate their impact. For additional information regarding risks relating
to privacy and cybersecurity, see &#8220;Item 1A&#8212;Risk Factors&#8221;.</span></p>

</div></ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_C0D_gBFCRMPFAIAMT-TOONT_zLE51Yg1NJyd"><ix:continuation id="ConU000065-03"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_006"></span>Item
2. Properties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Warren, New Jersey, and consist of 6,708 square feet dedicated to corporate, operational, and pre-commercial
activities under a lease that expires February 14, 2026. We also have two research and development facilities located in Philadelphia:
our 3,620 square foot research and development center under a lease that expires June 30, 2025; and a shared facility with laboratory
space dedicated to us that is focused on preclinical and pharmacodynamic activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_007"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are
not currently a party to any material pending legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_008"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_009"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="g_010"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock and public warrants began trading on Nasdaq under the symbols &#8220;TVGN&#8221; and &#8220;TVGNW.&#8221; As of March 21,
2025, there were approximately 90 holders of record of our common stock and 183,893,433 shares of common stock outstanding. We are unable
to estimate the total number of stockholders represented by these record holders, as many of our shares are held by brokers and other
institutions on behalf of our stockholders. We have never paid cash dividends on our capital stock and we do not anticipate paying any
cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about our equity compensation plan is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_011"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_012"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated
financial statements and related notes included elsewhere in this Annual Report. This discussion and other parts of this Annual Report
contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and
intentions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report,
our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the
following discussion and analysis.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>References to the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this section generally refer to Tevogen Bio Inc before the Business Combination
and to Tevogen Bio Holdings Inc. and its subsidiary collectively from and after the Business Combination, unless the context otherwise
requires.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a clinical-stage specialty
immunotherapy company harnessing one of nature&#8217;s most powerful immunological weapons, CD8+ CTLs, to develop off-the-shelf, precision
T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet
needs of large patient populations. We believe the full potential of T cell therapies remains largely untapped, and aspire to be the first
biotechnology company offering commercially attractive, economically viable, and cost-effective personalized T cell therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We believe our allogeneic, precision
T cell technology, ExacTcell<sup>TM</sup>, has the potential to mainstream cell therapy with a new class of off-the-shelf T cell therapies
with diverse applications across virology, oncology, and other areas. ExacTcell is a set of processes and methodologies to develop, enrich,
and expand single human HLA restricted CTL therapies with proactively selected, precisely defined targets. We are focused on using ExacTcell
to develop therapeutics that are intended to be infused in patients other than the original donor.&#160;ExacTcell is designed to maximize
the immunologic specificity of our products in order to eliminate malignant and virally infected cells while allowing healthy cells to
remain intact. In addition, through our Tevogen.AI artificial intelligence initiative, we are exploring ways to deploy artificial intelligence-powered
target detection to further accelerate our product development pace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The first clinical product of
ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk
elderly, with potential applications in both treatment and prevention of Long COVID. We have completed a Phase 1 proof-of-concept clinical
trial of TVGN 489 for the treatment of ambulatory, high-risk adult COVID-19 patients. No dose-limiting toxicities or significant treatment-related
adverse events were observed in the treatment arm of the trial. Secondary endpoints showing a rapid reduction of viral load and that infusion
of TVGN 489 did not prevent development of the patients&#8217; own T cell-related (cellular) or antibody-related (humoral) anti-COVID-19
immunity were also met. None of the patients who participated in the trial reported progression of infection, reinfection, or the development
of Long COVID during the six-month follow-up period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our commercial success depends
in part on our ability to obtain and maintain patent and other protection for our products and methods, preserve the confidentiality of
our trade secrets, operate without infringing, misappropriating, or otherwise violating the valid, enforceable proprietary rights of others,
and prevent others from infringing, misappropriating, or otherwise violating our proprietary rights. We rely on a combination of patents,
patent applications, trademarks, and trade secrets to establish and protect our intellectual property rights. Our ability to stop third
parties from making, using, selling, offering to sell, or importing our products without the right to do so may depend on the extent to
which we have rights under valid and enforceable patents, trademarks or trade secrets that cover these activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">As our patents were developed
internally, historical expenditures related to their development were all expensed as incurred per GAAP. We believe these patents have
significant value as the basis of our product pipeline. Our continued investment in our pipeline highlights our belief in future commercial
viability of these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14, 2024
(the &#8220;Closing Date&#8221;), pursuant to the agreement and plan of merger dated June 28, 2023 (the &#8220;Merger Agreement&#8221;)
by and among Semper Paratus, Semper Merger Sub, Inc., a wholly owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK Associates,
LLC, Tevogen Bio, and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and into Tevogen Bio, with Tevogen
Bio being the surviving company and a wholly owned subsidiary of Semper Paratus (the &#8220;Merger,&#8221; and together with the other
transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and Semper Paratus was renamed Tevogen Bio
Holdings Inc. (the &#8220;Closing&#8221;). See Note 4 to our consolidated financial statements in this Annual Report for additional information
regarding the net assets acquired through the Merger. The Merger was accounted for as a reverse recapitalization under GAAP because the
Company was determined to be the accounting acquirer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Since commencing operations
in June 2020, we have devoted substantially all our efforts and financial resources to establishing corporate governance, recruiting essential
staff, establishing research and development capability including securing laboratory space and equipment, conducting scientific research,
securing intellectual property rights to our inventions related to our product candidates and ExacTcell, carrying out drug discovery including
pre-clinical studies and our Phase 1 clinical trial of TVGN 489, raising capital, and pursuing the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">To date, we have not
generated any revenue. Our net loss for the years ended December 31, 2024 and 2023 was $13.7 million and $60.5 million, respectively.
Net loss for the year ended December 31, 2024 was primarily attributable to a $53.6 million loss from operations that primarily resulted
from non-cash, stock-based compensation expense recognized with the liquidity event condition contained in certain stock awards was satisfied
upon the closing of the Business Combination as well as $7.5 million in transaction costs in connection with the Business Combination,
partially offset by the change in fair value of convertible promissory notes of $48.5 million. As of December 31, 2024, we had cash of
$1.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On February 14, 2024,
we entered into a securities purchase agreement with The Patel Family, LLP (the &#8220;Patel Family&#8221;) pursuant to which the Patel
Family purchased 500 shares of our Series A Preferred Stock for an aggregate purchase price of $2.0 million. On March 27, 2024, we entered
into an Amended and Restated Securities Purchase Agreement with the Patel Family pursuant to which we amended and restated the original
agreement and the Patel Family agreed to purchase 600 shares of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0
million, of which $3.0 million has been received through the date of this Annual Report. On August 21, 2024, we entered into a securities
purchase agreement with the Patel Family, pursuant to which the investor purchased 600 shares of our Series C Preferred Stock for an aggregate
purchase price of $6.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">As described in more
detail in &#8220;&#8212;<i>Liquidity and Capital Resources&#8212;Funding Requirements</i>&#8221; below, on June 6, 2024, we entered into
a Loan Agreement (the &#8220;Loan Agreement&#8221;) with the Patel Family providing for (i) an unsecured line of credit facility (the
&#8220;Facility&#8221;), pursuant to which the Patel Family agreed to lend us up to an initial amount of $36.0 million (the &#8220;Maximum
Loan Amount&#8221;) of term loans in $1.0 million increments on a monthly basis, over a draw period of thirty-six months, and (ii) a contingent
option for the Patel Family to purchase at least $14.0 million of our Common Stock in a future private placement (the &#8220;Optional
PIPE&#8221;). The Loan Agreement also contains a contingent option for the Patel Family to purchase at least $14.0 million of our Common
Stock plus up to the then-remaining available amount under the Facility, in a future private placement if the ten-day trailing volume
weighted average price per share of the Common Stock (the &#8220;Trailing VWAP&#8221;) reaches $10.00 per share. Pursuant to the terms
of the Loan Agreement, we also issued to the Patel Family 1,000,000 shares of Common Stock as a commitment fee (the &#8220;Commitment
Shares&#8221;), subject to forfeiture by the Patel Family of the Commitment Shares or an equal number of shares of Common Stock in the
event the Patel Family fails to (i) make a deposit under the Facility when due or (ii) pay the purchase price for the Optional PIPE within
30 days after the Threshold Price Notice Date (as defined in the Loan Agreement) in the event we have satisfied all applicable closing
conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">In addition, in January
2025, we received a grant of $2.0 million from KRHP to further our development
of off-the-shelf, genetically unmodified precision T cell therapeutics to treat infectious diseases and cancers. KRHP is affiliated with
the Patel Family.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Based on cash
on hand as of the date of this Annual Report of approximately $1.3 million, the amounts available under our Loan Agreement, and the
$8.0 million of additional committed grant funding from KRHP, we have concluded that we have sufficient cash to fund our operations
for at least the next 12 months from the issuance date of our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We do not expect to generate
product revenue unless and until we obtain marketing approval or other authorization for and successfully commercialize TVGN 489 or another
product candidate. We expect to incur expenses related to expanding our research and development capability, building our manufacturing
infrastructure including through acquisitions, and developing our commercialization organization, including reimbursement, marketing,
managed market, and distribution functions, and training and deploying a specialty medical science liaison team.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Components of our Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">To date, we have not generated
any revenue, and we do not expect to generate any revenue from the sale of products unless and until we obtain marketing approval or other
authorization for and commercialize TVGN 489 or another product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Research and development expenses
consist primarily of costs incurred for our research activities, including staffing, discovery efforts, preclinical studies, and clinical
development of TVGN 489, and preclinical studies of other product candidates, and include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisition
    of supplies and equipment and leasing lab spaces;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred to conduct the necessary pre-clinical studies required by  FDA to obtain the regulatory approval necessary to conduct
    TVGN 489 clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries,
    benefits, and other related costs for personnel engaged in research and development functions&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of funding research performed by third parties, including pursuant to agreements with CROs, and investigative site costs to conduct
    our pre-clinical studies and clinical trials&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    costs, including expenses incurred under agreements with CMOs, including manufacturing scale-up expenses, and the cost of acquiring
    and manufacturing pre-clinical study and clinical trial materials&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of outside consultants, including their fees, stock-based compensation, and related travel expenses&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of laboratory supplies and acquiring materials for pre-clinical studies and clinical trials&#894; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility-related
    expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating
    costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Research and development activities
are central to the biotechnology business model. Product candidates in later stages of clinical development generally have higher development
costs than those in earlier stages, primarily due to the increased study sizes, which also leads generally to longer patient enrollment
times in later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several
years as we increase manufacturing, shipping, and storage of clinical batches required for clinical trials, incur increased personnel
costs, including stock-based compensation, conduct planned clinical trials for TVGN 489 and other clinical and pre-clinical activities
for other product candidates, and prepare regulatory filings for any of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The successful development of
our current or future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing,
and costs of the efforts that will be necessary to complete the development of any product candidates. The success of TVGN 489 and our
other product candidates will depend on several factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to products other than TVGN 489, successfully completing pre-clinical studies&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    initiating future clinical trials&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    enrolling patients in and completing clinical trials&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applying
    for and receiving marketing approvals from applicable regulatory authorities&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining intellectual property protection and regulatory exclusivity for TVGN 489 and any other product candidates we are
    developing or may develop in the future and enforcing, defending, and protecting these rights&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    arrangements with third-party manufacturers, or establishing adequate commercial manufacturing capabilities&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    sales, marketing, and distribution capabilities and launching sales of our products, if and when approved, whether alone or in collaboration
    with others&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    adoption of TVGN 489 and any other product candidates, if and when approved, by patients and the medical community&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with potential therapeutic alternatives in our target disease areas; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    reimbursement by private and public payors including health technology appraisal entities in non-U.S. countries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">A change in the outcome of any
of these variables concerning the development, manufacturing, or commercialization activities of a product candidate could result in a
significant change in the costs and timing associated with the development of that product candidate. For example, if we are required
to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are
unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are
not positive or are only modestly positive, if there are safety concerns, or if we determine that the observed safety or efficacy profile
would not be competitive in the marketplace, we could be required to expend significant additional financial resources and time on the
completion of clinical development. We anticipate that product commercialization may take several years, and we expect to spend a significant
amount in development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative expenses
primarily consist of personnel expenses, which include salaries, benefits, and stock-based long term incentive compensation for employees.
These expenses also encompass corporate facility costs such as rent, utilities, depreciation, and maintenance, as well as costs not classified
under research and development expenses. Legal fees pertaining to intellectual property and corporate matters, as well as fees for accounting
and consulting services, are also included in general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We expect that our general and
administrative expenses will increase in the future to support our continued research and development activities, potential commercialization
efforts, and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring
of additional personnel and fees to outside consultants, lawyers, accountants, and recruitment firms, among other expenses. Increased
costs associated with being a public company will also include expenses related to services associated with maintaining compliance with
SEC and Nasdaq requirements, insurance, and investor relations costs. If any of our current or future product candidates obtains marketing
approval, we expect that we would incur significantly increased expenses associated with sales and marketing efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Interest Expense, Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Interest expense, net consists
primarily of interest on our former convertible promissory notes and Loan Agreement, partially offset by interest earned on bank deposits.
(See &#8220;&#8212;<i>Liquidity and Capital Resources</i>&#8212;<i>Sources of Liquidity</i>&#8221; below.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b><i>Merger Transaction Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Transaction costs we incurred in relation
to the Business Combination were initially capitalized as deferred transaction costs up through the Closing Date, at which time such costs
were charged to expense in our statements of operations less the amount of cash received in the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b><i>Change in Fair Value of Convertible Promissory Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">U.S. accounting standards provide
entities with an option to measure many financial instruments and certain other items at fair value. As a result of us electing this option,
we recorded all convertible promissory notes at fair value with changes in fair value reported in our statements of operations at each
balance sheet date through the settlement of the convertible promissory notes in connection with the Closing, at which time the convertible
promissory notes were converted into our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b><i>Loss on Issuance of Commitment Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our other expenses consist
of losses on the issuance of the Commitment Shares for the year ended December 31, 2024 associated with the Loan Agreement. Since we intend
to elect the fair value option for future draws under the Loan Agreement, we expense all issuance costs associated with the Loan Agreement,
which are comprised of the fair value of the Commitment Shares as well as the issuance date fair value of the $14 million Purchase Option
and Additional Amount Purchase Option. For more information about the Loan Agreement, see &#8220;&#8212;<i>Liquidity and Capital Resources&#8212;Funding
Requirements</i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Income Tax Provision</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Since inception, we have incurred
significant net losses. As of December 31, 2024, we had net operating loss carryforwards (&#8220;NOLs&#8221;) for federal and state income
tax purposes of $25.6 million and $27.8 million, respectively. We have provided a valuation allowance against the full amount of our net
deferred tax assets since, in the opinion of our management, based upon our historical and anticipated future losses, it is more likely
than not that the benefits will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our utilization of our NOLs may
be subject to a substantial annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively,
as well as similar state provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Results of Operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Comparison of the years ended December 31, 2024
and 2023</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our results of operations for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td style="font: 12pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 12pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">31,033,276</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,403,526</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,531,212</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,439,499</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,564,488</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,843,025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(53,564,488</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,843,025</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(184,037</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,206,352</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Merger transaction costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,499,353</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(58,180</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of convertible promissory notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48,468,678</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(50,428,303</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on issuance of commitment shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(890,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,727,380</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(60,477,680</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We do not track our internal
research and development costs on a program-by-program basis. The following table summarizes our research and development expenses for
the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Personnel costs</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">466,955</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,263,711</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">27,012,127</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other clinical and pre-clinical development expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,584,651</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,226,402</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Facilities and other expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">969,543</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">913,413</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total research and development expenses</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">31,033,276</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,403,526</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt">Research and development expenses
for the year ended December 31, 2024 were $31.0 million, compared to $4.4 million for the year ended December 31, 2024. The increase was
primarily attributable to an increase in stock-based compensation due to stock compensation expense related to the restricted stock units
(&#8220;RSUs&#8221;) granted to Dr. Saadi on the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our general and administrative expenses for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Personnel costs</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">1,725,326</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">1,095,468</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">13,752,010</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Legal and professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,636,232</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,616,925</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Facilities and other expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">417,644</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">727,106</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total general and administrative expenses</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">22,531,212</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,439,499</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative expenses
for the year ended December 31, 2024 were $22.5 million compared to $4.4 million for the year ended December 31, 2023. The increase was
primarily attributable to stock-based compensation expense of $13.8 million, of which $7.7 million was recognized as a non-cash stock-based
compensation expense from certain stock-based awards that continue to vest through satisfaction of service conditions subsequent to the
satisfaction of the liquidity condition upon the Closing, and $2.3 million was recognized as restricted stock compensation expense related
to the RSUs granted. The increase of $0.6 million in personnel costs was primarily attributable to an increase in headcount and an increase
in premium for our director and officer insurance policy. The increase of $4.0 million in legal and professional fees was primarily attributable
to the additional services incurred as a result of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Interest Expense, Net</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We recognized $0.2 million and
$1.2 million in interest expense for the years ended December 31, 2024 and 2023, respectively, which was attributable primarily to the
outstanding principal balance associated with our convertible promissory notes that converted into Common Stock in connection with the
Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Merger Transaction Costs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Merger transaction costs in excess of cash
received from the Business Combination of $7.5 million were recognized as period expenses for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Change in Fair Value of Convertible Promissory
Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We recognized a non-cash gain
of $48.5 million and a non-cash loss of $50.4 million for the change in fair value of the convertible promissory notes for the years ended
December 31, 2024 and 2023, respectively. The change was primarily a result of the increase in the underlying estimated fair value of
our Common Stock during the year ended December 31, 2023 compared to a decrease in the underlying estimated fair value of our Common Stock
from January 1, 2024 to the settlement of the convertible promissory notes upon the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Loss on Issuance of Commitment Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">We incurred losses on the issuance
of Commitment Shares during the year ended December 31, 2024, associated with the Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Sources of Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024, we had
$1.3 million in cash, as compared to $1.1 million in cash as of December 31, 2023. To date, we have not yet commercialized any products
or generated any revenue from product sales and have financed our operations primarily with proceeds from the sale of convertible promissory
notes and preferred stock, funds drawn on the Loan Agreement, and grant funding. Since January 2021, we have raised aggregate gross proceeds
of $24.0 million from the sale of convertible promissory notes, $2.0 million from the sale of our Series A Preferred Stock, $3.0 million
from deposits related to the future sale of our Series A-1 Preferred Stock, and $6.0 million from the sale of our Series C Preferred Stock.
In June 2024, we entered into the Loan Agreement, which provided up to $36.0 million of term loans that can be drawn in $1.0 million increments
each month over thirty-six months, as described below. As of December 31, 2024, we had drawn $1.0 million with a remaining $30.0 million&#160;available
for future financing over the remaining&#160;30&#160;months. We drew an additional $1.0 million on February 10, 2025. In addition, in
January 2025, we received a grant of $2.0 million from KRHP. We expect to receive an additional $8.0 million grant from KRHP during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our cash flows for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash provided by (used in)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt">Operating activities</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(11,998,730</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(8,171,118</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Investing activities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(133,000</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Financing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,229,328</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,872,250</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net change in cash</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">230,598</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,431,868</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Cash Flows from Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, we used $12.0 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $13.7
million offset by $1.7 million of non-cash charges related to the change in the fair value of the convertible promissory notes, depreciation
expense, reductions in the operating right of use (&#8220;ROU&#8221;) assets, non-cash interest on the convertible promissory notes, and
the net change in our operating assets and liabilities attributable to the timing of our payments to our vendors for research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2023, we used $8.2 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $60.5
million offset by $52.0 million of non-cash charges related to the change in the fair value of the convertible promissory notes, depreciation
expense, reductions in the ROU assets, non-cash interest on the convertible promissory notes, and a $0.3 million net change in our operating
assets and liabilities attributable to the timing of our payments to our vendors for research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Cash Flows from Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the years ended December
31, 2024 and 2023, we used $0.0 million and $0.1 million respectively, for the purchase of property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Cash Flows from Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, we received $12.3 million of net cash from financing activities attributable to $2.0 million in proceeds from the sale of Series
A Preferred Stock, $6.0 million in proceeds from the sale of Series C Preferred Stock, $3.0 million of non-refundable prepaid proceeds
towards the anticipated issuance of Series A-1 Preferred Stock, $1.0 million drawn under the Loan Agreement, and $0.2 million of cash
in connection with the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2023, we received $4.0 million of net cash from financing activities attributable to the proceeds from the convertible promissory
notes, less $0.1 million related to payments of deferred transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Funding Requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our primary
sources of funds to meet our near-term liquidity and capital requirements include cash on hand, including the funding we have
received from the sale of our Series A and Series C Preferred Stock and the funding we expect to receive from the sale of our Series
A-1 Preferred Stock, our access to an unsecured line of credit (limited to a $1.0 million monthly draw) under the Loan Agreement
described below, and the $8.0 million of grant funding that KRHP has committed to provide to be used towards the Company&#8217;s
ongoing operational expenses. On February 14, 2024, we entered into a securities
purchase agreement with an investor pursuant to which the investor agreed to purchase shares of our Series A Preferred Stock for an
aggregate purchase price of $8.0 million. On March 27, 2024, we entered into an agreement pursuant to which that amount was reduced
to $2.0 million and the investor agreed to purchase shares of our Series A-1 Preferred Stock for an aggregate purchase price of $6.0
million. We have not yet received $3.0 million of the $6.0 million purchase price for the Series A-1 Preferred Stock. Even if we
receive such proceeds, we will still need additional capital to fully implement our business, operating, and development plans. On
August 21, 2024, we entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase
shares of our Series C Preferred Stock for an aggregate purchase price of $6.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On June 6, 2024, we entered into
the Loan Agreement, pursuant to which the Patel Family agreed to provide to us up to the Maximum Loan Amount of $36.0 million under the Facility.
The Patel Family is also the investor in our Series A, Series A-1, and Series C Preferred Stock. The Facility permits us to borrow up to $1.0
million monthly in a single monthly draw over a period of up to three years. Draws accrue interest at a fixed annual rate of the lower
of (i) the daily secured overnight financing rate, measured on the date we receive the draw (the &#8220;Deposit Date&#8221;), plus 2.00%
and (ii) 7.00%, accruing quarterly beginning on the Deposit Date and payable quarterly beginning on the three-month anniversary of the
Deposit Date. Interest will be payable in shares of Common Stock with an effective purchase price of $1.50 per share, and each draw will
mature 48 months after the Deposit Date. Prepayment will be permitted without penalty. We may repay or prepay any amount of outstanding
principal balance under the Facility at our election in cash or in shares of Common Stock with an effective purchase price of the greater
of $1.50 per share and the 10-day trailing volume weighted average price of the Common Stock (the &#8220;Trailing VWAP&#8221;) as of the
trading day prior to payment, subject to certain requirements related to resale registration. Pursuant to the Loan Agreement, we also
agreed to provide the Patel Family an option to purchase $14.0 million of shares of our Common
Stock plus an additional amount up to the total then-remaining available and undrawn portion of the Maximum Loan Amount (which amount
would thereafter no longer be available under the Facility). The Optional PIPE would be priced at a 30% discount to the Trailing VWAP
on the date such price first reaches at least $10.00 per share (the &#8220;Threshold Price Date&#8221;) and will be exercisable by the
Patel Family by written notice within three business days after we have notified the Patel Family of the Threshold Price Date (the date
of such notice, the &#8220;Threshold Price Notice Date&#8221;). Pursuant to the terms of the Loan Agreement, we issued to the Patel Family
the Commitment Shares, subject to forfeiture by the Patel Family of the Commitment Shares or an equal number of shares of Common Stock
in the event the Patel Family fails to (i) make a deposit under the Facility when due or (ii) pay the purchase price for the Optional
PIPE within 30 days after the Threshold Price Notice Date in the event we have satisfied all applicable closing conditions. There is no
assurance as to the amount of proceeds we will ultimately receive under the Loan Agreement. As of December 31, 2024, we have drawn an
aggregate of $1.0 million under the Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We expect to devote considerable
financial resources to our ongoing and planned activities, particularly as we conduct our planned clinical trials of TVGN 489 and other
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Identifying potential
product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process that
takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product
sales. In addition, our product candidates, if approved, may not achieve commercial success.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We expect our expenses
to increase in connection with our ongoing activities, particularly as we advance our pre-clinical studies and clinical trials. In addition,
if we obtain marketing approval for TVGN 489 in any indication or for any other product candidate we are developing or develop in the
future, we expect to incur commercialization expenses related to product manufacturing, sales, marketing, and distribution. Furthermore,
we expect to continue to incur increased costs associated with operating as a public company. Accordingly, we will need additional funding
to fully implement our business plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our future capital requirements
will depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress, costs, and results of our planned clinical trials of TVGN 489 and other planned and future clinical trials&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, costs, and results of our pre-clinical testing and clinical trials of TVGN 489 for additional combinations, targets,
    and indications&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of and development requirements for additional indications for TVGN 489 or for any other product candidates&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to scale up our manufacturing processes and capabilities to support clinical trials of TVGN 489 and other product candidates
    we are developing and may develop in the future&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of TVGN 489 and other product candidates we are developing and may develop in the
    future&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in the regulatory environment and enforcement rules&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaboration, licensing, or other arrangements and the financial terms of such arrangements&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product manufacturing, sales, marketing, and distribution, for
    TVGN 489 and other product candidates we are developing and may develop in the future for which we may receive marketing approval&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain acceptance of any approved products by patients, the medical community, and third-party payors&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount and timing of revenue, if any, received from commercial sales of TVGN 489 and any other product candidates we are developing
    or develop in the future for which we receive marketing approval&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    changes in pharmaceutical pricing and reimbursement infrastructure&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of raw materials for use in production of our product candidates&#894; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and
    proprietary rights, and defending any intellectual property-related claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024, we had
cash of $1.3 million. We believe that our cash balance and amounts available under the Loan Agreement, which allows us to draw down term
loans of $1.0 million per month over thirty-six months, will allow us to have adequate cash and financial resources, to operate for at
least the next 12 months from the date of issuance of our consolidated financial statements included in this Annual Report. In addition, KRHP has committed to provide an additional $8.0 million of
grant funding to the Company to be used towards the Company&#8217;s ongoing operational expenses. The grant funding will be used to satisfy
the Company&#8217;s obligations as they come due through March 31, 2026. The Company does not plan to initiate a clinical trial until
additional funding is received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We regularly evaluate different
strategies to obtain funding for operations for subsequent periods. These strategies may include but are not limited to private placements
of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology companies, and public
offerings of securities. We may not be able to obtain financing on acceptable terms and may not be able to enter into strategic alliances
or other arrangements on favorable terms. The terms of any financing may adversely affect the holdings or the rights of our stockholders.
If we are unable to obtain sufficient funding, we could be required to delay, reduce or eliminate research and development programs, product
portfolio expansion, or future commercialization efforts, which could adversely affect our business prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b><i>Contractual Obligations and Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our contractual obligations and commitments as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1 Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    to 3 Years</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual
    obligations:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease commitments <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">244,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,471</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,975</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable <sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,651,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,651,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    Agreement repayment <sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,028,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    contractual obligations</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,923,716</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,909,741</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,013,975</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    obligations pursuant to our office and laboratory leases in Philadelphia, Pennsylvania and Warren, New Jersey.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    notes payable obligations assumed as part of the Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    obligations to settle outstanding balances on our Loan Agreement, if paid in cash at time of settlement, as well as accrued interest.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The commitment amounts in the
table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed
or minimum services to be used, fixed, minimum, or variable price provisions, and the approximate timing of the actions under the contracts.
Our contracts with CROs, CMOs, and other third parties for the manufacture of our product candidates and to support pre-clinical research
studies and clinical testing are generally cancelable by us upon prior notice and do not contain any minimum purchase commitments. Payments
due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of our
service providers, up to the date of cancellation are not included in the table above as the amount and timing of such payments are not
known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">This discussion and analysis
of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance
with GAAP. The preparation of the consolidated financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements.
On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, the fair value of our Common
Stock, the fair value of our convertible promissory notes, and stock-based compensation. We base our estimates on historical experience,
known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions, including those factors set out in the &#8220;<i>Risk
Factors</i>&#8221; section and elsewhere in this Annual Report, including the section entitled &#8220;<i>Special Note Regarding Forward-Looking
Statements.</i>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">While our significant accounting
policies are described in more detail in Note 3 to our consolidated financial statements, we believe the following accounting policies
are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements or involve a significant
level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results
of operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt">Research and development activities
are expensed as incurred. As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued
research and development expenses, including those related to clinical trials and product candidate manufacturing. This process involves
reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed
on our behalf and estimating the level of service performed and the associated cost incurred for the services when we have not yet been
invoiced or otherwise notified of actual costs. Our service providers invoice us in arrears or require prepayments for services performed,
as well as on a pre-determined schedule or when contractual milestones are met. We make estimates of our accrued expenses as of each balance
sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm
the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and
development expenses include fees paid to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors
    in connection with preclinical and clinical development activities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs
    in connection with clinical trials; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMOs
    in connection with the process development and scale-up activities and the production of preclinical and clinical trial materials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Costs for clinical trials and
manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using
data such as participant enrollment, clinical site activations, or information provided to us by our vendors regarding their actual costs
incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from
the period in which the services were performed. We determine accrual estimates through reports from and discussions with applicable personnel
and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued
expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance
are deferred as a prepaid expense and amortized over the service period as the services are provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Although we do not expect our
estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed
relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low
in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development
expenses. However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as
we become aware of additional information about the status or conduct of our clinical trials and other research activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b><i>Fair Value Measurements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Our recurring fair value measurements primarily
consist of the convertible promissory notes prior to the Merger, for which we elected the fair value option, the freestanding $14 million
purchase option under the Loan Agreement, and the bifurcated purchase option that is embedded within the loan commitment under the Loan
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We used the Probability Weighted Expected
Return Method (&#8220;PWERM&#8221;) valuation methodology to determine the fair value of the convertible promissory notes prior to the
Merger for all the periods presented. The PWERM is a scenario-based methodology that estimates the fair value based upon an analysis of
future values for the company, assuming various outcomes. The value is based on the probability-weighted present value of expected future
investment returns considering each of the possible outcomes available. The future value under each outcome is discounted back to the
valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value. Significant
assumptions used in determining the fair value of convertible promissory notes include volatility, discount rate, and probability of a
future liquidity event. In February 2024, concurrent with the Merger, we converted our outstanding convertible promissory notes into 10,337,419
shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">We used a Monte Carlo Simulation (&#8220;MCS&#8221;)
valuation methodology to determine the fair value of the freestanding $14 million purchase option and embedded purchase option associated
with the Loan Agreement at inception and as of December 31, 2024. The MCS methodology simulates our future stock price to estimate if
and when the Trailing VWAP will reach $10.00 per share, and discounts the resulting payoff back to each valuation date using a present
value factor. Significant assumptions used in determining the fair value of these options include volatility and discount rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Awards under our compensation
plans are accounted for in accordance with Accounting Standards Codification 718, Compensation &#8211; <i>Stock Compensation</i>. Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. We use the straight-line
method to record compensation expense of awards with service-based vesting conditions. We account for forfeitures of stock-based awards
as they occur. We recognize share-based compensation expense for awards with performance conditions when it is probable that the condition
will be met, and the award will vest. Prior to the Merger, we estimated the fair value of our Common Stock in accordance with the guidance
outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of Privately-Held-Company
Equity Securities Issued as Compensation</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">See Note 3 to our consolidated
financial statements found in this Annual Report for a description of recent accounting pronouncements applicable to our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_013"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to
provide the information under this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_014"></span>Item
8. Financial Statements and Supplementary Data.&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
information appears following Item 16 of this Annual Report and is incorporated herein by reference.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_015"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_016"></span>Item
9A. Controls and Procedures.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures (as defined in&#160;Rules 13a-15(e) and&#160;15d-15(e) under the&#160;Exchange Act) as of December 31, 2024.
Based on such evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2024, our disclosure
controls and procedures were&#160;not effective due to the material weaknesses in internal control over financial reporting described
below. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance
with GAAP. Accordingly, notwithstanding such material weaknesses, management has concluded that our consolidated financial statements
included in this Annual Report present fairly, in all material respects, our financial condition, results of operations and cash flows
at and for the periods presented in accordance with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limitations
on Effectiveness of Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there may be resource constraints, and that management is required to
apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required by SEC rules and regulations implementing Section 404 of the Sarbanes-Oxley Act, our management is responsible for establishing
and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).
Our internal control over financial reporting was designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of our financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial
reporting includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain
                                            to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
                                            transactions and dispositions of the assets of our Company,</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
                                            reasonable assurance that transactions are recorded as necessary to permit preparation of
                                            financial statements in accordance with GAAP, and that our receipts and expenditures are
                                            being made only in accordance with authorizations of our management and directors, and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
                                            reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
                                            use or disposition of our assets that could have a material effect on the financial statements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control - Integrated Framework (2013).&#8221;
Based on this assessment, our management concluded that we did not maintain effective internal control over financial reporting as of
December 31, 2024, due to the material weaknesses in our internal control over financial reporting related to not maintaining a sufficient
complement of personnel commensurate with accounting and reporting requirements resulting in inadequate segregation of duties over the
preparation, review and posting of manual journal entries to the general ledger, and in not having a sufficient risk assessment process
to identify and analyze risks of misstatement due to error and/or fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Efforts
to Address the Material Weaknesses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to evaluate steps and measures to remediate our material weaknesses, including the potential hiring of additional accounting
personnel with appropriate expertise in accounting and reporting under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;)
and SEC regulations in order to better align with segregation of duties and perform appropriate risk assessment procedures to evaluate
risks of material misstatement. The status of any efforts to address the material weakness will be reported by management to the audit
committee on a consistent basis. The material weakness will not be considered remediated until the applicable controls operate for a
sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal controls over financial reporting during the quarter ended December 31, 2024 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_017"></span>Item
9B. Other Information.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)&#160;<span id="xdx_90D_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zTouFtewsDe8" title="Non-Rule 10b5-1 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90F_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zAN7bFL4ipZ2" title="Non-Rule 10b5-1 Arrangement Adopted" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000069" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000071" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>&#160;or&#160;<span id="xdx_90E_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zI6h9KT8xkB1" title="Non-Rule 10b5-1 Arrangement Terminated" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90D_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zSuvUwa1yJJk" title="Non-Rule 10b5-1 Arrangement Terminated" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000073" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000075" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span>&#160;a
&#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a)
of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_018"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_019"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="g_020"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
10. Directors, Executive Officers and Corporate Governance.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information regarding our executive officers is set forth in Part I of this Form 10-K under the caption &#8220;Information About our
Executive Officers&#8221; and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our system of corporate governance, our Board of Directors has adopted a Code of Business Conduct and Ethics that applies to
our principal executive officer and senior financial officers. Our Code of Business Conduct and Ethics is available on our website at
ir.tevogen.com/governance. We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or
waiver from, a provision of the Code of Business Conduct and Ethics that applies to our principal executive officer or senior financial
officers by posting such information on our website at the address above. The information on or available through our website is expressly
not incorporated by reference in this Form 10-K, and any reference to our website is intended to be an inactive textual reference only.
Printed copies of our Code of Business Conduct and Ethics may be obtained, without charge, by contacting us at 15 Independence Boulevard,
Suite #410, Warren, New Jersey 07059.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
additional information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule
14A within 120 days after December 31, 2024, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_021"></span>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within
120 days after December 31, 2024, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="g_022"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within
120 days after December 31, 2024, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="g_023"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Certain Relationships and Related Transactions, and Director Independence.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within
120 days after December 31, 2024, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="g_024"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Principal Accounting Fees and Services.&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within
120 days after December 31, 2024, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_025"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="g_026"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Exhibits and Financial Statement Schedules.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The following documents are filed as part of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Tevogen Bio Holdings Inc. are filed as part of this Form 10-K under Item 8. Financial Statements and Supplementary
Data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Financial Statement Schedules</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other schedules have been omitted because they are not required, not inapplicable, or the required information is included in the financial
statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated herein (numbered
in accordance with Item 601 of Regulation S-K).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_027"></span>Item
16. Form 10-K Summary.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
Index</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated June 28, 2023, by and among the Company, Semper Merger Sub, Inc., SSVK Associates, LLC, Tevogen Bio Inc, and Ryan Saadi, in his capacity as seller representative (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on June 29, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224010806/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on March 21, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224012650/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A-1 Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on April 2, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224033756/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series C Preferred Stock of Tevogen Bio Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on August 23, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921135566/tm2132195d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agreement, dated November 3, 2021, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on November 8, 2021 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465921124178/tm2126753d1_ex4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1 (Registration Statement No. 333-260113) filed with the SEC on October 7, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service Agreement, dated as of April 15, 2022, between Tevogen Bio Inc and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.15 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of June 9, 2022, between Tevogen Bio Inc and Wanamaker Office Lease, LP (incorporated by reference to Exhibit 10.16 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223042391/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of February 14, 2022, between Tevogen Bio Inc and Mitsui Sumitomo Insurance Company of America (incorporated by reference to Exhibit 10.17 to Amendment No. 2 to the Registration Statement on Form S-4 (Registration No. 333-274519) filed with the SEC on November 22, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465923057818/tm2315115d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated May 3, 2023, by and among Semper Paratus Acquisition Corporation, Semper Paratus Sponsor LLC and Polar Multi-Strategy Master Fund (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 9, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000110465923057818/tm2315115d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement, dated May 4, 2023, by and among SSVK Associates, LLC, Semper Paratus Acquisition Corporation and Semper Paratus Sponsor LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 9, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315223029606/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated June 20, 2023, by and among Semper Paratus Acquisition Corporation, Semper Paratus Sponsor LLC and Polar Multi-Strategy Master Fund (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed with the SEC on August 21, 2023 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Registration Rights Agreement, dated February 14, 2024, by and among the Company, SSVK Associates, LLC, Semper Paratus Sponsor LLC, Cantor Fitzgerald &amp; Co., and the other signatories thereto (incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Competition and Non-Solicitation Agreement, effective as of February 14, 2024, by and between the Company and Ryan Saadi (incorporated by reference to Exhibit 10.8 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224023230/ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Unit Agreement (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-8 (Registration No. 333-280075) filed with the SEC on June 10, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Unit Agreement, dated as of February 14, 2024, by and between the Company and Ryan Saadi (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224006751/ex10-10.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.10 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224012650/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Securities Purchase Agreement, dated as of March 27, 2024, by and between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 2, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224023483/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement, dated as of June 6, 2024, between Tevogen Bio Holdings Inc. and The Patel Family, LLP (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 11, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex19-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen Bio Holdings Inc. Insider Trading Policy</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">21.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex21-1.htm">Subsidiary of the Registrant</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of KPMG LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1860871/000149315224016796/ex97-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed with the SEC on April 29, 2024 (File No. 001-41002))</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EX-101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
    and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a
    copy of any omitted schedule or exhibit to the SEC upon request.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    management contract or compensatory plan.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#v_010">Report of Independent Registered Public Accounting Firm</a> (KPMG LLP, Philadelphia, PA, Auditor Firm ID: <span id="xdx_90C_edei--AuditorFirmId_c20240101__20241231_zQGUvgeBHyeb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000076" name="dei:AuditorFirmId">185</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#v_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets, December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#v_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations, Years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#v_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Deficit, Years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><a href="#v_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows, Years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#v_015">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="v_010"></span><b>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Opinion
on the Consolidated Financial Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_98F_edei--AuditorOpinionTextBlock_c20240101__20241231_z708kZ5JDAlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000077" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Tevogen Bio Holdings Inc. and subsidiaries (the Company) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; deficit, and cash flows for the
years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
for Opinion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_909_edei--AuditorName_c20240101__20241231_zRN5D7AXZbLd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000078" name="dei:AuditorName">KPMG LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--AuditorLocation_c20240101__20241231_zOOzlaUMNaob"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000079" name="dei:AuditorLocation">Philadelphia,
Pennsylvania</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="v_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zNOiVjVr2Vjh" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zRixDaXw3Bzh" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zgTL37f9Hirb" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; font-weight: bold; padding-left: 0pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_i02I_pp0p0_maACzVF6_zWQi3aP8kOrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-indent: 0pt; padding-left: 0.125in">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,282,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzVF6_zyCHvau8Amd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">919,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">670,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherReceivablesNetCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzW0w_maACzVF6_ziMFuhLyEgu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Due from related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000093" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">158,819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzVF6_maAzJRK_zwX9rerrYStk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,360,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,722,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzJRK_zRNKJ8zuHbl3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">296,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">458,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0_maAzJRK_z1CBk68BbuEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Right-of-use assets - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">228,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">469,862</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredCosts_i01I_pp0p0_maAzJRK_zJvvHFFsWdhg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,582,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsNoncurrent_i01I_pp0p0_maAzJRK_zVYKRunC6yO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">575,841</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_pp0p0_mtAzJRK_z3hfZDMJ8in1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,461,675</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,505,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; font-weight: bold; text-align: left; padding-left: 0pt">Liabilities and stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzRlS_zd5VkggZqIU" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,200,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,418,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzRlS_z2PdMrCg00Lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,712,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,096,450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzRlS_zTa67oIPUnac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">252,714</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayableCurrent_i02I_pp0p0_maLCzRlS_zMei7LPD0EQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,651,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0130">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pp0p0_maLCzRlS_zUOC4Px1Y0B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,712,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzRlS_zdguIIy88Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Due to related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000135" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzRlS_maLzUvu_zPIhUQ9htrR2" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,042,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,479,542</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ConvertibleLongTermNotesPayable_i01I_pp0p0_maLzUvu_zNKuFSI49bAj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,220,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LoanAgreementNoncurrent_i01I_pp0p0_maLzUvu_zFaUxXlfhOvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:LoanAgreementNoncurrent" contextRef="AsOf2024-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0_maLzUvu_z9htFgx9Gxa3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_pp0p0_maLzUvu_zbdnH2nKfKyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Derivative warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_pp0p0_mtLzUvu_maLASEzTUz_zaj7FwVUcMKl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,135,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,934,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAUBRU0i5cXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0.125in">Series A Preferred Stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWsWgC8s1ZS1" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
    par value; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8hWMnrTfHTj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></span>
    shares authorized; <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znps8m5P8ky4" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAtD5ZQGSvE6" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of December 31, 2024 (liquidation value of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zW4sQRz8ksKl" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,076,712</ix:nonFraction></span> at December 31, 2024)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000159" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z6knxXlf9W2h" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0.125in">Series C Preferred Stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zTJPkGvrjwrd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
    par value; <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zANAxczLmOv3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span>
    shares authorized; <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjso6rI5XTig" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zvnQatHYTiG2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of December 31, 2024 (liquidation value of $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zCtxCi6aPNM2" title="Preferred stock, liquidation value"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,082,603</ix:nonFraction></span> at December 31, 2024)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000172" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzG1Y_z8RuUGYjw1N1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0.125in">Preferred Stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000185" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzG1Y_zGBwZPX3Cz05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0.125in">Common stock, $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zRtAiCoYro7g" title="Common shares, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zyhhW2Rn70Ag" title="Common shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zwQLjZWAjgpf" title="Common shares, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zLIE8YVsTAE1" title="Common shares, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20241231_zqu9SiYzerzd" title="Common shares, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zPGk80SYvbjb" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20231231_zO3gu3TzsNm7" title="Common shares, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z8aicMTUPER9" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzG1Y_zozQ7hV1DASh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,893,322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzG1Y_zK2uclp2RPS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">113,385,117</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzTUz_mtSEzG1Y_zQ3Zj9pU8Jm7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,674,005</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzTUz_z3TSwgHzdUAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,461,675</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,505,503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="v_012"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zC7e2KJDBRt9" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zSVAB9Lo6za9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zhKSeQR4KGPc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzkfw_zXuxbuhCzVNd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0.125in">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,033,276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,403,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzkfw_zKffAuRKmkg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,531,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,439,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzkfw_msOILzXle_zhCCYoGp8Ofc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,564,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,843,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzXle_maNILz4Z0_z3Ee51mzwkGc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Loss from operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">53,564,488</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,843,025</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestExpense_iN_di_msNILz4Z0_zXwshujxaOy2" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,037</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,206,352</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_iN_pp0p0_di_msNILz4Z0_zYsbEGjtzBee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,499,353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_iN_pp0p0_di_msNILz4Z0_zUFpF2OrWayd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_maNILz4Z0_zNT4RNMigU4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2024-01-01to2024-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2023-01-012023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,428,303</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--LossOnIssuanceOfCommitmentShares_iN_pp0p0_di_msNILz4Z0_ze3deK75mdn8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Loss on issuance of commitment shares</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2024-01-01to2024-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">890,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILz4Z0_zwTwWNSz91Ra" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Net loss attributable to common
    stockholders, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20240101__20241231_zzFCb38Is975" title="Net loss attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20240101__20241231_z1T0rpANwZt5" title="Net loss attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,273,695</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20231231_zReQMxY5hY74" title="Net loss attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20230101__20231231_za0Ulbjcug3i" title="Net loss attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Net loss per share attributable to common stockholders, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zUEtfG0cj7oc" title="Net loss per share attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_z29yJUZ3XCAk" title="Net loss per share attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.07</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zP9ghYWblEag" title="Net loss per share attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zKUVdQDMEQ84" title="Net loss per share attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.44</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-left: 0pt">Weighted-average common stock outstanding, basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z0uGRMBxfPFl" title="Weighted-average common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zVK2WBYQ6r78" title="Weighted-average common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,672,534</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zvHtSOaZtxE7" title="Weighted-average common stock outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zEURwIwN3pz7" title="Weighted-average common stock outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,752,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="v_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_114_zvSF79Gy9oii" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_z5HX93Wk2ZCj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_z6A0cAHsiOP" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zhgqpPcbosIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zCpMH27dp1Oi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z52axlCh4sG5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zF7U3L1pNzd3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_zrRe45TqNXIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series A Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series B Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series C Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional Paid-in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Total Stockholders&#8217; Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43A_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zXvVuLsxixfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt; width: 12%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbBFDen1wXwl" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWTLEbpMF3I7" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuyDIDFLc53d" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRHIbQbQT9K9" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,180,057</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,951,217</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zwHf3oQmmLZk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zvNKwGW5M6Fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLPtHyGazW8h" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z5RFajpCH4h3" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQpvEh9xIG5b" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5d1eVqYi5g" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000305" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000306" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zhXVLPBv5Lg6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVkzo3LhIcN8" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zERJZIrYtif9" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbwFqnC3RGKe" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6ycK5fFPVSb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,999,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,216,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,657,737</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,428,897</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zsxd73DFowC7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwEQ6yOhpXQl" title="Issuance of preferred stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueNewIssuesTwo_zXbi3BOK6gz7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesNewIssuesTwo_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQGKXvenqkz3" title="Issuance of preferred stock, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-01to2024-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zghjOCcLgGd5" title="Issuance of Series B preferred stock, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-01to2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zMkU9xlh4ZMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Conversion of convertible promissory notes into common stock in connection with merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCCTwb4E2pZ7" title="Conversion of convertible promissory notes into common stock in connection with merger, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,337,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,621,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,622,627</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--MergerNetOfRedemptionsAndTransactionCosts_iN_di_zqQFLfiT6dYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Merger, net of redemptions and transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCHXY2lgye4" title="Merger, net of redemptions and transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,778,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,885,459</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:MergerNetOfRedemptionsAndTransactionCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,883,981</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of restricted common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zESOWQzBVUs9" title="Issuance of restricted common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock for Sponsor advisory service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zchUxVDsD7Cf" title="Issuance of common stock for Sponsor advisory service fee, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000400" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-01to2024-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_zP0UXqbFsY77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of commitment shares in connection with the loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJpjxcl7bjX4" title="Issuance of commitment shares in connection with the loan agreement, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">889,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" contextRef="From2024-01-01to2024-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">890,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_zl68YESCLWBe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock in connection with Polar note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zznPsufHQzvl" title="Issuance of common stock in connection with Polar Note, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000420" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000416" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueContributionFromRelatedParty_zjhZVuboDyVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Contribution from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesContributionFromRelatedParty_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6cOGE3vx0ej" title="Contribution from related party, shares" style="text-align: right">(<ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,613</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_zzOasmd24BI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2024-01-01to2024-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_zSfDUvz8ft0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock in settlement of vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVRjoxV5BFr9" title="Issuance of common stock in settlement of vested restricted stock units, shares" style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,876,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,088</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zV5xtDxf3Kl6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_z0hylcIgvjYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zFl21CcfBvy4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQqUUZGlE0lf" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkCrzQTv29v2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjgGzYvKuAo6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000478" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvr38ygbl703" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000480" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,893,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000471" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,385,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,674,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zEPZhvnOTmZh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLJEIVCw388" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,799,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwJPx88OuRDg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBpSUNJkfeT9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUFs6HHcFWc4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,893,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000487" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">113,385,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,674,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="v_014"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEVOGEN
BIO HOLDINGS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zzfFYKEa7Wz9" summary="xdx: Statement -  Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zNnQU2Ad9sK8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zsKrBJB6zMFa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzsTD_zcsVHsZN3le8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 0.125in">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Depreciation_i02_pp0p0_maNCPBUzsTD_z4hYBT4KqAge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUzsTD_z6i10VkPNJD1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaidInKindInterest_i02_pp0p0_maNCPBUzsTD_z8AqUDFvUxt7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">187,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2023-01-012023-12-31" id="Fact000514" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,206,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NoncashMergerRelatedCosts_i02_pp0p0_maNCPBUzsTD_zAEqJE0RUCDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Merger transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,099,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_i02N_pp0p0_di_msNCPBUzsTD_zPzKmMsqDm4d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Change in fair value of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2024-01-01to2024-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ChangeInFairValueOfConvertiblePromissoryNotes" contextRef="From2023-01-012023-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">50,428,303</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnPreferredStockIssuance_i02_pp0p0_maNCPBUzsTD_zk0EGdLI8153" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Loss on Series A Preferred Stock issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">799,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossOnIssuanceOfCommitmentShares_i02_pp0p0_maNCPBUzsTD_z0Xl8rMRLqX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Loss on issuance of commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:LossOnIssuanceOfCommitmentShares" contextRef="From2024-01-01to2024-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">890,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUzsTD_zdHyOVK5vk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Change in fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pp0p0_maNCPBUzsTD_zfbUJAN6fBo7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Amortization of right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-012023-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">215,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzsTD_zyPIbfcEk5yc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,005</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">317,605</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_pp0p0_di_msNCPBUzsTD_zLquE0HeUrui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">511,011</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-012023-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">323,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_pp0p0_maNCPBUzsTD_zFKwCFzaSz6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2024-01-01to2024-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,685,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2023-01-012023-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,114,261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_pp0p0_maNCPBUzsTD_zFKQsjCvFwWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.375in">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">681,450</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">603,832</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pp0p0_maNCPBUzsTD_zpL7HGeTck78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.375in">Operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">252,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">223,361</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzsTD_maCCERCzjKL_zBB9V6DID5Re" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.5in">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,998,730</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,171,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzU3Z_zsEFXQ7tF9f4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.25in">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzU3Z_maCCERCzjKL_zW9Op6YT7MBk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.5in">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CashAcquiredInConnectionWithReverseRecapitalization_i01_pp0p0_maNCPBUz0HS_zKnvhrCKYvc1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Cash acquired in connection with the reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:CashAcquiredInConnectionWithReverseRecapitalization" contextRef="From2024-01-01to2024-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_pp0p0_maNCPBUz0HS_zff7wySakpu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Proceeds from issuance of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-01to2024-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ProceedsFromIssuanceOfSeriesCPreferredStock_i01_pp0p0_maNCPBUz0HS_zXLrBcUNgo9a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Proceeds from issuance of Series C Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromLinesOfCredit_i01_pp0p0_maNCPBUz0HS_zen2S1Ln3yj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Proceeds from loan agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2024-01-01to2024-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_i01_pp0p0_maNCPBUz0HS_zbDUbhdRHZz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_i01N_pp0p0_di_msNCPBUz0HS_zvWOBiWDxMJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Payments of deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,750</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUz0HS_zGFvFEoWIVA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Proceeds from issuance of convertible promissory notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000586" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUz0HS_maCCERCzjKL_zBAm8S8BbSyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.5in">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,229,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,872,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzjKL_zq4ViZlNAACe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,598</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000592" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,431,868</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: 0pt; padding-left: 0.125in">Cash &#8211; beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,484,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0.125in">Cash &#8211; end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,282,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000598" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,397</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Supplementary disclosure of noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_i01_pp0p0_zlor4JTtnj4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Reverse recapitalization transaction fees included in accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,455,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtConversionOriginalDebtAmount1_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Conversion of convertible promissory notes into common stock in connection with Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2024-01-01to2024-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,622,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--RepurchaseOfSeriesBPreferredStock_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Repurchase of Series B preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:RepurchaseOfSeriesBPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssued1_i01_pp0p0_zg54kNlaiiA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.125in">Issuance of common stock for net liabilities upon reverse  recapitalization, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-01to2024-12-31" id="Fact000612" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,113,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="v_015"></span><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000615" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCNaGI6GbMM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82B_zN9tcoyn3jBc">NATURE OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage specialty immunotherapy company harnessing
the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases,
cancers, and other disorders. The Company&#8217;s precision T cell technology, ExacTcell, is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets.
The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of
ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the &#8220;Merger
Agreement&#8221;) by and among Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK Associates, LLC (the &#8220;Sponsor&#8221;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the &#8220;Merger&#8221;
and together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination (the &#8220;Closing&#8221;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately&#160;<span id="xdx_909_ecustom--BusinessCombinationSharesExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9kQzOCdLY6" title="Share exchange ratio"><ix:nonFraction name="TVGN:BusinessCombinationSharesExchangeRatio" contextRef="AsOf2024-02-14_us-gaap_CommonStockMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.85</ix:nonFraction></span>&#160;shares of Company
common stock for each share of Tevogen Bio common stock (the &#8220;Exchange Ratio&#8221;). See Note 4 for more information on the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_z8YaQSRt0PL" title="Equity holders percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_TevogenBioMember" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.0</ix:nonFraction></span>% of the outstanding shares
of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SemperParatusMember_zS1x4Q5pwyxe" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_SemperParatusMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.0</ix:nonFraction></span>%
of the Company.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000623" name="TVGN:DevelopmentStageRisksAndLiquidityTextBlock"><p id="xdx_80E_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zSEL1kYFLT55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_825_zdaGSlgqJht8">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring
additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in
development. Management believes that cash of $<span id="xdx_901_eus-gaap--Cash_iI_c20241231_zGHO8recjvFj" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,282,995</ix:nonFraction></span>
as of December 31, 2024, the amounts available under the Loan Agreement entered into in June 2024 (as defined in Note 8), and the
commitment for an $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zaK1MocjrLd5" title="Grant received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction></span> grant from KRHP LLC, a New Jersey limited liability company (&#8220;KRHP&#8221;), will allow the
Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these
consolidated financial statements. Subsequent to December 31, 2024, the Company received a grant of $<span id="xdx_907_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziCgx2cNVqQ6" title="Grant received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>
from KRHP and drew $<span id="xdx_90C_ecustom--GrantDrewFromRelatedParty_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUKBhXmPDXii" title="Grant drew from related party"><ix:nonFraction name="TVGN:GrantDrewFromRelatedParty" contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>
in each of February 2025 and in March 2025 under the Loan Agreement. The grant funding may not be used for repayment of existing
debt obligations and does not include any requirement to repay the investor or to issue equity in consideration of the funding. KRHP
has committed to provide an additional $<span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_ztrY5a1rcjvc" title="Grant received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction></span> of grant funding to the Company to be used towards the Company&#8217;s ongoing
operational expenses. The grant funding will be used to satisfy the Company&#8217;s obligations as they come due through March 31,
2026. The Company does not plan to initiate a clinical trial until additional funding is received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect
the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and a clinical trial, and pursuing and completing the Business Combination. The Company is
subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
The Company&#8217;s research and development projects may not be successful, products developed may not obtain necessary regulatory approval,
and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change
and is largely dependent on the services of its employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000635" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zFtpcnRqHCDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82D_zIoAw2Lo0PA">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000637" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z6zGIDk7hIo2">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000639" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z9OsFUUKNFM7">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000641" name="TVGN:FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock"><p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjZOTYXrYvW1">Freestanding
and Embedded Common Stock Purchase Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-linked
purchase options issued in connection with the Company&#8217;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;<i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity&#160;</i>(&#8220;ASC
815&#8221;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#8217;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#8216;Change in
fair value of written call option derivative liabilities&#8217; within the consolidated statements of operations and consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000643" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zBYIf29m4TMl">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000645" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zqy1DxfGgale">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zCdpbsx6vrej" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact000647" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></span> segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000649" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zTyoPxhDqOEb">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public offering
(the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </i>(&#8220;ASC
815&#8221;) and ASC 480,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480&#8221;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#8217;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000651" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zPsHFdIWiME8">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory
notes.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000653" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" title="Fair value beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,297,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" title="Initial fair value at issuance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" title="Accrued interest expense" style="text-align: right"><ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,206,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,428,303</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" title="Fair value beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,932,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" title="Accrued interest expense" style="text-align: right"><ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000665" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000667" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,468,678</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" title="Derecognition upon conversion of convertible promissory notes" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000669" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,622,627</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" title="Fair value beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (<span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z545EdZ4cnwb" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80</ix:nonFraction></span>%), discount rate (<span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zECVEqwfbOp5" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">35</ix:nonFraction></span>% - <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_zzwuKcFjoQk4" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">36</ix:nonFraction></span>%), and probability of a future liquidity event (<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zEjMN6sa3IMj" title="Volatility"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">85</ix:nonFraction></span>% - <span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_zbUb1Yp6ohjb" title="Convertible promissory notes measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">95</ix:nonFraction></span>%). The Company
used its stock price on the Closing Date to determine the fair value for the  derecognition of the convertible promissory notes
upon conversion on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuQ5OVhtN1ue"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000682" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,180</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#8217;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgANSzrkc1n5"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000683" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">375,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000685" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE OF FAIR VALUES OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written call option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at February 15, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" title="Derivative warrant liabilities, Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" title="Derivative warrant liabilities, Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" title="Initial fair value at issuance" style="width: 16%; text-align: right"><ix:nonFraction name="TVGN:DerivativeLiabilitiesFairValueIssuance" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" title="Initial fair value at issuance" style="width: 16%; text-align: right"><ix:nonFraction name="TVGN:DerivativeLiabilitiesFairValueIssuance" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember" id="Fact000697" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">375,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" title="Derivative warrant liabilities, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" title="Derivative warrant liabilities, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000703" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets <br/> (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs <br/> (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Unobservable <br/> Inputs (Level 3)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" title="Derivative warrant liabilities" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" title="Derivative warrant liabilities" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" title="Derivative warrant liabilities" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000709" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#8220;MCS&#8221;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;<span id="xdx_908_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zo9yBcrmtNi7" title="Stock, measurement input"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">75</ix:nonFraction></span>% to&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi" title="Alternative investment, measurement input"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact000713" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">85</ix:nonFraction></span>%, a holding
period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;<span id="xdx_907_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zNKj7Fj8NTb3" title="Holding period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000715" name="TVGN:EquitySecuritiesTerm">0.5</ix:nonNumeric></span>&#160;to&#160;<span id="xdx_905_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_z7eHCVkhCn6" title="Range in years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000717" name="TVGN:EquitySecuritiesTerm">10.0</ix:nonNumeric></span>&#160;years,
and a risk-free interest rate between&#160;<span id="xdx_903_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ztGJw2vPfY57" title="Risk-free interest rate percentage"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.3</ix:nonFraction></span>% and&#160;<span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z0dBlZtpCM79" title="Stock, measurement input"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.3</ix:nonFraction></span>%. The difference between the cash received of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsEMs6S6rOn8" title="Cash received upon issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>&#160;upon issuance
of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a MCS valuation methodology to determine the fair value of the freestanding $<span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zu2sTFTPziLj" title="Free standing purchase options"><ix:nonFraction name="TVGN:FreeStandingPurchaseOptions" contextRef="From2024-01-01to2024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></span>&#160;purchase option and remaining
embedded $<span id="xdx_90C_ecustom--EmbeddedOptions_c20240101__20241231_zc8eFNvcHCu5" title="Embedded options"><ix:nonFraction name="TVGN:EmbeddedOptions" contextRef="From2024-01-01to2024-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span>&#160;purchase option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the
Company&#8217;s future stock price to estimate if and when the Trailing VWAP (as defined below) will reach $<span id="xdx_907_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zV3ZldBNhFwg"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>&#160;per share, and
discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;<span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">78.3</ix:nonFraction></span>% and discount rate of&#160;<span id="xdx_90B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zXlSz5FcJLKh"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.3</ix:nonFraction></span>%. At December 31, 2024, the MCS produced
a fair value of $<span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zbJgzA6FSiy6" title="Fair value"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2024-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> relating to these freestanding and embedded options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000734" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zfPQfeKGxXZ1">Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_ziFSTW2Sk4gi" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zTSLrHP6qI37" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000736" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000738" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000740" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zoqVO2hfbssd">Property
and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000742" name="TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock"><p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000744" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000746" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000748" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000750" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000752" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000754" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z4mqZGMPTzPj">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zlzIGLkluEAc" title="Leases initial term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:durwordsen" id="Fact000756" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">12 months</ix:nonNumeric></span> or less and without a purchase option that the Company is reasonably certain of exercising are not
included within the lease ROU assets and lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000758" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z51STCTlamK2">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000760" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zN8KNyRNRiS1">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#8217;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000762" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zldsYnnmPWEb">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000764" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_znCeJn71YSG1">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#8217;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000766" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOYer4WwVUw5">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07,&#160;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;</i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) </i>(&#8220;ASU 2024-03&#8221;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.</span></p>

</ix:nonNumeric><p id="xdx_853_znCRnm9LZro" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000768" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zqNIOxtWAU41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4.&#160;<span id="xdx_82A_zDbQ2iMDygAd">BUSINESS COMBINATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including
that following the Merger, former Tevogen Bio (i) equity holders and holders of convertible promissory notes owned approximately&#160;<span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zjhGpEZDB0vh" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_TevogenBioMember" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.0</ix:nonFraction></span>%
of the Company, (ii) directors constituted the majority (six of seven) of the directors of the Company, and (iii) management held all
key positions of management of the Company. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire
the net assets of Semper Paratus. As a result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date
fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Tevogen Bio.
Immediately after the Merger, there were&#160;<span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20240214_z753sBkvdcH" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-02-14" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,614,418</ix:nonFraction></span>&#160;shares of the Company&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000774" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zCTQj89vyov1" style="display: none">SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February&#160;14,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2024-02-14" id="Fact000776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="AsOf2024-02-14" id="Fact000778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,819</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2024-02-14" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,501</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2024-02-14" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,175</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="AsOf2024-02-14" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,126</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" contextRef="AsOf2024-02-14" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Derivative warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="AsOf2024-02-14" id="Fact000788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2024-02-14" id="Fact000790" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,654,653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:MergerTransactionCostsLimitedToCashAcquired" contextRef="AsOf2024-02-14" id="Fact000792" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">229,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" contextRef="AsOf2024-02-14" id="Fact000794" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,883,981</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zqlUY39z45fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
transaction costs of $<span id="xdx_908_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240214__20240214_zP1fDqF5q1kd" title="Transaction costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-02-142024-02-14" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,728,681</ix:nonFraction></span>&#160;were incurred in relation to the Business Combination through the Closing Date, of which $<span id="xdx_909_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_zDfqsdo3iXNk" title="Transaction costs charged to equity"><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="AsOf2024-02-14" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,328</ix:nonFraction></span>&#160;were
charged directly to equity to the extent of the cash received from the Business Combination, with the balance of $<span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240101__20241231_zgddjwounOZ2" title="Merger transaction costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499,353</ix:nonFraction></span>&#160;charged
to Merger transaction costs for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240214__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zEzmDjBmWlb6" title="Earnout shares issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-02-14_custom_EarnoutSharesMember" id="Fact000802" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500,000</ix:nonFraction></span>&#160;shares of common
stock (&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Company&#8217;s common stock
reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5, Earnout Shares, for
further details of the earnout arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor in return for the Sponsor assuming $<span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_c20240214__20240214_zjD7fdFKOdr" title="Issuance of Series B preferred stock"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-02-142024-02-14" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></span>&#160;of
liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. The issuance date fair value of the
Series B Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. All of the issued
Series B Preferred Stock was repurchased by the Company during the three months ended June 30, 2024 in exchange for the Sponsor being
released from their obligation to repay the Assumed Liabilities. See Note 12 for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000806" name="TVGN:EarnoutSharesDisclosureTextBlock"><p id="xdx_806_ecustom--EarnoutSharesDisclosureTextBlock_zagX6b1RQoS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5.&#160;<span id="xdx_82B_znlZKg6laZk7">EARNOUT SHARES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, former holders of Tevogen Bio common stock may receive up to&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_z844gkSOWlx9" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember" id="Fact000808" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span>&#160;Earnout Shares in tranches of&#160;<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zuzU6iWvKd8d" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span>,&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zT17NDLXKdXi" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span>,
and&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zJTNwFOh7I2l" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,666</ix:nonFraction></span>&#160;shares of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP
per share of the Company&#8217;s common stock is greater or equal to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA1zCKVSTS11" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span>, $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuyvJJIBokQj" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember" id="Fact000818" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.50</ix:nonFraction></span>, and $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGw48JnhzVwf" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>, respectively, over any twenty trading
days within any thirty consecutive day trading period during the three-year period after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#8217;s three earnout tranches
are for&#160;<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z4KFltTC2ru6" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span>&#160;shares of common stock, for an aggregate of&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zBKKDaByl4Al" title="Earnout shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember" id="Fact000824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500,000</ix:nonFraction></span>&#160;shares of common stock across the entire
Sponsor earnout. The Earnout Shares are a form of dividend for holders of Tevogen Bio common stock, and the Earnout Shares earnable by
the Sponsor are treated as contingent consideration in a reverse recapitalization. In accordance with ASC 815, the Earnout Shares were
considered to be indexed to the Company&#8217;s common stock and are classified within permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000826" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z8VPehfYwEia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_823_zklmFykksWod">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000828" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zL4gRjUr8gL8" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ComputerAndSoftwareMember" id="Fact000830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerAndSoftwareMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,217</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,769</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,327</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,651</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zsRWGRsOH3c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_90A_eus-gaap--Depreciation_c20240101__20241231_ztgdRLVGznQd" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000851" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,209</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--Depreciation_c20230101__20231231_zfXzM9btM0hb" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,300</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000855" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6RfvuWeYq5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_827_zRrSDVU9XqN4">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000857" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zB2Az3kYPDPi" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    services</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,309,163</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,301</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,233</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,149</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,712,396</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,450</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_z7WvcneI6UYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000868" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zw2kLZQBNkj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8.&#160;<span id="xdx_823_zgdJfRsQOU48">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, previously issued promissory notes and accrued interest
were automatically converted into an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240214__20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEK5y4HKzDQk" title="Converted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-02-142024-02-14_us-gaap_CommonStockMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,337,419</ix:nonFraction></span> shares of common stock. These debt obligations were retired upon conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with The Patel Family, LLP (the &#8220;Patel Family&#8221;),
a related party of the Company, providing for an unsecured line of credit facility (the &#8220;Facility&#8221;) for term loans of up
to an initial total of $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zxsAadBIcza1" title="Line of credit maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000,000</ix:nonFraction></span>. Under the Facility, the Company may draw up to $<span id="xdx_900_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z8mf9puuQScj" title="Line of credit borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000874" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>&#160;in term loans per calendar month over
a draw period of 36 months. Each term loan draw will have a maturity date of&#160;<span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zrryz2lcOsJd" title="Debt maturity date"><ix:nonNumeric contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" format="ixt-sec:durmonth" id="Fact000876" name="us-gaap:DebtInstrumentTerm">48</ix:nonNumeric></span>&#160;months and will accrue interest at the lower
of (i) daily SOFR plus&#160;<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zuySRYwHK8Ei" title="Debt instrument variable rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.00</ix:nonFraction></span>% and (ii)&#160;<span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zIvaeYSPmbGa" title="Debt instrument interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction></span>%. Interest accrues quarterly and is payable on the three-month anniversary of the
draw date. Interest is payable in shares of common stock at an effective price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zM8NfIOFCS2f" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span>&#160;per share. Interest payable through December
31, 2024 relating to the first two draws on the Facility were settled in February 2025 through issuance of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_ziYglc8zbDJa" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,847</ix:nonFraction></span> shares of common stock.
Principal may be prepaid at any time without penalty, and repayments or prepayments may be made in cash or common stock at the Company&#8217;s
election. Payments of principal in common stock would be made at an effective price of the greater of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__srt--RangeAxis__srt--MaximumMember_zYzKJtAyeaec" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span>&#160;per share and the ten-day
trailing volume weighted average price per share of the common stock (the &#8220;Trailing VWAP&#8221;) as of the trading day prior to
payment. As an inducement to enter into the Loan Agreement, the Company issued&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_znCkx6wZyMk3" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of common stock to the Patel Family
during June 2024. As of December 31, 2024, the Company has drawn $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zo28h9XX9xBc" title="Line of credit borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>&#160;from the Facility, with maturity dates in July and August 2028, with a remaining $<span id="xdx_907_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zQJVNySeYQ54" title="Line of credit remaining capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000,000</ix:nonFraction></span>&#160;available
for future financing over the remaining&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z5ChVKGiEFQh" title="Debt maturity date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" format="ixt-sec:durmonth" id="Fact000894" name="us-gaap:DebtInstrumentTerm">30</ix:nonNumeric></span>&#160;months. The Company drew an additional $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpE8RJPFn8Pa" title="Line of credit borrowing capacity"><span id="xdx_909_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zR7pcG1mWobj" title="Line of credit borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></ix:nonFraction></span></span> in each of February and March 2025, with maturity dates in February and
March 2029, respectively (see Note 17).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement includes a purchase option whereby the Patel Family has the option to purchase up to $<span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJkZ50n7lT18" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000,000</ix:nonFraction></span>&#160;of shares of common stock
at a purchase price equal to&#160;<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zRuIZHYmEz7a" title="Percentage of price of common stock purchased"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the Trailing VWAP per share (the &#8220;$<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zsFqU9TPVtn2" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000904" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million Purchase Option&#8221;). The $<span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zMXzkmwIoSY5" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000906" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million
Purchase Option only becomes exercisable once Trailing VWAP reaches $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zUNpmbR6fKPh" title="Purchase, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>&#160;per share. The $<span id="xdx_90D_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zwRode1UFF2g" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember" id="Fact000910" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million Purchase Option was determined
to be a freestanding derivative liability under ASC 815 and is carried at fair value, with changes in fair value recorded to change in
fair value of written call option derivatives liabilities within the consolidated statements of operations and consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes a purchase option (the &#8220;Additional Amount Purchase Option&#8221;) that is identical to the $<span id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zLeBpQ0QG6vk" title="Option to purchase common stock, value"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember" id="Fact000912" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million
Purchase Option, except that the option is exercisable for an amount up to the then-remaining undrawn term loan amount under the Loan
Agreement at the time Trailing VWAP reaches $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_ztNbS6XR3JGg" title="Purchase, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>&#160;per share. The Additional Amount Purchase Option was determined to be an embedded
derivative within the written loan commitment that requires bifurcation under ASC 815, and thus is carried at fair value with changes
in fair value recorded to change in fair value of written call option derivatives liabilities within the consolidated statements of operations
and consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
$<span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630_z1KuAUxd4G0f" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30" id="Fact000916" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million Purchase Option and the Additional Amount Purchase Option are recorded to written call option derivative liabilities
within the consolidated balance sheet and have a fair value of $<span id="xdx_90F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_zxpXfB9xpIm7" title="Derivative liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement is a written loan commitment that is not eligible for the fair value option under ASC 825,&#160;<i>Financial Instruments</i>.
However, management intends to elect the fair value option for future draws under this commitment, and therefore has expensed all issuance
costs associated with the Loan Agreement, which are comprised of the fair value of the&#160;<span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zx9g5g8Kjcrf" title="Issuance of commitment shares in connection with unsecured equity line of credit facility"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of common stock issued
to the Patel Family as well as the issuance date fair value of the $<span id="xdx_900_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zN2WjAXBmPE9" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember" id="Fact000922" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million Purchase Option and Additional Amount Purchase Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notes
Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) for which the
proceeds were to be used for working capital purposes by Semper Paratus with an outstanding balance of $<span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PolarMultiStrategyMasterFundMember_znJ5ftS26bml" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,000</ix:nonFraction></span>&#160;on the Closing
Date and remain outstanding at December 31, 2024. The notes payable do not accrue interest. The outstanding balance of the notes was
required to be repaid in full within five business days of the Merger, and the Company is therefore in default of its obligations at
December 31, 2024. The notes&#8217; default provisions do not require the Company to transfer any shares or pay any amounts to Polar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000926" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock"><p id="xdx_80E_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zc3CeCOj6qU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82C_zArk9wUoyvf7">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using incremental
borrowing rates ranging from <span id="xdx_90D_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zB8YyCh7E3ma" title="Operating leases incremental borrowing rates"><ix:nonFraction name="TVGN:OperatingLeasesIncrementalBorrowingRates" contextRef="From2024-01-012024-12-31_srt_MinimumMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.0</ix:nonFraction></span>% to <span id="xdx_90F_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z1hEkSCxIZxi" title="Operating leases incremental borrowing rates"><ix:nonFraction name="TVGN:OperatingLeasesIncrementalBorrowingRates" contextRef="From2024-01-012024-12-31_srt_MaximumMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.2</ix:nonFraction></span>%, which was determined using a synthetic credit rating model. Lease expense for the year ended
December 31, 2024 was $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zih4CLa5lv95" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,065,784</ix:nonFraction></span>, which consisted of $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zgoV4EtlJzzj" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">897,958</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zx7xhLtqdISl" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,826</ix:nonFraction></span> recognized as a component of research and development expense
and general and administrative expense, respectively. This amount included $<span id="xdx_90E_eus-gaap--ShortTermLeasePayments_c20240101__20241231_zvXFayMDshW2" title="Short term lease"><ix:nonFraction name="us-gaap:ShortTermLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">785,424</ix:nonFraction></span> of expense under short-term leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining lease term for the Company&#8217;s operating leases as of December 31, 2024 was <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXQ2DP3bHQk6" title="Operating leases weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact000940" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.93</ix:nonNumeric></span> years. The weighted average
discount rate for the Company&#8217;s operating leases for the year ended December 31, 2024 was <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z209KcV9MlL8" title="Operating leases weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact000942" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.1</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000944" name="TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock"><p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z56qhGR4fHig" style="display: none">SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Years Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,975</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,859</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zNODONkrSBx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash payments related to leases for the years ended December 31, 2024 and 2023 were $<span id="xdx_900_eus-gaap--OperatingLeasePayments_c20240101__20241231_z3eSn06J9Nq" title="Cash payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,077,127</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20230101__20231231_zP05UIXT7Qpb" title="Cash payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,058,754</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000960" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHq3GNNa6Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_821_zsWcklDknXOc">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the applicable agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000962" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyMCODyWWnya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_827_z4dAxgKik4m6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Each RSU award granted under the
2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024
Plan with respect to the common stock of the Company (the &#8220;Rollover RSUs&#8221;). Such Rollover RSUs remain subject to the same
terms and conditions as set forth under the applicable award agreement prior to the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to covering the Rollover RSUs, under the 2024 Plan, the Company is authorized to grant awards up to an aggregate&#160;<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zHzCwRN2s0nk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, Restricted Stock, RSUs, and other
equity-based awards. As of December 31, 2024, awards for <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zp4OZxGfChc2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,670,118</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
remained available to be granted under the 2024 Plan.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#8220;Performance-Based RSUs&#8221;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued an aggregate of&#160;<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zozYmExqOUAe" title="Number of shares issued for RSUs"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></span>&#160;RSUs under the 2024 Plan to the Company&#8217;s Chief Executive
Officer, Dr. Ryan Saadi (the &#8220;Special RSU Award&#8221;). Such RSUs immediately converted into shares of Restricted Stock, the restrictions
on which lapse in four equal annual installments beginning on February 14, 2031 (&#8220;Vesting Period&#8221;). Pursuant to the terms
of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred,
pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock
in the event he departs the Company. The fair value per share for the Special RSU Award was determined to be $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdXnDus2lokl" title="Fair value per share for award"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></span>&#160;per share, equivalent
to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date fair value of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLG0Lg6jZtLa" title="Grant date fair value of shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,263,783</ix:nonFraction></span>. In accordance with
ASC 718,&#160;<i>Compensation - Stock Compensation&#160;</i>(&#8220;ASC 718&#8221;), the Company will recognize compensation expense
on a straight-line basis from the Closing Date until the completion of the Vesting Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000972" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_zKiyxUa8Uqya" style="display: none">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock and RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" title="Nonvested Shares, Beginning" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" title="Nonvested weighted average grant-date fair value, Beginning" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0976">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" title="Nonvested Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" title="Nonvested Shares, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0986">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" title="Nonvested Shares, Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" title="Nonvested weighted average grant-date fair value, Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" title="Nonvested Shares, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,329,882</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" title="Nonvested weighted average grant-date fair value, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.31</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" title="Nonvested Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,639,628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.96</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" title="Nonvested Shares, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,690,254</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" title="Nonvested weighted average grant-date fair value, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.54</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" title="Nonvested Shares, Beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,894,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" title="Nonvested weighted average grant-date fair value, Beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" title="Nonvested Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,027,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" title="Nonvested Shares, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,626</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" title="Nonvested Shares, Beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" title="Nonvested weighted average grant-date fair value, Ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" title="Nonvested Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" title="Nonvested weighted average grant-date fair value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" title="Nonvested Shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,610,540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" title="Nonvested weighted average grant-date fair value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" title="Nonvested Shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" title="Nonvested weighted average grant-date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" title="Nonvested Shares, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,289,578</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" title="Nonvested weighted average grant-date fair value, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z4eThjaJVWS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4Ufve4JqSjb" title="Compensation cost recognized"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,233,487</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;for
the year ended December 31, 2024 was recognized for the Performance-Based RSUs, of which&#160;<span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlIzAuY2Njn8" title="Number of shares issued and outstading RSU"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,237,319</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
shares were issued and outstanding as of December 31, 2024, and&#160;<span id="xdx_902_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z40DPp8wElZb" title="Number of shares issuable"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,373,221</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
will be issued subsequent to December 31, 2024. There was $<span id="xdx_902_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrEwkew1oNWi" title="Compensation cost"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,410,921</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
cost related to Service-Based Restricted Stock and RSUs, for the year ended December 31, 2024, and <span id="xdx_90E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zzgMC1eBnPy9" title="Number of shares issuable"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,639,628</ix:nonFraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
were issued and outstanding. There was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zms2tZhdeNc5" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,601,786</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Service-Based Restricted Stock and RSUs as of December 31, 2024, which will be expensed
over a weighted average period of&#160;<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zclEMmCJ3Dz9" title="Weighted average period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" format="ixt-sec:duryear" id="Fact001058" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">7.0</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.
There was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zIrQ7oNuc7Uc" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,984,909</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2024, which will be expensed over a weighted
average period of&#160;<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zY1GdZYbLZc4" title="Weighted average period for recognition"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember" format="ixt-sec:duryear" id="Fact001062" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.1</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001064" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_z0T6x9S9R0nc" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,019,781</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,744,355</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,764,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zolbzGpD9Gyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_do_c20230101__20231231_ze91l903pZjd" title="Stock-based compensation expense recognized"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-01-012023-12-31" id="Fact001072" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span>
stock-based compensation expense was recognized in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001074" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z39WwpxsIVGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12.&#160;<span id="xdx_823_zPEUk6aDyaG5">STOCKHOLDERS&#8217; DEFICIT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 15, 2024, the Company&#8217;s common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221;
and &#8220;TVGNW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had&#160;<span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_znAw7bEFMQ5h" title="Common shares, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zk1HMAnH51cj" title="Common shares, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></ix:nonFraction></span></span>&#160;shares of common stock issued and outstanding. For accounting purposes related
to earnings per share, only shares that are fully vested are considered issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001080" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a reconciliation of shares of common stock issued and outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zBobVkOAVlrc" style="display: none">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_zTz0o6SVpLl3" title="Total shares of common stock legally issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zub7NIVcS1ji" title="Total shares of common stock legally outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001082" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001084" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,991,365</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Vested RSUs not yet legally settled into common stock (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing" style="text-align: right"><ix:nonFraction name="TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" contextRef="AsOf2024-12-31" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,373,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Issuance of restricted common stock subject to forfeiture (b)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" title="Issuance of restricted common stock subject to forfeiture" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" contextRef="AsOf2024-12-31" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" title="Total shares issued and outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" contextRef="AsOf2024-12-31" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,015,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001091" xml:lang="en-US">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001092" xml:lang="en-US">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zFXyPlOcKyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s common
stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio, as discussed
in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to&#160;<span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zawzrFyiUhW8" title="Preferred shares, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span>&#160;shares of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zQGkdUfNumd3" title="Preferred shares, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>&#160;per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company authorized and issued&#160;<span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUfWFBKOpx95" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000</ix:nonFraction></span>&#160;and&#160;<span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4r56mILnzl" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500</ix:nonFraction></span>&#160;shares, respectively, of Series A Preferred Stock (the
&#8220;Series A&#8221;) to the Patel Family at a price of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQfbWQrcOZi3" title="Original issue price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000</ix:nonFraction></span>&#160;per share (the &#8220;Series A Original Issue Price&#8221;), for gross
proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxixjJLqeg62" title="Proceeds from issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>. The Company recorded an expense of $<span id="xdx_909_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQxnGU5zd5Tb" title="Loss on preferred stock issuance"><ix:nonFraction name="TVGN:LossOnPreferredStockIssuance" contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">799,990</ix:nonFraction></span>&#160;in its consolidated statements of operations related to issuance
of the Series A equal to the fair value of the Series A when issued of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhHdHpBEqGkj" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5,600</ix:nonFraction></span>&#160;per share less the purchase price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zAqqP6PNvXv7" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000</ix:nonFraction></span>&#160;per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of&#160;<span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztYDttjnovo9" title="Dividend rate, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum per share
on&#160;<span id="xdx_90D_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zF61u4UZsN72" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001114" name="us-gaap:PreferredStockDividendPaymentRateVariable">the Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding
(the &#8220;Series A Accruing Dividends&#8221;). These dividends become payable when and if declared by the Company. The Series A Preferred
Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common stock</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series C Preferred Stock in liquidation priority. In the event of a liquidation of the Company,
or certain deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price
plus all Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the
Series A converted into shares of common stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem the Series A at a price equal to the Series A Original Issue Price plus any Series A Accruing
Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds $<span id="xdx_909_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwbfq8s8aZ8a" title="Redemption price per share"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span>&#160;per share for&#160;<span id="xdx_907_eus-gaap--PreferredStockRedemptionTerms_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOlzljlEejp8" title="Redemption term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001118" name="us-gaap:PreferredStockRedemptionTerms">the twenty
days immediately prior to the Company&#8217;s call election</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal to the Series A Original Issue
Price divided by the Series A Conversion Price, which is initially $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAhs7sA9a3Hg" title="Conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span>&#160;per share and is subject to standard antidilution adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
A-1 Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Patel Family covering the
issuance of&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zyjFwzKjShS9" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span>&#160;shares of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSYuOdfosOrl" title="Stock issuance, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span>.&#160;<span id="xdx_907_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zwimI6SmD7Wc" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001126" name="us-gaap:PreferredStockDividendPaymentRateVariable">The terms of the Series
A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum, and the Series A-1
Issuance Price is defined as $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zpRWlyP2lmhc" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,000</ix:nonFraction></span>&#160;per share</ix:nonNumeric></span>. As of December 31, 2024, the investor had paid a non-refundable deposit of $<span id="xdx_907_eus-gaap--Deposits_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z0L4O5xe3d58" title="Non refundable deposist paid"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>&#160;towards
the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the Sponsor
assuming certain liabilities and obligations of Semper Paratus and Tevogen Bio. In March 2024,&#160;<span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztKdBv7rrvtf" title="Conversion of certain liabilities into Series B preferred stock, shares"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities" contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613</ix:nonFraction></span>&#160;shares of Series B were
issued in return for the assumption of the Assumed Liabilities. The issuance date fair value of the Series B was determined to be $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjWUK6RK25vf" title="Conversion of certain liabilities into Series B preferred stock"><ix:nonFraction name="TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities" contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></span>&#160;and
was recorded within Merger transaction costs in the consolidated statements of operations. The Series B was classified as permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, the Company and the Sponsor entered into the Preferred Stock Repurchase Agreement, pursuant to which the Company repurchased
all outstanding Series B in exchange for the release of the Sponsor from its obligations related to the Assumed Liabilities, but no cash
consideration. The repurchase was recorded as a deemed contribution from a related party and recorded to additional paid-in capital.
As of June 30, 2024, there were&#160;<span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8b7tstNVUK" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember" id="Fact001136" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span>&#160;shares of Series B outstanding, and on August 9, 2024, the Company filed a Certificate of
Elimination to eliminate the Series B. Although the Company was not legally released by the creditors, the Company has made payments
towards the Assumed Liabilities and approximately $<span id="xdx_904_eus-gaap--LiabilitiesAssumed1_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z49kJiiE3Ygk" title="Liabilities assumed"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001138" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span>&#160;million remains on the Company&#8217;s balance sheet at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2024, the Company entered into a securities purchase agreement (the &#8220;Series C Agreement&#8221;) with an investor, pursuant
to which the Patel Family purchased&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSPnuzVFW8I3" title="Stock issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600</ix:nonFraction></span>&#160;shares of Series C Preferred Stock (the &#8220;Series C&#8221;) of the Company at a price
of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z54wxKCwg1gb" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,000</ix:nonFraction></span>&#160;per share (the &#8220;Series C Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zWevHguMjFh8" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember" id="Fact001144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C is subject to a call right providing the Company the right to call the stock at any time after the fifth anniversary of the
date of issuance. The Company also agreed that so long as the Series C is outstanding, the Company will not, without the written consent
of the holders of 50.1% of the Series C, amend, alter, or repeal any provision of the Company&#8217;s certificate of incorporation or
bylaws in a manner adverse to the Series C. Assessed under accounting guidance within ASC 480 and ASC 815, as the Series C is unregistered
and without mandatory redemption features, the Series C is classified within equity at issued face value as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C carries an annual&#160;<span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znIWnoIckvq7" title="Dividend rate, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% cumulative dividend, compounded annually, beginning on the later of (1) September 30, 2024 and (2)&#160;the
date on which the investor has paid the entirety of the purchase price under the Series C Agreement and ending on the last business day
of the calendar quarter ending September 30, 2034 (the &#8220;Series C Accruing Dividends&#8221;). Dividends will be payable in shares
of Series C or, at the election of the Company, in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C ranks subordinate to the Series A and Series A-1 Preferred Stock and ranks senior to common stock in liquidation priority. In
<span id="xdx_90C_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9gScDguhoh2" title="Dividend variable rate, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001148" name="us-gaap:PreferredStockDividendPaymentRateVariable">the event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the
greater of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such
asset amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or
deemed liquidation event</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem that Series C at a price equal to the Series C Original Issue Price plus any Series C Accruing
Dividends accrued but unpaid thereon, subject to the conversion right described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series C will be convertible at the election of the holder, beginning six months after the date of issuance, into shares of
common stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#8217;s conversion option, subject to a floor price of $<span id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7dM0Y1ql89b" title="Floor price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6172</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing,&#160;<span id="xdx_90B_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember_zIGtQfTezVW6" title="Number of warrants issued"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightIssued" contextRef="AsOf2021-11-30_custom_SemperParatusMember" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,975,000</ix:nonFraction></span>&#160;warrants initially issued by Semper Paratus in November 2021, comprising&#160;<span id="xdx_905_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zn3BV62feMah" title="Number of warrants issued"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightIssued" contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,250,000</ix:nonFraction></span>&#160;public
warrants sold in the IPO and&#160;<span id="xdx_902_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVzxWQkVh4vf" title="Number of warrants issued"><ix:nonFraction name="TVGN:ClassOfWarrantOrRightIssued" contextRef="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></span>&#160;warrants issued in a concurrent private placement, were assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zIbJmxaroH8f" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span>&#160;per share, became exercisable on&#160;<span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zmhBTSemoD57" title="Exercisable date"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001160" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March 15, 2024</ix:nonNumeric></span>, and will expire at 5:00 p.m.,
New York City time, on February 14, 2029, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is
an effective registration statement and during any period when the Company has failed to maintain an effective registration statement
covering the shares of the Company&#8217;s common stock issuable upon exercise of the warrants, exercise warrants on a &#8220;cashless
basis&#8221; in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, or another exception.&#160;<span id="xdx_909_ecustom--WarrantsRedemptionDescription_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zCHigflJdi3f" title="Warrants redemption description"><ix:nonNumeric contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001162" name="TVGN:WarrantsRedemptionDescription">The Company may
redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days within a 30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of public
warrants</ix:nonNumeric></span>.&#160;As of December 31, 2024, there are&#160;<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zp8Nj2uoLvG3" title="Number of warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,386,580</ix:nonFraction></span>&#160;public warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Private
Placement Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the initial purchasers or their permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders
on a cashless basis. As of December 31, 2024, there are&#160;<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z69tfKiXr8nj" title="Number of warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">588,398</ix:nonFraction></span> private placement warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 for additional information on the Company&#8217;s warrant accounting policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001168" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zlDNnfZH9OPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13.&#160;<span id="xdx_825_zqPN9q60Q2sd">NET LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001170" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table is a reconciliation of net loss to net loss attributable to common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zqvjlw0tPPPc" style="display: none">SCHEDULE OF RECONCILIATION OF NET LOSS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact001172" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,727,380</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,712</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:StockRepurchase" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series C cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact001190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,273,695</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact001191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,477,680</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zG3z9K9LYeO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company excluded the following potential shares from the computation of diluted net loss per share because including them would have
had an anti-dilutive effect:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001193" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKc0WDQkU0cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zdSENhIO9rV3" style="display: none">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F44_zmfQq5K6hhX9" style="width: 60%; text-align: left">Outstanding RSUs (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,623,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,900,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember69680781" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,348,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember69680796" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,974,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4C_zJyDr0riXTXa" style="text-align: left">Convertible promissory notes (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">891,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Earnout Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_EarnoutSharesMember" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1208">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,447,157</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,791,426</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zykjScqdVvK1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F11_zmclaahZPjfi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001212" xml:lang="en-US">As
    of December 31, 2024 there were an additional&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85" title="Stock option vested" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember69680906" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,373,221</ix:nonFraction></span>&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0A_zTdx4tJUoNKl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F10_z19ovviNsVu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001215" xml:lang="en-US">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_ztzzjDJRdhf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above table excludes any potentially anti-dilutive shares as a result of the $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20241231_zD8TY04o0C1c" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31" id="Fact001217" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span>&#160;million Purchase Option and the Additional Amount
Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be determined until the conditions for issuance
are met and the share prices are known upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001219" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zOH3qqx6CUEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14. <span id="xdx_82E_zVru2JBQBEJ">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s net losses for 2024 and 2023, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001221" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zfqHypT5TS0f" style="display: none">SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Federal benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" contextRef="From2023-01-012023-12-31" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29.2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001235" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">66.5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2024-01-01to2024-12-31" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2024-01-01to2024-12-31" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2023-01-012023-12-31" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income Tax Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zI1V4O0T35ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Realization of net deferred tax assets is dependent upon future earnings, if any,
the timing and amount of which are uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001250" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items comprise the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDJj32uxJhO7" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,808,826</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,755,008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsAccruedExpensesAndOther" contextRef="AsOf2024-12-31" id="Fact001258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsAccruedExpensesAndOther" contextRef="AsOf2023-12-31" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="AsOf2024-12-31" id="Fact001261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="AsOf2023-12-31" id="Fact001262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,110,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsFixedAssets" contextRef="AsOf2024-12-31" id="Fact001267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Capitalized research and development expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" contextRef="AsOf2024-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,944,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" contextRef="AsOf2023-12-31" id="Fact001274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,589,105</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,478</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,455</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,610,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,549,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,551,169</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,426,952</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="Fact001286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="TVGN:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact001295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zlBeaG0lqf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred
tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company
considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative
earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company
for tax reporting purposes, and other relevant factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, based on the Company&#8217;s history of earnings and its assessment of future earnings, management believes that
it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation
allowance has been applied to deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the year ended December 31, 2024, the Company has federal and state net operating loss carryforwards of approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zKvRHdzwguA" title="Federal  net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001300" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.6</ix:nonFraction></span> million
and $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zneQ6a3fQVda" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001302" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.8</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
net operating loss (&#8220;NOL&#8221;) carryforwards in the amount of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zUCHXrTKyWh3" title="Federal  net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2024-12-31" id="Fact001304" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.6</ix:nonFraction></span> million have an indefinite life. Federal NOL carryforwards
generated after tax year 2017 are subject to an <span id="xdx_90B_ecustom--TaxableIncomeLimitationPercentage_dp_uPure_c20240101__20241231_zRxLMcaLeQXd" title="Taxable income percentage"><ix:nonFraction name="TVGN:TaxableIncomeLimitationPercentage" contextRef="From2024-01-01to2024-12-31" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% limitation on taxable income, do not expire and will carryforward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
net operating loss carryforwards in the amount of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zJC8GpWitUF5" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001308" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.8</ix:nonFraction></span> million begin expiring in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a U.S. federal limitation due to the &#8220;change in ownership
provisions&#8221; under Section 382 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations
may result in a reduction of the amount of net operating loss carryforwards in future years and possibly the expiration of certain net
operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files tax returns as prescribed by the tax laws of the jurisdictions
in which it operates. In the normal course of business, the Company is subject to examinations by federal, state and local jurisdictions,
where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from 2021
to the present in the United States. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was
generated may still be adjusted upon examination by the Internal Revenue Service and state and local tax authorities to the extent utilized
in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As required by the uncertain tax position guidance in ASC No. 740, Income
Tax, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would
more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount
recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement
with the relevant tax authority. The Company applied the uncertain tax position guidance in ASC No. 740 to all tax positions for which
the statute of limitations remained open. Any estimates of tax contingencies contain assumptions and judgments about potential actions
by taxing jurisdictions. Any interest and penalties related to uncertain tax positions would be included as part of the income tax provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001310" name="TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zf0aPlttrYT4" style="display: none">SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Valuation allowance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,426,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,175,241</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Increases recorded to income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="TVGN:IncreasesRecordedToIncomeTaxProvision" contextRef="From2024-01-01to2024-12-31" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,124,217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="TVGN:IncreasesRecordedToIncomeTaxProvision" contextRef="From2023-01-012023-12-31" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,251,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,551,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,426,952</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zp0wzhbf7Lr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater
than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain
tax positions as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2024, the Company had <span id="xdx_901_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_zuOXGDUSWMy1" title="Income tax penalties and interest accrued"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="AsOf2024-12-31" id="Fact001321" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> accrued interest or penalties related to uncertain tax positions and no amounts have been
recognized in the Company&#8217;s statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001323" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrerlloKSUG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15. <span id="xdx_826_zuwxRamozzMf">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
with Sponsor</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, the Company incurred $<span id="xdx_905_eus-gaap--SponsorFees_c20240101__20241231_zTy8sC0UubZ8" title="Sponsor advisory service fee"><ix:nonFraction name="us-gaap:SponsorFees" contextRef="From2024-01-01to2024-12-31" id="Fact001325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>&#160;in fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory
Service Fee&#8221;). In connection with the Merger and thereafter, the Company and Sponsor agreed that $<span id="xdx_906_ecustom--SponsorFeesPayable_iI_c20241231_zkE0us8TZD65" title="Sponsor advisory services fee payable"><ix:nonFraction name="TVGN:SponsorFeesPayable" contextRef="AsOf2024-12-31" id="Fact001327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>&#160;of the Sponsor Advisory
Service Fee is payable in cash, $<span id="xdx_901_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zbPCTNfYXcbh" title="Sponsor fee payable offset"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-12-31_custom_SponsorMember" id="Fact001329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>&#160;would be offset against amounts due from the Sponsor, and the remainder of the Sponsor
Advisory Service Fee was paid with the issuance of&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zhcrPARWOjwj" title="Number of shares issued for sponsor fees"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span>&#160;shares of the Company&#8217;s common stock at Closing. The Sponsor
Advisory Service Fee payable in cash is presented on the consolidated balance sheets under the line item &#8220;Due to related party.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Sponsor owes the Company $<span id="xdx_904_eus-gaap--OtherReceivables_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z4vWtjG20yL" title="Due from related party"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31_custom_SponsorMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,819</ix:nonFraction></span>&#160;to cover working capital expenses, which is presented on the consolidated
balance sheets under the line item &#8220;Due from related party.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series B issued to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__custom--WifeOfChiefExecutiveOfficerMember_zTnpqXQArEhh" title="Isssued shares to related party"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span>&#160;Performance-Based RSUs to the wife of the Company&#8217;s chair and chief executive
officer for advisory services provided to the Company, and&#160;<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MehtaphoricConsultingIncMember_zrYzQdMpRkNh" title="Shares issued to related party"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>&#160;Performance-Based RSUs to Mehtaphoric Consulting Inc, a company
controlled by the daughter of the Company&#8217;s chief financial officer, for information technology services provided to the Company.
In connection with the Closing, the performance condition was achieved and therefore compensation cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231_zOUwKIHuqzk" title="Compensation cost recognized"><ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,396</ix:nonFraction></span>&#160;has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information on the Loan Agreement with the Patel Family, which provides for an unsecured line of credit facility for term loans of
up to an initial amount of $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zLKScQ5vkAk3" title="Line of credit maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact001341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000,000</ix:nonFraction></span>
in the aggregate. As of December 31, 2024, the facility has remaining available capacity of $<span id="xdx_904_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z9y8tO1wTFIj" title="Line of credit remaining borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember" id="Fact001343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series A, Series A-1, and Series C Preferred Stock, which were purchased by the Patel Family.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consulting
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services to the Company in
support of the Company&#8217;s manufacturing development, including but not limited to identifying and developing real estate, establishing
quality management processes, attracting and hiring an executive to lead operations, providing medical advice, and addressing government
affairs and regulatory matters. In exchange for his consultation services, Dr. Patel was granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zfQ0S0ve5fg7" title="Granted, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> RSUs, of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zh6uXjAWemfi" title="Vested shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> immediately
vested, and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQvaOG3s7d5h" title="Vested shares"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0Juwz4Y4g4" title="Vested shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></ix:nonFraction></span></span> RSUs vested in both January  2025 and February  2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001353" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zjViOtEdXFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16. <span id="xdx_824_zz8eWF3pcbLk">SEGMENT REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one operating segment, and therefore one reportable segment, and is focused on the global discovery, development
and commercialization of proprietary therapeutics. The Company&#8217;s business activities are managed on a consolidated basis through
the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products
are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with
the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating
resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker
is the Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies.
Our single operating segment incurs expenses from the development of TVGN 489, which is developed by our research and development department,
designed to target various disease indications. The Company has not yet generated revenue in its operating history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the segment, the chief operating decision maker uses net loss, which is reported on the consolidated statements of operations as consolidated
net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget
and forecasting process. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative
information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment
in our various research activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001355" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zcq2drwDeQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17. <span id="xdx_823_zySUOK5HYSp2">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 2, 2025, the issuance date of these the consolidated financial statements, and has not identified any additional items requiring
disclosure except as noted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company executed an agreement with KRHP to receive a grant for $<span id="xdx_901_eus-gaap--OtherReceivablesNetCurrent_iI_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHPLLCMember_zTmBGFqf4706" title="Grant"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>.
KRHP is affiliated with the Patel Family. The grant is specified for use toward the Company&#8217;s ongoing operational expenses,
may not be used for repayment of existing debt obligations, and does not include any requirement to repay the investor or to issue
equity in response. Cash payment was received by the Company in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February  2025, the Company executed a draw on the Loan Agreement for an additional $<span id="xdx_902_eus-gaap--LineOfCredit_iI_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzvyNsOHXNv8" title="Line of credit Facility additional"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2025-02-28_us-gaap_SubsequentEventMember" id="Fact001359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> to be utilized for operational
expenses. An additional draw of $<span id="xdx_908_eus-gaap--LineOfCredit_iI_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9Pe2aZwH1z9" title="Line of credit Facility additional"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2025-03-31_us-gaap_SubsequentEventMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> was completed in March  2025. As of the date of filing, the facility has a remaining
capacity of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20250402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z33Qh5rDOJ1l" title="Line of credit Facility remaining capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="AsOf2025-04-02_us-gaap_SubsequentEventMember" id="Fact001363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000,000</ix:nonFraction></span> and remains effective for the next 26 months.</span></p>

</ix:nonNumeric><p id="xdx_81D_zQZ1kJRva8Tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="g_028"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tevogen
    Bio Holdings Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ryan
    Saadi</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
    Executive Officer</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 40.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="5" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ryan Saadi</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairperson of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Saadi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kirti Desai</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti
    Desai</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jeffrey Feike</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Feike</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Keow Lin Goh</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Keow Lin Goh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Curtis Patton</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Curtis Patton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Susan Podlogar</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan
    Podlogar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Victor Sordillo</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victor
    Sordillo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 123; Options: NewSection Last; Value: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF OUR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following sets forth a summary of the material terms of the securities of Tevogen Bio Holdings Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our,&rdquo; &ldquo;Tevogen,&rdquo; or the &ldquo;Company&rdquo;) registered under Section 12 of the Securities Act of 1933, as
amended (the &ldquo;Securities Act&rdquo;), including certain provisions of the law of the State of Delaware and the Company&rsquo;s
Certificate of Incorporation (the &ldquo;Charter&rdquo;), Bylaws (the &ldquo;Bylaws&rdquo;), and certain warrant-related documents. This
summary is qualified by reference to the full text of the Charter, Bylaws, and warrant-related documents described herein, which are
exhibits to the report to which this exhibit is attached. We urge you to read each of the Charter, the Bylaws, and the warrant-related
documents described herein in their entirety for a complete description of the rights and preferences of our securities. The summary
below is also qualified by reference to the provisions of the General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;),
as applicable.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter authorizes the issuance of a total of 820,000,000 shares of capital stock, each with par value $0.0001 per share, consisting
of (a) 800,000,000 shares of common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), of the Company and (b) 20,000,000
shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Power</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law or as otherwise provided in any preferred stock designation, the holders of Common Stock will possess all
voting power for the election of directors and all other matters submitted to a vote of stockholders. Generally, each holder of Common
Stock is entitled to one vote per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise required by law, holders of Common Stock, as such, will not be entitled to vote on any amendment to the Charter (including
any preferred stock designation) that relates solely to the rights, powers, preferences (or the qualifications, limitations or restrictions
thereof) or other terms of one or more outstanding series of preferred stock of the Company if the holders of such affected series of
preferred stock are entitled to vote on such amendment pursuant to the Charter (including any preferred stock designation) or pursuant
to the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the rights and preferences of any holders of any outstanding class or series of preferred stock of the Company,
holders of Common Stock will be entitled to receive dividends when, as and if declared by the board of directors of the Company (the
&ldquo;Board&rdquo;), payable either in cash, in property, or in shares of capital stock. All shares of Common Stock shall be of equal
rank and shall be identical with respect to rights to such dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation,
Dissolution, and Winding Up</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our voluntary or involuntary liquidation, dissolution, or winding up and after payment in full of our debts and other liabilities and
to any holders of preferred stock of the Company having liquidation preferences, if any, the holders of the shares of the Common Stock
shall be entitled to receive all the remaining assets of the Company available for distribution to our shareholders, ratably in proportion
to the number of shares of the Common Stock then issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preemptive
or Other Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law and the preferential rights of any other class or series of stock, all shares of Common Stock will have equal dividend,
distribution, liquidation, and other rights, and will have no preference or appraisal rights, except for any appraisal rights provided
by the DGCL. Furthermore, subject to applicable law, holders of Common Stock will have no preemptive rights and there are no conversion,
sinking fund, or redemption rights, or rights to subscribe for any of our securities. The rights, powers, preferences, and privileges
of holders of Common Stock will be subject to those of the holders of any shares of preferred stock that the Board may authorize and
issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is divided into three classes, each of which generally serves for a term of three years with only one class of directors being
elected in each year. Directors are generally elected by a plurality of votes cast at a meeting of the shareholders at which a quorum
is present, and there is no cumulative voting with respect to the election of directors, with the result that the holders of more than
50% of the shares voted for the election of directors can elect all of the directors and that the director nominees receiving the highest
number of votes will be elected at such a meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that shares of preferred stock may be issued from time to time in one or more classes or series. The Board is authorized
to establish the voting rights, if any, designations, preferences, and relative, participating, optional, or other special rights of
the shares of such series, and the qualifications, limitations or restrictions thereof, applicable to the shares of each series of preferred
stock. The Board may, without shareholder approval, issue preferred stock with voting and other rights that could adversely affect the
voting power and other rights of the holders of Common Stock and could have anti-takeover effects. The ability of the Board to issue
preferred stock without shareholder approval could have the effect of delaying, deferring, or preventing a change of control of the Company
or the removal of existing management. We currently have 500 shares of Series A Preferred Stock and 600 shares of Series C Preferred
Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Series
A Preferred Stock</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock does not have any voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A Preferred Stock are entitled to receive dividends accruing daily on a cumulative basis at a fixed rate of 5% per annum per
share on the Series A Original Issue Price (as defined in the Certificate of Designation of Series A Preferred Stock of the Company),
automatically increasing by 2% every year that the Series A Preferred Stock remains outstanding (the &ldquo;Series A Accruing Dividends&rdquo;).
The Series A Accruing Dividends become payable when and if declared by the Board. The Series A Preferred Stock will also participate
on an as-converted basis in any regular or special dividends paid to holders of the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock ranks senior to the Common Stock in liquidation priority. In the event of a liquidation of the Company, or certain
deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price plus all
Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the Series A
converted into shares of Common Stock immediately before the liquidation or deemed liquidation event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Redemption</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A Preferred Stock are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a
deemed liquidation event. The Company is entitled to redeem that Series A Preferred Stock at a price equal to the Series A Original Issue
Price plus any Series A Accruing Dividends accrued but unpaid thereon, if the volume-weighted average price of the Common Stock exceeds
$5.00 per share for the twenty days immediately prior to our call election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A Preferred Stock have the option to convert the Series A Preferred Stock into shares of Common Stock at a ratio equal to the
Series A Original Issue Price divided by the Series A Conversion Price, which is initially $4.00 per share and is subject to standard
antidilution adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Series
C Preferred Stock</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock does not have any voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock carries an annual&nbsp;7.5% cumulative dividend, compounded annually, beginning on October 25, 2024 and ending
on the last business day of the calendar quarter ending September 30, 2034 (the &ldquo;Series C Accruing Dividends&rdquo;). The Series
C Accruing Dividends are payable in shares of Series C Preferred Stock or, at the election of the Company, in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock ranks subordinate to the Series A Preferred Stock and ranks senior to Common Stock in liquidation priority.
In the event of a liquidation of the Company, or certain deemed liquidation events, the Series C Preferred Stock is redeemable for a
price equal to the greater of the Series C Original Issue Price (as defined in the Certificate of Designation of Series C Preferred Stock
of the Company) plus all Series C Accruing Dividends that are unpaid through the redemption date, or such amount as would have been payable
had the Series C Preferred Stock converted into shares of Common Stock immediately before the liquidation or deemed liquidation event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Redemption</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C Preferred Stock are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence
of a deemed liquidation event. The Company is entitled to redeem that Series C Preferred Stock at any time after the fifth anniversary
of issuance at a price equal to the Series C Original Issue Price plus any Series C Accruing Dividends accrued but unpaid thereon, subject
to the conversion right described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conversion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series C Preferred Stock will be convertible at the election of the holder, beginning six months after the date of issuance,
into shares of Common Stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days
immediately prior to the exercise of the holder&rsquo;s conversion option, subject to a floor price of $0.6172.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on the Common Stock to date and do not intend to pay cash dividends in the foreseeable future. The payment
of cash dividends in the future will be dependent upon our revenue and earnings, if any, capital requirements, and general financial
condition. The payment of any cash dividends is within the discretion of the Board. Our ability to declare dividends may also be limited
by restrictive covenants pursuant to any debt financing agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Anti-Takeover Provisions of Delaware Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Classified
Board of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that the Board is divided into three classes of directors, with the classes to be as nearly equal in number as possible,
and with each director serving a three-year term. As a result, approximately one-third of the Board is elected each year. The classification
of directors will have the effect of making it more difficult for shareholders to change the composition of the Board. Amending the classified
Board provisions requires approval by two-thirds (2/3) of the then-outstanding voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
but Unissued Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized but unissued shares of Common Stock and preferred stock are available for future issuance without shareholder approval, subject
to any limitations imposed by the listing standards of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;). These additional shares may
be used for a variety of corporate finance transactions, acquisitions, and employee benefit plans. The existence of authorized but unissued
and unreserved, Common Stock and preferred stock could make more difficult or discourage an attempt to obtain control of the Company
by means of a proxy contest, tender offer, merger, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholder
Action; Special Meetings of Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that, subject to the rights of the holders of any series of preferred stock, any action required or permitted to be
taken by the shareholders must be effected at a duly called annual or special meeting of the shareholders and may not be effected by
any consent by such shareholders. As a result, a holder controlling a majority of our capital stock cannot amend the Bylaws or remove
directors without holding a meeting of shareholders called in accordance with the Bylaws. This restriction does not apply to actions
taken by the holders of any series of preferred stock to the extent expressly provided in the applicable preferred stock designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the Charter provides that, subject to any special rights of the holders of preferred stock, special meetings of the shareholders may
only be called by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Shareholder Proposals and Director Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that shareholders seeking to bring business before our annual meeting of shareholders, or to nominate candidates for election
as directors at our annual meeting of shareholders, must provide timely notice. To be timely, a shareholder&rsquo;s notice must be received
by the Secretary at our principal executive offices not later than the close of business on the 90<SUP>th</SUP> day nor earlier than
the close of business on the 120<SUP>th</SUP> day before the anniversary date of the immediately preceding annual meeting of shareholders.
However, in the event that the annual meeting is more than 30 days before or more than 60 days after such anniversary date (or if there
has been no prior annual meeting), notice by the shareholder to be timely must be so delivered not earlier than the close of business
on the 120<SUP>th</SUP> day before the meeting and not later than the later of (x) the close of business on the 90<SUP>th</SUP> day before
the meeting or (y) the close of business on the 10<SUP>th</SUP> day following the day on which public announcement of the date of the
annual meeting is first made by us. The Bylaws also specify certain requirements as to the form and content of a shareholders&rsquo;
notice. These provisions may preclude our shareholders from bringing matters before our annual meeting of shareholders or from making
nominations for directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment
of Charter or Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws may be amended or repealed by the Board or by the affirmative vote of the holders of a majority of the voting power of all of
the shares of our capital stock entitled to vote in the election of directors, voting as one class. The affirmative vote of the holders
of at least two-thirds (2/3) of the voting power of the then-outstanding shares of our capital stock entitled to vote generally in the
election of directors, voting together as a single class, is required to amend certain provisions of the Charter related to the classified
Board and limitation of liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
vacancy on the Board may be filled by a majority vote of the directors then in office, although less than a quorum, or by a sole remaining
director, subject to any special rights of the holders of preferred stock. Any director chosen to fill a vacancy will hold office until
the expiration of the term of the class for which he or she was elected and until the director&rsquo;s successor is duly elected and
qualified or until their earlier resignation, removal from office, death, or incapacity. Except as otherwise provided by law, in the
event of a vacancy on the Board, the remaining directors may exercise the powers of the full Board until the vacancy is filled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preferred
Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Charter, during any period when the holders of one or more series of preferred stock have the separate right to elect additional
directors, the then-otherwise total authorized number of directors will automatically be increased by such number of directors that the
holders of any series of preferred stock have a right to elect. Whenever the holders of one or more series of preferred stock having
a separate right to elect additional directors cease to have such right, the terms of office of all preferred stock directors elected
by the holders of such series of preferred stock, and the total authorized number of directors, will be automatically reduced accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Forum Selection</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that (A) (i) any derivative action or proceeding brought on behalf of the Company, (ii)&nbsp;any action asserting a
claim of breach of a fiduciary duty owed by any current or former director, officer, other employee, or shareholder of the Company to
the Company or our shareholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Charter, or the
Bylaws (as either may be amended or restated) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware
or (iv) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest
extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject
matter jurisdiction thereof, the federal district court of the State of Delaware; and (B) the federal district courts of the United States
shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Under
the Charter, these provisions may be waived by us at our discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exclusive forum provision in the Charter does not apply to suits brought to enforce any duty or liability created by the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or any other claim for which the federal courts have exclusive jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that these provisions benefit the Company by providing increased consistency in the application of Delaware law in the types
of lawsuits to which it applies, a court may determine that these provisions are unenforceable, and to the extent they are enforceable,
the provisions may have the effect of discouraging lawsuits against our directors and officers, although our stockholders will not be
deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section
203 of the Delaware General Corporation Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the DGCL until the election to opt-out of Section 203 of the DGCL in the Charter becomes
effective 12 months from the date the Charter first became effective under the DGCL. In general, Section 203 prohibits a Delaware corporation
that is listed on a national securities exchange or held of record by more than 2,000 shareholders from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested shareholder&rdquo; for a three-year period following the time that such shareholder becomes
an interested shareholder, unless the business combination is approved in a prescribed manner. A &ldquo;business combination&rdquo; includes,
among other things, certain mergers, asset or stock sales, or other transactions resulting in a financial benefit to the interested shareholder.
An &ldquo;interested shareholder&rdquo; is a person who, together with affiliates and associates, owns, or did own within three years
prior to the determination of interested shareholder status, 15% or more of the corporation&rsquo;s outstanding voting stock. Under Section
203, a business combination between a corporation and an interested shareholder is prohibited unless it satisfies one of the following
conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    the shareholder became interested, the board of directors approved either the business combination or the transaction which resulted
    in the shareholder becoming an interested shareholder;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
    of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans,
    in some instances; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    or after the time the shareholder became interested, the business combination was approved by the board of directors of the corporation
    and authorized at an annual or special meeting of the shareholders by the affirmative vote of at least two thirds (2/3) of the outstanding
    voting stock which is not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, Section 203 of the DGCL would make it more difficult for a person who would be an &ldquo;interested shareholder&rdquo;
to effect various business combinations with a corporation for a three-year period. This provision may encourage companies interested
in acquiring us to negotiate in advance with the Board because the shareholder approval requirement would be avoided if the Board approves
either the business combination or the transaction which results in the shareholder becoming an interested shareholder. Section 203 of
the DGCL also may have the effect of preventing changes in the Board and may make it more difficult to accomplish transactions which
shareholders may otherwise deem to be in their best interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation
on Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Charter provides that a director or officer shall not be personally liable to us or our shareholders for monetary damages for breach
of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the
DGCL as the same exists or may hereafter be amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
and Advancement of Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws provide that our directors and officers are indemnified and advanced expenses by us to the fullest extent authorized or permitted
by the DGCL as it now exists or may in the future be amended. In addition, the Bylaws provide that our directors are not personally liable
to us or our shareholders for monetary damages for breaches of their fiduciary duty as directors to the fullest extent permitted by the
DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws also permit us to purchase and maintain insurance on behalf of any officer, director, employee, or agent of the Company for any
liability arising out of such person&rsquo;s status as such, regardless of whether the DGCL would permit indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage shareholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action,
if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder&rsquo;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
We believe that these provisions, the insurance, and the indemnity agreements are necessary to attract and retain talented and experienced
directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Public
Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
whole warrant entitles the registered holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment
as discussed below, at any time. Warrant holders may, until such time as there is an effective registration statement and during any
period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the
exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another
exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless exercise,
each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient
obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between
the exercise price of the warrants and the &ldquo;fair market value&rdquo; (as defined below) by (y) the fair market value. The &ldquo;fair
market value&rdquo; for this purpose means the average reported last sale price of the shares of Common Stock for the 10 trading days
ending on the third trading day prior to the date on which the notice of exercise is sent to the warrant agent. The warrants will expire
five years after the closing (the &ldquo;Closing&rdquo;) of the transaction contemplated by that certain Agreement and Plan of Merger,
dated June 28, 2023, by and among the Company, Semper Merger Sub, Inc., SSVK Associates, LLC (&ldquo;SSVK&rdquo;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.), and Dr. Ryan Saadi (the &ldquo;Business Combination&rdquo;), on February 14, 2029, at 5:00 p.m., New York City time,
or earlier upon redemption or liquidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption
of warrants when the price per share of Common Stock equals or exceeds $18.00.</I> Once the warrants become exercisable, we may redeem
the outstanding warrants except as described herein with respect to the warrants originally sold as part of units in a private placement
concurrent with our initial public offering (the &ldquo;private placement warrants&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.01 per warrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    a minimum of 30 days&rsquo; prior written notice of redemption to each warrant holder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number
    of shares issuable upon exercise or the exercise price of a warrant as described under &ldquo;&mdash;<I>Anti-Dilution Adjustments</I>&rdquo;
    below) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send
    the notice of redemption to the warrant holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the
Common Stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Common Stock
is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we may exercise our redemption
right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the
call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption
of the warrants, each warrant holder will be entitled to their warrant prior to the scheduled redemption date. However, the price of
the Common Stock may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon
exercise or the exercise price of a warrant as described under &ldquo;&mdash;<I>Anti-dilution Adjustments</I>&rdquo; below) as well as
the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the warrants for redemption as described above, our management has the option to require all holders that wish to exercise warrants
to do so on a &ldquo;cashless basis.&rdquo; In determining whether to require all holders to exercise their warrants on a &ldquo;cashless
basis,&rdquo; our management would consider, among other factors, our cash position, the number of warrants that are outstanding and
the dilutive effect on our shareholders of issuing the maximum number of Common Stock issuable upon the exercise of our warrants. In
such event, each holder would pay the exercise price by surrendering the warrants for that number shares of Common Stock equal to the
lesser of (A) the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied
by the excess of the fair market value of our shares of Common Stock over the exercise price of the warrants by (y) the fair market value
and (B) 0.361 per warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption
of warrants when the price per share of Common Stock equals or exceeds $10.00.</I> Once the warrants become exercisable, we may redeem
the outstanding warrants except as described herein with respect to the private placement warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    whole and not in part;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a price of $0.10 per warrant upon a minimum of 30 days&rsquo; prior written notice of redemption; provided that holders will be able
    to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the
    table below, based on the redemption date and the &ldquo;fair market value&rdquo; of our Class A ordinary shares, except as otherwise
    described below; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the closing price of the Common Stock equals or exceeds $10.00 per public share (as adjusted for adjustments to the
    number of shares issuable upon exercise or the exercise price of a warrant as described under &ldquo;&mdash;<I>Anti-dilution Adjustments</I>&rdquo;
    below) on the trading day prior to the date on which we send the notice of redemption to the warrant holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants
on a cashless basis. The numbers in the table below represent the number of shares of Common Stock that a warrant holder will receive
upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the &ldquo;fair market
value&rdquo; of the Common Stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants
are not redeemed for $0.10 per warrant), determined for these purposes based on volume weighted average price of the Common Stock for
the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants,
and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the
table below. We will provide our warrant holders with the final fair market value no later than one business day after the 10-trading
day period described above ends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="34" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Market Value of Common Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Redemption Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&le;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&ge;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">(period to expiration of warrants)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$10.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$11.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$12.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$13.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$14.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$15.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$16.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$17.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$18.00</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 19%">60 months</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.261</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.281</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.297</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.311</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.324</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.337</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.348</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.358</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">0.361</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>57 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.324</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.337</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>54 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>51 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.304</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>48 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.241</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.263</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.301</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>45 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>42 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.342</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>39 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.290</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>36 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.213</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.239</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.263</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>33 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.205</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.301</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.337</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>30 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.196</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.297</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.351</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>27 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.185</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>24 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.233</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>21 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.223</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.304</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>18 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.271</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>15 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.130</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.230</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.262</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.342</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>12 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.111</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>9 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.336</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>6 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.137</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>3 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>0 months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.233</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.281</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between
two values in the table or the redemption date is between two redemption dates in the table, the number of shares of Common Stock to
be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the
higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.
For example, if the volume weighted average price of the Common Stock for the 10 trading days ending on the third trading day prior to
the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and at such time there are 57
months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants
for 0.277 shares of Common Stock for each whole warrant. For an example where the exact fair market value and redemption date are not
as set forth in the table above, if the volume weighted average price of the Common Stock for the 10 trading days ending on the third
trading day prior to the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such
time there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise
their warrants for 0.298 shares of Common Stock for each whole warrant. In no event will the warrants be exercisable on a cashless basis
in connection with this redemption feature for more than 0.361 shares of Common Stock per warrant (subject to adjustment). Finally, as
reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis
in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
redemption feature differs from the typical warrant redemption features established by many other blank check companies, which typically
only provide for a redemption of warrants for cash when the trading price for their shares exceeds $18.00 per share for a specified period
of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the shares of Common
Stock are trading at or above $10.00 per public share, which may be at a time when the trading price of Common Stock is below the exercise
price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without
the warrants having to reach the $18.00 per share threshold described above under &ldquo;&mdash;<I>Redemption of warrants when the price
per share of Common Stock equals or exceeds $18.00</I>&rdquo; above. Holders choosing to exercise their warrants in connection with a
redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model with
a fixed volatility input as of the date of this prospectus. This redemption right provides us with an additional mechanism by which to
redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no longer be outstanding
and would have been exercised or redeemed. We will be required to pay the applicable redemption price to warrant holders if we choose
to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we determine it is in
our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best interest to update
our capital structure to remove the warrants and pay the redemption price to the warrant holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
stated above, we can redeem the warrants when the shares of Common Stock are trading at a price starting at $10.00, which is below the
exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant
holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem
the warrants when the shares of Common Stock are trading at a price below the exercise price of the warrants, this could result in the
warrant holders receiving fewer shares of Common Stock than they would have received if they had chosen to wait to exercise their warrants
for shares of Common Stock if and when such shares of Common Stock were trading at a price higher than the exercise price of $11.50.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Common Stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional
interest in a share, we will round down to the nearest whole number of the number of shares of Common Stock to be issued to the holder.
If, at the time of redemption, the warrants are exercisable for a security other than the shares of Common Stock pursuant to the warrant
agreement, the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than
the shares of Common Stock, the company (or surviving company) will use its commercially reasonable efforts to register under the Securities
Act the security issuable upon the exercise of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Redemption
Procedures</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&rsquo;s
affiliates), to the warrant agent&rsquo;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder
may specify) of the Common Stock issued and outstanding immediately after giving effect to such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-dilution
Adjustments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is increased by a capitalization or share dividend payable in shares of Common Stock,
or by a split-up of shares or other similar event, then, on the effective date of such capitalization or share dividend, split-up or
similar event, the number of shares of Common Stock issuable on exercise of each warrant will be increased in proportion to such increase
in the outstanding shares of Common Stock. A rights offering made to all or substantially all holders of ordinary shares entitling holders
to purchase shares of Common Stock at a price less than the &ldquo;historical fair market value&rdquo; (as defined below) will be deemed
a share dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold
in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable
for shares of Common Stock) and (ii) one minus the quotient of (x) the price per shares of Common Stock paid in such rights offering
and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable
for shares of Common Stock, in determining the price payable for shares of Common Stock, there will be taken into account any consideration
received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &ldquo;historical fair market
value&rdquo; means the volume weighted average price of shares of Common Stock as reported during the 10 trading day period ending on
the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market,
regular way, without the right to receive such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities
or other assets to all or substantially all of the holders of shares of Common Stock, other than (a) as described above or (b) any cash
dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on
the shares of Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution does not exceed
$0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in
an adjustment to the exercise price or to the number of shares of Common Stock issuable on exercise of each warrant) but only with respect
to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, then the warrant exercise
price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value
of any securities or other assets paid on each share of Common Stock in respect of such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse share sub-division, or reclassification
of the shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse share sub-division,
reclassification, or similar event, the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion
to such decrease in outstanding shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise
price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator
of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment
and (y) the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if (x) we issued additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with
the Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective
issue price to be determined in good faith by the Board and, in the case of any such issuance to our initial shareholders or their affiliates,
without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance)
(the &ldquo;Newly Issued Price&rdquo;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the Business Combination as of the Closing (net of redemptions), and (z)
the volume weighted average trading price of our Common Stock during the 20 trading day period starting on the trading day prior to the
Closing (such price, the &ldquo;Market Value&rdquo;) was below $9.20 per share, the exercise price of the warrants would be adjusted
(to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption
trigger price described above under &ldquo;&mdash;<I>Redemption of warrants when the price per shares of Common Stock equals or exceeds
$18.00</I>&rdquo; would be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued
Price, and the $10.00 per share redemption trigger price described above under <I>&ldquo;</I>&mdash;<I>Redemption of warrants when the
price per shares of Common Stock equals or exceeds $10.00</I>&rdquo; would be adjusted (to the nearest cent) to be equal to the higher
of the Market Value and the Newly Issued Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of any reclassification or reorganization of the outstanding shares of Common Stock (other than those described above or that solely
affects the par value of such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation
or entity (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification
or reorganization of our outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity
of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders
of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in
the warrants and in lieu of the shares of Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights
represented thereby, the kind and amount of shares of Common Stock or other securities or property (including cash) receivable upon such
reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder
of the warrants would have received if such holder had exercised their warrants immediately prior to such event. However, if such holders
were entitled to exercise a right of election as to the kind or amount of securities, cash, or other assets receivable upon such consolidation
or merger, then the kind and amount of securities, cash, or other assets for which each warrant will become exercisable will be deemed
to be the weighted average of the kind and amount received per share by such holders in such consolidation or merger that affirmatively
make such election, and if a tender, exchange, or redemption offer has been made to and accepted by such holders under circumstances
in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning
of Rule 13d-5(b)(1) under the Exchange Act) of which such maker is a part, and together with any affiliate or associate of such maker
(within the meaning of Rule 12b-2 under the Exchange Act) and any members of any such group of which any such affiliate or associate
is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act) more than 50% of the issued and outstanding shares
of Common Stock, the holder of a warrant will be entitled to receive the highest amount of cash, securities, or other property to which
such holder would actually have been entitled as a shareholder if such warrant holder had exercised the warrant prior to the expiration
of such tender or exchange offer, accepted such offer and all of the shares of Common Stock held by such holder had been purchased pursuant
to such tender or exchange offer, subject to adjustment (from and after the consummation of such tender or exchange offer) as nearly
equivalent as possible to the adjustments provided for in the warrant agreement. If less than 70% of the consideration receivable by
the holders of shares of Common Stock in such a transaction is payable in the form of shares in the successor entity that is listed for
trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or
quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days
following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based
on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide
additional value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant
to which the holders of the warrants otherwise do not receive the full potential value of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Private
Placement Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below, the private placement warrants have terms and provisions that are identical to those of the public warrants described
above. The private placement warrants (including the shares of Common Stock issuable upon exercise of the private placement warrants)
are not redeemable by us so long as they are held by <FONT STYLE="background-color: white">SSVK, Semper Paratus Sponsor LLC (the &ldquo;Original
Sponsor&rdquo;), Cantor Fitzgerald &amp; Co. (&ldquo;Cantor&rdquo;),</FONT> or their permitted transferees. <FONT STYLE="background-color: white">SSVK,
the Original Sponsor, Cantor, or</FONT> their permitted transferees have the option to exercise the private placement warrants on a cashless
basis. If the private placement warrants are held by holders other than <FONT STYLE="background-color: white">SSVK, the Original Sponsor,
Cantor,</FONT> and their permitted transferees, the private placement warrants would be redeemable by us and exercisable by the holders
on the same basis as the public warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering
their warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of
shares of Common Stock underlying the warrants, multiplied by the excess of the &ldquo;fair market value&rdquo; (as defined below) over
the exercise price of the warrants by (y) the Sponsor fair market value. For these purposes, the &ldquo;fair market value&rdquo; shall
mean the average reported closing price of the shares of Common Stock for the 10 trading days ending on the third trading day prior to
the date on which the notice of warrant exercise is sent to the warrant agent. We have agreed that these warrants will be exercisable
on a cashless basis so long as they are held by <FONT STYLE="background-color: white">SSVK, Original Sponsor, Cantor,</FONT> or their
permitted transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing
of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock and public warrants are currently listed on Nasdaq, under the symbols &ldquo;TVGN&rdquo; and &ldquo;TVGNW,&rdquo; respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ex19-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tevogen
Bio Holdings Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insider
Trading Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
February 14, 2024</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Insider Trading Policy (the &ldquo;<U>Policy</U>&rdquo;) provides guidelines with respect to transactions in the securities of Tevogen
Bio Holdings Inc. (the &ldquo;<U>Company</U>&rdquo;) and the handling of confidential information about the Company and the companies
with which the Company engages in transactions or does business. The Company&rsquo;s Board of Directors has adopted this Policy to promote
compliance with U.S. federal, state, and foreign securities laws that prohibit certain persons who are aware of material nonpublic information
about a company from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 34.5pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 18pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
                                            in securities of that company; or </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 34.5pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 18pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
                                            material nonpublic information to other persons who may trade on the basis of that information
                                            (also known as &ldquo;<U>tipping</U>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Insider
trading is a crime.</I></B> Violations are pursued vigorously by the Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;), U.S.
Attorneys, state enforcement authorities, and foreign jurisdictions. Violations can result in severe penalties, including significant
fines and imprisonment. See the Section below captioned &ldquo;<I>Consequences of Violations</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Persons
Subject to the Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to (i) all members of the Company&rsquo;s Board of Directors, (ii) all officers of the Company and its subsidiaries, and
(iii) all employees of the Company and its subsidiaries. The Company may also determine that other persons should be subject to this
Policy, such as contractors or consultants who have access to material nonpublic information. This Policy also applies to family members,
other members of a person&rsquo;s household, and entities controlled by a person covered by this Policy, as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
Subject to the Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all transactions in (i)&nbsp;the Company&rsquo;s securities (collectively referred to in this Policy as &ldquo;<U>Company
Securities</U>&rdquo;), including the Company&rsquo;s common stock, any securities that are exercisable for, or convertible or exchangeable
into, shares of common stock, and any other type of securities that the Company may issue from time to time, including (but not limited
to) warrants, convertible debt, notes, and preferred stock, as well as derivative securities that are not issued by the Company, such
as exchange-traded put or call options or swaps relating to the Company&rsquo;s Securities, and (ii) the securities of certain other
companies, where the person trading used information obtained while working for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statement
of Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the policy of the Company that no director, officer, or employee of the Company or its subsidiaries (or any other person designated
by this Policy or by the Compliance Officer, as such term is defined below under the heading &ldquo;<I>Administration of the Policy</I>&rdquo;,
as subject to this Policy) who is aware of material nonpublic information relating to the Company or its subsidiaries may, directly,
or indirectly through family members or other persons or entities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 34.5pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 18pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
                                            in transactions in Company Securities, except as otherwise specified in this Policy under
                                            the headings &ldquo;<I>Transactions Not Subject to Trading Restrictions</I>&rdquo; and &ldquo;<I>Rule
                                            10b5-1 Plans</I>&rdquo;; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 34.5pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 18pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
                                            that others engage in transactions in any Company Securities; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 34.5pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 18pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
                                            material nonpublic information to persons within the Company whose jobs do not require them
                                            to have that information, or outside of the Company to other persons, including, but not
                                            limited to, family, friends, business associates, investors, and expert consulting firms,
                                            unless any such disclosure is made in accordance with the Company&rsquo;s policies regarding
                                            the protection or authorized external disclosure of information regarding the Company; or
                                            </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 34.5pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 18pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assist
                                            anyone engaged in the above activities. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, it is the policy of the Company that no director, officer, or employee of the Company or its subsidiaries (or any other person
designated as subject to this Policy) who, in the course of working for the Company, learns of material nonpublic information about a
company (1)&nbsp;with which the Company does business, including a customer or supplier of the Company, or (2)&nbsp;that is involved
in a potential transaction or business relationship with the Company may trade in that company&rsquo;s securities until the information
becomes public or is no longer material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no exceptions to this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent
reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not exempted from this Policy. The
securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must
be avoided to preserve the Company&rsquo;s reputation for adhering to the highest standards of conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Individual
Responsibility</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not
engage in transactions in Company Securities while in possession of material nonpublic information. Persons subject to this Policy must
not engage in illegal trading and must avoid the appearance of improper trading. Each individual is responsible for making sure that
they comply with this Policy, and that any family member, household member, or entity whose transactions are subject to this Policy,
as discussed below, also comply with this Policy. In all cases, the responsibility for determining whether an individual is in possession
of material nonpublic information rests with that individual, and any action on the part of the Company, the Compliance Officer, or any
other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual
from liability under applicable securities laws. <B>You could be subject to severe legal penalties and disciplinary action by the Company
for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading &ldquo;<I>Consequences
of Violations</I>.&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Administration
of the Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chief Financial Officer shall serve as the Compliance Officer for the purposes of this Policy, and in the absence of the Chief Financial
Officer, another employee designated by the Compliance Officer shall be responsible for administration of this Policy. All determinations
and interpretations by the Compliance Officer shall be final and not subject to further review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
in doubt about a matter covered by this Policy, or if you have questions, please contact the Compliance Officer before engaging in any
transaction involving Company Securities. See &ldquo;<I>Company Assistance</I>&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
of Material Nonpublic Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Material
Information</U></I>. Information is considered &ldquo;material&rdquo; if a reasonable investor would consider that information important
in making a decision to buy, hold, or sell securities. Any information that could be expected to affect the Company&rsquo;s stock price,
whether it is positive or negative, should be considered material. There is no bright-line standard for assessing materiality; rather,
materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with the
benefit of hindsight. While it is not possible to define all categories of material information, some examples of information that ordinarily
would be regarded as material are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
                                            financial condition and results of operation of the Company, including quarterly and annual
                                            results, or financial results of any significant subsidiary, business, or unit, or of any
                                            of the Company&rsquo;s technologies, products, and services;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation,
                                            termination, or results of clinical trials or other research;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry
                                            into or termination of a material contract or other major transaction (such as a license
                                            agreement, joint venture, strategic alliance, or collaboration);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending
                                            or proposed mergers, investments, acquisitions, dispositions, or tender offers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            restructuring of the Company; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            related party transactions; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            offering of any Company Securities; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            establishment of, or any significant developments or changes regarding, a repurchase program
                                            for Company Securities (such as planned repurchases, increases or decreases in the program&rsquo;s
                                            authorization, suspensions, and similar changes); </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redemption,
                                            retirement, or modification of outstanding debt securities or other indebtedness;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bank
                                            borrowings or other financing transactions outside the ordinary course of business; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">major
                                            marketing changes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gain or loss of a significant customer or supplier or an expected increase in revenue from
                                            an existing customer; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            change in auditors or notification that the auditor&rsquo;s reports may no longer be relied
                                            upon; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">write-ups
                                            or write-downs of assets or changes in accounting methods;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
                                            of a significant new product, process, technical innovation, or service, including new product
                                            candidates or significant preclinical data or results; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
                                            Food and Drug Administration actions or other significant regulatory developments with respect
                                            to the Company&rsquo;s technologies, products, and services; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            actual or potential cybersecurity incidents (<I>e.g.</I>, a data breach or any other significant
                                            disruption in the Company&rsquo;s operations, or loss, potential loss, breach, or unauthorized
                                            access of its property or assets, whether at its facilities or through its information technology
                                            infrastructure);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            imposition of a restriction on trading in Company securities, or in the securities of another
                                            company with which the Company conducts business or may engage in acquisitions, joint ventures,
                                            or other transactions, or the extension or termination of such restriction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            actual or proposed change to the Company&rsquo;s capital structure, including a stock split;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            proposed dividend or a change in dividend policy;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impending
                                            bankruptcy or the existence of severe liquidity issues;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">forward-looking
                                            information regarding the Company&rsquo;s financial performance, such as earnings guidance,
                                            projections, or &ldquo;outlook&rdquo; for future financial results;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">confirmation
                                            of or changes to previously announced earnings guidance or the decision to suspend earnings
                                            guidance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unpublished
                                            financial figures, including revenue, expenses, net income, and earnings per share, as well
                                            as their expected growth or decline rates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            major change in management or the board of directors; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            pending or threatened litigation or government inquiries or investigations, and related developments,
                                            including the resolution of such litigation, inquiry, or investigation;&nbsp;or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            change in the Company&rsquo;s pricing or cost structure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this list to the Company or otherwise in the context of assessing whether information is material shall mean the Company and/or its
subsidiaries and business units, as the context requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>When
Information is Considered Public</U></I>. Information that has not been disclosed to the public is generally considered to be nonpublic
information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the
information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed through
a press release, a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine,
or news website, newswire services, or public disclosure documents filed with the SEC that are available on the SEC&rsquo;s website (such
as Form 8-K, Form&nbsp;10-Q, and Form 10-K). By contrast, information would likely not be considered widely disseminated if it is available
only to the Company&rsquo;s employees, or if it is only available to a select group of persons, such as analysts, brokers, and institutional
investors. In addition, please be aware that disclosure on the Company&rsquo;s website and the Company&rsquo;s social media channels,
by itself, may not be considered wide dissemination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
information is widely disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information.
As a general rule, information should not be considered fully absorbed by the marketplace until after two full trading days have elapsed
after the information is released. If, for example, the Company were to make an announcement on a Monday afternoon, you should not trade
in Company Securities until Thursday. Depending on the particular circumstances, the Company may determine that a longer or shorter period
should apply to the release of specific material nonpublic information. If you are unsure whether material information has been made
&ldquo;public,&rdquo; please contact the Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Precautions
to Prevent Misuse or Unauthorized Disclosure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a person covered under this policy has exposure to material nonpublic information, that individual should consider taking extraordinary
precautions to prevent misuse or unauthorized disclosure, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            files securely and avoiding storing information on computer systems that can be accessed
                                            by other individuals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoiding
                                            discussing confidential matters in areas where conversation could be overheard;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricting
                                            information on a &ldquo;need to know&rdquo; basis; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refraining
                                            from making any statement on the Internet or via social media (<I>e.g.</I>, X, LinkedIn,
                                            Facebook) regarding the Company, as it may be seen as a recommendation to buy or sell Company
                                            Securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
by Family Members and Others</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to your family members who reside with you (including a spouse, a child, a child away at college, stepchildren, grandchildren,
parents, stepparents, grandparents, siblings, and in-laws), anyone else who lives in your household, and any family members who do not
live in your household but whose transactions in Company Securities are directed by you or are subject to your influence or control,
such as parents or children who consult with you before they trade in Company Securities (collectively referred to as &ldquo;<U>Family
Members</U>&rdquo;). You are responsible for the transactions of these other persons and therefore should make them aware of the need
to confer with you before they trade in Company Securities, and you should treat all such transactions for the purposes of this Policy
and applicable securities laws as if the transactions were for your own account. This Policy does not, however, apply to personal securities
transactions of Family Members where the purchase or sale decision is made by a third party not controlled by, influenced by, or related
to you or your Family Members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
by Entities that You Influence or Control</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to any entities that you influence or control, including any corporations, partnerships, or trusts (collectively referred
to as &ldquo;<U>Controlled Entities</U>&rdquo;), and transactions by these Controlled Entities should be treated for the purposes of
this Policy and applicable securities laws as if they were for your own account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
Not Subject to Trading Restrictions of this Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Transactions
Under Company Plans</U></I>. This Policy does not apply in the case of the following transactions, except as specifically noted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Stock
                                            Option Exercises</U></I>. This Policy does not apply to the exercise of an employee stock
                                            option acquired pursuant to the Company&rsquo;s plans, or to the exercise of a tax withholding
                                            right pursuant to which a person has elected to have the Company withhold shares subject
                                            to an option to satisfy tax withholding requirements. Similarly, this Policy does not apply
                                            to the exercise of options on a &ldquo;net exercise&rdquo; basis pursuant to which a person
                                            either (i) delivers outstanding shares of common stock to the Company or (ii) authorizes
                                            the Company to withhold from issuance shares of common stock issuable upon exercise of the
                                            option, in either case, having a fair market value on the date of exercise equal to the aggregate
                                            exercise price. This Policy does apply, however, to any sale of stock as part of a broker-assisted
                                            cashless exercise of an option, or any other market sale for the purpose of generating the
                                            cash needed to pay the exercise price of an option. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Restricted
                                            Stock and RSU Awards</U></I>. This Policy does not apply to the vesting of restricted stock
                                            or restricted stock units, or the exercise of a tax withholding right pursuant to which a
                                            person has elected to have the Company withhold shares or units to satisfy tax withholding
                                            requirements upon the vesting of any restricted stock or units. The Policy does apply, however,
                                            to any market sale of restricted stock. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
                                            Similar Transactions</U>. Any other purchase of Company Securities from the Company or sales
                                            of Company Securities to the Company are not subject to this Policy. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Transactions
Not Involving a Purchase or Sale.</U></I></B><I> Bona fide</I> gifts of securities are not transactions subject to this Policy, unless
the person making the gift has reason to believe that the recipient intends to sell the Company Securities while the person making the
gift is aware of material nonpublic information, provided that Covered Persons must still pre-clear any such transaction as described
below under the heading &ldquo;<I>Additional Procedures&mdash;Pre-clearance Procedures</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Certain
Mutual Fund Transactions</U></I>. Transactions in mutual funds that are invested in Company Securities are not transactions subject to
this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special
and Prohibited Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons
subject to this Policy engage in certain types of transactions. Therefore, it is the Company&rsquo;s policy that any persons covered
by this Policy may not engage in any of the following transactions, or should otherwise consider the Company&rsquo;s preferences as described
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Short-Term
                                            Trading</U></I>. Short-term trading of Company Securities may be distracting to the person
                                            and may unduly focus the person on the Company&rsquo;s short-term stock market performance
                                            instead of the Company&rsquo;s long-term business objectives. For these reasons, any director,
                                            officer, or employee of the Company who purchases Company Securities in the open market may
                                            not sell any Company Securities of the same class during the six months following the purchase
                                            (or vice versa).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Short
                                            Sales</U></I>. Short sales of Company Securities (i.e., the sale of a security that the seller
                                            does not own) may evidence an expectation on the part of the seller that the securities will
                                            decline in value, and therefore have the potential to signal to the market that the seller
                                            lacks confidence in the Company&rsquo;s prospects. In addition, short sales may reduce a
                                            seller&rsquo;s incentive to seek to improve the Company&rsquo;s performance. For these reasons,
                                            short sales of Company Securities are prohibited. In addition, Section&nbsp;16(c) of the
                                            Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), prohibits
                                            officers and directors from engaging in short sales. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Publicly
                                            Traded Options</U>.</I> Given the relatively short term of publicly traded options, transactions
                                            in options may create the appearance that a director, officer, or employee is trading based
                                            on material nonpublic information and focus a director&rsquo;s, officer&rsquo;s, or other
                                            employee&rsquo;s attention on short-term performance at the expense of the Company&rsquo;s long-term
                                            objectives. Accordingly, transactions in put options, call options, or other derivative securities,
                                            on an exchange or in any other organized market, are prohibited by this Policy. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Hedging
                                            Transactions</U></I>. Hedging or monetization transactions can be accomplished through a
                                            number of possible mechanisms, including through the use of financial instruments such as
                                            prepaid variable forward contracts, equity swaps, collars, and exchange funds or other transactions
                                            which hedge or offset, or are designed to hedge or offset, any decrease in the market value
                                            of Company Securities. Such hedging transactions may permit a director, officer, or employee
                                            to continue to own Company Securities directly or indirectly, including those obtained through
                                            employee benefit plans or otherwise, but without the full risks and rewards of ownership.
                                            When that occurs, the director, officer, or employee may no longer have the same objectives
                                            as the Company&rsquo;s other shareholders. Therefore, directors, officers, and employees
                                            are prohibited from engaging in any such transactions. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Margin
                                            Accounts and Pledged Securities</U></I>. Securities held in a margin account as collateral
                                            for a margin loan may be sold by the broker without the customer&rsquo;s consent if the customer
                                            fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral
                                            for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin
                                            sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic
                                            information or otherwise is not permitted to trade in Company Securities, directors, officers,
                                            and other employees are prohibited from holding Company Securities in a margin account or
                                            otherwise pledging Company Securities as collateral for a loan. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Standing
                                            and Limit Orders</U></I>. Standing and limit orders (except standing and limit orders under
                                            approved Rule 10b5-1 Plans, as described below) create heightened risks for insider trading
                                            violations similar to the use of margin accounts. There is no control over the timing of
                                            purchases or sales that result from standing instructions to a broker, and as a result the
                                            broker could execute a transaction when a director, officer, or other employee is in possession
                                            of material nonpublic information. The Company therefore discourages placing standing or
                                            limit orders on Company Securities. If a person subject to this Policy determines that they
                                            must use a standing order or limit order, the order should be limited to short duration and
                                            should otherwise comply with the restrictions and procedures outlined below under the heading
                                            &ldquo;<I>Additional Procedures</I>.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established additional procedures in order to assist the Company in the administration of this Policy, to facilitate compliance
with laws prohibiting insider trading while in possession of material nonpublic information, and to avoid the appearance of any impropriety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pre-Clearance
                                            Procedures</U></I>. No Covered Person may engage in any transaction in Company Securities
                                            without first obtaining pre-clearance from the Compliance Officer. A request for pre-clearance
                                            should be submitted to the Compliance Officer at least two business days before the proposed
                                            transaction in order to give adequate time for the Company to administer the request, and
                                            shall comply with any other procedures established by the Compliance Officer. The Compliance
                                            Officer is under no obligation to approve a transaction submitted for pre-clearance and will
                                            have sole discretion to determine whether to permit the transaction. In evaluating each proposed
                                            transaction, the Compliance Officer may consult as necessary with senior management and outside
                                            counsel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Covered Person seeks pre-clearance and the request is denied, then such Covered Person should refrain from engaging in any transaction
in Company Securities, and should not inform any other person of the restriction. Moreover, pre-clearance does not, in any circumstance,
relieve anyone of their legal obligation to refrain from trading while in possession of material nonpublic information. In other words,
even if pre-clearance is received, if the requesting person becomes aware of material nonpublic information or becomes subject to a blackout
period or event-specific trading restriction (as discussed below), the transaction may not be completed. Pre-clearance of a transaction
is valid only for the 5-business day period immediately following receipt by the Covered Person of such pre-clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requests
for pre-clearance should be made by submitting the information set forth in the Request for Clearance to Trade attached as <U>Exhibit
B</U> hereto. When a request for pre-clearance is made, the requesting person should carefully consider whether they may be aware of
any material nonpublic information about the Company and should provide a detailed description of those circumstances to the Compliance
Officer. The requesting person should also indicate whether they have effected any non-exempt &ldquo;opposite-way&rdquo; transactions
within the past six months, and should be prepared to report the proposed transaction on an appropriate Form 4 or Form 5. The requesting
person should also be prepared to comply with SEC Rule 144 and file a Form 144, if necessary, at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
knowledgeable, alert broker can act as a gatekeeper, helping ensure compliance with pre-clearance procedures and helping prevent inadvertent
violations. Accordingly, the Company encourages each Covered Person using any broker to sign and have their broker sign a &ldquo;Broker
Instruction/Representation&rdquo; form that imposes two requirements on the broker handling transactions in Company Securities: (1) not
to enter any order (except for orders under a pre-approved Rule 10b5-1 Plan discussed below) without first verifying with the Company
that the transaction was pre-cleared and complying with the brokerage firm&rsquo;s compliance procedures (<I>e.g.</I>, Rule 144), and
(2) to report immediately to the Company the details of every transaction involving Company Securities, including gifts, transfers, pledges,
and all transactions under a Rule 10b5-1 Plan discussed below. Each Covered Person using a broker who signs and has the broker sign a
Broker Instruction/Representation form should return it to the Company immediately so that the Company can work with the broker to develop
a coordinated procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Post-Transaction
                                            Notice</U></I>. Covered Persons who have a reporting obligation under Section 16 of the Exchange
                                            Act shall also notify the Compliance Officer of the occurrence of any purchase, sale, or
                                            other acquisition or disposition of Company Securities as soon as possible following the
                                            transaction, but in any event within one business day after the transaction. Such notification
                                            may be oral or in writing (including by e-mail) and should include the identity of the Covered
                                            Persons, the type of transaction, the date of the transaction, the number of shares involved,
                                            and the purchase or sale price.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
both the &ldquo;<I>Pre-Clearance Procedures</I>&rdquo; section above and this &ldquo;<I>Post-Transaction Notice</I>&rdquo; section, a
purchase, sale, or other acquisition or disposition shall be deemed to occur at the time the person or entity becomes irrevocably committed
to it (for example, in the case of an open market purchase or sale, this occurs when the trade is executed, not when it settles).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Quarterly
                                            Blackout Period Restrictions</U></I>. Covered Persons may not engage in any transactions
                                            involving the Company Securities (other than as specified by this Policy), during a &ldquo;<U>Blackout
                                            Period</U>&rdquo; beginning fourteen days prior to the public release of the Company&rsquo;s
                                            earnings results for that quarter and ending on the second business day following the date
                                            of the public release of the Company&rsquo;s earnings results for that quarter. For illustration
                                            and ease of reference, these Blackout Periods are set forth in the following table:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 10%; text-align: center; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quarter</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 36%; text-align: center; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blackout
    Period Begins</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 50%; text-align: center; padding-right: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blackout
    Period Ends</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    weeks before Q1 earnings are publicly released<BR>
    (typically late April)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    business days after Q1 earnings are publicly released <BR>
    (typically mid-May)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    weeks before Q2 earnings are publicly released<BR>
    (typically late July)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    business days after Q2 earnings are publicly released <BR>
    (typically mid-August)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    weeks before Q3 earnings are publicly released<BR>
    (typically late October)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    business days after Q3 earnings are publicly released <BR>
    (typically mid-November)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    weeks before annual earnings are publicly released</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-top: 0pt; padding-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    business days after annual earnings are publicly released </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blackout
Periods are compliance requirements of the Company and do not create or constitute a legal right to trade when they are not in effect.
Accordingly and for the avoidance of doubt, even when a Blackout Period is not in effect, if you are in possession of material nonpublic
information, you may not trade in the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.25pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Event-Specific
                                            Trading Restrictions</U></I>. From time to time, an event may occur that is material to the
                                            Company and is known by only a few directors, officers, and/or employees. So long as the
                                            event remains material and nonpublic, the persons designated by the Compliance Officer may
                                            not engage in transactions in Company Securities. In addition, the Company&rsquo;s financial
                                            results may be sufficiently material in a particular fiscal quarter that, in the judgment
                                            of the Compliance Officer, designated persons should refrain from engaging in transactions
                                            in Company Securities even sooner than the typical Blackout Period described above. In that
                                            situation, the Compliance Officer may notify these persons that they should not trade in
                                            the Company&rsquo;s Securities, without disclosing the reason for the restriction. The existence
                                            of an event-specific trading restriction period or extension of a Blackout Period will not
                                            be announced to the Company as a whole, and should not be communicated to any other person.
                                            Even if the Compliance Officer has not designated you as a person who should not engage in
                                            transactions in Company Securities due to an Event-Specific Restricted Period, you should
                                            not trade while aware of material nonpublic information. Exceptions to this Policy will not
                                            be granted while an event-specific trading restriction is in effect. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 36.75pt; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 19.95pt; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Exceptions</U></I>.
                                            Blackout Period and event-specific trading restrictions do not apply to any transactions
                                            to which this Policy does not apply, as described above under the heading &ldquo;<I>Transactions
                                            Not Subject to Trading Restrictions of this Policy</I>.&rdquo; In addition, the pre-clearance
                                            requirements, Blackout Period and event-specific trading restrictions do not apply to transactions
                                            under approved Rule 10b5-1 Plans. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
10b5-1 Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 under the Exchange Act provides a defense from insider trading liability. In order to be eligible to rely on this defense, a person
subject to this Policy must enter into a Rule 10b5-1 plan for transactions in Company Securities that meets certain conditions specified
in the Rule (a &ldquo;<U>Rule 10b5-1 Plan</U>&rdquo;). If the plan meets the requirements of Rule 10b5-1, Company Securities may be purchased
or sold without regard to certain insider trading restrictions. To comply with the Policy, a Rule 10b5-1 Plan must be approved by the
Compliance Officer and meet the requirements of Rule 10b5-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a Rule 10b5-1 Plan must be entered into at a time when the person entering into the plan is not aware of material nonpublic
information. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price
at which they are to be traded, or the date of the trade. The plan must either specify the amount, pricing, and timing of transactions
in advance or delegate discretion on these matters to an independent third party. The plan must include a cooling-off period before trading
can commence that, for directors or officers, ends on the later of 90 days after the adoption of the Rule 10b5-1 plan or two business
days following the disclosure of the Company&rsquo;s financial results in an SEC periodic report for the fiscal quarter in which the
plan was adopted (but in any event, the required cooling-off period is subject to a maximum of 120 days after adoption of the plan),
and for persons other than directors or officers, 30 days following the adoption or modification of a Rule 10b5-1 plan. A person may
not enter into overlapping Rule 10b5-1 plans (subject to certain exceptions) and may only enter into one single-trade Rule 10b5-1 plan
during any 12-month period (subject to certain exceptions). Directors and officers must include a representation in their Rule 10b5-1
plan certifying that they are (i) not aware of any material nonpublic information; and (ii) adopting the plan in good faith and not as
part of a plan or scheme to evade the prohibitions in Rule 10b-5. All persons entering into a Rule 10b5-1 plan must act in good faith
with respect to that plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
adoption of a new Rule 10b5-1 Plan, or amendment to or early termination of any existing Rule 10b5-1 Plan, must be submitted to the Compliance
Officer for approval at least five business days prior to the entry into the Rule&nbsp;10b5-1 Plan or amendment. No further pre-approval
of transactions conducted pursuant to the Rule 10b5-1 Plan is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicability
of Policy to Former Insiders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy continues to apply to transactions in Company Securities even after termination of service to the Company. If an individual is
in possession of material nonpublic information when their service terminates, that individual may not engage in transactions in Company
Securities until that information has become public or is no longer material. The pre-clearance procedures applicable to such individual
specified under the heading &ldquo;<I>Additional Procedures</I>&rdquo; above, however, will cease to apply to transactions in Company
Securities upon the expiration of any Blackout Period or other Company-imposed trading restrictions in force at the time of such individual&rsquo;s
termination of service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consequences
of Violations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insider
trading is a crime.</B> Violations are pursued vigorously by the SEC, U.S. Attorneys, and state enforcement authorities and foreign jurisdictions.
Punishment for insider trading violations is severe, and could include significant fines and imprisonment. While the regulatory authorities
concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws
also impose potential liability on companies and other &ldquo;controlling persons&rdquo; within the organization if they fail to take
reasonable steps to prevent insider trading by company personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
federal securities laws, individuals found liable for insider trading could, among other things, face (i) up to 20 years in jail, (ii)
a criminal fine of up to $5 million, and (iii) civil penalties of up to three times the profit gained or loss avoided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, for failing to take steps to prevent insider trading, the Company (and/or its executive officers and directors) could itself
face (i) a criminal penalty of up to $25 million, and (ii) civil penalties of the greater of $1 million or three times the profit gained
or loss avoided as a result of an employee&rsquo;s violation. Please note that individual states may impose their own penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
an individual&rsquo;s failure to comply with this Policy may subject the individual to Company imposed sanctions, up to and including dismissal
for cause, whether or not the employee&rsquo;s failure to comply results in a violation of law. Any sanctions imposed upon or liabilities
incurred by an employee for insider trading will be the sole responsibility of the employee. The Company will not cover or indemnify
the employee for these costs. Neither the Company nor any of its directors, officers, or employees will be liable for the legal or financial
consequences of any approval or pre-clearance, refusal to approve or pre-clear, or delay in reviewing any requests for approval or pre-clearance
of any transaction, Rule 10b5-1 Plan, or other request under this Policy. Needless to say, a violation of law, or even an SEC investigation
that does not result in prosecution, can tarnish a person&rsquo;s reputation and irreparably damage a career.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Assistance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions about this Policy or its application to any proposed transaction, please contact the Company&rsquo;s Compliance
Officer, who can be reached by telephone at 1 877 TEVOGEN, Ext 705 or by e-mail at kirti.desai@tevogen.com, for additional guidance.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
must sign, date, and return the Certification attached as <U>Exhibit A</U> (or any other certification the Compliance Officer deems appropriate)
stating that you have received, read, understand, and agree to comply with this Policy. The Company may require you to sign this Certification
on an annual basis, including in electronic format. Please note that you are bound by the Policy whether or not you sign the Certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
*</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy supersedes any previous policy of the Company or its predecessors concerning securities trading. In the event of any conflict
or inconsistency between this Policy and other materials previously distributed by the Company or its predecessors, this Policy shall
govern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adopted:
February 14, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CERTIFICATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have read and understand the Company&rsquo;s Insider Trading Policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            understand that the Company&rsquo;s Compliance Officer is available to answer any questions
                                            I have regarding the Insider Trading Policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
                                            February 14, 2024, or such shorter period of time that I have been an employee or director
                                            of the Company, I have complied with the Insider Trading Policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            will continue to comply with the Insider Trading Policy for as long as I am subject to the
                                            Policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            understand and agree that any violation of the Insider Trading Policy by me, my family members,
                                            or other persons who are subject to the Policy because of their relationship with me may
                                            result in fines, penalties, and/or disciplinary action, up to and including termination of
                                            my employment or service.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REQUEST
FOR CLEARANCE TO TRADE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
    Bio Holdings Inc.</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15
    Independence Boulevard</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warren,
    New Jersey 07059</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Kirti Desai, CPA</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    1 877 TEVOGEN, Ext. 705 </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    <U>kirti.desai@tevogen.com</U></FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line; width: 5%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby request clearance for myself (or a member of my immediate family or household) to execute the following transaction relating to
the securities of Tevogen Bio Holdings Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
of Transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
wish to purchase. Number and type of securities to be purchased: ________________</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
wish to sell. Number and type of securities to be sold: ________________</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
wish to exercise an option and sell all or a portion of the shares of common stock purchased at the then market price in a &ldquo;cashless
exercise&rdquo; or &ldquo;same day sale&rdquo; and hold any remaining shares of common stock in my brokerage account.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-left: 1.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Number of options to be
exercised: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin-left: 1.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Number of shares of common
stock to be sold: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin-left: 1.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Number of shares of common
stock held in account: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
transaction:</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the request is for a member of my immediate family or household:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 39%; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Person: </FONT>
________________________</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 7%; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 27%; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationship:
_____________________________    </FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 27%; padding-right: 0pt; text-align: justify; text-indent: 0in; layout-grid-mode: line; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby represent and certify that I am not aware of any material, non-public information concerning Tevogen Bio Holdings Inc. at the
time of submitting this request, and I agree that should I become aware of any material, non-public information concerning Tevogen Bio
Holdings Inc. before completing the approved transaction, I will not complete the transaction. I understand that once approved, this
authorization is valid on the date of approval and for five business days thereafter. I further understand that the approval will lapse
if I become in possession of, or, in the judgment of the Compliance Officer, I am likely to be in possession of material, non-public
information, or otherwise on the earliest of expiration of (i) the five-business day period of this approval, or (ii) the trading window
in which approval is granted, whichever is the first to occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; width: 48%; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 4%; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; width: 48%; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: justify; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding: 0pt 0pt 1pt; text-align: justify; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; padding: 0pt 0pt 1pt; text-align: justify; layout-grid-mode: line">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved
    by:</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    Officer</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
    Entity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    of Organization</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
    Bio Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the registration statement (No. 333-280075) on Form S-8 of our report dated April 2, 2025,
with respect to the consolidated financial statements of Tevogen Bio Holdings Inc.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
KPMG LLP</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
13a-14(a) Certification of Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Ryan Saadi, Chief Executive Officer of Tevogen Bio Holdings Inc., certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024, of Tevogen Bio Holdings Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 2, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Ryan
    Saadi</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Saadi</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
13a-14(a) Certification of Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Kirti Desai, Chief Financial Officer of Tevogen Bio Holdings Inc., certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024, of Tevogen Bio Holdings Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 2, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Kirti
    Desai</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti Desai</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial Officer)</I></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
pursuant to 18 U.S.C. Section 1350 by the Chief Executive Officer, as adopted pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code),
the undersigned officer of Tevogen Bio Holdings Inc. (the &ldquo;Company&rdquo;), does hereby certify, to such officer&rsquo;s knowledge,
that the Annual Report on Form 10-K of the Company for the year ended December 31, 2024, as filed on the date hereof with the Securities
and Exchange Commission (the &ldquo;Form 10-K&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and
results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 2, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Ryan
    Saadi</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Saadi</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
pursuant to 18 U.S.C. Section 1350 by the Chief Financial Officer, as adopted pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code),
the undersigned officer of Tevogen Bio Holdings Inc. (the &ldquo;Company&rdquo;), does hereby certify, to such officer&rsquo;s knowledge,
that the Annual Report on Form 10-K of the Company for the year ended December 31, 2024, as filed on the date hereof with the Securities
and Exchange Commission (the &ldquo;Form 10-K&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and
results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 2, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Kirti
    Desai</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirti Desai</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  K ,@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_;8G]U?^
M^1_A7CGQ9^//P1^ NE:=K?QL^+/PY^$VDZQ=FQT>]^(7C#0?"<.L7:>29[;1
MQK-]:OJ<UJMS%+>)8K,+."07%TT, :0?-_\ P4*_;7\+?L'?L[:W\7M1T_3O
M$GC?5-0MO"7PH\"7FH?V<GB_QOJ<4L\27DT"/>0^'O#VFV]]X@\1W5M&)!I^
MG_V?:RQZIJFG*_\ !M^T#\</C-^V-\5]7^,_QT\22>)O&&IHEEIEE:Q26/A?
MP9X>@D>2Q\*>"=">>ZCT'0+(R/)Y(GN+W4KV2XU;6K[4M6O+J^G_ %GPW\*<
MPX\]IC\1B)Y9P_1JU</+&0ITJF+QN)I*//AL#1K<D7"DYQ>(Q<Y*A"</8P]M
M4YU3_G3QO^D-D7A%"EEM'#4LYXKQ%"EBHY;4KU*&"R[!UF_9XK,L10O5C4K1
MA4^KX*E'V\J=Z]65&FH>U_T@? _Q!\!?$G2(_$/P[\:^#O'V@7 5X=<\$^)M
M%\6:/*LF[88]1T*]U"R8/L<(5G^8I)M)V''=*BX&57H/X1Z5_F$^'](\5>"K
MZ+7O!'B#Q-X-UN B2'6_!^O:QX8UB&3:<-'J>A7=C>H0#U$R]QTXK^HC_@C+
M_P %2?&'Q \1>'OV+OVE-8UGQ/X_OK36T^"7Q;UFZO\ 6=;\81:)INK>*M3\
M"?$'4;IIY[C7=+\/:?J=_P"%?%-U,BZQIFD3:!K4XUNVT>YU[V^-O O-N%LJ
MQ6=97F:SW!X*,ZV+P\\(L%CL/A(0E*IB[4ZN(P^)HX>,5+$2HS56%)RJPH5(
M4JB7QWA-]+GA7Q%S[!<,YOE2X:S7,I1P^ Q4,P6/RW%8^<XQHX)NI0H8S!SQ
M7OQPKK*O2GB%3H3J4Y8BC,_IOV)_=7_OD?X4;$_NK_WR/\*8&*QH=I)(4%1P
M0=OX\YX SR>]>,W'[2G[.EG<7%G>_'WX*V=[9W$]I>6=S\5/ L%S:7=M*\%S
M:W,$NO++!<6\\<D,\,J))%*CQR*KJRC\+_K71_-='W738_KP]IV)_=7_ +Y'
M^%&Q/[J_]\C_  KC/!_Q(^'_ ,0[6]OOA]XX\'>.['3KI+&_O?!GB?1/%%K8
MWSPI<I9WUQHE[?0VET]O(DZ6\[I*\+K*$\M@U<1KG[2G[.WAG7+SPQXD^/?P
M5\/>)-.N&M-0\/:Y\5/ VDZY872'$EM>:3?ZY!?6URG\4$T*2J2-RCK0![5L
M3^ZO_?(_PHV)_=7_ +Y'^%<=XA^(O@+PC'H<OBWQMX/\+1>)[R#3O#4OB/Q/
MHNB1^(=0N5C>WL="?4[VV35[R=9H6AMM.-S-*LT31HXD4G4\0^*?#OA#1;[Q
M'XMU[1/"WA_2UB?4]=\1ZM8:)HNG1SW$-G#)?:KJ4]M8VB37EQ#:Q-<3Q^9<
M2Q0H&DD12 ;NQ/[J_P#?(_PHV)_=7_OD?X5D6'B#1-5T:T\1Z7J^E:EX>O\
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M?:>&M0M/$['6_$]U/IT<MWX<O+^U8Z@IGN_M$B1O]KD2O;/^"P'[./Q@^/\
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MQ?I-WJ$FH-/I\7AI_!^E>%QI\\;W%S:>']%U:,/+K9! /ZDEZ#Z#^5?S>_\
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79/[WZ+_A0!<HJJLKD@%OT'I]** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *2 M@# 2(  A$! Q$!_\0
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M-'"\J+))G8A89;'7 [XJ2@ HHI'=41G8X51DF@!:*KWM]:Z;9R7E[<1V]M&
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MV<$'&W.0#TS7._V3XMT*WFM=+OWG2*U>:)$C'EF9Y?\ 5KO+, J$[1GKCZ4
M3)X'UGRBCW]IYSV0MUNTWK):D(ZXB48&#N!/3H>.F > ;]Q!F]AM$:Y_TBUM
MV<Q_9BJ;HT)YRS1ALX_B;\8Q+XNF@>&\^WNDEHZP^1#&NYCY@_?9Y4@>7@KC
M/IU%4;>/QO9V+I:K<Q&.!G11'&QDD6*W"*Q(.<GS1Z\=:0%[3_AU=Q3K_:5Z
MM[;B]%Q*KR,?/4++@E<#YLNO4G.WKT%6?#OAO4CX7U>WN'DAFO";6V^T9#QV
MB92,,,G#;2Q_$5':3>*;:[<2V][Y/FSO#';1Q;7)FDXD+?=&SRR"/4]34?AH
M^*KK7[*XUN&Y6"$W 4RA1A6CB(#;< _,' ..U 'H4:+%&L:#"* J@=@*=FHM
M]&^G8+DN:,U%OHWT6"X7/_'K+_N&LKQ/HLNOZ3'90W!@874$QD5BK )(&.TC
MH<#BM"Y?_1I?]T_RK!\;6\][X?CB@MI[D"\MWEA@^^\0D!<#D9XSQF@+F3-\
M.E@U9;O3)EC\L0%))G9I?,6X,LK$]RP8C\?2LE?AMKXAFW:C9F5[A)U 9O+5
M@A5FV;<')P<=?]K/-/M_^$NTX6T&FV5_!8O?-+''*R2&*W:51L<')!"[V'S<
M @=14VA2>,+.[T*SEAU VL9"7LEQL<."9-QSC(P=G.>0?K2 WO#?A6^TC7M4
MO[R^-S'=E\?.?F#.6&Y<<%0=HY/'ITI]MX3>U\/:KI$+010WM[)*JQC:J0NP
MRN,==H(].:Q+BU\3R^.)=6BMY8;.21M/1EGRT<!3 E\HC'$GS9SG'&*@GO\
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MN&U%WU"T+7,J2HJNRH&!D^8IL(.0Z\'/W>O0CH/#_A/4M*\37>J7FHBZ69&
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MK;M]?A6Y6>>&61U!&0_4;RV".XP0/PZ4V+7$7RBWVD,B1*2CC^#/R\_PGO\
M3O1=CY(?S&/)$\6W>N-RAQ]#T-(L;N"5' !8Y..*V(];C15_<R(5V_+&P ?
M(VM_L\U:N]5M8[>$1L)E5-GDC./NJ,G/3[N,?4TKL.2#UYCG,'THP?2M-M30
MZJ;O-PRD.!N8;DW _=^F>/Z58BUJ"*W">7/(XE60O(^<D/NS[''%%V2HQ[F)
M@^E* ?0UK/K*RV?E.)EF**&E5AF0C=PWM\P_*I+K7O.,AA1HB\;(N, IEE.
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M !-+_P *IUS_ )^K'_OMO_B:]3^V2?W5H^V2?W5JOK%0CZI1\SRS_A56N?\
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MT/[9)_=6C[9)_=6CGD']GX?S^\\]_P"%<:O_ ,_%G_WVW^%'_"N-7_Y^+/\
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MVSS20JT1EC +H",J#TR.V<&GB*)@"JH0>A %','*9F:,UI^5%_=3\A1Y4?\
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MN[JRF@,:W?VV]<C9=[Y5:'!SEMJ ]1\O2M>SU[7+G1I#=6HL]2FNDMK>-H6
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M?XU[*;U,_=:C[:G]UJ7MI=@_LZG_ #,\:_X1'Q!_T";C]/\ &E_X1'Q!_P!
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M";>W9P%&W(.=I!SSC!S70?;E_N'\Z/MR_P!P_G19A=')MJ'C**UBFBB^TRF
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MMUJJE[JE].LL5J&9ED*[0>A18FZGM@?B:4:C?P7-PPL1%),//E"[U)*D_/\
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MF>H4445@?0A1110!%=?\>LO^X?Y5+VJ*Z_X]9?\ </\ *I>U !1110 4444
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M"M8>&]4M)8[.:X$FGFY$KXD+$A6=P2#T+,4!49'RDYYJM?\ A+5+ZVN(@MC
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M'\!0%BUH^LVNMVTD]KO"QR&-@V.N >H)!X([UHUFV$6F:7 8+&%((BVXJBD
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M3-N"'EP^S9CUSC\#4<&CWL\7F1Q _O!&5+ ,&)P,@].31[*EV,W7Q'=G9_\
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M)9C,NU<-M()SU!(&*D;0[P1QE$#R'Y7BW#<IWE.F>F0.?>I<("^L8GNSJ/\
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M:CR+C_GDU%@N+GWHS[TGD7'_ #R:CR+C_GDU%@N+GWHS[TGD7'_/)J/(N/\
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MZJ;VM90N[;G;QG./Y\4]]-NX[:2XDA*1QLJMGJ"PR/PXI>RIB^N8C^D>C?\
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MO^X?Y5+VH **** "BBB@ HHHH **** "H;O_ (\Y_P#KFW\JFJ&[_P"/.?\
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M^>;_ /?-'ER_\\W_ .^: '?:;C_GJU'VFX_YZM3?+E_YYO\ ]\T>7+_SS?\
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M1]R;@?E8EN,D9P3QG%+V%/S)>*JKJCTW_A9?AP_QW7_?@TO_  LKPY_?NO\
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MF 8@3Z4P,@Z+*_C"?57:-K673EM#&<[LARQ]L8-<O:?#W4(M*NX)K^!KF*2
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MK*[_ .@E!_WZ/^-+GCW%]2Q'\OY'"T"NZ_X5E=_]!*#_ +]G_&C_ (5E=_\
M02@_[]G_ !I<\>X?4L1_+^1PU=I\.+&275Y[[:1%#$4W>K,1Q^0JY:_#,B4&
M[U(&,'E8H\$_B3Q7<Z?I]KI=FEI:1".).@'4GU)[FHE-6LCLPF!J1J*=16L6
M:***Q/<"BBB@"O??\>,W^Z:L57OO^/&;_=-6* "BBB@ HHHH **** "BBB@
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ML# .,[,$C/<@GH*R;OX6VUW+/(VJ2CSDN@Z>4-I>5I"CD9ZH)7 ]<]J] HH
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M>J_E4OET>70!%]JN/5?RH^U7'JOY5+Y='ET 1?:KCU7\J/M5QZK^52^71Y=
M$7VJX]5_*C[5<>J_E4OET>70!%]JN/5?RIDLLTT31N1M88.!5CRZ/+H B^U7
M'JOY4?:KCU7\JE\NCRZ (OM5QZK^5'VJX]5_*I?+H\N@"+[5<>J_E1]JN/5?
MRJ7RZ/+H B^U7'JOY4?:KCU7\JE\NCRZ (OM5QZK^5'VJX]5_*I?+H\N@"O+
M--+$T;$;6&#@4_[5<>J_E4OET>70!%]JN/5?RH^U7'JOY5+Y='ET 1?:KCU7
M\J/M5QZK^52^71Y= $7VJX]5_*C[5<>J_E4OET>70!%]JN/5?RH^U7'JOY5+
MY='ET 1?:KCU7\J9++--"\3D;7!!P*L>71Y= $7VJX]5_*C[5<>J_E4OET>7
M0!%]JN/5?RH^U7'JOY5+Y='ET 1?:KCU7\J/M5QZK^52^71Y= $7VJX]5_*C
M[5<>J_E4OET>70!%]JN/5?RIPN9_]G\JD\L4HCH :)I2.<?E47EU9"4NR@"!
M6DC7:IX^E(9KC^\/RJQLH\L4"*WGW/\ >'Y4>=<_WA_WS5GRQ2^6* *OG7/]
MX?\ ?-'G7/\ >'_?-6O+%&P4 5O.N/[X_P"^:/-N/[P_[YJSL%&R@"MYMQ_>
M'_?-'FW']\?]\U9V4;!0!6\VX_O#_OFCSKC^\/\ OFK.P4>6* *WG7']X?E1
MYMQ_?'_?-6?+%'EB@"MYUQ_>'Y4>=<?WA_WS5GRQ1Y8H K>=<?WQ_P!\T>=<
M?WA_WS5C91LH K^=<?WA_P!\THFN/[P_*I]E+LH A$LW<C\J<B5+LIP% QJB
MBGT4AABDQ3J* &XI-M/HH 9MHVT^B@!FVC;3Z* &;:-M/HH 9MHVT^B@!FVC
M;3Z* &;:-M/HH 9MHVT^B@!FVC;3Z* &;:-M/HH 9MHVT^B@!FVC;3Z* &;:
M-M/HH 9MHVT^B@!FVC;3Z* &;:-M/HH 9MHVT^B@!FVC;3Z* &;:-M/HH 9M
MHVT^B@!FVC;3Z* &;:-M/HH 9MHVT^B@!FVC;3Z* &;:-M/HH 9MHVT^B@!F
MVC;3Z* &;:-M/HH 9MHVT^B@!FVC;3Z* &;:-M/HH 9MHQ3Z* &XI<4M% "8
MI<444 &*,444 &*,444 &**** "BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
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MWZ0VEO%.J7GEM+@]48KQ@\'U&*WHY=2?4M#\.#7KF*"6Q:Z>[0(LDA_A0'&
M /;- '=76IV=E<VMM<W"QS7;E($.<NP&2!^%6Z\EMM6O=4N_"DE[*+F6VU>Z
MMUG  \Y47AN.,GI^%2P:_K1T73O$QU>5YKK4A;MIVU?*V%RNP#&=P SG- 'J
MM%>6VFJ:]K/B3R[;4=04?VE)%-Y2)]F2V0D#:2"=W%3VGB+6Y=6M_"[WCG4X
MM4<3S[%RUHHW@],<@@4 >ET4W-&: '44W-&: '44W-&: '44W-&: '44W-&:
M '44W-&: '44W-&: '44W-&: '44W-&: '5'/)Y4+.!DCM3LU!=G_19/I_6@
M"AXGUB?1-&-W:P1SSM/# B2.57,DBIDD G W9Z5SR_$2.TN)[;5K3RKBT,J7
M"VY,BED:( JQ ^4B522V,<YZ5N^*WTM- E.L6\MS9^;$/*ASO9RZA,8(.=V.
M]85@? UQ;H%$-G*HGC,5Q,T4ZX8&7=EMQ.4!+9/3K0!I_P#"<Z5Y3S^5=FVA
MMQ<3SK&&2%2I8!B">2!VR.1SS3)/'VDP,T=Q#>07 )7R)(AO+_(0@P<%B)%(
M&>F?0U7DM/ ]I!"^+ HUJWE1)-GSHE5LX3.'."XR03R:99S>"6MK1S]D@$5R
MMS;FZFP_G;%PV68DD*ZCGIQ[4 30_$71KLA;.&]N9'G$$:11 F0G?@CG&/W;
M=<$<<<U=M_&.G7ND7^H6BRM'9VPGD#KMY*EMG^\,<CMD56LD\)V]Q"(6MK>?
M[5(T$3W&,2(71BB[L ?,_ XY/&:KZ%'X<@@.CVUW'J)U6XN+J62+!1Y 59P=
MO"XW+@>E '6VSR26L+S((Y612Z YVL1R*EIN:,T .HIN:,T )*_EPNX&2JDX
MK&\6:[)X=T/[?%%%(YGBA F8J@WN%R2 3@9SP*U;D_Z++_N'^59GB2\TZRTN
M.?4[>6XB6YA\N.%2S&7>/+P 1_%B@#G=*^(KSWL5OJ6DRVR/&A\Z/++N>=H5
M;Y@IV,0"#C//3O5O_A9>A_,-EUN680D;4P"5W [MVWD \9SVQ4OV[PGK4BWE
MV88[J5UMC%=L8I0\,F\(5)ZJQS[Y'7-4M,T_P#J5K##8BU:.^4&.#[0ZM*J;
ME VELD !ACI@=.* -S2O%NF:SJ=YI]F9FFM=VXE/E?:VQMISV88YQZ]*JV?B
MR6?PWJVJW&GFWEL9YH!;-(&9BAPH)'&22!QGKWI+>_\ #>C>)KK381]EO&MV
MNIFRPA5<[FZG:IYW$ #CFK+3>&;=7M'NK%!=70F:-IQ^\F8JX/7J?E./<>M
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M^\M*+:7^\M&@:F9I6E&QUG5KX[%2[,*0QIT6.-,#/ODM^&*V-]-$+CN*AWT
M6"]-\RF*CR+E<8H,$O\ L_G0 [?1YE,^SS>WYTGV>;_9_.C0-23S*/,J/[/-
M_L_G1]GF_P!G\Z- U)/,IBK$LSS+&@E< ,X4;F Z GOBD^SS?[/YT?9YO]G\
MZ- U(GLK&2..-[*V9(WWHK1*0K9SD#'!SWITMO:S+*LMK!()L>:'C!\S'3=G
MKCWI_P!GF_V?SH^SS?[/YT:!J0?V?IQB:(V%KY;KM9/)7##.<$8Z9)/UIXM;
M,$$6D (*D8C7C;]WMV[>E2?9YO\ 9_.C[/-_L_G1H&I =/TYHI(FT^T,<K[Y
M$,*X=O4C')]ZM!PJA5   P .U,^SS?[/YT?9YO\ 9_.C0-23S*/,J/[/-_L_
MG1]GF_V?SHT#4D\RCS*C^SS?[/YT?9YO]G\Z- U)/,I0]1?9YO;\Z403>WYT
M:!J3!Z>&J$0R#KC\Z53S@T@)Q135-%(97D-6(N8E^E5):MP_ZE/I5,2W'T5R
MMSXLOK6XU")]#8BPC$TQ6Y4_(<X(&.> 3BK%[XLBM[HV]M:O=2%81%L< /))
MDJO/3Y06)]*KV<B?:Q[G145RTWC'[%;6\UY9)MDN#$[6]RLRHH7<7R/0=1P>
M*U;77+>XL;V\D_=06DTD;N6R"$_B'UI.$EJ-5(O2YJ45QTWCKRM,CNSIC1NT
M\L)2><($*#/+8^\>P]:G7QJC:I!:M8M'&\D,+M)*!(CR)N V=2!D FG[*?8G
MVT.YU5%%%9FH4444 %%%% !1161XIOY-+\+ZC>0\2QPG8?0G@']::5W84G9-
MLYOQ/\2K31KJ2RT^ 7ES&<2,6Q&A],]S]*Y?_A;6MY_X\['_ +Y;_P"*K@5(
M+ N6()RQ'4^M;=SH:EC]A=W$=LES,9B!M1ESGCL.A]R*]14*<59H\:6(K3;:
M=CH_^%LZW_SYV/\ WRW_ ,52_P#"V-:_Y\['_OEO_BJX_3[*&YOO(EN5 *;D
M*,!O; P@+8 /U]*O#P_)_9ING$T;B?9Y;Q](]^PDGU#<8H=.DNA"K5VKJ1T?
M_"U]:_Y\['_OEO\ XJE_X6OK7_/G8_\ ?+?XUC7'ARW@OC;"XE:0JQCBRF^0
MA]ORG.WG!..O&*S8=-$=I-=7RSQ1(R*JJF&8MGGGMA32]G2>R!U:ZWD=9_PM
M76O^?.Q_[Y;_ !I?^%JZU_SZ67_?+?XUS-MHCS/%YDR+'(4R <N@?_5EATP3
MCOWJ&?3GMDA:193\@>XVIGRLDX'UP >?6E[.GV)=>O:_,SK?^%J:S_SZ67_?
M+?XT?\+3UG_GTLO^^6_QKF)M,C348[6)Y#O@\TJ^ R'86VGMGC]:G@T!A,?M
M<\2QI&[MY;Y(*IOV]."01Z]Z7)3[![;$7^(Z'_A:>L_\^EE_WRW^-+_PM+6?
M^?2R_P"^6_QKFYO#U[;$F<PQ*H)=G<@)@@8/'7+#IFG#0I'6,031S2211R *
M<!=S8YSVXZTN2GV%[;$=V=%_PM'6?^?2R_[Y;_&E_P"%HZQ_SZ67_?+?XUS4
M>A7,H#)-;%&V!'\PX<L6  XZY4CFHK73GNK8RJZ)M9@S2-A0%7<?>ER4^Q/M
M\1_,SJ_^%H:Q_P ^EE_WRW^-+_PM#6/^?2R_[Y;_ !KE%TN<W-Q TD,9MU#2
M.[_+@D $''/WA5J#P]=R2 2-'$@G$#L<_(22/3!Y'8TG"GV#V^(>S9T/_"S]
M8_Y]++_OEO\ &FR?$O5I8RAM;/!]%;_&L"+0+JXB22WV.A0'>3P268 #COM/
M7%)%HDS[#)/!&K*&)W$E<H77(QW -+DI]@]MB>[.C_X6=J__ #Z6?_?+?XTO
M_"SM8_Y];+_OEO\ &N3?3IHVM06C/VG'E[2<<\#)QCO4\.C7,RAM\"*QP"[X
MYW[,=/6ER0[$_6,0_M,Z7_A9NK_\^MG_ -\M_C2_\+-U?_GUL_\ OEO\:Y^+
M0;B2%@63[22FR$-SAB1EO0<5!<:5/:1R22O$ FT#YCEMPR,#&>QZXI<L.P.O
MB4K\S.G_ .%F:O\ \^MG_P!\M_C2_P#"S-7_ .?6S_[Y;_&N<.CR%5:.XA?,
M4<A&2""YP%Z<G-/_ .$?OOM:VV(_,8$J,G!(.,=..>_3WHY8![?$]V=!_P +
M+U?_ )];/_OEO\:7_A9>K_\ /K9_]\M_C7/#1)6:-8[FW)>.-SN8K@N<!>G7
M-+'H%[*Q\ORF7 .]6)4Y)&.G7*GVXI<L ]OBN[.@_P"%EZO_ ,^MG_WRW^-+
M_P +*U;_ )];/_OEO\:YZ#1)I6BWSP1JX!)W$E,J67(QWP:;9:8+RSGD65?-
M2141=V!R"2Q..F%-+EAV%]8Q/\S.AD^(^JR1LAM;3##!PK?XT[_A96K?\^MG
M_P!\M_C7,3:;+#;M<-+"8AMVL&)W[@2-O'L?3I4\&CM+$Q:XA20QHZ OQ\S
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M;_ERN>:V=*U2TUK38K^R=G@DR 64J002I!!Y!!!&/:@"Y1110 4444 %%%%
M!1110 4444 %%%% !5,'YV^IJY5$?ZQ_]XTT)EE#12)10!7EJW#_ *E/I560
M5:B_U2?2FQ+<HIH\2ZK?WS.7^V1)$\9' "@C]<UD6W@N"TTA;2*^G%Q'<+<1
M71 +(RC:HQT("\8KJ**:G)=1.G%]#FK+P?#;R>9<W(G9KB2>11"J(^^/RRNT
M=!BI].\*65CH$NC2R2W-M)*9#O8JW)! R.>,"MZBAU)/J)4X+H<A-X#@,96W
MOY5S-+*1.OG+B08(PQZ@=&ZU;3PC']ML)9;OS8;$1^6K0KYC%%P-TG4C/.*Z
M2BG[6?<7LH=@HHHK,U"BBB@ HHHH *IZKI\>JZ3=6$O"7$31D^F1P?SJY133
ML[B:NK,^:-2TVZTC4);&]B,<T1P0>A'8CU!IRZK>H25N&&46,\#E54J%/J,'
MI7T+JNAZ9K<0CU&RBN OW2PPR_0CD5@?\*S\,9_X])O^_P"_^->@L5%KWD>7
M+!33]QZ'BT5[-%/YR%-^T+S&I&!CL1CL*F.JW[3&9KEVD*%"3SD$Y_GS7L?_
M  K3PQ_SZ3?]_P!_\:7_ (5IX9_Y])O^_P"_^-/ZS3[$?4JW<\>CU>^C?>)@
M6WM("R*<,3DD9'!SSQ4=M?7-L9#')Q)C>'4.&YR,@Y'6O9?^%:^&?^?2;_O^
M_P#C2_\ "M?#/_/K-_W_ '_QJ?K%/L'U*MW/'9-2O)8!"\Q* @\* 3CID@9.
M,\>E))?W4U^;Z64O<EPY=@#EATXZ=J]C_P"%;>&O^?6;_O\ O_C2_P#"M_#7
M_/K-_P!_W_QH^L4^PG@JSZ_B>.O?W,EV;HNHF((+*@7.00>@[Y-..I7;;\SM
M^\SNX'.5VG].*]@_X5QX:_Y]9O\ O^_^-'_"N/#7_/K-_P!_W_QI?6*?87U&
MMW7WGDG]K7IE,IE4N5VL3&IWCC[W'S=!UH35;Y @2X*[  I"@' ;<.<>M>N?
M\*Y\-_\ /K-_W_;_ !H_X5SX;_Y]9?\ O^W^-+V]/L'U*OW_ !/)#JEZ6#>=
MC:R,H50 I7.W  P,9/YU%'=SQPM$DA"-NR/7(P?TKV#_ (5UX;_Y]9?^_P"W
M^-+_ ,*Z\.?\^LO_ '_;_&E[>!/U&MW7WGD]OJMQ;R7,HVO+/&(V9U!Q@J>A
M&#]T"E_MC4-H4W+'#A\E1G(8L.<9ZDG\:]7_ .%=^'/^?67_ +_M_C1_PKOP
MY_SZR_\ ?]O\:7MH=A_4:_=?>>3?VI>;2AD4H1C88U*@9)X&,#EC^=":C=HP
M99CD;>H!'RJ5'Z$BO6O^%>>'/^?67_O^W^-17'P_\/1V[NMM+D=/WS?XT>V@
M+ZA7[K[SRA[VXD2)"X"Q'<@50N#QSQWX%32:K>S$%Y^F" %  PV[H!Z\UZM_
MPKWP[_SZR_\ ?]O\:/\ A7OAW_GVE_[_ +?XTO;0%]0K]U]YY7_;%^%51<'Y
M2&!VC/!)'.,XR3Q[U!+=2S*5<KM+!BJJ%&0,9P*];_X5[X=_Y]I?^_S?XTO_
M  K[P[_S[2_]_P!O\:7M8B> KO=K[SR8WUR8EB\T[5"J,  X4Y'/7@U,FKWT
M<[3)*JR-@DB->2#D'IUSWKU/_A7WA[_GVE_[_-_C1_PK[P]_S[2_]_F_QI>U
MB/ZA7[K[SRD:A=;47S?N;=ORC/RG(Y[X-*NHW:IL\W*8QM90PZD]"/4G\Z]5
M_P"%?^'O^?:7_O\ -_C2_P#"O_#W_/M+_P!_F_QH]K$7]GU^Z^\\I34+J-E9
M9B"-N.!_""!^A-)!>7%NQ,,FS+A^ ,9 (Z?0GCWKU?\ X0#P]_S[2_\ ?YO\
M:/\ A /#_P#S[2_]_F_QH]K$7]GU^Z^\\HFO+BX4K+)E<@[0  ,# P!TXH%Y
M<*>)".%'3LO*_EBO5)_ >@)!(ZVTN54D?OF_QI__  @'A_\ Y]I?^_S?XTO:
M1#^SZ_=?>>6_VG>%D<S?/&VY7VC<#DGKC.,D\=*&U.\9U?SL%2"N%  P"!@
M>A->I?\ " >'_P#GVE_[_-_C2_\ " ^'_P#GVE_[_-_C1[2(?V?B.Z^\\L34
M[Q(3$LQV%=F"H.!MV\<<<<4O]J7A5U\[ANORC/3&0<<$C@GO7J7_  @/A_\
MY]I?^_S?XT?\(#X?_P"?:7_O\W^-'M(A_9^([K[SRYM4O&C>-IB5<$-E1G!
M! ..,X'3TI$U*\CACB2;"1D%?E&1@DCG&>I->I?\(#X?_P"?:7_O\W^-'_"
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MUJCW/0_L]S_>/_?5'V>Y_O'_ +ZKSW_A:VH?] NU_P"^VH_X6K?_ /0,M?\
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MN)]ZVH]*MTU.\OLNSW<:1R(V-N%SC'YFLJW\&:?:Z0+"&>Y4K<"XCN-X\Q'
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M(JEU"Y<*S'..G8]: /4**\NN/B'KZG43#80^7;R(4:2W=7V$R KMW8+ HO\
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M:A96FBS:;9#?J4$DPBF@DE<;45E7;'R"=V,]!20_$&.*4V^H:?/%=-,((HD
M^:;$68@<\L/-SGCA3Z5T;Q6[W$-PT*&: ,L3XY0, "!Z9P/RJ$Z?IQG6<V4!
ME6<W(<IR)2NW?_O;>,T6"Y@S?$:)I+&.STV9VO)XA"TKJH>%Y"AD'/&".AP>
M15:7XD?;KA+;2[.;S#)(C?N_.9@(6D1HPK8;.W'7%=!_8.B8E']EV@\Z199/
MW0^9U.0?P))^I-+9Z#HMA<)/9Z9:P2HVY7CCP0<%<C\"1]#18+B^'M;NM0GO
M+'4(4CO+1('?RP0")(PW0\@A@P_ 5NYK-L[*"UO;V[0LTUXZO*S'^ZH50/8
M?J:M^918+D^ZDW5 9*:9?>BP7+.ZC?53S?>CS?>BPKEO?1OJIYOO1YOO18+E
MO?7GVK>"KG7_ !SJ-W<.EM8-'9E9O(5Y7:-F8B-R<Q]@3CG-=MYOO1YOO18+
MGG-U8>/1;V4L-YJ#2RSW#3J'0F(^9B'Y<J/+V9R,G.>:T;R'QHDNKQA[B>U@
M.VR:"54DN%DD#,V>QC7*@<$YZ]Z[7S?>CS?>BP7/+$TKQV(A=M'="]-K%;W$
MBNGG/&MQ,2%(;[VPQG.<D9YS6O!:>.!<VL\MW>,\+V2E2R+&ZD,)RZ@G)'RY
MYZ]*[SS?>CS?>BP7/-Y;?QT=#C1#K NO-0WI:XB)=MC[C!@@A-VPX)'';KGT
MG33=)I=HM\^^[$*"9L 9? W' X'/I2>;[T>;[T6"Y;WT;ZJ>;[T>;[T6"Y;W
MT;ZJ>;[T>;[T6"Y;WT;JJ>=[THE]Z+!<MAJ7-5Q)4BM0,ES12 T4AE>1J<L"
MN@8L>14$K5;@Y@3Z4R2(V2'^-J;]@3^^U6Z*+CLBI]@3^^]'V!/^>CU;HHN%
MD5/L"?\ /1Z/L"?\]'JW11<+(J?8$_YZ/1]@3_GH]6Z*+A9%3[ G_/1Z/L"?
M\]'JW11<+(J?8$_YZ/1]@3_GH]6Z*+A9%3[ G_/1Z/L"?\]'JW2,P52S$  9
M)/:BX615^P)_ST>C[ G_ #T>O+/$WQ.O9[N2VT-U@MD)7[05!>3W&> /UKF/
M^$R\2$_\AJ[_ .^A_A75'"S:N]#BGC*<79*Y[U]@3_GH]'V!/^>CUX-_PF/B
M3_H-7?\ WT/\*7_A,?$?_09N_P#OH?X4_JL^Y'UZG_*SWC[ G_/1Z/L"?\]'
MKP@>,/$?_09N_P#OH?X4H\8>(_\ H,W?_?0_PH^JS[A]?I_RL]V^P)_ST>C[
M G_/1Z\+_P"$O\1?]!F[_P"^O_K4O_"7^(O^@S=_]]#_  I?5I=Q?7Z?\K/<
M_L"?\]'H^P)_ST>O#1XO\1?]!BZ_[Z'^%+_PEWB+_H,77_?5'U:7<7]H4_Y6
M>X_8$_YZ/1]@3_GH]>'_ /"7>(?^@Q=?]]4O_"7>(?\ H,77_?5+ZO+N']H4
M_P"5GM_V!/\ GH]'V!/^>CUXC_PEOB'_ *#%U_WU2_\ "6^(/^@Q=?\ ?5+Z
MO+N']H4_Y6>V_8$_YZ/1]@3_ )Z/7B?_  EGB#_H+W7_ 'U1_P )9X@_Z"]U
M_P!]"CV$NXO[1I_RL]L^P)_ST>H;JQ1;9SO;I7C7_"6>(/\ H+W7_?5#>*M>
M=2K:M<D'J-U+V$NX?VC3_E9[7]@3^^]'V!/^>CUXK_PE>O\ _07NO^^J4>*]
M?_Z"]U_WU1[&7</[1I_RO\#VG[ G_/1Z/L"?\]'KQ?\ X2O7_P#H+77_ 'U2
M_P#"5Z__ -!:Z_[ZI>QEW%_:5/\ E?X'L_V!/^>CT?8$_P">CUXS_P )5K__
M $%KK_OJC_A*M>_Z"US_ -]4>REW#^TJ?\K_  /9OL"?\]'H^P)_ST>O&AXJ
MU[_H+7/_ 'U1_P )5KW_ $%KG_OJCV4NX?VE3_E?X'LOV!/^>CT?8$_YZ/7C
M?_"4Z]_T%KG_ +ZH_P"$IU[_ *"MS_WU2]E+N']I4_Y7^!Z_<6*"VE.]N%-2
M_8$_YZ/7C;>)]=92K:K<D'@C=2_\)3KW_05N?^^J/9ON+^TZ?\K_  /8_L"?
M\]'H^P)_ST>O'/\ A*=>_P"@K<_]]4O_  E.O?\ 05N?^^J/9ON']ITOY7^!
M[%]@3_GH]'V!/^>CUX[_ ,)3KW_05N?^^J/^$IUW_H*W/_?5'LWW#^TZ7\K_
M  /8OL"?\]'H^P)_ST>O'O\ A*==_P"@K<_]]4?\)3KO_05N?^^J/9ON']IT
MOY7^![#]@3_GH]'V!/\ GH]>/?\ "4:[_P!!6Y_[ZH_X2C7?^@K<_P#?5+V;
M[A_:=+^5_@>P_8$_YZ/4-U8H+28[VX0_RKR9/%>O1N&&J3DCLV"/R(KL_#WC
M(ZO!-87ZHEWY3%'7@28'3'8TG!HVHXZE5ERVLSK!8)C[[T?8$_YZ/5L=**BY
MWV14^P)_ST>C[ G_ #T>K=%%PLBI]@3_ )Z/1]@3_GH]6Z*+A9%3[ G_ #T>
MC[ G_/1ZMT47"R*GV!/[[4HLD'\;5:HHN%D5Q:J/XFJGYE:AZ5A;Z:$]#1@A
M6:/<6(YQQ3S9(?XVI+ YML_[1JU2&D5?L,?]]Z3[!'_?>K=%%PLBI]@C_OO1
M]@C_ +[U;HHN%D5/L$?]]Z/L$?\ ?>K=%%PLBI]@C_OO1]@C_OO5NBBX614^
MP1_WWH^P1_WWJW11<+(J?8(_[[T?8(_[[U;HHN%D5/L$?]]Z/L$?]]ZMT47"
MR*GV"/\ OO1]@C_OO5NBBX615^P1_P!]Z462#^-ZLT47"R(!:J/XFJ)6PQ'H
M<5<K.#?O7_WC0#+BFBFH:*0%6:KL'_'O'_NBJ<HJY!_J$^E-B1QEPNN'5M;M
MK76[EGL[=)H$9(\,S!CM/R].,5#)XGO=4*7%E=_9;&XEM[,3;0?+=E+R-SW'
MRISQFNX6VA2XDN%B032 !W Y8#H"?;-0?V3IPL7L18V_V5R6:'RQM))R3CUK
M55(]49.E+HSBI-:U6-(H=/N;V2XAO9$EAO%C+N$BWF/*<$'L>O-:NF^)VE\+
M:CK1+W")<2B!=O.W("*<>F>:WK31]-L%1;6R@A$;EUV(!AB,$_7'%6+:TM[.
M,QVT$<*%BY6-0 2>IHE.+Z!&G-/<\U;Q)JUQI:Q0:G-<W*7-R'^SHL;NB)E2
M-RXV@]1U((K076-;74M+N&N99;:ZEMXXFC5!#,C)\Y(/SA\Y/L!7876AZ5>Q
M[+G3[>5?,,N&0??/4_4]Z='HVFQ7RWL=C MRJA%E"#*@#  ]..*IU8=B%2G_
M #%ZBBBN<Z@HHHH **** "L+QG-+!X-U62$D.+<C([ \']":W:BN;>*[M9;:
M9=T4J%'7U!&#51=FF3)7BT?,2G:0< X.<'H:Z6ZLK&XFB4B.U!CM0#" !NE7
M+,V>PQTJ/Q+X/U'PY>2!H7ELL_NKA5R".P;T-<_D>M>S=35XL^?:<&XR1U$?
MAFWEOG@6>8(J\LPP48EL<%>1\O7@<]:1-&TZ>6(DW$,<BVRJ0RG+2*=S<]@1
MT_E7,Y]Z=GWJ>5]Q<\>QT<.@V,L!N!=2B-HD=4V[G7.[)(4'(!7VZ]:=;Z/I
M_FJI,\S;,,@8#<S0F0;?H1CWKFP1ZTH/O2<7W%SQ[&QINE17EH\LCRKAV0E<
M8B 7=N?/8]/P-67M;6?6#;6]O\BV1*)U)?RMP/'4Y-8&1ZTH/O2:?<GF25K'
M06V@120P&:2:)G\O<Y VY:3:4&>=P'/X5-;Z!9SPFY$UQY/EA@@P7!RX[ YY
M0<>_M7- CUJS;W]S:*RP3% QW' !YZ9&>AY/(J6I=P4X=47[:W!T=9H;5)Y&
ME=9V(+&)0!C@'CJQS[5IR6EE#/*+JTCBM5N$BMY5SF1&!!;.?FP,-G_&N7!'
MK2@CUI.(E-+H=5::7:1SK:30Q23P311RG.=S,LC,/?\ A'X53G-M:6H\^U6*
MZN+8AX5081MQVMR?E.,<5A CUI<CUI<HG45M$.I:;D>M+D>M,Q'"EIH(]:7(
M]:0A:44F:4$>M(0M+29I<CUI"%H%&10#2 44M("/6ER/6D(6@4F1ZTN1ZT@%
MHHR/6C(]:!"BBDR/6C(]:0"T"C(]: 1ZT"%HHR/6C(]:0 *6D!'K1D>M(!:L
M6+O'J%L\9(82KC'UJN/F.!R3V%=GX6\*7+%M4OXFBBB0M%&XPSMC@X[ 4I.R
M-\/2E4J)1/3Z*!THKE/K0HHHH **** "BBB@ HHHH #TKGJZ$]*P=O6J1,C3
MT[_CT_X$:HW^CWUUJD=[#KM[:PH4WVL:(4=5.2.1D$G'/IQWJ_IXQ:_\"-6J
M3&MCQ?4M5U:7PS=Q6U[K#NNLS;)KA+B/,)C8QY9%# %A\H48W8!P*ZK7-5\3
M6GA[2GTH7"3_ -ERW,_VBU\V1I(TC*HV. S$L#^.*[ZBD,\EUVY\374%W;7"
M7,[Q+<HD\,#Q[A_H[KPIQ_$XSS]WZU))J&O:5<W4MO%<HADG#W#0O+Y,;7Y!
M<)T;$9R!CISTKU:B@#S*V\0^,9_L\N&\B(0L2;$@W:-=M%N(_@S%A\#IUX%>
MFT44 %%%% !1110 4444 %%%% !1110 4444 %9@_P!<_P#O&M.LX#]Z_P#O
M&FA,LQ]**6,44 12+4T<L:QJ"P&!0RU$T= $WVB$?\M!1]IA_P">BU4,5-\D
M46%=EW[5!_ST6C[5!_ST6J7D^U'D^U.R"[+OVJ#_ )Z+1]J@_P">BU2\GVH\
MGVHL@NR[]J@_YZ+1]J@_YZ+5+R?:CR?:BR"[+OVJ#_GHM'VJ#_GHM4O)]J/)
M]J+(+LN_:H/^>BT?:H/^>BU2\GVH\GVHL@NR[]J@_P">BT?:H/\ GHM4O)]J
M/)]J+(+LN&Y@((,BD'L:@\O3?^>-O_W['^%1>3[4>3[4 2^7IO\ SQM_^_8_
MPH\O3?\ GC;_ /?L?X5%Y/M1Y/M0+Y$OEZ;_ ,\;?_OV/\*/+TW_ )XV_P#W
M['^%1>3[4>3[4!\B7R]-_P">-O\ ]^Q_A1Y>G?\ /*W_ ._8_P *B\GVH\GV
MH#Y$OEZ=_P \K?\ []C_  H\O3O^>5O_ -^Q_A47D^U'D^U ?(E\O3O^>5O_
M -^Q_A1LT[_GE;_]^Q_A47D^U'D^U ?(FV:=_P \K?\ []C_  HV:=_SRM_^
M^!_A4/D^U'D^U ?(FV:=_P \K?\ [X'^%&S3O^>5O_WP/\*A\GVH\GVH#Y$V
MS3O^>5O_ -\#_"HKB*Q:W=4B@+'IA!2>3[4>3[4!\B;9IW_/*W_[X'^%&S3O
M^>5O_P!\#_"H?)]J/)]J MY$VS3_ /GE!_WP/\*-NG_\\X/^^!_A4/D^U'D^
MU 6\B;;I_P#SS@_[X'^%&W3_ /GG!_WP/\*A\GVH\GVH"WD3;=/_ .><'_?
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M*EQ1B@"+91LJ7%&* (ME&RI<48H BV4;*EQ1B@"+91LJ7%&* (ME&RI<48H
MBV4;*EQ1B@"+91LJ7%&* (ME&RI<48H BV4;*EQ1B@"+91LJ7%&* (ME&RI<
M48H BV4;*EQ1B@"+91LJ7%&* (ME&RI<48H BV4;*EQ1B@"+91LJ7%&* (ME
M&RI<48H BV4;*EQ1B@"+91LJ7%&* (ME&RI<48H BV4;*EQ1B@"+91LJ7%&*
M (ME+LJ3%&* &!:-M/Q2XH&1[11LI^*,4 1[!2;*EQ1B@1%LHV5+BC% $6RC
M94N*,4 1;*-E2XHQ0!%LHV5+BC% $6RC94N*,4 1;*-E2XHQ0!%LHV5+BC%
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MK+N+^T)?RH^@/[>T#_H)6'_?U:/[=T'_ *"5A_W]6O @C;-^T[,[=V.,^E
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M72RPR-MP&C ;R_Q.5!_W!70^)_A?.]W)=Z$T9CD)9K5VV[3_ +)Z8]C7,_\
M"OO% /\ R##_ -_D_P :]7VE.:O<\1TJM-N-AK7^E6_G26K O+O8*(<; 0F$
M.>#R&]JLB]L+JYO93-;[MTLR226V57<T>WY,<G[PZ>IYJ(?#_P 3_P#0,/\
MW]3_ !I1X \3_P#0,/\ W]3_ !J6X?S$VJ_R_@2Q:GHGG-N@4QJ&$2RH=JJ9
M&8C&&QD$=.GJ*S]/N-/CM+A+M%^:564!,N5!&5!(X&,]P?K5T> ?$W_0,/\
MW]3_ !IW_"!>)O\ H&G_ +^I_C2O#N2XU7]G\!8=1TQ962X,4T9E+KY=OL0?
M(0I*XYP2.Q_&F?VAIGGA1!;HC22L6\G<%)4!#R,E0V3C'X4__A _$O\ T#3_
M -_4_P :</ ?B7_H&G_OZG^-3>'<3C6_E_ !?:2"6VQJRS1/N2#!?&W>>GRJ
M<,0 0>>G/%66XL2VFLFS=&X\X+'@8R#DG&2>OJ/Y5;_X03Q)_P! T_\ ?U/\
M:7_A!?$G_0-/_?U/\:5X]R7&L_L?@/DOK>*6 2W"&2VO7DDP')8&7=E2/E(Q
MS3VU73WN%CG;S+<1Y8QJV-ZN70 -SR"03_M5&/ OB/\ Z!Q_[^I_C2CP-XC_
M .@<?^_J?XU/N]PM6_D?W,H0WUOBYEE@#7,B<M)APS%P20"/EXSZUH75]I+S
MD0(L4# *=D?.WS%.", $@ ^N?4T?\(-XC_Z!Q_[^I_C2_P#"#^(O^@<?^_J?
MXTFX]R5"LE;D_ E?4M)\PQA4-L7A>11 /WFW<&P<#'5>P[T0:EID5\9E$,>U
ME)98"V\ '.W@;3DCL.E1_P#"$>(O^@<?^_J?XTO_  A'B+_H''_OZG^-3[O<
M=J]_@_ S-092;50062VC5R#WY/\ (@53K?\ ^$(\1?\ 0./_ ']3_&D?P7X@
M1"S:>0!U_>)_C3YEW,94:K=^5_<85%=!_P (3XA_Z!Y_[^I_C1_PA/B'_H'G
M_OZG^-+F7<GZO5_E?W&!16__ ,(3XA_Z!Y_[^I_C2_\ "%>(?^@>?^_J?XT<
MR[B^KU?Y7]Q@5T_@""27Q5%(F=L4;LY]B,?S-,M_ FOS2!7MDA7N\D@P/RR:
M]%\.>';?P_9F-&\R>3!EE(QGV'H*SE)6.S!X2HZBE)62-FBBBL#Z(**** (K
MK_CUE_W#_*I>U177_'K+_N'^52]J "BBB@ HHHH **** "BBB@ J&[_X\Y_^
MN;?RJ:H;O_CSG_ZYM_*@"8=**!THH **** "BBB@ HHHH ****  ]*Y['6NA
M/2L/9UJD3(T=._X]/^!&JUYX<T>_U"/4+K38)KR,JR3,OS KG:,^@)SCIGFK
M5@,6V/<U:I,:V."TCP_KMMH6MZ4=.L;*/4KJX=#%<Y$$<L9 ( 09((7CCJ?2
MHM.\*:XGA;7X#'!8W]]:Q6\$<,YPACB$>_< ,9(SQR !7H5%(9YA=> -:B>[
M;3+CRO--VB;KR0XC=$\M><XPX<_C4TG@G7!J4ES#) FZ:5PPE(.UKN*7T_N(
MWX\5Z310!Y?;>"/$3W$PN)?+C>2,7+K?.3>XN!(TF/X/W>5Q[XZ"NV\*:9=Z
M/X>AL+UP\D4DNTB0OB,R,4&3SPI4?A6U10 4444 %%%% !1110 4444 %%%%
M !1110 5F#_6O_O&M.L\+^]?_>--"98CHI4%%(!CKFE$Y10NS./>I66HVCI@
M,-Z1_P LOUIOVX_\\O\ QZE,5)Y7M1H+4/M[?\\?_'J/M[?\\?\ QZD\KVH\
MKVIZ!J+]O;_GC_X]1]O;_GC_ ./4GE>U'E>U&@:B_;V_YX_^/4?;V_YX_P#C
MU)Y7M1Y7M1H&HOV]O^>/_CU'V]O^>/\ X]2>5[4>5[4:!J+]O;_GC_X]1]O;
M_GC_ ./4GE>U'E>U&@:B_;V_YX_^/4?;V_YX_P#CU)Y7M1Y7M1H&HOV]O^>/
M_CU'V]O^>/\ X]2>5[4>5[4:!J+]O;_GC_X]1]O;_GC_ ./4GE>U'E>U&@:B
M_;V_YX_^/4?;V_YX_P#CU)Y7M1Y7M1H&HOV]O^>/_CU'V]O^>/\ X]2>5[4>
M5[4:!J+]O;_GC_X]1]O;_GC_ ./4GE>U'E>U&@:B_;V_YX_^/4?;V_YX_P#C
MU)Y7M1Y7M1H&HOV]O^>/_CU'V]O^>/\ X]2>5[4>5[4:!J+]O;_GC_X]1]O;
M_GC_ ./4GE>U'E>U&@:B_;V_YX_^/4R:[,L3)Y6,]\T[RO:CRO:C0-1?M[?\
M\?\ QZC[>W_/'_QZD\KVH\KVHT#47[>W_/'_ ,>H^WM_SQ_\>I/*]J/*]J-
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M !1110 4444 %%%% !1110 4444 %%%% !2BBB@!12]Z** $-)113 2BBBD
L4444 %%%% !1110 4444 %%%% !1110 4444 %+110 HIU%% "T444#/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &# 80# 2(  A$! Q$!_\0
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M=MB,WH,T +17S?>?&#Q?->3207L-O"S'9$MNC!!V&2"34/\ PMOQI_T%4_\
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M$>M0:U=6\D,#IY47EM+*5,DQS]YMH SVJ%/$&K)IATX7\OV,J4\HX(V^@)Y
M]J?,KLTC1FXP<EJKZ/SZ]=NGYG3^(=%\/Z;:WUFC0Q7ELBF%Q.[23-QD,I&T
M @\8J]K_ /QZ>)O^N5A_Z"*XR;Q%J]SIWV":_EDMMH4HV#D#H,XS^M-FUG4+
ME;A9KIG6X""4$#YPGW?RK3F70QCA*NG/*]O\U_D4QTKZ&T3_ ) .G?\ 7K%_
MZ"*^>>U?0^C*4T/3U8$,+:,$'M\HK:D>?GGP0]7^1=HHHK8^8"BBB@ HHHH
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MO]GA%SA))$_)R*C!I^C'-G(<=;B7_P!#-=-%WFOG^AC47NFA1117<<P4444
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MKO:X+0/^0W;?4_\ H)KO:^DR#_=Y>OZ(\C-?XJ]/U"BBBOH#R0HHHH ****
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M7'^-_&\WBR>.""-[?3(6W)&_WI&_O-CCCL/\CFK62XM;A;BVGD@G4$+)&<$
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M(8#<CKP58?Y[5#9^'+.'4FBF+3A(U<;N!DDCH/I7S6:Y?B*^)5E9:+7OJ=.
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MOFIQ&'YTZD=T=5&K;W6>VT445Y)UA1110 4444 %%%% !1110 4444 %%%%
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M.W)K7\-:+I&M%X+K4+NWNU2279' &78BY)R3UZ\54L#2BN:[L)5I-VL>S_\
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M%=4;_0=/\71>([;4S=H]X9FM#;,KQJV<G)X)7/XUVW_"H- _Y^M0_P"_B?\
MQ-'_  J#0/\ GZU#_OXG_P 31/%T).]WVV!4IHY:;Q'I\.H:8(M1L9+&/4UN
MY%M[*2-DQG+,6SDX/(%8.LZK9W?AN*TAEW3C4[BX*[2/D;[I_&O1_P#A4&@?
M\_6H?]_$_P#B:/\ A4&@?\_6H?\ ?Q/_ (FHCB,/%IW?W#=.HSQ,]#7T[HG_
M " -._Z]8_\ T$5R$?PC\/)(K//?R*#DHTJX;V.%S7>1QI#$D4:A410JJ.@
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 WX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJ">]M+;_ %]U#%SC]Y(%_G0!/16:-?TLL56\1B#CY 6_D*&U[3%&
M6N<#U*,/Z4 :5%9T6OZ1/]S4K7.<8:0*<_0UH*ZN,JP8>H.: %HHHH ****
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M[8?W2<N@]CW^AKK+&_MM1MQ/;2!T/7L0?0CM0!9HHHH **** "BBB@ HHHH
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M2A2%) )Z9[UU05E8YI.[,C5;B:W?CA3W!K,749L8+5>U.>$ KA=^,'U-8L3
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MIA0H-G;';UYSSZ_2N3?3+B.0@1ON0_-E2-OUKZ$UO0;35I(9F+17<((CF3J
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M6\ZVNMVK64YX$F,QM^/;]:Z*(B8*T3!E89#*<@CUS39K"&_@:&XA62(]0PK
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M/\Q2H6BKXJ]^E]/GZGKM7]VG&_IO_P ,;CV"ZC;PDO<3QR6T,[L@4%4;(;D
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MD$LW)[#L*D8MG:R7<PED!QV%=)!$(D Q3;>W6)1@5/0 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:474:GL=!I>AV>DKF%2\I^]*_+'_  %:5%%>1*3D[L]R,5%604445)04444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0HK/^P7G_07N?^_47_Q-7P"  3D^M)H:8M%%%(84444 %%%% !1110 4444
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M]1?_ !-.R[A=]C0HJO:P30!O.NY+C.,;U4;?^^0*L5)2"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXDW@.N!YVT)E3GD;!Z=ZZ"@ HHHH **** "BBB@ HHHH *S=;N[RPTZ6[M!
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M263.5W!<.!G#*00<=^0.*RM0T&ZU*2VNKDV,EU"KQE'B8Q%6(.1\V01M_6@
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MU,DD#C./?B@#3HHHH **** "BBB@ HHHH Q-:U]=(DP1%(%57DC!8R!2V,X
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M[,>^3G\JFM]$L[6*..,/MCCAC7+9XB)*_P ZBT[319:E>7D\D8FO& 6-7)
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M/-YDDK+&9#LCWY!*CL=K$9]S4MSX>LKI859IT$<0@/E2E?,C'\+XZCK^9]:
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MY*C[8RM/Y$(9EQS^_P"#QQG&,X[UU51K;PHH588U4#  4  9S_.I* "BBB@
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M3^%6-1\06NGW4MF0[726KW*IM(5@HSC=ZT 0Z3::E;->V\LL:_Z3YRS+#A)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+CS[)]T>(=0FN6Y/W&60#''7YQ^M;=%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]1T]=1CA5I7B:&
M99D9,9W+TZ@\<U<HH R$T%(I4G2[F%R-^^9E1C('()!!&, @8QC&*MW.GI=K
M:"61RUM*LRD8&Y@".>.G/:KE% &5'H-M$ML!)+_H]O);KDCE7*Y)XZ_**;?^
M'X[Z%XA=W$*R6OV601[?F3\0<'D\^]:]% &3=:#!?3;[J5Y$$3Q!-JCY67:1
MD#/3WI\FCF6U6&2]G+(Z21R!45E93D'A<'WR*TZ* ,^VTF.WL+JT,TCBY>1Y
M';&<OUQ@8[T@T: +<KYDF+BY2Y;D<,NS ''3Y!^9K1HH H7>DP7EU)<2/(&>
MV:V(4C&UB"3TZ\4UM&@:\GN3))OFD$C#(P"(S'QQZ'\ZT:* ,B7P]:RZ;%8M
M)-Y<=J+56!&=HVD'IU^4>U(V@)(EQYMY</+-<1W!D(4%63;MP ,8^45L44 9
M]OI0M;F66&XD599#*\952"Y&"0<9&<9ZTR#1A!>378NYO.F:,R,JHH8)G@@#
MG.<$]<=Q6G10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 O0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBDS0 M
M%-R:7)H 6BDR:,F@!:*3)HR: %HI,FDR: '44F31F@!:*2B@!:*2B@!:*2B@
M!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4?\ "V_''_0;_P#)2'_XBCZM(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\
M"V_''_0;_P#)2'_XBCZM(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_'
M'_0;_P#)2'_XBCZM(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;
M_P#)2'_XBCZM(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)
M2'_XBCZM(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_X
MBCZM(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_XBCZM
M(/K<.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_XBCZM(/K<
M.S/I^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_XBCZM(/K<.S/I
M^BOF#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_XBCZM(/K<.S/I^BOF
M#_A;?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_XBCZM(/K<.S/I^BOF#_A;
M?CC_ *#?_DI#_P#$4?\ "V_''_0;_P#)2'_XBCZM(/K<.S/I^BOF#_A;?CC_
M *#?_DI#_P#$5ZA\'_%NN>*?[9_MF^^U?9O(\K]TB;=WF9^ZHS]T=?2HE1E%
M79<,3&<N5'I]%%%8G2%-[TZF]Z "BBB@ HHHH **** "BBB@ HHHH 6BBB@0
M4444 %%%% !2BDI10,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBHA
M<P&X, FC,P&3'N&X#Z4 2USOB3Q-_8DL,$<*R2R+O)<G &<=OQK7N-4LK6]@
MLY[A4N)_]6AZM6+XSTE+_2Q<* +B!AM;U4D C]<T :6D:Q'JFD"^V&/&X.N<
MX(ZXKDE\>W;7AD\B+[-NXBP=Q7Z^M=G8V%OIFEI:(!Y4:88GOZDUQ'AWP>=0
M"WMZ2EJ3F.,=9!ZGT% 'H4;K+&DB_=8!A]#3J0 *  , < 4M !1110 4444
M%?-7QD_Y*'=_]<XO_0%KZ5KYJ^,G_)0[O_KG%_Z M=.&^)^AQ8SX%ZG 4445
MW'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7M7[
M/_\ S,7_ &[?^U:\5KVK]G__ )F+_MV_]JUC7^!G1AOXJ/:J***\X]<*;WIU
M-[T -DD6*)Y'.%12Q^@K@M('B#QA%-JBZY)IUMYK)!#!&#P/7D9KNKJ(S6D\
M2]7C91^(Q7$> -7L-/T&33[Z[AM;JWG</',X0_K0!K>*-2N_#WA#<ET9;\[(
M$G*@%G/5L>N :K>$-0U)-5U+1-5NFN9[8))'(XY*D<_7J*S_ !I-)K6M:%I>
MFO#*SDW2EFS&<?=)QVP&J!?[6TGXAZ;=ZPUJ7OT,!:VR%/89SWSMH E7^VM>
M\9:Q80Z[<V4-H046-01C@8[5J>$-7U&?4M4T?4YA<RV+@+<!<;ADC!_SZUSB
MZ++K7C;Q'%!>W%I-&-T;0N5W-V#8[5J>!8DF\/:C96SM8ZPLI2YF(WN&R<-@
M_B,>N: .JUBPO[^&)+#5'T]U;+.D8?<,=.:XWPPWB'7;B]W^(IXUL[@1E?(0
M^8,G\NE=II%E?6,#I?ZFVH.SY5VB";1CI@5ROPY_U^O_ /7Y_P#%4 =?JLTD
M&D7LT3;9(X'96'8A3@UP&FQ^(KSPHWB%/$MPLB)))Y#H"I"$Y'XX]*[S6_\
MD ZA_P!>TG_H)KA/"GA0:UX6MI+C5M02UD9]UK'(!'PQ'ZT 6)/$FH7T?A*Y
M69X#=SLEPB<+)A@#QZ=?SKHM4\766E7LEM+9W\IBP9'B@+(H(SG-8GB>S@T_
M6/"-I:QB."*YVHH[#*TMYKVH7VN:O8KJMKI=K8KMQ+&K-+QS]XC]/44 :^J>
M+K6U\.+JMDDERLJ,8B(R5##L^/N\U0C\;+/X2EOQ!<"[6/:Q2W8HLA4D'_=S
MWK*T7_DC]]_N3?SK7LIXI?A>5CE1VCTXJX5@2IVG@^E %;P7K4?]CW=_J.IW
MTK1HKSM= ^7'R?N'OGV]JU--\<Z/J=_':)]HA>4XA::/:LGT-<Y>1R2?!F#R
MU)VHK-CL!)R:=XDO['4K7PQ;Z;/%-.+B(JD1!9%  .0.G;CVH Z34_&FE:5J
M,UA,+E[J(#,<41;=D \?@:9?^.=(T^[N;1UNI+F @-''"23QG@]*HZ6/^+JZ
MWQ_RZ1_R2H_#_P#R4'Q/_NK0!9/Q'T,+&X6\:)OO2" [8SZ$_P"&:ZV.1)8U
MD1@R. RD="#7E5C_ ,D@U3_KY/\ Z$E>DZ+_ ,@+3_\ KVC_ /010!>HHHH
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ME@%N%R%Z\BI@]VSJQ\.54J<$VG+:[5]'UN1OHVDS:CX<U"UL_*M]0DQ+:O\
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M,L0![T9 (&1D]!0 M%8]_P")++3CJ(F28_8(XY)=J@Y#G QS6JLBLJ'(&X9
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MVG^"8X7_ -:ULTDG^\P+'^=<CHNB:?<2^&4FM=RW=G*UP"S8D*XVYY[9KT[
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M1"#'N)Z]R,?4UL:3>27NG)/+M+EF7<@^5]K$;A['&?QH NT4F:* %I,T4F:
M%HI** "BLO7+Z6RM[<QRQVZRSB.2XD&5B4@G<>W4 <\<UB3^)YX;K3D2XCN(
M,@W4\<#;&5GV*<_P]SGH<<5K&E*2NCLHX.K6BI0ZW_#\/QOY'7YI,URFF:[J
M!U"1;M)IH6$IC6.%23MEV#;M.2 .N<5H:;-?M=:FMQ>^<EL_EHOE*O\  K9.
M/KBB5)QW"I@YT[\S6EG]^AM9HS7"6OB759M,C>&ZM[F>6&*0D( (7:0+L;'J
M"?<8J2?Q==B..2-2 MS(TR&$DI"A4%3@<')/)_NU?U:=['0\JQ'-RJWW_P#
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M!%@@8!)QG' /^[P.U &JUO;R/YC0Q,P&-Q4$X!SU^M17T=H;-S>;1;IAG))
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M06UTYKE"&!4;".ASTJ6>V$^X23SA",;$?:/TYKG/$2QV6E6UI""L2,%4$YP
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M<-S!)+-;PGFW(5P%("DC(&>G0C\Z +&:3--S2$T .S29IN:3- #B:3-)29H
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MO$\].1TZYXJJ?$2IJ$\<BI]DB5W\U<DE5CC?./\ MH?R% %&VT*ZE"QW5O\
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MQI$W"DNJG(R2,@\G)&,YK.F\0WMO:O(T4#NDOE[.[ INW85FP%ZGG[OI4_\
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MEE48W,!G@9/6END22W=V #HI(;OQ5QEIJ<]2FG)M*U_N,>:#*FN!\3:-'+?
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MX1AR+YL^XH8.E2IO"4W9+6I/]$_/\%=[M#-)M;_7/$<-P&*>6ZN3VC0'./\
M/4\U[ JB09-86AZ3'IULL48RQY=\?>-=#&NU:\RM44Y:;'QF.JTIU;4%:*T7
MGYE6:T#=JIM8G/2MFDVBL3BN926'K7A_Q0@$?C2X7_8C_P#0!7T+@5X%\5O^
M1XN?^N<?_H"UT8=>\SDQ3]U>IP>R@)BI:*Z['#S,=, VV4?Q]?\ >[_X_C3V
M5I@CHI9F^5@!DY'_ -:M73-%%[9&5YOD8\!1RI'K4OAR18;N>RE4"4'(..3C
M@BM5#57ZG%/$1C&7)JXF"058J000<$'M2?6MOQ+IQM+T7*#]U-SGT;O6&:F2
MY78VHU55@IQZFLACTR*+4+-F93E&\XX,OJ HZ >M:MGK%KJ8\G,B39+!6YQ]
M#W^E<F=S  DD#H">E(JN'4Q[@^?EV]<^U:0K2AML95,)&HKR?O=SNQ#,5_UB
MU;NY'O)()+MA))%&(PP7&<="WJ< #/L*XN/6]1M9,O(90#M*2#T'/O4-YK%[
M? HS^7$?X(^ ?KZUT_6:=KVU.%8"LW:ZMW-2_P!6AU2]2S1HXK=)-WF2#*NP
MZ?0>]4-5$,=T8DM!;R(</M<LK>X]JJV>FWE](L=I:3W#L<!8HRQ)_"N]T/X-
M^)]4VR7HATV$]YVW/C_=']2*\ZIB8W?.]3UZ.!<6O9IV7]7_ *^1Y]6EHV@:
MKX@NOLVEV4MS)_$5'RK]3T%>IW7P*%NEO+%K)G42I]I5HMGR9&XJ<GG'K7K&
MEZ;8Z-8QV6GVT=O;H,!4'7W/J?>N&KC4M(;GI4L#)ZSV/*M ^!:E%EU_42&/
M/D6G;ZN?Z"M'7/@CH?\ 9\LNF7UU:S1H6S,?,0X]> 1^%>HAZ7?D8/2N-UYO
M7FU.Y8>FM.70^1M:T:;1+P6\LT4P9=RO&3@_G6;7TYXS\!Z;XET&2VMK>&VO
M8R9+>5$"_/Z''8U\T7-M-974MK<QM%/"Y21&&"I'45WX.M*<.6H_>6]NIYV-
MH1ISYJ:]U[7(J***[3A"BBB@ HHHH *Z?4-.\-1>!M-OK347DUV60BYMB<A5
MY[8X[<]\US%%)JXT['I7PVT+3;G2[NYU5;$C4)AIUO\ :F4%<J2S1YZN"4 Q
MSUI\/@RRTSPC?//%//=S6D.^Y8(8H9#<JC1IQD2* <\]Z\SWM@#<< Y'/2G_
M +YE_P"6A'7OBH<'>]S55(VM8](U/P'X=MX[P6MUJ7G1+>"/S6C*[K8KDG !
MPP88^E27O@G1KJ_OS+/=1SR:A-:6_DB-8UV6XE!90HXSD<8KS'S'/\;=^_KU
MH\Q_[[=<]:.27</:1_E/3)O ^G:G/JTIEG66VMX&B6)4CC&;99"6(7'7CG;G
MKDFH]:\+^'U;4K[[+>V]M;:?92P1PRH!*\PV[LE>F<9]PWX>;[WY^=N>#SUH
M+N1@NQ&,8SVHY'W#VD?Y3UNU\!:9HVNZ<K)<70N(KR&6"=5;+I!N#)E0.IXZ
MC(&":J?\(5I2VJ:7YS6WVJ_LMTERJ&>U$D,C-$Q&.<@>G49%>7F1SU=N/>@L
MY&2S$$YY/4TN27<?M(_RG5Z_X<TG1/%.FV37%V+&XV-<+(-LL(+;3R5&>.0=
MHKK(?AYI&D:GISR:A)/,=0ALFC(1E\XDL^5*D%1'LZ]S^%>3EBQ)8DD]R:7S
M'SG>V<YSGO3<6UN2IQ3ORGJD>C:!!;_:'TR3[,_AJ:>60%"7D64 LA(P)!Z]
M@1QZU[OP5I-OY5E-/.UM =0FWQK&LK+''&Z@MCD_-CGCTQ7F?F/C&]L=,9H,
MCGJ[?G2Y'W*]I'L=K9:!I]C\3]/TP#[58.8I@ET1EE:(2;3C@GG '0G [U;U
M;3K2/XF>'H_LD,<=S]D:>W>%8SN+8;S(A\J$XSM'&"/6O/BQ)R22?4FC<Q;<
M6.[.<YYJN5]R>=6M;J>CR^"M&O+K[;:-J$L,L%Q.MA%L\^1XY_+*Q\8Q_%C!
M( I8_AQ827<\<5W=3PV]Q<1SR1E?W*K;B1 W!PV\E3V..*\X\QP0=[9'0YZ4
M@=AG#$9ZX/6ERR[CYX?RGHVG^!] OM8ATU9M3,PT^&ZF(*X+RA"%&%) &X\D
M'L,CK7 :A:_8M2NK3=N\B5X\Y!S@D=1Q^50AW#;@[;L8SGFFU236[(E)-:*P
M5[5^S_\ \S%_V[?^U:\5KVK]G_\ YF+_ +=O_:M9U_@9KAOXJ/:J***\X]<*
MC/4U)49ZF@ I,T5AZ=K\E_K]]IC:=-"EMTG;H_./3OVH$;F:2N8UC59K#6H7
M2^=XA,D<EK$JG:I4GE?O,S=L<#%)<^)IH+Z680-]B2Q\\12J8Y2V_;R".!_3
MF@#IZ,USG_"3OY%Y&UHYNX=RJ;8&:$ML##+ # Y'6JV@>()7B,=V;RYF?RB-
ML8D5=ZYR60?*,]CTH ZO-)FN2A\;&698CI[!^0P#YY1290./X< >^:6/QC*]
MB9SIV)&>-8P),J=X)&3C(QCT],4 =7FC-<>/%%R=9LE,1CBNH$!21ODB<R,I
M8L!WQ@>N1TK7UC6Y-+NK>%;42FY^2$[\9DW*-IX]"3GV-,#9I,UR,_BR6:TO
M_+M'A6)',<JR?-\KA3D$<9_&K*>*'%ZT4UDWD[YHU:$F1V,9 /R =\T =&32
M9KF'\1W46H7,9AC,;201VZR-Y90NN<OQD#C\^*E3Q/YNGR3QV,S31H[L I,1
M",0V),8/ )'K0!T!-)FN6?Q@V83%8&1)0TBMYF-T>_:"..IQG'TYHE\27%I]
MI"VXG\M[AV,DNW"1E1@<>_2F(ZC-)FLC5=1N;>723;>6$N;@))YAQ\I4G'2L
MJ/Q/<Q6T)%J)QL1G=YL-\\C(/X>>10(ZS-)7,3>+)(HH,:?NF;S3(HEX&Q]I
MP<<G/KBM'5M8.G);E(HV,VXYFD\M5"KN(S@\GL* L:N:3-<RGBT//8H+5=MP
ML1?$AW1F0<#&,'\ZLZ/K[:I<+$]O''OA,R%)=^ &VD-P,&F(W,TF:3-)0(7-
M)129H "<"L^:7?<8[)_.KDC86L";4(+2WDN[F41Q EBQ_2L:TK(]++Z+J5&T
MKV_-B:KJE_I]Q:+::=)=QRN%=D_AY[^GU/%;Z/7#+X\M6DVQ6<S)_>+ 9_"M
M_3=>M+_ 4M&Y_A?_ !KDA4BWHSWL3@JT*:YJ=K=>_KJ:&LZ+;:]9K;SRS0E3
ME)(6PRG^1JZ(_L.BQV?GRS,L8A$LIR[<<D^^,TD;U!<R[YPO9!^I_P BMM%K
MU/,O.25-OW4[V)XF"@*HP!P!5N-ZY>PCUA->NY+J>-M.*_N44\YSZ=L#/UKH
M(WHC*X8BBH.R:>G02[T+3-2OK>]N;8-<VY!CD5BIX]<'D?6ENX1:LI#$QMTS
MV-6XWJ.\C6X,$;\J&+D>H Z?J*OF4$Y(XI\U2T9.Z6WEZ&;+-.(#+;V<MQZ!
M!C/TSUJ*5=0EL#,-/F2386\LE20?3K6\&IX:L.><FWS;^A'+!)+EV]?N/)[N
MSU?5[=A):7$<!/WY$*KP:UM"TA;2$9VM(>I'0>PKT=6SWKDY-7L]0O)/LL#)
M<1SF!P<#S#S@\>X_(T8>I'"4E1<M&WONV>A6QF)Q-*5*"M!:V7W;[_UV+<,0
M114V:FBL(MH\UGD?N=Q4?@!4PT^V/02#Z2-_C6ZKI[(\ET;=2G14:Z3J7]L,
M1<QC3]AVY^9\]@1_7-+&LTMP]OPC1'$C8R!Z8^O6B.(33<DU^OH.=!II)I^G
M0?7@7Q6_Y'BY_P"N<?\ Z M?0@L">MR^?]T5S6M?"_0O$.I/?W\]Z9W !\N1
M5'  '&/:NBCB81=VF<M?#3G%),^::#TKZ N_@;X>FMV%I>W\$V/E9W5US[C
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MZ5D1W?O5J.Z]ZQIXF#+G1DC1#5BS.!=W _Z:'^0K2CF\S\*PKN8)J%P/]O\
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MQ\TW=W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]J_9_\
M^9B_[=O_ &K7BM>U?L__ /,Q?]NW_M6L:_P,Z,-_%1[51117G'KA5.0_.WUJ
MY5&3_6-]330F-)I**3-,0M)FD)I":!!FD)I,TA- @S2$T9I,TQ!FC-)FDS0
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M6BB@1H:?K-YIB!+9PH$ZSGK\Q4$ '!Y'/2KJ^+=3!@+>2_DIL7<IYX SUZX
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M]JUXK7M7[/\ _P S%_V[?^U:QK_ SHPW\5'M5%%%><>N%0-;;F)W]3GI110
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M_P#7HHHNPLA/[)'_ #U_\=_^O1_9(_YZ_P#CO_UZ**+L+(7^R_\ IM_X[_\
M7I/[*!_Y:_\ CO\ ]>BBB["R$_LD?\]?_'?_ *]<!XI^#@\2Z_-JG]N_9O-5
M%\K[)OQM4#KO'IZ44549RB[HF5.,E9F-_P ,_P#_ %,W_DA_]LH_X9__ .IG
M_P#)#_[9115^WGW,OJU+L'_#/_\ U,W_ )(?_;*/^&?_ /J9_P#R0_\ ME%%
M'MY]P^K4NP?\,_\ _4S_ /DA_P#;*/\ AG__ *F?_P D/_ME%%'MY]P^K4NP
M?\,__P#4S_\ DA_]LH_X9_\ ^IG_ /)#_P"V444>WGW#ZM2[!_PS_P#]3/\
M^2'_ -LH_P"&?_\ J9__ "0_^V444>WGW#ZM2[!_PS__ -3/_P"2'_VRC_AG
M_P#ZF?\ \D/_ +9111[>?</JU+L'_#/_ /U,_P#Y(?\ VRC_ (9__P"IG_\
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M_P"&?_\ J9__ "0_^V444>WGW#ZM2[!_PS__ -3/_P"2'_VRC_AG_P#ZF?\
M\D/_ +9111[>?</JU+L'_#/_ /U,_P#Y(?\ VRC_ (9__P"IG_\ )#_[9111
M[>?</JU+L'_#/_\ U,__ )(?_;*/^&?_ /J9_P#R0_\ ME%%'MY]P^K4NP?\
M,_\ _4S_ /DA_P#;*/\ AG__ *F?_P D/_ME%%'MY]P^K4NP?\,__P#4S_\
MDA_]LH_X9_\ ^IG_ /)#_P"V444>WGW#ZM2[!_PS_P#]3/\ ^2'_ -LKM?A_
M\/\ _A!?[1_XF?V[[9Y7_+OY6S9N_P!ILYW?I114RJSDK-E1H4XNZ1VM%%%9
$FQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *E P8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &R<QM]#7!^%/#EW=:?IT]_<
MR1P6EP\T5F8=A#AC@ECR1WZ5WU%4I-*R.:KAXU9QG+IT^[_(\NTG2[H:[ UX
MUU%?I?%W9; MO&>IFSC81^530Z'/_P (=JUQ!92C47N74G:1(T.\$J/8C/3K
M7I=%:.JSCCED$FF^_P"*M?U/-]7M;>XTRU;1M,NK:Q2Z!NT:T9MQV\-Y9/S
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MG44 ,_>_['ZT?O?]C]:?10 S][_L?K1^]_V/UI]% #/WO^Q^M'[W_8_6GT4
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M-$TL"0#3[8"5Q(^(A\S#D$^_)ITND:;/>"[FL+:2X&")6C!;CIS3]HKWL9K
M58P45/96Z]GK^-^QQ>H:AK$]YKKQZE/:+8VL5PD**"-Q0$@Y'3K7;Z9</=Z5
M9W+XWS0)(V/4J":5].LG:X9[6%FN5"S$H/W@ QAO6IXXTAB2*- D: *JJ,
M= *B4DUL=E"A.G-RE*]_7O?\M!U%%%0=@4444 %4K/2K:QO+VZA#^9>.'EW-
MD9 QQZ5=HHN2XIM-K8****"@HHHH **** "BBB@ JEJ.E6VJ?9OM(?\ T:99
MX]K8^8=,^U7:*$[$RBI*TE=!11104%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]3TVW
MU:Q:TN@WEL0V5."I!R"#5RBA.Q,HJ2<9;, , #.?K11104%%%% %/4=,M]4C
MACN@S)%*LP4' 9EZ9]1[5<HHHN2HI-M;L****"@HHHH **** &F-6.2#GZFD
M\I/0_P#?1I]% #/*3T/_ 'T:/*3T/_?1I]% #/*3T/\ WT:/*3T/_?1I]% #
M/*3T/_?1H\I/0_\ ?1I]% #/*3T/_?1H\I/0_P#?1I]% #/*3T/_ 'T:/*3T
M/_?1I]% #/*3T/\ WT:9'&I4YSU/\1]:FID7W#_O'^= !Y2>A_[Z-'E)Z'_O
MHT^B@!GE)Z'_ +Z-'E)Z'_OHT^B@!GE)Z'_OHT>4GH?^^C5#7_M8T2Z>RNOL
MLJ1L_F! Q "D\9X!Z<G-3Z7*\^D64TK%I)($9F/<E02: +'E)Z'_ +Z-'E)Z
M'_OHT^B@!GE)Z'_OHT>4GH?^^C3Z* &>4GH?^^C1Y2>A_P"^C3ZYOQ5=:I!/
MI2Z5*5F::1VBP,3A(V;RSZ9QC/KB@#H?*3T/_?1H\I/0_P#?1KD8O%4K)J5_
M;*;FV\VW$0?(6!7C!8MM!( .<\'!J[)XAOY)8X;&QM;ES8B\9Q=?)U(VJP4Y
MSC@\>^* .A\I/0_]]&CRD]#_ -]&N3UBZEO])L+_ $W4;ZWN=4\I+6%'7:I8
M9+$%3]U<D_2NN12J*I8L0,9/4T -\I/0_P#?1H\I/0_]]&GT4 ,\I/0_]]&C
MRD]#_P!]&GT4 ,\I/0_]]&CRD]#_ -]&GT4 ,\I/0_\ ?1H\I/0_]]&GT4 ,
M\I/0_P#?1H\I/0_]]&GT4 ,\I/0_]]&CRD]#_P!]&GT4 ,\I/0_]]&CRD]#_
M -]&GT4 ,\I/0_\ ?1H\I/0_]]&GT4 ,\I/0_P#?1H\I/0_]]&B8R+!(8E#2
M!244]"<<"N AUG6X1$D$M]<:C<6$[RV]U;;%CN$ (\OY0",DC&2#Q0!W_E)Z
M'_OHT>4GH?\ OHUS'A[49GUZ6Q^UWUS;FS2?-[ 8W1]Q4@95>#^A!JCJVK:G
M8W]W/)/?120WD26]NMOFWE@8H"2^WJ=S?Q @@<4 =KY2>A_[Z-'E)Z'_ +Z-
M8<<FH)XPFMI+WS()+)I8H1&%6,AP![D^I_2N?CO]3LG.G7DEXKR^2)F$GF2*
MV&W["#QOQP.,!6.!Q0!WGE)Z'_OHT>4GH?\ OHTRTN8;RTAN;=]\,J!T;U!&
M14U #/*3T/\ WT:/*3T/_?1I]% #/*3T/_?1H\I/0_\ ?1I]% #/*3T/_?1H
M\I/0_P#?1I]<1J>K:E9:E<32SWT4D=_%'!;K;YMY(&9%)+;<9.YOX@00!B@#
MM/*3T/\ WT:/*3T/_?1KBX=6U.#6++[5/>BXGU![>:UDM\0"([]A1MN"<!3G
M<<\UI>(;B]34X(O/OK:Q-N[":R@\QC-D8#85L#&3TP?6@#HO*3T/_?1H\I/0
M_P#?1K@H_$6HZA!!)+]O6*#38KJX:P$:L6;=ECO[ +]T>IJS?ZIJ%A?'44DD
MDMYP[P%Y,Q/%Y2E3L!R-I#,QP..,G(% ':>4GH?^^C1Y2>A_[Z-9^A7,<^FA
M%EN)986\N9K@8??@,<CMD,"!TP16G0 SRD]#_P!]&CRD]#_WT:?10 SRD]#_
M -]&CRD]#_WT:?10 SRD]#_WT:/*3T/_ 'T:?7,^(KB]CU.*+S[^UL3;.RS6
M4'F$S9X#85L#'/8'UH Z/RD]#_WT:/*3T/\ WT:\^GU[5Y=).HSW%[:E=-CN
M;8VUMOBEDVDOO.TX&0."1@'-=/K=W?#1+6>U$T?FR1?:&MX]\D<1^\5&#D_@
M: -KRD]#_P!]&CRD]#_WT:XB&]U>^@F@M)M2N(;34?+>1%2*X:$Q;@#O '#,
M.P)&*?>WUU-IEMJ%C<WIM($9'>20*\<RRJ#YB\;N RX .3VY!H [3RD]#_WT
M:/*3T/\ WT:PO#VJB^NKD3O,+J4LXA8'9&BMLVKV)!X8]R?3%=!0 SRD]#_W
MT:/*3T/_ 'T:?10 SRD]#_WT:/*3T/\ WT:?10 SRD]#_P!]&CRD]#_WT:?6
M/XDGO(-/A:T,ZJUPBW$EO'OD2(_>*C!YZ=CP30!J^4GH?^^C1Y2>A_[Z-<-#
MJVHS@VYNM1-A#?R0RW4=L?M 3RE= R[<CYF(SM[#UK:T34;^]\)3W";I[V(W
M$<)D389"C,J;AQ@G STH W_*3T/_ 'T:/*3T/_?1K@5UC6(A)!97&H7-S+IQ
MG9+JUVO'*KH&V J,\,W'(R!5F"[U"[NKRPM+G4;JVB-O.?.7R)RC%@ZJ2$_N
M@]NXS0!VOE)Z'_OHT>4GH?\ OHUQ^A:Y++=6::A<3D1QI"A7E9)') =R.N2I
M5?7!/<5V= #/*3T/_?1H\I/0_P#?1I]% "*H48'\Z6BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "F1?</\ O'^=/J*.-2I)S]X_Q'UH EHI
MGE+_ +7_ 'T:/*7_ &O^^C0 ^BF>4O\ M?\ ?1H\I?\ :_[Z- %?4;"/4[-[
M666:.-^&,,A0D8P1D=N:73[&/3;*.UBDF>.,84RN7('89/:I_*7_ &O^^C1Y
M2_[7_?1H ?13/*7_ &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7_?1H ?5>
M>RAN+JUN9 3);,S1D'&"RE3]>":E\I?]K_OHT>4O^U_WT: ,I/#6GP_:_LQN
M+9KN?[1(T$S(=^,<8Z ^G2J+^$+9M13:TL-C'8BU589W1S\Y+ D=00>]='Y2
M_P"U_P!]&CRE_P!K_OHT 55TFS2ZLYUBVM9Q&&!0?E12 #@>N !GTJ[3/*7_
M &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7
M_?1H ?13/*7_ &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7_?1H ?13/*7_
M &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7
M_?1H ?13/*7_ &O^^C1Y2_[7_?1H <1D$>OI69;Z#:V[RR^;=RS21F(32W#,
MZ(>H4D_+VZ>@K1\I?]K_ +Z-'E+_ +7_ 'T: ,V/P_9QP7,?F7327*A9;AKA
MC*0.@#9R .>GJ:?+HEK<7ZW4\ES+M<2+"\S&)6'1MF<9'7Z\U?\ *7_:_P"^
MC1Y2_P"U_P!]&@#._L&W_MG^U/M-Y]HQMQYYV;<YV[>F,]J670K*:%XR)0S3
MFX,JR$/YG3.?H<8].*T/*7_:_P"^C1Y2_P"U_P!]&@!MM;Q6EK%;0($BB0(B
MCL ,"I:9Y2_[7_?1H\I?]K_OHT /HIGE+_M?]]&CRE_VO^^C0 ^BF>4O^U_W
MT:/*7_:_[Z- #ZS9=$M9[];N>2XE*N)$A>9C$KCHP3ID?SYJ_P"4O^U_WT:/
M*7_:_P"^C0!0BT2UCU 7KR7$TJ%FC$TS.L1/7:#P.#CZ4R70+::VCMVN;X1(
M&! NG&\,<D,<Y/7\N*TO*7_:_P"^C1Y2_P"U_P!]&@#+O/#6FWC(626("$6[
M+!*T:O$.B,!U'7\S5F31[&9Y6DAW"2W^S;2?E6/NJCMGOCT'I5ORE_VO^^C1
MY2_[7_?1H KV&G0:;"\<)=B[[W>1BS,< 9)^@ _"K=,\I?\ :_[Z-'E+_M?]
M]&@!]%,\I?\ :_[Z-'E+_M?]]&@!]%,\I?\ :_[Z-'E+_M?]]&@!]4-1TF'4
MRHFGND3:59(9V17!ZA@#S5SRE_VO^^C1Y2_[7_?1H SKK0+*[,:RF?[.BJGV
M59F6$A>@*#@CVJ6?2HIS<-]HNXVG*%C%.R[=HP-OI[XZU<\I?]K_ +Z-'E+_
M +7_ 'T: ,W_ (1^T2T6WAENX<.9#)%<,KNQZEFS\Q/O4D.AV$%O:6\<3"&U
MD\U$+D@OR=S9^\<DGGOS5[RE_P!K_OHT>4O^U_WT: *5GHUG8WLMU"KB23=P
MSDA-S;F"CMEN36A3/*7_ &O^^C1Y2_[7_?1H ?13/*7_ &O^^C1Y2_[7_?1H
M ?13/*7_ &O^^C1Y2_[7_?1H ?5>\M%O;?R6FGBY!WP2%&'XBI?*7_:_[Z-'
ME+_M?]]&@#.&@6B62VL,MW H<R,\5PRO(QZEFSEB?>I8]'M(([:.#S88[='1
M$CE8##=2>>3WR><DFKGE+_M?]]&CRE_VO^^C0!G0:!:P"<B:[>:9!&UQ)<,T
M@4<@*V>!GGBEBT*SAM+J -.QNAB>9YF:1QC&"W7&..*T/*7_ &O^^C1Y2_[7
M_?1H H/H5@][#=>45:((%16(0[,[,KT^7)Q6E3/*7_:_[Z-'E+_M?]]&@!]%
M,\I?]K_OHT>4O^U_WT: 'T4BJ%&!G\3FEH **** "BBB@ HHHH **** "BBB
M@#GC:^()+^[#ZTMM ),V^+:-MR$=.3G(Z5:T&RO;(Z@+Z8SO+<[TEVA=Z[%&
M<#IR"/PK"FLK.*_O&UG0KV_GDG9HYTA,R&,GY0,'Y<#C&!6WX:@F@T^8/!-;
MP-.S6T$[9>./ P#R<<Y..V: -FBBB@ HHHH *9%]P_[Q_G3Z9%]P_P"\?YT
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MI0KX!:)MRGZ\ 'U % &9<R3)H0F2[U[Y7;A;93.QQP,%.%X]._6JK>+IM/\
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MXT <7#K.H3 P&\O_ +!#?R0RWD=KF?9Y:N@*[./F8C.WL/6MWP_K#2^&7O\
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M27Z6N9MGEJZ KLXR6QNV]AZUT'AJ^N-5\/\ F3S.91)-!YP38S!790VTC@X
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MBF>6/[S_ /?1H\L?WG_[Z- #Z*9Y8_O/_P!]&CRQ_>?_ +Z- #Z*9Y8_O/\
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MD3H 0J_*"1R1@DDX'/->@$9!&2,^E9<&@Q1323O>7L]PT1A2:60%HE/79@
M\#G&>!0!E^'M7EN=;EL?[0EOX#:+.))K?RF1]Q5EP%&1T/MZU2U/7-1@\226
MT=X\<:74$:!8U-N$;&X2OC*OUP,CJOK701Z!#''=9O+U[FY0(]TTN)0HZ!2
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M$==M6=%O(K[3(Y8[J6YPS([S1A'# D%64 8(/'2@"[Y?^V__ 'U1Y?\ MO\
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M_MO_ -]4^B@!GE_[;_\ ?5'E_P"V_P#WU3Z* &>7_MO_ -]4>7_MO_WU3Z*
M&>7_ +;_ /?5'E_[;_\ ?5/HH 9Y?^V__?5'E_[;_P#?5/HH 9Y?^V__ 'U1
MY?\ MO\ ]]4^B@!GE_[;_P#?5'E_[;_]]4^B@!GE_P"V_P#WU1Y?^V__ 'U1
M,SI!(\:;W5257^\<<"N"@\4:JD<9BN6OKR>PFE>T>V\LP3H 0HP 2.2,$DG
MYYH [WR_]M_^^J/+_P!M_P#OJN9\/:S+=:U+8_VBVH0FT6X$KP")D;=M9< #
M(Z'U'K5+5/$5_9:C=L]VT+07D445B;?*SPL4!??C.3N;D$ 8Q0!V?E_[;_\
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MV>_>VFT]K?:(D^;8P;&2?E4YR0<\"M'Q#J5W:ZG!;"]?3[5[=W%PEN)=\H(
M3D$#CGU/8T =%Y?^V_\ WU1Y?^V__?5<5?\ B'4!X:T_5X[R2">>"-A"MKNA
M+$@,9'(.Q>?48]ZGU+5M3TK5YKA_,:!F<1(Q'DLGEJ5(/7(8.6/90?:@#KO+
M_P!M_P#OJCR_]M_^^JHZ)<I<Z:N+J2YEC.R9Y(RC;^I^4@$#D8'IBM&@!GE_
M[;_]]4>7_MO_ -]4^B@!GE_[;_\ ?5'E_P"V_P#WU3Z* &>7_MO_ -]4>7_M
MO_WU3ZYGQ#J=W:ZI%;"]?3[5K9Y%N%M_-\R4' 0Y! XYQU/8T ='Y?\ MO\
M]]4>7_MO_P!]5P$_BO4I-.-Z]W]A9=/BNH(Q;[TNI""7!)!P 0!@$$9S7;2"
M6^TZ)XKJ2S9U63?&%8@8SCY@1^E %GR_]M_^^J/+_P!M_P#OJN7TR:_N]"N-
M2N=<N(K42R2PS>3%N,"C )^3'."W3H15![WQ!%H]E?W-Q<;6B:<N$10F9%*K
M* !P(\]!USWQ0!V_E_[;_P#?5'E_[;_]]5BZ!JPU&>Y,L[B=R62V9"!%&IVX
M!QAFS][!."<=JW: &>7_ +;_ /?5'E_[;_\ ?5/HH 9Y?^V__?5'E_[;_P#?
M5/HH 9Y?^V__ 'U1Y?\ MO\ ]]4^L;Q+?75AI\,EL[1*]PD<TZQ^888SU?'/
ML.00,YH UO+_ -M_^^J/+_VW_P"^JX>/Q'?2H(6U%UM([YX)-26V!;8(U=,K
MMP"2V,[<<>];>C:O>7OA2>]"BYO(?/1,)M\YHV8*=O;.!Q[T ;OE_P"V_P#W
MU1Y?^V__ 'U7 _\ "67UK%)Y=_\ ;9)+$2_O;;R_(FWHF, #(_>=#D_+UYK2
MNKC6;;49M*^V3WBB."Y,L4:+,L9=E<#  [ CC.": .L\O_;?_OJCR_\ ;?\
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MSH\O_;?\Z 'T4SR_]M_SH\O_ &W_ #H ?13/+_VW_.CR_P#;?\Z 'T4SR_\
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MO0'C=CL0#S5BXTM+F&^B:ZNECNXQ&55P!$-N#LX^7/>KGE_[;_G1Y?\ MO\
MG0!3N]'M;S25TM@T=H B[(SC*J1A?H<8/M4MW80WI@$Q8QPR"01@X5B.FX=P
M#SCU J?R_P#;?\Z/+_VW_.@"A9:':V%])=Q-*SMO"JY!6,.V]@O'=N><UI4S
MR_\ ;?\ .CR_]M_SH ?13/+_ -M_SH\O_;?\Z 'T4SR_]M_SH\O_ &W_ #H
M?5>\MFNH/+2ZGMFR")(2N[]01^E2^7_MO^='E_[;_G0!F)H,<-IY%M?7L#&1
MI99D=3)*QZEBRD>G0#&!BI8-&@M8K>*VGN88X$==JR<.7ZLV>K9R<^I-7O+_
M -M_SH\O_;?\Z ,@^&;2:.Y6]GNKU[B+R6DG<;E3.<+M  YP<XSD#TI\/A^&
M)+LM>7DMQ=1B*2YD<>8$&<*I  '4]L\YK4\O_;?\Z/+_ -M_SH S&\.V)O(+
MA \:Q","%" A\O.S(QGC<>A^M:U,\O\ VW_.CR_]M_SH ?13/+_VW_.CR_\
M;?\ .@!]%(HVC&2?K2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4R+[A_P!X_P Z?3(ON'_>/\Z 'T444 %%%% &'XEU6XTZ*RAM=XFN[CR@
MZ1>8R@*6)"]SA<<\<YJUH5ZM]IV\7,UP\<C1R--$(W5@>590  14FIZ7%J<<
M(:66&6"42PS1$!D8 C(R"#P2,$=Z=INFPZ7;-#$\DC/(TLDLARTCMU8XX_+T
MH N4444 %%%% !7.^*=2U/3Y=-_LP*[/*[2PE03*B(6*#T)QQ[UT55;BPBN;
MVSNG9P]HS,@!X)92IS^!H YX>+507]VN+BT\VW2VY"*HDC#9=CT&3U/3I5RX
M\1W$<R00:3+<3&T%VZI,F%7)&,YP3QQCK[4Z#PM:V2WHL;JZM?M<_GOY94A3
MC!4!E(VGT(-41X2,>HQQ6US=6MC%IXM0\,B[F^=BP((/8]0!CMB@"/7/$$T5
ME9:EI^H.B7*PO# ]KF-@S#/F2$87@^HQCO77UB77AFWNK5;'[9=QZ?Y2PM9H
MR^6R*, 9*EAD#G!&:VP   .@H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!DSO'!(\:;W5257^\<<"N"@\5ZFD2-'<K?W<]A-,]I]GV&WF0 A!
MCDCDC!R>/>N_(R",D9[BLJ'0A'.]Q+J%Y<7/E-#'-*R9A4]=H"@9X')!Z"@#
M-\/:U+=ZS+8G4EU&$VJW"S>2(RC;MK+@ <=#ZCO5/4]?U&W\3/9QW0C5;F".
M./RE,+(V-WF2=5?[V!D?PX!S6['H*HETS:A>O=W""-KLNHD11R N%"@<GMWJ
M*?PO;3SW!-W=K;7,RSSVJLOER.,<GY=PSM&0".E &-#K^I2>*!9?:E_X_)83
M"T2B'RPI*[9.ID^[E<^O Q4,.MZG;@V-[/<Q33"(O))%EX3@^9L50<Y(PO!_
MB/05OQ>%[6*>-A=7;6T5R;J.U++Y:R$DYZ;L9)."<5--X?MID<^=.MPUQ]I^
MT @N&P5 Y&,!25 QT]^: -*":*YMXYX7$D4BAD<=&!'!J2H+.TBL;*"T@!$4
M*"- 3DX Q4] !1110 4444 %<3J'B2]M-4N/,O!"T-]%!'8-!_KH6*C?NQG/
MS$@@X&,5VU9EQHJW=ZLUS>W4L"2"5;5BHC##H>%R<$9P21F@#G+;Q)>_VO:)
M/>+YD]\]K+IY@V^2GS;6#8R3\H.2<'=Q5[Q7K%UIES:I%<200212LS6\ FEW
MJ 0-ISA.N3CTY%:JZ*IU&.\N;RZN?)=GABE*[(F.1D *,D D#).,U!)X=5I8
M9TU._CNHXVB-P'0NZ,V[:=RD<'IQF@#F]4\2ZM;06Q-Y'%*^GQSJ;:-98WF)
MP?,8_<CZ8;@=>>*N7VLZIIFJ23S;VA8L(X^/)9?+4J5;KPV\D]E!/I6A_P (
M?91PF&UN[RUA>W6VF2)U/FHN<9+*2#\QY&.M7Y=!LIPRRAVC-J;1(RW$<9&#
MM]R,<^PH =HMRESIJ8NVNI4)6:1HRAW]2-I ('(P/3%:-4M-TV/38I56625Y
MI/,DDDQN9MH7L .B@=.U7: "BBB@ HHHH *YGQ%JMU::I%:K??V=;M;-(MQY
M'F>9*#@)R"!QSCJ>U=-5#4=-?4,*-0N[:,J5=(&4;P?<J2/J"* .-N/%VH/8
M&]:[2P9=/BNH(3!O6Z<@EQDC( (Q@8(SDUTFN:I<VVB6MW;'R1/)$)9O+W^1
M&W5\>W3GCG-37/A^"YA2U^U7,6GK&L1LXV41LH[$XW8QP<'FK$VG22&<Q:A=
MP&4H5\LJ1%M&,*"I&#WSF@#GK36[BZTW4-VK2;+.Z\L7EO9^8\J% P^0*0#E
ML$@8X[9JJ=:UJ?0].U(S$)Y#/)) J["XD _>==HV;LCL<CKBNC305@MO+MM0
MO8)6E,LMPK*7E8C!+;E(/ &..,#%+!X>L[>RM;-6F:""8SE7;/FN26R_'/S'
M=C@9Q0!#H.K#4I[DRSL)G)9+8H1Y4:G;C..6S][!."<=JW*S+'0[:POY+N-Y
M69MX1'(VQAWWL!QGEN><UIT %%%% !1110 5C>);^YT_3X9+=_)5[A(YKCR]
M_D1GJ^/R'/ SFMFJ]Y;O=0>7'=36S9!$D.W=]/F!'Z4 <9'XEO9$$+:D$M4O
MGMY-36W!^01JZ9&-H)+8SC''O6_H&JW&I>&VNW>*2XC::,2$;%D*,RAB.P.
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M[Z'^%'V!_P#G^NO^^A_A5VB@"E]@?_G^NO\ OH?X4?8'_P"?ZZ_[Z'^%7:*
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M/L#_ //]=?\ ?0_PJ[10!2^P/_S_ %U_WT/\*/L#_P#/]=?]]#_"KM% %+[
M_P#S_77_ 'T/\*/L#_\ /]=?]]#_  J[535+F>STF\N;:'SIXH7>./&=S 9
MH ;]@?\ Y_KK_OH?X4?8'_Y_KK_OH?X5QX\5WT4=REOJ$.I-]C2X$JV^/()D
M5'RHZ@!MV.HP<UM^&]7DO[[4;-KZ._CMA$\=RB!=P<-D'''!4\CUH U?L#_\
M_P!=?]]#_"C[ _\ S_77_?0_PK#M=4O$U^2'4;RYMT>Z>*VA>T BE7'R@28Z
MGD]>U9T6N:K;AK.\FGBGG6+=)+#S Q+"38H'S#[H3@Y.>H!H ZW[ _\ S_77
M_?0_PH^P/_S_ %U_WT/\*L6T\5S;13P2"2*10R.#]X'H:EH I?8'_P"?ZZ_[
MZ'^%'V!_^?ZZ_P"^A_A5VB@"E]@?_G^NO^^A_A1]@?\ Y_KK_OH?X5=HH I?
M8'_Y_KK_ +Z'^%'V!_\ G^NO^^A_A5VL;Q)J%QINGPR0.(1)<)%+<,F\0(>K
MD?D.>!GF@"Y]@?\ Y_KK_OH?X4?8'_Y_KK_OH?X5R2>)[R1%@.I1);I?/;OJ
M@A!&T1JZ<?=!);&>G''6MG2]?EF\(7.JS[)I+5;C+(-HE\HL,@=LA<_C0!J?
M8'_Y_KK_ +Z'^%'V!_\ G^NO^^A_A7+W7B#5="@CGO9X[P7.GR7**(MGERKL
M^48Y*_..O/%2IJ=_+;RP+>WDMTDD+3I]B\J2.%B0S1J1\P./<C!H Z/[ _\
MS_77_?0_PH^P/_S_ %U_WT/\*Y_1/$$MY=6D5]=>4R1B-EV?Z^8Y&20, #:0
M.1E@V.E=;0!2^P/_ ,_UU_WT/\*/L#_\_P!=?]]#_"KM% $<$1ACVF5Y#G.Y
MSDU)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3(ON'_>/\
MZ?44:$J3O8?,>!CUH EHIFP_\]'_ $_PHV'_ )Z/^G^% #Z*9L/_ #T?]/\
M"C8?^>C_ *?X4 5]3LFU&QDM5NI;82 JSQ!22I&"/F!'>C3;)M.L(K0W,MP(
ME"J\@4':!@#Y0!5C8?\ GH_Z?X4;#_ST?]/\* 'T4S8?^>C_ *?X4;#_ ,]'
M_3_"@!]%,V'_ )Z/^G^%&P_\]'_3_"@!]9^IZ3'J36\OG36]S;.7AGA(W)D8
M(Y!!!'4$5=V'_GH_Z?X4;#_ST?\ 3_"@#';PQ;2VEW%/<W,TUV\;S7#E=[;"
M"H&!@ 8Z =S3[KPY:W4UY(99D%W)!+(B$8WQ,"&''4X /L!6KL/_ #T?]/\
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MU7+K1;>^DE:[>2;?;-; $@!%888C X8\<^U7]A_YZ/\ I_A1L/\ ST?]/\*
M*NFZ:FFQ2J)9)I)I/,DDDQECM"CH .B@?A5VF;#_ ,]'_3_"C8?^>C_I_A0
M^BF;#_ST?]/\*-A_YZ/^G^% #Z*9L/\ ST?]/\*-A_YZ/^G^% #Z9*ADB=%=
MHRRD!UQE?<9HV'_GH_Z?X4;#_P ]'_3_  H S(=#,37$[:C=R7LR",73!-T:
M@Y 4!=H&>O'-+!H8@CF(OKLW4\J237)*[WVD87@8"X&, =S6EL/_ #T?]/\
M"C8?^>C_ *?X4 9CZ$)[^*XNK^ZN(H9O/AMW*A$?G!X4$XR< DT3:!!-YDGG
MS+<O<+<"<8+*R\*!D8V@$C&.Y[G-:>P_\]'_ $_PHV'_ )Z/^G^% $5C9Q:=
M806< /E0($7)R<#UJQ3-A_YZ/^G^%&P_\]'_ $_PH ?13-A_YZ/^G^%&P_\
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MAO3:H7!E_=[Q*G=#R#@]\'VJW803VUHL5Q-%*R\ Q1>6H7L N3C% %FBBB@
MHHHH *P/$VMWFBM8-:VZ3I)*QG0@[O*5"S%,?Q8%;]4KO3EN]0L+HR%?LCNP
M7&=^Y"N/;K0!E?\ "4PQSWK./.MUE@BM?(&6E,D88<D@=_:K%UXE@M9%B-C?
MR3&V%RT4<.61,D'=SP1CI^6:I6_@];*VU"WM;M/)NYQ((KBW65$0#'EX)Y'I
MTQQ59/#FH6^IQ6]GJ$T,,>F+;&Y>(2;SO8D<G@@'CT]Z )]9\2RV<=I=6-W8
M21W(B:"U<-YMP'('RG(QP?0^^*ZFN=O/"[W.EII$>H>7I8A2$PF!6<*H ^5\
M\$XZX/M70@8  [4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,
MFD\F"27:7V*6VKU.!T%<5%XUNH[6.ZE-C=BXL);M(+4G?"R '8_)SP>N!R#Q
M7;G)! .#ZUA6WAZ6.\>]FO(GNA$\<+1VJQJA;&6*Y.YN!U/\Z &:)KD]YJTF
MGW%S871^S)<I-99V@$X*D$GV(/<'I3=4URZL->M+-+BPE^T3I&+, ^?L/5\Y
MP,<G&.@ZU-:^'IK4W5PE\BW\T8B2:*V5$B4'/"9.<DDDDGMZ4[4="N-4N4%Q
MJ.;-)TG$(@ <%"" 'SP,CTSVS0!'<ZEJEEK]E:.+2>&\:4+%&K"2-54D,6)P
M1T!X'+"LBW\47PA,%S-'%<2B-A+-%Y:V^1^\!!Z[3@#U+8[&MFTT.^MM<N-2
M;4XYO/?E7MOF6,=(U;=P!].3R:6Y\/?:&:X^UD7IN!.LS1Y  #*J;<_= 8]^
MIS0!M(ZR1JZ,'1@"K Y!'K3JK:?9IIVG6UE&S,D$:QJ6ZD 8JS0 4444 %%%
M% !7(W?BJYM]0N?GL4@MKZ.T:U<GSW#%1O!S_M9 P<@'FNNK$O= ;4=16:ZN
M8VMDD601+;J'.T@A3)G)7(SC H S+7Q5<RZC:^8]EY-S>R6?V52?/BV[@&;G
MG.WD8&,CFMC7KJ\L+&6^@N[:"""-GD$UNTA8CH!AU^E1#0&EUB.^O+F.40R&
M2*..W6,[L$ NV26P"<=*EN='FO[2SM[V^,RPW FE/E!?.VDE5('  .WZ[?>@
M#$G\47MM)!:7<UE9726B7%W))!)(BLV?E 4_*!@Y8G'2I+GQ+=V.K2^<N^U#
M%4B6/&X;%*,K]#N8D>P&>QK1U/P_+>WEQ<6U^UK]KMQ;7*^4'WH,X*Y/RMAF
M&>?I3[GP[;W<?D22O]G2T-K!&/\ EEE2I?/=L8'MSZF@"WI%R;O38I7NH+F0
MY\QX#E W<#Z=*O5GZ5IITZ.?S)_.EGE\V1PFT9VJHP,G'"CO6A0 4444 %%%
M% !7,^(=8N;/5(K-+Z#3H6MFF6XFBWB20' C&3CIR>Y[5TU4-1T^>_PL>I7-
MK&5*NL(3Y@?<J2#[B@#CKCQE?/8F\^U6U@4L(KN*"6/=]K8@EE!)Z#&..><F
MNUD:XO-.1[29;:255<.R;]H/)XR.:HW/AY+BVCLEO+B'35B6%K2,*%9!QC=C
M=@C@X-.U+1&U*TN[7^TKJ"&XV#;%M C5>JKQT;O0!@KXFU'^R[9"XDFN;Z6W
MANXK9G\R) 3YBQCJ3C'IWZ4MUK6H?8[>ZM;R::")7\V;[-L'F+(H*RJ1\@"[
MO3I]!6RWAYI+6VC;49Q-:2>9;3)'&AB^7;M"A=I&"1@BI(?#UO%:16S332QB
MX-S-O(_TB0G.7P.F<' P.!0!'H6KC4YKEGN/WC-NCM2N#%&#CDXY8GKR<'CM
M6W658:%!8:A)=I+*Y;S B-C$8=][ <9.6]:U: "BBB@ HHHH *Q_$FI3Z9I\
M,D+I")+A(I+ATW+ AZN1^0YXYYK8JO>037-OY<%W):OD'S(U5C],,"* ..3Q
M3=R(MNVI6R0K>R6[ZH(@4VB-77C.T$[L9Z<'UKH?#>J2ZMHBW,K1R2K))$7C
M&%D*.5# =LXS^-+'H;V]H8K74KJ&:24RS7&U&>5B,$G<I Z#& ,8%36FD)81
MVL5M<SI%"'W(2#YS-R6<D9)SD\8ZT 4M'O=6N#J\-T;5[JVF"1*@*QC,:L 3
MR3RW7]*IP:AJ]QH+/)(7N(]0>">2TARRQ+(5)53GL!ZFM&PT.XL9[V;^UKB5
M[OYF+11C:^T*&&%[!1QTI+'09;*RO+8:K=.+EW<N5161F)+%2%'7/X4 9NB>
M(9KV[M(;VY6%DC$;ILYGF.1R<84#:1VRVX#[M=96,?#5F+R":)GBBB$7[A<;
M6,18H>F>-Q[\ULT %%%% !1110 4444 %%%% !1110 4444 %%%% !44-S#.
M\R1.&:%]D@'\+8!Q^1%<;=6OABWUB_%[--<2R2[RD8F8PDCD$IQUYQVS6[X;
ML["VM+B73)UEM+B8R)M).SY0I!).<Y'>@#:HHHH **** "HHU8J2)&'S'C ]
M?I4M,B^X?]X_SH -C?\ /5OR'^%&QO\ GJWY#_"GT4 ,V-_SU;\A_A1L;_GJ
MWY#_  I]% #-C?\ /5OR'^%&QO\ GJWY#_"J6L7<ME9>='=65J PWS7F=BCZ
M C)SCN*9X?U&;5M#MKZ>-(Y)03A,[6 ) 89YP0 1GUH T-C?\]6_(?X4;&_Y
MZM^0_P *?10 S8W_ #U;\A_A1L;_ )ZM^0_PI]% #-C?\]6_(?X4;&_YZM^0
M_P *?6!XFURZT0V#6ULDZ22L9U.=PB5"S%<=P!G% &YL;_GJWY#_  HV-_SU
M;\A_A6%_PE$,<]Z9%\V!)8(K7R!EIC)&&'4X[^U377B:VM9%B:TOGF-N+DQ)
M 2R)D@EAV(QT_+- &OL;_GJWY#_"C8W_ #U;\A_A7-ZSXDELDM+FRN-/EBN1
M$8+9RWG7 <@?)R,<'/0^^*Z>@!FQO^>K?D/\*-C?\]6_(?X4^B@!FQO^>K?D
M/\*-C?\ /5OR'^%/HH 9L;_GJWY#_"C8W_/5OR'^%/HH 9L;_GJWY#_"C8W_
M #U;\A_A3Z* &;&_YZM^0_PHV-_SU;\A_A3Z* &;&_YZM^0_PHV-_P ]6_(?
MX4^B@!FQO^>K?D/\*-C?\]6_(?X4^B@!FQO^>K?D/\*-C?\ /5OR'^%/HH 9
ML;_GJWY#_"C8W_/5OR'^%$TGDP22[2VQ2VU>IP.@KC(_&MU%:1W<ZV5PEQ82
MWD<-JQWQ% #L?).>#UP,$'B@#L]C?\]6_(?X4;&_YZM^0_PK"T;6[B[U:33[
MJ6QN&^S)<I+9D[0"<%2"3STP>X/04:S?ZQ87=LMM+82"ZN4AA@>!]^#RQ+!\
M<*&/3M0!N[&_YZM^0_PHV-_SU;\A_A6#=W^LVNN65FLEC.MR[L8U@=72%1DL
M6WD9R5'3J:R[;Q5>F$PW$L$=Q*(V666,QK!D?O P)YV' 'J6 ]: .RV-_P ]
M6_(?X4;&_P">K?D/\*5&5T5U8,K $,#D$>M.H 9L;_GJWY#_  HV-_SU;\A_
MA3Z* &;&_P">K?D/\*-C?\]6_(?X4^B@!FQO^>K?D/\ "C8W_/5OR'^%/KDK
MKQ5<P7UR0;);:VOH[-[=V/GN&*C>.<8RV0,'(!YH ZK8W_/5OR'^%&QO^>K?
MD/\ "N5M?%5S+?VID^Q?9[F]DLQ;JQ\^(KN 9N<'.WD8&,CDUJ^(M3OM*LDN
M+.WAD42()7E8@*I=5X ZGYO8#% &KL;_ )ZM^0_PHV-_SU;\A_A6+XCO]4TN
MTDN[.6S*C:D4$L#,\DC'"J"''4D=JS[CQ)?:?JLJ7:*T2$H84C(R=BE65CUW
M.2N.V/8T =5L;_GJWY#_  HV-_SU;\A_A572;EKO38I7N;>XD.=[VY!0-_='
MTZ?A5V@!FQO^>K?D/\*-C?\ /5OR'^%/HH 9L;_GJWY#_"C8W_/5OR'^%/HH
M 9L;_GJWY#_"C8W_ #U;\A_A3ZYKQ!K5S9:I%91WUMI\;6S3+<7,>Y9'!P(Q
MR![GOZ4 =%L;_GJWY#_"C8W_ #U;\A_A7"3^,[U[(W8N;.Q,=A%=QP3IG[4S
M EE4Y' QCC)R>:Z+7-8FLM&M;N I"+B6)'GE7<L"/U=AQTZ>G- &SL;_ )ZM
M^0_PHV-_SU;\A_A7)1Z_J<^@ZQ)9W%C<W&GR,HN@I\MT$8?<%!Y;G&,X[^U3
MZQJNJ6\-E<PLZ0FV$SLL6Y&?<F0YP=J[2QSQTZ]J .FV-_SU;\A_A1L;_GJW
MY#_"LC0M7&J37+/<+O+9CM=N#%&.,GU8GKZ<#J*VJ &;&_YZM^0_PHV-_P ]
M6_(?X4^B@!FQO^>K?D/\*-C?\]6_(?X4^B@!FQO^>K?D/\*-C?\ /5OR'^%/
MK'\2:G-I=A#)"\<(EN$A>XE7<D"MU<C(^G)QDB@#5V-_SU;\A_A1L;_GJWY#
M_"N*3Q5=2*MN=1LXXQ>R6SZIY>8MHC#KQG )W8ZXX-;6DZW<7OA6?4O+2XN(
M!.H$(.V9HRP!4?[6T?G0!M[&_P">K?D/\*-C?\]6_(?X5Q^E^+2+D?;-2M+R
M!K$W;M;IM,# J"A&3G.X  \Y%20:MKD]M?"=3%+%>Q(PMHM[P0NB.1CG<PW8
M)QZ\4 =9L;_GJWY#_"C8W_/5OR'^%<OHOB&:^N[2&\N4A9(]CH5P9YCD'_=
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M+CTB._6/3%A2'RS;AI % &5?/!..N#CM71 8 'I3=C_\]6_(4;'_ .>K?D*
M'T4S8_\ SU;\A1L?_GJWY"@!]%,V/_SU;\A1L?\ YZM^0H ?13-C_P#/5OR%
M&Q_^>K?D* 'T4S8__/5OR%&Q_P#GJWY"@!]%,V/_ ,]6_(4;'_YZM^0H ?13
M-C_\]6_(4;'_ .>K?D* 'T4S8_\ SU;\A1L?_GJWY"@!]%,V/_SU;\A1L?\
MYZM^0H <<D'!P?6L&V\.217KWTMS;M=")XXC%:"-%+8RS#)W'@=_7UK<V/\
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M9 ]:Z.@!FQ_^>A_(4;'_ .>A_(4^B@!%! Y;)]:6BB@ HHHH **** "BBB@
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M>G_CM #ZHW>GFYU33[WS=HM#(2FW.[<NWKVQ5O;)_P ]/_':-LG_ #T_\=H
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M4/#AU34UFN39>0LB/E;0>>VT@A3(3]W([#IQ6YMD_P">G_CM&V3_ )Z?^.T
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M FWS06+; ,_*F3C'/ Q6WMD_YZ?^.T;9/^>G_CM &/I>@'3M4ENS<*Z8E6-
MFT@/)O.XYYP>!TXK;IFV3_GI_P".T;9/^>G_ ([0 ^BF;9/^>G_CM&V3_GI_
MX[0 ^BF;9/\ GI_X[1MD_P">G_CM #ZIZG:R7MDT$7V4EB,K=0^;&P]"N15G
M;)_ST_\ ':-LG_/3_P =H YZ/PPUMIC6L)T^1YIS/.+BR#1%L #:@8;<  #D
M]*N:?HTVE6=O:6ET@A02F8/"#YDCG.X8("@$GCTXK5VR?\]/_':-LG_/3_QV
M@#$TOPZ;&_EU!S9K<F(Q1K:VODQJ"<DD9)8D@=^U6;#29M.T$V-O=#[6P9GN
MF3.Z1B2SXSZDX&?2M+;)_P ]/_':-LG_ #T_\=H P!X4CBO[>6"?9!&86967
M<[-&78$-G^(N=W'/XUT5,VR?\]/_ !VC;)_ST_\ ': 'T4S;)_ST_P#':-LG
M_/3_ ,=H ?12*"!R<GZ4M !1110 4444 %%%% !1110 4444 <;KGV>"[B,?
MB:ZC>6\6.6);Q (U.<X&.,>]=%I$<$=HP@U*6_3>?WLDPD(/'&1_GFI'TC39
M9&DDTZT=V.69H5))]SBI[>UM[2,QVT$4*$Y*QH%&?7 H EHHHH **** "F1?
M</\ O'^=/ID7W#_O'^= #Z*** "BBB@ HK.UC5DTFWB8Q^;--((HH]X4%L$\
ML>   23[58L+B6ZLTFFBCC=L_+'*)%QG@A@!F@"S1110 4444 %8?B'6IM)D
MT^*%K2/[5*R-+=N51 $+=1],5N5F:GI":E?:=/(4,=I([M&Z;A(&0KC]<T 8
M4WC*Y@T[2;U]/'EW+R_:=K$[(T.#(G'S#'S?2M.3Q"(K?69VC5H[!E$6TY\W
M<BLOYE@*99>&WM6L$DN5EM[)IQ&C)R8I!A4)S_"./<51M_!'DV\EDU^[V3WJ
MW&P95Q&B@)'N!SP0ISZ** -K0]4DU+3?-NXT@NHI&@N(E;(213@@$]CP1[&L
M[Q)XGCTZTNXK-I&O(3&"XA9XXRS# 9L8!(/ZBI[7PM:6]W>^8!=65T4D,%UF
M8B5007W.3G(VC\*JZAX6NKC^T(+2^A@L[Z2.62-H"S(R!1A2&  (0=N* -.;
MQ%IT%^;1Y)-PD6%Y!&QC1VQA6;& 3D?F*9'XFTV2]6U#S!C.UL)&A81^:I(*
M;L8SP:I#PJ(];GO473Y8Y[@7#&XM-\J-QD*^>!QD9'&:K:;HFH73'[5.L5E%
MJT]VL)@(D8B5ROS9QM)(;IGWH V(/$FFW%X+:.23+%UCD,3!)"F=P5L8)&#^
M1IEEXITJ^&Z.65$-N;E7FA:-7C'WF4D<XR,U1TGPF-*N $73GB0R&.7['BX^
M;/!?/;.,XY%2-X5\W3["SEN<QV^FR6#E5P6WJJ[ASQ]WI[T ,@\4Q7&NLN^2
M'3X]/:Z<SP-&?O@!AN'(QFKG_"5:6+:XGD>>%;<(TBRP,K;7.U6"D9()]*H/
MX5N[[SQJ>H12++I[6($$!3 )!W<L<GCITIT?A:0:?-;L-,@D=H3YEI9^42$<
M,=WS'.<?A0!/>>+;2WTZ:ZAMKJ5X)XX9(#"R.A<C!((SC!R/7I5C7-9DTW01
MJ$,:AF>)0+G*!=[A<MW&,YJ'4/#TEX=59+I4>\:!X\ID(T1!&>>02/:K6JZ7
M+JVDQVDTL:R"6*21E0[3L<,0 3T.,=: ,23Q7J"Z/=SP6=M=7$%Y';1-#*3#
M<;MOW6]1G'U%:ECXAAU"]C6(*+1[$7?F,<%3N*E2.V,'/N*B;PTRR3I!<+':
MO>PWD<(3B-E(+@<]&(!]B356X\'NU[JTMK?&&#4(1%Y6S/E;FS(5.?XAGZ$D
MT 7?#FORZT+E;BV%O(FV6)0<[X'&4;ZG!S]*W:P[3PW%IVLP7UE/,J+ UO+'
M-*\NY<@I@L3MVG/YFMR@ HHHH **** "BF2RK#"\KG"(I9C["N;7QBL5NMU?
M:?);6TUH]Y;N) YD10"00/NMA@<9/UH Z>BLG3=8FNM0DL+VQ-I<K"LZ*)1(
M&0DCJ ,$$8(_4U5N/$YAN9RM@[V-M<I:SW/F %7;:.$ZD LH)R/H: .@HKGA
MXI_?QN;!_P"SI;IK2.Z$@):0$C.S^Z64@'/X5!9>+);R':MI&UW*(FMXDER&
M$@+?,<<;0"6_#U% '444#IS10 4444 %%%% !117/S>)S%=3;;!VL8+M;.:Y
M\P K(Q4<)W4%E!.?PH Z"BN?M_$YGNK?-@Z6-S<O:PW/F EG7=U3L"5;!S^
MJWK^MIH6FM<^2UQ-@^7 C8+X!9N>P"@DGVH U:*PIM?G_M.*QM;*&1WMH[@F
M6Y$?#E@ !M.3\IJ*;Q2EMJT]O<1(MM$SQEP^7W*BOG;CH=P ]\>M '1457LI
M9Y[.*6YA$$SC<T0;.ST!/KC&?>K% !1110 4444 %%%8FJ:Q=V^IKIVGVL$U
MP+9KIS/*8UV@XP, Y)/X"@#;HKDF\8S3VLMY86,;V]M9QWEP)IMC[7!.U!@@
MD 'DX&>*Z.>6YELDET]87D<!E$[%5VGZ G- %JBN=T_5M8U&SN)HK;3U\FY>
M$.TS['5>"P.W/WLC\*SQXOOS9V5R]M:Q"=6E52S'SD$BH AXP2IW<@\8H [*
MBLW2=2.J&XF7RA;!L0 'YV7^^WH#V]N>]:5 !1110 4444 %%%9NM:F^F6]O
MY42RSW-PEO$KOM4,V>6.#QP>U &E17,)XGO)9TT]+*W&IFZDMF#3'RAL0.6#
M;<G(8<8SU]*U=(U.35M)-RL*Q7"M)$T9?*B1&*GG'(R.N.E &E17,2^)+[3[
MN^CU&VM3#9VGVB5[:5F(8G")\RCDX/Y4@\2W+:>9_,TK)GBB+PW)F2#<>3)C
M'3Z\YH ZBBL#1_$$FKRVR".*,>2'N,GGS",A$'? ^8^@('4\;] !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R+[A_WC_.GTR+[
MA_WC_.@!]%%% !1110!C>(-(DU-;&6&.WEDL[CSA#<_<D&TJ03@X^]D'!Y%/
M\/:7)I-A+'+Y2O-<23F*#_5Q;C]U>G ^@Y)K6HH **** "BBB@ JK>ZG8Z:J
M->W44 ?.WS&QNQUQZU:KF_$/VD:_H#VD$4TJ/.0DK%0?W?K@X/X4 :DVN:5!
M9PW<NH6ZV\_^JDWC#_3UJO-K]O#J<,;2P"Q>S:Y^T[^.'51STP=U9-EH.JZ5
M-:7T,5I<7 6X$MNTI1(S+)YGR-M/3&#QS3['PK)!%!;W;Q/;_P!GSVT^WCYI
M) Y"C^Z.0/H* -^YU73[-I%N;R&$QA2^]P-H8D+GTR0?RJ"#Q%HUS+#%#J=J
M\DQ*QJ)!ECZ8]>#Q7,Z)I%YJGAZWO+EHY;FXO8)G9^ T,+ +^84M]6K0F\.W
M3&_9! &N-6AO%.<?(GEYSQU^5OSH W!J^G-J!L!>P&[!QY6\;LXSCZX[5%_P
MD.CF*60:E;%(B%=@XP"<X'UX/%8EAX9FM=6+3VR3PK>R7<=P;V4;2Q)'[K[N
MX;L9]*E71M6M/#5I96;Q)<1W#/,$DV%T+,2%?:<'D<X]: -B37=*BMH+E]0M
MUAN/]4YD&']<?2GR:OIT-^MC)>P+=,0!$7&XD]!]3Z5RR^&M7@TJWC@6%=0C
MDG9;H73 Q>8^[GY,2*>,@@<BK'_",3C6KF6:W2[M[B[2Z\PWLL>PC;UB'RL0
M5R/PS0!UU%%% !1110 4444 %%%% !1110 4444 (PRA& <CH>AKD;3PHR7;
M7$EA8PI';20Q6J3R21N7QG<6'RK@8V@=S77T4 <OIGA^\TV>[U"""TANV@6"
MWM_/DDC4 YRSL,_@!@8I-3\,MJ>JES:6D,#S1RRSI,^^380<&/ 7/&-Q)XKJ
M:* .6@\/:BAMK%WMO[.MK\WB2AF\UAO+JA7&!AFZYZ#I1>^&);EWNO*M#,;C
M<+?[L1A&?E) ZDD,3CD@#L*ZFB@"KIEK)9:7:6LTIEDAB5&D/\1 P35JBB@
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M2/%MF !RIP<8)!&0><]J +F9/[B_]]?_ %J,R?W%_P"^O_K4^B@!F9/[B_\
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M^L1F+#KV!'/2F3^'=373K:U\AI?L=\9G>&1%>\5E;$AW<;P2,[NN.#TKI?\
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MDEV#VD.Z^]?YFC(BR1.C*'5E(*GN/2N*M_#,LTH$]C>C3[:TE@CM+F[1R^\
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MC3__  )3_&C_ (2/0_\ H,:?_P"!*?XT<DNP>TAW7WK_ #-.BLS_ (2/0_\
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M"ET90PRI8$9'J* &T444 %%.>-XPI=&4,,J64C(]13: "BBE +$  DG@ =Z
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M%> ?5A7G7QC_ .19L?\ K\'_ * ]>BUYU\8_^19L?^OP?^@/71AOXT3DQO\
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MCA;G^TH-1TF*[L;VY^U>0TC*8WX'##Z4#Q_<MJUQ<3V$$EC/:BS:R!(41#H
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M,,OG"&. K)C!(.2/QYKC?#FDVVKWDL-R;[")N5+*W\UV.?R ^M:VH>.Y;_\
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MISR.]3+$._NK^M/\RX8-6]]_U[W^1XC15^[L[Z>*?59+$PVS3F-BB;$1SSL
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MFJ%%+ECV'SR[EFWU&\M+[[=;W4L5UDGSE8ALGKS[Y-7(/$VN6R!(-5NXU (
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M<!_O$?ZZ'KM%%%> ?6!7G7QC_P"19L?^OP?^@/7HM>=?&/\ Y%FQ_P"OP?\
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M;752*53<SVQLD*C:D<+ @-SQP/UKF/[*C_Z"VG_]]/\ _$4?V5'_ -!;3_\
MOI__ (BN?V5.]_ZWN=?MZUN7_+M;N=9?^+M#+ZQJ=C%?'4]5MOL[Q3;?*BR
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M8Y.0W YSR*Q;OQ'IFI^&]1T^\:]-PU^][;2@*=Y*[0']/? K"_LJ/_H+:?\
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M9<=ZM_\ "8:!)K^G:Q-;W;3I9BVF4QHRQ,%P'3/WCG/6N/\ [*C_ .@MI_\
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M2T&22JL,>E<I50FIJZ,ZE.5.7+(****LS"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BK%A%!<:C;0W4WDV\DJK++C.Q2>3^ KH;_ ,,&75XK&SM39*R2
MR+/-<>9#*B#.Y6 ] <U$IJ+LS2-.4E='+45T,?AQHTDF\RWO;9[&:XAFC=E
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MN10 4449'K0 44F1ZTN1C.: "BG.CQG#HRG&<,,<4V@ HHHH **** "BBB@
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MT4_9Q[ JTUU-P^(8Y-.BLYM.C<6ZNENPF=3&K$M@@'YL$G&:BFU^6:UD@,"
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M1]C/E"BBBM3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,BS8_\ 7X/_ $!ZZ,-_&B<F-_W>?I_D>*T445] ?(CO,?9LWML_NYXH,CE
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MQL^)[F&\U6*XBDCD:2U@:5D[R;!NS[YZUC445K%<JL<\Y<TG(****HD****
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M,_X0/PO_ - 6U_[YH_X0/PO_ - 6U_[YH^OP[,7]DU/YD?.=%?1G_"!^%_\
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M'SG17T9_P@?A?_H"VO\ WS1_P@?A?_H"VO\ WS1]?AV8?V34_F1\YT5]&?\
M"!^%_P#H"VO_ 'S1_P ('X7_ .@+:_\ ?-'U^'9A_9-3^9'SG17T9_P@?A?_
M * MK_WS1_P@?A?_ * MK_WS1]?AV8?V34_F1\YT5]&?\('X7_Z MK_WS1_P
M@?A?_H"VO_?-'U^'9A_9-3^9'SG17T9_P@?A?_H"VO\ WS1_P@?A?_H"VO\
MWS1]?AV8?V34_F1\YTH)4Y!(^E?1?_"!^%_^@+:_]\T?\('X7_Z MK_WS1]?
MAV8?V34_F1\YT5]&?\('X7_Z MK_ -\T?\('X7_Z MK_ -\T?7X=F']DU/YD
M?.=*23C))QP,U]%_\('X7_Z MK_WS1_P@?A?_H"VO_?-'U^'9A_9-3^9'SG1
M7T9_P@?A?_H"VO\ WS1_P@?A?_H"VO\ WS1]?AV8?V34_F1\YT5]&?\ "!^%
M_P#H"VO_ 'S1_P ('X7_ .@+:_\ ?-'U^'9A_9-3^9'SG17T9_P@?A?_ * M
MK_WS1_P@?A?_ * MK_WS1]?AV8?V34_F1\YT5]&?\('X7_Z MK_WS1_P@?A?
M_H"VO_?-'U^'9A_9-3^9'SG17T9_P@?A?_H"VO\ WS1_P@?A?_H"VO\ WS1]
M?AV8?V34_F1\YT5]&?\ "!^%_P#H"VO_ 'S1_P ('X7_ .@+:_\ ?-'U^'9A
M_9-3^9'SG17T9_P@?A?_ * MK_WS1_P@?A?_ * MK_WS1]?AV8?V34_F1\YT
M5]&?\('X7_Z MK_WS1_P@?A?_H"VO_?-'U^'9A_9-3^9'SG17T9_P@?A?_H"
MVO\ WS1_P@?A?_H"VO\ WS1]?AV8?V34_F1\YT5]&?\ "!^%_P#H"VO_ 'S1
M_P ('X7_ .@+:_\ ?-'U^'9A_9-3^9'SG17T9_P@?A?_ * MK_WS1_P@?A?_
M * MK_WS1]?AV8?V34_F1\YT5]&?\('X7_Z MK_WS1_P@?A?_H"VO_?-'U^'
M9A_9-3^9'SG17T9_P@?A?_H"VO\ WS1_P@?A?_H"VO\ WS1]?AV8?V34_F1\
MYT5]&?\ "!^%_P#H"VO_ 'S1_P ('X7_ .@+:_\ ?-'U^'9A_9-3^9'SG17T
M9_P@?A?_ * MK_WS1_P@?A?_ * MK_WS1]?AV8?V34_F1\YT5]&?\('X7_Z
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31110 4444 %%%% #6HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $^ W$# 2(  A$! Q$!_\0
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MQB\52J[);6+*@W.5@8A1TR?FXH^L0*_L3%>7W_\  />J*\%'QD\2G_EEI_\
MWZ;_ .*JS+\5O%D$-O+-:V*1W"&2)C$?G4$KD?-Z@C\*/K$!?V+BEV^__@'N
M-%>&#XO>(S_RRL/^_3?_ !56K?XG^*[J*>6&TLY([=-\K+"V$7.,GYO6CZQ
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MQ3ZAMO\ 5M_UT?\ ]"-6<!-1110 4444 %%%% !1110 4444 %%%% !1110
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M24\)S+9M?J=E4-M_JV_ZZ/\ ^A&IJAMO]6W_ %T?_P!"-=!\B34444 %%%%
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MR'(!RR]ZI3_$:\NI+":6WF,MM-#-(HO&\F4QX_Y9XPN2 ?8UZ]_PK+P;_P!
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M/I2R;Q80;O\ =X_+I4< \F:[3TN7/YG/]:M+)3C9I-G8N:*]UV+J.  !@ =
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M[*2![$ _S)JY5"Q_X_+KW"']#5^N^B[P1RU/B"BBBM2 HHHH **** "BBB@
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MB@ HHHH **** "H;;_5M_P!='_\ 0C4U0VW^K;_KH_\ Z$: )J*** "BBB@
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MHID<T4O^KD1_]U@:?5IWV)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH **** "BBB@ J&V_U;?\ 71__ $(U-4-M_JV_ZZ/_ .A&@":BBB@
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MIE_5FU>)T-%5[6[2Y!&-L@&2N?U'J*L5VQDI*Z.9IIV844450@HHHH ****
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M!X)]O;VH [6VN([NUBN(MWERH'7<I4X/(X/(J6BB@#YW^)4LB^,K^)EMUVL
MOD(%X(#9;'5N>2:XP#)P.M=-XYTV?3O%6HP7%P+B7S3*9 ,;@_S#CL<']*YZ
MW4&3UKZBE94XV['(MV"PD#/XUM36(MXUEE0LH8%ESC<O<5?TC09KW;<L%6W5
MLY/\7TKIM-L(+_Q-I]K*%,?F^8RD9#!06VX]\8K*==)^AG+WI)(]&M_&FA/L
MC>X>"3RT<Q2Q,&4,H(!XZX(JY!KVGW\OV>SN0\[ D HPP.YY%<!?W?@W4-7N
MW>WU.TN%<QM+"OR$K\O"@GT]*FTI[<:U8PZ>\TI24,KNN',97+,P^AQ^7>OE
MI5-3ZMY?35/FM).U]4K;?D=1KNO6=E'<Z<)YHKH0!@8\*RJQ(+(S?*S*,MCD
M\=*\MOOB/&)[-)89=0>R<,DQ*@;E1TWH2,G<2K_-TY%;?Q'N]4;2[Z.YAB2(
M\+Y<SOF$2##%-A4-D@9W ^E>.9 7.[Z^U<>(K24K(]K)\LHUJ3G4?W/R_P"#
M^9[5H'C2WNXKF_N;VXDA"*K1R*N8RH SM')9SN.%R !75!]H$ENVP,-V,?*<
M^HKPKP2TB:T9;9B&$3^:P++L7(P0RJQ'^>:]IM9;LVBM?I#'<9.Y8F)4#)Q@
MGVQ3IR]I'WD<F-PL:,[1-)+Y20LO[MCT.?E/XU3O696^88'K7.ZMXEBLR52(
M2^N6P#46D>+H+UC H^8#)MY3GCU4UQXC#\ZM!F"PU2"]IRZ%Z[FP#S5[PY8M
M/*'=>)CM_P" #EC^/ HAATR]'G!7X.&1L\&NJTFS,2M.Z;&8!40C&U1[=L_X
M5GA,,W42?0Y<3B$H-+<TZHZS;W5WHUW;V,HBNI(BL;EBNTGOD<BKU%?0GBGD
M-YX;\<Z9:S7#:G))#'&SR%;UB H&3PWM5[X:6OB.W;>$\O1I/F*SY&3ZQC_(
M->GNBR(4=0RL,$$9!%*!@8% !6)J&H:5'KEK!=2.EP@^1MV%!;H#^5;=<QX@
M\,:=>WO]JWLMT(T"B2&$9W\X'09[]JF5[:&]#DYO?;^1J+%<V>K7=PSM)92Q
MB0[Y,^6XP-JKV!'/UJ1)+>,?VA%#-(UV8PVS+8'0'&< #/.*6W-Q):W"75HJ
MJKLD2(VXO'V)ST-/@MY+>)(O/S&D6S(4*<^O' _*@3?<CEW0R.0K,C-NRHY'
MKQ4 GCD^XX)].X_"K,2&WMHXFF>4HN/,D.6;W/O5.Z*2$!XPW^T1TKFJ4K[,
MUAKH*6S2*1N%9[R21']U(<?W7^8?XTHU!1Q,A3_:'(_QKBG"<=T=/([!?2]:
MPKJ3 -:ERK2+YD1$B'NIS6%=EW?RU5BQZ*!S7CU+RJ:G?12433\-*TDYQGYI
MD&<9&!\Q_E^M=W7,^&;$V[*KCYHT+-[,Q_P!KIJ^BP,.6E?N>/BY\U5V"BBB
MNXY HHHH *9-)Y,$DF"=BEL 9)P*?4<X!@<,X0$?>/;WI/8$5XAY5O&A.2%&
M3ZGO2,U53>[4!DC=EQ_K(E+H?RYIJW<$O^KE1B>V>?RK@G4MH=48DS-49)8X
MI"<TBMA@:YG*YLE8AO'VC Z"L&X?J:T[V3K6)=/A37E8B7-.QZ%"-HES1KZ0
M3O&"28QYB>WJ/H:[@'(!]:\[T&,S7TWH5$?UW$5Z+T%>UEU^5GGXY)35@HHH
MKU#SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CJ^GC5-
M-EM2VUFY1O1ATK@Y]:G\-Z)JFGR%([TJ#&4D5BI8A"3CI@'(S73>.-2N=-\/
M_P"B2&*:XE6$2#JH.22/0X%<UX9TG3KZTU;2)B%GNH% <\L1R2P]2&P?RK*<
MG\*/5PF%C[/ZS5^%/9>35[^0:0+:+34"JO3D]S7,^*7MV#+Y;;L9#JO /U]:
MBNIM4\,2-8:I \94X24 E)!ZJ?Z=:H6UGJOB^^6TTZ!V0MB2=@1'&/4G^G6N
M.51-<MM>Q]/3H<K=;G2CO?I8["Y\5R:QH&C:?)!<->31J[OY1/F$97*_WL\G
MBMB2:VL?#AM8]/U0NKB1I'LG4%L\GVXXIOBG2],L-#TC1D4,\(V1YZ[ N&8_
M4X/UJ7PI?75]X8U2SN96G:TRD;MR2I7(!/?'/Z5K77-1E3DNC_(^;>'5EBJ;
MTYMK=+V37EY&'-JB,G_'I>_C;M7=#Q'%M'_$LU?I_P ^+_X5R,I_="O1U^Z/
MI7A</.+53E5MNM^XLR4DH7=]_P!#B?'.J)J'P^UY5M+V#9;@YN(&C!RPZ9ZU
M\UQQM+(D:#+NP51ZDU]8^+=)FUWPGJ6F6S*L]Q"5C+G W=0#^5>"6_PP\<6=
MW%<0:6%FAD#QN)XCA@<@\GU%>YB(2<DTCTLEQ%*G1E&<DG?J[=#=UWP%9/<:
M39VT*602\_L^>>)Q*TG[L,)&&>&W"08..U8FG>&=$DE@G>ZO9[*YTZZN8\Q+
M&Z-$'!R Q!^[D<\]ZOVG@WXE64\\T%JZR3SBXE8S0L6D&[#<GK\S?G26O@CX
MBV36C0690VB.D/[V$A5<DN"">0<GKGK6;5W?E.R-7ECR^W7W_P##]?P%;P7;
MWLR2/<^5%'9V38MH$0GSE)W-N<#@ Y.<GTJN_@FPCT^2Z_MM0'-P;5V$8CD6
M)BHR2^<L0<;01R*Z+2=$\?6/G"\T9KOS%A0,+J*,A(LA4(Y#*0V""/2J<WA7
MX@NM[!;Z8EM8W4CO]D26(I$&ZA,G*_AC--P7\I,<1+FM[6-M.J,?6_"-II6G
MWT]M?SS36,ENDZ20A5/FIN&TAB3CW J_HMI8VNH>%+.73K6Y&IION&G3<3OE
M*C'I@)_X\:DN/!WQ"O([I+FU:1;IHVF!EB&\QC"=#V%3CPAXV6'2?*TD176F
M;A#<+/&3M+;@""<<$M^=+E=[J)HZT90Y954WKU_NZ=MF9NGV5GK?Q"6QFMH+
M:T\^1## -BL$#$#KU.T#\:DT^PM?$IN[V2*#3+>T6-&2T4#<7) )\QP. #GF
MI$\ >-$O/MBV++<^9YOFK<(&#9SD8/7-:PT'XB_;#=F)O-9/+;YX=K+G."O0
M\\\BA1?5%3K4_L58[);[=^^_=["V.AZ?%IS(R6]VT<>I 7"@$2>6J;&'TR2/
MK69X>GMUT+5GFTRQN)+.%98WFBW'+.%(//3!K0C\,>/$1D%NP5O-!'F1?\M<
M;^_? _I4$'@CQ?;P7$$5B5CN%"2KYL?S '('7U%.STM$A5*3C)3JIW:Z^>O4
M6W\'17+6X:ZGMY'F2.:*2-"T>^-G! #D_P /1L'FH[;PS83Z7_:#:C+'"ZS,
MA>-%P$Z!LMG+'IC-:8T/X@@1C8Y\LJRDR1$Y"E02>YPQ'/\ 2KMEHOB>UT5-
M-D\/QSHBRJ-]PFQB_P#$R\Y([$$52BNQG+$R2_BIZ]&MOF8LWA6SL9K:.XOV
M>7SH$FA&P%A)C.S#$\9&<@>HJ/5M,LHM.U)K6,K]AU+R%=OO,C \'UP5X/N:
MO2^&?'$]K#;2PLT<)4IF6/<-O3YLYX[<\5-=^&_%]]8O;SZ:&DEN//FF\V,&
M0A=JC ( QS]2:M+R&JZNG*JG\UW_ ,C \*_\C7I7_7RG\Z]]KR3PWX'UZU\0
MV-S=6JPPP2B1V:13P.P )YKUNMZ::6IXV<585*L7!IZ=/4*AMO\ 5M_UT?\
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M$V^7(254&Z//>M.FNI9&56*DCAAVI-%1DUL9]_<2V:VBF\BCS*JLTJY,BXY
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MJ&4CN#7ERPTJ$5%[:[>IV>U55\R'4445 PHHHH **** "BBB@ HHHH ****
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M>K.^/PH****S*"BBB@ J&V_U;?\ 71__ $(U-4-M_JV_ZZ/_ .A&@":BBB@
MHJC=:Q865Y%:3W 6XE *QA2QP3C)P.!GN:M2W$,$1EFFCCC49+NP  ]<T 24
M4TNH!)8  9))[4V&>*XA26&5)(W&4=&!##V(ZT 245#<745M;M/(6*+_ '%+
M$\XX Y/6I&=5#$G[HR<<F@!U%9VGZYI^J320V<SR/%PX,3KM/'!R!SR..M:&
MX<\CCKSTH 6BL^?6K"WOOL4LQ$^8QMV$\R$A><=RIJ^"#G!!Q0 M%%% !111
M0 4444 %%%% !139)%BB>1\[44L< DX'L.M4M/UFQU0.;25G"':Q:-E&<X(R
M0.<@C% %^BDW#GD<=: RD A@0?0T +14/VJ#;.5E5_(SYBH=Q4XS@@<YQVIT
M,\<\$<J$A74, P*G!&>0>10!)152PU*UU.!IK5V:-9&CW,A4%AP<9ZCW%3S3
MPV\3RSRI%&@RS.P 4>I)H DHI RL 58$$9&#U%0"]@-^;$/FX$7FE<'[N<9S
M]: +%%%% !1110 4444 %%%% !14%Y>06%LUS<,RQ)]XA"V/P )IECJ%MJ-N
ML]K(7C;[I9"N>^0"!D>] %JBD+J!DL,>N:-R^HZ9ZT +14<4\,\8DAE22-C@
M,C @_B*9->P075O;2/B6X+"-<9R0"Q^G - $]%)D9QD9ZXJE?ZQ9:;G[5*4Q
M"\_"D_(F-QX_WA0!>HI%(90PZ$9%+0 4444 %%%% !156_U"VTRU-S=N4A7[
MS!"V.^3@' XZTME?VVH6ZSVSEHW^Z64KGW (!Q0!9HII=0,EACUS2EE R6
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MEJK6VDQ^0T*6UN('2WEC!60-GS02/XL9R/FK8TG0KZU\2K=7%M'MC:Y9[OS
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #[ 9@# 2(  A$! Q$!_\0
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M N453^UR_P#/A=?^0_\ XJC[7+_SX77_ )#_ /BJ +E%4_M<O_/A=?\ D/\
M^*H^UR_\^%U_Y#_^*H N453^UR_\^%U_Y#_^*H^UR_\ /A=?^0__ (J@"Y15
M/[7+_P ^%U_Y#_\ BJ/M<O\ SX77_D/_ .*H N453^UR_P#/A=?^0_\ XJC[
M7+_SX77_ )#_ /BJ +E%4_M<O_/A=?\ D/\ ^*H^UR_\^%U_Y#_^*H N453^
MUR_\^%U_Y#_^*H^UR_\ /A=?^0__ (J@"Y15/[7+_P ^%U_Y#_\ BJ/M<O\
MSX77_D/_ .*H N453^UR_P#/A=?^0_\ XJC[7+_SX77_ )#_ /BJ +E%4_M<
MO_/A=?\ D/\ ^*H^UR_\^%U_Y#_^*H N453^UR_\^%U_Y#_^*I]M<_:!(/*>
M-HVVLKXSG /8GUH LT444 %%%% !1110 4444 %%%% !1110!3U3_D%7?_7%
MOY5)=74%E:R7-U,D,,8W/)(V%4>YJ/5/^05=_P#7%OY5QGQ6T*+5_"-W=7%U
M<K%9PM(+:-]L<C\8+^N/2@#L;S5+#3['[=>7D%O:8!\Z5PJ\].32?VQIITO^
MTO[0MOL.W=]I\U?+QZ[NE<-JL*7WB3P+8W,:R6A@>8QN,JSK$-N1WQ7+/!'_
M ,);)X>$:_V.?$Z,;<#Y.8=^W'INYQ0![)IVJ6.K6HN=.O(;N G'F0N&&?PJ
M[7G6G^9HWQ \4P:38K(ILX+E;2,B-6EZ?09K1TSQ?K,WB2STC5_#;::;N.1X
MI/M2R9V#)& />@#M**** "BBB@ HHHH **** "BBJ>H7PT^T:X-O<3A>J6Z;
MW_*@"Y169H^L1:U:_:8;:[AC/W3<1;-P]16G0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %4[3_ (^K[_KLO_HM*N53M/\ CZOO
M^NR_^BTH N4444 %%%% !1110 4444 %%%% !1110!3U3_D%7?\ UQ;^50:[
MI$>O:)=Z7+*\4=S'L9TZK]*GU3_D%7?_ %Q;^57* .:UKPG%JUAIT<5]<6=Y
MII5K6\A"ET(7:<@\$$=15 ?#VR&@/8MJ%V;UKO[<=2ROG?:/[_3'3C'3%=I1
M0!SOAOPRNARWEW/?3ZAJ%ZP:>ZG"@L ,!0%X %<_>6^J1?%G1)+V_BN+62*Z
M^S0I!L:(;5ZMGYJ]"KS)H]$3XS::^G7XGOFCNOMD(N-_E':,?+_#0!Z;1110
M 5@>(;K4++[(]I>VMNDLRPL)X\\L>H.16_7C/QN\(>(?$=UHTVDMYD"-Y+1;
M]NV1CPU 'L,*R+"@E</(!\S 8!/TJ6O/M/\ !?B:/3[:*[\<ZB'2-5=(H8\
MXZ!NIJ\/ MVW^O\ %^N/_NS!/Y"@#LZ0D#J:XX_#JQ?_ %^LZ[-Z[[YJ8?A;
MX;?_ %POYO\ ?O9/\: .N>ZMX_OW$2_[S@5B>(O%NBZ!HMS?7M]#Y4:$;8W#
M.Q/0 503X7>$%ZZ5O_WYY&_FU5-9^%7A#4-&N;9-)BMG9#MGB!WH1W&: +?P
MZ\4:9XF\+PR:<[%K?]U+&XPR'_"NQKROP?\ ";0K+P_;317-^EY*-[7,,YC;
MZ8'%;A\/>,M,.[2_%2W<8Z0:E;AOPWKS0!W%%<5_PDGBW3^-5\(M<H.LNEW*
MR_\ CC8-20_$KPUY@AO[FXTJ8_\ +/4;=X/U88_6@#L:*J66HV6HQ"6RO(+F
M,C(:&0./TJW0 4444 )28%,9@H+,0 .236%:^);>X\0W>F;H0L,,<JR^8/G+
M%AC\-OZTKI%1A*2;2V-\CBD' Z5RWCV^NK#PO-/97#6\IEB02KC*AG4'K]:Q
M+/6I]!\426=WK3ZAIZV374S2[2]N5([J.A]*3FD[,VAAY3ASI]]/0]&Q17)6
M7C>&>\A@N-.O+3[4C26S3 8E"C)'!.TXYP<54MOB+:SI:W+:9?16-Q((A=N@
MV*Y.!GG.,]^E+GCW%]6J_P IV_2C KA[3Q5J4OC74-+;3YC:QK'L<!?DSN^=
MCGE3CCOQ2V'BJVL/!]G>,][>R7$[PP+( 9IGWL,<<=ORIJ:8Y8:<?G;\3M3S
MCVH Y->>Z3XF+^+-8N[Y;FSM[6RC:6&X_P"69!;) '!R.XK8L?&<-S?6UO=:
M=>60NT9[:2=1B0 9(X)*G'.#0JB82PM2+M:^AUH.:.U<UH'B@Z_(KPZ==16<
MB%H;ERNQP#CH#D?C72YX-4FGL8RBX/EEN.HHHH)"J=I_Q]7W_79?_1:5<JG:
M?\?5]_UV7_T6E %RBBB@ HHHH **** "BBB@ HHHH **YKQ1K<N@"VN5O=.C
M1B5:WO',9F_W'&=I'N".>U<YX2@;_A,9[B>_EAN95DD-G<+()9E9@02Q<QNJ
M] 8Q]: .\U3_ )!5W_UQ;^57*IZI_P @J[_ZXM_*KE &)XB\2V'AJSBFO?.D
M::010P01[Y)6]%7O5%?'NA/X;;7/-F%NLOV<PF(^<)LX\O9_>]JQ/B&D][X@
M\,:=82I9ZB]R\T%[(-RQ;5Y&W^(D<8KCM/5K/5;*QOY$FEL_%&Z^O ?W=Q(\
M9*MC^''3% 'K/A[Q+8>)()VM%GBEMW\N:WN(]DD;?[2UREQ>)/\ %_2(%TB:
MT:&.ZS<O$JK<?*O*D<G\:ELS=/\ $KQ4VD?9VF6QMU_>D^7YW/WMO/2H%/B0
M_$KP[_;ZZ6!Y%UY7V%I#_"N=VZ@#TFBBB@ K)U;1O[5>$G4+RV$3!U6W90"P
M.03E36M10!##&8H$C:1Y&48WMU;W.*FHHH **** "JE];275H\,=S);,W62,
M L!^(-6Z* ,W1]+;2;(6OVR>Y1!A#*%RH]. *TJ** "H9X(KF(Q3PI+&>JNH
M8'\#4U% ')WGPX\*7DK3#2([2X)SYUDS6[Y]<H15&X\(ZYIMK,^C>,=1"JC8
M@U)4NDZ=-Q ;]:[JD//6@#YB^%'B._TWXC,NNWDB6UP'BWW!;RUDS\H4GA<]
M*^G<Y%4-0TFPU2PFL;VUBFMYEVNA7K_]>N0BO;_P!.MIJDLM[X;<[;>_;YI+
M/T27U3T;\Z .XFA2XA>&5%='!5E89!!ZBN0M? &DP>(;F]?3;'[*T40@B$0_
M=NI8LP&,#.1^5=A%*DT221.KQN,JRG((]<T\'WI-)[EPJR@FHNUSF?'&DW.L
M>&9;&UA$TCRQ$H6 R X)Z^PIFH>$+%_"^H:5IEI;6<EU$5W1QA06[9Q74G&.
M:.*3@F[E1KSBDHO9W/,]'T P2PR7/A>2VF@B?==M?%T5MI&47<>OT&*SM%M-
M>U[P7I>C)IL:61=':]\X8\I7W8V]=W&*]9<*R%6&01@@]ZAL;.WL+6.VM84B
M@C&$1!@ >U3[+4Z?KLK.ZUO=;Z'+?8-5L?'5U>16'VBROX(HGF655\DIGD@\
MD<]JR(?#>M6?AG1'BM$>_P!,O))VMFD'SHS/P&Z9PP->D$@ THP1GTI^S1DL
M5-=%T_ \VF\.ZWKUUKLMY9)8K?6*P0 RARK D_-C^E/T#0);>_M9)_"C0W-N
MC'[2]_O0/MQ\HW'K].,UZ*,]11@9SZ4>S5[E/&3::M9'G_AG1M3MO$HNH=,D
MTBP:)OM%N;D21RR'H44$@=^>/I7H7:CI[4M.,5%6,*M5U'=H=1115&853M/^
M/J^_Z[+_ .BTJY5.T_X^K[_KLO\ Z+2@"Y1110 4444 %%%% !1110 4444
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M5$/4$D=,>M>9>$/$>B:-JB)>QWC2VR- VH6\_P!KL_,EDW/(TB@8=FV@_04
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M#G\Z /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Q?QI\)[WQ#\2(]=@1OL3-&UP/.4,Q4#[OITKV5%VHJ],#%/HH ****
M "BBB@ HHHH **** "J=I_Q]7W_79?\ T6E7*IVG_'U??]=E_P#1:4 7****
M "BBB@ HHHH **** "BBB@#E?%^HF"V:P>/2Y8;FUF:6._N#&K*H4>GW<MR>
MW%8_@?PY>Z/J\T]QHUA;*\!07$>IRW4@&1A!O^ZOT]!5WX@Z)#K.F;KJPL)[
M>VAED-Q=7#0F!L#&& Z''/TK&\":=#8^)9%&D:'8S-8B4&RO9996C=AM.UQC
M:<=?IZT >A:I_P @J[_ZXM_*KE4]4_Y!5W_UQ;^57* *&K:E;:/I=SJ-TVV&
M!"[>_L/<]*Y"W^(4ESX)TW6H],)OM2N/LUM9;\9?<1\S=A@9-2>.=,\1:EJ&
ME_V98VE[IMLQFGMY[DQ>9(/N9X.0.N*X/19KVV\(>&=8U2UC@T_3=9=WEC<O
MA&9P788X 8XH ]1\->([G5KN_P!,U*Q6RU.Q*^;&C[T96&593Z5A7J:NGQ9T
M-KZ>TDLVBNOLJ1(0ZC:N=Q/7\*BT,P>*?&?B34M-NY?[.EM8;1+VV;&YQRQ1
MO;UJK;Z=:Z;\4="AAU^\U.98+E98[JZ$IB^4=A]V@#U&BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JG:?\?5]_UV7_T6E7*IVG_'U??]=E_]%I0!<HHHH **** "BBB@
M HHHH **** ,3Q3:6-]X6U*VU*Y^RV;P-YL__/,==WX>E<GX,FCU;Q!'J5YX
MA&HWJ6<D5K"-/-IB+S '8@]3N4<=O3FNI\9FQ'@_53J:S-9>0WFB#_68[;??
M.*XKP%:7UGXI:/Q!%JJZC);S36?VIXF38SJ93^[Z.3LSG\* /1]4_P"05=_]
M<6_E5RJ>J?\ (*N_^N+?RJY0 5%Y,?EF/RUV'JN.*EHH BABC@C$<2(B#HJ+
M@5YS+<:5+\8]+CL].>WO$CNOM,YM?+$QVCG=_'7I=>?7LNJO\6-$2^M;:*T6
M*Z^RR12EG<;5^\,<4 >@T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[3_CZOO\ KLO_
M *+2KE4[3_CZOO\ KLO_ *+2@"Y1110 4444 %%%% !1110 4444 <QXLU&P
M"6^@WL5U(-6$D;_9SM,42C+R,W8 8_.N!\):9H>LZU!M3Q-9-+;^?87$^I,P
MN8$<#L<J,[3M/8UZ#XG\)6OBA8/-N[NSFA#H)K5PK&-QAT.0>&%+IOA.STS6
M_P"TXYIG$-HMG:6[$>7;1 #(4>K%0230!KZI_P @J[_ZXM_*KE4]4_Y!5W_U
MQ;^57* .<\2-XBDEL;/0%AB$\A^TWTR!Q;H!V3(W$]*X^/QOK[6DFD)+93ZP
M=7_LR&^6,^2PV[F?;GJHXQGK6O\ $C5M;L[&UL-&L;^7[8^VYN;.'>\,7\6W
M_:/:L+[*/^$?T>\T/PYJ=O'H-^LK6EQ#MFG5@0[C^\W.: .I\,:SJG]NZIX?
MUN>"XN[)8YH[F&/RQ+&_JN3@@UFW=I>0?%G0YY]4:[@FBNC# 8U40#:O (Y/
MXT:!IS>)]?\ $&LZEID]OI]]!'9Q6]VI1Y$7[S$=N:R[+3_"NE_%C2+/P[;Q
M0W,4-RMVD>[CY1C.[^E 'JU%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 RE-%<IXXU^_T#1H9]-ABFN9;A8E23)!SGCZ\4I245=E0@YR48[LZNDK
MC7\9M<VF@75BJ>7J%VL,RN.4X.X?4$5I:EXQT32[MK6\O DJ -(H5F\L'H6(
M'R_C2YD6Z-1.UM3H".M-*\&HDN8YK5;B%U>-U#*RG(8'TKSEO&/B*#2KK776
MPET^WNGB>W"LLFQ7VY#9QG\*;DEN%.C*I>WH>G?7K2<]ZY^\\8Z)IUS]GNKT
M)*JJ7&QB(P>FX@87\:+[QEH>F3M!<W@$P17V*A8[3T(P.E+FCW%["II[K.@'
M3I2_2N.U?Q]INF_V7)"XN(;Z0#S$#$*G.6&!R<C&.M7K36_M.O-$M] ;4V:W
M"P>61( 3]\D]O;K1S*]ANC-*[5D=$>.^*.M<%JOCRSN;O2[?1[]6>2^CBE_=
MG#QG(."1R/<5O7_C#1-,NVM;J]"RH 7 0D1@]-Q POXT<\>XWAZBM[KNSH/J
M*6N?N?%>D6-ZEI-=9F8*<(C.%#="2!QGWK>W9&:::>QE*$HI<RM<?1113$%4
M[3_CZOO^NR_^BTJY5.T_X^K[_KLO_HM* +E%%% !1110 4444 %%%% !1110
M 4444 4]4_Y!5W_UQ;^57*IZI_R"KO\ ZXM_*KE !1110 5Y[>75U-\6M&BG
MT=[2***Z$5R9$87'RKR .1^->A5Y]>Q:LGQ9T1[ZXMI+-HKK[*D495T&U<[C
MWH ]!HHHH ***\D^(]\Z:]<0ZAJ-Q8V\-BLNG(ETULEQ-N.[+@'+*,87O0!Z
MW17FWAOQ)XY;P[8RWGA3[6YB!,OVU4=QV8JPX-:W_"7>(T_UO@/4_K%=0/\
M^S4 =G17&CQS?)_KO!?B%/\ <@1_Y-2'XB6R#]]X>\20_P"_IK?T- '9T5Q?
M_"S= 4?OH]4@_P"NFFS?T6LSQ#\8- TW2S+IKO>7KL$B@DBDA&?4EE'% 'H]
M%>9>$/B_I.L131:W<6.EWD1! ^T9CD4]U)[^U=I#XM\.W'^IUW36_P"WI/\
M&@#9HJG'JFGS?ZJ^MI/]R93_ %JT&5AE2#]* '444QW6-"[$!5&23V% #L5R
M/C>WFN8-($,,DFS4X68(I.T G)/M6EIGB[P]K-X;/3-9L[NY +&*&4,V!U.*
MV3[TFKJQ4)\DN;L>5ZEH-_IGCG3$M;>232[F^6[RBDB"3!#@^@.<_G5F*[/A
M_4/$EM?Z=>7$M]<-- T5LTBSHR@!<@8!'3G%>E@ <GJ*"JDY(%1R6V9U?6W)
M+F72WXW,#PCIUQIG@W3K*Z&+B*$!USG:3SC\,XKEO"G@ZWO[.:YU1;L[;^9U
MM9798N'.&V=#ZUZ1U/TI%(VY&*KD6GD9+$S7-;1MW/)+JQ>RU?7K74[C5H(;
MV=I(_LEKYJ3HR@8SM8AATQQ5BUO[7P]XRN%:RO)X5TVWB2183(\> <!@.03_
M $K?U;XF>'-(UI],N6N'>)E2XFCBW1P,>@8Y_EG%=';Z19)JUQJ\19IKJ)$8
M[LJ57.,#\:AT]=#H6,NFI+I;\CS>/3[W2?#>@7UQ8W C@U5KJ6!(RSPQ,7Q\
MH],C\ZU=1M+K5O$>J2VD$JK=:%LB=T*_,S'"\]#[5Z+M4\4N,=*?(9RQ3;YK
M:GDINC?V?A6Q@T>]CFL+J'[0S6[*L6.",D<@GGBF7-H]IJGB"UU.XU:"&]G:
M2,6MMYJ3HR@8SL;!&,8XKUP >U!4'KS1R%+&6>B_'SN>4WR'1-0B.@+J:ZD(
MX(C;RVK/%<H  "S8PI /)R.E>IQDM&"PPQ'(IY4<'BG#I5Q7*85:WM$DUJNH
MZBBBF8A5.T_X^K[_ *[+_P"BTJY5.T_X^K[_ *[+_P"BTH N4444 %%%% !1
M110 4444 %%%% !1110!3U3_ )!5W_UQ;^57*IZI_P @J[_ZXM_*KE !7'^.
M=2O[=-(TK3;EK6XU6]6V-PHRT:8+,1[X%=A7)^-=)U"]BTO4-*MTN;[2[Q;E
M+=G"><N"&4,> <'O0!1\.ZI=:/X@UO0=7U-[NWL8H[J&[NB XC;J&/?![UA7
M5_X<M/BEH^J0:Z)5GBN3,9;S?'$=HP%!.%S[5T'AW1[_ %+7=9US7M+2T6_C
MCMXK&5UE(C3N^,KR>U;A\'^&R0?[!TW(Z?Z,G^% "?\ "8>&_P#H.6/_ '^6
MC_A,/#?_ $'+'_O\M/\ ^$1\.?\ 0!T[_P !D_PH_P"$1\.?] '3O_ 9/\*
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M444 %%%% !1110 4444 4]4_Y!5W_P!<6_E5RJ>J?\@J[_ZXM_*KE !1110
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M7.#@#CTK'LO"6@Z?KW]LQ^(=3DO20',NIEA(H.0C#NHSTKN<48H I_VE8_\
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M1*OXHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#EHM-N+>'5O*G?4X]2BE2T0+%(@ P$!QMXZ5-)X"9)3=VFKRV^I+J$U_%<K
MK!3*JJZ%"?F4[: .CT/6[3Q!IWVRR\P(':*2.5-KQNIPR,O8BM6L3PYH,?A[
M3I+9;B2YFGG>YN+B0 &65SEFP.!]*VZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'M Y$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF=J=U<****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.[BL]-#117;E49]V'< *V6Z?3=[U+/IUSIFAQ03B!(SJ]N\,$#EEA4R)\H)
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M&QT"PN39P+',]W)Y<<:L"P50%8CCG( 'OQ63;:=9:Q#X&EU*TANY)[5EE>=
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M/[W<X9ML@//W<C()' X%95AI=_K.BW5P+/36NY9YB;V6=Q-%(KL%/"?+MP,
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M* ,NV\.Z/:7+7$&GPI*6W[@/NG.?E'1>?3%69-,LI8[B.2UB9+EQ),I7B1@
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M 'HW^] $N:,U%O\ >C?[T 2YHS46_P!Z-_O0!+FC-1;_ 'HW^] $N:,U%O\
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M4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\
M9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\
M]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_
ML]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^
M>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:
M!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7
MFT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;
M4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\
M9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\
M]&H_L]?^>C4:!9D7FT>;4O\ 9Z_\]&H_L]?^>C4:!9D7FTHDJ3[ O_/1J46*
M_P#/1J- LQ@DIX>E%DH_Y:-22P"*,L&)Q2'J+OI"]0;Z?$HE8@DC%,5QQDII
MDJ7[(I_C:D^PJ?\ EHU&@[,A\VCS:F^P+_ST:D_L]?\ GHU&@K,B\VCS:E_L
M]?\ GHU']GK_ ,]&HT"S(O-H\VI?[/7_ )Z-1_9Z_P#/1J- LR+S:/-J7^SU
M_P">C4?V>O\ ST:C0+,B\VCS:E_L]?\ GHU']GK_ ,]&HT"S(O-H\VI?[/7_
M )Z-1_9Z_P#/1J- LR+S:/-J7^SU_P">C4?V>O\ ST:C0+,B\VCS:E_L]?\
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M ,]&HT"S(O-H\VI?[/7_ )Z-1_9Z_P#/1J- LR+S:/-J7^SU_P">C4?V>O\
MST:C0+,B\VCS:E_L]?\ GHU']GK_ ,]&HT"S(O-H\VI?[/7_ )Z-1_9Z_P#/
M1J- LR+S?>G"2I/L"_\ /1J46*C_ ):-1H%F-$E2*U M /XVICKY3A0<\4AD
MNZBHMU% RT::>E.--;I2&0N:K[OWB_[PJ:2JQ/[U/]X52(9J4R66."%YIG6.
M)%+.[' 4#J2:?61XJ_Y%#6?^O*;_ - -**NTAS?+%OL3V>N:3J!<6>I6LYC7
M<XCE4E1ZGGI26>OZ/J$X@L]3M)YCTCCF4L?PS7 Z%H.HWEMIFLW%M:V5M9:8
MZ1^2^Y[G='@%L# '.<>M9/AB&02>#FU!+>*Q:21K6>"/$C2@G"2L>Q[8KK]A
M#6SV_P"#_D<"Q53W;QW]?+[M_P"KGJTFN:5%;/<2:C;+"DODM(91@/\ W2?7
MVJ:XU"SM+,7=Q=0Q6Q (E=P%.>G/O7DHMX[K0FMIE#12^+!&X/<'(-,NGN=2
MT>;PW<AROAZWNI+AV'#E%*P_H<_A3^K+O_PVG^8OKLK;=-/77]$>N3ZG8VUB
MM[/=PQVK %9G<!3GI@^]%UJ=C96BW=U=PPV[XVRNX"G/(P:\UU.YCOK/POHS
MV5W>V\5@EW=0VD>]CF/:G&1P"2?RJL;^XOOA]I-E(H6_L=7@M&2X4\$$[=PZ
MXP0#]#4K#[:]?\_\BGB]6DNGXZ7_ #/3$U[2)+87*:G:- 9!$)!,I7>>BYSU
MJU]LMOMOV/SX_M.SS/*W#=MSC./3->=:/HD6KS>+=/U,10:G(45XK=-L2 +F
M.1!UZ\__ *ZU?AQ!+=Z=<:_?2":_O'\IGQ]U(_D _$@FIG2C%-WV_4TIUYRD
MDUO?\-_T.EO/$.C:?<M;WFIVD$RXS')*%89Y'%6$U*QEOFL4NX&ND4.T(<%P
M/7'XC\ZX4QS/\2]>\J33$ BMM_VZ(OD;/X?F&#_]:J&J6L\?C#Q#KU@"UWI,
MMK-L7_EI"8B)%_(9_"FJ,7I?H2\3-:VZM?)7_P CT.77=)@MA<RZC:I 9#&)
M&E 4L.HSZC%20:MIUS9R7D%];2VT8)>5)054#DY/:O)X;FVE\/\ AVZD9%M7
M\0/(QEP $+D_-GCI5[59;*XUOQ-+HAB:Q_L-Q=-;_P"K,O.WIQG']?>J^KK;
M^MTOU(6,EO9=/75-_=H>D6.M:7J<C1V.H6URZC++%*&('K@57/B?0UU'^SSJ
MUH+K.WR_-&<^GU]JX71=#U:ZL=/UHVMM9)9:9(EO]G;=+<LT9"EL#CKG')S5
M=V\/'X/*J?9#>-"%QP93<9Y_VLY_3VI>PA>R=^@_K-3ENTEI?6^NVQZ=)J5E
M%-+#)=PI+#%YTB,X!1/[Q'8>]-75M.:SCO%O;<VTC!$E$@VLQ.  ?7/%>;7:
MS)K&MK<Y\\>%<29Z[MHS^M9-PDNAZ;I6F$,;#4WL[ZV/:.3Y?,7\<@TUAT^O
M]6%+&23>FFOYI(]4D\5:!#(\<FLV*NC%64SJ"".H/-:J.LB*Z,&5@""#P17&
MWMG:GXI:>AMH2K:;*S*8Q@G?U/O79@!0   !P *YYQBDK=3KI3E)RYNCL+11
M169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5[TXMF^H_G5BJU__P >C?4?SIH3V,_?5BR;
M+M]*HYJWIY_>/]!5,S3U-,#B@NH."P!]S0.E>:W^G)JGQ'U>*;2#J:)# =IN
MO*$61R>O/_UJ=."E>[V%5J."5E>[L>E9!Z$<4;UX^8<].:\I\:SR:-XCN[;3
MKIXK;4;:-=1(!86R[@@D]B1Q^/TJ7Q'964/B_3K :==ZA:1Z45A@M6.[(;Y6
MSD?G[ULJ%[.^^ISRQ=FU;9V^_P"7];'J61G&>::SJ@R[!1ZDXKSS2[;4K#6O
M!-KJDCM=K;WGF!GW$?*"H)[D# J9--M/%7CS7+?6E-Q!8+$EM;,[*JAADM@$
M9.>]0Z*3U>F_XV+6(;2M'5NVOI<[XL ,DC'K2@@C(.17C=U),OA;4=-5I+BS
MM->2WM@TARR9/[O=Z=OQK;\-7Z:+#XJOS&UE;VFT+ICRF0PN%ZY/]X],?TJY
M8>RNG_6G^9$<6G))K^M?\CTC<,$Y''7F@.I. P)]C7D7@]].N-8_L:[NS?PZ
MM:+/<*S,NVY4EBN>.Q[>E.M+2#2O"?BK5K*,QW]G>SVUO,'8F.,E5P.?1CSU
MIO#V=K]NG?04<8VE)+37KV5_R/6@Z,Q4,I8=0#R*7<N<9&?3->9:[H&G>&]$
MTG6-',B:C]H@'V@2DFXW==V3@YK"U\9UGQ1,UI(S)=Q1QWXG919%OXB!R1^%
M*.'4MG_5[!/%N&DHZ^OE?L>U9!SSTHR,9R,>M>:^)+/5-+U6&'3KK?\ \)#
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M-8C]LG$B22EV)8"1@!@G'85V]8U(J,G%=#II3<X*;5KA1114&H4444 %%%%
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MGJ >N*EHHI#L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !574/\ CS;ZC^=6JJZC_P >
M;?4?SIK<3V,@'BK>G?ZV3Z"JG:K>G?ZU_H*M[&2W-4=*Q;OPKIMYJ<VHLUY%
M=3*JR/;W<D6X#@9VD5LCI3JE2<=C248R7O(R!X:TLC4=]N9#J("W+2.6+@#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_054[5;T[_6O]!5O8R6YJ#I3J:.E.K,V"BBB@ HHHH **** "BBB@ HHHH
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MV7_O\_\ C1_9EK_=E_[_ #_XU<HH I_V9:_W9?\ O\_^-']F6O\ =E_[_/\
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M9?\ O\_^-7** *?]F6O]V7_O\_\ C1_9EK_=E_[_ #_XU<HH I_V9:_W9?\
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MA_N?J:/LT/\ <_4T 2T5%]FA_N?J:/LT/]S]30!+147V:'^Y^IH^S0_W/U-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6?>_\ 'RO^[6A6?>_\?*_[M-$RV(Z***HDTS3&IYIC5!97DJJ?
M]<G^\/YU:DJJ?]<G^\/YU2)9K44A 8$$9!X-1?98/^>2_E4EDU%0_98/^>2_
ME1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5
M$U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_
ME1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5
M$U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_
ME1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5
M$U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_
ME1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5
M$U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_
ME1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5 $U%0_98/^>2_E1]E@_YY+^5
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MRG!;YI 4P,X #9((H [^BN:UW7;O3->L+19;:*TN0J!V7S'\UFVJI4,"%/\
M> ;G.<8S6#_PF^KW4, M8;2.5;FUTZZ\V-B$NG<K*HPPX4!2.?XA0!Z'17GV
MK>)-4_LV6QEO--M9_(OO-N)8V"3>2^P*@WY5B&R>3CMFF6WB36+'0?.B-F;2
MSMK&!?,1BP>5(\R.VX (F_<>Y&>1UH ]$HKC8->UF[D^PVMWIDLXU VOVU(F
M:)D\@RY"A_O X!&[%8\?C[6X=%&HW-M93&?3#>0QP*R^6PF2([B6^9?G#=L8
M(SWH ]*HKE-/U[5+CPOK-[<0()[193;NFW]Z!'N!*J[[3G(QN[9[UBV%UJEM
M=Q6VG[9HE\-V\S+/=N@5RTF7&%;+'')XZ#F@#T6BN T+Q/J:VV@Z5($FN;ZU
MLIH)I-S%XC'F=F.>6&P\_P#31<^]2'X@:H-*BO6?3+IKBR\_R[<,/LC>;''F
M4[CE?WA8]"-A'O0!Z517GNH>-M4TR"X*2:;J1M[GR"]NC .&BW[\!FQY?5^O
MR\\'BH[GQ==V#ZQ''<0?:EU 10D1-(LP%I'(Q :1509;/WNG0$DF@#T:BN3N
M/%4I\%Z/JZM';76I1PLB>5YHW.F\J,L@Z \E@.*Q_P#A,]=G\/?VM;IIZK;Z
M6+^>-T9O,8.ZE5(;"@A#SS@XZT >B4@8%BH(R.H]*\[O?$%UJ7B73X7N;2&&
MWUXVRV@R)R$B<[R=W*G.<;>F.:EMM7N4FCO8;JSLVUV::=+N]3*+!$ L2 ;E
MR67Y^O0M0!Z!17'>'/$>L:_J=N&CM;6U&GP7<T9C9I':1I5^4[@ O[L,,@G!
M_&J6MZCK$,7BS[,4^SPW$064W;I)"##"2$4*1W)^\.2: .^HKAKWQ?J=M/JM
MDL-L+O2XKJYG9U;:8E0- >O&[<,]?]6_3M$?&.HI<&R^VZ3*9;F")=0B5O(A
M$D<CD,-W+#RP!\PSO7/H0#OJ*\^A\4:K+>6-W)>VGD+!?!H(H_EO'@D508V+
M9&X= ,XY^]1IGC#7-1TDW"162O,]F(7=1M4S/M8%4D8D 8()VY].* /0:*X/
M_A+]3MV@%Z]G'#%?36=U/''EG*R*J%8RX(!#<D;L''&#27'B>^M%FB@N=/L_
M+%[<E[S<XF\N=T"+EQC@#//&1@8H [VBN&MO%>M7=^TH@M;>SCN;*&2VEC;S
MA]HCC8@MG *M)Z<X[5L>$)G:RU*W;/EVNIW,$1))^0/D#)]-Q'X4 =#1110
M4444 %%%% !17EVJ3W>F>)-?UJ.65[6*9;2[CR2%B>)=K@=MK8_.I=/UO4O[
M,T[3[;5(-.6WT5+LS7$8?SFQC'S=ACG'-=/U=VNF<?UM7::_J]OT9Z917F\W
MB?Q!>VT]U:W<%HL&CQ:@T9@#[G(8E03T!Q_*GW7BKQ'>7\@TJ#(M[:VG,*B+
M8_F*&;>SL"!@X&WTI?5Y=T/ZW#LST6BD!)4$C!QTI:YSK"BBB@ JKJ/_ !YM
M]1_.K55=1_X\V^H_G36XGL9':K>G?ZU_H*J=JMZ=_K7^@JWL9+<U!TKS7QCJ
M9TKQ)?I<>(]9M;>:P$I2RA@Q"JK*Q 9OFW,$?;CN.3TKTH=*\7\43:_?ZW?S
M3Z+>7,MK)<"Q4^'4N$^1AY*K*RD[7Y9CVXQBLS8]EMF5[6%E9V4HI!?[Q&._
MO6/K>D7M_K6B7UJUJJZ?</+()0VYPT;1X!'3AR?J!6S SO;Q/(FQV0%E_NG'
M(J2@#!T#1+G2+N_)F5+*8@P6L<CNL1RQ9@7/!;<.!QQ[UJ?8F_Y^[G_OH?X5
M:HH J_8F_P"?NY_[Z'^%'V)O^?NY_P"^A_A5JB@"K]B;_G[N?^^A_A1]B;_G
M[N?^^A_A5JB@"K]B;_G[N?\ OH?X4?8F_P"?NY_[Z'^%6J* *OV)O^?NY_[Z
M'^%'V)O^?NY_[Z'^%6J* *OV)O\ G[N?^^A_A1]B;_G[N?\ OH?X5:HH J_8
MF_Y^[G_OH?X4?8F_Y^[G_OH?X5:HH J_8F_Y^[G_ +Z'^%'V)O\ G[N?^^A_
MA5JB@"K]B;_G[N?^^A_A1]B;_G[N?^^A_A5JB@"K]B;_ )^[G_OH?X4?8F_Y
M^[G_ +Z'^%6J* *OV)O^?NY_[Z'^%'V)O^?NY_[Z'^%6J* *OV)O^?NY_P"^
MA_A1]B;_ )^[G_OH?X5:HH J_8F_Y^[G_OH?X4?8F_Y^[G_OH?X5:HH J_8F
M_P"?NY_[Z'^%'V)O^?NY_P"^A_A5JB@"K]B;_G[N?^^A_A1]B;_G[N?^^A_A
M5JB@"K]B;_G[N?\ OH?X4?8F_P"?NY_[Z'^%6J* *OV)O^?NY_[Z'^%'V)O^
M?NY_[Z'^%6J* *OV)O\ G[N?^^A_A1]B;_G[N?\ OH?X5:HH J_8F_Y^[G_O
MH?X4?8F_Y^[G_OH?X5:HH J_8F_Y^[G_ +Z'^%'V)O\ G[N?^^A_A5JB@"K]
MB;_G[N?^^A_A1]B;_G[N?^^A_A5JB@"K]B;_ )^[G_OH?X4?8F_Y^[G_ +Z'
M^%6J* *OV)O^?NY_[Z'^%'V)O^?NY_[Z'^%6J* *OV)O^?NY_P"^A_A1]B;_
M )^[G_OH?X5:HH CAB,2D&223)SESDU3O?\ CY7_ ':T*S[W_CY7_=IHF6Q'
M1115$FF:8U/-,:H+*\E53_KD_P!X?SJU)54_ZY/]X?SJD2S6HH) !). .YJ/
M[1#_ ,]H_P#OH5)91O=!TZ^TV\L&MTA@O 1<>0JH9 >N3CG(X/L:NM;6[RQR
MO!&TD0(C<H"4!X.#VS2_:(?^>T?_ 'T*/M$/_/:/_OH4 1Q6%G!$L4-I!'&K
M^8$2, !O[V!W]Z!8V:G*VL .0<B,=0Q8?^/$GZG-2?:(?^>T?_?0H^T0_P#/
M:/\ [Z% $<MA9SQF.:T@D0OYA5XP06_O8(Z^]3&*-MF44[#E,C[IQC(].":;
M]HA_Y[1_]]"C[1#_ ,]H_P#OH4 1M86;2RRM:0&29=DCF,9=?0G'(]C2_8K3
M[2ES]EA\]%V++Y8W*OH#U ]J?]HA_P">T?\ WT*/M$/_ #VC_P"^A0!7.E:<
M8I(CI]KY<IS(GDKA^<\C'/))J5[*UEEBEDMH7DA_U3M&"4_W3V_"G_:(?^>T
M?_?0H^T0_P#/:/\ [Z% #7M;>2XCN)+>)YX@1'(R LF>N#U%5K+1[.QCF5(_
M,,MRUV[2X8F1CG/X< >@ JW]HA_Y[1_]]"C[1#_SVC_[Z% #)+&TF"B6U@<*
MYD7=&#ACU8>_/6G+;6ZHR+!$$8!64(,$ 8 /X<4OVB'_ )[1_P#?0H^T0_\
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M!QS33IMB8_+-E;E-ROM\I<;@  <8Z@  ?2IOM$/_ #VC_P"^A1]HA_Y[1_\
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M#[%:?\^L/_?L4?8K3_GUA_[]BIZ* (/L5I_SZP_]^Q1]BM/^?6'_ +]BIZ*
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M+3@ G (9>N#VQQ74^3??\_D7_?C_ .RH MT54\F^_P"?R+_OQ_\ 94>3??\
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M53R;[_G\B_[\?_94>3??\_D7_?C_ .RH MT54\F^_P"?R+_OQ_\ 94>3??\
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M2WA2/RF!>-HW(N%YX#XX'.,$')KT? ]*6@#@+/Q#<:E8:'<27MG=7-U=P>;
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M_CY7_=K0K/O?^/E?]VFB9;$=%%%42:9IC4\TQJ@LKR55/^N3_>'\ZM255/\
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M&Q/[J_E0 S[3!_SWC_[Z%'VF#_GO'_WT*?L3^ZOY4;$_NK^5 #/M,'_/>/\
M[Z%'VF#_ )[Q_P#?0I^Q/[J_E1L3^ZOY4 ,^TP?\]X_^^A1]I@_Y[Q_]]"G[
M$_NK^5&Q/[J_E0 S[3!_SWC_ .^A1]I@_P">\?\ WT*?L3^ZOY4;$_NK^5 #
M/M,'_/>/_OH4?:8/^>\?_?0I^Q/[J_E1L3^ZOY4 ,^TP?\]X_P#OH4?:8/\
MGO'_ -]"G[$_NK^5&Q/[J_E0 S[3!_SWC_[Z%'VF#_GO'_WT*?L3^ZOY4;$_
MNK^5 #/M,'_/>/\ [Z%'VF#_ )[Q_P#?0I^Q/[J_E1L3^ZOY4 ,^TP?\]X_^
M^A1]I@_Y[Q_]]"G[$_NK^5&Q/[J_E0 )(D@RCJP]0<U7U'_CS;ZC^=60 .@
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M+*\E53_KD_WA_.K4E53_ *Y/]X?SJD2S6HHK-\0QWTWAO4X],+"^>UD6WVL
M=Y4[<$\ Y[U)9H+(CLRJZDKU /2G5Y@UY]BLM2;PSIT5N\.D2M&ZZ;)'<PS
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M6W3."P!/#GH#G\*N?:;K_H<M._\  >/_ .+H]G/L_N8>UI_S+[U_F=#ON_\
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M_F?XA]1Q?\B_\E/)_LOB'_H+67_@$?\ XNO6?ALNIQ>&)%N9+:Y?[2Y#JIB
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M?D: +=%5/[2L_P#GN/R-']I6?_/<?D: +=%5/[2L_P#GN/R-']I6?_/<?D:
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MH_MR;_H!:K_WQ'_\70!L45C_ -N3?] +5?\ OB/_ .+H_MR;_H!:K_WQ'_\
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MBNK6Y9#?X;(>82A3G& K1'!XX..<UUGA&#5K30Q#K+2-=+*V'EF\QW3LS')
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M4:)_T%['_P "%_QH_P"$HT3_ *"]C_W_ %_QKY8P/2C ]*/JZ[A];?8^I_\
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M !H_X2C1?^@O8_\ @0O^-?+.!Z48'I1]77</K;['U-_PE&B_]!>Q_P# A?\
M&E_X2C1/^@O8_P#?]?\ &OEC ]*,#TH^KKN'UM]CZG_X2C1/^@O8_P#?]?\
M&C_A*-$_Z"]C_P"!"_XU\L8'I1@>E'U==P^MOL?4_P#PE&B?]!>Q_P# A?\
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MIN4C</;UIDC**=)')"Y25&C<=5=2"/P-6K'3+F^U&SLE7RY+N18XFE!53N.
M<XZ<]J+CLRG14T]K-;S^2\;;LD+\I^;G&1ZBD%M.9C"()3*O5-AW#\.M 69%
M13DC>3.Q&; R=HS@>M-Q0(**D:"9)A"T,BRG&$*D,<].*LW^ESZ=#923E?\
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MVMRKM=2:>T6T/A_+A99#EAGACU;D]:/#WB>VTVV\+P-?R0Q6MS=27B+NV@.
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MT^VW-O?200><8HY%,C?O"H0AV48*DLOTKQ:VM9[R4Q6T32R!&<JO7:H)8_@
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MFBU]+6_NU%UI5M:V@ 9<2)C?_N]^>^:NGQQH-Y=ZPCR1C[7':-%/=PRE"T2
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M  K7Q/\ \^D7_?\ 7_&C_A6OB?\ Y](O^_Z_XT<\>X>SEV.2HKK?^%:^)_\
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M\^<7_?\ 7_&C_A6WB;_GSB_[_K_C1SQ[A[.78Y*BNM_X5MXF_P"?.+_O^O\
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MQR5%=;_PK7Q/_P ^D7_?]?\ &C_A6OB?_GTB_P"_Z_XT<\>X>SEV.2HKK?\
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MQR5%=;_PK;Q-_P ^<7_?]?\ &C_A6WB;_GSB_P"_Z_XT<\>X>SGV.2HKK?\
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M)O\ GSB_[_K_ (T<\>X>SGV.2HKK?^%;>)O^?.+_ +_K_C1_PK;Q-_SYQ?\
M?]?\:.>/</9S[')45UO_  K;Q-_SYQ?]_P!?\:/^%;>)O^?.+_O^O^-'/'N'
MLY]CDJ*ZW_A6WB;_ )\XO^_Z_P"-'_"MO$W_ #YQ?]_U_P :.>/</9S[')45
MUO\ PK;Q-_SYQ?\ ?]?\:/\ A6WB;_GSB_[_ *_XT<\>X>SGV.2HKK?^%;>)
MO^?.+_O^O^-'_"MO$W_/G%_W_7_&CGCW#V<^QR5%=;_PK;Q-_P ^<7_?]?\
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K"BX<IFBU]J>MM[5H;!2A!2N/E*B0 58CCQ4P05(JBE<I(BV45/@44AG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (/ @X# 2(  A$! Q$!_\0
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M44 %%%% !1110!S]_P#\CAIO_7-OY&N@%<_?_P#(X:;_ -<V_D:Z 4 %%%%
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MBBB@ HHHH **** "BC.:0'- "T4F11F@!:*3.*B2Z@DN9+=)%,L8!=0>5^M
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MS(WIOF7LW\C<R*6H+:=+F!94.585.*T3N8--.S"BBBF 4444 %%%% !1110
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M8_[&O/[0A,UIY9\V, DL/3CFO-=*T_Q,UU"_A,3Z/IV25AU2598)1_L!#O\
MS->B>)[?4+OPUJ$&ENR7SQ8A96VD'V/;C-<'<7Z:K8:3I6B:3KUKJ5G*OE2S
MVTD2( 1OW2$8((S]<T =]H%[J-[8.=5M%MKN*5HF"?<?!^^O?![9YK5I,TM
M!1110 4444 %%%% '/W_ /R.&F_]<V_D:Z 5S]__ ,CAIO\ US;^1KH!0 44
M44 %%%% !1110 4444 %0SN(H7<G  J:LW691'IDH[M\HJ9.R;*A'FDD5_#T
M>;:65OO.YY]JV<"J6DQ&'3H5(YV\U>I05HHJK*\VPHHHJS,**** "F21+)$R
M.,JPP13Z0]* ,"QE;2]1:RE.(I.8S6^IXK.U6P^UVN5&)8_F0_THTB_^U6NV
M0_OH^&'?ZUE%\KY3HFN>/.OF:5%)FEK4YPHHHH **** "BBB@ HHH- !7/\
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M10 4444 %%%% '/W_P#R.&F_]<V_D:Z 5S]__P CAIO_ %S;^1KH!0 4444
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MB8MW$VCT%&!Z"EHJQ";1Z"C:/04M% ";1Z"L*08\9V__ %P:MZL&7_D<K?\
MZX-0!O"DS2CI7BO[1UQ-;^'=%,$TD1:[?.QBN?D]J /:=WTH'(KY6^!%[=3_
M !/MTFN9I%^S3?*\A(Z>]?5/>@ )"@DD >IIB3Q2-A)$8^@-8'CG/_"'WX'4
MA1UQGYAQ7+6MO=Z#HUK=)IME9SW+0VL=Q$[DH)."QW$C(XH ],HK@5UG5-*U
MJ+1Y+YKQ!?11&XEQO*LA8AL<9ST]J6XUK5[_ %@:;:7L<"MJLML9 ,L(TB#X
M'OG- KG>T4R)2B*K,7( &X]3[T^@84444 8?C">XMO"6IS6EP+>=(<I,6V[#
MD<YKSS2;GP_+?VA35_';R,XP)Q-Y9.?XLKC%>B^*[>WN_"^I07D\=O;O"0\L
MI^5!GJ:X?2/&327-I:-X[T*[8L$*H%#2>P&.M 'J(ZFEI!WI: "BBB@ HHHH
M **** .?O_\ D<--_P"N;?R-= *Y^_\ ^1PTW_KFW\C70"@ HHHH **** "B
MBB@!H;/:H;N7R[61NF%->4>.;C49_'GV*#4[BUMTM"^R)B,G(YZT>#+Z_6?7
M+*ZU":Z1(T,?FG)&6Q53IR5/GZ'-2Q=.>*^K?:/1] 0BR,AZNV:V*J6$0BL8
M4Q_",U;K*"M$[*CO-L0]:R!_I>N'ND(_6M2>010O(>,#-9^C1DPR7##YI6)K
M.IK)1".B;-2DI:*W($(XIK*&7:P!![&GUD:GKL%@?*C_ 'UR>!&O]:5NY+DE
MJ9WBN[TWPWH=SJT[^2T2_N@#C<YX48[\XKYSGO9WN)-5FO&^USEC>;7Y>-OO
MI],<"OH.X\+?\)4JMXC4O #N2W!(P??%./PT\*8YTL'_ (&:GDCJNYC452HX
MRB[6/++;Q'%I=Q8ZYHGF.8D$+HL)99(3U48_B!QS[5ZXMOXAN5#M<1Q!@"-O
M:M/3]#TO3+**TM+&".&+.Q=@..]:*@ 8%94*/L8\M[G35?M'=Z'/#0=3D_UN
ML2'U !J.Y\)M+9S*E[)]I9"(W?E5/J1WKIZ*Z#+V<3Q&+X+:[%'M.NV;DDEF
M-L<L3Z\UWO@#PMJGA+2I]/OM0ANX#(9(1''L\O/4=>G2NPKGO$FK20*NG6?S
M7EQ\N!U4&FM784:,(-RBM6<[XA=M5UL1V.[[+"?])=>AKNK$P+91+;*!$%PH
M':J6D:-#IVF?9V :209E8_Q&JUB[:9?M92M^[?F,UG)J,K+8[$O:0\T;X-+3
M1]:=5F 4444 %%%% "8-&#VQ2T4@$' I:**8!1110 4444 %8,O_ ".5O_UP
M:MZL&7_D<K?_ *X-0!O#I69J_A[2/$$446KZ=;WL<3%XUG0,%)&,BM,=** ,
M+3/!GAK1;Y;W3-$LK2Z52HEAB"L >HS6Z.E%% %>\LH+^U>VN8Q)"^-RGO@Y
MJ*[TNTO=/^P7$*O;[0H4C[N.A'H15VB@#!7PCI2Z;)9%)6\QQ(UPSYFW@8#;
MO4#@>U6+'PWIFG&-K>V =)6FWMRQD9=I8GN2.*UJ* "BBB@ HHHH IZE*T5E
M+Y:PO,PQ'',0 [>G/6N#OK;6=;EATQ['1+"82I*9 1YB!6!^4 YR0,5-XSGM
M;'QKI=_K4-Q+I4%H[0A(FD1;K<-I('?;G!KE3IEN-#L=4ELI/^$PU:\2ZA?R
MSY\:[P&!/\*[ ?SH ]K'4TM(.II: "BBB@ HHHH **** .?O_P#D<--_ZYM_
M(UT KG[_ /Y'#3?^N;?R-= * "BBB@ HHHH **** ."\8^"[#6=6AU)KR[MK
MHIY.8".5]\_2JMMX*M?#-V&L;JXN;JYQO,Y'('/:NNOOWNJVT78<FHV_TCQ(
MHZB):*LFHI&.'IQG5G-]"W9:@DQ\F0>7,O&TUH9JC>Z:EU\Z_)*.0PJM;7\M
MK(+>^!!_AD[&KY4]B%4E!VJ?>3:S+MM!$.LK!:N6T7DV\<?]U1FLV4B[UF)!
MS'&N3CUJ?6M8MM"T>ZU.Z($4"%L9P7..%'N:YH:R;.N32BC1S44]Q%;1F29P
MB <DUYOX*^)D^M6EU;ZG;K_:D;EX8XQ@21'D'\,@&NGM])O=8D%SJKE(LY6
M&MS#VE_AU";5+W6)#;Z8A2+HTS5I:9HEOIPWD>;.WWI&YK0A@CMXA%$BH@Z
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M&XN(Y&N8Y%VC8P/R '.3MQ^- 'K2\9IU)ZTHZ4 %%%% !1110 4444 <_?\
M_(X:;_US;^1KH!7/W_\ R.&F_P#7-OY&N@% !1110 4444 %%%-8X&?2@3,B
M+][KTS=1&E1Z./.O[NX/<X!IMI)LBO[D\8R!5K0(MFG[B.7;=4U-9I!A=*,I
M=V:=5[JWAF@83#*@=?2K59VK2^58L.[G:*)2Y5<?*I:,Q-,>>P>6X=3) [;=
MW<5ROQ5MM=URWL8]-ABDTF)O,G^?!>3C;QCMS^=>E6MNL=E'$XR-O->9_$RY
MO-.NM,L-+OGM1<R_O2F"0,C&,U=)<R2ZG%7_ '2=W[OY'+Z)X0\:Z?K6GZQ:
MZ7 &B<%E:0C?'W4\?C7OJ$D<]>]>,Z1XA\2V/C+0[&YUF:\M;R;R7CE11@8/
M(P/:O9U[U=2+B[2#!3I3I*5+8=11169VA1110 444G>@!3TKDM<O)=9U!=$L
M6^3.9Y!Z>E:/B+6#IUL(+?YKR?Y8U'4>]/\ #ND#2[/=+\US+\TC'U]*I::L
M1HV5G#8VB6\*@(@Q]:L445(PIIIU% $%S ES;O$XR&&*PK34H=&,EMJ-PD$:
MGY))&P#[5T3?=KQ?Q^'F\=NFI B)(!]B#'"LO&XYZ9W>M<]>7LX\Z6QVX.G[
M:?L6[)GLL%Q%<PI-!(LD3C*LIR#4M>5?"B2?^TM6M[?<=*558<DJL^?F )]L
M5ZF.M:TY\\5(PKTO95'"][#J***LQ"BBB@ HHHH **** "BBB@ K!E_Y'*W_
M .N#5O5@R_\ (Y6__7!J -X45@>,->D\->&[G4H85EF0 ('!*@D]6QSBLG3-
M2\36^I6OVN73M2TV<,T\UHQW6N%+ G)Y4XQZT =K16(GBC2WT^VOQ.3;W%TE
MK&V.LC' 'YUS.E_$RS>%O[4C>(QW,D$\\:'RH2&(7<?< =* /0:*YZ3Q';6*
M:G<W][;FVM) @6(-O4G&%/J22.GK3+#QGI=Y:WLTYELFL4\VXBG7#(A!(;WS
M@]* .DHK@[[XF:?!HFH7D5M<"XMH?/C@E0CS8\@;ACMR*ZW1M235](M-01&C
M6XC#A&&"* +]%%% !1110!B>+K*;4?"FIVEL&,TL.%"'!)R.*XW1X]-^T6JC
MX?PVMPA 8HRL83Z\"NU\4_VA_P (QJ/]E!C?>5^ZV=<^WOC-><L=#$=C_P (
MS<:H^NB5/W+7#NR#<-_FJ3C[N[K0!ZZ.]*.E(.]+0 4444 %%%% !1110!S]
M_P#\CAIO^XW\C70"N?O_ /D<--_W&_D:Z 4 %%%% !1110 AJ"[?R[65NX4U
M.:S]8DV6#^^!3BKLSJNT&S*E)C\/_P"U,^*W;&/RK.)/1:Q+Q,G3K/L?F-=$
MF ,#L*SWJ-FT5RT(1^8ZL>]_TG58+?JJ?,PK69@JDDX ZUDZ7F>\N+IAU.T?
M2HJ:M1''2[-1V"(6/"J,FO/=1\*+XXF>[ENYK8V\V8)(SSC/2NM\1W9MM+9$
M.)9CL2K.DVBV.F0PXPVW+#W/6MUIL<TDIRY7L>?Z=\/1IWB[3[V\UBXN#:MY
MD*-G!/O^=>G+67K,)\E+A/OQ'.1Z5H6LPGMTD'\0JYMR]XSH)4Y.FE9=":BB
MBLSJ"BBB@ JIJ-_#IMG)<SL J#@>I]*LLP52S'  R37'NS^*];"+D:;:G)/9
MS32N!/X?L9M1O7UO4%^=S^Y0_P (KJL<TB*J(JH JJ, #L*=0W< HHHI %%%
M% "'D5GZGH>FZU"D6IV-O=HAW*)4S@UHT4 FUJBI8Z;::7:+:V%M%;0+]V.-
M< 5: I:* "BBB@ HHHH **** "BBB@ HHHH *P9?^1RM_P#K@U;U8,O_ ".5
MO_UP:@!?%DE_%H4KV%A%?D']]:RCB6/N![UP5G86=YXETY_!^D7>EHOFC4=]
MNT$3*4( (8#>=WI]:]9P,YHQ0!Y%;M?-IVG>'X]+O!=V>O12SLT3"-8EDSN#
M8P>/2F[M0'A'5/"9T6Y&H7US*+=_+)C=3(6W,^,+^->OXXHQVR: /(-9T>ZU
M.#7HK1KAI+344DD6W?;(5 3)4^H )I?[".LVNJ7VF)KMT\:1M')JTI!GVYS&
M$901Z9KT[2]#L='-TUFCAKJ4S2L[EBS'CJ?I6AB@#SJ^U&;Q3X=U"RL-#N8Y
M$T[RC//&8CY@*_NE##)'!.1QQ79^'YVN=!LI6BDA8Q#,<@PRGW%:6/K2XH *
M*** "BBB@#B_&4L$FL:98)=ZD+Z?(6WL=N0F>9&W<8!X_&LFZL;?P[XDLH;V
M]U=()B"M\5B\DOGB-B!NS^G-;'B:VU;3?$MIXFTRQ&HI#:M:7%J'".$+!MZD
M]<8 Q65J.HZSXZBBTBUT*:QLFECDN;RZ;&P(P8!5(!))&.* /1AWH- HH KS
M7UM!/#!+.B2S$B-">6QS5@FN:UVRM_\ A)-"O?LZFX$KH9@O(7:>,^E6]?O;
M^R\EM.C\Z8ALPE201_>SVQZ=Z -EY$C0N[!5'4L< 51DUO3H],346NE^R2?<
MD )W=N .:8D,6IZ'LO46X21#O61, GTP:Y32@+71?"$\B^5;0&3S"1A8P58#
M/IS0!V,&K6-Q;QSQ7"M'(2JG!ZCJ*KV.KK?:E<6Z*/+C&4DS][UX^M4_#L$<
M\=],4#1/>2-&2,@\]1[&M:+3;."9YX;>..9UVM(@P2* ,J^'_%8:;_N-_(UO
MBN&L?#YT3QG:NVKZG?\ G1M\MY/Y@3J?EXXKMQ'_ +;_ )T /S1FF>7_ +;_
M )T>7_MO^= #\T9IGE_[;_G1Y?\ MO\ G0 XUDZS\S6T/]]JTS'C^-_SK(NA
MYFLP+N;$8W'FJCO<PK_#;NQB+YWB+ Y6% !6X*P]%0SW-W<%FR7*]:VMG^V_
MYUA3V;.VMHU'LBMJ<WD6,A'5AM'XT:;!Y%C&I^\1DU3U(>?>V]J&8\[FY[5>
MN94L[229V?9&N>M*/O3;[&;=HF)=?\37Q/';_>AMAEQ_M5TG:N?\,6KM;37L
MK-YL[9SG^'M6]Y7^V_YUL8PVOW$EC$D;(1D$8K,TB0Q/-:.?F1LBM0Q9_C;\
MZQ]0C-IJ$-T"<'Y6Q5QUT,JWNM370VA3LU"J[@"'<@^]/\O_ &W_ #J#H3'Y
MH[4SR_\ ;?\ .LG7M472;$E79KB3Y8DSDY]:%J,SO$>HS7=RFB:>V9I2/-8?
MPCTK>TS3H=+L8[6$<*.6[L?6LOPWHK64#7=RS->7 W,2>5![5N^7_MO^=4WT
M0A^:,TSR_P#;?\Z/+_VW_.I&.I<TSR_]M_SH\O\ VW_.@!^:,TSR_P#;?\Z/
M+_VW_.@!^:,TSR_]M_SH\O\ VW_.@!^:,TSR_P#;?\Z/+_VW_.@!^:,TSR_]
MM_SH\O\ VW_.@!^:,TSR_P#;?\Z/+_VW_.@!^:,TSR_]M_SH\O\ VW_.@!^:
M,TSR_P#;?\Z/+_VW_.@!^:,TSR_]M_SH\O\ VW_.@!]8,O\ R.=O_P!<&K;\
MO_;?\ZPW&/&4')/[ANOTH WJ:65022 !U)[4R=WCA=HUW,!POK7F'Q%UC4F3
M3+&5I;*TN966=XVVF3"Y"Y[<UG4J*"NS:C0E6DHIGJ$<L4HW1R(Z^JMFGFO#
M?"=]>:/XNL[333(T5Q&_G60/R8&,/CL1FO9K"YGN(W,\/ED' 'K44:RJQND:
MXK"2P\W&33+I(4$D@ <DFF1313#=%*D@]48$?I7.>/9Y;?PE.T+LA>:&-B#_
M  M(H8?B"1659:-:VOB#7-&TQI=/L6M86Q9/Y9B8AN5/8GU]JV.0[I2&&5((
M]0:4LH(!(&>F:X?PGJ\&A^ K*6Z-Y<KYTL>^.)II#B1N6VCVZU'K.O1:O=:'
M+9B[A07K(XGA:$M\OHPY% '>T4@ZFEI@%%%% %6_EFM[*::VA\^=%RD6<;SZ
M5SMMX^TL,D6L176BSN<*NHIY0D/^P<\U;\4:EJ-I;FVT_2]1N9)T(%Q9^7F$
M_P# SUKBK#2[>>_ADUCPMK.J79;'VS4)H24S_LJV/TH ]3C99(U=&#*PR"#P
M:=WK-T/1;?0;.2TM'D:%IGE57;.S<<[1["M.@!I125)4$CH2.E+@?C2T4@$P
M ,8ICV\,D)A>&-HCP8V4%?RJ2BF V.-(D"1HJ(HP%48 _"G444 <_?\ _(X:
M;_US;^1KH!7/W_\ R.&F_P#7-OY&N@% !1110 4444 (:P))/],OIS_RSC*B
MMV1MJ$^@KEY7/]GW#=YI0!^=-NT&S.W-6A$UM"CV:<C'JYR:T\X&:AM(_*M(
MD]%%-OY?(LY']L"L5[L#HF^:;91LO])U2>X/1/E6JOB:=GC@T^+_ %EPXR!Z
M5I:3#Y5BI;[S_,:R; ?VIXEGNR"88!M3V-%)6C=F-9WT1T%K MM;1PH/E10!
M4U(*6M1K0*J:C;BXLW3OC(JW36&333LQ3CS1:*&E7!GLU!^\GRD5HUBQ'[%K
M#QGB.;D?6M@XP:<]S*@VXV>Z(KNZBLK:2XF8+&@R2:YC1[:77=3;6;U3Y*'%
MO&?YTR_ED\3:P+"W8_88#F5QT8UUL$*00I%&H5$ "BC9&VX_O2T45(PHH[4T
M\ D]!0 ZBN$E^*_AB*XGA$\KF%RCE8R1D5TVA:W8^(M-CU'3Y"]N[%02,<CK
M3LR5.+=DS5HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 5@R_P#(
MY6__ %P:MZL&7_D<K?\ ZX-0!NU0U;1[#6[%[/4(%FB;UZJ?4'L:T!TIO&:0
M)M:HP= \(Z+X<>1]/MW$K\&69S(^/0,>0*WL"EZ=:4'-"5MAR;D[MD%U:07M
MK);7$8DBD&&4U1T?P_8:)!+%:+*?,^^\TID=AV&X\X':M6C-,16L+"VTVT6U
MM8Q'"I)"CU)R?U--N]-M;Z2WDN(][6[[XSGH>E6LBC(H 6BBB@ HHHH Q/%_
MVO\ X1/4_L,DT=SY)\MH02X.1T [XKA]'E\)&6R86NO)<EA@W%I*/F_VB5Q7
M0>)[C5-3\3V7AG3K_P#L^.6U:[N+A%W.45@NQ?3.1S6?J%CJO@:./5K;6KB^
ML!*D=S:79WEM[!058DD8)!Q0!Z$.II:04M !1110 4444 %%%% '/W__ ".&
MF_\ 7-OY&N@%<_?_ /(X:;_US;^1KH!0 4444 %%%% %:_D\JSD?T%<]LW'3
M[?N6WM]#BMC6GQ8E!U<@?K6?9*)M97^[#$!^.*FI\"7=BH?QW+LCH1P,>E96
MKN97@M5ZNV2/:M7M61!_I6LR2]5B&!6=791+CW)M5N5T_2)6'4+L7Z]JB\/6
MAM-+0N,22?.]4=:8W^L6FG)]U3OD'M71H@5 HZ 8%;)6,5[TKBBEHHH- I".
M>M+2&@#+UB%C"DZ#+Q'/X5E:WK4DEO#I]C\UW<C!(_A'>M;7-1BT[39))>68
M;47U-8?A&SV7$UQ=H?M;C*AOX5K5:QNSE?N5?)F]HVE1Z58+ N"YYD;^\:TJ
M04M9/4Z@HHHH 0]#4<C 1L2<#:>34AZ&L:]G>]N/L=N?E_Y:,*:5S*I4Y$>(
MZ>NHV/\ :-NVD7LFZY=E9(6(((]<5Z-\/HM7TWPC&)K-DW3R/Y;C# $\5WD$
M2P0K&N<+3R,^M:RJMI+HCDI8*,)RJ)M2D9J:W&#B>)XC[BKL5Y!,,I(I]LTY
MX(I!B1%;ZBJ4NC6[G='NC;U4U'NLZ/WL?,T=U ;-9!M-1MN89Q*H[-UH&J3P
M'%U;,H_O 4<O87M[?$K&QNHS5&'4[67[LH4^C<5=5@P!!!%2TUN;1G&6S'44
M44BPHHHH **** "BBB@ HHHH *P9?^1RM_\ K@U;U8,O_(Y6_P#UP:@#:ED\
MJ)G()VC.!7 >-?%%^AT_3-,9K1[UV$D_\2JHS\OOQ7H1 (P1Q6'XB\,V'B2S
M2"Y#1O$V^&:,X:-O48K&K&<HM1=BX.*?O(X+P[XCU71_$-K975]<ZC9WJMQ<
M-OD1EZ%3Z<\UZA:78ND9A&R[3CFN<\.^!;+1-0.H2W,M[>!2B22# 13U 7..
M:ZL* ,  #VK+#PJPBE4=V54E%OW41W(G>VD6V=$F*G8SKN /N*\U37M8M_!$
MC7MX]S?2:TU@TL *DJ9-N$Z[?;TKT_.*Y[_A$K(:3/8I+(OF7C7J2=3'*6W
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M9<)<T4Q:::7-5+^]6TA+'[YX5?4TDKZ#E)15V5]2O#'BVAYFDX^E3:?9BTA
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M97GAR_M]1F\BS>(B67.-H]?SQ7FT.HZAK$MKI^OZEJ<6CM*I6:?3! MP58%
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M@"/<_P#<HW/_ '*DQ1B@"/<_]RC<_P#<J3%&* (]S_W*-S_W*DQ1B@"/<_\
M<HW/_<J3%&* (]S_ -RC<_\ <J3%&* (]S_W*-S_ -RI,48H CW/_<K$?/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2UHW<L****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *P9?^1RM_\ K@U;U8,O_(Y6
M_P#UP:@#>'2B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\
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ME1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E6%(,>,X/\
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M_9/C#_H:+7_P7+_\574T4 <M_9/C#_H:+7_P7+_\52C2?%^>?%%MC_L'+_\
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MR_\ Q5=0#DTM '+?V3XP_P"AHM?_  7+_P#%4?V3XP_Z&BU_\%R__%5U-!H
M\]U>Z\8:3K&CZ?\ V[;3?VE*\9D^P@>5M7=G&>:V?[)\8?\ 0T6O_@N7_P"*
MJWJ/B"UM;S:;&:Y2!@LLZ("L+$XQSSGD5N*X8 @Y!&0: .8_LGQA_P!#1:_^
M"Y?_ (JC^R?&'_0T6O\ X+E_^*KJ:* .6_LGQA_T-%K_ ."Y?_BJR_$;^,/#
MWAV]U;^W[:Y-JF_R18*N_D#&=W'6N]-9FJ:G#;O#9F'[1/<=(2 1M[LV>PH
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MA[J>V/2N_M8C!:Q0EBQC0+N/? J+3K"/3K.&W0E_*C$>]N6('3)JW0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117.Z[
MJTT5['ID,RVADC,C74@^4 '&U?\ :H U;_4[33HU:ZN(X2YPF\]37%ZG/?WT
M,D-ZLZK+<*J%@%V9/RF(KR?QICW5WJJ1)/92M?R0A-N0HN(P2<KG[IZYSVKI
M="T".PA66<,TH),*2'=]G4]$7V% %C2-)>R=IYYS+*RA , !5_#J3UK7HQ10
M 4444 %%%% !1110 4444 07EG!?VSV]S&LD3C#*:+:TAL[:.WMT"11@!5'^
M>:GHH **** "D90P((!!Z@TM% %.QTNRTT2"S@6+S&W-CN?\/:KE%% !1110
M 4444 %%%% !6=J^CVNM6AM[E 2/FC?'*-ZBM&C% '-:/X<%M=1WMVH%W$'B
M^1B4E4_Q$'@$^@XKI ,=.!Z48%+0 4444 %%%% "4M%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%9^K:1:ZU8M:7D0=#RI[HW8CT-:%% &-I6CW%M,;K4KL7EV!L1PFU43V'K[U
ML"EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>tvgn-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSLibP9z5Z8uekhvWB0bVmq/y4llHIkyCFdXYTmYQkF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:TVGN="http://tevogen.com/20241231" elementFormDefault="qualified" targetNamespace="http://tevogen.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://tevogen.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" id="StatementsOfChangesInStockholdersDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000006 - Statement -  Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NatureOfBusiness" id="NatureOfBusiness">
          <link:definition>999014 - Disclosure - NATURE OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" id="Development-stageRisksAndLiquidity">
          <link:definition>999015 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombination" id="BusinessCombination">
          <link:definition>999017 - Disclosure - BUSINESS COMBINATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/EarnoutShares" id="EarnoutShares">
          <link:definition>999018 - Disclosure - EARNOUT SHARES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>999019 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
          <link:definition>999020 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Debt" id="Debt">
          <link:definition>999021 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Leases" id="Leases">
          <link:definition>999022 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999023 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999024 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficit" id="StockholdersDeficit">
          <link:definition>999025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetLossPerShare" id="NetLossPerShare">
          <link:definition>999026 - Disclosure - NET LOSS PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999027 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999028 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999029 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999030 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombinationTables" id="BusinessCombinationTables">
          <link:definition>999033 - Disclosure - BUSINESS COMBINATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>999034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
          <link:definition>999035 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999036 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999037 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficitTables" id="StockholdersDeficitTables">
          <link:definition>999038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
          <link:definition>999039 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999040 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
          <link:definition>999041 - Disclosure - NATURE OF BUSINESS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" id="Development-stageRisksAndLiquidityDetailsNarrative">
          <link:definition>999042 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" id="ScheduleOfFairValueMeasurementDetails">
          <link:definition>999043 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" id="ScheduleOfFairValuesOfWarrantsDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>999045 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" id="ScheduleOfPropertyAndEquipmentUsefulLifeDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" id="ScheduleOfNetLiabilitiesAcquiredInMergerDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" id="BusinessCombinationDetailsNarrative">
          <link:definition>999049 - Disclosure - BUSINESS COMBINATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" id="EarnoutSharesDetailsNarrative">
          <link:definition>999050 - Disclosure - EARNOUT SHARES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
          <link:definition>999052 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999054 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" id="ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999056 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" id="ScheduleOfRestrictedStockAndRsuActivityDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999058 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999059 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" id="ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" id="StockholdersDeficitDetailsNarrative">
          <link:definition>999061 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" id="ScheduleOfReconciliationOfNetLossDetails">
          <link:definition>999062 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" id="ScheduleOfAnti-dilutiveNetLossPerShareDetails">
          <link:definition>999063 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" id="ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical">
          <link:definition>999064 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" id="NetLossPerShareDetailsNarrative">
          <link:definition>999065 - Disclosure - NET LOSS PER SHARE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" id="ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails">
          <link:definition>999066 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999067 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" id="ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails">
          <link:definition>999068 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999069 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999070 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999071 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tvgn-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="TVGN_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" name="WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TevogenBioMember" name="TevogenBioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SemperParatusMember" name="SemperParatusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ProbabilityOfFutureLiquidityMember" name="ProbabilityOfFutureLiquidityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesMember" name="EarnoutSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TevogenBioCommonStockMember" name="TevogenBioCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorMember" name="SponsorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ComputerAndSoftwareMember" name="ComputerAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ThePatelFamilyLLPMember" name="ThePatelFamilyLLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_AdditionalAmountPurchaseOptionMember" name="AdditionalAmountPurchaseOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PolarMultiStrategyMasterFundMember" name="PolarMultiStrategyMasterFundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TwoThousandTwentyFourPlanMember" name="TwoThousandTwentyFourPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PerformanceBasedRSUsMember" name="PerformanceBasedRSUsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ServiceBasedRestrictedStockMember" name="ServiceBasedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorAdvisoryServicesFeeMember" name="SponsorAdvisoryServicesFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WifeOfChiefExecutiveOfficerMember" name="WifeOfChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MehtaphoricConsultingIncMember" name="MehtaphoricConsultingIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DrManmohanPatelMember" name="DrManmohanPatelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_KRHPLLCMember" name="KRHPLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LoanAgreementNoncurrent" name="LoanAgreementNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" name="ChangeInFairValueOfConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LossOnIssuanceOfCommitmentShares" name="LossOnIssuanceOfCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" name="StockIssuedDuringPeriodValueNewIssuesTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" name="StockIssuedDuringPeriodSharesNewIssuesTwo" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" name="StockIssuedDuringPeriodValueNewIssuesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" name="StockIssuedDuringPeriodSharesNewIssuesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MergerNetOfRedemptionsAndTransactionCosts" name="MergerNetOfRedemptionsAndTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" name="StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" name="StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" name="StockIssuedDuringPeriodValueContributionFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" name="StockIssuedDuringPeriodSharesContributionFromRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" name="StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" name="StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LossOnPreferredStockIssuance" name="LossOnPreferredStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" name="CashAcquiredInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" name="ProceedsFromIssuanceOfSeriesCPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" name="NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" name="ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_RepurchaseOfSeriesBPreferredStock" name="RepurchaseOfSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" name="DisclosureDevelopmentstageRisksAndLiquidityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" name="DevelopmentStageRisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureEarnoutSharesAbstract" name="DisclosureEarnoutSharesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EarnoutSharesDisclosureTextBlock" name="EarnoutSharesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" name="FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" name="PropertyAndEquipmentUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" name="ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" name="ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationSharesExchangeRatio" name="BusinessCombinationSharesExchangeRatio" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_GrantDrewFromRelatedParty" name="GrantDrewFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DerivativeLiabilitiesFairValueIssuance" name="DerivativeLiabilitiesFairValueIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EquitySecuritiesTerm" name="EquitySecuritiesTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_FreeStandingPurchaseOptions" name="FreeStandingPurchaseOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_EmbeddedOptions" name="EmbeddedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_MergerTransactionCostsLimitedToCashAcquired" name="MergerTransactionCostsLimitedToCashAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" name="StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_OperatingLeasesIncrementalBorrowingRates" name="OperatingLeasesIncrementalBorrowingRates" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" name="VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" name="SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" name="CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" name="StockIssuedDuringPeriodSharesConversionOfLiabilities" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" name="StockIssuedDuringPeriodValueConversionOfLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_WarrantsRedemptionDescription" name="WarrantsRedemptionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockRepurchase" name="StockRepurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" name="DeferredTaxAssetsAccruedExpensesAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsFixedAssets" name="DeferredTaxAssetsFixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_IncreasesRecordedToIncomeTaxProvision" name="IncreasesRecordedToIncomeTaxProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_TaxableIncomeLimitationPercentage" name="TaxableIncomeLimitationPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_SponsorFeesPayable" name="SponsorFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" name="StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivateInvestorMember" name="PrivateInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_PrivateWarrantsMember" name="PrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LinesOfCreditNoncurrent" name="LinesOfCreditNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="TVGN_LoanAgreement" name="LoanAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>tvgn-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tvgn-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20241231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20241231.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Debt" xlink:href="tvgn-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Leases" xlink:href="tvgn-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20241231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShare" xlink:href="tvgn-20241231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxes" xlink:href="tvgn-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SegmentReporting" xlink:href="tvgn-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20241231.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesTables" xlink:href="tvgn-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20241231.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareTables" xlink:href="tvgn-20241231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesTables" xlink:href="tvgn-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20241231.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20241231.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DebtDetailsNarrative" xlink:href="tvgn-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesDetailsNarrative" xlink:href="tvgn-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20241231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfNetLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:href="tvgn-20241231.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:href="tvgn-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="loc_TVGNLoanAgreementNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_TVGNLoanAgreementNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement -  Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaapNoncashMergerRelatedCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNoncashMergerRelatedCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:label="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="999014 - Disclosure - NATURE OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="999015 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="999017 - Disclosure - BUSINESS COMBINATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="999018 - Disclosure - EARNOUT SHARES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:title="999019 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999020 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Debt" xlink:title="999021 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Leases" xlink:title="999022 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="999025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShare" xlink:title="999026 - Disclosure - NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="999028 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SegmentReporting" xlink:title="999029 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="999033 - Disclosure - BUSINESS COMBINATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:title="999034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999035 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesTables" xlink:title="999036 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="999037 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="999038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareTables" xlink:title="999039 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999041 - Disclosure - NATURE OF BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="999042 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="999043 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999045 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:title="999046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="999048 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:label="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="999049 - Disclosure - BUSINESS COMBINATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="999050 - Disclosure - EARNOUT SHARES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999052 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DebtDetailsNarrative" xlink:title="999054 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="999055 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesDetailsNarrative" xlink:title="999056 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="999057 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999058 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999059 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="999060 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="999061 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:title="999062 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="loc_TVGNStockRepurchase" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_TVGNStockRepurchase" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="999063 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="999064 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:title="999065 - Disclosure - NET LOSS PER SHARE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:title="999066 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:label="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999067 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:label="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsFixedAssets" xlink:label="loc_TVGNDeferredTaxAssetsFixedAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:title="999068 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:title="999069 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999070 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="999071 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>tvgn-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tvgn-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20241231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20241231.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Debt" xlink:href="tvgn-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Leases" xlink:href="tvgn-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20241231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShare" xlink:href="tvgn-20241231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxes" xlink:href="tvgn-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SegmentReporting" xlink:href="tvgn-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20241231.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesTables" xlink:href="tvgn-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20241231.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareTables" xlink:href="tvgn-20241231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesTables" xlink:href="tvgn-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20241231.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20241231.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DebtDetailsNarrative" xlink:href="tvgn-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesDetailsNarrative" xlink:href="tvgn-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20241231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfNetLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:href="tvgn-20241231.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:href="tvgn-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_TVGNCommonStock0.0001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNCommonStock0.0001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:label="loc_TVGNWarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNWarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssetsCurrentAbstract_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapAssetsCurrent_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapDeferredCosts_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapOtherAssetsNoncurrent_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssets_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapAccountsPayableCurrent_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapNotesPayableCurrent_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapLiabilitiesCurrent_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="loc_TVGNLoanAgreementNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_TVGNLoanAgreementNoncurrent_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilities_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapStockholdersEquityAbstract_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapPreferredStockValue_90" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapCommonStockValue_90" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapAdditionalPaidInCapital_90" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapStockholdersEquity_90" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_90" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:label="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty_80" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty_80" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_80" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_80" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_80" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement -  Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="999014 - Disclosure - NATURE OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="999015 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="999017 - Disclosure - BUSINESS COMBINATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="999018 - Disclosure - EARNOUT SHARES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:title="999019 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999020 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Debt" xlink:title="999021 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Leases" xlink:title="999022 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="999025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShare" xlink:title="999026 - Disclosure - NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="999028 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SegmentReporting" xlink:title="999029 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="999033 - Disclosure - BUSINESS COMBINATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:title="999034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999035 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesTables" xlink:title="999036 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="999037 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="999038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareTables" xlink:title="999039 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999041 - Disclosure - NATURE OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNSemperParatusMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationSharesExchangeRatio" xlink:label="loc_TVGNBusinessCombinationSharesExchangeRatio_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNBusinessCombinationSharesExchangeRatio_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="999042 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_GrantDrewFromRelatedParty" xlink:label="loc_TVGNGrantDrewFromRelatedParty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNGrantDrewFromRelatedParty_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="999043 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CallOptionMember" xlink:label="loc_us-gaapCallOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapCallOptionMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:label="loc_TVGNDerivativeLiabilitiesFairValueIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNDerivativeLiabilitiesFairValueIssuance_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999045 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:title="999046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProbabilityOfFutureLiquidityMember" xlink:label="loc_TVGNProbabilityOfFutureLiquidityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TVGNProbabilityOfFutureLiquidityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="loc_us-gaapEquitySecuritiesFvNiMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiMeasurementInput_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EquitySecuritiesTerm" xlink:label="loc_TVGNEquitySecuritiesTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEquitySecuritiesTerm_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreeStandingPurchaseOptions" xlink:label="loc_TVGNFreeStandingPurchaseOptions_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNFreeStandingPurchaseOptions_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EmbeddedOptions" xlink:label="loc_TVGNEmbeddedOptions_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEmbeddedOptions_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharePrice_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_200" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="999048 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="999049 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="999050 - Disclosure - EARNOUT SHARES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="loc_TVGNTevogenBioCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ComputerAndSoftwareMember" xlink:label="loc_TVGNComputerAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TVGNComputerAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999052 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/DebtDetailsNarrative" xlink:title="999054 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PolarMultiStrategyMasterFundMember" xlink:label="loc_TVGNPolarMultiStrategyMasterFundMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNPolarMultiStrategyMasterFundMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_60" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_AdditionalAmountPurchaseOptionMember" xlink:label="loc_TVGNAdditionalAmountPurchaseOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TVGNAdditionalAmountPurchaseOptionMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_160" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="999055 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesDetailsNarrative" xlink:title="999056 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:label="loc_TVGNOperatingLeasesIncrementalBorrowingRates_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNOperatingLeasesIncrementalBorrowingRates_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeasePayments_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="999057 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999058 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999059 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TwoThousandTwentyFourPlanMember" xlink:label="loc_TVGNTwoThousandTwentyFourPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNTwoThousandTwentyFourPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_100" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="999060 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="999061 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSemperParatusMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNLossOnPreferredStockIssuance_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="loc_us-gaapPreferredStockDividendPaymentRateVariable_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentRateVariable_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaapPreferredStockRedemptionTerms_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionTerms_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDeposits_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities_240" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_240" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLiabilitiesAssumed1_240" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ClassOfWarrantOrRightIssued" xlink:label="loc_TVGNClassOfWarrantOrRightIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightIssued_240" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_240" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsRedemptionDescription" xlink:label="loc_TVGNWarrantsRedemptionDescription_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsRedemptionDescription_240" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_240" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:title="999062 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="loc_TVGNStockRepurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_TVGNStockRepurchase_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="999063 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNEarnoutSharesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="999064 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:title="999065 - Disclosure - NET LOSS PER SHARE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:title="999066 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999067 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:title="999068 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:title="999069 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999070 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MehtaphoricConsultingIncMember" xlink:label="loc_TVGNMehtaphoricConsultingIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNMehtaphoricConsultingIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DrManmohanPatelMember" xlink:label="loc_TVGNDrManmohanPatelMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNDrManmohanPatelMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServicesFeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSponsorAdvisoryServicesFeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WifeOfChiefExecutiveOfficerMember" xlink:label="loc_TVGNWifeOfChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNWifeOfChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSponsorFees_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorFeesPayable" xlink:label="loc_TVGNSponsorFeesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNSponsorFeesPayable_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_120" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="999071 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_KRHPLLCMember" xlink:label="loc_TVGNKRHPLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNKRHPLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCredit_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>tvgn-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStock0.0001ParValuePerShareMember" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStock0.0001ParValuePerShareMember" xlink:to="TVGN_CommonStock0.0001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock, $0.0001 par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:to="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_lbl" xml:lang="en-US">Warrants, each exercisable for one share of Common Stock for $11.50 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="TVGN_TevogenBioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioMember" xlink:to="TVGN_TevogenBioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TevogenBioMember_lbl" xml:lang="en-US">Tevogen Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="TVGN_SemperParatusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SemperParatusMember" xlink:to="TVGN_SemperParatusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SemperParatusMember_lbl" xml:lang="en-US">Semper Paratus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="TVGN_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementMember" xlink:to="TVGN_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProbabilityOfFutureLiquidityMember" xlink:label="TVGN_ProbabilityOfFutureLiquidityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProbabilityOfFutureLiquidityMember" xlink:to="TVGN_ProbabilityOfFutureLiquidityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ProbabilityOfFutureLiquidityMember_lbl" xml:lang="en-US">Probability of Future Liquidity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CallOptionMember_lbl" xml:lang="en-US">Call Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="TVGN_EarnoutSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesMember" xlink:to="TVGN_EarnoutSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesMember_lbl" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="TVGN_TevogenBioCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioCommonStockMember" xlink:to="TVGN_TevogenBioCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TevogenBioCommonStockMember_lbl" xml:lang="en-US">Tevogen Bio Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="TVGN_SponsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorMember" xlink:to="TVGN_SponsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ComputerAndSoftwareMember" xlink:label="TVGN_ComputerAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ComputerAndSoftwareMember" xlink:to="TVGN_ComputerAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ComputerAndSoftwareMember_lbl" xml:lang="en-US">Computer And Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="TVGN_ThePatelFamilyLLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThePatelFamilyLLPMember" xlink:to="TVGN_ThePatelFamilyLLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ThePatelFamilyLLPMember_lbl" xml:lang="en-US">The Patel Family LLP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xml:lang="en-US">Unsecured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_AdditionalAmountPurchaseOptionMember" xlink:label="TVGN_AdditionalAmountPurchaseOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AdditionalAmountPurchaseOptionMember" xlink:to="TVGN_AdditionalAmountPurchaseOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_AdditionalAmountPurchaseOptionMember_lbl" xml:lang="en-US">Additional Amount Purchase Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PolarMultiStrategyMasterFundMember" xlink:label="TVGN_PolarMultiStrategyMasterFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PolarMultiStrategyMasterFundMember" xlink:to="TVGN_PolarMultiStrategyMasterFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PolarMultiStrategyMasterFundMember_lbl" xml:lang="en-US">Polar Multi-Strategy Master Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TwoThousandTwentyFourPlanMember" xlink:label="TVGN_TwoThousandTwentyFourPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TwoThousandTwentyFourPlanMember" xlink:to="TVGN_TwoThousandTwentyFourPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TwoThousandTwentyFourPlanMember_lbl" xml:lang="en-US">2024 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="TVGN_PerformanceBasedRSUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PerformanceBasedRSUsMember" xlink:to="TVGN_PerformanceBasedRSUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PerformanceBasedRSUsMember_lbl" xml:lang="en-US">Performance-Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="TVGN_ServiceBasedRestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServiceBasedRestrictedStockMember" xlink:to="TVGN_ServiceBasedRestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ServiceBasedRestrictedStockMember_lbl" xml:lang="en-US">Service-Based Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="TVGN_SeriesAOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US">Series A1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PublicWarrantsMember" xlink:label="TVGN_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsMember" xlink:to="TVGN_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServicesFeeMember" xlink:to="TVGN_SponsorAdvisoryServicesFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember_lbl" xml:lang="en-US">Sponsor Advisory Services Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WifeOfChiefExecutiveOfficerMember" xlink:label="TVGN_WifeOfChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WifeOfChiefExecutiveOfficerMember" xlink:to="TVGN_WifeOfChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WifeOfChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Wife of Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MehtaphoricConsultingIncMember" xlink:label="TVGN_MehtaphoricConsultingIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MehtaphoricConsultingIncMember" xlink:to="TVGN_MehtaphoricConsultingIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MehtaphoricConsultingIncMember_lbl" xml:lang="en-US">Mehtaphoric Consulting Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DrManmohanPatelMember" xlink:label="TVGN_DrManmohanPatelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DrManmohanPatelMember" xlink:to="TVGN_DrManmohanPatelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DrManmohanPatelMember_lbl" xml:lang="en-US">Dr. Manmohan Patel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_KRHPLLCMember" xlink:label="TVGN_KRHPLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_KRHPLLCMember" xlink:to="TVGN_KRHPLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_KRHPLLCMember_lbl" xml:lang="en-US">KRHP LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="TVGN_LoanAgreementNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementNoncurrent" xlink:to="TVGN_LoanAgreementNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LoanAgreementNoncurrent_lbl" xml:lang="en-US">Loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 800,000,000 shares authorized; 177,991,365 and 119,999,989 shares issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock, liquidation value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnIssuanceOfCommitmentShares" xlink:to="TVGN_LossOnIssuanceOfCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares_lbl" xml:lang="en-US">Loss on issuance of commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average common stock outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Issuance of Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Issuance of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Issuance of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Issuance of Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:to="TVGN_MergerNetOfRedemptionsAndTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts_lbl" xml:lang="en-US">Merger, net of redemptions and transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Merger, net of redemptions and transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for Sponsor advisory service fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for Sponsor advisory service fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_lbl" xml:lang="en-US">Issuance of commitment shares in connection with the loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_lbl" xml:lang="en-US">Issuance of commitment shares in connection with the loan agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock in connection with Polar note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock in connection with Polar Note, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:label="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_lbl" xml:lang="en-US">Contribution from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:label="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_lbl" xml:lang="en-US">Contribution from related party, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:label="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common stock in settlement of vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common stock in settlement of vested restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_2_lbl" xml:lang="en-US">Change in fair value of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="TVGN_LossOnPreferredStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LossOnPreferredStockIssuance_lbl" xml:lang="en-US">Loss on Series A Preferred Stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnIssuanceOfCommitmentShares" xlink:to="TVGN_LossOnIssuanceOfCommitmentShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares_2_lbl" xml:lang="en-US">Loss on issuance of commitment shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:label="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:to="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Series C Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_lbl" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Payments of deferred transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash &#8211; beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash &#8211; end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplementary disclosure of noncash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:label="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:to="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_lbl" xml:lang="en-US">Reverse recapitalization transaction fees included in accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Conversion of convertible promissory notes into common stock in connection with Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_RepurchaseOfSeriesBPreferredStock" xlink:label="TVGN_RepurchaseOfSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RepurchaseOfSeriesBPreferredStock" xlink:to="TVGN_RepurchaseOfSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_RepurchaseOfSeriesBPreferredStock_lbl" xml:lang="en-US">Repurchase of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract_lbl" xml:lang="en-US">Development-stage Risks And Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_lbl" xml:lang="en-US">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="TVGN_DisclosureEarnoutSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureEarnoutSharesAbstract" xlink:to="TVGN_DisclosureEarnoutSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureEarnoutSharesAbstract_lbl" xml:lang="en-US">Earnout Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesDisclosureTextBlock" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesDisclosureTextBlock" xlink:to="TVGN_EarnoutSharesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock_lbl" xml:lang="en-US">EARNOUT SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="TVGN_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureLeasesAbstract" xlink:to="TVGN_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:label="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:to="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_lbl" xml:lang="en-US">Freestanding and Embedded Common Stock Purchase Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE MEASUREMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUES OF WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:to="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:label="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:to="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:label="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:to="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationSharesExchangeRatio" xlink:label="TVGN_BusinessCombinationSharesExchangeRatio" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationSharesExchangeRatio" xlink:to="TVGN_BusinessCombinationSharesExchangeRatio_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationSharesExchangeRatio_lbl" xml:lang="en-US">Share exchange ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Grant received</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_GrantDrewFromRelatedParty" xlink:label="TVGN_GrantDrewFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_GrantDrewFromRelatedParty" xlink:to="TVGN_GrantDrewFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_GrantDrewFromRelatedParty_lbl" xml:lang="en-US">Grant drew from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_lbl" xml:lang="en-US">Accrued interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_lbl" xml:lang="en-US">Derecognition upon conversion of convertible promissory notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Fair value beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Derivative warrant liabilities, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:to="TVGN_DerivativeLiabilitiesFairValueIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance_lbl" xml:lang="en-US">Initial fair value at issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_3_lbl" xml:lang="en-US">Derivative warrant liabilities, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Convertible promissory notes measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US">Stock, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EquitySecuritiesTerm" xlink:label="TVGN_EquitySecuritiesTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EquitySecuritiesTerm" xlink:to="TVGN_EquitySecuritiesTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EquitySecuritiesTerm_lbl" xml:lang="en-US">Range in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Cash received upon issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreeStandingPurchaseOptions" xlink:label="TVGN_FreeStandingPurchaseOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreeStandingPurchaseOptions" xlink:to="TVGN_FreeStandingPurchaseOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_FreeStandingPurchaseOptions_lbl" xml:lang="en-US">Free standing purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EmbeddedOptions" xlink:label="TVGN_EmbeddedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EmbeddedOptions" xlink:to="TVGN_EmbeddedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_EmbeddedOptions_lbl" xml:lang="en-US">Embedded options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Leases initial term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Due from Sponsor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xml:lang="en-US">Derivative warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total net liabilities acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:label="TVGN_MergerTransactionCostsLimitedToCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:to="TVGN_MergerTransactionCostsLimitedToCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MergerTransactionCostsLimitedToCashAcquired_lbl" xml:lang="en-US">Plus: Merger transaction costs limited to cash acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_lbl" xml:lang="en-US">Total net liabilities acquired plus transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_2_lbl" xml:lang="en-US">Merger transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Transaction costs charged to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Earnout shares issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Earnout shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Converted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xml:lang="en-US">Line of credit borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument variable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US">Line of credit remaining capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xml:lang="en-US">Option to purchase common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of price of common stock purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Purchase, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_lbl" xml:lang="en-US">Issuance of commitment shares in connection with unsecured equity line of credit facility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DisclosureLeasesAbstract" xlink:to="TVGN_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Minimum Rental Payments Under Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:label="TVGN_OperatingLeasesIncrementalBorrowingRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:to="TVGN_OperatingLeasesIncrementalBorrowingRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_OperatingLeasesIncrementalBorrowingRates_lbl" xml:lang="en-US">Operating leases incremental borrowing rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US">Short term lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Nonvested Shares, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Nonvested Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Nonvested Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Nonvested Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4_lbl" xml:lang="en-US">Nonvested Shares, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Nonvested weighted average grant-date fair value, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Nonvested Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of shares issued for RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value per share for award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Grant date fair value of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Compensation cost recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_2_lbl" xml:lang="en-US">Number of shares issued and outstading RSU</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_lbl" xml:lang="en-US">Number of shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Stock-based compensation expense recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Total shares of common stock legally issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Total shares of common stock legally outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_2_lbl" xml:lang="en-US">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:to="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_lbl" xml:lang="en-US">Issuance of restricted common stock subject to forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:to="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_lbl" xml:lang="en-US">Total shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred shares, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="TVGN_LossOnPreferredStockIssuance_2_lbl" xml:lang="en-US">Loss on preferred stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_3_lbl" xml:lang="en-US">Price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="us-gaap_PreferredStockDividendPaymentRateVariable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPaymentRateVariable" xlink:to="us-gaap_PreferredStockDividendPaymentRateVariable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendPaymentRateVariable_lbl" xml:lang="en-US">Dividend variable rate, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionTerms" xlink:to="us-gaap_PreferredStockRedemptionTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xml:lang="en-US">Redemption term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Floor price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock issuance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Non refundable deposist paid</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_lbl" xml:lang="en-US">Conversion of certain liabilities into Series B preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_lbl" xml:lang="en-US">Conversion of certain liabilities into Series B preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ClassOfWarrantOrRightIssued" xlink:label="TVGN_ClassOfWarrantOrRightIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightIssued" xlink:to="TVGN_ClassOfWarrantOrRightIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Exercisable date</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsRedemptionDescription" xlink:label="TVGN_WarrantsRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsRedemptionDescription" xlink:to="TVGN_WarrantsRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_WarrantsRedemptionDescription_lbl" xml:lang="en-US">Warrants redemption description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Cumulative preferred stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="TVGN_StockRepurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockRepurchase" xlink:to="TVGN_StockRepurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockRepurchase_lbl" xml:lang="en-US">Stock repurchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Stock option vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:label="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:to="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_lbl" xml:lang="en-US">Convertible note interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:label="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:to="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_lbl" xml:lang="en-US">Accrued expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsFixedAssets" xlink:label="TVGN_DeferredTaxAssetsFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsFixedAssets" xlink:to="TVGN_DeferredTaxAssetsFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsFixedAssets_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:to="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_lbl" xml:lang="en-US">Capitalized research and development expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:label="TVGN_IncreasesRecordedToIncomeTaxProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:to="TVGN_IncreasesRecordedToIncomeTaxProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_IncreasesRecordedToIncomeTaxProvision_lbl" xml:lang="en-US">Increases recorded to income tax provision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TaxableIncomeLimitationPercentage" xlink:label="TVGN_TaxableIncomeLimitationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TaxableIncomeLimitationPercentage" xlink:to="TVGN_TaxableIncomeLimitationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_TaxableIncomeLimitationPercentage_lbl" xml:lang="en-US">Taxable income percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Income tax penalties and interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="us-gaap_SponsorFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SponsorFees" xlink:to="us-gaap_SponsorFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SponsorFees_lbl" xml:lang="en-US">Sponsor advisory service fee</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorFeesPayable" xlink:label="TVGN_SponsorFeesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorFeesPayable" xlink:to="TVGN_SponsorFeesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_SponsorFeesPayable_lbl" xml:lang="en-US">Sponsor advisory services fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Sponsor fee payable offset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Shares issued to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Due from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_2_lbl" xml:lang="en-US">Compensation cost recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_2_lbl" xml:lang="en-US">Line of credit remaining borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_2_lbl" xml:lang="en-US">Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit Facility additional</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_3_lbl" xml:lang="en-US">Line of credit Facility remaining capacity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStock0.0001ParValuePerShareMember" xlink:to="TVGN_CommonStock0.0001ParValuePerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStock0.0001ParValuePerShareMember_doc" xml:lang="en-US">Common Stock, $0.0001 par value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:to="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember_doc" xml:lang="en-US">Warrants, each exercisable for one share of Common Stock for $11.50 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:to="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ChangeInFairValueOfConvertiblePromissoryNotes_doc" xml:lang="en-US">Change in fair value of convertible promissory notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnIssuanceOfCommitmentShares" xlink:to="TVGN_LossOnIssuanceOfCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LossOnIssuanceOfCommitmentShares_doc" xml:lang="en-US">Loss on issuance of commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesOne_doc" xml:lang="en-US">Stock issued during period value new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:to="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xml:lang="en-US">Stock issued during period value commitment shares in connection with unsecured equity line of credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_doc" xml:lang="en-US">Stock issued during period shares commitment shares in connection with unsecured equity line of credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty_doc" xml:lang="en-US">Stock issued during period value contribution from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:to="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty_doc" xml:lang="en-US">Stock issued during period shares contribution from related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits_doc" xml:lang="en-US">Stock issued during period value settlement of vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LossOnPreferredStockIssuance" xlink:to="TVGN_LossOnPreferredStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LossOnPreferredStockIssuance_doc" xml:lang="en-US">Loss on preferred stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CashAcquiredInConnectionWithReverseRecapitalization_doc" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:to="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock_doc" xml:lang="en-US">Proceeds from issuance of series c preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:to="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance_doc" xml:lang="en-US">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_RepurchaseOfSeriesBPreferredStock" xlink:to="TVGN_RepurchaseOfSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_RepurchaseOfSeriesBPreferredStock_doc" xml:lang="en-US">Repurchase of series B preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:to="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities_doc" xml:lang="en-US">Reverse recapitalization transaction fees included in accrued expenses and other liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationSharesExchangeRatio" xlink:to="TVGN_BusinessCombinationSharesExchangeRatio_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationSharesExchangeRatio_doc" xml:lang="en-US">Business combination shares exchange ratio.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioMember" xlink:to="TVGN_TevogenBioMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TevogenBioMember_doc" xml:lang="en-US">Tevogen Bio [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SemperParatusMember" xlink:to="TVGN_SemperParatusMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SemperParatusMember_doc" xml:lang="en-US">Semper Paratus [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DevelopmentStageRisksAndLiquidityTextBlock_doc" xml:lang="en-US">Development Stage Risks And Liquidity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:to="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_doc" xml:lang="en-US">Freestanding And Embedded Common Stock Options [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:to="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ProbabilityOfFutureLiquidityMember" xlink:to="TVGN_ProbabilityOfFutureLiquidityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ProbabilityOfFutureLiquidityMember_doc" xml:lang="en-US">Probability of Future Liquidity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:to="TVGN_DerivativeLiabilitiesFairValueIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance_doc" xml:lang="en-US">Derivative liabilities fair value issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EquitySecuritiesTerm" xlink:to="TVGN_EquitySecuritiesTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EquitySecuritiesTerm_doc" xml:lang="en-US">Equity securities term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_FreeStandingPurchaseOptions" xlink:to="TVGN_FreeStandingPurchaseOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_FreeStandingPurchaseOptions_doc" xml:lang="en-US">Free standing purchase options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EmbeddedOptions" xlink:to="TVGN_EmbeddedOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EmbeddedOptions_doc" xml:lang="en-US">Embedded options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:to="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock_doc" xml:lang="en-US">Property And Equipment Useful Life [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:to="TVGN_MergerTransactionCostsLimitedToCashAcquired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MergerTransactionCostsLimitedToCashAcquired_doc" xml:lang="en-US">Merger transaction costs limited to cash acquired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed net plus transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesMember" xlink:to="TVGN_EarnoutSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EarnoutSharesMember_doc" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_EarnoutSharesDisclosureTextBlock" xlink:to="TVGN_EarnoutSharesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_EarnoutSharesDisclosureTextBlock_doc" xml:lang="en-US">Earnout Shares [Disclosure Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TevogenBioCommonStockMember" xlink:to="TVGN_TevogenBioCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TevogenBioCommonStockMember_doc" xml:lang="en-US">Tevogen Bio Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorMember" xlink:to="TVGN_SponsorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorMember_doc" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementMember" xlink:to="TVGN_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ThePatelFamilyLLPMember" xlink:to="TVGN_ThePatelFamilyLLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ThePatelFamilyLLPMember_doc" xml:lang="en-US">The Patel Family LLP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_AdditionalAmountPurchaseOptionMember" xlink:to="TVGN_AdditionalAmountPurchaseOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_AdditionalAmountPurchaseOptionMember_doc" xml:lang="en-US">Additional Amount Purchase Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PolarMultiStrategyMasterFundMember" xlink:to="TVGN_PolarMultiStrategyMasterFundMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PolarMultiStrategyMasterFundMember_doc" xml:lang="en-US">Polar Multi-Strategy Master Fund [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TwoThousandTwentyFourPlanMember" xlink:to="TVGN_TwoThousandTwentyFourPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TwoThousandTwentyFourPlanMember_doc" xml:lang="en-US">2024 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ServiceBasedRestrictedStockMember" xlink:to="TVGN_ServiceBasedRestrictedStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ServiceBasedRestrictedStockMember_doc" xml:lang="en-US">Service-Based Restricted Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PerformanceBasedRSUsMember" xlink:to="TVGN_PerformanceBasedRSUsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PerformanceBasedRSUsMember_doc" xml:lang="en-US">Performance-Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:to="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_doc" xml:lang="en-US">Stock issued during period shares settlement of vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:to="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_doc" xml:lang="en-US">Vested performance based restricted stock units from satisfaction of liquidity condition upon closing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:to="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_doc" xml:lang="en-US">Shares subject to future vesting issuance of restricted common stock subject to forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:to="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_doc" xml:lang="en-US">Common stock shares issued and outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SeriesAOnePreferredStockMember" xlink:to="TVGN_SeriesAOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SeriesAOnePreferredStockMember_doc" xml:lang="en-US">Series A1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities_doc" xml:lang="en-US">Stock issued during period shares conversion of liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:to="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities_doc" xml:lang="en-US">Stock issued during period value conversion of liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ClassOfWarrantOrRightIssued" xlink:to="TVGN_ClassOfWarrantOrRightIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ClassOfWarrantOrRightIssued_doc" xml:lang="en-US">Class of warrant or right issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PublicWarrantsMember" xlink:to="TVGN_PublicWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PublicWarrantsMember_doc" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WarrantsRedemptionDescription" xlink:to="TVGN_WarrantsRedemptionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WarrantsRedemptionDescription_doc" xml:lang="en-US">Warrants redemption description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorFeesPayable" xlink:to="TVGN_SponsorFeesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorFeesPayable_doc" xml:lang="en-US">Sponsor advisory services fee payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_SponsorAdvisoryServicesFeeMember" xlink:to="TVGN_SponsorAdvisoryServicesFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_SponsorAdvisoryServicesFeeMember_doc" xml:lang="en-US">Sponsor Advisory Services Fee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_WifeOfChiefExecutiveOfficerMember" xlink:to="TVGN_WifeOfChiefExecutiveOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_WifeOfChiefExecutiveOfficerMember_doc" xml:lang="en-US">Wife of Chief Executive Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MehtaphoricConsultingIncMember" xlink:to="TVGN_MehtaphoricConsultingIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MehtaphoricConsultingIncMember_doc" xml:lang="en-US">Mehtaphoric Consulting Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PrivateInvestorMember" xlink:label="TVGN_PrivateInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivateInvestorMember" xlink:to="TVGN_PrivateInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PrivateInvestorMember_doc" xml:lang="en-US">Private Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DrManmohanPatelMember" xlink:to="TVGN_DrManmohanPatelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DrManmohanPatelMember_doc" xml:lang="en-US">Dr Manmohan Patel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:to="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Company Lease Liabilities [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:to="TVGN_OperatingLeasesIncrementalBorrowingRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_OperatingLeasesIncrementalBorrowingRates_doc" xml:lang="en-US">Operating leases incremental borrowing rates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:to="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_doc" xml:lang="en-US">Income tax reconciliation income tax expense benefit convertible noteinterest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsOperatingLeaseLiabilities_doc" xml:lang="en-US">Deferred tax assets operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:to="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsAccruedExpensesAndOther_doc" xml:lang="en-US">Deferred tax assets accrued expenses and other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsFixedAssets" xlink:to="TVGN_DeferredTaxAssetsFixedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsFixedAssets_doc" xml:lang="en-US">Deferred tax assets fixed assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:to="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_doc" xml:lang="en-US">Deferred tax assets capitalized research and development expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_doc" xml:lang="en-US">Deferred tax liabilities right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:to="TVGN_IncreasesRecordedToIncomeTaxProvision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_IncreasesRecordedToIncomeTaxProvision_doc" xml:lang="en-US">Increases recorded to income tax provision.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:to="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Valuation Allowance For Net Deferred Tax Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_TaxableIncomeLimitationPercentage" xlink:to="TVGN_TaxableIncomeLimitationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_TaxableIncomeLimitationPercentage_doc" xml:lang="en-US">Taxable income limitation percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_GrantDrewFromRelatedParty" xlink:to="TVGN_GrantDrewFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_GrantDrewFromRelatedParty_doc" xml:lang="en-US">Grant drew from related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueNewIssuesTwo_doc" xml:lang="en-US">Stock issued during period value new issues two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_doc" xml:lang="en-US">Stock issued during period shares new issues two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_ComputerAndSoftwareMember" xlink:to="TVGN_ComputerAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_ComputerAndSoftwareMember_doc" xml:lang="en-US">Computer And Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PrivateWarrantsMember" xlink:label="TVGN_PrivateWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_PrivateWarrantsMember" xlink:to="TVGN_PrivateWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_PrivateWarrantsMember_doc" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:to="TVGN_MergerNetOfRedemptionsAndTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts_doc" xml:lang="en-US">Merger net of redemptions and transaction costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LinesOfCreditNoncurrent" xlink:label="TVGN_LinesOfCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LinesOfCreditNoncurrent" xlink:to="TVGN_LinesOfCreditNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LinesOfCreditNoncurrent_doc" xml:lang="en-US">Lines of credit non current.</link:label>
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreement" xlink:label="TVGN_LoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreement" xlink:to="TVGN_LoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LoanAgreement_doc" xml:lang="en-US">Loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement_doc" xml:lang="en-US">Stock issued during period value commitment shares in connection with loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:to="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement_doc" xml:lang="en-US">Stock issued during period shares commitment shares in connection with loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_LoanAgreementNoncurrent" xlink:to="TVGN_LoanAgreementNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_LoanAgreementNoncurrent_doc" xml:lang="en-US">Loan agreement non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockRepurchase" xlink:to="TVGN_StockRepurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_StockRepurchase_doc" xml:lang="en-US">Stock repurchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_KRHPLLCMember" xlink:to="TVGN_KRHPLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="TVGN_KRHPLLCMember_doc" xml:lang="en-US">KRHP LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_2_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_3_lbl" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesNewIssuesTwo</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:to="TVGN_MergerNetOfRedemptionsAndTransactionCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_MergerNetOfRedemptionsAndTransactionCosts_3_lbl" xml:lang="en-US">MergerNetOfRedemptionsAndTransactionCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_2_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_2_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:to="TVGN_DerivativeLiabilitiesFairValueIssuance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DerivativeLiabilitiesFairValueIssuance_3_lbl" xml:lang="en-US">DerivativeLiabilitiesFairValueIssuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:to="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="TVGN_DeferredTaxLiabilitiesRightOfUseAsset_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>tvgn-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tevogen.com/role/Cover" xlink:href="tvgn-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheets" xlink:href="tvgn-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:href="tvgn-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfOperations" xlink:href="tvgn-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:href="tvgn-20241231.xsd#StatementsOfChangesInStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="tvgn-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusiness" xlink:href="tvgn-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombination" xlink:href="tvgn-20241231.xsd#BusinessCombination" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutShares" xlink:href="tvgn-20241231.xsd#EarnoutShares" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Debt" xlink:href="tvgn-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Leases" xlink:href="tvgn-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/CommitmentsAndContingencies" xlink:href="tvgn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensation" xlink:href="tvgn-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficit" xlink:href="tvgn-20241231.xsd#StockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShare" xlink:href="tvgn-20241231.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxes" xlink:href="tvgn-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactions" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SegmentReporting" xlink:href="tvgn-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEvents" xlink:href="tvgn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationTables" xlink:href="tvgn-20241231.xsd#BusinessCombinationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="tvgn-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesTables" xlink:href="tvgn-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationTables" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitTables" xlink:href="tvgn-20241231.xsd#StockholdersDeficitTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareTables" xlink:href="tvgn-20241231.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesTables" xlink:href="tvgn-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:href="tvgn-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:href="tvgn-20241231.xsd#Development-stageRisksAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValueMeasurementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfFairValuesOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="tvgn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:href="tvgn-20241231.xsd#BusinessCombinationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:href="tvgn-20241231.xsd#EarnoutSharesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="tvgn-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/DebtDetailsNarrative" xlink:href="tvgn-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/LeasesDetailsNarrative" xlink:href="tvgn-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="tvgn-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:href="tvgn-20241231.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfNetLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:href="tvgn-20241231.xsd#ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:href="tvgn-20241231.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:href="tvgn-20241231.xsd#ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:href="tvgn-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="tvgn-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:href="tvgn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_TVGNCommonStock0.0001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNCommonStock0.0001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:label="loc_TVGNWarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNWarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementNoncurrent" xlink:label="loc_TVGNLoanAgreementNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_TVGNLoanAgreementNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerNetOfRedemptionsAndTransactionCosts" xlink:label="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNMergerNetOfRedemptionsAndTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueContributionFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesContributionFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement -  Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaapNoncashMergerRelatedCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNoncashMergerRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ChangeInFairValueOfConvertiblePromissoryNotes" xlink:label="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNChangeInFairValueOfConvertiblePromissoryNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnIssuanceOfCommitmentShares" xlink:label="loc_TVGNLossOnIssuanceOfCommitmentShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_TVGNLossOnIssuanceOfCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TVGNCashAcquiredInConnectionWithReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock" xlink:label="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TVGNProceedsFromIssuanceOfSeriesCPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:label="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_TVGNNonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:label="loc_TVGNReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_RepurchaseOfSeriesBPreferredStock" xlink:label="loc_TVGNRepurchaseOfSeriesBPreferredStock" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_TVGNRepurchaseOfSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock_2" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusiness" xlink:title="999014 - Disclosure - NATURE OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidity" xlink:title="999015 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DevelopmentStageRisksAndLiquidityTextBlock" xlink:label="loc_TVGNDevelopmentStageRisksAndLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="loc_TVGNDevelopmentStageRisksAndLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombination" xlink:title="999017 - Disclosure - BUSINESS COMBINATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutShares" xlink:title="999018 - Disclosure - EARNOUT SHARES">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="loc_TVGNDisclosureEarnoutSharesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesDisclosureTextBlock" xlink:label="loc_TVGNEarnoutSharesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureEarnoutSharesAbstract" xlink:to="loc_TVGNEarnoutSharesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNet" xlink:title="999019 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999020 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Debt" xlink:title="999021 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Leases" xlink:title="999022 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLessorDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficit" xlink:title="999025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShare" xlink:title="999026 - Disclosure - NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxes" xlink:title="999027 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactions" xlink:title="999028 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SegmentReporting" xlink:title="999029 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:label="loc_TVGNFreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNFreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="loc_TVGNPropertyAndEquipmentUsefulLifeTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_TVGNPropertyAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationTables" xlink:title="999033 - Disclosure - BUSINESS COMBINATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetTables" xlink:title="999034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999035 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesTables" xlink:title="999036 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:label="loc_TVGNScheduleOfCompanyLeaseLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_TVGNScheduleOfCompanyLeaseLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationTables" xlink:title="999037 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitTables" xlink:title="999038 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareTables" xlink:title="999039 - Disclosure - NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:label="loc_TVGNScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999041 - Disclosure - NATURE OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNSemperParatusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationSharesExchangeRatio" xlink:label="loc_TVGNBusinessCombinationSharesExchangeRatio" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNBusinessCombinationSharesExchangeRatio" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative" xlink:title="999042 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:label="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureDevelopmentstageRisksAndLiquidityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_GrantDrewFromRelatedParty" xlink:label="loc_TVGNGrantDrewFromRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_TVGNGrantDrewFromRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails" xlink:title="999043 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:label="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails" xlink:title="999044 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CallOptionMember" xlink:label="loc_us-gaapCallOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapCallOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DerivativeLiabilitiesFairValueIssuance" xlink:label="loc_TVGNDerivativeLiabilitiesFairValueIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_TVGNDerivativeLiabilitiesFairValueIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999045 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" xlink:title="999046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaapMeasurementInputDiscountRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDiscountRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ProbabilityOfFutureLiquidityMember" xlink:label="loc_TVGNProbabilityOfFutureLiquidityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_TVGNProbabilityOfFutureLiquidityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="loc_us-gaapEquitySecuritiesFvNiMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EquitySecuritiesTerm" xlink:label="loc_TVGNEquitySecuritiesTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEquitySecuritiesTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_FreeStandingPurchaseOptions" xlink:label="loc_TVGNFreeStandingPurchaseOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNFreeStandingPurchaseOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EmbeddedOptions" xlink:label="loc_TVGNEmbeddedOptions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_TVGNEmbeddedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails" xlink:title="999048 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MergerTransactionCostsLimitedToCashAcquired" xlink:label="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNMergerTransactionCostsLimitedToCashAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:label="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_TVGNBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/BusinessCombinationDetailsNarrative" xlink:title="999049 - Disclosure - BUSINESS COMBINATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioMember" xlink:label="loc_TVGNTevogenBioMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_TVGNTevogenBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueNewIssuesOne" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/EarnoutSharesDetailsNarrative" xlink:title="999050 - Disclosure - EARNOUT SHARES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureEarnoutSharesAbstract" xlink:label="loc_TVGNDisclosureEarnoutSharesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureEarnoutSharesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TevogenBioCommonStockMember" xlink:label="loc_TVGNTevogenBioCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNTevogenBioCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ComputerAndSoftwareMember" xlink:label="loc_TVGNComputerAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_TVGNComputerAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999052 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/DebtDetailsNarrative" xlink:title="999054 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PolarMultiStrategyMasterFundMember" xlink:label="loc_TVGNPolarMultiStrategyMasterFundMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNPolarMultiStrategyMasterFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_AdditionalAmountPurchaseOptionMember" xlink:label="loc_TVGNAdditionalAmountPurchaseOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_TVGNAdditionalAmountPurchaseOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails" xlink:title="999055 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/LeasesDetailsNarrative" xlink:title="999056 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DisclosureLeasesAbstract" xlink:label="loc_TVGNDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_TVGNDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_OperatingLeasesIncrementalBorrowingRates" xlink:label="loc_TVGNOperatingLeasesIncrementalBorrowingRates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_TVGNOperatingLeasesIncrementalBorrowingRates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails" xlink:title="999057 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999058 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999059 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TwoThousandTwentyFourPlanMember" xlink:label="loc_TVGNTwoThousandTwentyFourPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_TVGNTwoThousandTwentyFourPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ServiceBasedRestrictedStockMember" xlink:label="loc_TVGNServiceBasedRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNServiceBasedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails" xlink:title="999060 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:label="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNVestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:label="loc_TVGNSharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNSharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:label="loc_TVGNCommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_TVGNCommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/StockholdersDeficitDetailsNarrative" xlink:title="999061 - Disclosure - STOCKHOLDERS&#8217; DEFICIT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SeriesAOnePreferredStockMember" xlink:label="loc_TVGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_TVGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SemperParatusMember" xlink:label="loc_TVGNSemperParatusMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSemperParatusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PublicWarrantsMember" xlink:label="loc_TVGNPublicWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_TVGNPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LossOnPreferredStockIssuance" xlink:label="loc_TVGNLossOnPreferredStockIssuance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNLossOnPreferredStockIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentRateVariable" xlink:label="loc_us-gaapPreferredStockDividendPaymentRateVariable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentRateVariable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaapPreferredStockRedemptionPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaapPreferredStockRedemptionTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodSharesConversionOfLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities" xlink:label="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNStockIssuedDuringPeriodValueConversionOfLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLiabilitiesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ClassOfWarrantOrRightIssued" xlink:label="loc_TVGNClassOfWarrantOrRightIssued" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNClassOfWarrantOrRightIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WarrantsRedemptionDescription" xlink:label="loc_TVGNWarrantsRedemptionDescription" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_TVGNWarrantsRedemptionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails" xlink:title="999062 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_StockRepurchase" xlink:label="loc_TVGNStockRepurchase" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_TVGNStockRepurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails" xlink:title="999063 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_EarnoutSharesMember" xlink:label="loc_TVGNEarnoutSharesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_TVGNEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical" xlink:title="999064 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/NetLossPerShareDetailsNarrative" xlink:title="999065 - Disclosure - NET LOSS PER SHARE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails" xlink:title="999066 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:label="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNIncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999067 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsAccruedExpensesAndOther" xlink:label="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsAccruedExpensesAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsFixedAssets" xlink:label="loc_TVGNDeferredTaxAssetsFixedAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNDeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails" xlink:title="999068 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_IncreasesRecordedToIncomeTaxProvision" xlink:label="loc_TVGNIncreasesRecordedToIncomeTaxProvision" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNIncreasesRecordedToIncomeTaxProvision" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/IncomeTaxesDetailsNarrative" xlink:title="999069 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_TaxableIncomeLimitationPercentage" xlink:label="loc_TVGNTaxableIncomeLimitationPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_TVGNTaxableIncomeLimitationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999070 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorMember" xlink:label="loc_TVGNSponsorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_MehtaphoricConsultingIncMember" xlink:label="loc_TVGNMehtaphoricConsultingIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNMehtaphoricConsultingIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_ThePatelFamilyLLPMember" xlink:label="loc_TVGNThePatelFamilyLLPMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNThePatelFamilyLLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_DrManmohanPatelMember" xlink:label="loc_TVGNDrManmohanPatelMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNDrManmohanPatelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorAdvisoryServicesFeeMember" xlink:label="loc_TVGNSponsorAdvisoryServicesFeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNSponsorAdvisoryServicesFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_LoanAgreementMember" xlink:label="loc_TVGNLoanAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_TVGNLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_PerformanceBasedRSUsMember" xlink:label="loc_TVGNPerformanceBasedRSUsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_TVGNPerformanceBasedRSUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_WifeOfChiefExecutiveOfficerMember" xlink:label="loc_TVGNWifeOfChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_TVGNWifeOfChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaapUnsecuredDebtMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapUnsecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SponsorFees" xlink:label="loc_us-gaapSponsorFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSponsorFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_SponsorFeesPayable" xlink:label="loc_TVGNSponsorFeesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_TVGNSponsorFeesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tevogen.com/role/SubsequentEventsDetailsNarrative" xlink:title="999071 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tvgn-20241231.xsd#TVGN_KRHPLLCMember" xlink:label="loc_TVGNKRHPLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_TVGNKRHPLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 21, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tevogen
Bio Holdings Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001860871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1597194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15
    Independence Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite #410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-6434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,893,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions
of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2025 Annual Meeting of Stockholders are incorporated
by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the
Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Tevogen Bio Holdings Inc. and subsidiaries (the Company) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; deficit, and cash flows for the
years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia,
Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_CommonStock0.0001ParValuePerShareMember', window );">Common Stock, $0.0001 par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TVGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember', window );">Warrants, each exercisable for one share of Common Stock for $11.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants,
    each exercisable for one share of Common Stock for $11.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TVGNW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_CommonStock0.0001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_CommonStock0.0001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,282,995<span></span>
</td>
<td class="nump">$ 1,052,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">919,088<span></span>
</td>
<td class="nump">670,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,360,902<span></span>
</td>
<td class="nump">1,722,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">296,442<span></span>
</td>
<td class="nump">458,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">228,490<span></span>
</td>
<td class="nump">469,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,582,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">575,841<span></span>
</td>
<td class="nump">271,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,461,675<span></span>
</td>
<td class="nump">5,505,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,200,245<span></span>
</td>
<td class="nump">3,418,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,712,396<span></span>
</td>
<td class="nump">1,096,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">229,063<span></span>
</td>
<td class="nump">252,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80,712,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,042,704<span></span>
</td>
<td class="nump">85,479,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LoanAgreementNoncurrent', window );">Loan agreement</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">234,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">87,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,135,680<span></span>
</td>
<td class="nump">99,934,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000 shares authorized; 177,991,365 and 119,999,989 shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="nump">17,800<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">97,893,322<span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(113,385,117)<span></span>
</td>
<td class="num">(99,657,737)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(6,674,005)<span></span>
</td>
<td class="num">(94,428,897)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">3,461,675<span></span>
</td>
<td class="nump">5,505,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="nump">2,799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related party</a></td>
<td class="nump">158,819<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related party</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LoanAgreementNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan agreement non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LoanAgreementNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 2,076,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 6,082,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 31,033,276<span></span>
</td>
<td class="nump">$ 4,403,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,531,212<span></span>
</td>
<td class="nump">4,439,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">53,564,488<span></span>
</td>
<td class="nump">8,843,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(53,564,488)<span></span>
</td>
<td class="num">(8,843,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(184,037)<span></span>
</td>
<td class="num">(1,206,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger transaction costs</a></td>
<td class="num">(7,499,353)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="num">(58,180)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">48,468,678<span></span>
</td>
<td class="num">(50,428,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnIssuanceOfCommitmentShares', window );">Loss on issuance of commitment shares</a></td>
<td class="num">(890,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,727,380)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(10,273,695)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (10,273,695)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic</a></td>
<td class="nump">146,672,534<span></span>
</td>
<td class="nump">24,752,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted</a></td>
<td class="nump">146,672,534<span></span>
</td>
<td class="nump">24,752,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInFairValueOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnIssuanceOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnIssuanceOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 5,216,840<span></span>
</td>
<td class="num">$ (39,180,057)<span></span>
</td>
<td class="num">$ (33,951,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">5,216,840<span></span>
</td>
<td class="num">(99,657,737)<span></span>
</td>
<td class="num">(94,428,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,727,380)<span></span>
</td>
<td class="num">(13,727,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A preferred stock</a></td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,799,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock, shares</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesTwo', window );">Issuance of Series C preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Issuance of preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of Series B preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,613,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Issuance of Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="nump">46,621,593<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">46,622,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes into common stock in connection with merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MergerNetOfRedemptionsAndTransactionCosts', window );">Merger, net of redemptions and transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="num">(2,885,459)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,883,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Merger, net of redemptions and transaction costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,778,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,935<span></span>
</td>
<td class="num">(1,935)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for Sponsor advisory service fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">676,485<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">676,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for Sponsor advisory service fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement', window );">Issuance of commitment shares in connection with the loan agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">889,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">890,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement', window );">Issuance of commitment shares in connection with the loan agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock in connection with Polar note</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock in connection with Polar Note, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty', window );">Contribution from related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,613,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty', window );">Contribution from related party, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits', window );">Issuance of common stock in settlement of vested restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="num">(1,088)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits', window );">Issuance of common stock in settlement of vested restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,876,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,764,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,764,136<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="nump">$ 97,893,322<span></span>
</td>
<td class="num">$ (113,385,117)<span></span>
</td>
<td class="num">$ (6,674,005)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MergerNetOfRedemptionsAndTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger net of redemptions and transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MergerNetOfRedemptionsAndTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares commitment shares in connection with loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares contribution from related party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares settlement of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value commitment shares in connection with loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value contribution from related party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value settlement of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong> Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,727,380)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">162,209<span></span>
</td>
<td class="nump">163,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">40,764,136<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">187,575<span></span>
</td>
<td class="nump">1,206,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Merger transaction costs</a></td>
<td class="nump">7,099,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes', window );">Change in fair value of convertible promissory notes</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">50,428,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on Series A Preferred Stock issuance</a></td>
<td class="nump">799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnIssuanceOfCommitmentShares', window );">Loss on issuance of commitment shares</a></td>
<td class="nump">890,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">58,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">241,372<span></span>
</td>
<td class="nump">215,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(246,005)<span></span>
</td>
<td class="num">(317,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(511,011)<span></span>
</td>
<td class="nump">323,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,685,692<span></span>
</td>
<td class="nump">1,114,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(681,450)<span></span>
</td>
<td class="num">(603,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(252,713)<span></span>
</td>
<td class="num">(223,361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,998,730)<span></span>
</td>
<td class="num">(8,171,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_CashAcquiredInConnectionWithReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">229,328<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series A Preferred Stock</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock', window );">Proceeds from issuance of Series C Preferred Stock</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from loan agreement</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance', window );">Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments of deferred transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(127,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,229,328<span></span>
</td>
<td class="nump">3,872,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">230,598<span></span>
</td>
<td class="num">(4,431,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of period</a></td>
<td class="nump">1,052,397<span></span>
</td>
<td class="nump">5,484,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of period</a></td>
<td class="nump">1,282,995<span></span>
</td>
<td class="nump">1,052,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities', window );">Reverse recapitalization transaction fees included in accrued expenses and other liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,455,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of convertible promissory notes into common stock in connection with Merger</a></td>
<td class="nump">46,622,627<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_RepurchaseOfSeriesBPreferredStock', window );">Repurchase of Series B preferred stock</a></td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs</a></td>
<td class="nump">$ 3,113,309<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CashAcquiredInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CashAcquiredInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ChangeInFairValueOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ChangeInFairValueOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnIssuanceOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on issuance of commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnIssuanceOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of series c preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_RepurchaseOfSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of series B preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_RepurchaseOfSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization transaction fees included in accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (13,727,380)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risks</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management processes are integrated into our overall approach to risk management. Given the nature and size of our
Company, we do not have a dedicated enterprise risk function, but our executives regularly consider and evaluate risks to our Company.
As part of that risk management process, members of our executive team identify, assess,&#160;and evaluate risks impacting our operations,
including those risks related to cybersecurity, and raise them for discussion with other executives, and where it is determined to be
appropriate, issues are also raised to the Board for consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_dbT_c20240101__20241231_zgQ8dgrVqXk6">we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zkXZL3j403Tc">no</span>t aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity
incidents, that have materially affected our business strategy, results of operations,&#160;or financial condition or are reasonably
likely to have such a material effect</span>. While we have implemented a cybersecurity program, the techniques used to infiltrate information
technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement security
measures adequate to prevent cybersecurity incidents or fully mitigate their impact. For additional information regarding risks relating
to privacy and cybersecurity, see &#8220;Item 1A&#8212;Risk Factors&#8221;.</span></p>

</div><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Program</b></span><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
security and availability of our information systems and the protection of the information we collect, create, process, and store are
important to our business. We have implemented a cybersecurity program that is designed to support both the effectiveness of our systems
and our preparedness for information security risks. This program includes a number of safeguards, such as: multi-factor authentication;
monitoring internal and cloud-based systems for threats; email filters; cybersecurity awareness training; limitation on the use of third-party
devices; conditional access rules; and regular evaluations of our cybersecurity program.</span></p>

&#160;<span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_i01_dbT_c20240101__20241231_zAHdpa5PWZpk">We
use a risk-based approach with respect to our use and oversight of third-party service providers and vendors, tailoring processes according
to the nature and sensitivity of the data accessed, processed, or stored by such third-party service provider. We use numerous means
to assess cyber risks related to our third-party service providers, including for example use of a managed security service provider
(&#8220;MSSP&#8221;) that monitors cybersecurity events for our cloud systems. We also seek to include appropriate security terms in
our contracts where applicable as part of our oversight of third-party service providers.</span></span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zkXZL3j403Tc">no</span>t aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity
incidents, that have materially affected our business strategy, results of operations,&#160;or financial condition or are reasonably
likely to have such a material effect<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management
Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
controls and processes employed to assess, identify,&#160;and manage material risks from cybersecurity threats are implemented and overseen
by <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_i01_dbT_c20240101__20241231_z2qwTKXXXNql">our Chief Information Officer (&#8220;CIO&#8221;). Our CIO has more than 20 years of information technology experience, including
seven years specializing in cybersecurity. Our CIO is responsible for assessing the impact of cybersecurity threats and incidents, assessing
whether and to what extent they can be contained and mitigated, containing and mitigating them, remediating incidents, and performing
post-incident analysis and program enhancements. In the event of a significant cybersecurity incident, our CIO would engage senior management
to inform them of the incident and related threats and response. We would also likely engage a third-party incident response vendor to
assist us in the event of a significant cybersecurity incident. Our Chief Executive Officer directly oversees our CIO and receives information
on cybersecurity risks from our CIO. Our CIO, in turn, is informed about risks from cybersecurity threats through dashboards, email alerts,
reporting from the MSSP, and regular review of our systems and information technology environment</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board
Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Board has overall responsibility for risk oversight, the Board delegated to the audit committee the responsibility for assisting
the Board with oversight and monitoring of matters relating to our risk assessment, risk management, and risk mitigation policies and
programs, including matters related to privacy, information technology,&#160;and cybersecurity, and for reviewing and discussing with
management our risk exposures related to these matters. In its oversight role, the Board is expected to specifically consider risks that
relate to our reputation and the general industry in which we operate, including with respect to privacy, information technology and
cybersecurity,&#160;and threats to technology infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CIO may report to and brief the Board and the audit committee on cybersecurity matters, including key risks, the potential impact of
those exposures on our business, financial results, operations, and reputation, as well as the programs and steps implemented by management
to monitor and mitigate risks<b><i>.</i></b> The reporting cadence and structure continues to develop.</span></p>

</div><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Program</b></span><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
security and availability of our information systems and the protection of the information we collect, create, process, and store are
important to our business. We have implemented a cybersecurity program that is designed to support both the effectiveness of our systems
and our preparedness for information security risks. This program includes a number of safeguards, such as: multi-factor authentication;
monitoring internal and cloud-based systems for threats; email filters; cybersecurity awareness training; limitation on the use of third-party
devices; conditional access rules; and regular evaluations of our cybersecurity program.</span></p>

&#160;<span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_i01_dbT_c20240101__20241231_zAHdpa5PWZpk">We
use a risk-based approach with respect to our use and oversight of third-party service providers and vendors, tailoring processes according
to the nature and sensitivity of the data accessed, processed, or stored by such third-party service provider. We use numerous means
to assess cyber risks related to our third-party service providers, including for example use of a managed security service provider
(&#8220;MSSP&#8221;) that monitors cybersecurity events for our cloud systems. We also seek to include appropriate security terms in
our contracts where applicable as part of our oversight of third-party service providers.</span></span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF BUSINESS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCNaGI6GbMM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82B_zN9tcoyn3jBc">NATURE OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevogen
Bio Holdings Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage specialty immunotherapy company harnessing
the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases,
cancers, and other disorders. The Company&#8217;s precision T cell technology, ExacTcell, is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets.
The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of
ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024 (the &#8220;Closing Date&#8221;), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the &#8220;Merger
Agreement&#8221;) by and among Semper Paratus Acquisition Corporation (&#8220;Semper Paratus&#8221;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#8220;Merger Sub&#8221;), SSVK Associates, LLC (the &#8220;Sponsor&#8221;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#8220;Tevogen Bio&#8221;), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the &#8220;Merger&#8221;
and together with the other transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the closing of the Business Combination (the &#8220;Closing&#8221;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately&#160;<span id="xdx_909_ecustom--BusinessCombinationSharesExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9kQzOCdLY6" title="Share exchange ratio">4.85</span>&#160;shares of Company
common stock for each share of Tevogen Bio common stock (the &#8220;Exchange Ratio&#8221;). See Note 4 for more information on the Business
Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_z8YaQSRt0PL" title="Equity holders percentage">91.0</span>% of the outstanding shares
of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SemperParatusMember_zS1x4Q5pwyxe" title="Equity ownership percentage">9.0</span>%
of the Company.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT-STAGE RISKS AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract', window );"><strong>Development-stage Risks And Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DevelopmentStageRisksAndLiquidityTextBlock', window );">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</a></td>
<td class="text"><p id="xdx_80E_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zSEL1kYFLT55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_825_zdaGSlgqJht8">DEVELOPMENT-STAGE RISKS AND LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring
additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in
development. Management believes that cash of $<span id="xdx_901_eus-gaap--Cash_iI_c20241231_zGHO8recjvFj" title="Cash">1,282,995</span>
as of December 31, 2024, the amounts available under the Loan Agreement entered into in June 2024 (as defined in Note 8), and the
commitment for an $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zaK1MocjrLd5" title="Grant received">8,000,000</span> grant from KRHP LLC, a New Jersey limited liability company (&#8220;KRHP&#8221;), will allow the
Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these
consolidated financial statements. Subsequent to December 31, 2024, the Company received a grant of $<span id="xdx_907_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziCgx2cNVqQ6" title="Grant received">2,000,000</span>
from KRHP and drew $<span id="xdx_90C_ecustom--GrantDrewFromRelatedParty_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUKBhXmPDXii" title="Grant drew from related party">1,000,000</span>
in each of February 2025 and in March 2025 under the Loan Agreement. The grant funding may not be used for repayment of existing
debt obligations and does not include any requirement to repay the investor or to issue equity in consideration of the funding. KRHP
has committed to provide an additional $<span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_ztrY5a1rcjvc" title="Grant received">8,000,000</span> of grant funding to the Company to be used towards the Company&#8217;s ongoing
operational expenses. The grant funding will be used to satisfy the Company&#8217;s obligations as they come due through March 31,
2026. The Company does not plan to initiate a clinical trial until additional funding is received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect
the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and a clinical trial, and pursuing and completing the Business Combination. The Company is
subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
The Company&#8217;s research and development projects may not be successful, products developed may not obtain necessary regulatory approval,
and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change
and is largely dependent on the services of its employees and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DevelopmentStageRisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Stage Risks And Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DevelopmentStageRisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zFtpcnRqHCDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82D_zIoAw2Lo0PA">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z6zGIDk7hIo2">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z9OsFUUKNFM7">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjZOTYXrYvW1">Freestanding
and Embedded Common Stock Purchase Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-linked
purchase options issued in connection with the Company&#8217;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;<i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity&#160;</i>(&#8220;ASC
815&#8221;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#8217;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#8216;Change in
fair value of written call option derivative liabilities&#8217; within the consolidated statements of operations and consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zBYIf29m4TMl">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zqy1DxfGgale">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zCdpbsx6vrej" title="Number of operating segments">one</span> segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zTyoPxhDqOEb">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public offering
(the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </i>(&#8220;ASC
815&#8221;) and ASC 480,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480&#8221;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#8217;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zPsHFdIWiME8">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory
notes.</span></p>

<p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance">39,297,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance">4,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense">1,206,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">50,428,303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance">94,932,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (<span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z545EdZ4cnwb" title="Volatility">80</span>%), discount rate (<span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zECVEqwfbOp5" title="Volatility">35</span>% - <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_zzwuKcFjoQk4" title="Volatility">36</span>%), and probability of a future liquidity event (<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zEjMN6sa3IMj" title="Volatility">85</span>% - <span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_zbUb1Yp6ohjb" title="Convertible promissory notes measurement input">95</span>%). The Company
used its stock price on the Closing Date to determine the fair value for the  derecognition of the convertible promissory notes
upon conversion on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuQ5OVhtN1ue">58,180</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#8217;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgANSzrkc1n5">375,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.</span></p>

<p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE OF FAIR VALUES OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written call option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at February 15, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance">29,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance">375,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">58,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(375,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance">87,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets <br/> (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs <br/> (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Unobservable <br/> Inputs (Level 3)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities">87,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#8220;MCS&#8221;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;<span id="xdx_908_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zo9yBcrmtNi7" title="Stock, measurement input">75</span>% to&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi" title="Alternative investment, measurement input">85</span>%, a holding
period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;<span id="xdx_907_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zNKj7Fj8NTb3" title="Holding period">0.5</span>&#160;to&#160;<span id="xdx_905_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_z7eHCVkhCn6" title="Range in years">10.0</span>&#160;years,
and a risk-free interest rate between&#160;<span id="xdx_903_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ztGJw2vPfY57" title="Risk-free interest rate percentage">4.3</span>% and&#160;<span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z0dBlZtpCM79" title="Stock, measurement input">5.3</span>%. The difference between the cash received of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsEMs6S6rOn8" title="Cash received upon issuance of preferred stock">2,000,000</span>&#160;upon issuance
of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a MCS valuation methodology to determine the fair value of the freestanding $<span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zu2sTFTPziLj" title="Free standing purchase options">14,000,000</span>&#160;purchase option and remaining
embedded $<span id="xdx_90C_ecustom--EmbeddedOptions_c20240101__20241231_zc8eFNvcHCu5" title="Embedded options">30,000,000</span>&#160;purchase option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the
Company&#8217;s future stock price to estimate if and when the Trailing VWAP (as defined below) will reach $<span id="xdx_907_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zV3ZldBNhFwg">10.00</span>&#160;per share, and
discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;<span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7">78.3</span>% and discount rate of&#160;<span id="xdx_90B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zXlSz5FcJLKh">4.3</span>%. At December 31, 2024, the MCS produced
a fair value of $<span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zbJgzA6FSiy6" title="Fair value">0</span> relating to these freestanding and embedded options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zfPQfeKGxXZ1">Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_ziFSTW2Sk4gi" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zTSLrHP6qI37" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zoqVO2hfbssd">Property
and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life">5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life">4</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life">5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life">7</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z4mqZGMPTzPj">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zlzIGLkluEAc" title="Leases initial term">12 months</span> or less and without a purchase option that the Company is reasonably certain of exercising are not
included within the lease ROU assets and lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z51STCTlamK2">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zN8KNyRNRiS1">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#8217;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zldsYnnmPWEb">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_znCeJn71YSG1">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#8217;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOYer4WwVUw5">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07,&#160;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;</i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) </i>(&#8220;ASU 2024-03&#8221;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.</span></p>

<p id="xdx_853_znCRnm9LZro" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zqNIOxtWAU41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4.&#160;<span id="xdx_82A_zDbQ2iMDygAd">BUSINESS COMBINATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including
that following the Merger, former Tevogen Bio (i) equity holders and holders of convertible promissory notes owned approximately&#160;<span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zjhGpEZDB0vh" title="Ownership percentage">91.0</span>%
of the Company, (ii) directors constituted the majority (six of seven) of the directors of the Company, and (iii) management held all
key positions of management of the Company. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire
the net assets of Semper Paratus. As a result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date
fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Tevogen Bio.
Immediately after the Merger, there were&#160;<span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20240214_z753sBkvdcH" title="Common stock, shares outstanding">164,614,418</span>&#160;shares of the Company&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zCTQj89vyov1" style="display: none">SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February&#160;14,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">229,328</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,819</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,501</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,175</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,269,126</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,651,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Derivative warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,654,653</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(229,328</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,883,981</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A2_zqlUY39z45fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
transaction costs of $<span id="xdx_908_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240214__20240214_zP1fDqF5q1kd" title="Transaction costs">7,728,681</span>&#160;were incurred in relation to the Business Combination through the Closing Date, of which $<span id="xdx_909_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_zDfqsdo3iXNk" title="Transaction costs charged to equity">229,328</span>&#160;were
charged directly to equity to the extent of the cash received from the Business Combination, with the balance of $<span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240101__20241231_zgddjwounOZ2" title="Merger transaction costs">7,499,353</span>&#160;charged
to Merger transaction costs for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240214__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zEzmDjBmWlb6" title="Earnout shares issuable">24,500,000</span>&#160;shares of common
stock (&#8220;Earnout Shares&#8221;) if the volume-weighted average price (the &#8220;VWAP&#8221;) of the Company&#8217;s common stock
reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5, Earnout Shares, for
further details of the earnout arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor in return for the Sponsor assuming $<span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_c20240214__20240214_zjD7fdFKOdr" title="Issuance of Series B preferred stock">3,613,000</span>&#160;of
liabilities and obligations (&#8220;Assumed Liabilities&#8221;) of Semper Paratus and Tevogen Bio. The issuance date fair value of the
Series B Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. All of the issued
Series B Preferred Stock was repurchased by the Company during the three months ended June 30, 2024 in exchange for the Sponsor being
released from their obligation to repay the Assumed Liabilities. See Note 12 for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNOUT SHARES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureEarnoutSharesAbstract', window );"><strong>Earnout Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EarnoutSharesDisclosureTextBlock', window );">EARNOUT SHARES</a></td>
<td class="text"><p id="xdx_806_ecustom--EarnoutSharesDisclosureTextBlock_zagX6b1RQoS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5.&#160;<span id="xdx_82B_znlZKg6laZk7">EARNOUT SHARES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Closing, former holders of Tevogen Bio common stock may receive up to&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_z844gkSOWlx9" title="Earnout shares">20,000,000</span>&#160;Earnout Shares in tranches of&#160;<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zuzU6iWvKd8d" title="Earnout shares">6,666,667</span>,&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zT17NDLXKdXi" title="Earnout shares">6,666,667</span>,
and&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zJTNwFOh7I2l" title="Earnout shares">6,666,666</span>&#160;shares of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP
per share of the Company&#8217;s common stock is greater or equal to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA1zCKVSTS11" title="Shares issued, price per share">15.00</span>, $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuyvJJIBokQj" title="Shares issued, price per share">17.50</span>, and $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGw48JnhzVwf" title="Shares issued, price per share">20.00</span>, respectively, over any twenty trading
days within any thirty consecutive day trading period during the three-year period after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#8217;s three earnout tranches
are for&#160;<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z4KFltTC2ru6" title="Earnout shares">1,500,000</span>&#160;shares of common stock, for an aggregate of&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zBKKDaByl4Al" title="Earnout shares">4,500,000</span>&#160;shares of common stock across the entire
Sponsor earnout. The Earnout Shares are a form of dividend for holders of Tevogen Bio common stock, and the Earnout Shares earnable by
the Sponsor are treated as contingent consideration in a reverse recapitalization. In accordance with ASC 815, the Earnout Shares were
considered to be indexed to the Company&#8217;s common stock and are classified within permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureEarnoutSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureEarnoutSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EarnoutSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout Shares [Disclosure Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EarnoutSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z8VPehfYwEia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_823_zklmFykksWod">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zL4gRjUr8gL8" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,341</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,341</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,217</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,468</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,769</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(425,327</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(263,118</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">296,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zsRWGRsOH3c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_90A_eus-gaap--Depreciation_c20240101__20241231_ztgdRLVGznQd" title="Depreciation expense">162,209</span> and $<span id="xdx_905_eus-gaap--Depreciation_c20230101__20231231_zfXzM9btM0hb" title="Depreciation expense">163,300</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6RfvuWeYq5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_827_zRrSDVU9XqN4">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zB2Az3kYPDPi" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    services</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,309,163</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">976,301</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403,233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,149</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,712,396</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,096,450</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8A2_z7WvcneI6UYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zw2kLZQBNkj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8.&#160;<span id="xdx_823_zgdJfRsQOU48">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2024, in connection with the consummation of the Business Combination, previously issued promissory notes and accrued interest
were automatically converted into an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240214__20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEK5y4HKzDQk" title="Converted shares">10,337,419</span> shares of common stock. These debt obligations were retired upon conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company entered into a Loan Agreement (the &#8220;Loan Agreement&#8221;) with The Patel Family, LLP (the &#8220;Patel Family&#8221;),
a related party of the Company, providing for an unsecured line of credit facility (the &#8220;Facility&#8221;) for term loans of up
to an initial total of $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zxsAadBIcza1" title="Line of credit maximum borrowing capacity">36,000,000</span>. Under the Facility, the Company may draw up to $<span id="xdx_900_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z8mf9puuQScj" title="Line of credit borrowing capacity">1,000,000</span>&#160;in term loans per calendar month over
a draw period of 36 months. Each term loan draw will have a maturity date of&#160;<span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zrryz2lcOsJd" title="Debt maturity date">48</span>&#160;months and will accrue interest at the lower
of (i) daily SOFR plus&#160;<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zuySRYwHK8Ei" title="Debt instrument variable rate">2.00</span>% and (ii)&#160;<span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zIvaeYSPmbGa" title="Debt instrument interest rate">7.00</span>%. Interest accrues quarterly and is payable on the three-month anniversary of the
draw date. Interest is payable in shares of common stock at an effective price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zM8NfIOFCS2f" title="Share price">1.50</span>&#160;per share. Interest payable through December
31, 2024 relating to the first two draws on the Facility were settled in February 2025 through issuance of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_ziYglc8zbDJa" title="Shares issued">18,847</span> shares of common stock.
Principal may be prepaid at any time without penalty, and repayments or prepayments may be made in cash or common stock at the Company&#8217;s
election. Payments of principal in common stock would be made at an effective price of the greater of $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__srt--RangeAxis__srt--MaximumMember_zYzKJtAyeaec" title="Share price">1.50</span>&#160;per share and the ten-day
trailing volume weighted average price per share of the common stock (the &#8220;Trailing VWAP&#8221;) as of the trading day prior to
payment. As an inducement to enter into the Loan Agreement, the Company issued&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_znCkx6wZyMk3" title="Issuance of shares">1,000,000</span>&#160;shares of common stock to the Patel Family
during June 2024. As of December 31, 2024, the Company has drawn $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zo28h9XX9xBc" title="Line of credit borrowing capacity">1,000,000</span>&#160;from the Facility, with maturity dates in July and August 2028, with a remaining $<span id="xdx_907_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zQJVNySeYQ54" title="Line of credit remaining capacity">30,000,000</span>&#160;available
for future financing over the remaining&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z5ChVKGiEFQh" title="Debt maturity date">30</span>&#160;months. The Company drew an additional $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpE8RJPFn8Pa" title="Line of credit borrowing capacity"><span id="xdx_909_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zR7pcG1mWobj" title="Line of credit borrowing capacity">1,000,000</span></span> in each of February and March 2025, with maturity dates in February and
March 2029, respectively (see Note 17).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement includes a purchase option whereby the Patel Family has the option to purchase up to $<span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJkZ50n7lT18" title="Option to purchase common stock, value">14,000,000</span>&#160;of shares of common stock
at a purchase price equal to&#160;<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zRuIZHYmEz7a" title="Percentage of price of common stock purchased">70</span>% of the Trailing VWAP per share (the &#8220;$<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zsFqU9TPVtn2" title="Option to purchase common stock, value">14</span>&#160;million Purchase Option&#8221;). The $<span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zMXzkmwIoSY5" title="Option to purchase common stock, value">14</span>&#160;million
Purchase Option only becomes exercisable once Trailing VWAP reaches $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zUNpmbR6fKPh" title="Purchase, price per share">10.00</span>&#160;per share. The $<span id="xdx_90D_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zwRode1UFF2g" title="Derivative liability">14</span>&#160;million Purchase Option was determined
to be a freestanding derivative liability under ASC 815 and is carried at fair value, with changes in fair value recorded to change in
fair value of written call option derivatives liabilities within the consolidated statements of operations and consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also includes a purchase option (the &#8220;Additional Amount Purchase Option&#8221;) that is identical to the $<span id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zLeBpQ0QG6vk" title="Option to purchase common stock, value">14</span>&#160;million
Purchase Option, except that the option is exercisable for an amount up to the then-remaining undrawn term loan amount under the Loan
Agreement at the time Trailing VWAP reaches $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_ztNbS6XR3JGg" title="Purchase, price per share">10.00</span>&#160;per share. The Additional Amount Purchase Option was determined to be an embedded
derivative within the written loan commitment that requires bifurcation under ASC 815, and thus is carried at fair value with changes
in fair value recorded to change in fair value of written call option derivatives liabilities within the consolidated statements of operations
and consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
$<span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630_z1KuAUxd4G0f" title="Derivative liability">14</span>&#160;million Purchase Option and the Additional Amount Purchase Option are recorded to written call option derivative liabilities
within the consolidated balance sheet and have a fair value of $<span id="xdx_90F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_zxpXfB9xpIm7" title="Derivative liabilities">0</span> as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement is a written loan commitment that is not eligible for the fair value option under ASC 825,&#160;<i>Financial Instruments</i>.
However, management intends to elect the fair value option for future draws under this commitment, and therefore has expensed all issuance
costs associated with the Loan Agreement, which are comprised of the fair value of the&#160;<span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zx9g5g8Kjcrf" title="Issuance of commitment shares in connection with unsecured equity line of credit facility">1,000,000</span>&#160;shares of common stock issued
to the Patel Family as well as the issuance date fair value of the $<span id="xdx_900_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zN2WjAXBmPE9" title="Derivative liability">14</span>&#160;million Purchase Option and Additional Amount Purchase Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notes
Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;) for which the
proceeds were to be used for working capital purposes by Semper Paratus with an outstanding balance of $<span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PolarMultiStrategyMasterFundMember_znJ5ftS26bml" title="Notes payable">1,651,000</span>&#160;on the Closing
Date and remain outstanding at December 31, 2024. The notes payable do not accrue interest. The outstanding balance of the notes was
required to be repaid in full within five business days of the Merger, and the Company is therefore in default of its obligations at
December 31, 2024. The notes&#8217; default provisions do not require the Company to transfer any shares or pay any amounts to Polar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zc3CeCOj6qU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82C_zArk9wUoyvf7">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using incremental
borrowing rates ranging from <span id="xdx_90D_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zB8YyCh7E3ma" title="Operating leases incremental borrowing rates">11.0</span>% to <span id="xdx_90F_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z1hEkSCxIZxi" title="Operating leases incremental borrowing rates">11.2</span>%, which was determined using a synthetic credit rating model. Lease expense for the year ended
December 31, 2024 was $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zih4CLa5lv95" title="Operating lease expense">1,065,784</span>, which consisted of $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zgoV4EtlJzzj" title="Operating lease expense">897,958</span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zx7xhLtqdISl" title="Operating lease expense">167,826</span> recognized as a component of research and development expense
and general and administrative expense, respectively. This amount included $<span id="xdx_90E_eus-gaap--ShortTermLeasePayments_c20240101__20241231_zvXFayMDshW2" title="Short term lease">785,424</span> of expense under short-term leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining lease term for the Company&#8217;s operating leases as of December 31, 2024 was <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXQ2DP3bHQk6" title="Operating leases weighted average remaining lease term">0.93</span> years. The weighted average
discount rate for the Company&#8217;s operating leases for the year ended December 31, 2024 was <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z209KcV9MlL8" title="Operating leases weighted average discount rate">11.1</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z56qhGR4fHig" style="display: none">SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Years Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">230,471</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,975</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,446</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,587</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">234,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zNODONkrSBx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash payments related to leases for the years ended December 31, 2024 and 2023 were $<span id="xdx_900_eus-gaap--OperatingLeasePayments_c20240101__20241231_z3eSn06J9Nq" title="Cash payments">1,077,127</span> and $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20230101__20231231_zP05UIXT7Qpb" title="Cash payments">1,058,754</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHq3GNNa6Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_821_zsWcklDknXOc">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the applicable agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyMCODyWWnya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_827_z4dAxgKik4m6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#8220;2024 Plan&#8221;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). Each RSU award granted under the
2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024
Plan with respect to the common stock of the Company (the &#8220;Rollover RSUs&#8221;). Such Rollover RSUs remain subject to the same
terms and conditions as set forth under the applicable award agreement prior to the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to covering the Rollover RSUs, under the 2024 Plan, the Company is authorized to grant awards up to an aggregate&#160;<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zHzCwRN2s0nk">40,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, Restricted Stock, RSUs, and other
equity-based awards. As of December 31, 2024, awards for <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zp4OZxGfChc2">10,670,118 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
remained available to be granted under the 2024 Plan.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#8220;Performance-Based RSUs&#8221;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company issued an aggregate of&#160;<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zozYmExqOUAe" title="Number of shares issued for RSUs">19,348,954</span>&#160;RSUs under the 2024 Plan to the Company&#8217;s Chief Executive
Officer, Dr. Ryan Saadi (the &#8220;Special RSU Award&#8221;). Such RSUs immediately converted into shares of Restricted Stock, the restrictions
on which lapse in four equal annual installments beginning on February 14, 2031 (&#8220;Vesting Period&#8221;). Pursuant to the terms
of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred,
pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock
in the event he departs the Company. The fair value per share for the Special RSU Award was determined to be $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdXnDus2lokl" title="Fair value per share for award">4.51</span>&#160;per share, equivalent
to the Company&#8217;s stock price on the Closing Date, resulting in a total grant date fair value of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLG0Lg6jZtLa" title="Grant date fair value of shares">87,263,783</span>. In accordance with
ASC 718,&#160;<i>Compensation - Stock Compensation&#160;</i>(&#8220;ASC 718&#8221;), the Company will recognize compensation expense
on a straight-line basis from the Closing Date until the completion of the Vesting Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_zKiyxUa8Uqya" style="display: none">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock and RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0976">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0986">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0990">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted">29,329,882</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted">3.31</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested">(2,639,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested">0.96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1004">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning">26,690,254</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning">3.54</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning">9,894,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning">2.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted">1,027,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted">4.16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1020">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited">(22,626</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited">4.39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning">10,900,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending">2.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1030">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested">(9,610,540</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested">2.87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1040">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning">1,289,578</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending">3.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z4eThjaJVWS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4Ufve4JqSjb" title="Compensation cost recognized">25,233,487</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;for
the year ended December 31, 2024 was recognized for the Performance-Based RSUs, of which&#160;<span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlIzAuY2Njn8" title="Number of shares issued and outstading RSU">8,237,319</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
shares were issued and outstanding as of December 31, 2024, and&#160;<span id="xdx_902_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z40DPp8wElZb" title="Number of shares issuable">1,373,221</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;shares
will be issued subsequent to December 31, 2024. There was $<span id="xdx_902_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrEwkew1oNWi" title="Compensation cost">11,410,921</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
cost related to Service-Based Restricted Stock and RSUs, for the year ended December 31, 2024, and <span id="xdx_90E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zzgMC1eBnPy9" title="Number of shares issuable">2,639,628</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
were issued and outstanding. There was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zms2tZhdeNc5" title="Unrecognized compensation cost">85,601,786</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Service-Based Restricted Stock and RSUs as of December 31, 2024, which will be expensed
over a weighted average period of&#160;<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zclEMmCJ3Dz9" title="Weighted average period">7.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.
There was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zIrQ7oNuc7Uc" title="Unrecognized compensation cost">2,984,909</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;of
unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2024, which will be expensed over a weighted
average period of&#160;<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zY1GdZYbLZc4" title="Weighted average period for recognition">1.1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_z0T6x9S9R0nc" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">27,019,781</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,744,355</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,764,136</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zolbzGpD9Gyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_do_c20230101__20231231_ze91l903pZjd" title="Stock-based compensation expense recognized">No</span>
stock-based compensation expense was recognized in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z39WwpxsIVGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12.&#160;<span id="xdx_823_zPEUk6aDyaG5">STOCKHOLDERS&#8217; DEFICIT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 15, 2024, the Company&#8217;s common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#8220;TVGN&#8221;
and &#8220;TVGNW&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had&#160;<span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_znAw7bEFMQ5h" title="Common shares, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zk1HMAnH51cj" title="Common shares, shares outstanding">177,991,365</span></span>&#160;shares of common stock issued and outstanding. For accounting purposes related
to earnings per share, only shares that are fully vested are considered issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a reconciliation of shares of common stock issued and outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zBobVkOAVlrc" style="display: none">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_zTz0o6SVpLl3" title="Total shares of common stock legally issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zub7NIVcS1ji" title="Total shares of common stock legally outstanding">177,991,365</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Vested RSUs not yet legally settled into common stock (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing">1,373,221</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Issuance of restricted common stock subject to forfeiture (b)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture">(19,348,954</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding">160,015,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</span></td></tr>
  </table>
<p id="xdx_8A5_zFXyPlOcKyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#8217;s common
stockholders received shares of the Company&#8217;s common stock in an amount determined by application of the Exchange Ratio, as discussed
in Note 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to&#160;<span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zawzrFyiUhW8" title="Preferred shares, shares authorized">20,000,000</span>&#160;shares of preferred stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zQGkdUfNumd3" title="Preferred shares, par value">0.0001</span>&#160;per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company authorized and issued&#160;<span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUfWFBKOpx95" title="Preferred stock, shares authorized">2,000</span>&#160;and&#160;<span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4r56mILnzl" title="Preferred stock, shares issued">500</span>&#160;shares, respectively, of Series A Preferred Stock (the
&#8220;Series A&#8221;) to the Patel Family at a price of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQfbWQrcOZi3" title="Original issue price per share">4,000</span>&#160;per share (the &#8220;Series A Original Issue Price&#8221;), for gross
proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxixjJLqeg62" title="Proceeds from issuance of preferred stock">2,000,000</span>. The Company recorded an expense of $<span id="xdx_909_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQxnGU5zd5Tb" title="Loss on preferred stock issuance">799,990</span>&#160;in its consolidated statements of operations related to issuance
of the Series A equal to the fair value of the Series A when issued of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhHdHpBEqGkj" title="Price per share">5,600</span>&#160;per share less the purchase price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zAqqP6PNvXv7" title="Share price">4,000</span>&#160;per
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of&#160;<span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztYDttjnovo9" title="Dividend rate, percentage">5</span>% per annum per share
on&#160;<span id="xdx_90D_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zF61u4UZsN72" title="Dividend variable rate, description">the Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding
(the &#8220;Series A Accruing Dividends&#8221;). These dividends become payable when and if declared by the Company. The Series A Preferred
Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common stock</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A ranks senior to common stock and Series C Preferred Stock in liquidation priority. In the event of a liquidation of the Company,
or certain deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price
plus all Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the
Series A converted into shares of common stock immediately before the liquidation or deemed liquidation event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem the Series A at a price equal to the Series A Original Issue Price plus any Series A Accruing
Dividends accrued but unpaid thereon, if the VWAP of the Company&#8217;s common stock exceeds $<span id="xdx_909_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwbfq8s8aZ8a" title="Redemption price per share">5.00</span>&#160;per share for&#160;<span id="xdx_907_eus-gaap--PreferredStockRedemptionTerms_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOlzljlEejp8" title="Redemption term">the twenty
days immediately prior to the Company&#8217;s call election</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal to the Series A Original Issue
Price divided by the Series A Conversion Price, which is initially $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAhs7sA9a3Hg" title="Conversion price per share">4.00</span>&#160;per share and is subject to standard antidilution adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
A-1 Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Patel Family covering the
issuance of&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zyjFwzKjShS9" title="Stock issuance">600</span>&#160;shares of Series A-1 Preferred Stock for a gross purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSYuOdfosOrl" title="Stock issuance, value">6,000,000</span>.&#160;<span id="xdx_907_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zwimI6SmD7Wc" title="Dividend variable rate, description">The terms of the Series
A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum, and the Series A-1
Issuance Price is defined as $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zpRWlyP2lmhc" title="Share price">10,000</span>&#160;per share</span>. As of December 31, 2024, the investor had paid a non-refundable deposit of $<span id="xdx_907_eus-gaap--Deposits_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z0L4O5xe3d58" title="Non refundable deposist paid">3,000,000</span>&#160;towards
the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the Sponsor
assuming certain liabilities and obligations of Semper Paratus and Tevogen Bio. In March 2024,&#160;<span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztKdBv7rrvtf" title="Conversion of certain liabilities into Series B preferred stock, shares">3,613</span>&#160;shares of Series B were
issued in return for the assumption of the Assumed Liabilities. The issuance date fair value of the Series B was determined to be $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjWUK6RK25vf" title="Conversion of certain liabilities into Series B preferred stock">3,613,000</span>&#160;and
was recorded within Merger transaction costs in the consolidated statements of operations. The Series B was classified as permanent equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2024, the Company and the Sponsor entered into the Preferred Stock Repurchase Agreement, pursuant to which the Company repurchased
all outstanding Series B in exchange for the release of the Sponsor from its obligations related to the Assumed Liabilities, but no cash
consideration. The repurchase was recorded as a deemed contribution from a related party and recorded to additional paid-in capital.
As of June 30, 2024, there were&#160;<span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8b7tstNVUK" title="Preferred stock shares outstanding">no</span>&#160;shares of Series B outstanding, and on August 9, 2024, the Company filed a Certificate of
Elimination to eliminate the Series B. Although the Company was not legally released by the creditors, the Company has made payments
towards the Assumed Liabilities and approximately $<span id="xdx_904_eus-gaap--LiabilitiesAssumed1_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z49kJiiE3Ygk" title="Liabilities assumed">2.6</span>&#160;million remains on the Company&#8217;s balance sheet at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2024, the Company entered into a securities purchase agreement (the &#8220;Series C Agreement&#8221;) with an investor, pursuant
to which the Patel Family purchased&#160;<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSPnuzVFW8I3" title="Stock issuance">600</span>&#160;shares of Series C Preferred Stock (the &#8220;Series C&#8221;) of the Company at a price
of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z54wxKCwg1gb" title="Share price">10,000</span>&#160;per share (the &#8220;Series C Original Issue Price&#8221;), for gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zWevHguMjFh8" title="Gross proceeds">6,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C is subject to a call right providing the Company the right to call the stock at any time after the fifth anniversary of the
date of issuance. The Company also agreed that so long as the Series C is outstanding, the Company will not, without the written consent
of the holders of 50.1% of the Series C, amend, alter, or repeal any provision of the Company&#8217;s certificate of incorporation or
bylaws in a manner adverse to the Series C. Assessed under accounting guidance within ASC 480 and ASC 815, as the Series C is unregistered
and without mandatory redemption features, the Series C is classified within equity at issued face value as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C carries an annual&#160;<span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znIWnoIckvq7" title="Dividend rate, percentage">7.5</span>% cumulative dividend, compounded annually, beginning on the later of (1) September 30, 2024 and (2)&#160;the
date on which the investor has paid the entirety of the purchase price under the Series C Agreement and ending on the last business day
of the calendar quarter ending September 30, 2034 (the &#8220;Series C Accruing Dividends&#8221;). Dividends will be payable in shares
of Series C or, at the election of the Company, in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C ranks subordinate to the Series A and Series A-1 Preferred Stock and ranks senior to common stock in liquidation priority. In
<span id="xdx_90C_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9gScDguhoh2" title="Dividend variable rate, description">the event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the
greater of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such
asset amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or
deemed liquidation event</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C does not have any voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Redemption</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem that Series C at a price equal to the Series C Original Issue Price plus any Series C Accruing
Dividends accrued but unpaid thereon, subject to the conversion right described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series C will be convertible at the election of the holder, beginning six months after the date of issuance, into shares of
common stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#8217;s conversion option, subject to a floor price of $<span id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7dM0Y1ql89b" title="Floor price">0.6172</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing,&#160;<span id="xdx_90B_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember_zIGtQfTezVW6" title="Number of warrants issued">17,975,000</span>&#160;warrants initially issued by Semper Paratus in November 2021, comprising&#160;<span id="xdx_905_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zn3BV62feMah" title="Number of warrants issued">17,250,000</span>&#160;public
warrants sold in the IPO and&#160;<span id="xdx_902_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVzxWQkVh4vf" title="Number of warrants issued">725,000</span>&#160;warrants issued in a concurrent private placement, were assumed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public warrants have an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zIbJmxaroH8f" title="Exercise price">11.50</span>&#160;per share, became exercisable on&#160;<span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zmhBTSemoD57" title="Exercisable date">March 15, 2024</span>, and will expire at 5:00 p.m.,
New York City time, on February 14, 2029, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is
an effective registration statement and during any period when the Company has failed to maintain an effective registration statement
covering the shares of the Company&#8217;s common stock issuable upon exercise of the warrants, exercise warrants on a &#8220;cashless
basis&#8221; in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, or another exception.&#160;<span id="xdx_909_ecustom--WarrantsRedemptionDescription_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zCHigflJdi3f" title="Warrants redemption description">The Company may
redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days within a 30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of public
warrants</span>.&#160;As of December 31, 2024, there are&#160;<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zp8Nj2uoLvG3" title="Number of warrants outstanding">17,386,580</span>&#160;public warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>Private
Placement Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the initial purchasers or their permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders
on a cashless basis. As of December 31, 2024, there are&#160;<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z69tfKiXr8nj" title="Number of warrants outstanding">588,398</span> private placement warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 for additional information on the Company&#8217;s warrant accounting policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zlDNnfZH9OPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13.&#160;<span id="xdx_825_zqPN9q60Q2sd">NET LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table is a reconciliation of net loss to net loss attributable to common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zqvjlw0tPPPc" style="display: none">SCHEDULE OF RECONCILIATION OF NET LOSS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,727,380</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(60,477,680</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,712</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,613,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,613,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series C cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(82,603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(82,603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,273,695</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,477,680</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8A2_zG3z9K9LYeO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company excluded the following potential shares from the computation of diluted net loss per share because including them would have
had an anti-dilutive effect:</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKc0WDQkU0cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zdSENhIO9rV3" style="display: none">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F44_zmfQq5K6hhX9" style="width: 60%; text-align: left">Outstanding RSUs (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">8,623,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">10,900,128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,348,954</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,974,978</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4C_zJyDr0riXTXa" style="text-align: left">Convertible promissory notes (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891,298</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Earnout Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1208">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">70,447,157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,791,426</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zykjScqdVvK1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F11_zmclaahZPjfi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024 there were an additional&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85" title="Stock option vested">1,373,221</span>&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0A_zTdx4tJUoNKl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F10_z19ovviNsVu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</span></td></tr>
  </table>
<p id="xdx_8A5_ztzzjDJRdhf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above table excludes any potentially anti-dilutive shares as a result of the $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20241231_zD8TY04o0C1c" title="Derivative liability">14</span>&#160;million Purchase Option and the Additional Amount
Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be determined until the conditions for issuance
are met and the share prices are known upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zOH3qqx6CUEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14. <span id="xdx_82E_zVru2JBQBEJ">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s net losses for 2024 and 2023, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zfqHypT5TS0f" style="display: none">SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Federal benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.4</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(66.5</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.4</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income Tax Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AD_zI1V4O0T35ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Realization of net deferred tax assets is dependent upon future earnings, if any,
the timing and amount of which are uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items comprise the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDJj32uxJhO7" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,808,826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,755,008</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,330</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,427</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,110,942</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">718,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Capitalized research and development expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,944,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,589,105</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">234,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">317,455</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,610,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,549,750</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,551,169</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,426,952</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">59,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">122,798</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59,716</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(122,798</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59,716</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(122,798</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zlBeaG0lqf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred
tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company
considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative
earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company
for tax reporting purposes, and other relevant factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, based on the Company&#8217;s history of earnings and its assessment of future earnings, management believes that
it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation
allowance has been applied to deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the year ended December 31, 2024, the Company has federal and state net operating loss carryforwards of approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zKvRHdzwguA" title="Federal  net operating loss carryforwards">25.6</span> million
and $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zneQ6a3fQVda" title="State net operating loss carryforwards">27.8</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
net operating loss (&#8220;NOL&#8221;) carryforwards in the amount of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zUCHXrTKyWh3" title="Federal  net operating loss carryforwards">25.6</span> million have an indefinite life. Federal NOL carryforwards
generated after tax year 2017 are subject to an <span id="xdx_90B_ecustom--TaxableIncomeLimitationPercentage_dp_uPure_c20240101__20241231_zRxLMcaLeQXd" title="Taxable income percentage">80</span>% limitation on taxable income, do not expire and will carryforward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
net operating loss carryforwards in the amount of $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zJC8GpWitUF5" title="State net operating loss carryforwards">27.8</span> million begin expiring in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a U.S. federal limitation due to the &#8220;change in ownership
provisions&#8221; under Section 382 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations
may result in a reduction of the amount of net operating loss carryforwards in future years and possibly the expiration of certain net
operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files tax returns as prescribed by the tax laws of the jurisdictions
in which it operates. In the normal course of business, the Company is subject to examinations by federal, state and local jurisdictions,
where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from 2021
to the present in the United States. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was
generated may still be adjusted upon examination by the Internal Revenue Service and state and local tax authorities to the extent utilized
in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As required by the uncertain tax position guidance in ASC No. 740, Income
Tax, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would
more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount
recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement
with the relevant tax authority. The Company applied the uncertain tax position guidance in ASC No. 740 to all tax positions for which
the statute of limitations remained open. Any estimates of tax contingencies contain assumptions and judgments about potential actions
by taxing jurisdictions. Any interest and penalties related to uncertain tax positions would be included as part of the income tax provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zf0aPlttrYT4" style="display: none">SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Valuation allowance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,426,952</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,175,241</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Increases recorded to income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,124,217</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,251,711</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,551,169</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,426,952</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zp0wzhbf7Lr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater
than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain
tax positions as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2024, the Company had <span id="xdx_901_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_zuOXGDUSWMy1" title="Income tax penalties and interest accrued">no</span> accrued interest or penalties related to uncertain tax positions and no amounts have been
recognized in the Company&#8217;s statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrerlloKSUG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15. <span id="xdx_826_zuwxRamozzMf">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
with Sponsor</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Merger Agreement, the Company incurred $<span id="xdx_905_eus-gaap--SponsorFees_c20240101__20241231_zTy8sC0UubZ8" title="Sponsor advisory service fee">2,000,000</span>&#160;in fees to the Sponsor for advisory services (the &#8220;Sponsor Advisory
Service Fee&#8221;). In connection with the Merger and thereafter, the Company and Sponsor agreed that $<span id="xdx_906_ecustom--SponsorFeesPayable_iI_c20241231_zkE0us8TZD65" title="Sponsor advisory services fee payable">250,000</span>&#160;of the Sponsor Advisory
Service Fee is payable in cash, $<span id="xdx_901_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zbPCTNfYXcbh" title="Sponsor fee payable offset">250,000</span>&#160;would be offset against amounts due from the Sponsor, and the remainder of the Sponsor
Advisory Service Fee was paid with the issuance of&#160;<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zhcrPARWOjwj" title="Number of shares issued for sponsor fees">150,000</span>&#160;shares of the Company&#8217;s common stock at Closing. The Sponsor
Advisory Service Fee payable in cash is presented on the consolidated balance sheets under the line item &#8220;Due to related party.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Sponsor owes the Company $<span id="xdx_904_eus-gaap--OtherReceivables_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z4vWtjG20yL" title="Due from related party">158,819</span>&#160;to cover working capital expenses, which is presented on the consolidated
balance sheets under the line item &#8220;Due from related party.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series B issued to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__custom--WifeOfChiefExecutiveOfficerMember_zTnpqXQArEhh" title="Isssued shares to related party">40,000</span>&#160;Performance-Based RSUs to the wife of the Company&#8217;s chair and chief executive
officer for advisory services provided to the Company, and&#160;<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MehtaphoricConsultingIncMember_zrYzQdMpRkNh" title="Shares issued to related party">20,000</span>&#160;Performance-Based RSUs to Mehtaphoric Consulting Inc, a company
controlled by the daughter of the Company&#8217;s chief financial officer, for information technology services provided to the Company.
In connection with the Closing, the performance condition was achieved and therefore compensation cost of $<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231_zOUwKIHuqzk" title="Compensation cost recognized">800,396</span>&#160;has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 for additional information on the Loan Agreement with the Patel Family, which provides for an unsecured line of credit facility for term loans of
up to an initial amount of $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zLKScQ5vkAk3" title="Line of credit maximum borrowing capacity">36,000,000</span>
in the aggregate. As of December 31, 2024, the facility has remaining available capacity of $<span id="xdx_904_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z9y8tO1wTFIj" title="Line of credit remaining borrowing capacity">30,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 12 for additional information on the Series A, Series A-1, and Series C Preferred Stock, which were purchased by the Patel Family.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consulting
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services to the Company in
support of the Company&#8217;s manufacturing development, including but not limited to identifying and developing real estate, establishing
quality management processes, attracting and hiring an executive to lead operations, providing medical advice, and addressing government
affairs and regulatory matters. In exchange for his consultation services, Dr. Patel was granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zfQ0S0ve5fg7" title="Granted, shares">6,000,000</span> RSUs, of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zh6uXjAWemfi" title="Vested shares">2,000,000</span> immediately
vested, and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQvaOG3s7d5h" title="Vested shares"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0Juwz4Y4g4" title="Vested shares">2,000,000</span></span> RSUs vested in both January  2025 and February  2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zjViOtEdXFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16. <span id="xdx_824_zz8eWF3pcbLk">SEGMENT REPORTING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in one operating segment, and therefore one reportable segment, and is focused on the global discovery, development
and commercialization of proprietary therapeutics. The Company&#8217;s business activities are managed on a consolidated basis through
the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products
are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with
the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating
resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker
is the Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies.
Our single operating segment incurs expenses from the development of TVGN 489, which is developed by our research and development department,
designed to target various disease indications. The Company has not yet generated revenue in its operating history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the segment, the chief operating decision maker uses net loss, which is reported on the consolidated statements of operations as consolidated
net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget
and forecasting process. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative
information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment
in our various research activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zcq2drwDeQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17. <span id="xdx_823_zySUOK5HYSp2">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 2, 2025, the issuance date of these the consolidated financial statements, and has not identified any additional items requiring
disclosure except as noted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company executed an agreement with KRHP to receive a grant for $<span id="xdx_901_eus-gaap--OtherReceivablesNetCurrent_iI_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHPLLCMember_zTmBGFqf4706" title="Grant">2,000,000</span>.
KRHP is affiliated with the Patel Family. The grant is specified for use toward the Company&#8217;s ongoing operational expenses,
may not be used for repayment of existing debt obligations, and does not include any requirement to repay the investor or to issue
equity in response. Cash payment was received by the Company in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February  2025, the Company executed a draw on the Loan Agreement for an additional $<span id="xdx_902_eus-gaap--LineOfCredit_iI_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzvyNsOHXNv8" title="Line of credit Facility additional">1,000,000</span> to be utilized for operational
expenses. An additional draw of $<span id="xdx_908_eus-gaap--LineOfCredit_iI_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9Pe2aZwH1z9" title="Line of credit Facility additional">1,000,000</span> was completed in March  2025. As of the date of filing, the facility has a remaining
capacity of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20250402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z33Qh5rDOJ1l" title="Line of credit Facility remaining capacity">26,000,000</span> and remains effective for the next 26 months.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z6zGIDk7hIo2">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z9OsFUUKNFM7">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
areas that require management&#8217;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock', window );">Freestanding and Embedded Common Stock Purchase Options</a></td>
<td class="text"><p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjZOTYXrYvW1">Freestanding
and Embedded Common Stock Purchase Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-linked
purchase options issued in connection with the Company&#8217;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;<i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity&#160;</i>(&#8220;ASC
815&#8221;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#8217;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#8216;Change in
fair value of written call option derivative liabilities&#8217; within the consolidated statements of operations and consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zBYIf29m4TMl">Concentrations
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zqy1DxfGgale">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zCdpbsx6vrej" title="Number of operating segments">one</span> segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zTyoPxhDqOEb">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#8217;s initial public offering
(the &#8220;IPO&#8221;) in accordance with ASC 815, <i>Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </i>(&#8220;ASC
815&#8221;) and ASC 480,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480&#8221;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#8217;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zPsHFdIWiME8">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unadjusted
    quoted prices in active markets for identical assets or liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s convertible promissory
notes.</span></p>

<p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance">39,297,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance">4,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense">1,206,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">50,428,303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance">94,932,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between levels during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (<span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z545EdZ4cnwb" title="Volatility">80</span>%), discount rate (<span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zECVEqwfbOp5" title="Volatility">35</span>% - <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_zzwuKcFjoQk4" title="Volatility">36</span>%), and probability of a future liquidity event (<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zEjMN6sa3IMj" title="Volatility">85</span>% - <span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_zbUb1Yp6ohjb" title="Convertible promissory notes measurement input">95</span>%). The Company
used its stock price on the Closing Date to determine the fair value for the  derecognition of the convertible promissory notes
upon conversion on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuQ5OVhtN1ue">58,180</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#8217;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgANSzrkc1n5">375,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.</span></p>

<p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE OF FAIR VALUES OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written call option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at February 15, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance">29,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance">375,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">58,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(375,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance">87,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets <br/> (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs <br/> (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Unobservable <br/> Inputs (Level 3)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities">87,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#8220;MCS&#8221;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;<span id="xdx_908_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zo9yBcrmtNi7" title="Stock, measurement input">75</span>% to&#160;<span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi" title="Alternative investment, measurement input">85</span>%, a holding
period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;<span id="xdx_907_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zNKj7Fj8NTb3" title="Holding period">0.5</span>&#160;to&#160;<span id="xdx_905_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_z7eHCVkhCn6" title="Range in years">10.0</span>&#160;years,
and a risk-free interest rate between&#160;<span id="xdx_903_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ztGJw2vPfY57" title="Risk-free interest rate percentage">4.3</span>% and&#160;<span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z0dBlZtpCM79" title="Stock, measurement input">5.3</span>%. The difference between the cash received of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsEMs6S6rOn8" title="Cash received upon issuance of preferred stock">2,000,000</span>&#160;upon issuance
of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used a MCS valuation methodology to determine the fair value of the freestanding $<span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zu2sTFTPziLj" title="Free standing purchase options">14,000,000</span>&#160;purchase option and remaining
embedded $<span id="xdx_90C_ecustom--EmbeddedOptions_c20240101__20241231_zc8eFNvcHCu5" title="Embedded options">30,000,000</span>&#160;purchase option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the
Company&#8217;s future stock price to estimate if and when the Trailing VWAP (as defined below) will reach $<span id="xdx_907_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zV3ZldBNhFwg">10.00</span>&#160;per share, and
discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;<span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7">78.3</span>% and discount rate of&#160;<span id="xdx_90B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zXlSz5FcJLKh">4.3</span>%. At December 31, 2024, the MCS produced
a fair value of $<span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zbJgzA6FSiy6" title="Fair value">0</span> relating to these freestanding and embedded options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zfPQfeKGxXZ1">Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_ziFSTW2Sk4gi" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zTSLrHP6qI37" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zoqVO2hfbssd">Property
and Equipment, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life">5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life">4</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life">5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life">7</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z4mqZGMPTzPj">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zlzIGLkluEAc" title="Leases initial term">12 months</span> or less and without a purchase option that the Company is reasonably certain of exercising are not
included within the lease ROU assets and lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z51STCTlamK2">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zN8KNyRNRiS1">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#8217;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; <i>Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zldsYnnmPWEb">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_znCeJn71YSG1">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#8217;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOYer4WwVUw5">Recently
Issued Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s
Own Equity </i>(&#8220;ASU 2020-06&#8221;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07,&#160;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;</i>(&#8220;ASU
2023-07&#8221;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TEVOGEN BIO HOLDINGS INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) </i>(&#8220;ASU 2024-03&#8221;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Freestanding And Embedded Common Stock Options [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">SCHEDULE OF FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zLwMSvweVTPg" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance">39,297,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance">4,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense">1,206,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">50,428,303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance">94,932,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense">159,305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value">(48,468,678</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Derecognition upon conversion of convertible promissory notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes">(46,622,627</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUES OF WARRANTS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zKxxJeSEy77b" style="display: none">SCHEDULE OF FAIR VALUES OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>warrant liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Written call option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>derivative liabilities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance at February 15, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Initial fair value at issuance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance">29,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance">375,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">58,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(375,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance">87,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zMdNzDoPK375" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets <br/> (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs <br/> (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Significant Other <br/> Unobservable <br/> Inputs (Level 3)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Derivative warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities">87,180</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</a></td>
<td class="text"><p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zJYD2SpYrHLa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Estimated Useful Lives</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: justify">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life">5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life">4</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life">5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life">7</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property And Equipment Useful Life [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the net liabilities acquired in the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zCTQj89vyov1" style="display: none">SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February&#160;14,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">229,328</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Sponsor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,819</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,501</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,175</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,269,126</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,651,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Derivative warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total net liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,654,653</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Plus: Merger transaction costs limited to cash acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(229,328</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net liabilities acquired plus transaction costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,883,981</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zL4gRjUr8gL8" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,341</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,341</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263,217</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,468</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">33,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,769</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(425,327</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(263,118</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">296,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zB2Az3kYPDPi" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    services</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,309,163</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">976,301</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">403,233</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,149</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,712,396</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,096,450</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock', window );">SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z56qhGR4fHig" style="display: none">SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES</span>&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Years Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">230,471</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,975</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,446</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,587</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">234,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Company Lease Liabilities [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock and RSU activity was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_zKiyxUa8Uqya" style="display: none">SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Service-Based Restricted Stock and RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0976">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0986">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0990">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted">29,329,882</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted">3.31</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested">(2,639,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested">0.96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1004">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning">26,690,254</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning">3.54</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Performance-Based RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average grant-date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning">9,894,958</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning">2.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted">1,027,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted">4.16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1018">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1020">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited">(22,626</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited">4.39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning">10,900,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending">2.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1030">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested">(9,610,540</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested">2.87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1040">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning">1,289,578</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending">3.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B4_z0T6x9S9R0nc" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">27,019,781</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,744,355</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,764,136</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a reconciliation of shares of common stock issued and outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BF_zBobVkOAVlrc" style="display: none">SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total shares of common stock issued and outstanding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_zTz0o6SVpLl3" title="Total shares of common stock legally issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zub7NIVcS1ji" title="Total shares of common stock legally outstanding">177,991,365</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plus: shares to be issued:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Vested RSUs not yet legally settled into common stock (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing">1,373,221</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Shares subject to future vesting:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Issuance of restricted common stock subject to forfeiture (b)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture">(19,348,954</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding">160,015,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">SCHEDULE OF RECONCILIATION OF NET LOSS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table is a reconciliation of net loss to net loss attributable to common stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zqvjlw0tPPPc" style="display: none">SCHEDULE OF RECONCILIATION OF NET LOSS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,727,380</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(60,477,680</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,712</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,613,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,613,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series C cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(82,603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cumulative preferred stock dividend</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(82,603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss attributable to common stockholders</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,273,695</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(60,477,680</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKc0WDQkU0cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zdSENhIO9rV3" style="display: none">SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F44_zmfQq5K6hhX9" style="width: 60%; text-align: left">Outstanding RSUs (a)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">8,623,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">10,900,128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,348,954</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,974,978</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4C_zJyDr0riXTXa" style="text-align: left">Convertible promissory notes (b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891,298</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Earnout Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1208">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">70,447,157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,791,426</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0C_zykjScqdVvK1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F11_zmclaahZPjfi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024 there were an additional&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85" title="Stock option vested">1,373,221</span>&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F0A_zTdx4tJUoNKl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"><span id="xdx_F10_z19ovviNsVu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#8217;s effective
income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zfqHypT5TS0f" style="display: none">SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Federal benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.4</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(66.5</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.4</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income Tax Expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following items comprise the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDJj32uxJhO7" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,808,826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,755,008</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,330</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,427</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,110,942</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">718,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Capitalized research and development expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,944,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,589,105</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">234,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">317,455</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,610,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,549,750</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,551,169</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,426,952</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">59,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">122,798</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59,716</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(122,798</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59,716</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(122,798</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock', window );">SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zf0aPlttrYT4" style="display: none">SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Valuation allowance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,426,952</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,175,241</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Increases recorded to income tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,124,217</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,251,711</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,551,169</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,426,952</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Valuation Allowance For Net Deferred Tax Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember', window );">Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_BusinessCombinationSharesExchangeRatio', window );">Share exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationSharesExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination shares exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationSharesExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_SemperParatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_SemperParatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,282,995<span></span>
</td>
<td class="nump">$ 1,052,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Grant received</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_GrantDrewFromRelatedParty', window );">Grant drew from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_GrantDrewFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant drew from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_GrantDrewFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE MEASUREMENT (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value beginning balance</a></td>
<td class="nump">$ 94,932,000<span></span>
</td>
<td class="nump">$ 39,297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest', window );">Accrued interest expense</a></td>
<td class="nump">159,305<span></span>
</td>
<td class="nump">1,206,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(48,468,678)<span></span>
</td>
<td class="nump">50,428,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable', window );">Derecognition upon conversion of convertible promissory notes</a></td>
<td class="num">(46,622,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 94,932,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUES OF WARRANTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="nump">87,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Call Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DerivativeLiabilitiesFairValueIssuance', window );">Initial fair value at issuance</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="num">(375,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DerivativeLiabilitiesFairValueIssuance', window );">Initial fair value at issuance</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="nump">58,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities, Balance</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DerivativeLiabilitiesFairValueIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liabilities fair value issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DerivativeLiabilitiesFairValueIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 87,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,180)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Cash received upon issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_FreeStandingPurchaseOptions', window );">Free standing purchase options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EmbeddedOptions', window );">Embedded options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Leases initial term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Cash received upon issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="num">$ (58,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EquitySecuritiesTerm', window );">Range in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_EquitySecuritiesTerm', window );">Range in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory notes measurement input</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory notes measurement input</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory notes measurement input</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember', window );">Probability of Future Liquidity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory notes measurement input</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember', window );">Probability of Future Liquidity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory notes measurement input</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Stock, measurement input</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EmbeddedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Embedded options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EmbeddedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_EquitySecuritiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity securities term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_EquitySecuritiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_FreeStandingPurchaseOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Free standing purchase options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_FreeStandingPurchaseOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=TVGN_ProbabilityOfFutureLiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 14, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 229,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Due from Sponsor</a></td>
<td class="nump">158,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(96,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(1,269,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Notes payable</a></td>
<td class="num">(1,651,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Derivative warrant liabilities</a></td>
<td class="num">(29,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities acquired</a></td>
<td class="num">(2,654,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_MergerTransactionCostsLimitedToCashAcquired', window );">Plus: Merger transaction costs limited to cash acquired</a></td>
<td class="num">(229,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts', window );">Total net liabilities acquired plus transaction costs</a></td>
<td class="num">$ (2,883,981)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed net plus transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_MergerTransactionCostsLimitedToCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger transaction costs limited to cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_MergerTransactionCostsLimitedToCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger transaction costs</a></td>
<td class="nump">$ 7,728,681<span></span>
</td>
<td class="nump">$ 7,499,353<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs charged to equity</a></td>
<td class="nump">229,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of Series B preferred stock</a></td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares issuable</a></td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember', window );">Tevogen Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TVGN_TevogenBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EARNOUT SHARES (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember', window );">Tevogen Bio Common Stock [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">6,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember', window );">Sponsor [Member] | Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember', window );">Sponsor [Member] | Earnout Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Earnout shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_TevogenBioCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 721,769<span></span>
</td>
<td class="nump">$ 721,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(425,327)<span></span>
</td>
<td class="num">(263,118)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">296,442<span></span>
</td>
<td class="nump">458,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TVGN_ComputerAndSoftwareMember', window );">Computer And Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">292,341<span></span>
</td>
<td class="nump">292,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">263,217<span></span>
</td>
<td class="nump">263,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">132,468<span></span>
</td>
<td class="nump">132,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 33,743<span></span>
</td>
<td class="nump">$ 33,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=TVGN_ComputerAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=TVGN_ComputerAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 162,209<span></span>
</td>
<td class="nump">$ 163,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">$ 1,309,163<span></span>
</td>
<td class="nump">$ 976,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">403,233<span></span>
</td>
<td class="nump">120,149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,712,396<span></span>
</td>
<td class="nump">$ 1,096,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_PolarMultiStrategyMasterFundMember', window );">Polar Multi-Strategy Master Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Option to purchase common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of price of common stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility', window );">Issuance of commitment shares in connection with unsecured equity line of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Additional Amount Purchase Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Option to purchase common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">18,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Unsecured Debt [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember', window );">Loan Agreement [Member] | The Patel Family LLP [Member] | Unsecured Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Converted shares</a></td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,337,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares commitment shares in connection with unsecured equity line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_PolarMultiStrategyMasterFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_PolarMultiStrategyMasterFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=TVGN_AdditionalAmountPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=TVGN_AdditionalAmountPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 230,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">13,975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">244,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9,587)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 234,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1,065,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Short term lease</a></td>
<td class="nump">$ 785,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases weighted average remaining lease term</a></td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases weighted average discount rate</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments</a></td>
<td class="nump">$ 1,077,127<span></span>
</td>
<td class="nump">$ 1,058,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">897,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 167,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_OperatingLeasesIncrementalBorrowingRates', window );">Operating leases incremental borrowing rates</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_OperatingLeasesIncrementalBorrowingRates', window );">Operating leases incremental borrowing rates</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_OperatingLeasesIncrementalBorrowingRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases incremental borrowing rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_OperatingLeasesIncrementalBorrowingRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service-Based Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Nonvested Shares, Granted</a></td>
<td class="nump">29,329,882<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Granted</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Nonvested Shares, Vested</a></td>
<td class="num">(2,639,628)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Vested</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">26,690,254<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">10,900,128<span></span>
</td>
<td class="nump">9,894,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Nonvested Shares, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,027,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Nonvested Shares, Vested</a></td>
<td class="num">(9,610,540)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Vested</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Beginning</a></td>
<td class="nump">1,289,578<span></span>
</td>
<td class="nump">10,900,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested weighted average grant-date fair value, Ending</a></td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(22,626)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 40,764,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">27,019,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 13,744,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,764,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Number of shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,373,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation expense recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,233,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits', window );">Number of shares issued and outstading RSU</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,237,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,984,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Number of shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,373,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,410,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service-Based Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,601,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember', window );">Service-Based Restricted Stock [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Number of shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,639,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember', window );">2024 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,670,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember', window );">2024 Plan [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued for RSUs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share for award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant date fair value of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,263,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares settlement of vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vested performance based restricted stock units from satisfaction of liquidity condition upon closing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_ServiceBasedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=TVGN_TwoThousandTwentyFourPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Total shares of common stock legally issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock legally outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing', window );">Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,373,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture', window );">Issuance of restricted common stock subject to forfeiture</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(19,348,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture', window );">Total shares issued and outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160,015,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued and outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares subject to future vesting issuance of restricted common stock subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vested performance based restricted stock units from satisfaction of liquidity condition upon closing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,991,365<span></span>
</td>
<td class="nump">119,999,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,614,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on preferred stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuance, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_WarrantsRedemptionDescription', window );">Warrants redemption description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may
redeem the public warrants if the Company&#8217;s common stock equals or exceeds $18.00 per share for 20 trading days within a 30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of public
warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,386,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember', window );">Semper Paratus [Member] | Public Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding
(the &#8220;Series A Accruing Dividends&#8221;). These dividends become payable when and if declared by the Company. The Series A Preferred
Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Redemption term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the twenty
days immediately prior to the Company&#8217;s call election<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_LossOnPreferredStockIssuance', window );">Loss on preferred stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember', window );">Series A1 Preferred Stock [Member] | The Patel Family LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The terms of the Series
A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum, and the Series A-1
Issuance Price is defined as $10,000&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuance, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Non refundable deposist paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities', window );">Conversion of certain liabilities into Series B preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities', window );">Conversion of certain liabilities into Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentRateVariable', window );">Dividend variable rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the
greater of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such
asset amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or
deemed liquidation event<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | The Patel Family LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuance</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_LossOnPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_LossOnPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_WarrantsRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants redemption description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_WarrantsRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentRateVariable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis of dividend, such as adjustable rate. Excludes percentage rate dividend payments or fixed dollar amounts per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentRateVariable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SemperParatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=TVGN_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=TVGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF NET LOSS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,727,380)<span></span>
</td>
<td class="num">$ (60,477,680)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(10,273,695)<span></span>
</td>
<td class="num">(60,477,680)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative preferred stock dividend</a></td>
<td class="num">(76,712)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_StockRepurchase', window );">Stock repurchase</a></td>
<td class="nump">3,613,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative preferred stock dividend</a></td>
<td class="num">$ (82,603)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_StockRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_StockRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,447,157<span></span>
</td>
<td class="nump">11,791,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,623,225<span></span>
</td>
<td class="nump">10,900,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,348,954<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,974,978<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">891,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31, 2024 there were an additional&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85" title="Stock option vested">1,373,221</span>&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#8217;s common
    stock derived from the Company&#8217;s most recently completed convertible promissory notes valuation as of the balance sheet date.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=TVGN_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Stock option vested</a></td>
<td class="nump">1,373,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest', window );">Convertible note interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Permanent differences</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="num">(17.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(66.50%)<span></span>
</td>
<td class="num">(5.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit convertible noteinterest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 6,808,826<span></span>
</td>
<td class="nump">$ 3,755,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsAccruedExpensesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">385,801<span></span>
</td>
<td class="nump">42,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">61,380<span></span>
</td>
<td class="nump">127,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,110,942<span></span>
</td>
<td class="nump">718,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsFixedAssets', window );">Fixed assets</a></td>
<td class="nump">33,834<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">30,823<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures', window );">Capitalized research and development expenditures</a></td>
<td class="nump">2,944,801<span></span>
</td>
<td class="nump">2,589,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">234,478<span></span>
</td>
<td class="nump">317,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">16,610,885<span></span>
</td>
<td class="nump">7,549,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(16,551,169)<span></span>
</td>
<td class="num">(7,426,952)<span></span>
</td>
<td class="num">$ (4,175,241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">59,716<span></span>
</td>
<td class="nump">122,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(59,716)<span></span>
</td>
<td class="num">(122,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(59,716)<span></span>
</td>
<td class="num">(122,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsAccruedExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets accrued expenses and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsAccruedExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 7,426,952<span></span>
</td>
<td class="nump">$ 4,175,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_IncreasesRecordedToIncomeTaxProvision', window );">Increases recorded to income tax provision</a></td>
<td class="nump">9,124,217<span></span>
</td>
<td class="nump">3,251,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 16,551,169<span></span>
</td>
<td class="nump">$ 7,426,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_IncreasesRecordedToIncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increases recorded to income tax provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_IncreasesRecordedToIncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 27,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_TaxableIncomeLimitationPercentage', window );">Taxable income percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_TaxableIncomeLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxable income limitation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_TaxableIncomeLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Sponsor advisory service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_TVGN_SponsorFeesPayable', window );">Sponsor advisory services fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember', window );">Performance-Based RSUs [Member] | Wife of Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to related party</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember', window );">Sponsor Advisory Services Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Sponsor fee payable offset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_MehtaphoricConsultingIncMember', window );">Mehtaphoric Consulting Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to related party</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember', window );">The Patel Family LLP [Member] | Loan Agreement [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember', window );">Dr. Manmohan Patel [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember', window );">Dr. Manmohan Patel [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_TVGN_SponsorFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsor advisory services fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">TVGN_SponsorFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>TVGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SponsorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SponsorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=TVGN_PerformanceBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=TVGN_WifeOfChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=TVGN_WifeOfChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_SponsorAdvisoryServicesFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_MehtaphoricConsultingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_MehtaphoricConsultingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_ThePatelFamilyLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=TVGN_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_DrManmohanPatelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit Facility additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit Facility remaining capacity</a></td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">KRHP LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_KRHPLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=TVGN_KRHPLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'N*@EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( 'N*@EK6:+AK\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( 'N*@EJ:6F$AJ H  *-    8
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M^A<7D-%J< =HDL+<@+A  YY!8X0VR6-S7VZP&-=&@$Z=@2NU*L#2&WCVA+X
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M2G$?L"<N,;LU'L#;"B0,*^3O0O-P07@TSXA(%/7[=GBBO9IFET.KGC LG\8
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M<O-W!)L++5;U5_%W0FM1UB^7G!DAL0'F\X40^OG"?KN__6N.R7]02P,$%
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M0&+@>H)ZOF1,/@STN4)]CC3]#U!+ P04    " ![BH):_JS$OI<$   N$0
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MRSQ4L 7=5/I1['YE':'8V,M%I9IOM&MED\A#^49I47?*@* N>?M+7[N%.%+
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MAI[K^W9_GM"U=!P<!.' /.&=!]7[F7E".[A&XH3!!>)$0)S8&SU/7)%Q>)Z
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MB_HZ4+[[2BJIJPO#_=3PI<SU2\+FS%.D! 2*H$!Q ^HZ"4%_21BK]OM<;99
M]2H% '7OE&X]<OM*CWR:BDS3I;D'4Z=+4%H$2HMMU;,6JO&]T.G=T[@&S9N
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MQ/L[2OG[@7QNU?GA;'?_!U!+ P04    " ![BH):BYT/^?$'  !P)0  &
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M/L57&&6PH373=Z+Y!%T^EY:7"J;<+VI:W\C#**V5%F4G-A&4!6^_]+&KPX'
M'QT1!)T@>"F(C@C"3A"Z1-O(7%H+JFD22]$@:;T-S2Y<;9S:9%-P^R^NM#2G
MA='I9$F?T$ZA)4CW(G@*:%&HE E52T#GZ'ZU0&>OW\9$F\NLA*0=>-:"@R-@
M/T"W@NM<H0\\@^PY@)@H^U"#?:BSX"1Q >D%"OUW*/"":""@^=_+PQ/AA'WE
M0L<;_5/E?GRE:P8_A^K68L-AK.W:B:IH"E-LVE*!W %.WKSR1][[H9S_$^Q9
M!:*^ M$I>O+%#)D;GHH2T-EGH=3@*VD18X>P(V67G/OA.!B'5UY,=H>I#'B.
MO&@\'AUXMG&2@_=>@MRZ,:!0*FJNV_?4[[:39F8FC>O(%_MF EV[QB-_,.WX
MNJ5R6W"%&&P,TKL87V(DVY'0&EI4KJO60IL>=<O<3%&0UL&<;X30>\->T,_E
MY#=02P,$%     @ >XJ"6NAQH'E  @  F 8  !@   !X;"]W;W)K<VAE971S
M+W-H965T."YX;6RUE5UOFS 4AO^*Y4F[6LM'OJ8,D))VTR*M4Y1VV\6T"P<.
M8-78S#:E_?>S#6'9E%"I4F_ QS[OZ^<8^1"U0MZK$D"CQXIQ%>-2ZWKI>2HM
MH2+J4M3 S4HN9$6T"67AJ5H"R9RH8E[H^W.O(I3C)')S6YE$HM&,<MA*I)JJ
M(O)I#4RT,0[P86)'BU+;"2^):E+ +>AO]5::R!M<,EH!5U1P)"&/\2I8KA<V
MWR5\I]"JHS&RE>R%N+?!)HNQ;X& 0:JM S&O![@"QJR1P?C=>^)A2RL\'A_<
M/[G:32U[HN!*L!\TTV6,WV.404X:IG>B_0Q]/3/KEPJFW!.U7>XTQ"AME!95
M+S8$%>7=FSSVYW D,#ZG!6$O"!UWMY&CO"::))$4+9(VV[C9@2O5J0T<Y?:C
MW&II5JG1Z61CCC<#B>XDR2@OT$I*P@LPQZY5Y&FS@\WSTMYMW;F%9]PFZ$9P
M72KTD6>0_:OW#-F %Q[PUN&HX36DEV@2O$.A'TY'_"9#N1/G-W]!N>CG%Y.-
M-AHJ]>M4[9WUY+2UO3U+59,48FRNAP+Y #AY^R:8^Q]&P*<#^'3,/?DJ^,6N
M88 "?S^["([!T2H3M?[_N#OD<=.<, 4C<+,!;O8:<..FS\'-![CYB^'N0)H[
M1<[PC?L^Q[<8^!:OQ#?N>Y;/.^H6%<C"]42%4M%PW36.879HNZNNV_Q-[WKV
M#9$%Y0HQR(W4OUR83RJ[/M@%6M2N]^R%-IW,#4OSZP!I$\QZ+H0^!':#X6>4
M_ %02P,$%     @ >XJ"6H!2Q;"F"0  ="$  !@   !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6SM6EEO&SD2?N]?06B P2Z@6)9R3GP =C)'@ T2.-G-0[ /
M5'=)(MS=U))LRYI?OU\5V8<<64YF![O[D!>K#[+N^JJ*[=.-===^1134;576
M_FRT"F']<C+Q^8HJ[8_LFFJ\65A7Z8!;MYSXM2-=R*:JG,R.CY]-*FWJT?FI
M/'OOSD]M$TI3TWNG?%-5VFTOJ;2;L]%TU#ZX,LM5X >3\].U7M('"G]?OW>X
MFW14"E-1[8VME:/%V>AB^O)R.N,-LN(?AC9^<*U8E;FUUWSSIC@;';-$5%(>
MF(3&SPV]HK)D2I#C7XGHJ./)&X?7+?5?1'DH,]>>7MGRDRG"ZFST8J0*6NBF
M#%=V\QLEA9XRO=R67OZJ35I[/%)YXX.MTF9(4)DZ_NK;9(BOV3!+&\00D\A(
MI'RM@SX_=7:C'*\&-;X0564WA#,U>^5#<'AKL"^<O]K.R7G*&V?"5ET9?ZW>
MZAK^@.6#TG6AL%H'6F[5:^/STOK&T>DD@#43F.2)S65D,[N'S72FWMHZK+SZ
MN2ZHV"4P@<R=X+-6\,O908JO*3]2CZ=C-3N>/3E [W%GB,="[]D?,<2XL\)8
M;/*KO2%7ZSHG]?EB[O$N#__<9Y7(\_%^GIQQ+_U:YW0V0DIY<C<T.O_QA^FS
MXY,#&CWI-'IRB/H#KGWO;$[>DU=(;77!5][4R[%Z4^"U66SEAI653;A3'U?(
M^^#5YX]T&]1E:?/KO4H?%&N_TCNR9BRK5^\:E^4[.CC6H>IU6'<Z:$?*U' 0
M>ZG@2ZMLXQ3[29>ETFNLU?E*X?D=*D?J5^!"K<**5*T#PENT]N9W4G;!5+)7
MMEKK&K[?D"JLJFU0*WV#=<C_PN3"$I3(K4&;(H-%4PONC-6\"2(+W4(/QB /
M.%LVI7;E5N46 %>0$YYTH\L&U(2"5TF'Q/THN_!JK5U@J<)*A_O,,58556RV
M)'[/6 72E3+)P?"N>'V\C[<!3\@/KXL9US C:^/'F:GSLBGX35A9WZYW5(H9
M(/..SR)QI]DNL' ET58 21HOP+XQ8:4LW@SM$S=M\!!>#<IXV!G6!?Q%#G/*
MQ*$P-YB.L< W*0ATZ6UD)RO9J9=6NT+XML8658X0])F8$DYEQ>4:O"[JNM&E
MNJ*U=4%\SH1KJP[DY-,N)Y_^*3GYIH_ES[^4>KDWSPZS"JZA Q(_ZR1^]J=+
M_  ^'&3X-?@ KF!5 9 HZT3CD-$WVI1Z;DI^D*+?U+%WX6CS6Q^H\K*6_8X8
M"JD]2)$P7 W/H[QR_S!6.4,?0JW+,<&(8)U$1X9T0;!H6"0E[;P!FF+AD?I$
M$2RPI!2CP4)Z-TF8JB@D:2WA[LTR!;MOUDQ;S9$E(B(M%B2]#--OM4R:92P6
MW\-TP HJ9 W'_HX9AH *$3]RV+<RQ/SF=%)UPSC"++Q> +*01]#<-\!1[5^J
M"IV/>;0 3H"^;B ;<"47%B=996N#YXP3#,RHEJ78#"U$4SSB1JKHW,'RA5A<
M3A2Z3E.JA2FQ";>[AM(;*"4ZH>::&M1/5&DJ$Z)B-L)XX]ML=L4CALQM5M"-
M@>-.& ,*PXM9GIQ]J5Q3\AL!J@C,+1HRXK46WNLQ=F_&[+38,NG551M!-P3Q
M&@YK(T-6LY=0FCSWC'=$51SRD)59W#!:Q7"%NPOK8/X \T2[#LI?GEO'F)PE
MS!L6,FZA$2XI)1+<Z:0\%5U,\R4<(4%=J/DV.OJ09!+<K \"A9QM/"J/KCT+
M$4M+--J7)8+M<%#EL>K+#$<'W6I.G]:S.I6]H@_ENR2RO_SXPXO9[/CD[8</
M[^5R>O+7F& I-/T=EQ),'&(PBK\Y4-L0%4VEMGBB:U8AI8D:%*)>&"Y6J*%U
M)H30^'*#Z%-%PXX2:3*'.KJOZ&VW\G4A<72H&#WOH/WY?P+MUIN4 -*#(,D"
M(=:N$,Y<1UG^6"/9'+'(WE^K#DOR0*UZT2GTXML5@B\,6L"MNA#<1,Q GRO2
M'A PQ^._F6O"#W3X8BV6+0UW]S#'_:H=EFF!J#FDVT^=;C_][W1[H& ?EJQK
MD YH.3WNY]'C;]4SQA92XK5QE$OFONLRY2'9#[/;WVT,QKL^(;*>)_<=DM48
MO@5C>R0FP)3=1I1KV^M!PXVU$;GP$QV2P''A;'4'CU)%C+/-L'EHBP=1G0&F
M9498&5J@!^MK_+O% HCA5 N#K]Z\:U'PB$<KA0=H3 #9W,, %VM,TFI+.LX-
MPW8!+=*JMJ5= B-O,0D8@F4&"(T>C >HN)=K'=0RO\?*OZM3S]EXJ8LMD##H
MZG8&C8V8#" LRCU6J7G,R\6V?MQOS@"R,DY(CV>!N4!\A A#&IYCXH*F<Q)4
MUC)0B%, =4NN3N/V!<LQ>)/$JL80N\+0%Y\,!> P(,=68RG6UH='[6N\U.76
MFRY8I-&B>L4AQEX%GK^)K8L4H5CBN 4T<")GZ*X-6KKCZ'N8<V.;DF?0)8<6
M*KZ!/?O),)-ZQ:+%&:SK=3OQBKXZ#^R;/$12_2(+J8%EA)7$3N^4JHYHNSEU
M+O!%!B<!<E#$.3"^6=L4/!+I/W<C;1OGA6 #I$JIX3O;1$URDLE[$->9O1.=
MPU1,F[N '8O(C:MYVDQ4.';FM@D/IS!^;;-<H?'RJ[F-;73L<W5)#N&3.:FD
MTNXP&38.-R[CG:[4H8FES9V6/V7"_G2M;XRSM=1S0=$!B'U:F9*R?D!F+&B/
M2[K4C),49Z<<-G0-RG@P61=4TK+M[/BQ!BK B6W+(,_V4(S1($UK1RL>!W0R
M2@+V@P04AXX\%\1PE:2,W:2(%T$@'MC=.1Q)AI2'*:-AJK5%)V9(;)BEO-SI
M/7?810W1Z]WH?#N^Q^:1T9XS$#&B.+"%EO88!+>L=S8XRNE4 N#*D>N."+"7
MIU8V@0X3_,!LJ$LT]! BEH$[3]L%HCG5RN$!5#IS EQFD55G6EHW:;YJY^8E
M9C $"DQ0-.@A.$<!M(8G'DJ'1<,"\<4<]( -Q1U[3-BEDQTN!@VG(463\\PC
M&9MQWE=ZJUS7H/+^N6/LZ.W2JG,W8+\ AF3JH4K7E/ B&GIMN<)P/>\*5Q;/
MQWH/\H Z.!H88\CE)D.: /(8IO%H<-*64K\U/M<XF)</,WU[>"'QFHXB:.UW
MVH3Y]DX%2(FT4^^2UP^.$]/!MX3I?_NLZ##'[X=%WP^+OA\6?3\L^GY8](</
MBZ:S'MUG_S?'10^(<M]YT63P(1Q!MI3/_7"=;>H0OXEW3[M_*;B(']+[Y?'_
M$=YJMS30IJ0%MAX?/7\Z0FC*)_YX$^Q:/JL#:H.MY')%&O;F!7B_L"@7Z889
M=/]H<?YO4$L#!!0    ( 'N*@EJNAND(;08  #@.   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;(U76V_;-A1^UZ\X\("APQS?DG9IFP1P+MVZM6D0
MN]W#L =:.HZX2*1&4G&\7[_O4+(C=VXPH(U%BN<[]^]0)ROK[GW.'.BQ+(P_
M[>4A5&^&0Y_F7"H_L!4;O%E:5ZJ I;L;^LJQRJ)060PGH]&K8:FTZ9V=Q+T;
M=W9BZU!HPS>.?%V6RJW/N;"KT]ZXM]FXU7=YD(WAV4FE[GC&X7-UX[ :;E$R
M7;+QVAIRO#SM3<=OSH_D?#SP1?/*=YY)/%E8>R^+]]EI;R0&<<%I$ 2%GP>^
MX*(0()CQ=XO9VZH4P>[S!OU=]!V^+)3G"UO\KK.0G_:.>Y3Q4M5%N+6K7[CU
MYZ7@I;;P\2^MFK.'T)C6/MBR%<:ZU*;Y58]M'#H"QZ-O"$Q:@4FTNU$4K;Q4
M09V=.+LB)Z>!)@_1U2@-X[21I,R"PUL-N7!V/9U_OKVB3^_H_//L_?75;'8R
M#,"5M\.TQ3AO,";?P!A/Z*,U(?=T93+.=@&&,&AKU61CU?GD6<1+3@=T..[3
M9#0Y>@;O<.OE8<1[]0V\:9K:V@1M[NC&%CK5[.F/Z<('AZKX<Y_'#=[A?CSI
ME#>^4BF?]M *GMT#]\Z^_V[\:O3V&6N/MM8>/8?^/W/R+,9^"Z\_S:^2\8#^
MJX#F_&#OV"3GVM(OML@0*D_O33KHDZ)++M1*.:;4NLHZ%?OI1<B9OO_N>#(9
MO;VP9:7,.J[&;W_HD_802V&43E5QX /ZFWS%J59%6),NR]I8R#M5K0$:A2E7
MSK#WT)P(=&57[,@NZ>+R^$=*U\$&^ZA3FE.Q+JO<8@=9#!8]^ !NJ7!T>0#!
M S1#L>P3W$YUY(XYI>AZ:O1)ZL%ELJ( &@M@F"!JM%E&IJ@]9=HS.MWWDU29
ME)U'$$Q&T6)Y:5V&S0'-@=%Q??S36[]'+:>YL86]6_?IZE&E<]EM(^0YJJZ<
M3>$Y+!,U)8?<9B*AHX-)ZV"?V#B=YHTQ_%C)CX2K8,KK4ADJN+Z/<<&)H)'.
M Z0^0"9P1A?S#YT0K'3(16_#BL6:&J+D;!,XV0.[H:PR"LK=,;@_Z3B,=/F8
MNH(%7=$--IC& FJ7!_B76L2N"H@RLKZ-^5(['[:E(:>S.HU1Z 1G_N7G:SHZ
M?MW?FZI$E8NZ4,$ZA#0'[1XX[>])96!BNOCTY?WEP?@U52A3G&]S)]8V^=MH
M1&HSG2DI(FU(!Z1.5RQ]-*!/)GG'"U=C3-'XJ*&AW8(OK$2>P+G\5/55[7R-
MT$M5RN'IG6..1HL)-P52!#\_,J*).E(2MU]KPS0YCBH.=U0TQY(MQD8-+=81
M3I46!LRXK !VH]"5J-QI^G>-ZHL->M%MUA9T]_B3Y>U^:]JL7O2WS;_*;5&L
M$[N22O#UPNM,2US@R5?*7^Q8+B@=!;,OO]'4>PL*0,C[].'#Q8Z[L\H:--:3
M1,M()(P$6^B%&=X/5?+5]N"'K=K.FR<4B=2E&]#M&L&?*97IOJ0[1_NE"ORH
M04<H#91[ 9,=1[(T04E7]#OQ0%?B,6OZ!J")-DAR1V6_>=4U;\%2(N*CK]V#
M?I 5L*-*26 ;6OH_H?U/8;0N)H(4H#+6=C1!CC:ECO%FO(K7'^E5$P!:Q+)#
M#<FQUK]MC?6IH^>\1HF#EJ3C%]K$0MH6H:C=M3%9(8Z.C2J!WPW#SCC!GP26
MF/92MC4X;1L*KLMRG^Y]#?B4Z$@2.2@/-T_,&R,JR6.FH+\!"J9"OQ#N4^F]
MK#OS#IGC.-O, SL)3DSMDV@T[ROQT"%")>T-/DYS93#F8L?)&56!:AXU;H["
MI4>#XY=H@ 3C ]<Z']70M057'_6[N9 HJN:Z@C-"?[*!P,(X\"NX&00>5*'_
M:8)2X\H%J1R#(<*@LD&,D5M!WAA?0KX(2(@)WCB4;(ROG!:&M5T39-)C!$';
M4Z DDP.:8IYA3L;K<',K;\JIE?]&D&,5["AJLQ>+M^VX)B -"HB@T T_[O5!
MQ'!_D.F(,F> "KTOF,6BT!EJ*OL+5^C&0-SV9<)%%5>;9-V*'P-ZASZTJ\W-
MHPE#DQ7Q%2%AT"K:%OTJD[^9*.US+*Y8.GJ!28R<EQH\AS9N3/PJ#KB<9/1Z
M/!C1:_S?=UL<=F[SD77DFT7Z%R717.RWN]O/HFGS-?!TO/FF^HC!K='[!2\A
M.AK\]+)'KOE.:1;!5O';8&$#OC3B8XY/.W9R .^7%CZT"U&P_5@\^Q=02P,$
M%     @ >XJ"6L:7HA((!@  ,0T  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&ULG5??4]LX$'[/7[&3WO0IS2]H2UM@)D"NS1PD'$E[<X^*+<<Z9,F5
MY-#TK[]O92<$"LS-/;38LG;WVV^_72G'=];=^ES*0#\*;?Q).P^A_-CK^227
MA?!=6TJ#+YEUA0AX=:N>+YT4:30J=&_8[[_K%4*9]NEQ7+MVI\>V"EH9>>W(
M5T4AW.9,:GMWTAZTMPLW:I4'7NB='I=B)><R?"VO'=YZ.R^I*J3QRAIR,CMI
MCP8?SPYY?]SP3<D[O_=,G,G2VEM^F:0G[3X#DEHF@3T(_%G+<ZDU.P*,[XW/
M]BXD&^X_;[W_'G-'+DOAY;G5?ZDTY"?MHS:E,A.5#C?V[HML\GG+_A*K??R?
M[NJ]!]B<5#[8HC$&@D*9^J_XT?"P9W#4?\9@V!@,(^XZ4$1Y(8(X/7;VCASO
MAC=^B*E&:X!3AHLR#PY?%>S"Z<7XV_AR=GTUGB[>S!>CSV.ZF<S_F--H>D&7
MDS^_3BXFB[^/>P&AV*"7-&[/:K?#9]P.AG1E3<@]C4TJTX<.>L"X SK< CT;
MONCQ0B9=.AAT:-@?'K[@[V"7^$'T]^Y9?VLHLH2^PAL?H#^Z4?[6T\BD=*F^
M5RI58?-4XK7;@Z?=<@]]]*5(Y$D;3>*E6\OVZ>M7@W?]3R^ /MR!/GS)^_^O
MUHMNGP8]G2W&K6&7_E-,6N2R=6Z+4I@-Y<+32AKIA-8;4B:IG),I:>N]]"1
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MU=Z2&>3.\KK+%2)$:+^0%KM]64&ETL>V]R560<9LUS6M1[,)$X]G&;XHS[V
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MS/&;1CK>@.^9A5";%PZP^Y5T^B]02P,$%     @ >XJ"6N5A,G^Q%   Z3@
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MNV"ES-P4#\LDL+&/'9FX(Q<"9@/212V>L1N  B6"V5&NW84TSV<1R*IJPMX
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MRND GD^SK'!_$(+JUXT?_@]02P,$%     @ >XJ"6KX9+''R!   ,0H  !D
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M?N/H&L]M:/:QHL$)N[K1#[.']]"P>@9\-Z\>4X],K;D@.>&*7)OURTX-5/5
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M0BB- 7U/A=#]P008_M86_P-02P,$%     @ >XJ"6@W=$A&P @  ]@4  !D
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M5Y0Z*HDCB=F>P$<X\4,W"B(W['MP:M8]S^U$D=LS:V>!DJ."$3547F7,G -
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MI3D4I1&@[VM!GC4+8^ PV0[_ 5!+ P04    " ![BH):*/K%IN@+   S'P
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M-AM#S]'DB@$#/@((YC?C6:U,CU3OU7,=@PD5T@9%1*&WB,]>L4$X; _#833
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MI1*+=7BB]W'E6*'QY#N8LA-R (*EI')K4-NZ>+(_-74)W\S%HZ'(.YYCD>I
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M03WX&Z!NL?@YL+-&8+=-;0_;8;\M4- ODJ!)^RJ;@GW/';E";.UE=*W#_^^
MB0<-KS'LO80E+ ?#:Q7N8-2LXN'(2&]V6-/+LM/:BTRDU+U]74L=!>%W[S2K
MI]4;X9%[$;I;[EXG?T:8)6Q)Q1);VZVS_@G3[A6M^V+4QKX672ACU-I^7 D.
M[DH+\/M2H3_Y+W1 ]9[\XK]02P,$%     @ >XJ"6IKU+8FO!   + H  !D
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MZ J6?D',?NZ<D=:R,;^P9)4,V9DAS%-,8!@IM:LZ\K8C'V2A0'39ZNR65,H
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MK1FI&:OS P=):&R3INP$T:PI%FY0PH7)*Y(G[$N;:]I&JRF'*JG9G::)<JD
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M.A"98:;F])[_LW*W[KNJE.AW2P6D%=YQ6D$EN1X4"H)KM*L#[^7X!<5D^B\
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ME$!+>LM)3P^"Q>VM-_L*]R,(QA_NQJ/QT+N;@S<<WB_NYN.[#S"]GXR'8S^
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MY4!?+K3([1"]%)I&<OL8TS<02B- [U>"JG&W, ;V7U6#?P!02P,$%     @
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MJ>6 JN9K)1B9ES-M*PU-R'*9T).$RAJ0?B_I7$Z"#7!^Y(8_ %!+ P04
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ME&I<GL%_TM*:D)@DVL?C21K\($U:)FH2OII"HVNV04%] Q84.%6-F4*8LT3
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MA<(8Z/<;KB]!.3$;5.W<\"=02P,$%     @ >XJ"6OA+MTB>!   Y!\  !D
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M"C[Y6*" \,_@"WB<^N#3[Y_[MI#)%<*>I8FNDT3P2"+7!?<T$BL.;J(YGI<
MO'< 4 .P9=E9[?"U]FNH)?IX=@D:[@6 #FR6->ACX?[IX0U--8WL239B7OL(
M[X$@H<8!\&V-&1*470"/_5H+"D:<RP'D^YT, &.!0_Y/V>-+Z(URNAI^>GR-
M9GA@R?&%8[;%UO"/W]RV\V>9<B9AOB%80=5FIFI31Y=/B05;I,8FL$.,H4@
M$J"7@ 0BP/P"7"."HADN$U0+KBKH&3!0IJ6A1A6T;&5:MK1:>BL4+3$((K!
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M(]\;EFPI)R>"KN--UA<J! WCPQ5&<\S4#?+W!:7B]40ER#;VA_\#4$L#!!0
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M+RJHE^B0>@GDC8*\4:)#[-J5DPZY*BBOWNL0LC[I$&N.,_?YNJC@ND2'7)=
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MH'Y_C)7LR2]2 ]NW&H[^!U!+ P04    " ![BH):5YX6B50#   ;"0  &0
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MM![N\>L%I-F [[<"(_\T,0VU_1Y*_@-02P,$%     @ >XJ"6@8+1%"5 P
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M&C9X1^6<'2;0^#$",T:%^46'.K>O*F8[(5G1@%5<D+)^XONF#T< -W@%X#4
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M:W-H965T<R]S:&5E=#4Q+GAM;(6486_:,!"&_XJ535,G;4U(2%)8B$1+.I"
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MJ%&*EM-!,D>+H0J:)?/^8C3]B<9)/TU2=#, B0D57R-;*C<ZIYV=R/<5V;U
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M@S##G>K(P'6 ^KYA3+Y-=)>H>WS\#U!+ P04    " ![BH):Y81)5;4#  "
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MII"11'CF(O$ZCKVB,UXA O<T%!L.;L,E6>8!3$DAY8'>>(R1%G%*%BU@PRN
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M7LE_Q^+:3JZ:_Q?ZV<D6UZ7+:=!^4"B:J4=1Y!-[D3]2Q*!82E>9:.SDRGI
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M81A?"TRK=*D-C\??T:],[IC+FDJ8\NAO%JK=R.I9)(0-S2*UXH=K*/)I:[R
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M=+$R1'Z#R">*I^:(O.8*^3?#'5ZZ0&@%?+_A2$8QT0[*:]SX/U!+ P04
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MR38_Q1_-B6@%>*,# 7X3X.\$3 <' H9-P' WP_A P*@)&)V:8=P$C$\-")J
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M<J4DUBW#</2$1*DV'N9G"S8>TDS$48H+!CQ+$L)^3C"F^Y%F:J\'C]$F%.I
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MZ,_A2^$=RLWT4D!:M-5G*B6$S$I(_0T9B=]47B<DS,J^;*P N28JN3O]A5.
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MX*7B0J>D-*:^"0)=E%A1W9,U"KNSE*JBQKIJ%>A:(5UX4,6#. S[0469(-G
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M965T-C(N>&ULK5=KC^(V%/TK5JI6L]**/( P,P4D'D&#-#.,(+/;JNH'D]Q
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M\Q/L^W.ES..3/$&U[]'P7U!+ P04    " ![BH):+3C*J^X"   K#0  &0
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M5.;[Z \0V_Z[M1H*1$J=%_J"$ML.CQ*E:NJRV.I/W[)Y7N;51K(NA T M!!
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M^K=\-OXC;O$"4$L! A0#%     @ >XJ"6D;'34B5    S0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ![BH):UFBX
M:_(    K @  $0              @ '#    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " ![BH):F5R<(Q &  "<)P  $P              @ 'D 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'N*@EJ:6F$AJ H  *-
M   8              " @24(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " ![BH):9\-1@L0&  #9(0  &               @($#$P
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ >XJ"6O1*&\R5
M P  4Q(  !@              ("!_1D  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( 'N*@EK^K,2^EP0  "X1   8              "
M@<@=  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " ![BH):
MV.FI60H)  "H30  &               @(&5(@  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ >XJ"6HN=#_GQ!P  <"4  !@
M     ("!U2L  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M 'N*@EJ27A4#3@(  *,%   8              " @?PS  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " ![BH):Z'&@>4 "  "8!@  &
M            @(& -@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ >XJ"6H!2Q;"F"0  ="$  !@              ("!]C@  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( 'N*@EJNAND(;08  #@.
M   9              " @=)"  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ >XJ"6L:7HA((!@  ,0T  !D              ("!=DD
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " ![BH):Y6$R
M?[$4  #I.   &0              @(&U3P  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( 'N*@EJ^&2QQ\@0  #$*   9
M  " @9UD  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M>XJ"6D8-S$BG @  VP4  !D              ("!QFD  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " ![BH):(H)?'"\#  #B!@  &0
M            @(&D;   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( 'N*@EH-W1(1L (  /8%   9              " @0IP  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ >XJ"6OJ834&\!
M4 H  !D              ("!\7(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " ![BH):]^@:1A@$  "'"   &0              @('D
M=P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( 'N*@EKZ
MSR5I7 ,  %8'   9              " @3-\  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ >XJ"6@ZQTT'5!P  'Q0  !D
M     ("!QG\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'N*@EI&8S9T8@4  %L,   9              "
M@12K  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ >XJ"
M6C@)[RL1 P  L 8  !D              ("!K;   'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " ![BH):_(LYC>D5  "(00  &0
M        @('ULP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( 'N*@EH<#1C$< 4  &$-   9              " @17*  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ >XJ"6M+0L&]/ P  \ 8
M !D              ("!O,\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " ![BH):QHLK5 ,#  !T!@  &0              @(%"TP
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( 'N*@EJFQT-(
ML (  -P%   9              " @7S6  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ >XJ"6I$Y5\7# @  Z@4  !D
M ("!8]D  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ![
MBH):*=;+[QX$   3"@  &0              @(%=W   >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( 'N*@EJ"<>0"O ,  !D(   9
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M970S."YX;6Q02P$"% ,4    " ![BH):12'_JVL#  #:"0  &0
M    @(&Q]0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M 'N*@EKX2[=(G@0  .0?   9              " @5/Y  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ >XJ"6O9(X 4S P  LPX  !D
M             ("!*/X  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " ![BH):!>C@U_\"  !R#0  &0              @(&2 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( 'N*@EI!;,A4Y @
M .%0   9              " @<@$ 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ >XJ"6E>>%HE4 P  &PD  !D              ("!
MXPT! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " ![BH):
M!@M$4)4#   L#0  &0              @(%N$0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( 'N*@EJFI3*XTP,  *$7   9
M      " @3H5 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ >XJ"6C ><)BU P  5Q$  !D              ("!1!D! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " ![BH):.]]05W,"  "U!0
M&0              @($P'0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( 'N*@EKCW5'8A0(  $4&   9              " @=H? 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ >XJ"6B8 E#H>
M"0  SVD  !D              ("!EB(! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " ![BH):RKR&\GD"  #O!0  &0
M@('K*P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( 'N*
M@EKEA$E5M0,  ( /   9              " @9LN 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ >XJ"6NMKD@3]!   D1L  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( 'N*@EJH.7$!LP,  *H/   9
M  " @4-8 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M>XJ"6D63Q:A3!   M!4  !D              ("!+5P! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " ![BH):_6K\W8X"  "I!0  &0
M            @(&W8 $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( 'N*@EJL8\E(, (   (%   9              " @7QC 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ >XJ"6A3J.SJP P
M00P  !D              ("!XV4! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    " ![BH):0_9I$7,$  !2%   &0              @('*
M:0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( 'N*@EJQ
M0$K\V (  "@'   9              " @71N 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ >XJ"6MXMC+2? @  5P8  !D
M     ("!@W$! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M" ![BH):/4:Y,ET'   #20  &0              @(%9= $ >&PO=V]R:W-H
M965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( 'N*@EHM.,JK[@(  "L-   9
M              " @>U[ 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L!
M A0#%     @ >XJ"6J?V66Q/ P  S!0   T              ( !$G\! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ![BH):EXJ[',     3 @  "P
M        @ &,@@$ 7W)E;',O+G)E;'-02P$"% ,4    " ![BH):*Q?6_;@%
M   U+   #P              @ %U@P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ >XJ"6LA<P5(@ @  T"<  !H              ( !6HD! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ >XJ"6N(A,D+Q 0
M&2<  !,              ( !LHL! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $L 2P"$%   U(T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>182</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement -  Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName> Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NatureOfBusiness</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Development-stageRisksAndLiquidity</Role>
      <ShortName>DEVELOPMENT-STAGE RISKS AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombination</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - EARNOUT SHARES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/EarnoutShares</Role>
      <ShortName>EARNOUT SHARES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - STOCKHOLDERS??? DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficit</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - BUSINESS COMBINATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombinationTables</Role>
      <ShortName>BUSINESS COMBINATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/BusinessCombination</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/Stock-basedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - STOCKHOLDERS??? DEFICIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficitTables</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/StockholdersDeficit</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/NetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tevogen.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - NATURE OF BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>NATURE OF BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/NatureOfBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative</Role>
      <ShortName>DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Development-stageRisksAndLiquidity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE MEASUREMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUES OF WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails</Role>
      <ShortName>SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - BUSINESS COMBINATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/BusinessCombinationDetailsNarrative</Role>
      <ShortName>BUSINESS COMBINATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/BusinessCombinationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - EARNOUT SHARES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/EarnoutSharesDetailsNarrative</Role>
      <ShortName>EARNOUT SHARES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/EarnoutShares</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Debt</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/StockholdersDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/StockholdersDeficitTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF NET LOSS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - NET LOSS PER SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/NetLossPerShareDetailsNarrative</Role>
      <ShortName>NET LOSS PER SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/NetLossPerShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/IncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/RelatedPartyTransactions</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tevogen.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tevogen.com/role/SubsequentEvents</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>tvgn-20241231.xsd</File>
    <File>tvgn-20241231_cal.xml</File>
    <File>tvgn-20241231_def.xml</File>
    <File>tvgn-20241231_lab.xml</File>
    <File>tvgn-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>logo_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "TVGN",
   "nsuri": "http://tevogen.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "tvgn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "tvgn-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tvgn-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tvgn-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tvgn-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 281,
   "keyCustom": 56,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 39,
   "memberCustom": 23,
   "hidden": {
    "total": 170,
    "http://fasb.org/us-gaap/2024": 127,
    "http://tevogen.com/20241231": 40,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 182,
   "entityCount": 1,
   "segmentCount": 68,
   "elementCount": 616,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 617,
    "http://xbrl.sec.gov/dei/2024": 44,
    "http://xbrl.sec.gov/cyd/2024": 7,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://tevogen.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://tevogen.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://tevogen.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://tevogen.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000006 - Statement -  Consolidated Statements of Cash Flows",
     "shortName": " Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaidInKindInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://tevogen.com/role/NatureOfBusiness",
     "longName": "999014 - Disclosure - NATURE OF BUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://tevogen.com/role/Development-stageRisksAndLiquidity",
     "longName": "999015 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
     "shortName": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://tevogen.com/role/BusinessCombination",
     "longName": "999017 - Disclosure - BUSINESS COMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://tevogen.com/role/EarnoutShares",
     "longName": "999018 - Disclosure - EARNOUT SHARES",
     "shortName": "EARNOUT SHARES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:EarnoutSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:EarnoutSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://tevogen.com/role/PropertyAndEquipmentNet",
     "longName": "999019 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://tevogen.com/role/AccruedExpensesAndOtherLiabilities",
     "longName": "999020 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://tevogen.com/role/Debt",
     "longName": "999021 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://tevogen.com/role/Leases",
     "longName": "999022 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://tevogen.com/role/CommitmentsAndContingencies",
     "longName": "999023 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://tevogen.com/role/Stock-basedCompensation",
     "longName": "999024 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://tevogen.com/role/StockholdersDeficit",
     "longName": "999025 - Disclosure - STOCKHOLDERS\u2019 DEFICIT",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://tevogen.com/role/NetLossPerShare",
     "longName": "999026 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://tevogen.com/role/IncomeTaxes",
     "longName": "999027 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://tevogen.com/role/RelatedPartyTransactions",
     "longName": "999028 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://tevogen.com/role/SegmentReporting",
     "longName": "999029 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://tevogen.com/role/SubsequentEvents",
     "longName": "999030 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://tevogen.com/role/BusinessCombinationTables",
     "longName": "999033 - Disclosure - BUSINESS COMBINATION (Tables)",
     "shortName": "BUSINESS COMBINATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://tevogen.com/role/PropertyAndEquipmentNetTables",
     "longName": "999034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables",
     "longName": "999035 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://tevogen.com/role/LeasesTables",
     "longName": "999036 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://tevogen.com/role/Stock-basedCompensationTables",
     "longName": "999037 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://tevogen.com/role/StockholdersDeficitTables",
     "longName": "999038 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Tables)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://tevogen.com/role/NetLossPerShareTables",
     "longName": "999039 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://tevogen.com/role/IncomeTaxesTables",
     "longName": "999040 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
     "longName": "999041 - Disclosure - NATURE OF BUSINESS (Details Narrative)",
     "shortName": "NATURE OF BUSINESS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TevogenBioMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_SemperParatusMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
     "longName": "999042 - Disclosure - DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)",
     "shortName": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-06-012024-06-30_custom_LoanAgreementMember",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:DevelopmentStageRisksAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
     "longName": "999043 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE MEASUREMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF FAIR VALUES OF WARRANTS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUES OF WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember",
      "name": "TVGN:DerivativeLiabilitiesFairValueIssuance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "999045 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)",
     "shortName": "SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
     "longName": "999049 - Disclosure - BUSINESS COMBINATION (Details Narrative)",
     "shortName": "BUSINESS COMBINATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-142024-02-14",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
     "longName": "999050 - Disclosure - EARNOUT SHARES (Details Narrative)",
     "shortName": "EARNOUT SHARES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-14_custom_EarnoutSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "TVGN:EarnoutSharesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "longName": "999052 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://tevogen.com/role/DebtDetailsNarrative",
     "longName": "999054 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)",
     "shortName": "SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://tevogen.com/role/LeasesDetailsNarrative",
     "longName": "999056 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999058 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999059 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
     "longName": "999061 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-11-30_custom_SemperParatusMember",
      "name": "TVGN:ClassOfWarrantOrRightIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
     "longName": "999062 - Disclosure - SCHEDULE OF RECONCILIATION OF NET LOSS (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF NET LOSS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
     "longName": "999063 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
     "longName": "999064 - Disclosure - SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember69680906",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember69680906",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://tevogen.com/role/NetLossPerShareDetailsNarrative",
     "longName": "999065 - Disclosure - NET LOSS PER SHARE (Details Narrative)",
     "shortName": "NET LOSS PER SHARE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails",
     "longName": "999066 - Disclosure - SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999067 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails",
     "longName": "999068 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "TVGN:IncreasesRecordedToIncomeTaxProvision",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://tevogen.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999069 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999070 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SponsorFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SponsorFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://tevogen.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999071 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/AccruedExpensesAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r66",
      "r848"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r655"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r128",
      "r481"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "TVGN_AdditionalAmountPurchaseOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "AdditionalAmountPurchaseOptionMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Amount Purchase Option [Member]",
        "documentation": "Additional Amount Purchase Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r655",
      "r892"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r797",
      "r798",
      "r799",
      "r800",
      "r858",
      "r893"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable prepaid proceeds towards anticipated Series A-1 preferred stock issuance",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r96"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r317"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r707",
      "r721",
      "r747"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r710",
      "r724",
      "r750"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r742",
      "r751",
      "r755",
      "r763"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r352"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alternative Investment, Measurement Input",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r861",
      "r862",
      "r863"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r111",
      "r130",
      "r152",
      "r192",
      "r200",
      "r213",
      "r216",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r394",
      "r396",
      "r423",
      "r471",
      "r550",
      "r627",
      "r628",
      "r655",
      "r667",
      "r817",
      "r818",
      "r876"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r135",
      "r152",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r394",
      "r396",
      "r423",
      "r655",
      "r817",
      "r818",
      "r876"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r703"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r703"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r703"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs charged to equity",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Merger transaction costs",
        "verboseLabel": "Merger transaction costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS COMBINATION",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r390"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from Sponsor",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities acquired plus transaction costs",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed net plus transaction costs.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Derivative warrant liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "TVGN_BusinessCombinationSharesExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "BusinessCombinationSharesExchangeRatio",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share exchange ratio",
        "documentation": "Business combination shares exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF BUSINESS",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r85",
      "r86"
     ]
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CallOptionMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call Option [Member]",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r474",
      "r518",
      "r544",
      "r655",
      "r667",
      "r787"
     ]
    },
    "TVGN_CashAcquiredInConnectionWithReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "CashAcquiredInConnectionWithReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "Cash acquired in connection with the reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r126",
      "r617"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash \u2013 beginning of period",
        "periodEndLabel": "Cash \u2013 end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r82",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r82"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary disclosure of noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ChangeInFairValueOfConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ChangeInFairValueOfConvertiblePromissoryNotes",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      },
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible promissory notes",
        "negatedLabel": "Change in fair value of convertible promissory notes",
        "documentation": "Change in fair value of convertible promissory notes."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/Cover",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r131",
      "r132",
      "r133",
      "r152",
      "r176",
      "r177",
      "r184",
      "r186",
      "r194",
      "r195",
      "r228",
      "r249",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r287",
      "r288",
      "r292",
      "r295",
      "r302",
      "r423",
      "r498",
      "r499",
      "r500",
      "r501",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r536",
      "r559",
      "r581",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r782",
      "r793",
      "r802"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r194",
      "r287",
      "r288",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r498",
      "r499",
      "r500",
      "r501",
      "r639",
      "r782",
      "r793"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "TVGN_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants issued",
        "documentation": "Class of warrant or right issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r241",
      "r242",
      "r613",
      "r811",
      "r816"
     ]
    },
    "TVGN_CommonStock0.0001ParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "CommonStock0.0001ParValuePerShareMember",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.0001 par value per share",
        "documentation": "Common Stock, $0.0001 par value per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r797",
      "r798",
      "r800",
      "r858",
      "r889",
      "r893"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r536"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares issued",
        "verboseLabel": "Total shares of common stock legally issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "TVGN_CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares issued and outstanding",
        "documentation": "Common stock shares issued and outstanding inclusion of shares to be issued and exclusion of shares subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "terseLabel": "Total shares of common stock legally outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r536",
      "r556",
      "r893",
      "r894"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized; 177,991,365 and 119,999,989 shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r476",
      "r655"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99"
     ]
    },
    "TVGN_ComputerAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ComputerAndSoftwareMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer And Software [Member]",
        "documentation": "Computer And Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r115"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible promissory notes",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r775"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r776"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r775"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r768"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r769"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r769"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r767"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r770"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r688",
      "r772"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r688",
      "r772"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r774"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r771"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with Merger",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r16"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r149",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r247",
      "r248",
      "r258",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r281",
      "r282",
      "r284",
      "r432"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument variable rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r285",
      "r432",
      "r433",
      "r653"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r260"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r283",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r653",
      "r794",
      "r868",
      "r869"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r31",
      "r35",
      "r55",
      "r94",
      "r95",
      "r157",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r283",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r653",
      "r794",
      "r868",
      "r869"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt maturity date",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred transaction costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r788"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r105",
      "r371"
     ]
    },
    "TVGN_DeferredTaxAssetsAccruedExpensesAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsAccruedExpensesAndOther",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other",
        "documentation": "Deferred tax assets accrued expenses and other."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development expenditures",
        "documentation": "Deferred tax assets capitalized research and development expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTaxAssetsFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets",
        "documentation": "Deferred tax assets fixed assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "TVGN_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Valuation allowance",
        "periodEndLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use asset",
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "DeferredTaxLiabilitiesRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non refundable deposist paid",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r409",
      "r410",
      "r419",
      "r422",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r551",
      "r553",
      "r554",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r618",
      "r861",
      "r862",
      "r863",
      "r890"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "TVGN_DerivativeLiabilitiesFairValueIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DerivativeLiabilitiesFairValueIssuance",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Initial fair value at issuance",
        "documentation": "Derivative liabilities fair value issuance.",
        "label": "DerivativeLiabilitiesFairValueIssuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative warrant liabilities",
        "periodStartLabel": "Derivative warrant liabilities, Balance",
        "periodEndLabel": "Derivative warrant liabilities, Balance",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47",
      "r48",
      "r49",
      "r50",
      "r156",
      "r171"
     ]
    },
    "TVGN_DevelopmentStageRisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DevelopmentStageRisksAndLiquidityTextBlock",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEVELOPMENT-STAGE RISKS AND LIQUIDITY",
        "documentation": "Development Stage Risks And Liquidity [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureDevelopmentstageRisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DisclosureDevelopmentstageRisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Development-stage Risks And Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureEarnoutSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DisclosureEarnoutSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Minimum Rental Payments Under Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r319",
      "r348",
      "r349",
      "r351",
      "r644"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r703"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r703",
      "r743"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "TVGN_DrManmohanPatelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "DrManmohanPatelMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Manmohan Patel [Member]",
        "documentation": "Dr Manmohan Patel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r173",
      "r176",
      "r184",
      "r185",
      "r186",
      "r191",
      "r388",
      "r392",
      "r406",
      "r407",
      "r469",
      "r485",
      "r619"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r184"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r176",
      "r184",
      "r185",
      "r186",
      "r191",
      "r388",
      "r392",
      "r406",
      "r407",
      "r469",
      "r485",
      "r619"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r188"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r187",
      "r189",
      "r190"
     ]
    },
    "TVGN_EarnoutSharesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EarnoutSharesDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/EarnoutShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNOUT SHARES",
        "documentation": "Earnout Shares [Disclosure Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_EarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EarnoutSharesMember",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares [Member]",
        "documentation": "Earnout Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r646"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r359",
      "r379",
      "r646"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r646",
      "r796",
      "r849"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r646",
      "r796",
      "r849"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r796",
      "r849",
      "r850"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r646",
      "r796",
      "r849"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r365",
      "r796",
      "r849"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r796",
      "r849",
      "r850"
     ]
    },
    "TVGN_EmbeddedOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EmbeddedOptions",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded options",
        "documentation": "Embedded options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense recognized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation cost",
        "verboseLabel": "Compensation cost recognized",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r122",
      "r141",
      "r142",
      "r143",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r171",
      "r193",
      "r229",
      "r230",
      "r231",
      "r305",
      "r377",
      "r378",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r435",
      "r450",
      "r484",
      "r490",
      "r491",
      "r492",
      "r507",
      "r581"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r384",
      "r783",
      "r784",
      "r785",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity ownership percentage",
        "verboseLabel": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, measurement input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413"
     ]
    },
    "TVGN_EquitySecuritiesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "EquitySecuritiesTerm",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range in years",
        "documentation": "Equity securities term."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r707",
      "r721",
      "r747"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r693",
      "r704",
      "r718",
      "r744"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrants",
        "label": "Change in fair value of warrants",
        "verboseLabel": "Change in fair value",
        "negatedTerseLabel": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r418",
      "r419",
      "r421",
      "r462",
      "r463",
      "r464",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r647",
      "r862",
      "r866"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r312",
      "r410",
      "r419",
      "r462",
      "r640",
      "r641",
      "r642",
      "r647"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r312",
      "r410",
      "r411",
      "r419",
      "r463",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r410",
      "r411",
      "r412",
      "r413",
      "r419",
      "r464",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUES OF WARRANTS",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE MEASUREMENT",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r417",
      "r420"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r647",
      "r862",
      "r866"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest expense",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition upon conversion of convertible promissory notes",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability derecognition upon conversion of note payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial fair value at issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r420"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value beginning balance",
        "periodEndLabel": "Fair value beginning balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r420"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r418",
      "r419",
      "r421",
      "r462",
      "r463",
      "r464",
      "r635",
      "r636",
      "r640",
      "r641",
      "r642",
      "r647",
      "r649"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r866"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use asset",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r442",
      "r654"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r751"
     ]
    },
    "TVGN_FreeStandingPurchaseOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FreeStandingPurchaseOptions",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Free standing purchase options",
        "documentation": "Free standing purchase options."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Freestanding and Embedded Common Stock Purchase Options",
        "documentation": "Freestanding And Embedded Common Stock Options [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r561"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "TVGN_GrantDrewFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "GrantDrewFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant drew from related party",
        "documentation": "Grant drew from related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r681",
      "r703"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r239",
      "r240",
      "r415",
      "r417",
      "r420",
      "r487",
      "r489",
      "r566",
      "r616",
      "r648",
      "r888"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r415",
      "r417",
      "r420",
      "r487",
      "r489",
      "r566",
      "r616",
      "r648",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r356",
      "r359",
      "r366",
      "r367",
      "r368",
      "r369",
      "r375",
      "r380",
      "r381",
      "r382",
      "r383",
      "r503",
      "r646"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax penalties and interest accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r357",
      "r358",
      "r369",
      "r370",
      "r374",
      "r376",
      "r497"
     ]
    },
    "TVGN_IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitAtFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note interest",
        "documentation": "Income tax reconciliation income tax expense benefit convertible noteinterest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r792"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "TVGN_IncreasesRecordedToIncomeTaxProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "IncreasesRecordedToIncomeTaxProvision",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfValuationAllowanceForNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increases recorded to income tax provision",
        "documentation": "Increases recorded to income tax provision."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r711",
      "r725",
      "r742",
      "r751",
      "r755",
      "r763"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r766"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r766"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r766"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r200",
      "r201",
      "r202",
      "r216",
      "r431",
      "r627",
      "r628"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r873"
     ]
    },
    "TVGN_KRHPLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "KRHPLLCMember",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "KRHP LLC [Member]",
        "documentation": "KRHP LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r447"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases initial term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r871"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60",
      "r61",
      "r62",
      "r65",
      "r66",
      "r67",
      "r70",
      "r152",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r395",
      "r396",
      "r397",
      "r423",
      "r535",
      "r620",
      "r667",
      "r817",
      "r876",
      "r877"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r108",
      "r478",
      "r655",
      "r795",
      "r810",
      "r867"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r125",
      "r152",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r395",
      "r396",
      "r397",
      "r423",
      "r655",
      "r817",
      "r876",
      "r877"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit Facility additional",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r107",
      "r885"
     ]
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit borrowing capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit remaining capacity",
        "verboseLabel": "Line of credit remaining borrowing capacity",
        "terseLabel": "Line of credit Facility remaining capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64",
      "r248"
     ]
    },
    "TVGN_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_LoanAgreementNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LoanAgreementNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan agreement",
        "documentation": "Loan agreement non current."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r26",
      "r812",
      "r813",
      "r814"
     ]
    },
    "TVGN_LossOnIssuanceOfCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LossOnIssuanceOfCommitmentShares",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      },
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on issuance of commitment shares",
        "label": "Loss on issuance of commitment shares",
        "documentation": "Loss on issuance of commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_LossOnPreferredStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "LossOnPreferredStockIssuance",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on Series A Preferred Stock issuance",
        "verboseLabel": "Loss on preferred stock issuance",
        "documentation": "Loss on preferred stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r715"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r716"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r717"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r717"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r717"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r717"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r314",
      "r353",
      "r413",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r819",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r649"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r649"
     ]
    },
    "TVGN_MehtaphoricConsultingIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "MehtaphoricConsultingIncMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mehtaphoric Consulting Inc [Member]",
        "documentation": "Mehtaphoric Consulting Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MergerNetOfRedemptionsAndTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "MergerNetOfRedemptionsAndTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Merger, net of redemptions and transaction costs",
        "documentation": "Merger net of redemptions and transaction costs.",
        "label": "MergerNetOfRedemptionsAndTransactionCosts"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_MergerTransactionCostsLimitedToCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "MergerTransactionCostsLimitedToCashAcquired",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails": {
       "parentTag": "TVGN_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfNetLiabilitiesAcquiredInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus: Merger transaction costs limited to cash acquired",
        "documentation": "Merger transaction costs limited to cash acquired."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r314",
      "r353",
      "r413",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r656",
      "r819",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r84",
      "r109",
      "r123",
      "r138",
      "r139",
      "r143",
      "r152",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r182",
      "r228",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r388",
      "r392",
      "r407",
      "r423",
      "r483",
      "r558",
      "r579",
      "r580",
      "r665",
      "r817"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to common stockholders, basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r174",
      "r183",
      "r186",
      "r392"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to common stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r186"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashMergerRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger transaction costs",
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "TVGN_NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance",
        "documentation": "Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock Issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r804"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r621",
      "r803",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfMinimumRentalPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r654"
     ]
    },
    "TVGN_OperatingLeasesIncrementalBorrowingRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "OperatingLeasesIncrementalBorrowingRates",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases incremental borrowing rates",
        "documentation": "Operating leases incremental borrowing rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r51",
      "r52",
      "r101"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor fee payable offset",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r472",
      "r531",
      "r532",
      "r667",
      "r886",
      "r891"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related party",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r655"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due from related party",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r545",
      "r628",
      "r887"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related party",
        "verboseLabel": "Grant",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r709",
      "r723",
      "r749"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r712",
      "r726",
      "r752"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r712",
      "r726",
      "r752"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of deferred transaction costs",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "TVGN_PerformanceBasedRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PerformanceBasedRSUsMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance-Based RSUs [Member]",
        "documentation": "Performance-Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://tevogen.com/role/ScheduleOfFairValueMeasurementDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "TVGN_PolarMultiStrategyMasterFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PolarMultiStrategyMasterFundMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Polar Multi-Strategy Master Fund [Member]",
        "documentation": "Polar Multi-Strategy Master Fund [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_PreferredStockDividendPaymentRateVariable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendPaymentRateVariable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend variable rate, description",
        "documentation": "Description of basis of dividend, such as adjustable rate. Excludes percentage rate dividend payments or fixed dollar amounts per share."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r31",
      "r71"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate, percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r590",
      "r592",
      "r593",
      "r606"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cumulative preferred stock dividend",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r292",
      "r304"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664",
      "r889",
      "r893"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "verboseLabel": "Preferred shares, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r287"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption price per share",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r34"
     ]
    },
    "us-gaap_PreferredStockRedemptionTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionTerms",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption term",
        "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r536"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r287"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r536",
      "r556",
      "r893",
      "r894"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r475",
      "r655"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ProbabilityOfFutureLiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ProbabilityOfFutureLiquidityMember",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probability of Future Liquidity [Member]",
        "documentation": "Probability of Future Liquidity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible promissory notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series A Preferred Stock",
        "verboseLabel": "Cash received upon issuance of preferred stock",
        "terseLabel": "Gross proceeds",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "TVGN_ProceedsFromIssuanceOfSeriesCPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ProceedsFromIssuanceOfSeriesCPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series C Preferred Stock",
        "documentation": "Proceeds from issuance of series c preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loan agreement",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r794"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant received",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "TVGN_PropertyAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PropertyAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE",
        "documentation": "Property And Equipment Useful Life [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r116",
      "r119",
      "r120"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r127",
      "r482"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r447",
      "r470",
      "r482",
      "r655"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r116",
      "r119",
      "r480"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://tevogen.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r306",
      "r314",
      "r342",
      "r343",
      "r344",
      "r353",
      "r413",
      "r465",
      "r466",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r659",
      "r815",
      "r819",
      "r862",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r306",
      "r314",
      "r342",
      "r343",
      "r344",
      "r353",
      "r413",
      "r465",
      "r466",
      "r467",
      "r486",
      "r488",
      "r495",
      "r527",
      "r528",
      "r589",
      "r591",
      "r594",
      "r595",
      "r605",
      "r614",
      "r615",
      "r633",
      "r639",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r659",
      "r815",
      "r819",
      "r862",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r693",
      "r704",
      "r718",
      "r744"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r313",
      "r454",
      "r455",
      "r473",
      "r479",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r588"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r454",
      "r455",
      "r456",
      "r457",
      "r473",
      "r479",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r588"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r562",
      "r563",
      "r566"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r313",
      "r454",
      "r455",
      "r473",
      "r479",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r588",
      "r875"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r455",
      "r458",
      "r504",
      "r505",
      "r506",
      "r564",
      "r565",
      "r566",
      "r585",
      "r587"
     ]
    },
    "TVGN_RepurchaseOfSeriesBPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "RepurchaseOfSeriesBPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of Series B preferred stock",
        "documentation": "Repurchase of series B preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement [Member]",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r616",
      "r627",
      "r884"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r705",
      "r719",
      "r745"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r706",
      "r720",
      "r746"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r713",
      "r727",
      "r753"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r96",
      "r477",
      "r493",
      "r494",
      "r502",
      "r537",
      "r655"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r171",
      "r229",
      "r230",
      "r231",
      "r377",
      "r378",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r398",
      "r400",
      "r401",
      "r403",
      "r405",
      "r434",
      "r435",
      "r490",
      "r492",
      "r507",
      "r893"
     ]
    },
    "TVGN_ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse recapitalization transaction fees included in accrued expenses and other liabilities",
        "documentation": "Reverse recapitalization transaction fees included in accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET LIABILITIES ACQUIRED IN MERGER",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "TVGN_ScheduleOfCompanyLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ScheduleOfCompanyLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES",
        "documentation": "Schedule Of Company Lease Liabilities [TableTextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r20",
      "r176",
      "r177",
      "r184"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://tevogen.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF NET LOSS",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r20",
      "r801"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r646",
      "r849"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r384",
      "r783",
      "r784",
      "r785",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r860"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://tevogen.com/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r562",
      "r563",
      "r566"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r31",
      "r32",
      "r33",
      "r35",
      "r92",
      "r94",
      "r95",
      "r96",
      "r131",
      "r132",
      "r133",
      "r194",
      "r287",
      "r288",
      "r290",
      "r292",
      "r295",
      "r300",
      "r302",
      "r498",
      "r499",
      "r500",
      "r501",
      "r639",
      "r782",
      "r793"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "TVGN_ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS",
        "documentation": "Schedule Of Valuation Allowance For Net Deferred Tax Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r192",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r205",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r223",
      "r622",
      "r625",
      "r626",
      "r627",
      "r629",
      "r631",
      "r632"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r219",
      "r222",
      "r623",
      "r624",
      "r630"
     ]
    },
    "TVGN_SemperParatusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SemperParatusMember",
     "presentation": [
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Semper Paratus [Member]",
        "documentation": "Semper Paratus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A1 Preferred Stock [Member]",
        "documentation": "Series A1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r790",
      "r820"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r790",
      "r820"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r790",
      "r820"
     ]
    },
    "TVGN_ServiceBasedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ServiceBasedRestrictedStockMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service-Based Restricted Stock [Member]",
        "documentation": "Service-Based Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "verboseLabel": "Compensation cost recognized",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Forfeited",
        "negatedLabel": "Nonvested Shares, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout shares issuable",
        "verboseLabel": "Earnout shares",
        "periodStartLabel": "Nonvested Shares, Beginning",
        "periodEndLabel": "Nonvested Shares, Beginning",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested weighted average grant-date fair value, Ending",
        "periodEndLabel": "Nonvested weighted average grant-date fair value, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Nonvested Shares, Vested",
        "label": "Stock option vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested weighted average grant-date fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value per share for award",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested shares",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetailsParenthetical",
      "http://tevogen.com/role/ScheduleOfRestrictedStockAndRsuActivityDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value of shares",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of price of common stock purchased",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "verboseLabel": "Purchase, price per share",
        "terseLabel": "Price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock subject to forfeiture",
        "documentation": "Shares subject to future vesting issuance of restricted common stock subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term lease",
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r148"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "TVGN_SponsorAdvisoryServicesFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SponsorAdvisoryServicesFeeMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Advisory Services Fee [Member]",
        "documentation": "Sponsor Advisory Services Fee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SponsorFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SponsorFees",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor advisory service fee",
        "documentation": "Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "TVGN_SponsorFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SponsorFeesPayable",
     "crdr": "debit",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor advisory services fee payable",
        "documentation": "Sponsor advisory services fee payable."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "SponsorMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]",
        "documentation": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/Cover",
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r131",
      "r132",
      "r133",
      "r152",
      "r176",
      "r177",
      "r184",
      "r186",
      "r194",
      "r195",
      "r228",
      "r249",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r287",
      "r288",
      "r292",
      "r295",
      "r302",
      "r423",
      "r498",
      "r499",
      "r500",
      "r501",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r536",
      "r559",
      "r581",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r782",
      "r793",
      "r802"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r75",
      "r76",
      "r122",
      "r141",
      "r142",
      "r143",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r171",
      "r193",
      "r229",
      "r230",
      "r231",
      "r305",
      "r377",
      "r378",
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r435",
      "r450",
      "r484",
      "r490",
      "r491",
      "r492",
      "r507",
      "r581"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/Cover",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r193",
      "r435",
      "r468",
      "r496",
      "r519",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r560",
      "r561",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r660"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/BalanceSheetsParenthetical",
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/Cover",
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/LeasesDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r193",
      "r224",
      "r435",
      "r468",
      "r496",
      "r519",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r560",
      "r561",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r660"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r722",
      "r748"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to purchase common stock, value",
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger, net of redemptions and transaction costs, shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares in connection with the loan agreement, shares",
        "documentation": "Stock issued during period shares commitment shares in connection with loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares in connection with unsecured equity line of credit facility",
        "documentation": "Stock issued during period shares commitment shares in connection with unsecured equity line of credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodSharesContributionFromRelatedParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesContributionFromRelatedParty",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution from related party, shares",
        "documentation": "Stock issued during period shares contribution from related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with merger, shares",
        "verboseLabel": "Converted shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r72",
      "r75",
      "r96",
      "r275"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesConversionOfLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfLiabilities",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of certain liabilities into Series B preferred stock, shares",
        "documentation": "Stock issued during period shares conversion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Sponsor advisory service fee, shares",
        "verboseLabel": "Shares issued to related party",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock, shares",
        "verboseLabel": "Issuance of shares",
        "terseLabel": "Stock issuance",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r72",
      "r96",
      "r498",
      "r581",
      "r608"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesNewIssuesOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOne",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B preferred stock, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodSharesNewIssuesTwo": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesTwo",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of preferred stock, shares",
        "documentation": "Stock issued during period shares new issues two.",
        "label": "StockIssuedDuringPeriodSharesNewIssuesTwo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with Polar Note, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock, shares",
        "verboseLabel": "Number of shares issued for RSUs",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vested restricted stock units, shares",
        "verboseLabel": "Number of shares issued and outstading RSU",
        "documentation": "Stock issued during period shares settlement of vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of commitment shares in connection with the loan agreement",
        "documentation": "Stock issued during period value commitment shares in connection with loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodValueContributionFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueContributionFromRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution from related party",
        "documentation": "Stock issued during period value contribution from related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes into common stock in connection with merger",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r75",
      "r76",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueConversionOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConversionOfLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of certain liabilities into Series B preferred stock",
        "documentation": "Stock issued during period value conversion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Sponsor advisory service fee",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series A preferred stock",
        "verboseLabel": "Stock issuance, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r72",
      "r96",
      "r507",
      "r581",
      "r608",
      "r666"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueNewIssuesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesOne",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B preferred stock",
        "documentation": "Stock issued during period value new issues one."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockIssuedDuringPeriodValueNewIssuesTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesTwo",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series C preferred stock",
        "documentation": "Stock issued during period value new issues two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in connection with Polar note",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r71",
      "r72",
      "r96"
     ]
    },
    "TVGN_StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vested restricted stock units",
        "documentation": "Stock issued during period value settlement of vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_StockRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "StockRepurchase",
     "crdr": "debit",
     "calculation": {
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock repurchase",
        "documentation": "Stock repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tevogen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tevogen.com/role/BalanceSheets",
      "http://tevogen.com/role/StatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r76",
      "r87",
      "r538",
      "r556",
      "r582",
      "r583",
      "r655",
      "r667",
      "r795",
      "r810",
      "r867",
      "r893"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://tevogen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r151",
      "r286",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r305",
      "r404",
      "r584",
      "r586",
      "r612"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative",
      "http://tevogen.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://tevogen.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r461"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "TVGN_TaxableIncomeLimitationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TaxableIncomeLimitationPercentage",
     "presentation": [
      "http://tevogen.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxable income percentage",
        "documentation": "Taxable income limitation percentage."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TevogenBioCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TevogenBioCommonStockMember",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tevogen Bio Common Stock [Member]",
        "documentation": "Tevogen Bio Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_TevogenBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TevogenBioMember",
     "presentation": [
      "http://tevogen.com/role/BusinessCombinationDetailsNarrative",
      "http://tevogen.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tevogen Bio [Member]",
        "documentation": "Tevogen Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_ThePatelFamilyLLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "ThePatelFamilyLLPMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Patel Family LLP [Member]",
        "documentation": "The Patel Family LLP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r874"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "TVGN_TwoThousandTwentyFourPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "TwoThousandTwentyFourPlanMember",
     "presentation": [
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Plan [Member]",
        "documentation": "2024 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/Development-stageRisksAndLiquidityDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://tevogen.com/role/DebtDetailsNarrative",
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r113",
      "r114",
      "r117",
      "r118"
     ]
    },
    "TVGN_VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfReconciliationOfSharesOfCommonStockIssuedAndOutstandingDetails",
      "http://tevogen.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issuable",
        "verboseLabel": "Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing",
        "documentation": "Vested performance based restricted stock units from satisfaction of liquidity condition upon closing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://tevogen.com/role/EarnoutSharesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://tevogen.com/role/ScheduleOfAnti-dilutiveNetLossPerShareDetails",
      "http://tevogen.com/role/ScheduleOfFairValuesOfWarrantsDetails",
      "http://tevogen.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664"
     ]
    },
    "TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each exercisable for one share of Common Stock for $11.50 per share",
        "documentation": "Warrants, each exercisable for one share of Common Stock for $11.50 per share."
       }
      }
     },
     "auth_ref": []
    },
    "TVGN_WarrantsRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "WarrantsRedemptionDescription",
     "presentation": [
      "http://tevogen.com/role/StockholdersDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants redemption description",
        "documentation": "Warrants redemption description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common stock outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://tevogen.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r186"
     ]
    },
    "TVGN_WifeOfChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tevogen.com/20241231",
     "localname": "WifeOfChiefExecutiveOfficerMember",
     "presentation": [
      "http://tevogen.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wife of Chief Executive Officer [Member]",
        "documentation": "Wife of Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tevogen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001641172-25-002426-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-002426-xbrl.zip
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M!$X@$A-=%O1S^ZKJ\9C^AAD-![2"U5S%\\8O9383,\EK\->D\RC1\/FD-$@
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MPL<&U7E!71 ]\%VJB06FUK,:KEPB'$A@3H$Y!>9T;YG3*E>%/"B7/8-0".)
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MS.E*GE/ D\6154QL"^]++?R>A/&\ ,=Q3 #-,ZJ-:86JEF51GP@LE*S_<K0
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MBDQ?1,,7-J2%2@+&B-Y[.?[;==SNIB5?@V3HG!Z^8>\#+EMHH[D@;=&&VS8
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M*ARZL,8[N 37)\0WM^%JM57N,P[#]M^'ZRFNV#K[VI XO*=3"[SV*J7(UO_
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M(J/9V*J*-G1YY9Z$-L^TL94.<0]@,TE4EA$]4W-&&DJ'VR,%!YV10V ># _
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M,#W_XM<#7-GN"@C/3RPCD])F7/7\T?\&?-1\]YB<C[#8.M!/%.-PZ%KR:"N
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M?ECL]N6P?2F<O26V+Y/_!5!+ P04    " ![BH):KE-0/"$$  "@%@  "@
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M) M0E)VUR;BU[D>]!S >QR@,KG=>MIOGL.^,%KG+.^HE4S5A.6U<%7SNNJT
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MM)/NYUPT9"9YO9&I4_&.;_3+B?I/X!M;V "FK$R+3H5J2(=-P%S(MY<*]2D
MN5I>%-YQC;6.80YH.!Q<Z2GU#D_+2?[\N*,)+QZ-@C(7,:<0KL!R:HTQTF(_
MR3Q2S48"IA>]#R![B>O-&8)9DE'-A0;H^]'A@_'#R<YJZCS?GE/D^L]UW[W)
M7XDG_$$Z]"7K"23-4 "B>>]E4VH?1[VI4<:G&BVK.*//X4C+E"0[J.?-,4S3
MC QK>B6;-MQ @U0$W9N*Q'C'E_2V94ZQ7$A"2E M\ 166)8&*D?%($F1(SOR
MBNI,RSO=?77.EAB^JXN90:E(@3DI;'$'9SM6E%K@0V=:B#0!Y-IJ#6>L0,9+
MGTGJ)-BW *(I_T+L<:JL-PXU',$\V*GDBCO="<:6VUTB3X8U"KQGP6\_BD!A
M&R^S!"SP.L=&+]<>O[E6QK)=SL/1+N=AE_/0YYR'?HN6:Q;2IR9_]P2+7,],
MD>N[VFTJ]H:4UV*YRW2X->,(2]'IPAO32F37\*6W":H;>A.XPO"-K6"ZVIJ8
MQR4I$J((4E"&L%,+V4^@I>@V(O $KSA \P[+D*B9'0Q!I?JV)4DA\TNN%Z>Y
M#[@02>;SP^"DP'P6ZJ$2<E'Z)S5G,RI+Y0$H1$R!M>685B5>9YDS [/M.$!:
MH&N6XOK7U<O<YX(ZTZF2.S'$:@8#8$<7-/5J[64P?8?+W=DM,X>%JQ85[62N
MHW.E!Y,[3MZ545J++%PU/N;G+#->=A'L3>X=[9O1X7_I@5^3Y3<;V*7EWPIS
M//'Z<*#O[K=4MQ3X0#Z('7?L'W=TK5.TMU7O6)?7R+:"KU_E4._XJ\U(ZRK>
MW&G$]^BBD>4W0E'(15QB7J);8YB$.K[[$1Z\$44L_M) _BKRC[(,7K\^M;<_
M\O-:5+\ J&,V0(5M8PKF(=YP%U2%[CXE@DN1*\G=1,P]B%+;@!*]7&DA(MW"
M143 L)CI:;-7SA=)MI(844OE#+CH(H$/F!]3HP];O]"^#RPSJA0-^OQ2QN'5
MV\$=2X!ORR;+YE[,\)R\>)B\4988(:)\_RG%4[O:E #^YU*PXHE>_^S3BMX%
MJSD,T"-!,=(9NBGG,C_'_YKV.'@=RX[_W@K__>#.%]@.1)5@Y.O"W5^Y71F[
MI3W!O>/*_>/*K3IK6.^^*[O[)E$+7MEQ\T;(?9$YQ&"O24(O.FB<]O:L*4"!
MW952PWIKNMZ\*OB:)'/3#T43XBI94=&03?/R"\<WMB9,N15PFM6'G:[X-B6\
M71!]@P +]]+R/FXJR>9"+\W*$M:LY^)/2C8QC9)KEW-@)T&<FNX=8EV5+[*E
M/ESS#/N<^ZHR2[,+OF>XWG6QMBR-"RRFCT!VQ%88>G/P5;=^NR^7!XK=OLB/
M*>QM3OZ6;+OC+M92(A+E)^SY6% DQMWEAB]XW<4VW*BTN_>L'YQ"MRP/N=O<
MU2R#:*39JJY)2&O,HG%\B];S2VH3M3V=2D/UM>X4=TN8OK(D<L>N%-9F6'PI
M*&WD#9C P''>>]$84FH]\8].15"Q1<),V'BR@C?8)I65\)V"T*MC3PJ"ED_Z
ML'OM-LV)+*0DQPV*\IPZW9B\:9UZAT)0"^D.\44J?)EQQUPT>B+TK,1T:2%2
MD;0]KS'OT;7=+;<:FU0("S\L.2'Q#_0*$I&\:OPC2G3O2YL9P.]:340W,7+7
M.GR0&"'$2WPT0 M  _:]23#G(*HHTI>A::2%;2(XDT*DVC.EKS>PB-,1VL>C
MIQ]^>_>LO'AZ#_]+>>@IHD/DB=(C,$ON'&(\:1G#2XGT<JYL6@?^7L^B@!7K
M"Q W8?IP./@E6V*'H]"(>4ZSM6[0QO>@C-C.S)C(037BAFAR[]D#_8Q34#B9
MM DX7EG)5>PY!<$+3BVE.S)4UJ22_=!LZ[K2J5VMFE+,MA<8XTUP3I XE(;G
M[4+[/MIR@JMVP2 $^6(+@20F,7COT_[G4PS/PW1B=RX/]E97C#5N&6L&6FZV
M-"Y5JHM(=:'BHIJ"1H=HSBH0"2; [N<+47GD.@W,5 XHGHN8-J,R+7>9[U $
MG32#V<KF8OM!?W1\:ZT3UCG7S5O3TN9W^R2JS_1P8,\_>6<\3S#:!DCP217+
MM?NCN'\P<3ENF\J7 6_-YQ#O- 3[NA$,*_OT!5::M^UNDKIV5<7<]$KA"*/#
M LZ9T&Y0]=AI&5MK&;I;-UG'["K(Y4**II*/#_3? N1JC@WW+J6]A;MIL=9,
M<DXW]+I#XQM)TM)+>]UX7[M&V(BY]JL)3/?JPEW1H-M&;P::L[!!#$@L0^L*
M0S47T1J:^JS5N&L@>%WZ\HC.A979N41Y2Y>A!MCE,-'+#+GL17M\T"(D?X?A
MWXM:>H%O4_)5U;'AZ.M!.V3OSFV/GWL7'-[UW*C[N]RH76[4+C>JYYH$,:+A
MX'<187+F+MC<,WWB!*.(E[0Y*V/+N"L \2)#9;R&GF;@BV'G82CIKM=46^]X
M#24ZY,\OX( 6!1MHYHJC4"LE AFN=W&M\^?_;1?I87""F<'&<1;AM8C4S&9&
M/7<#LVC.L(%A--Q!!9(^8?5&?EJH7/C),NYR*7.-%%HB;-1=D"%>P'^6PF7[
M<* 8AJQAR_I+P#Z/ #UHCQ<<J?$^' [T;22LWMEAE'-KY"X $-KK*LAL,ML0
M2U%>Z&O00:<1$34O?<GW<:*Z9:+!+NX .T.W:EK-QA4 M]%*J$M9S>W#CB20
MB&PI";[$%UX:#-)5S$QN#D5F!C)VD?CNEI?ZSG)J[]Z17>)D/[GU;RFE$'@V
M !SO*F=OV HCQ2J+N2EY@SGZUS9U!R1MHF$A%X(2:KAV$R]OX@O=;&:.%WD-
M/6O*\I(R0]O)2Y]Q%[@ULAOK3>#Q^BGN \]\B/R7;=\:/VFM''ASO)7[]S36
M=!C\ 9"C(_:+<4:"2VR!-/^2/%PAM6E'H&B5]%EHQ0S#P#))F]UKT5\[G!8:
MULWN+<.[Y:HC[8!CZ]OL6&AKD.J[!L-5$<HLBJ>C;;O:<>W;N>'T4Y14!5WY
M_C-J5O"Z=D/L>'>O>/>&I/>]D_U@3^WK4K9<7;*S2^<"42%MAHV#*5Y(O4-*
MU+^F\D(DL[4V+'M*[3/.O(0B3(O/V<$V'(#BJDB+12\ WZB*5X; $584(:K0
M^;?46C^F^? 59^20S_*Y=*[W4#,H_ <YMTQB)3<R\<)$C68*9:;%F&NNT(P?
MT$HT5M97$? B1*[HPI!F1:!UFIF)\3KY,*A)3BZ*MNY4;!,C%:VBS;-:E.AK
MVZ?;[2F(PDJ_&1O#*#/DN'^"/"YBG3)DJT>KG/1GF#N-\%(3T[BFM!UHN&J(
M;I[;4Y=7+/L<"X]2Y^C%\M,<!8R8S80"*.(L*D$O<'TMQ+)S3L1ZDH0V, 1*
M.5VYJO.27/Z9,0LP%<RP'139FB35YRZ6.FXI+:$B^JS>:\^F('/PJ([;TER^
M2$#+F.I88\7Y6GJXKIF?D-3;>[Z_X6-KI?R68CDJ#U)0%P$6@6PA:CS@R0#N
M:RKM@5XRW4[4%,X"I</>44\?;SM%Q0%%L]6:GBM*W=4!<UAU2;V=4%MITP'+
MML#<%.U0C+USH-#$VUV-[BYAK$>2H4E(CH&98Z5%QWH68E$I(%9S"E'M3&&,
MB%M5,C//K>,?")%Z9WE-=2U]@2Y!E4*4I(Q$.7Y\=#^D@(7FA'Z;/O,VDJ7)
MX">F2OR<^"@S*^<A\0^;/F-TSMWB_1.^H\]^T.>)]N,-!TLLF$B4O)36_*KS
M'5-.X8OVJ4EHI0P&:]MA[C 76JP:>:Z&:UHQ@<)+OU*N%I)#?BBSB?"M*%9\
M)O@V7RT D!'&$LTI%(;M0'-K-GUH,,M6VT2U[%SXYTI?T>;>8S;<X+MME]*:
M\@Y$@05<G..%988K^]>C:Z6J\'RHI!VAP68L.S+$.#';WK%AS$G-]RF*B6)'
MN0QG<_P*=^PY=41;@7F5R$)?M7Q.'4/M1<<DDW9FW>V4C)@<OLGHR*JPYCS\
M6S?M.-5U3WA>J-I\9_#UB&UB>QG2KNO5(?5POM[GP-]FM":<.]QF%6 UV*+$
MA(5-'S:T!;ZO$#@F,R,4L>.):5+%%[R;G#/_,\XR@X]!\ ?N4Z>5XEQT YI.
M@PAK ,$:+]24>)RCVLA1*_)-X,2JH,I!Y%08&N(H1ITW2:-D@ YQ(2E(@SFE
M64[ZBTMZG(0C<YMV+?U,IN?,=;'8PV@N+N40D#/5.65:A6$N"2/J=\FRD@1D
M+=V57^921*\\7+M@ZZE_F!RI<X$;53)N?T0:M$\5 M9U $VZM$,/<$0C5VWJ
MFA9T\9E>>T"HL#^'P4ES[4'+TD$X8R9?@27Q0"+G6HO#]C[83<@DI' E(0HG
M,&3(*\#>R$(DLG %AK4B3%T'9'?"]AMR*D/F+-DU)!QBSXWMM@2Q@=M04+)E
M%KK$&]Y9$*V)HF1I%'*PA"RB/P'P9<K@QRK&/UQG(^P\@-M;4#-:UR7-:!96
M96D'#>MBRPK&'A__8#W*)HCH3H6-";:4R^N0)AE_@2\<4-5II8JI+)>8TRO\
M*7C-7:2&N#-'5\:&[F!O"OBXF)$#V;D4+(U[+:.*G[Y-X>.27OPDEV82S&>O
MM)8#TYDK\QUEJ7@9,=M/T)([\YW)>5G+EQD=3FKM,<]>K+^Z_=2M6]>8Z1JW
M[?\]?O#PL=NW:X?].H$U2>8(7S.=7LM<=T#9OS4U/6T\0\'P?.VT[)0/YFXY
MQXZUP<0\&:-&"(G6'-:D$T<7.UA&#>.47P6G16=8?3.G_ZZMH@G_AB3*XUT2
MY2Z)LL])E-N?GT8"\DYD[T3V]0&+C589.O1;5O-Y/2NP4[1^F50--YA"# 68
M)]S>@<L>'J%A4:MT8)-LW<BH&1>ZTE#;I_5U (QSE!&@@)![GCY >W=1Y=C\
MI]" S*P59,S=.@1NNM 66"QUZ)+-M +MM(#[P?I>4*IF\URA?M\>'IRZ]H16
M?2DRTIQPOD@63T#Q:=%.;N18WMP!O$'MYH[!NMN_.\4Q1:D91.XUP[><9AN3
MI\V6P<QJ:_CH"&:+;;3.]Q@88BLNPXTNV/C,GC@;2NG\*K2@K0K-8X8,3XU5
MVCM,,:IC>>0&IUC[Z;A6Z\NH6 ??AJ5U4QFYQC4:J3RJYEH U7WBOI-^Z7K!
MM7?P]#V8^NVIW-8K31W[=/ 1N^1E5=%ZF KM$:VI!QT>;=T.R64E4&9_:IK6
M113K10>A@PSON>#6>Y2@7%&D-I7G0/*"JT$%-T3Q6B_1249^4!7K?,*V&_4J
MVCWD7&;<,\GONJI9!<8__IZ3I/@R1>ZP00(<,"8:(.VF(UZ\H';^Q!HX_&&G
M=W6=^&D'!5%G*@[\%A=U-SRM2=^$XG4)\HI ^%ZBC!.Q=;')%!9F5WB]A:.[
M$'!K"/BUK=JEOABO3?;.+K[;&]:_(:%7N+JS+#<F#*=9FEYZS-\I>1Y3LQ*J
M!:B*MD18XLGS+.6V.;&8BW/=ZH?S=RD=II&^2T7F+DM7<K57/:6%@I'RD[E_
MD.*E+DV,<L9LZ;A.MC3:B<L)M2'AX8#9&@<J"PH<8R=56A+Q.1B!-4&76GNW
M6 F<2T.[=ZRO/T#^"O ]3[T^XRA$=$LRTW_FY:>%3 MY[9<0[;C,];<5Z\X:
M(U>*,MNM2U"UKA5C32OML<X*KB=]&];@V4A^!U);7F2..N@>:;9L'/3ZI47>
M8<=\$5,,Q3;>%@O3]SBN\4O2<K^,84IC(*J\A6]Z)6:MN*GEPUO&MTM6[=]Y
M(16;MTN3^J+*0:$NI-:@0:5%JTVE!9@QU/';KZJA/&93WN+)4K_$!2C+M>XR
M&:\S3H(>#IPT-7G].GN+1"^3M*L$IR01I$!\BL7<YZ#K4PH&?+&\D-: \6Q(
MO3I59^X[8NP-,182<X9J"<)>L_<-_=*$213NR!-V[*R+F:TW; .AO\'JI").
MX\1/U$>9J(LL8\^:JTK#YD'GK!0:P+J2E]&(#73^LNY#J.M<\!+,F>E] /PU
M#.94,^O,4),65NE!&RS^,-!M=M'T[>I%J5(P_4M2;DQ%5XQM$+%H2>A>UO;"
M6LW=EW3CG?8>%EP$5,BR3%A)HBO_2* $F-48%U<@H5:8QIGGC;/J;<_A</#'
M%1GV)C*D&9:KWM6C(JNQM]^Q\)2(8Z0)= N492ZB4N=W$_,K10+O:BT!E8-<
M4=C';ZWMKVC'6_K!6UZE1383.75Y;9+4S"OX0:?<555EYGC46LW7V$W8",3Y
M7=QU% _X7)W6Z<++\XQ>\0C8OX BQ//FKK:'XZFP-H2S@UF-S!8J]4*M'N (
MARU"POLW5%&094.\IHD3Y8ZJ[KZYR.#_D\JG6Z^[<&T#/3B3XK.74[9'6"\8
MV9V)O[.*+=*4'NS2E'9I2M]DFE+?W49_B#S'.W?OG,OK;OK]L0\322=0!2WF
M=V5=/=*[7I+'?7F!?>N6O$6F.6RA2__/L:@).^RX%NG6\8 %%&2K!&MWN)54
MNJ/;_7P_'A\>CU"WXM?K_?!B7"SW9R:/51%5I+Z [9 M0\YK6%&VQ6&@Z2CP
MPGVAKB\C18ER,H2N\20U*?5*OG@U.CA,/3"<'60[3X'JY[6>6NJ.$JS8S832
M;7.MOV6+"4+7-DXCN> B,;Q_G'PB4U&H-?,*Z^A-/,/O9F>BL$=[8G_O\7Z+
M,@EJ7N@^<<5:;CS$C+E.[S!X->.7['-=^DZJK0=&:$(F]MLP:"GA#4P(R.^6
M!Q;]IL63/Y5,5].>CQMIF)?,4&!LDYM 4Z-V'&DCU\['E$<=M[#;"UK\VA5@
M8>#F%K!HUQFJXSY"OF]5FP%@C .*J9<XW6;'6T*7N^(4ID\_(#^N(NM,NW(.
M,F:251-*O,(B*176@=O\&0R- W&CAT^719G^CK7%ZYGM>HUMK9,NL+,*,A^\
MQ/!2))4T)6?8.2:6,UX9GL!]G-C<&;#V&;>U]@;%_B;KHS*VF<8QX5+?]$?)
M1Z GH>:2RT66H[F68-81UM_55]*!.=.D9#S"Y #:!+PQ LB$TT)UUQJ^Q=9[
M(Z@7OU%/E=1K[: OB8#I+&(57GGB+$+#,,EMRGBPV*;30!TWX1C/D#50R9V7
M/8:W+Q#%>)MRRK^9!A1M&;ETP0$V7[$^>R!AD[%S8KPEM-OO$D&6YJ]\6>)P
M$--'_Q^LO6#R* PFH\E1R&V1XH!K)#W'+PJ-.7)L_CSX4$U#.*/1(3SX\/O_
M!B=>L:%_"R8^=!TTSN1E!N@)GJL,/P[VTGL?[XGAH/'[X3Y;XB_RP^#]"L#^
M(&"C:KAY;A)=3M=J/;%31QK\+*=YA:ZA\7U:VV,2'<<_C4#P',X!;!2+_\GR
MC\$I>I904H34H<AT'\6T:/0;&AY)?H>_*KR-9N>&[HW* DKE>[M'E"W@#IWI
M%<E\PZH;[1R=HFV82R#C C241X>CT2&JI\%;NG35/\U<V&P8 <L]4 S0T83T
M(N?,@?UL=/NMM+UI8UO(C,J)XI)<3,E:>!7U3D;F"K!,,<("&_KB+=^"NT!5
MJ>(<+E*Q+I%U 4/@R#?5KYH>9S0!NKX4?(&YH-I91+>H-IG/VE 6%G/,;J(>
M=E?ZNJNCN:M9X4HG8K/]9*YPPELNX*#NTOUWY1K?TO[=I8-IRC5\%\3H<#0F
ME4!+M=W^[L[GM[1_=^E\N@)4$6"MY;RB#K[Z(DB=\J -]&6.0=S4L\<]$PU]
M3.@-6M;<@M00=4<>N^/]#>W?73K>:A:Z"D6ZL5OISL;&Z55S[&UEFGO6/'HH
M.6@@8TY/M!$$F^;*#E=;U:U]AZHH*O)-DZO'^O6T!W'=@2J<C\\WWSGS1)O-
M/\YC45P\P7LFTU(=O%"Z4_*) PJ]"K:<#2'2?E6=6AE,ZJY+TZI+ $,\J'DL
M.2[Q-QR;&,V0:>RZ]71Q5=^_:;+4;J%"<^<0^[+6C#;XPNZHAN??IUTQS:CW
M(0551%=$K#.W*L)>[29*0<<IM0=Y.*B=Y*[#UHA+*'W7E@NBD3O:]NE?Y!DY
MR*J"KXC4%XZ7> 561TQ@./##6UC_B5F;F*V,,\.ABK7CS@37=%7HJQG-;=V(
M3?\?(Y?&I'H#ZP1TBZMR;^#A@"]/H=11-<.WN3VOB8^9Z"IR(+X<BT,\7C3(
M:Q^)[(+"(KP[&)34389Q.-J\9B?<G=.Z/V>4FX/#-DVQDE5R-(YB7?I(>!0)
MA[5$HDR]<#B?7 R_<T$MG5[W!9*#:ZZI@]]>2Q1S1NE%O+/UG/,)Z8C)N:KF
M3;Y?EX<Z2NPG0KI.B437IK$B9]\NF3_@'45M0H8\]_509XLF;V_H\6^LK063
MZ]*NB "Q%;[GH09%X&%@+ZAW 0)3PEQC6WB>9X)F!2%-;VL-Q)>0<+#/J5(2
MQ]E>(>G212C&?OW*2+Q9&3%Z"(RWE$@5!>-#IVOL<:][]&TRS/L=I.%%-3T<
MZ5U7O-3;*(_<\:*M<JUGU/N>^,!:1H2W?^MJ0TCR#>80YZPF7.@"V<SJC;J;
M 0DGDQE"(>HE5>]GZYDP5+,09P&V1_+:&C>R0PS%ODIK'9IL(5''S%>DH#3F
M&@YHLM!,UE@MYYI0JW]J:^6W%9X)DUE.EVW#6A=@Z;C:0'?\+01<7)W7PX9T
M3R9G>>#1O70E+>EZ92"5,!>54<?FXA-Y4MQ<&_2Q&H_1EX0;T# 71R>>DZ31
MK/G:4VZVR+<9#G!C>#5XLY2?@A/<=@:.K1A%T[1P%W\V<V(,/CMFRLSU?%=D
M[&Q*N^&*9[SS9W1X]*#FV/Y*?/:F4X&_.-W^X2[=?I=N_VVDV^]TF5M*!AKU
M(QFH.R7GUEO37_O6[1)T=@DZNP2=_N!J%R&\X_MWEPYF>X+.>.3;,6RG_KT$
M@2>-*IA:L8HN5-'!L,^J5G%>1]]A0GT((JE,OX,UF]->WD<F*]U=3G4<QM8E
M0#B^P+5/,!E?*-7PK5%4;]N*#FV-GB8"P#\)Z$YSS)-GH$)/*;&E[ R*TU$(
MG%U:Q8YI?FO[=Y>8YG6G58Q,6H6N"M@ZNX*AV!S1N)GLBBL"&K7L"I,?\5F9
M$7<N*>+@!E3\;\,W\%S"Y"EU)]>D8&^&;-U@D.KG"B/U[KI*ET*1F^@_-Q$T
MQ!R'?B4R7V^Y094@2-8K7\^L?]JV1O:T "R,A..E[^V]VI&MF[:V!5*U=C(<
MT EM+[!%"*(L3761L>ZJ[>&)6RW6:Y55X;\QDP*[)3;4EW4U93AHZBEK?$M_
M&V4YND8R=J<T%2%@645%O:O-9ERU$<1":?UN:TQS1KO/R/S6M-+]T-?B=/$I
M<C5]D8A;\V665'.@(8DY(!A"TW6NW4P:1F/?4:.6]>]D?&TB=[^8U8LIV= '
M!QGJ1*=O6S7]O*[8F0527*Q["5 YK' /VQ, L&6@I,;QY84^#8 4=QP.@S\D
M4[-IM.F%KCP%7W=AQ[LYDY8039H%6$-+ :F4&AG83NJ(41?1'ML</"R@M4EX
MS8PJV*+KS;:Y35_;-7OHMUGIFJ^MJ4YR-*%#HVRH9P=\R/"C) :;#_NRIN<V
M(#'V<5!3\4[?XEK?_.N[H_O?;1C0EUX1-IC+KPX-_8PD]RN3W.\F*N@?]^9"
M6J#66^D#LQZH^%P\;ECG56MROO;@!1R>F]F*R77OQ(^)7*.:+T'VQJ^W7Y6_
M!,H/_-)9=@#M -H!=(L ]96_G5\/?[ME8;*G-2G2TJUFZ.F?^W<$_^Q)N5X)
MT]NECO\Y2YW\<Y9Z],]9ZOU_SE*/_SE+??#/6>K#?\Y2'UW34K?6;  H .(\
MSZHT1E]'EH/V>#[=FXSNAY.C1^'D^'B_.Z]G_/B'[YX]&&D?61-P_=+DAPY$
M-L;ZH2UYL7W_]"?'C4^TVCLZG#P8=WSR!;-\#?@?W7'X'S^\T_ ?C>\V_H\F
M]^\V_$=WG'[N/[K;\!_?<?C_!O__6Z+SCPM52M^%?_RP(1PWHF+;];<SW>.U
M0W/5>#<(S,,^ ?-XC1U^/6".QFL:WE<$9EU0?$5@UKG^5P1FG85_16#6^?%7
M!&:=N=X@1]U@C#P[OG^+S'72GQV8/.P3,(\_DQQNE#9'?6(ADQYMT]'1<8^
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M%:19&4QE4,"+0,'E1:#2H+R002FF"7PUS2YEB+\M+U1T$42BP#]G],KZ)*J
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M[_CA<,!F6%"EI4IX"SXM5,X[W1@_M!/C\8DNLJR T3(Z)%&6IC*BKY:JQ*4
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M*9;D7V4QG#G;73-A.YB='$#A;G1GFV?W+/)-[H9:LX>F Z%[^'T @UO\ZM9
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M 7,"]>K2MX,^1QX]&Q\N'H$GA8OU"Y[6;" \*5RH6O"T9L-A\?KS]TP+98G
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MUQ>! /P\N/;J-(3B8]]6/.W9.%'QL7$KGO9L'*CXV+E%3GM&SG.R/)/A:.;
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M)TZYF^L2)X6?>9JSZ36_%K=NMY>N6YFW)84.8$J-R-@+:';^%5.(H8(;X3X
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M-9.6PSNNK]+CT*=F[=<.S*XDFXD;M*<7+3T-FB=EZ2-AO[>B >B<-I- G7\
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MMK/N]ZR?&(\[Y8]'9[G-A8^#T#!-.0R4?*8\CPGSXQTTWE,)MDCN63 ?-"[
MZK0Q9(!>)0C Y$S,?2H] =\920N]HI4V7AU(?<\CG,Z,ZF'&MB]ZCYSFWX;U
M>L#.8Q:S_*C?YH+"!5SY#68<X21Q62D2XHT,^D1>*@B 5I0/ ]^I(+WA!HC
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M^@?*LVHQ9Q7L"!#6W(*WX&Z_'8'H3<XXDZ!D"KI2//0#'&,$5(PV4)6-C*=
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M4C4,E&E.(F_JIV&CVPXR8"*/6/=%=9K),#WRY]?K/Z0;;RDBD&$@='EEX+W
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MT^O?+L^J]9/L"6\4?L4E4-D##NVB'$&5ZGJJBDX5V\P"5P#@>$/-%1.2S,C
M\*9V@$PSMB#@@S![#*_&Z" LHRT"'W4)Q++2*N6P#SQ?I=B07JQ 7#%BZZ<
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MJ#6:.&R57\(I#1X><D/9K75\8]"IPO]@95!4J,2D$PIC"#&+EVO08OTV\M1
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MW<;R+=1C,<#M>="2@ID([#10JODJH6#D#Q6$(@C,'O"U$(>CT6^Q3HA2E\$
M#4?W!(W9H0(VC45'!1-Z]!GH?OA(^F9+V22I_(/Z"8D*]4R@J'T]<5R0 :><
M!G0IC%H5)9H!?55^GAHAH#U$U?HV"5X33<OY]N0@"F-3JD.]84+5HW*WHI@.
MG6!::-%*!0FY4R0A8YPQY$V\1IVC(1RXL5*,G-O7 ??N0Q#F\8A*^G",L4AG
MW$<U'R,$VRXW.H$,X<#164HD6.EB<P^1A]UMT+&?'B]>PFFC4XP=#3]H3Z!0
M,V[@5TG#F>8WY21-83W6X=*H9 DF0\TGT XG'@+J&Y"^/^9WFRY2K50P5*^;
M$EIR6(:6K#*TY+ ,+2D(ZL4$G"S)@6YB%BJG0;^M1?@-"P/8#GWWVJ]<\+8@
M,;^^OTN""=S$'] J;7UTL1>R;;WQWWU[QT:_WGL;>S%2O\3>C*RRD*I7 B(
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M*HI/I=UNR.>22L]$F*D"T<"[J:+X2!7]I#W4_>EMJE*5DL:INY FRI%F'2+
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M']P]9&WNAUUM,(@+6/O=M]EI88%\[ Q"I4T\[G<1)7#M@"FAK*(/)=UXB%O
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MMBLI=8[^0+-F!(6BQY!8!1.\;K0>^R?$9<3;6X /I$*190ZNIR(S0@70ID?
M7_YV^LMIN6CF0+R7KR0X^U[HRE[H(2\Q%;]X@5.W$WAF\%"M]2_K$$3S>)$S
M1\G3P4^D"RIB,1#8M@MHCR/[I73V8S+Q4SS?/_P)?_^F[>=NN2LVU[W@<J3,
M',X,ED!^8KMGV)_AS^+3OVXW?5?CGY^]JM\MD6\0P,__-&^7VQ 1?!;"+F"K
MPU<^KUSR_=OG9R=[6=\L"V&K^[3X^V4;G!2[/BRNIH?MI_%GK:](C+&G+E:C
MHA:0(8.J$*$)1S"1$5&-/0L/ZVWPWVG7"UQD^VMYIZJ$"926N=1H> !EU/6P
M*:D]SS!B %F?ED\1$HF(K6@$:J=@.&F68,QK1@Y'U*Z$X2(&T'ZRIL0?3 [B
MNB=\9C8_B>#?5)PH-DJB]-)  S;8:M)6].M8A9>R#7]>L->H>2O,*ETM@:XC
MR&*4'.SVJGXK9"?!! %9 3 >GP5'E6<>1 >Q1I-HG-9F360 AZV$K_';P;A&
MA1PW)M<OWB_09,Q?(I403[UXB52ZRT%I<8%-)A9O):D?[5&L)&1#>&B4RFTL
M<9F%]353.%@MF0G\_T</_Y-=80FXF%96.'?[P>+^6GE F-T;+U/SYEG7U2)R
M]5*IKXL?,27P0L)7,@JZ27QJF18=<JF)'IFIL-:T*Z =)9EZ#=#?O _'+!SO
MN2A2A,F;M6N6:#>)?D:D';3R259N6>V\HIM93NLJF#O\; 11=NP2+Q=847,P
MB".5+-6V;%<IHL;2+*?EZVA_XC79;%?H%5'E[.22K(./TD.0]<_[1E<@^"JW
M4J!!T6@L;YA*[7MU)S&CDFPP6 -XTD)X1"=[E,VX9=/]<P?=BG.A.!(4*E7T
M:HA*8.?BX(?&A"-<0?Y]B@S3YE]-Q>('2 M$L5$@H0K7XR?L-+$6JIF>W-;Z
M1!/(8,!)(/8R6?D!22)I*DZ9KYA"T-+0I)9!&6?)-D Y0/@(+G=+F*C90=!;
MY@NE'I>J?-6L %RJP^$4'N"J/0]KZ7/!0$1:Q":Z6V2*4%,OJ6E<>-7/A6F>
MJ@NHB--/I&M[R/@'+U3%![BX#XV7[=J:1&46!PXN\Z= S8E/OH]8V\4,IJSQ
M8&A1\;:]ZT%]\J+CB68LL;G$B44&,?$>S(([BQS'K1[31:2[%BS"I!YKKFVL
M@6=%(8DI?+R#TZP>U#+K63+IK-U-#@21I-,&'=C2I8JT1;F9W'5/#5&?HC=[
MYV%6_V^S*\[00AY9K@S0=Y]1<)]&?><[GH'8K[;WM"?-FW7K)S<F+^'<L+0&
M 28>3U(IS .N43D+<>>0O%_G$4HDKJD %W(6A@;)['F(Z6F* '3J)G!J<T)^
M!45] UK:#M/-Y385A6%9@%4K!(5R0RX#@*U#N8P]*"MS$IE"5QS\08J3\WU<
M>/$;8=M3^:?(6!)M>I7-G.]X3?HXYD(GA055BTT"0\ QS'GMF6^AB0*KPM-&
M2@0X#-=]A.\F%\&:,.EK1>!UYI3P(,7TEQ%=$@[#=$"=;W?B16"YQ,J15<<B
M($(K*@L"IIA4XD3UR^1Z5!D$74KF>Q><MV&2-E+I+B)YC6 1XMG_<:S"QTFP
M_GH)X_&QA/%12QB/CR6,WXG<4 =UB.+P22X7<G^U4#XER@C8\R+8\]BAF+44
M238MG%+MJ.I-2*. 1_;P^<T?Q;C)SHJ]:WNE]B4K^\+E4H&8H).0NB9W#VLI
MF_*"ZI6#GN9LEY(J ],O&XMB-0P76@!VM"XCEXQR_]"Y]NA JZELI.&(CU#8
M4T8-$LNKM1DEPT089I,4\]CG0S7I37LBA_7!)K3D<*1\US(V3176<B7=N^\)
MP,?R,Z69>_&W,U,X^-SPI7,)3R\&43-U*B!=?WW"FHM_I3\IZ$W++<6TW'(,
M$>_$4\0.(P=F0<ZO60$>+(SA(120[(IDCEJ'Z92B+#K;\LX/*V2FCKGO^^N&
M[-.N8J?TR)'6S$BDBDPW@CQ<YC&*RDOB$E-M%_%G]<@=XSJ?%CPK<$9%%N]*
MF:FB.F0]Q[3#C0[^:X@$\$ 9RS8>N1M%RD(2,[L,M9,<^U@:S"*7Q9;DW3G0
MN!U=<3A"NC),7B1*3K2L[<(IT6,,S%5%SC0,;S(:,2J:@&V))>XFLIP((A#E
M 6D[?85 !M;Q^\;O-@^O;VWD+?IXB<IT V[KT_(7H:0&?JL50VH7C;STH]#<
M3?HF53%8ARZW+*+4B=XNWB8N,:UW2%4:K=O2\Q/L_H6$P]ER,KV@Q(M]B$Y,
MR_06<A==7UYL:QK#)MI]336*?).T1]G/C_;NCXU^OCA&/Q\U^OGB&/W<Z_S"
M[QX,Q)+M1+9A0?[)F<HO*#HZ::)O*>=0T[(S 0HQ@OCC-827A5 T'#"N!YY'
M\:(5"PVX1+TK"(_2IAL5-3R#;$6=$YIX9G'XU</*I!N,4$0(SY R)+-(US..
M62F<(E9@K%<%*;@^5BIWX(ZSFC@15A:#2 MB./XN&KWF^6YO=!((U6EP<@Y]
M_?@_/03A/<\"S[UK+I@++KIZ1#7RNCXOU_UR%WPD/&$X&5M4#VN5?&:#4#KM
MKLE$_,TW_^G9;3+ZF]I/JT[#PR_X\-)C@V8SA'^B_B<]!HU1^/$&VIC$BN4B
MJ^9*.CSAU= "HPV;[G%<\3^_+A/90HP<,7Z"@B]8WO8(%N$0ZJPC8:\#@<E/
M[8#X3%XP7;/+!BSRR_Z"JR2JJL###(M!X/@X9LH-:'C&SZ.S!7'JY7:]':WK
MBRG6K*G @/5>P:76;B#JR2@J0>F)4F\R4J9"<HOEZ,)5-VNOGKVVQ1&FM,"$
M??5(RO,9VD.)B-USNJ>4UA2PW4<A%/>./#82GZF@>;GFYGHIHP^KY#HE=HO>
MJ(9(Y-.(PBD%Z]%53AZ4V#5>&SG@?@.XL,C.J16DJ[(6KD)ZW@EF\I.BDF+W
MK8MD"]D75WJ?/:K%R-Z\D7VCY6!E]1"]Z:XVT1XCMQ71Y;^#4_@]_5]TV-O@
MJ,"]+E+7H-BX6-1Q'<87X75K32=6)%*'-TVLX'( *EJCKQV!1M_-A+4Y(5^$
M.UB<? <$FK?CL&7+): EC"4N@Y4)9CNR0Q(^>N4K+9(]:0<_Y:R([6=WY+"P
MS3XV)K50'62W!#NP1(/OF<1-))DT<5,+7X<FO!;K=!>BE0,H))M5A7.%HP#Z
M5_-F">MV].H_?*%;Z8*UFS$N!KS<'QM$>>W((_R,W[EG]>Y/D2\ENH3)SQN#
M?Q4)Y0_0PBH9U1XWK.B#'CP>W]!>J,1-NM$A(5" V9\\>"#DYT0=(8^ 5$"8
M$#+&Z4FV"L8!O!*I/CLA=DI974 % 8$A,/!\)]JE[C(F,'>BP%)P,>DP =41
MKB^FH23+;&?I#2D=*>!F16-/P-M.R>^4F&III&4)O3FEJOH-;+D5<(N7YL<N
M^IE("(5QXP9Z>EN.Y\3C!;*:<P*+%L*=%2SK$ ?(IKL0*V3-%P=Q!:?EWX*+
M8326#O=_4&.PFH8<0__/AD=.X013-+GDL8B&-SP:_3OQ%&>Y!HH_"D3L2!:O
M8@##T4TBIB'?4 EWY\/4X,LA/32Q,BF,%%.C'=GKL+I$>Y!;ZD01'*0]CV*8
M",PZS5N>,TSMM1G;FECS>WAVRE02@EL3\[7*VI;4;W@SAC!>">BT>!5_D@1P
MI! 7/,-_;+O$M,#+@.]R%7;R;+M,6EZ\=J)P4$' PX,=#?4*RZI1PJ9(-HJ1
MO,74L,J&545@,R&*-Q Q=2?$A,2!3GE1HSE,TEEOK$\<EPX+KUD6(IUU$K\<
MGLRI"4U$/L^'$.L2Q&+N8X)D.AY0L)D@8="%%3_-%F3:9-?6,I70G7F,1;/>
MOO,$I/%Q#HFZB )9)(T/?]]<8S4_>?"?'.Z32 IY8#6[)RC^WD!KJ<OZD'E<
MCA+C8[VF!'D<4KD-WUT2ACXTHE$V%Z!9G0;SC0XF,53Z6'QF(FJ<#QS.I@2"
M*37<ZM'HWHFGF'*M@ARZE-:%O71;-=4#V%R*G=T,_4[359G-LY(3/)?:SO$8
MV%MZ9=QU2*(7MKIP(37M(EV8BEVNQU'HB19.EP*5[.W2(';N[-! 5JYAQIZ,
M"<9EL X6Q7)NA56GPKVC*5HUJ_-P^4;UC$=L]O8"-#=UE+:15A;DUL)FV$#[
MD$1U;)>J@7B3QR$]@6NK.=^VRXUN2" 3MNKMGA9AH&!8%L3BWN0&1ZD2)2ES
MMY,+9 $QV(,2;5RP!W^@:MCOCZFY<WJL7TW 2G?S27]-PO5]5;<OCU6WCUIU
M^_)8=;OULOYCZVN_<R[HN8GOL-G\U=!$[Q)\I,?<UD=WB""79:@<ND!S\NVQ
M4PNA1<RJH+-2G7P$,]L-["(]W>"[A[ JDB?12Y):0E3>2F'?0N,U1DZ\VAL[
M__\NXJZUR#"VP18D'V/3;*!T" LGXEH,0,DYCF(8DSD6&,<DD^7@U<.Q,53Z
M0[@6YDVAV*,1:>%8:B?RC'B\KN\F:HV5RX A^\(6R_3 J0<\^FB]MJ9\$$KR
M8V3P6R,#%)JV?(>QKR4<"5=M\/<5\YNUI9'')(2NM9)U,.W6+BWE\?*GY[+
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MZ,W#[/3#>3MW-J^*7\=22J*'>W1:8GWBE]-%$S;ALI=Y])I80  OZG9II";
M><\37:ZX\;I0UI/GVU]W]WW??AK6)Q__^TI_3XZEOX]:^GMR+/W=N=WS:=B
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M*SUQ$IF<AK6%74*%E6HU$M3<JG?C% $1%YG*6(?7&L+#G8F=73+R]Z)D[G(
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M_:\<+W=DEH[;_7<99DJX-]6M=IH5/_/S6..Q+. QL5S1#<E+6WZS:T[O5J.
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M=&9Y,]+,MA<LX@F.@8BJAP_@G(=%B_/6 BHY(S\+GGFP^+,MA<?J\W#*?^[
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MNW4GCNSWP)WNUDW>;'YMY1?+JP IV+3\!5'1DM\1/]L59Y6^0B#A5Y(AB@Z
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MQBK<Z@0%.9^1P*Z!^:"U03R(+D8:IOPPZ:"^_9-..J@/31S*[K23M'?$(S&
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MYVKV:[-K!]0"GTF9]KX_Q=-55N@1AK+JBOC&M L^6)OA9I->WCFH.A(0I]9
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M3-BN0\)J3ZNFOD(:&%P,<T?M7CWGR#@[1=Z.OSUEIW-I&*CV#+'3?^44?RU
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M,Q<+&8TAN(FW8!(>=FVEG^X =\?WTO2_-\:Z52A8#FV983 #>>'D0;,!-1;
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M2.(LY;/+=5&VH@L!;_F)9'!GG_\:_&OI!S9[XKKB_B[ ;^[/ OQ!J:[L GP
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MPHPM-X.X$38+<3;^61*WONM(O@;W^!ZB5?["^>PG[C"[H#8.GJ478._U#[K
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M(G53,V?&M+?OZ>-%E_4@__:&/?[V^:"WW_S9"1>]W9.MB%WDL?$Q?VV8A??
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M#$1LK(LP=C(5!@YL\ID6%W]LVC.=]K<Y4H?6MG/<(< =M1B$=D9QUX.<UVV
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MWON=Z"=JO\#S23"+B+U'[YA@!):M/QQF5R!+Q-&[;!8[VIATV.OA27N+V*Y
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M'],'%D2?6I/PUBGCL.IQ4])I6L7O#EX@,M30BC%LP-@$G$[2C:$GT=0^,2U
M1FT7IP-KBZO62?-9TAX 64KIF?!FD[( ,+C!ZPF6U^:5NMD7PCAV^?SG3DC"
M?G-RUFK WM>5U%%.S'LTJBC0Z6=N[L99>FMWU2B+'VAU3QD$_$"6UXRA->C
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M>>XC\R: :G9)I+I)03,Q0[*["D#BYLW[./><&VAX+W5G)L2R3!9Q$**N":+
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MF3WCKOO-#'C-]0[8.J>FYR'6\\80 #U+GD:\###!XF2D K!0;^,KE)&U=?H
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M<,RC+/A,>59!N';DK.UJ\QIL8S1^Q<LQB8'*"?CO?KF53=5G'.XW/,#8!R)
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MMSJ@\H*"7/J2[TA#2'P?_\6_X9?^L6_IFAFG?.CP=NS,Q?>Q>@NF*NGC/BR
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M;HDQ$+E,9?ADHJQ$B5D](P/A,=,(C\E%4RHT$&I5%6A6 _RM&^"EKC M[O(
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MUYUDM'SR2QPU$5>'4HY,YHC!="'$I#2O>@N,D<^I_NEMIR^K76#L"FZ#>#_
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M.&K[BP,^'S"U.Y(HS;3GX:\5KG^U^7ZK>.!?L"%)QM.'//QP+:M"J/174-I
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M@?MA,$[IG3*SY;M1.5;,4#>_#Z!T9R^8:U]Z]7#"Y0(N]]\ RBG^L/^6KT9
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M#$2SAG->R0(_%YZKXH[:V2>+749*YH%6!@0?Q2"ADE0#"TK)<D.)L6E29 Q
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MB%YMGC<G70.:PI+GIY:=8&)P+ZT/-!@\6T[NG%QZ #'[KPG>W9P,9P)@V_5
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MD>EG(E^@+TT7U)0\].U0.DS]%W).U4&J;V$8V0PI^9.]'4*U9L:DL] &]L=
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M?</ O; L!!K&P*-$V2()16Z0&H598_-P65SBR*PGD9LD2P2R8X@H4A<29:0
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MN+X6L&N41D@MIC>([C:JP">?0F21)2A:EC/#6#LN#+>$:85X Z(>I)OA_HW
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M0AK>2CN5D-JRK0(UE42Z$79I57U3=<B#\X]5]OD9U43%F?%O&6KK?D+#);.
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M:$=M4J8ZRP6@"9:CQH8\G!,C.$H2Q8MN^)F?X2B+1J&-P$V0O+%3W!$RDU)
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M"DG.>.]@+\ 18GJR:HOR,**&]:E-1!7?& M#T2T+@F1?4 $X-HYAZ7O3, %
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M?1I01MCE#2^_0=P&=&W "T)$.+X;I7=JM)WNI_SDQ>]MM1GKE#0)>LW.'6B
MN#!8GX)M]R;+4Y=B'87HO@H1]\5OKH/RX@R#7EK.-%FY=I]1Y=Q3:?'!/3?2
M.UA4P2F1NA%*6HKT$=:#A%(Q;,?2-(K//14?%ZG=C"RQ++@;+CU/JXSD1PP?
M#6$C:(E$JT?AN9_"0U5A]0=<5%Z5&5D[CKG'X4-0[5A X.:ZX,82W/LK5)M2
M$ >\/FM3=$,HY%XP^\:J;6]EP.3NY<M^Q;)_+$UQE86G);+PV32A(\&C;E\,
M=V&9"^8^0<M0FX 0-:QB!<'E9GFOTM1^U9:5..21*6,1S^>17VO@RQ+E/M>Q
M?6GCSM! "?[8*](B'#7"E"& -1Z>#H6J<4 -UK,5T=_ZX%<I5^VF55XS\"W!
M[V8"A*?U0P,CF)5>]S\76,Q; 4'&KD)>'(O,;S]*B?%H?86=P@P.8;Q,VF80
MB4:>YEX75K#U*P#L?+:C([\SO?])RB5S%KS*N913TLO]?'SBL7A@S=,,A#T[
M8210\Y[8SH87,XDX%:Y9.*YK3.O3P:;L\(JC!%R_&7SD&;[Q$IH.K%<K^U88
M!=!#N2::N&E:52L0;&OXEK-9#1^SW _O24X1DV]AQ=M#E]?"8ZI/8GMFK#RZ
M)=>,B:CC@31Y9;*PD*4D_,6,T2U0.$[A=B$D%02V8KA$U\ MT.0$R-&(1) ^
M+4RJA<9AV;*A"X8+&2/]'DGD=OR6BYJH#KKQ@-9=.3FAXM/]( +(XT68+D*B
ME^%S&3J*<"PR?)D()U%.==+XI":?<^%/^%"8=5[!C?.C$VEI*;>D1D+WB(_]
M'5:P)OQ6_%R_8Z6%MZ#Y%IR]:.#L^86!<MQ@Z*:6ZOIEBC1*H+US:N%#^&GZ
M@OX)ID5S\0XB+*K4X"(N,RMH#I+8-T7TG:OH!5X562IJ9S IUDSAG4! ,4IK
M)$@QVFHY@9V<Y6207.E=V]%SKK=%:)9D316\%0]$T62 RJZJ\I;^2JI/8%8(
M^%,D('KA,S C'=490V=CJT PM R.($(,$C-'I4S)BM%"E#ZR#IXK>.E*!&T/
M41\_HSR'5:A/\V7 "'1J.U%\4'):_DE-&> FAB_-&DOY ^=^^LX]+9%YS#R^
MN(G16GV''$_-?]OQD7M+0BLD!88@JP7-L7, >P=D_>5$M:_I^WB*",E-N#I1
M'R:&1!^%TX=V0A(N>KXLBGN%0M+ F?9KTQVQ@_\U'(;773O66'^"&_I-7K^K
MHS>N,O:)8>BMUTQ]]I000?D&>V7/!LCKL8$#2R[.W3-+/AKOQ/6;4T@X2/P?
MEJB=V&3B8](WN$N_$B6!8#[-YBUVO#==J%;\(#8?"54]0KN0@JVDB6Z&?ZTD
M7\1A.*>21F/T=N@;E 7+ 7(ED3A-\5(VG$+.:]#N[U ]"ZR!UW=X1LC8<P9F
ME\M,7@47')L*<Z73LJ- 9WZ2EVOYQ /B2\&G<W<OMB,UE5G8M]N0!0Z[G(%A
MRX-OBTXEO[,!_?YKCE@( !IV!CC.38^"XRB\T DFR[T_V>R4;,<_8;^@("WZ
MK"47L'%[/$;!-M96PWI0&QP50?M(;F98@Q%.:2S/&E,#'Y(:H!!B,15\,D><
M(UW$U _CHRQB;V5Q4HI;)F9LCP2DK#8;1.AH^-@0-7B=;;V^0VG,F]Y/.<:.
MKDU$*#/3'-.L')FGZB!P"O&6"'Y1$IB&;8I',JU =D=QNI_BU!:.@W&SEA],
M@R"1EX '@Y4X-551=ULIA?]D5%*?DU2AI;N9DII3#E3*62W,^"S'?M/Z@E2@
MQ0!0X[DD,J"IR<^,39AM.!9WR5+J%V%,)2[?"4;[@.AM<XJD8ZO_\U^/]G8?
M?ELKQIT&8F4JH\3?3XGW:"TW$;9T*M _#C 1Z:$H!(I01B3'0\#[24\VA\_'
M9M5551=K7J39(R\>U?CG(]2;VIJ>Z*[E3AB%9126KK!HYK#+13G@]FY@2H[M
MPI>T"^^-[<*?M%UX;VP7OK?G;@Q<C_?JIPE<2Q&K5-U:7B/?@O<OV=$<NY]B
M@W!<K>0O-O,")RN"D^WY@A3*\$E>D%R;B==@'$I*,^4KFUC1^2^_ESE\FE"Z
MP%W=C,NB^ZQINLP;3APO<LJKXJN]0?FV(BR<J9NR,'7B^ZWJ0H^B?T]%_R]X
M(M(_4,"[_):%M&JPOFD4F%%@A@7&-M@L AI#4%=@[#'BM:J?NETNYRL+E:;
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M5J*5A<=DH'GP2942"2^UF7!O&=!@J#HD%HUI#C-I?!T6$"B!_C91Y_0%<:/
M4;C -_#B1M1SVH6[EOMFO5,<Z4WGG62KG -16#*2.BEK CKKZVF%/K/$#E67
MY\'[ C-;P7RVXR.;:9RODHCUIC5S71N0+[:R*SWI[?J:KLX";R$&J:++Q%Y^
M>C7C8/D%>4%Q '+%.6:@B/]!9:Q;=UXHWCFBP'IG_$U06,M/I1&O#69B(P5V
M.:;+_HCIPM_X1)@N^R.FRZV[K>]NF$,);]C:IHNMR$#M&E2TR*#K^/P"TA7'
MG.+Y/@CN:V^8U_9Z=1<8UKA0P(0N'A]?,-)TRN8/OGJXP[\MT[PV"O; A0_S
M',P N-+ JY4"Y1ZU#5\>IG^K<-%$YP\"6+&R5 5^B9<&>;E;8Q!Y?Z2ZN!VG
M^V<KM:N.9>&)QO4<DBO)<A1&SS$J@$.'.1UU'ZC429B;0++.DQ.<  @J6,1<
M!TMR]^7>]@Z"F<PYW@UF)I=1PW\HDG3P-S"X%FB18UT0*'!L2\J2R*-6 F=B
M[V],(891%@[JKQL6NK-PU\Z91HK#_))F.C?YR2GFNU(A_[2' S_4B9[3BD9[
M.W&&D1+X)(.,HX<"W[89!'P5:CE\$+P9UB!ME'3MRX/MG1VT2+G$4H\J1VW2
MPC%)H:9*&9)WP,&/RD(BPLBSJ;$!VO7Y"G_T1Q[LV=,/W;/#@3V+W)X]W%ZS
M:Y2$*EN*@O%GP7Z'.WZE-(!<:\H\2^N&B $55JIFKGD2I$5-Z]/MR-OZWE>#
MK4<<"? ;T(('V=;(TBR?-4A'6A"!=^KV$3TP"J!A1]L8J+@5L^C:$!Z!'YL2
MZ*<[HC]!,W&Q2W'J\RICCAR.=8 T<JQ!A':H\;\C6!&???C9& X3="5OV58H
M/Q;+F-1"A>JF=E>THUO6=WLTP#;8*$.4/%]W)'GM+!U2A+7IF#[7;K/$@S9+
M]"ELECMCJ]Q=JYT88)78T&2:CP_9I%PI"/U!(D%2@9#89(E+W6.'<8D-5GZJ
MGW0SPRW# 23M*YP>H)TY9#XMJV5),G:"EU]!'UI6&&6<CE;L;5'41[!9/2$X
M%S;A(+5,L"L)!MM0%1+O%PD+%5A8+ T-C6H2DI_#HE;E9R@.MMJ%#(*TFJ2@
M8[9>O9^;5:3IL?A9F65;SZNT>!?_B@KYN*F,:>(WAC)&^.*G8$"#:8@:'^N!
MR?"R7]=8M*AF1HD!Z>>(LC]R[P9Q^BJJ6@4CDIBS1P\,QA8SD(0/+\)E##G2
ML$\1WI'7IQQJIRH1(KK72BQG469Y/9V7-0;Z>]3J6'%8QU<X7O&OQO(ZRY9P
M_L[P/76*++]>5XB_K?Q&XZT29G3KLBC,G,PY_!<O.#GK9.]Q+XG5"2L7<.[N
MP<2P\%Q%][A]LB.(6!]A"M%32.Z"%M7$=+^TR/!_!(KF=)6.K0Y'I[=R,&):
M]7S2=@DK-3;!<$3=G;*O(B5L'SPH5NA@<(F8Q[@.0D8> @I)M:Q,HVD!V "J
M2T5*YCK*F!\1YI)C?@8)?F<QQDYPG,06F*)QG_KLO?QA$7PM_5+1X;0A7.M8
M<8CDWFR&UX1-> )F!2M[]*M*M(0PKQSY1!$P.99(\O_*C"@-WV)Q53>>+P2/
M^#EG!ZUBYTQ[R[C PK&*U^X4C#-3R?7&,2E$5#%9-%E9,C2LT:FY@K+TCI0W
MOMZ%=&<NHKMKHMB,F:][G&?9RV]A$HHO&$[&>0DJQ=.A-)E'3T)>,I.F9_D<
MCRU]PK%HTXD"?<QF"HXH,W# ,(,T4 "Z<GV6GZC4Z4Y6WWTL#_.:A DOX#^H
MA-B"F9#M$3*M]^^^)(*+!\-^]%QP6(L3+$X&EXPL;#<LZY\I:7L 8EP9\!L=
MST2#UUK&VA]SSR;C,CX,K^"]9D,>$D&D>L"WH+1/X YYDI?QW\MY1GG=%\5T
MFZN@7BT*N,3H-YB-!>W^>H[+K,?(S_.[TX1Y\[AHJ20*$^IY-6T7.+JID0I=
M-\=(EUZ7V:^.+@M*I7$L"6].M!FY%H=L+\NTQ3:!/$HYZ3%/C7$I/9=DTFB
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M9C7/N%3B-9)>EY3OAIOCH'[2:W$3J?4;VV"R*S$/S(*J5"JLBZ LQQ111&D
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MS.A<!]VV(%U%A2QU=#.!V<6]0L7)W,2G+>Q+_/<?C]!Z:>!3:'2"#O#. 4V
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M@F]"@!3G^MF28_D$MD_JD&Q_]#= 5A<Y"%JUPBM7Y*M+44Z@_(0#4\YFM:'
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MXA>1&]CJZ0CBADA1/##M4"0\^ @;>$F_"":B=J\8QECHZAP%4:4?!H0@LBY
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M#E$8622'6(NB$&I"1  H%F#L@ J<C.AOBSVM]-NT'LT-86!M3I,@[%0'<-V
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M>]NYN+YX!P8GZ_*>BH+O86#\GM9R'MM$5!XM^[?PME*6Y'?[K",\J(+ _'9
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MX.;P()XS=L!CPIDK7!?<^[J IC8.+$!$1^PD'O&#)"D+B @*H.9C5/  !D-
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MO#N9)7^E+"Q+!0MGJ#UE*?N[-\!78RA0G8&N]8FI2IQH3$Q;"#]A"R//=CQ
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MOE85'5&L4K:I%A.O>:S*/E ,+"F]'FB:2[YTJ/7HW&.98[I ^ P&C4V64;]
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M_[E$9&SF,43#8L>V-<3(9EDB_[A64I2SDD&;&;E3RK(L5AKSH;UG$BN>=5_
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M?^=7Z.8]7=5=+_9A'CI]4H49'&(;B,%QDB^40 )D"XE(8 =^_;/6'J0M(8'
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M 6QO1#>C_I[@_R"X0,,:S>"20;>9/1*XD,I*N,XSRPF:2N7.M0 "XA^%]Y*
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M:[:#&:?@P!MLWC7X8I8ZG.FR!5:A^B3K,V(I*MJ 3(0"JW***B1+YP/<F<K
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M8U1['JX3Q.YZJS0XWP47MKI@=Z_4/EUWOW!#I(LHR2V/\>$(-%4<%IGI4\)
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M<4&"'ZI!1Q)$"%W&G:1[W[+X2N*EZ,UC_IQ\H3<Z7@0P4JRK094%WDWS]\@
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MV;D?F)M-)_,<Q&V#8K;!RPW<G+]_APU/V^!IZ<#M3F^\W;E4,I//)W-;VNY
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M1*Y@V'XJTPSJVTTEE2G6E-I(G"3P/>]3U*!WB6DA8>K"0^'94Y9(%SAKAC4
M"93Q2UKH$\D&3%E +O^6AM\M86WKS$&C#2Q543$T\_;I=LQI%TS;Z(_</TC
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MYZJXOK,QB/V +0B.[!RJ.W-('O2CKQ %"$<7PH'+AH?LP_RRAKFF 6)YA8L
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M35;1</RSP=X*:812@6'93G$*[R=H5FZ@$>KA6EJX6E5<B)0E$U_3\1X_W#D
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MFL3WO2EG/=G83R;55E0#,:;T9+A5S]PN6A 9@J6"ERAWN]U$P*[C"*S#O]>
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MY3 JG+H/5,#-1>,-ZVL],!\'A5+_XE$1ZR[A#W.1=4./=N^BX=X%LNZ%"L_
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MZ@HS3"LWPN<LWYA//^35;^T0K32X8.1J:#=S4G<*MJ&+2P;!,/A_ 6\\O\=
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MAWP=&0YHBH^PLD#XJ=U.4]=2=X]K770FYCKX<L@(5P15 UJY11DI$?%*66:
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M:.YFLT'/_[:P/ZFYL[\/OX"D2 @ZL2XZ"5L3K([3%@V-C8+&0W]?I>\\O0-
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M6M*_!/UA51+H=4JPZ/0VIWOK9D6R\DM3N84+F9JXZR2$@@@%<IP"NU]$P"7
M$/ WT/#>!^;=Z7E]E]4QM+.42V$.[*LUX"V4 ]2*E KZA^8>@XPGC@62?Z(O
M300Q2.AJV=.&)NM0A#6P]WGP='R:OJ07J8R68L0(QA*.Z</NR[)'0DO3 & !
M2/-I^ NH2M"][#? 2KM"@9\\-L$_#5U7<K/A76H(B:EI94+_ OLXSTWUV<M;
M?#V0%]QH_[U?_5?_?XRU35.,=(JK_^X=(&T ?$B^)HR/(O,_(X7_<P!R]E.R
M3! Z3)^VY//D&8C76YU1;9LSRLI7C.]2ES9^D;-DXNY\ZS5%L;A2)2D3B46)
M]\(\/%A.K-75N,#.CO,.D,2=^($V73VL9XH TT^*(FD@*MDN-(8<0@$EOA%.
MN&$3>GXL\'-@;>_7VFW_WB XSI$]]*PIGAL-T&*%8B:;JI"A_36ULB9"SY:&
MZ7BQ6(S=,%S4[]I&BZ@JQ*A("UU[/"85A8;J^PH&JT]117 >2KASP8P?L1_
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M>V:@I8]O89,6)CCFR8.R.HO8JL? Y)\&79191 X'T66WD9;!+6I59/(V8>!
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MVQ-U1Z4?B@^MN%9NVJ!7&3""0_A2VV"+) RV.LGF=NE*:7T6Y [#-.G#=?D
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M_2!P058.4:50N\_.9+U=(-?N9V+=Y\Y'O'.A9W[OW#%M/GF_YK+-36;':Q_
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M*'4(O$=)P58'W@?)[N-I_@<,TO+E>897$GJ2_4]-0*676M[OG#3)C@H;N>X
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M-0 6?&][HR!ZVOU#SYPYH5*I:ZP02-*'(N#UKGO@!@@P="6%"!OP/X##=LZ
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MVS/AMJB"P5HO;TB$^:]_1$"] [QK[M _(VB 5,C-/\::CY*NPL#^/,#+H3L
MBKYZDL-]G#GP'W'025F.\6X1F9NA:4 BN$$BX.E?CI-!I('F*F!USZ@_K+I\
M!X"(!/T48;EYN@!=;N7;Y.VY[,[) =D,]AT@(7WQ OX.D![U,Z?<HFZ>?OU+
MZ [PP"Y8>(L-4CB\E'\T-@1=! BOFWVYA5IH^&>T5S00(3.($ M42.G/ Q3!
M=PUA($F(!K,_LY2H$%O'C'\VQVWRYFDZ="6;)D@B8FZ%KYSI9ZI[D/+F9:=D
M:X'FHQ E]/]V'K?2FZ<>=X!;A(/FPP*EE28@V.\2H@UIIUX[%+RYY2+C;[?9
M_089?3!,W@&VF.Y)WP':-$KO $/:N^ ?.7LF<_HSJA"=P4B5_]"! T);O?D.
M(&I5"MJ)NGI1??@#%7IW7=63SA5SGQ[X_0X -_UGSA&2TD\V;S$Y_5)9O0D:
M-P,2UX1Y^39'X5I_R9/ECVQ8!1[%[RZ>X4*7G\N#9'KN*XCRQ8,0"T]#%+90
M 6M<D38[&/K-J#35JBC?4YN,J DYGU N+IB+=J-TAF0=W^4M@BWPL$#PPP'+
M/M\]I:D_'8/X'[@04O)04CI04J:@H(LTEG6@[]Z?'AX)L8U**7!(?1/\(QO\
M*,T5[%<C#+%K_R7F/I_^/?Z?*I-"\?5^X4M!^!S^Q8=LYDTSQ*9E_["I((2"
M9,-O"E<ON!9_H$"?AJ@V_2O"&(\Z+1,U_^P[X>^-R0(:I9++@?F\E)4&4=VA
M>S>"JY2%K5P!/[+TKE\J3?I2([UTX4PEY,Z.S%'7_5+)UVKP_J\ZAH0VKV[1
M6/7/>J!X6**M._]/__Z?UT2@_1>,T4 BM0)H-?.M(&K%,G=#_>.VIL[V1T%T
M_"=:V7.:D0[?!*"5W*<RWB^#(,EB94()_;*NV\M/('C@XF\@2C!H^ (9DM&_
MJS2IV\OL/2R(I_RNTJ*@E"%BOVJT5K++A2BH5.$;)?L*>B\_X<,F,JB0^A:D
M7E.]Q[X7^J4-%/OL7NI>&8U[[&V)6,Q5CTHH!1C+[*N4+/5VK"T'#89G/-"7
MST385U+H\LP_(6@5[)$='Y*!LO*_WR^.MBT70FS2MAND/K%?[-R0Z,G_)@72
M(4+KP]\79I%G4^Q9\9Q7S/F6L#AM;?NTIO*Q#5*OB_()CV#7]]3CE /<&>S:
MV&5#44X?)'M> SY8KTI%H/%VV[<]B8CF:=U$\[?E5;&.\H)6:LJ"2G$YS.$K
MGR:J-4=HWX ^3#,_:8IY&GALQ+Q,L6#TW5YTS^-4N]XN9$8?U9)OF,4^Q('6
MU^6TAIPBU<,L9:%J^&P60:*ZP@^+*$DO&!$__/%Y%X[AS,C"  =)%59;0%A"
MA A\^N<0>99,R=31N5/U8^IBAYPB14LGW;F<_FY@95;G07"R,@\SM_^8,WGH
MD)Z1CIZL;*U5LLF7^L2%9RE<HFC=/:>QF -DO$(M&J^=/VYKE._5C>ZOZ[/V
M!HI>#JJ<"VX/;\U8:_1ZDH2C.A9@F2"S9Z(!!)^MY(\'&>+0W0'8/$)I2YSR
M?L_1QX#:Z22+Y.^L]83J60TE99D V5#*?%Z)S4I#=>*,R3QVGM+D&):_&IYI
M,KM&F%3?"Y=H>PP,>P_";=NB(EOJ$.G(,?Q]$58?Q&T-QO[T=A)ZX4=7PDI'
MZVN^']VM*T&% ;I^_(AG7(-K'I.5SEQNE9LS]K;L4DID@3;K7]UPW?WH3_I8
ME4*L[35B3LZ7G"9B.&WXW VIYL2(PZP+Q.AZI7.=G*:P1J\U.#(\7+QVW/4=
MG+K*A]LSIWIA:O&4@V>HG.4:TIP:J *0R'$N=B?2[+*WP9;Y''VSK-WXZ'U#
MR8B+'_$O2ZRQ=E]@-M'@S>D>[UE;U*MJ)$8Q1M$O3S_0-23'<]D<-!H]XC+9
MMS&;0*]N:N[^(I[E_/2FN.5X;&T"4:J85N@LQ:MG0T:[2]0F4X**E>!3"C60
MQ2F:>_W3C*)96HO3E>K$#X34HP\Q7%UQZX'(K+K$M7L8[J)=S=5.(E':E79
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M1"R)]AF%728,2!-^#!'B+7HZ#^N04T;YPK(O.'EA&Q#HYPI5Y[R[0LX5^-0
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M&^0HZ,H.X9L NEQ30:E5JN7AFP>:2& Q6L<9%<>?\]#%(<0EPI3C[B4U%6I
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M7]_5:PT K6$0EI18L0QK'IW6Z42\%OJ"!(C$=A$0W&;&4#8;NL?;%[/?O>>
MD"L-D2^*;,(>18UTEA\MU5W]Z\=&==V/1;.&HRG1((U52$!XHA]"XBO66,,"
M:B8?WK+R)Q\B<%S?J"T2-/DQ&3J#"-]FRI/D<7N<4_[&?,Y$]A!<IL4S,=H&
M4QI@R@HU_-<.T&3Y,J-VY@?8:W8U_ZHP7["8YR01$GCH"KV?@ARN>U(1HVVV
M'GVS>NZ*V+5UBGH;/H8$VAA*#O 33[*!ZV;6$?,,0E$[G%VEAT;/'S@ZO;8@
M#.#U!UZ^Q!8SV=8/E (\CHX2*IY^XMQ#'/[L7D<IAH=IU3%NKW0*3QLF,Y3%
MJ"&HW^35!CV/W;A=;!&^MP M/X&[6@]X@1HWCJ\U,D;%J#U;B.!$M8QQT!V&
M/[D0'"L5(X^(8YAS?9EXEJ_PD;N0.N-!F\C=,*+:3=N[;,KYUDME-ER6N+:P
MF.<#%E\K%&+2%MV&KMM_*;Z5/3Y)PC:I<2G!<\I8'W<ZEWY$ NFT7>V0@<P3
MO1[.1XGZZF4K?K:J0EZ!OF)9\F3IK6^@>ZT,7%<?'#.QRTDIS7/98'#'1/Z1
M5(A!S,8RN) 6"<BWMQZ_*BL=V,Z1MRX1;^LC]HCQ.AWQJ0X1V0RM*A2^XOT9
M\G#3^"H:O 3)_;3+4*1-W2Q<E .OD+MP0T37%[FK7((C\@(#!UA[9][\]@:U
M59SMRTXI!$>853O=]N@:$^V(X+NT$!P'^# $Z7A]"VS)M45+H/51IUDPL+.=
M&'+/:A,!:4<; C(L(1*1TT,R&ZSO5E5$8,(W546?=_C!TF$QW90:&!*S&?;4
MK\Y587<@7.,B/AAT?XV:LJ+ADSV#,\U!;/3-5UDDX-C*/_ +"6ATRN/93&:+
M!N.K3>23-P_EMZVEDCUP?_*&)M4:SA&(!-8(D8"-=DWQ(8H,76K[?#OBA'2G
M%RCKYG=PD PO$^)[M\")$S;D$L@ZDF9R_!T=)GVM>I# LJM[&<)C>_%RN?6J
M:"O5_,]T*IEU3<LKZK%4Z,9PYE99.G:7'2E9TV+EE,>G_<4+URYO[H;O7RR/
M->Y.8:V'[9!C-1HM/]A]2.C)+1)8HI%0-@"U'\=V5@Y\[[0SHB]U+6)H?&:T
M!=A:Z*PRAHY.4S_'=.$W,2=[[/UP7@9.2S.5"*WZ>R,U$I!R?WC5OQ)UO8FJ
MQHL)J+)3N+I*$S)\5PE# H?]D../WH9H]R%A_^B'^E+*7?#NTS$GK8<K1OJ-
MX>*=FC8XE)K3(?Z7KZ^]@_F]M^#H^3><M;K<YI;3V8(R?-"S+^\CE9<KU+$Q
MWS]Z"+J<>(\$B.]4'ZNR5V=A;6G/!_DD\7@;HB,Z.CV\-VN4]5D).VF>SHGV
M0/?IK9]6TQK:"S!^57G;@:J2TN55"1<%%?@]VEAHP06;T:@H./9TU6>\-RN5
M]847B9HTB[1*/JNAT__4 'RJ">_808]1D]B/N*=!L*3#:?$8.D6@EVG#4NZ_
MKW)7" ]0)38;"72JMBZ;7WV]33"X1(GVXX_W3>BWI"3KETC@MTA"Z''KE;8@
M:E;96@]'_SZ7_6/N#J99?58I_J%';" HR(H(8F38U/+W3-FO47TINV.0-BE1
MTG*5>RU^7\''Z#TG_;IP*I)@:?+B\-BIE8ZEG67HOF"8%+$:I9\4\0>T_\:P
M2$-X>"?8X>9KLJ4OL!]MXFK4,5;;>^:UC%XIW<IHQ=A$D7']=LO*YN]+V!X^
MYX5T4P0.Y:Z@9;&%)WS(JBK*IS:B]C@'C$+KL\WYDB?]SMD%7Y8/LI6\-3H0
M7,KS;J#I@#^UE>MBK ]N@[5WD24/%[GN_9Q'N+*83Q)!8WS%5HIWW_JQS\<_
M"@<%$,7J0EMR7;*'7Z462(_HMKE6O#VESE[(&'>9, :!=G41TXY3EW!<E4+W
M\QW-HXM\D?2(/5MV:$Z,*3MYK<I;V5PP^?84M3>KBXM5^A.KD\;MR2=<-13S
M#%+?F?;0B:Z2P8$(ROJFB=9ENL:(F!D&D^HYS@W.I5\7Z'2B^3/0JY:^!8,G
M^KSUTSR?Z1>",0VHOFUY4HR%65+"YTXY$SW=PW6R-F;#W6 RWJG-BOO@C^//
MI:V,CZK7.*715$RB<+%7=;?'#_L@/120VYOT53V[(!>Y\V'L][:SW@,2LO1?
MO%>PL4]>EG,G!H^UV(G81V@J_A$J/<P^$;"/RR?P5%)W\)':1]>9R(2Y2BTW
M%OX8,&HV"R<<A^??T5-,WN/^2+\B(KV:2,=# CTTB)EJ&XW1)6UW2QM6\RA&
M8JBVW*5P^BKF1.=F^ZU<:8EQ1=P.KG AE:9?^77/2A-+2]15<[;!KBC^1]C^
MPHKF:W732,X$%A*_WX?C&OZ$CW:1P!GZ>.L1JOBT578P#GGK*ZC@X9E.'-RD
M55IDRZ'*A*XHQ:U4HE:51IV5T9O3"-B;>*6A'( S>?,LG=#==<W=33%=(;JT
MVD9DPZNSWM[(H16#4?+2)WYHM2M?7]'N%O01,?H>\^>>XF^\JD<V79S=\LZ2
M7=%Z6KK=^3M6O.$V)(UXK^YG4M:,[&ZE?W#MZ9HK,<]D3>KM0]/3&F8/IG:<
M.?-UW>W:B")X7R3;&/6]?3RP2\NBP?90H/<NV%HYS]U.)@:G&N]6LS0@N0E^
M*K*1\8GH77Z"ZG>]^LU8W:&T+U9Y6MT6%I\+NS&<PN(DC0=KQ,0?<34YD\"N
MW#0FSO:9M W,M2^.72]5>*L+6)T:R;5(QL,=QCUA86!G17,E7*646F_JFD9O
M)* ,3Z,^BIF"6 RO\<;OWXVTG2PTO213_H5K[\8GT$X=ER"('909)1&D0%>
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M!")U?TC&I7/IWK%I%J [['CO_B#9\WBQM^_3ZGAOU]+*2D4L4B9<CV(^_DA
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MU !5IZ[45^:_E7LZ8?BXL+O^(SH#WW5?*-\J*\X++?:2-<>'>3H5MVOD@^)
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M^Q3W3<;X4WS+!TP%5C;0ZIOW/'X( ;:VPS&?LMU1XF5[8 WD57]"9)IZEB6
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MX5][\Y-Z M'8LGU*<@8H[D_7]-[RV_@==9&-&TPV7X2,'Y/1)!6+A[HJ-<Y
ME6EUC/+8,S&Q7]95#A%49C7*Q +#%9:3M57FM3^?7%T_1V:Q?)JIJ%0^1HCM
MVL!L7&5U("2!K#X0K"_9RH^5"239N'W[>8N_:3RS7EL7'3(C^)HQ>V]D8:2V
M1$BNR.P8U^@<-\Z6^5@E->7R 15^M<^<='3@,Z73&$0H<VY"KQNKU;6)[7>Z
MK=-8S2#HHVKP16J#!$[OVGA8&2,<MI)T]O\8V9SBU7@EY$Q-[PW9\0()!99O
MC:+CZF*ZQ^0RT@Z*;H*,W%Y'\.[#NY!E5+6F%DU-2?118)9LZ72V\ND.L0Q-
M.["=6]E6%W)D"-*H]D4%6A1 J]KFOP,PQEQ8]:0<A%1"SHLJ/&.O:+*X*Q.=
MI(< P@)M\%[HNEX+>M@E%$S5TN5%,8-+I,D5#LFE4P]KD]4\FG7Y":U/Q,PX
M"?#Y1\'Q]B1M)V*,886DE($^_ NU"JT,-A,L+@6H0W]CY-5!NMS2XR]W3_H9
M@I"9LQ!8EH$G'T59^26]*#8G2^91OX\/]0LB;;5@UQNJE 9IJ'V>)[N79R^"
M0XSYKQJ2*!%0RGP8/X3TK)((VHN$2IS\O/C//RRINBB=P@%#_<$=?&MU*5F?
M,2\::%M]!C;]Q'6Q';TANOIKZ/D#)AL:W6+EOM17?OH_8I?_^K9#4LY_=;<:
MK8W/G'"A+!Y*%UJY'+ ZOT:KQA5ORM!\YWQEW@%JZ*31?C=G\A\.)B84CT30
MJL$PF'\.'D1/&?I&M^E,# H"*Z6)%<'28]4.?#.J!F;^ D_W7265WPREGF%_
MXSXF&9JL#T1 ._&<3$PWCWWZ6GWY&KW$I!08U[24##J+ N=VB=<"8(A,GK:3
MY2T90* &,55E;#"'0-SJC$QA8ODP&V0#7:I,CGA6^?%3;&2N&#N^#^(;N%]^
MBY=%#ZZOKYQJG")M1*Q/9O?&7WCHMDIN[/O;:,!NDZ6O'V^07[/?$%<=0V/,
M9EJ3M4)M]+>9BE-#<XM-D7#=:Q%(F6$ISI;(N .; GR-W5/B-X+6C6W2T-0;
M]=\J\7_ K.5FWW8E.].A^6&R)D[TPU!Y#$/PH-%A22#?TX*:L1/FHN&G7[A<
MG2MU1&V(%P<+4G&$6[Y%U'L9M9U+X^0MC: 8[^]F59AI+JYU":C("+E=2'Z+
M2Z"EO*[PMY:=\US&-C9.A[HMNXHRLDMY4[/#)3#++N1X"W9Q:@];3W#^7J>3
MYJ;K/$LJKFJ+=9;(OCCH\/K7%+H&&RA-!L6F:H]/VZ5Z?:?:_LI/Y!4^]9]F
M&!D8W!5.3N1W8K)I_ =2BDK0]3'"9YN72\!$5W?$937W,DOQYN5H<F!_K*F%
M**L"X''0RRQT9X_S:$T448A-Q^TV8*_O/%$UW?1EAH4R)H#P7/S&5'H%4I7#
MU08_HP["3Z[3< BD3.'S]R)5RG34#:G.X>0HR(#,@H9<HIB7L:^GTJ&"W7B[
M:*,$FW#.E$;)D1T5<P)SU/,?#:J<S;=&01T_R2W-,0,H*>CPKF<=&XIF[T_T
MY 2-/,SNY@_$&^0\C.LM8A@[@P@5*_DVGU+G:%I3P3@R395%XD4,BDLCKCF_
MMVVQK7&K1_!^@)=!5Y@(8P/TF7^]NX &1NG1U%JU3@6?2W,$X$V;Z&9PG&^A
M"+?26*\Q<:6WV63#TN,L >];R^#WB@0FJ>+!5T9MCQ)E]=7OW3Y&;@KC$Y=2
MJ%M_+;ZB7X7.V&L6^0RF;6U=%HWCK).3YT[X[:OODX^P6%/FG#-?L>8#%;0T
M/L\IA^;;!V/4R+XX?NFIH0XOH=.@@1\/J-8GSMH]>7J"1X;VM:AU)L_&&YS'
M1FN>DL[:+,&SW7Q<Q'C\[9D^T:@+-E4Y';$79I[F#O@9R: E8F?M3+CY\U,!
M4=./J2IVUV'K9!OTJ $SF9LDO-MUK7(FU\7P]"PD/ DOA]\S2B5%'%]H$7BX
MBC;]8.7MW4D*2G7H(N@\C&)>^J(E*5<V$+C.%#'DMU;BM/,")*UT*[3R6F9O
M>< ZNXF6>%*[R1FJU[X&PU*&@1RI%=LMSQ5?>JB9]9:/C>I//I,%2C''3E[I
M&)8)_Z@/O)!*L*/5Q&6GTL(/+#:<H;H;JLHL&"$(5UZ\*.&+"PP\JMX$@H/7
MVG8WK,PLY4P2>6D%;];CI-H3QY_HL:LQZL]RPG?=\8DC77T9&I2_KX>$;&8O
M/@[+MI<",90\&+L6""H+[)T%R^J3\>I ;,N54/T(" (0DI2JXKNI.X&9E:?%
M&[6-%EM%V3_I*]+58S?B[#"#E Q2.0<W%80(MMP/B[5F2$(>A"O32=]G9DZM
MZJ_*C3["6@5!B9P*EN*HMT_?5;UXZV1<9;ZX527X2GE.P<1*J,Z<!\_E2@N'
M.4/*7/S_,UEQ)D%<#).91+3?^.JT%O38$G!0X+K B]SKBC-\?/X#*CS32R-/
M5,@XI$R=_:-J8Y\D3[\PP<*,"^.8[.H$8@3-69-;OSP0%&]016L\NA>?D5MI
MGD/9A+\Y.Z(#TYWJ+VCP#FA_!SS-,3SHO[BR_HVV_5ZM^K;I_=A)YX[? 8QL
M\:J'X/)V@C;B;\+W"^\ [7P2DE;B[;\GE7W1SW)JK])XU +A%JA5L&7K _O>
M 3Y^D)(=\7_O4>H#%MJ" #N&1^?TK:9)$BPL&N0FSB=>D,NJX(LRV9<23O?0
M?VEFJ&*,R=OZLV5:P0W=E[&R('%%W/'1GULO^@P\S0T7&=Z3'C/L.2@Z3X=V
M8_^'B_P&DOCUH:D3^ZFGM>DFGY8G$N@7Z;Q07B+Y*F^IXDK\JW VW\F[(];'
M:]Z[N7S*(&^(_$Y [4NKUB_DQ1_B_58);P6VA2MU,^V 0P2JA0FU?@7[M=A3
M<52\\Z@LQ?GI79QD',/9^4:#3ARRH%4-N*V6!RXYC59)"G6G2'S*/9A%/[[I
MQBNXS(BT\\\Y87X.]7(^V$Y^R+>7R:GS2L65[P"L( S9Q)J@FA>TFNH+^]X&
M9NL/!^9H@&,?QH\GP(&P:M2?MOE:7]"]'#K:#-\!WV8>?"L>-20*#N?Y3$L'
M );.(W(<*?A#O%1Q&UQG*O&X%6MW[P".X>(B0<K<BXW)SOE;ZPK),:-P-G T
M%82X\>Y Z*%80/CR': XDS:>0& Y[LR4AS #Y>6C(.]VJYZEF5$>2B##HI^5
M53RX(VV,T9^CZ@ HFI)P3OL;OXC\/V"H5VU=@O1VQ^A6:W=*G&]I]%@[I \9
M^/VS &[8Q7 /;T0EJV5FW?-EL6A1NH>19=,W/4)9M$"RHGWOYRB:2#^V+_'$
M?)V6%J$U/<)DN.SE:P1O4^HLQ*>\R=8'D86IPBX6Y&61C[K@!)/:%=>C0> =
M*10,O#OUY+XF'MPX6&_69I2LU&.2D-66.%HZ;M_)J+_BUQFO;UXKTU+PP#1F
M:]A9@52&4] @3[&:&L8,.R%"QKBM$>TW+>S(M2@$Q9$[?;ZH7):'',ANN!=A
MI=@2[<4 JQY?CN/U+XS5BQ>F24Z??9(.GX1IBU(6):]+;2TUWSB;A(INRL]H
MM6KF;5M/9)RD-B(;382VZQBK^2LF6 IXQ10XU(UVGU)O['\UWXQ0\1&Q8Y9^
MK;V9_2O'[X ?PVW03]?,0MW;U\9AFQ$M7ILN57"@8UM%]<3KS?-$#?8O#^I<
MA=,UQU[XW)^6Y^\B+4DGWJ#X1)1P7O9NKQ\'*\98GJSIF:ML)RXJ5LC\/-Q_
M]#KJOLS$\P (0,.0O&28F+;.*JECKI.92%N<Q%^N[X! %SF.[BVK"=0+>5[^
MAIKV2""I^.*Z>/&BJ"?4J J9ZXN76OBF-TPYWDZ6G&/"CPWQB<NX&_2)K/Z6
M_ PJ'@2$R?GX,DE'O8FT_BU]DKJ<F:(B,5FZW :>P']>T7F-24,-GOS%.R?*
M:H+B3+%?A2,'CMXD !+8OFJY55?23E;6KL>+)U\[3A"),5B%"=S<)/H *O+*
MPYYKQHV8V+;E&'(&;S"+-RJ"NPQ-(SO+-,+3Q99NW,VF'4FVT-VZYP[YZ5DE
M!R0)9B=J=3.]/ZR2I?;K9Q%*A#<94[F:,D-5BRNMQ4YC"T60F-C2O0YF2-KG
MLAR+1W#SX'*/[IV0)+WG(L[T'8=>/0=P"IBL[!*=(X([\2Y.'AT5,;WF^)H7
MPR28M9OT-?<C.^8X6-BU'$1>.+*F:^P^0^!FC>OKIDT;@^OW#]QF8=-)UD*Y
M"E.#9ZPNK&QT=1CL/E$WTA(#GJX>5,ZND#D-@PQ7KU:8%(2U4]2JE8J&7_=\
MA"M^ZEA7?6:J_C2QIL$S,!M>Y>B4&#/&/&@QC\W.0TE%AS]![(?<PM739_OW
MKIG&?JSI1_L0PX-_7][(17KFP_ AQ<#:T_N"/L\P\\%T%TT8+3<+7-.8@+O
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M./0E: "GV:<_)GYC063B(X*0.>I;1F>T@\="?F+OYYY'H0SG9U'5;]SR$?[
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M\X:B#87<F9YH+6>F>94D?V9FP;(D%7#"Y+[D519$\^-KP4QF.:CVC9(;R+I
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M6F-5;KJBN(L(4=YQ5JU0I-\")^1V!*F!RS*Q74BLIT!1!&Z'V!-;:M@%2 S
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M@ETIM ,( 8X3*\LA"&[JH2Y@0OC)$P6D8!5&5.0 U$$]@2%;^C$=KO[SGW1
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M[? OZR 5?WS4W"'J_:K!&.#OWN^N]U#66V+.*=8MF+;$%Z<RB4474&5F/!+
MV;':%5/8]KV!(D(^4@TW# @@>C L-]O3>]T_C[>8L=$4Z_EJAS4EN^G--GY9
M)YH+]EGFH<0 I&/]^.?9^U-(*&=NRW5QXOR:98D!@T>>9SU:7#' VC=*>9 A
M:A-<;H& \9G@>>2Z"/4\^Q&")4RC)B?^3,'52QENJ1=E:[#19J!",/6)Q\(F
MHO^QESIVKH/!:%5M2AEU\!P !1FB27R"T>9TE.,:#KW7+8RL_B(;V,_3C*J
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MYJ(?YYHA6'C(:+OLMQ58?5L&F$;]] <0.@#LYXN]GM-Q<L5EU0T7T. &: "
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M1!JI.S?[^):M-E!+SDV!XJ:Z/PJPO3M=/9X'.G$%.V)#!"6.:Y<;/A $K4W
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M*/N'%4-W;74_,.%OM=E!A"?74,EC+5*HP9UOT=66_=B+J+<D7PO=5/_U/O'
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M6')3GB$'I$MDOW5$^\7^8WO^GP!M#?\!4$L#!!0    ( 'N*@EKJ5'_KP*$
M **L   0    9F]R;3$P+6M?,# U+FIP9^R\95 =0=<NN@D0('B">Y#@@> N
M(7A@X^Z^V6S<78*[N[N[6PCNKAMW=]>3]ZU/[E?GK7//.77OOZ^GGJGIZ54S
M]?3JZG[6ZJEY6WA;!V!(B4F* 6!@8 !Z?P_ &Q0@ D!\_Q[A/3PB @("$A+B
M!Q0L5!1D9!3\CY_0L8@)2$F("8B(R"B_4I.1,U 0$=%PTC(P?V-C8R.EYN;G
M8N'[RLK&\H^'P" B(:$@H^"AHN*Q?";ZS/)_7-Y^ S 187#>7</"D />8<+
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MJ[1L"A38ZO5[ZL+MUXS>M%QXBD>-<+_,PC#IR&O\#'1IF*/8JD3,$,R:ZV(
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MJBI6C:-A?[Y2L5@^I*%S)V;KV42\7[Y:JGL6*94IH#18+DR:'/R"+SP@QYL
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M)K&8V7*CSW5-$T1#?$Z86]K8I2*TR>[QJU7K6@:!2F(L:4L;<Q3":\(68=Z
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MNA9W0-!3U45B!WW-H>D,F0X*O \H_S&L0>Y;;-8SVY90S6UD5*6"'TI'0=F
M0BJEL?%=I#./8+TD,WVB.;PH6@'[2 E.[):AZG. %]S%ICQI?4NR-PW>Y;B&
MH6#V]^BOACE-&\>Z&@D9FI3\T<FD,*^9_+FG75N '.NJZA]#QYPR2> NE-KJ
M%.RCYX77;AJ4@O1C@[8MSH8'Y,#A==>?*;+952[FZR1-"4XX-ES3V;TG@ <6
M% 6S7@!5>KG7\.@,ZGQO#Z-;.!W3U'@<MPB#?6BG$:KQPEO22?))M?<:TC0E
M '=NG^0[[0!?["E:VTPP  .X.B.H"&40EEPX;,Y>BMY&:V\.V5(.G1?%!Z[
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MU_R3BUHS_B=FI[Q4CS( 5_#OTH=8SJ^-EU@?G;\MS<8XN.]Q(Z5DI.2N(.=
M H^!FQN9<^[>+M8RX8ECL!0_Y)P0Y4 <^'LQ9^_'D^A'+[A20VB9E"QK\?QB
MM*:*;?3B_ZMR<$'O@<SG_U& 0H]CC7\6K@I5>0=KGF@@_5A.Z(S5_"C1\W6:
M081X81'OU-_=%2C#S!8[8J4?I3+&J\?0>[M3#=#IK.L #[@8C'9L;Y'PT"D
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MCHT\>\ONAC:>_%&P,ZU_?&\<8TLKSL W@Z#@,PB./5:,T )JD7/YVA %:)^
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M8>V7RS4\\]'G70K;,<XXJ]6#E^(EHVL_I0^7P5HKF]!RZ?0D]D)C>3!;VP!
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M3OS8H->*P<ODYFP8^)VE3N\^$+[<ZW'21)),V;_9]. D9M.F)XD> K$*47U
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M9<53'P^A_8IEMLC0.%TFD*-<J/8T[5B;KRX35:8G*R_SY(]_]6+WFZ2S[?Y
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M'*4D(2?.2-G73U[I,2 ^3KVE;B%(@C-^KRM(!,.-5=JQ+CJ\X8;>'D\"@ -
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M+Q_8__[*\(_!8!CQ)B+]1^61G'-?>>A,V.?&D'J;]10)+'TU(:FLJ3AJ548
M@7AD(R*%&6P[F#=@]%$'>*)C+5.G^4D^)P1UY3CU"I@841WF;:&?[0YHP0(&
M3J[R\9H.Z@25L[/3"<PI]K--'S>N L-Y%!<.MX/Q324=.,%C5&\^CUGJ5==7
M$]3"/A!!.R;\HK&,:[_U%:P[2*WGO<EU516_*B!F,Y+":KP![0!-EI-7("CE
M:>HO2QB_W/482IU0F9T-/W.9EY\/M_9;]/X[5=,8R$=$W7WF6OX&6^+\F^.9
M=S.@>9CS_(@MM:0$/(XC]5;G5SRVEL<DPE_FRV&6G0G(=Z!Q42A+HT3+8BXA
M!].I\3-E OGP5'2VVS(]J5-]2&D,A2'69U$,C03N](DW*#,N,K!7Z@$6NX0U
M7N<M%/#"IS#Z"A4816 EA_NHE4!X'[4N 3H*M7_[2HTR8+0B27Q KCI2(J@Z
M,_"2/+4"<\I;!3O"1MM2OJ9FAHX/JWBNW&"(>H]V?,NYV !AZ977V@M2ZT'?
ML^W3-4_V;^_$+=]I&Y=NT=$D[S(A ?:]P:GOUJM[]$'SV/MJC10),A4CF&O=
M!^J%-AUK("Q#*WW%=FG@3>)A2I;V/:C(6\C)/:AYZU^@AO/GG!SFSJ5"V]7K
M]DFQREK7;9.F_9:<V>ZSUJ>MD.0, V?WKUM'PY2N_-0I$>9K(DP^UF_639H7
MA1G8V'-+F#65OAZ8HCDG:W3WX3#%O4_[('IA&U'A4XYKAR?%5QRXSE=5KR"1
M4#"EHX!PR+2NG^KQ#J7QMF'+->1%_Y9)9C(C80RT!3\7E5$N=*7K#7P6()*F
MT6&=[:NZ'J^BKM_'$>WV#=GFD1368VZ$(HJ\G,W!S=)Z*W"HOMO>$<N:83,V
MV09P33'[;VZ+T?O-;^^,6H[<?<352-\\:=Q,PH,)/+6HOOH6V7::IUY94H$9
MCX);VCAF;8\)HICAIQNX<,:6BD+A@6HZO"DB$[^V-5B<@-=7ZCW]3EX,'#OG
MD(CL21_A::M9G[7/E!FU*VW4@"D2P;(*Q^#\AN]RS+7DT=3LA77G.=08JOS.
MAY<JJLJI%)RNCAFR@]3VHC2IU?$;0C8RM22MH*I4Z%3XZGT^K#-6Y7/\9ZYQ
M^\R80;NT9\[F;Y22C1F/T%@B!C06]/7&R^\ L/V':]Z<+7-[8@J!.?TR-K[/
MB'PW2X=18 P*T,5G^N':L!W2*X:6FXS<56V;3AH$G7;ZYG;N@)R6-)7I:;5I
MX;"5:7%#12,RVTBIM8$Y=I+C^7@@8_%&17MFYN)(_+YZVH:&0F.2KS)-?N]S
M'I9W E7[8*!\Z.V.I4'=>]Y/5Z78GW.QJ^ADIZG[C'^^2_H^5&Y)JNLK1Q;-
ME.(PBE$M2+UYZ9<#;M84OZRG;E@GCK<IUX.?QMS*)CLYP[][5.:_S(>KP=&?
M1D?WK.<.*!7T(&&8$S&+.W,VW7BPL[RFRUA5>EHT_VC[(:V?UAT@DQA=Y1R]
M9C>I2NSP+* #'CHB$,R$9+P3 T$*Z@1LB;O05[B"76(L5D8'C<]B>DS#/Z!1
MVMNKO/?7L]A2\4#=CYJ)!];!>!;["F,5Z+=#5=3,A;:0Z54-_JCG7[YTL2&H
M)^=4B)F]*+)/%<U><LU+&\T,- HHM.&2((2AH0.U<Y[LJ_L(ETO4!>7*M' =
M%%(=ZHCG4O'C^Z]QW5 TY/B;%^[L[<IMG2[54NG/LTBI1+;B6DE)&4,_%9@@
M3=[J8T:*\X_%^5K'3TD5+#JWP_:][GJ>O%1'T>L&]V5?IP;U,];[-\(A[SD9
MRXEO$A/O*_G_[.2U'3&[5!F'%J\*H)XJNAU5]*VV#<[C9HP(CN@H,MZ,5 =?
M>O.1PG%&DC"POU')3XDE\_)F*_S8J-)WFN47XIRKCKURG$!.3"/=GV&-C3VP
MK51/"_L14YFHRT*O[\NQ3@V[DPK X@9 XR:30]O\BLY0Z:%T"HE5<]Q8EZ/@
MSL;%.\#I#N  N+).+7]DB 4>O\IG;:6?.=]EU:]VPU\I<K>IB50L)8(Z!4JI
MWBZB=;8,0N5<*'H@:4OG?G.!K&WI4*W4EK^!6PP >6Y,0A-/,(&*?BX,>^FF
M_J_&X7?.QD>Q8TV_NI:_$7PYI+KT;9HBJ3+++(.]G2!--#U*[>@6*&776&>#
M.4E]V/23SEEB:_Z^R+:_EF##UTHQK8T4T8TUMUU': UT1(%[U.N0S$8@/C#&
MO!K??;3W<H_82_+]8M !ZLP33S@1/&?V5)2>WW":)=0<.D88&/!.EI[OM$^I
M"?!_X..<S"_#AK$";:NK"6?<%&2U.*^(@<)Q.YX_SX,)7;#N@!_VI/XI1<8O
M7CR!@-''QJ*?)>5WI?WHF_[?(7G"F(G&)(K/EYD?-;KLI8&.3]Y8)KJ>O+6V
MICRRGKP&69KH?MR'X_<U*2-4M%U:+Q[8?_=7.]?< 2A;3R3LQB>J<'RTN&L'
M5F>%< @U%L"NG/I>WK;#(89FVYIZTICQP6',?=TEDY6$TB0>A7KMBU[]MJ->
M?'CPOXDW@1Z_EH69]Y:LIEH]K@*^,K);XNVKB*0OV-J69" I1]R50YFV?%.'
M]YOGG^=$2+X2,'?]#-46[H??0S4^/1_>_.]XS8N):BL"E^ ?(>?B83G"Z./$
M_.E'_Z6C+3%3V\J4CQ;CJQ=\TJ+<2/<;V9GR4\&.EG@Z/;I'QNF'T/Z]L?AC
ML<BOAR\M3#!CG08QU]34/!EP/QM1Y:Z<C.1-T*/<75E46+?NE\;(6GHVW<G,
M]OQ*<2PZ2KWNPV[1]? (%%W.?6C2/UG_T5K\J_L2VA>)FTE0*QUI"C_D!G_+
MBI' RJ#X;% 5@XRD]TP:CSWOE%I9;H19E995].SHZ9$@VY$6+[5X(HKP,-ZG
MY52>=$_.1W_EEX^#U^N(8YH_(\E5QM*5K$]Q=8"U@I_B]".P_@.OVHX[?'BZ
M@I,I@U170,GX=J]\>OHB*WO@@;M2<P=;\T ).FCHXC<6SM>WI&,&PWW75<J8
M;VOM'%EZ'A9_VR/Y0EN]RX8-Z!$#Z\S3HB4>V:W;MLQQ]JI(;57$P<MK,'H'
MJ4A:?[66QONG'+V-CT:9R9G%Z-I5B[*228P>4R15 Z 88O;G"SBQZC5CQ.#/
MC8&J,;"5JGC+;]#%:E T')\Y(B,?N1BA@\9^1Z;SS4,)Q[=O((DJ?4U TWQ*
M5&5(:C;?!>W1''%-!Q^E^__8=SH.2<=FLU.0(."R @TB:2;9BS!TD7TZ#0*=
MP67V-L#T=ZU8'9I5'96$6Y;PM&!<AXNYQ]0D&,44>Q;W,Z@_JSS#KQAT,KU<
M5CRX ^*X^@W0).$3G^C1*1L\!(>B &P=6J.@LK\^G+EOTL.XL2&7WSQ_P-K2
M! A(R!)H,K;\Y#8F[ZNA;_0MG]*DPK4(BF_BB:8D9OKAZP/?4.$/^L]]V^FL
MX-\M-P#V/+\I.M2_N,?:W@@_S9;BPKJ0V#2R7+PUI+\EV$"\) _9C;+L/W 2
M(9D,:-X/?=3H_YXW_/M C?#APTW$UVPOLC?/V"Y7*^<4HX)#CQ!\TB4WRSA!
M(*]^J15?:UZ7DT1RU$,8HYK5OJ[GE<R&"]#OJC"D('^SE4T^=DGH962B?Q[Q
MT94B+!::N K/S$.R(>9V<H TL3*UJO-S1$UL^6/$CF%/FG^]XI,GNO*_6;[>
M/$4W?A 5<]610: &Q 0:Q?#6WP'WHO<0S'E<;0Q";V0[ZUT-_/#OLIOU'ZT@
M?C>]LXTA]Q%;B\YIG^DN\,TC&9%1.9-:\\9H0^HBG[<S_;T[JDF?5C]%C4::
M=OPW&/+\_;%;H6G903?^N[$.;?S85;&&"VXBQ(?;2M>_EN"KW!Y_[]AZLF<?
M!-/F,61&36]NZ^&E4SW!H()F-["4X<<]W5:S7-R&.^83$8KJ["YX T+L!NVJ
M:?U:&$;EX7P'?.]3P+=@$C&IZ-=4T;\^YAOL G_5WJ>X?'F[3U1AGHHYOHD0
MJ>H0;!E=17\9[_C/H/Q_3Q7024QB-/PY_> T'MQG2]JV+8'$I[8E>:5G69^1
MS=@N+>_59W+Q)Q]]_L4$%>)/2 5K,:*OD!BEWG4NPQ/*G-T:)L[AO=]^8FKB
MYH9[;(Z"QE]E>B(;;L7MGU>D_4N)(K\$2'V F/[E)KVJ7$-3@X.32[:/1NX%
M.TSN)1J<K:=3=E^JFN23/),8I>HKL23M]4?>',NI\N!'XD-''><IWX_C7Q(!
M!O<UHE(XI+E.Q_=GC6CZ#_6PS6".AI1P6EM=71LMQT^A7M]4JXR',F]1GV@4
M/_CG4P?"7GG98S3$+&TM+AL:1YHXDKPZ$ _30&/OAV701'Q1$3I;\?"5<)J/
M[L(:7P<)_?8\KE[@R)],>NH.5K-FS$#Q6YST.*WC9:^57O"W(YQTX*+&E_&$
M&-F2E# 9M,:L39OP4@B[^.*5MTN7GA0D_^F3&. ;#CR6EVAD$1"18Y)(X1[&
M-\@I7_BN*589?T(;6@W;Y_W5VOMS1Q (_4GTO<\9*]<<N;>'=1;MM!#[QLH5
M_PZ(H5C_0U]P!A/^NS3C;,GJT>6O5&Z[<!-T#;0\0ZO/!IBYVZ,Q>I6'N,X)
M:1\+;WT.?ZQ'0'9NPS$V\#</4(:\8JV5&7E?KCZ]<W0(#4M*'U+OT_ZRS+B4
MM"*KOEQ#&J_ GY_2)Y)G;P>4:(^_H'@'_(T'BQII5LA)E=6%[[P#1@*%5X(M
M+-[GF?&0?X9>ZVAT3OU"8,G5-ERP>5K%W2_K3ZOU:4(A%+95-,SN-NWCB,2P
M-SE3XF=]@.==QV"NC#(WI,:<R@[E-#!0:?4WV]O2\$ =8.?N^@^L1LV42U68
M75GE+-_O&+$Z&TNS$CEUNGZ"H3304CHU-0LIVMWNL%-->9?QO(PTX#GRDRBU
MQK^=1@.I*LP[K(1X7&E8J(1?"6@Y&7BG9JS5/OY-T?!#K_^$X88>R!*LGY+7
M1_T?UT]J_3XFE@:Y&OQN/,FQH)#^+VO$>PN1.4W<9>H<NMI"QD1-++M$>/F#
M^G R<(CP:=>2MI<= >-;#\6'1Z34TTR+SL+ XL3:L5&^5WTC@X]<YH9]SR??
MQYZC2E+Y.QUE3.8B8,EVD6WS/<W]+[N>R$6N"K?]%:'DF2&T-"G=GIU\BFQ=
M>LG=#!Z$<W&+9IOV!"AJ&M)6-&2$[R,!.%%==FBO=DKQI6'(#GE-5>";>B\B
MN(YUF4T7S>*P-S$.)I4D)"?8)(G'@4#-OQ7EM7VS\V?9<5D0Z3,]Q[7Z*%_D
M[@ 0(?\R2>F*3[N9:>Z6F@).2O@P5YDD]+Z?D[I9&C$\_& H CLZJ-<TOC$O
M2]U,R?!B-7*,>M5[O5N;CBK2G(+OF1@6VW*#X(NZO!>^!=(8NRTBL#MT@DRE
M%#/D5-Y\\I;:"<'%4BYVQ4&WJ DORFN]56E(77-$DIU)>D-EO#/8FJ'Q@ ZU
MR.V6<67;6?$U159II.[\2=CTMWF;$YZ/<J$\&8N+7P0)7@F8JG4^V(W!!/IG
MK%@NWM'B.=PR:]:KLZ0L%CP4V'V[[DS];O.39J9K  &=$/O,K-."4?"$D$=.
MPFZ"I<6N*F-?O9?-H]SG/JKR3HRO(V'\R&JK0LQ#"A"RUD2[2/Q(GHQ&182"
M04VXWBJ10OWC,BT\)UMOK0/212<X906"K^1S@;]^F?3' $5]+Y%,&N]+I,M$
M*THOG];XSR($4=;,NSMG3R1(,RL;M2,X (&2;D3<"&\Q-MQC+4]A?FQBGNA8
M.!]T>3'..:T!JR$L.1-]V'3Y"4, .&!O=T('Q2[N:JDG6:@3["):+K $L46:
M>;R,.,<P:):-&+QR&:.6UAA]<T@2,S3'99TUBIJJ,CK]_JT%6B-#R00T<?[E
M!#^^%[+UK.'1Z9Z%#/$L4_5'\@UT3ZA0:?ZY])2O9\I/G]1)VY7.B)=+OOVL
MRXZK%TF?LH@->%KS82,6F(9@9!?2,C[L3S?G:=?3#,)V")&RKG/@(UG'$Z;(
M5*O,,97TW9FP[J(+Z-YA[<+^<LP".S!'C+0!C>]=*WK-;(!Q-(-(@VS"J9%5
M%G4N]K)?!=F(G629K:N?0@R,))9AI9]D:!8&OMAJ<7KWF)T8ZX&#5^A'4)HY
ME[+2D ;?XF(T= ;*0K"/W"A+3)FJ:HL9U&X@.H(/-X"%P?SOG;M64X[;-*.\
M&7"LO,"AMA"RDK9AKTUSFT+E34W7C)0C0!^L;*D:M1&A,4_=UC8V6I;IK5AI
M O^QD ,7%.73CTC,!!)0/47RP%15$\KE[K5%)*FI,AZE0M5;></7R5G*3L9U
MJ1CV1(*[.)9Y12TQQOVU>87>!XTNPJN@8^C$9#IV]FVI\H,3!XZ/YV6F3]O6
M/_90,*8I<WM=V'IR(!^^KCGH917N2I$=99V*-4[I4^+\=,KY<25X ?^K)WW%
M .K\])3Z%[Q>EJK!-ICSUEU."0Q\-9_M&/8=^.H<4[7BG*RMX5GZB 4'ZP?E
MCTA'>N0R]2+\4'K=0&=%TP./3"Y]8Z?VB9[4/,!Q%#I6-X$Q*-N5FS$>=Y03
M'R$TB)R9ANG'(.9U(L>[3VE*4^$V'%]:9^>JQUF0!NS$K0J$-.5U1S2O_"CC
M<G),ADS*1"/J(YE*UL1(,C$-F[6L@(U4=PR;?W\WM/9.,%=+?2M"/:AKAQIG
M:M:"L.K8L1<%BN#C@EZB=8H6978^3F@,,Q6EUAP__G!QN"@Z&T^]T2$,#K!,
M=BB<\R+A;),F\[/!2$9-E>AN58?M"T2K#I/F3FC &]1OEC5A'Q3$#3>W-(6E
MH=F%+E;!^I%&6!2O$[NC0=IV\<HL,Q0N>94J&I/1"-?K>]0--L+/X!J-C2=M
MN-0@.=:(CLZP@WJ-H,JS&7:50\QS NK7V(ZE5Q%!5Z[UBK-\Q4I)6F^XJY"]
M@ JU:]'Q')]Q4P9/7C56J'Q4<C0$A\0W*\QT\7T&E,'IT1$"05O$!,:@QU=J
MHZ-.&DO8I5[#JS?ASEF!N^S+6!"@G;Y-&MY_9Z'*[^$(APA[C27]\5JGE"-O
M"1G;9C@W.52EU_T9M+32Q^2]]+,HC)":@0[^612:SA5.4Z,-?[V4J [VG7=2
M-.QNQZLJU>*LXEH#__NI4FB)-J>I:G+04,YE>HX0-8"KI2>(?=7[%'[2CJW?
MS+!@3BVAFBNK)GEF!94$&=H]-6S8DZVSGM^#XN+%[8)JQ[L#L5S28OVIU8)L
M90LX"3V'&>M]=1>:"J9;C 39&DL."3TVVG*=<.%>4(>NP$F!1&H;QJ>JJH:&
MJA?"D6(9X<Z195LJX;8W=/1R+>F0Z19+&$F&Z:^A?@1TT;$><A=7'7D#>4P@
M_S13Q]A5PMK&!K^SO8G^  ESG%8._0ZOJ)!FG;!W2QF!V\HU8;*!2 5!TVRT
M1"$6Q(JJFL#-5AX [=,N4KVK9OU-JI\<G]#QG<=07Z&4X45J\#*%/ZX=;F(R
M/#-WMA=><L*+Y-B)$(NA@&B)YT<3-TGY]'Q8$/P&ZKZQ1!??D;Q0Y@ @\T/6
MVY#>YC?(>;);@@3B.Y0OZ[G?6!)6*SJU"M 1";[GT7+0U_OFB&NK!O[//N4$
M^>>S^EGV?,F3SN$L5OA *K.]Q9@8R,7,)(UQPG).:VT..Q"+'L*:<+0C[SGG
M&;6M"@'C^%9 V$;LL-'65EZ%D+S67NM'LKX8/XLRMS4S[;*%_4BC$5YIJDB_
MGWP"<O]7HS0MA %QIF6-^U&#Y.N@/8+SL.-4Z)X[P/P^9\GG:CJ;O[W\\5G6
M'3#M<;451GM3=9^UY7UOE/Z8R_@7:=<A+B2893Q'^DH4;@$1 B&-Y,<?W\!"
MG3!7';(D:APACN',L[#J#3T61FV!XE>2@4/@LDM%:M2^LKS/@&17[X#*^^1H
M['M3)O9V^CZS4G#VV&VZ.?W1C/@UB?^36'X[\5 J(U]%(CN$RL\Q&J(B[FWX
M2J -M"/%Q@,&#?Y<)_*3BV+/(\SW3\\_!"7PLLR:'PE0(!(C2U2R89.1G&PJ
MDQWB=?>&JYM(6M.7/[7 7&3)7PF&VY#&U?/9Y7OVIV16D(% 2^0\9M_I-IA*
MJQEU6%]-AO5;];*!F ;VY28N98<<"A3^SMUASV=_BON]\_17F12^-US^">[_
M78QD&3GXB=L39A6BM?=QK2B]?=IP\D6P U=+2LA*XY7!KI947^XS@6! ="48
M3:QY_7NS]'=;K[WC+NRQ+Y+0NTF'O'\Q9 %3 GR(J#(W:(8F3CO%KY!0.,2X
MB<EP&' 8!#^-$,+X4-4]@(0.>[[,SID0SH?5!CBX_R&US?Q!^'TZE ^A5/^D
M+.40#RL(CM,7ZGI["K!VTT_ 0\H7QYDEWDYJ#=BCER,$1W)8.(4^BBLE9Y\1
M?KK1D9J*LOZ[PV96)5,F&.=XM;01^8L0M")T,I,"C/_ I]VL.?P#+ M/)7Q(
MIP4&YX60'5[,4U)1*3KNM]LX/@FWH@^6@3?Z0[G*V)9+ST['=M&6=NNG]N<@
MYMQ%9P%1:Y-?RB+=%=F[X+D>#!VB9#F:Y7UY2ZLM7>'J:&T5LZ1YY U(\4.'
MNDGK\>$]_<U^&O=E5H ]:+&(5SGT2)0L&6%2H+(NC4H46=\&I6U]5&\N9[3"
M7%I\;*W:@S[5T!J-'E^"+"9+E-L&BUUOBO\L%:7N=^#Y'*3=&IL%07DT!L$[
M<2O!&99;[G(@Z BOS<"A?^1?Q4:M'$FSQ7D8I0UN/&-%R4+5ZAZLO1]Q8=AA
M4-@[Y"<'X47^5!&(-_#T)=.RR[F'CL'(4JTWO64#3>;S6)AP*Q#PYK&PK2;8
M6WV7@RQP2X+%7I6U'2, JY_GC<@F'^8??KAZTE6R=T(9(KZN41TX*D%2VK?2
M5MV< :1$X2Y42;U7A&\XA%'CCK[I:VL?_Y!#@XK^0E^N@!RP(A[@G^ ^Y,-K
M^@V)2BU<(3/VWNORZJ0N_4K]YT(X2=7P6(8#<U_8R/ *'/[A?BRKEW"SU\EI
M(2T'BY\CXHX4NNOX,8X=#I2N/&:,!\9_]\$"_[!6Q^%4WXJGZJ+[R8C,I)6P
ME0AC(Y150.1D_X]PR5+B[+HHMB\0E-#Y[N3UBWGV#,,'#F?]\/@GH+H_U0Q]
M!R :G!;*.3O>ZRM2 I5VW[R^B<A\X]/]/CU/0I'NF8@?KJT>-Z_ !I=42CNE
ML]&\+A,.8FC7C&YNABXE#EZ(![;_V!$K)]PNZ@4%HOM[\8RXNE0PG<E*G3UT
M6-"KSVU[X$XP)@;_MH70@9^E;=;_RW^X::D[:&4MCS,8K>"_&F"6M1!5L)@6
M9FLS45$)0D 66%M;IJYS:TV8=#4:+OK+WT@RT%9[S/'VI\BTQ\'LZQSC^\]Y
MODB/^ZF I._X+WYTFNZML_[=.+=V(-C3!"WAP-A8EL*B\ ,ZF,-@O&9OW@>2
MK%(^$F#,\:ON&"/'B"K&.MQR^CTQ9KV?XG-\!W/\HV#_;J;^[U:ZWOC>O/A^
M_Q=&#L!-L;HT<.UH>+/G(J:P#PO>6U4\\18NYZ]KH'$>(4%4@X8,K.U-+=:/
M9UJWCQ+?>"(0FYP\'T-=?!P?;#T]HZFNTI83I&AL )I>UVU>P>\HL9@L3OE-
M$F2Q>E+=;1*K 7MSF,',)X(PGE0!&<;PSR..#L.%+(2#T,UPD(D\\[F!S/]<
M8/2!'Q,_B7YT7OY'>/]GRUOU42,99Y0T.-"$&&?$W%RM;73I.IB*Z^[K2 MT
MP DW7!H*7/_; WK#^$.9:E]<GNX5RPA/2#Y'RP_U$@7(5T[P-L]QJ!P="[C;
M9D?+2((H(.5AY S+\(#^0O!"HB'X=S'[/5 V)7.GM:D_H@Y8]&[)D6*3Z)&%
MBFYQ;[XXN"GLO(BQ3RKF&3GS_%[A<02_>0F!XW"WS_K=AZBI=<O*_89AI]')
MB?FDG*"ALO_J5-\_$/Y.-_1KT?=.YH^)'S1\CPJ[3E3V2I1<@^KR=,5@"M[V
M<Z6VI#5CLW$M1#*JX?^VTB@[B. L4$O:T=Y&U]!)+ZZ]\T-G)X"<B 9G&SQB
M,(1<F6=AKRDF*T@9'>THBCA 4NSFA<561/M7.S!87+.:.[ZEAAV;P>21\2W2
M"4>8@L=:06-;6 @>"PK![-]<8:3D:"BK0)#N#G _FQ=PZCK#</W-= \@#@F8
M">CYD6*4W;?ZD>+\AF]AUP&40'BI,9O_;'?]71&YIAPZHU;9ET=S#%F:S^UE
M%BXC$0ED^ M^)S.8^>8^MT52R?I4=K+0#+L\Y&MK=P-HV8'S\2-FW64)B4^6
MZ68%6:%[]-B*5C""%BC]/!KG?["0KQO:M62*'IYD<O DVKG/UC-UW/VQ>,:H
M9]^S9H/H]7 9$&'>+*J$)OA;/6([A?IM5T+YQOB;Z;B1SDA2<EH^*.97::D\
M0^IP6$\<C_X?[@CE^DJS7"YP;?+49X1(M+HF&9%-N8N_G#Z?XI&M(,Z8$Q.E
M]!%9,?KV#.(=>;K=(CE\]%Z!,0]QD%2*EBJ3U[ 61#0+R%"T"UA<*FULMR2U
M_A_FWCHNRJYI'%]"0DI*ED98I)'N5"GID%I* >EN$"E!J0466*1!2E*ZD>YN
M6$*Z.T40OGC?WF$\[W-_G_?YQ1_[N?ZXYLR9F3-S)LY<9[_;0J@^/1LRW5$_
M\<@=KPSN-*.SJU+E;]H&8-LZA"SA/'HN0AD JF%Q<V-I'7G*P&IDMX),W)0-
M0!@YZ>?/5_R[GG"2-I??/<!XB4/20H-(0'7GX+"$AGC1;NU%6?Z_L_O?MO+\
M7Q<IO_O]V7'A^6VGOMXE?J_OH5 &.H%#!9CHK5P""W:$4M:)WG0APD#W'/S;
MA1SBRE+U\D\2:W5Z;?<[!CN&'](X&;BI*P&0U>*28FYGD=W)@!$;1,EB#MXB
M!B)R<* )X;%)N3O'9S9G3'&Q"T$Y.X8ZF5^QT%2H\RT>'*5@1/U1B.G[E*4R
M<G3F^'&KH:"?J;0P&KGKM7\0SGV[]CK'Q^H+34SQ4X)9)CBF/1T(<S"5+%&?
M%&Q7US(E_9D"5A:A*<?R)>IW4+9)9V$41=7A#)W*??(6!] M,XYI.:L;4SER
M;QYW OMLK_.&]V4".!C:DRQK1=759><ZEQYGQM*J(80(4:%9 WYJ4B]#W$/L
MP#HSVA/7^[S27D=-_/4^[XMC.(( F4A!.^Z_)4\8#<O(VL .M"^L91,N,#3H
MX5R1EB3RVV"''(^/T8X'6.WDJ[=OQ]BM7ZHTC9EV+Q?3-Q S:AIAVTI:6 (
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MOD]*[F+#TG\3O1W16^!?; VQ;V=8QN)>;3_;4!,T#D]]4)]-*HV,+2E<I$V
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M1<<\4J=DFO5@$C)NC:D,X?#43/J0@/VV_-W_0DY?G:>#F?.M3HQV--C\'8]
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MK515L#<ZGO2'/V^5L&G&1,O^08,Y# ?2*TK8M3=46[F@L5D);9"A(N 2KL^
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M1%5DUYAJE-.?(TI<A>&6'#PIRP+OU_4CY_D,[V#_D$>S/TODU]!OGU2V+[]
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M!:/V8+ 34Y2WD'W^9#\QB$E+ZWM;-TUDN%.'B(2#;AQ.9V ]^;VA^5'&E.5
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MK$P/UXY7@:=^<MFY4"?D?@EXO_>"F5 _0C%T$Q-\:6YO(65S%US2DF_.KO=
M.3(T9=N2'I(Y(5Z7=?(6@;.+\EG5!C%L@EBE&2=%@J!36.Y454-<EI,]'FT[
M8^27--! 9A+4*^-5MTT_Q9UKH1<7%_%E5T5*5,Q=(@-8QE%QO6VB RFVIV )
ME<V'O,!XFJ\$8$&H?M2V@!K8O#N]MKJJ5BG_9?2K803']XF//D[:)>)*L)D+
MB.68W<KALFZ,]]<=A^&@ZN):5@>@UM<\IN*$SYOH+W=LO[P%**^NK4DU[!UY
MGA3QG"?I0RDR(K3J=3*I3:1?M82:8.T7%[(NAZS_"Z'GJ6"K$7<FR]4P!&-&
ML_HFOD&:X5B)+W)M4XC8)T?38GKYXHLGUA;T3VD\*YE?,9OV-J$Q$4G_JM,O
MG!,B?8IBW.DYHRXI0*W)ZPP?B:X(,>P2/3L?MC"2&JU3 @_0./^G\2IW_J6\
M]@+]G 1L#_87> &CG^+&VZC:8Q,JJD9W,^!K9PJO\ 8-V06A(HP3OB,^DZ;6
MY/Z=VPRK1N47J?:Q=2MSU]N>8T6E3\%"<(AI[1A7+F*>8E9-8RG'7%6.PPLO
M54^_S!;B9D%R,*6O0*S_LEN3^M[X$ 9:85&ZB?$IJ*H8+4GW6_ZY%/EE\&Y=
M@DC.WN0Q5W!/;'GF_C2]),APL%]-;HI_01U1D ,?=P$+FT.G5&N@(C\KH=%$
M-*G9ER@?$L?.7Z/+</-*0Y9QXU2/Q;&2$=TNWNH?*UT4E%?L/#E1N;P599'P
MQ>6C-'T,DC4W,ZY+Q=&K0O;,:.R$W=C6J\! _\U#!A$F)E^-M*G$TBFUH\NW
M2SL\G2M,=0,KP-V C7Z+8:4X,1W?$;>&[NT]N\K+V.J*ZNA'\=E196KL%HH'
MRM-T+&5C)PJ[W+Y];0MS+!2,6%*@M?7,/T(1TE318<7]/D9MGG%%#BP)7HZH
M%M<X"L.W[[VCI=C\#9PTDV<H7?""A*S)YBO29K\,"96P2T))&&*+";*GZLPC
M#Q[\0KR>#E-<!S[QU7!\1'#'SMI(;/V[X@;,'#S/V6[L"9@G<O>QIY\/.^^?
MRR.1?5G>GYKAEC=-'2*6\/QG@=H!G(!0-9&C"J]?5#NN9U6>R9FUG_ICK(3T
M:>&H>OFG.S.SG &CJW:B)V>LA?CTN'B>=2F&.B]F(4_"E!2.I"KV\N!'PI!7
M/;N8,;97CAVH7Q<K7G-J[3O7LUG"J:>K2L%OO\TQV@G3XHBNJ3;4I[XJL<N)
MT_G!9->G\(<HP.M3X;!*E_Y@38'+HK+=*1-T2[,NX6E 87VV7VL&!AI^9CA6
M11Y<*D"=@":;H?1X-.$CUV QK/"6/7U&H6%*@*M> 6;8RB0$RID>[@(X>R@\
MN=?5A4$^:"H*D[M\;RW$<&0W*-4G!L=8C%3D9T5+!*"5MUS!<^Z!NY>R01^\
M'Z(L:A(.E8#LD&?/UH4+'T'<:+_&O7)@0,LWSQ+-L;]>E[]B:R!AS2Z.%.FN
M@UM"[*WG;"\M3L,ZT=Y-+/VS;C8WNSYL2D;$8"W! EMPH4$KML4K*L4W1CEF
MPW),7O<+!&"3(]:23($0/!W+TRB5:!F1VE0/(^8<QNCJ=5Z%XMX=B/8H#(4W
MH[BZ2"KRB.EK*,J%)%:XY)MB\4H=5W>Q-9_UT[EN+S%#N; 8<K%XVM=6*,QL
M@>4XIWV^_ON[.+G];W$R7Q48)_%]+7;/*</H:;8DCCUA*TVF0HGW1C;G82PM
M"6&SLO&4_J#%YW@RI#C?BYZN,'_"LOS\#&GVJ?P5-;4J#/F>0(.Z:N*K4@&\
MX.6OJX+1;UWI:NAB0;N[BYA5I:2:5*ME$0^:982=\CL9 1+X6\>8F41&P[&X
M7?:R_.F0[YF')C$>TP770SZOX&A4G@6)JIX1D,1!WCQ,M>OQ,I&.UWQBA@R7
MSBF]>%V<[0EUK](>0F]&B12E<!3[W2:U_G)YK$M<N43ON;R 7O7H?8"N/.!9
M#"8:S :E^?0OKLYO*W!MV#*KY*6LN$F1S9Q"_/8>2T$A'!$O**3@ A9K_?PU
M-HJ XEFG44=Z9AK;-I>'54E[6:$1K!*^Y?8Z4%=\@TBD5<J@<Q9FX!ZOWX#P
M\H)I[5H:N):+9P?2?I8Q4U6*DP@:9,[IC=Y$?\4X@[P1,1+)<CR_!Q1?K:5?
M*0/IOY_DV_BVTQ6XQM6Y7KQ51]"E*?9EANO<14=..YWRQCIDB>2PF0-S_93B
M7MBOSYY0;\^48\'A*3DWWG<DC9X,-?=,-ZJ]+L<47TWRO!*HX-\3ERG>?,U/
MGI@R>L"#$ZWP"#M<CF3C3@/]CP*500=+/#^AE=G^0?D8+4V2FG\)J'.S)*HR
MJO?^61=,6Y#[G%?L,_W>TYM:NCH9$FT_GX_:?VU[K5?]X[D'9^.FL&<QU#=[
M4L!#<2TH:VFZY/O=W2KEEV=*^SF_1Z-%CEMIG*9X!;=Q]>&>'P'*0*'OE9/<
MWC:KY[Q&;63(%TT>H?O"2P>E$IF_3I_N71NN&:%RIC!538QCI5?&5FXT;AC?
M&C-3W^Z5AGHX]>H37#9JBF;,F#)U6Z)$U6  "+PL4P9/X5+0NIXT^XT;?C.V
M^D/C&B18!C%(\D;=E*2MZS15>]5-KGH8&@RT\1$K8,?,UMT"R*V'K/<548:<
MP38W/5#GZW+O[:PH)$TD^P KC%E9(6^BA319(QZBWEA3.^2M ,[0GP$KY?4;
MWY=VP(ZL('OL](,QW&<3Z=XJ+YH6++"3J;NKRLEI:SJ=L_2;H"T\H;,$W+^>
MCZGWN@5HU^2A5FKOX-P^AZOG+B)[J_%Q^?MP=O9K22<:K4+=BD>TP6>=ZNAT
M ^M9[D"EW'?N:N>;DB;O:[ [$26>)L(E*M <V5=Z \OB[Y,<-\<B-('DNM,Z
M&VYDGC-Q29RPPE8.]8D$4RTL>D:3C.-^C?U!Z'$(A$"&*T?X!CD"<BU_FW>6
M-#KO?"*57BJ0F;4Y7!7F6Z>V,85!7H4?CJN.N)0^L2)SJ^U"WF6;^#B#@PJ/
MYB37!403"KYS\]SJ\^QYA'J$E54N0G!?/H^/[2//,2ZE^*7V#]5WK>U[UV '
M.4IA=*_1.9F$9*?!T/&UDI'_G%9$S]A](,Y8VTO-L'*%L-%P3R3G%=#BNM0)
MG+_U69FTXR<J:E8/]'/)+UIEVH5QMGX *@FC6\(L'Y=?7=T"^O9<Q,(>K+7>
MT \U(<0G=DKT]:>__[11CXE\N#& XZ ]K-><KR]C)9(ZR60&5>-ID)Y?FBT:
M!K6DL:@_KO+)W<)4^4-984_>_B??COP_-OYRDFBE:M,(YQ:P=*1S"RAQ@ B6
MV!CMF[K.2\TR7CM+N-YY#P#S^Q\JU&'P/YX]6V^%4+&\%+J>]4U;=H>1J!J]
M\?ZN:I#LBP=/^QT,>^?"9_V O/I2\@&22A+523E/9)G4_(?>.=ZEG5)"4Z5@
M)_?D;^JW\I?:XA9,IBC)6?JP\+0BC=D9[D/A'O;,^GW9*I.\?C=^U[4N::8A
MIN:<8*"KX1C'[+WQYY71"W&C7P-VZ$ #3\+H>'6X]1^7@@F6?0Q+#RM^9M:*
M&6%MN25ZNSG( 7C;S*$SN?>MB"#$>0Z:\_NI>9(1U_F^_4]P=)=T5Q\>?MO4
M!((DLL5")D9OU(FA.U5S#_C.@[8].5Z1UKNJZBLS'=G*'Q(HF" %?C;BCE-K
M^$A\^MH'OP58:1&'1<M%\L*&3K*+I(NF:XP+6<!&&0.J>D?G8AKP45N;9;#4
M<7Y?F0H7>0^;:,JU,"P,MUE&7 X_M8)&?0IHQ;'?;2^X[).5;[QNZ9(>N\NZ
ML*F GI5[*D.BE?NWWZ3X7PZ@*2?^LI$='Y[^S7YKV/GI(.G$IB_),".TA59P
M\:+4A=JL!B$$I'I?Z"$V(#Q/%YM<R%J94,S:8U4UM+!>$ES_K!A?=J2'QY9O
M5O90KYND.2OR>2^@M4$9U\\E*6&6*;IUQ8'"R5FP+BH%ZO5KE_7TUZY 4.'Q
MBH@G>Q9B7[;4B6,]S#SS57^U!]?]XG*"PJ_72^K]\TDAD,>290(K]>J=8NW,
M%5WWJ*6[;@$0QEV,DQ*Z%1QFO%GE17-G3:"?_W[&[A\&*1IL2(1T]A&<\S[;
M\W @L:?MC&LRY6CSSJD-)3@AJ)H7"^/3J"P/^*/BY[1<$^^'@HK0:!_R<$+/
M=JV 36<E?%7GG?/D,-))*P@AM]W)S^V2W1UCJ Z5^UJ@*D,7+CUW":&18D?-
M?O])5=:,/3P.NX[,:S'^,^_3J(#ICR>%FA]G8I@7-IE=0ZW9<XRPP"]7#W$%
M/U]'RT 57E8__#9QG^39Z#QT=8+T4UZ^L(!JLED%@\8*8;".(FMFOM]_\H6#
M_VN4JIUSWP+H$SNOG4(NJCQL/>.;(>=7**FM9*/^HB3R*TK::L*S[[<  T*#
M3"C[;\E?__W3H*29_/E=N)=:ORW*+&X!B^ Y6\[!:(6&\"3%@["X-/N%+L-7
MJ6),U8$G@J'BCE&_UU)3#D92($M@I2);%[57&M.#-C:1^>BHEM]^TP>_K\$_
M;WHB;OS1D.OC6\"5#/VDZAU-/> MH#'M%O"]!&*F<G:#J!G?V=*+OZK3JT$9
MG=>]XRZV=N4QH@5JPB_%V@7GV#C\*/Q%)%@AE!MAB_0(#S=)N5.1LH[A-#ZZ
MA W]M%,-R#$9\A:PEW?'+>M?J-'UI)W< IX(?8>MG$/2$L9!YZWO]%+X0*EX
M>SNVDGUZ3(\0W8XD^9\\P_.@?76H8PF35M3K308,Y]L6<B@/0)TF041-8=D)
M5295GG4'(.!W+/M(W0*>ROV5IL9\RM@=QHA,L8;IYMP1BIHP.$?*CMH)4.OE
MEY(#&RO\R:(%C'CH>%7>L&";(DT.2F)Q>M\]$7K;@_]BFW/R-Z^8(,'J&L!!
M/^*?R,)M C2^_E2UE[=P8Z&:<UXG7P4DR.FO'(%83 %)8"M%-F[/BUA9<"GV
MMD!J[K< !='&!$?EXVZPE3BQ I,\[>1!@)\#NMIH._\6L,YY-_W<W1JTJ5['
MTE_C5-X"+C=N >=06BK;.<Q58)E =#E"94;2W)8TYZ\W_(,>#&BZEI>CDF2L
M(&9RMP!I6ZD;#.2&(>(?:/0%1,O^5S/)\1(H4%9JQ?\3!=!TB3"9#X.,_FI!
M69=L4A@\JUO V=V_#DB<GO___/Q_EI^J:;USA(*R7BN";TJ)0]0WE3,'AR3J
M)6%?>C*-USC?/YU 58!RUTI%/6__PG7=3<W]4N%F?)A+:6X@[M'G\FXF^9*5
M\<=OU*$-^S?\D$>R;Q28;X8\GL*S Z=W ")/9&>O0L>3;@'_48@?5I8- E[W
MCCVDSA-;-(Q[>\GM[\@FC#U1EI&T8O]S3U,X&MF.2A1H0(4Y%!ARQ(V/R"/@
MJK(W[B8QD=,$3EW%>DU/-Q+3 D]H)0]*E5N-&G8JTU_-*N[<NY;89\?[JQ;_
MHCZ86FX*YA9@*.M8JEGD/(49[<^L;/IG\8O=U]3Q4/Z_NHMU5;J;41 Z\L_"
M>58"+E,HFEWIGW 7;DH3S6<)X_ZG<4@DTO'_-G["XV^(;:F!^QT9N3K*A08A
MU5^M[#T0O7YG9IV>B%O H\ O+YORP,_T_A=W;QD6=_"EB3:00-#@P2'06) $
M=P@0M'%W$AR:QIT0" 2W  &"->XNW7@(P1VZT<:":^,6(&0S<W?NG?\\=V=G
M9^?9#_OA?/T]]3M5I\Y[3KWUUG+3GAU/B2X-?V^W&[W =8+G;,L?P+\[RIX%
MW?.';TJ&S94EL9K(;5_2FS\ M8>5*9>!11?FIE '^V3E*?/F#0+ 1K,&%W./
MV<DFC<)XDIL095/";U=(T>O\53SLV4,9O)U__S_URHMM@P^VMI^2Z+<W=57Z
M_V*!1_;?OKPZJ@P6V,=&[6NM6O,I3HWF WJPKC5D-WWZ_)>.DLU43P>V^L=5
M\\10N#\_4 3^.S-20?))6*!<//5OA%EN_\\"EJ*6G^__XAWD/S">?SS&Z_C[
MM7_PSQ[CDVH#U+G!HJ^K>YMHUW2:Z%;;)MYVGXHX]^%WA:HWP361%5,*%&N,
M>O\I608)=:[O^.6[LX9=*#M.E_5D/7EG-2?BS[[*1,]* [H3>\2GV[1G6)";
M8*;B^TFE97I3ZG&I4W.+Z(T<$;6IIJ^LXKDY;Y.Y9/$K>J37E9]"E:G++E:I
M'=),:+NO<#<ZDF<=Z KR=2Q%)1+'$K*]:H3$ASI?EN^V^3FR5C?=:P2\Q/:+
M"=1KC57)6?,V-# O=7/Y1+#3:5)_DCUXVRO>(6 R85L*6W)X\BN*B0 J2Q]@
M$.,W.\-.1+K+--G5&!HJFGZW'/"AJ6<#7[C)(9-Z).>)8ZOH'X!QN]@!HGRX
M<5<U@A[LB;?Q [55G&WHN==01)J*UQLV$K04MVF_4M1Z H65^O,[T3B??#_G
M9HU >&CPS9U-4"#-;^;DQ8%P'^%GQ)+5+GT^)3-G"RJTD:,+W9LSH$1JE,;M
ME,.1D<5JM^<3Y_?1M)BR.V$?Y7(,KV01/;6PWT'];(5K60<0^2%X8ZN#;:OP
M[+9Y^\+ R6=<P'3MFND>4WT"8O@(M)!F#;1A6UV&(^O"4A)^'2.%)DW\;OOQ
MERW\(6R?05YS:=0#1\4<ACP3+7OZ@JO4*./YO2D5BAYUB*TO5MM&>FK#DYWS
MPDP8G$A-ZH'G#V#B]A?5N=_+7I]3=>ZV-_N?2[^B4YE>EG7OG%3L])@,(F1@
MP8V;=Y03 F.#=UTK_9Z)[PUE2_W&47-W=*KIO' #,E-5#!Q/:3<E*7&]NINN
M-\TG12@O88$^7V$HA"Y<KOCTNCGH2-,E#)$04)G7F4;_NR9W3BXRZI["OX1Y
MQ0BU!"K%=]A*MF-"VU%+>G^_->0TO]R);TJ'MV>NH.[0YWN5I>BD@2_/ )0#
M9I<UV$T%VW/?;*/TIFO5P\FU3>FZ_PMJS\>QM(I=TSQ54U,,_@:OQMTPV*FE
M9XK]UZ[,=>]$-,!9E; 58 0HF#/=U0U7[)'- T4J9#/VZP-RVU\BX@^ (V3^
M:B+@2'#,I__H"#%3W-X" H,;K@U9#73B23"%)$_X^E4V9X58.=H+2^*>LSJZ
M>++T7+N!!'WAYXH&,T?6?!"W[L!-.FLI]V2I%^JZ/4C34<(O_".N6Z;) W1#
MS%P0AE+V/+1A9)37'9BU#@9*;T[H7W^<K(4EF/S9X_5N(6:U3%PU,%T]%6UK
MCT#AP/NQT165S,WUBY\#8A*<TCMC-PO!9MNN3;%H(>VCG_,)JI5<E7$)A2\T
MGEP<Z ;_D*@,BD1W6;DV_K)P@XPDYZY@B;%,;\2TKA-"A#BL(V@7]]9)F[)X
M22AT6;!H W(#YMIF!-'"]/P[(J26A'2OHXK5+,7;MMKC,/V.^W2S#YNF4S6R
M4N;>>!;V9+92%AGSW6EA$U-[_(S;H1[G6SHU@$BR5BRMP"H'Z'BN?%L,_+4J
M*\*NC>@8%,5/5ZJ4UKFT*V4%DS0@78T*G]J5B;K:YXV#&9R,)&5+4+#X;!6O
M*^&KZU<=5>3*:M]#Y2Z^;\3=(CS*Y]W#&6IO[^+\+@@UC!@<T+[,+GO,6_#?
MZX5B;Z44G2QOE(YVDCD.(=M?LMZTIHRB\O43!+(W7-R'JOTD]0EHA&#9(KY7
M$W;)?8Q?HJ/U,Z* 4+W[>=$QG9:YZJV&3'(5>>ETPL^2U@'*59I( '*[;.7[
MF@+/J.D(5X[T'KIFC4_MZW V0R'3IINBQ#1%<;43R;ZA&XBT+0K][M/QOBJ3
MSH=L PB8$C6]G:FJKO2V(.9%--Z_O)CTU\3I-7O<]N"3C9I^9R-TO+2'7R.O
M0^C\L]I"@L1CPCO$#8UG_N[Y38DWZ0J"[5?!56=WUI)V56"3SH1".@%YS_>-
M?01/>):54ELI]+)WYJ&I4G-1@O"6&2%:AYKPJV*LWE/I55[FFQ79_0 Z(O$Y
M<6]N'U'$MZS@[\'ET ?Z)$G>M@EH\0CF[)V_42P%J?UD0Y)>E6 L6ITM4%2R
M-Q+;@+>"3*Q?A65R3O&!MR&P')V00X5DF#A4[<:!LN"?9>]0+V$9$$(+Z;^%
ME<_SMR:C\SF49.N2/7_-*$PWMC%K%WO;%W=1/%@1XNB"%=HH2X??5DE[+S=E
M8W-EAP,3E <$NPOVU;FG\,4(/H_#SSCZWWSZ_&SI)"# X*IXO6E:L"':,_!1
MK5/:L7,,5!L%&#]J$1V7"IR>V) (AN_Y\J&&6ADGNG88O+X9)7I 5WF5KZUU
M)W3K+<;C'UA>3/08@JJ,_\*2)BVS=$SE92/2"A6,CRPL"2^R XA*610+ILO]
MWFP$5@ ^_>0#QK>BL^W@SAWR)7ML/_!9V])6\$O;DE5"([EUWVKA4-%K5AN%
M]<U";3>KFH61^W^14<9S?4AR_G[>'P ^46$<PQ=/O4,A/.%&.XKF2"%0;"ND
M+RLB?,9V:;@=Y 5("57>B]LNF*NR0EP>W%$9QQF<=SB9G;T6W887G1+&'QI2
MWGYJ^U1^5794D TYIZMP1BV']/,E0"\SRL >H'4PVJ0[DTQR?*\%\[7UY(S"
MV(C>FPT5):6Y^U$WV5T%R,#: O"DYX A(%+'R!2]V4O%F2*=%<68H_=MUO62
M(TVB/8R9RP7+@4HFW(O$KVV8JPP2D1VI!I*I%R!G\(^K'?7,MO?GT7#Q,9 K
MI5'_9O<N\:G3F/55MTW_4ZYQPE8/W;OO]D"B&SH]$1.%R]2B9X:O_-W&L=Z
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M6:XW#0E2*A:]*303]Z\3S^F&<5CSI?TL1U_46-IK.]_FK*!2;M+5FR;1@G\
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MRR)5</0'H)^2$N/-J>KZ8;5<T)VXE+Y][]RR)-+3D2<ULN<.5'3&8YL6&%(
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M-_<'$Z6MF=O[H/)B>Z@2[QG9D/4X6/&X]W;KLL+4;-^7OS?<B$O&?7('58V
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M*,@H>*BH>&P?B3ZR_9<+I . B0 E .T(#44&>(<)!8T)!>D!D ( 4+!0?RN
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MNI(J(R?M!P>L)85"*RJ=5/0;5U^Q2@$BXM]!T*XKE_,%GET00""[<IQ.?LA
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M]A)AG$;[1C,4R6/]O(MAL+@$!%"1#!:I+6@<3I560!RIL_M>8*:X#"IQ>#J
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M6;-AXVP+J!%"6^2D?<]:41@!PK\_X#^6E)TL^Y;G^H,C&>N:<Z3@6URF,JA
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MK"5##_[8$-14+NIHCA,"85HJJ\@JBB@TLMT-NE@/$>]2;_Q])#WHZ78#;2(
MC=#K@MI'--305/GY'\?%2H.0E,(;_7PVR] D/F@AG%$8/Y>U:5!D2)^NMZI7
M3H(JAX=QW)23"%W;NH3&I E!%9LZ2?U.M=T^A_(27LP7T<.9/3,1M_MU]?S
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M+[1E8Q@(=B]_%KI$T9A3GU@=R5&RS>DKEMCB'B#Y639H%.8^XBP1]_&H_'?
M T&95>[A'59-79*BT F+-@=TM,S5-F[&?O./7J-CD;7QQ$?-1G$<]9"?_[(%
MK_U8C1#H\JON.['" :I6L8:%W0IL$]!,Y;P3+'I36'B*JZJVL+5 ]*UP\;!T
M%IOSJTS6+%ZT1>$.KP9UV0>^G5F=HJ=KW5HZ+=TEEN9*HOI\]@F"H-&HO.?&
M+1*CPPST#>N$*=/XE/$,IX(/&U'B'L.8 @[DK4KJUQ_;+[*7..8_?1?)SN'%
M52SS99,0V@_+LT[FL15<"L>/DC578\+7I?_L"DAC@L*_+W^:A1VYR"DT,Y0M
M.I#@'GAQU*VK-H,/Y&PX-TT'59;/_DY936AN^/#BB]9PA,CWK<(+%7]&VZ:(
MXU(QFJWXR4"_I/C6!^WZR\S'68X#AX^&ZN*#@'VK,T%H]>/!DQ9)%PN"9??O
M2_3T&(2(--?$"Q  -JE^1GNDE9:W6-/TV>\ /3_49N\R%PQ>OQ.9J-6&"CVC
M8IV1QZ/$(B^)WS<'GIPXT#$(Y^+."?]85XTX28\O2G3I#6NC$UY0*[.2-6EI
MJ0G]OW]$OZ84U-HN/X:4Y@Z L/L/P]2M]Q.:4B4.#TQ'S=PBP$<*]](&^V#.
M3&><(3QIAP_PR^0WH]\89I'KX&R2U AX/ZI+7=N9R*4(C=I\<(8 ^!8VYA&+
MPL/UUFS9R+_AJ^@?.W*67/()]S_+H"JE2DX[)/R4CFQ5:OH.U_A:0W'BI<J.
M/ZW_8A]-<#&7^-5!/L^%4.('0JBN89S7]C3P!/SN#ZV58R'7GOG5].OL\1,$
M0#=6=_&EWBEF_J"X8*_'@NLTRJ:EIC:L;XI>\[VM$HT:\$ QK)YMX9J=R*)N
MNN) [HT4*&W_XR^K0(<&J5Q!%TJ4?GYX<L$RM)GW<?NN_8AH,F?+#?4F$9?1
M8\4@"[P%G-8&14'?MS6QV[XHMTY>)119E28NQN7FJ(#IYDI7((*+?MR8@;57
M*19[<5+[(1A+.M=@\;W_BZVHAP"[YO3P3,I\.M^L@"D;+73Q!@3 U)YHIJ?9
MN,6M<;!15,'40DUKD+4NH233QSB3%P5/<4%?XD]U9>3KLP44)$E,-,MATV6X
M9RJKV57SP+^E:I)C(_UT," YC $!]$=# -KUW5/V,OP#/6KJTUE5Q4"1*  >
M3HV2@92[W[\]>#BXQJZN0&33.5,$GDC;B/BJ&P.BTV/7]A_O:EI+N!PP;[=Q
MC0S^5)'4DP9VN87="\@YPGZ\;U*+'%GH_\79Q&MR)*[Q1F@4NC-O %,0P 66
MX$6Y8,G0:;X/GW.3_AA+ DG249/.2W0:1[J&K !)JOALW*GQ9Y$C[K)/2:CU
M5LIXVWC]G/6"$7;4%R_JCJ_9^'%3]!K"*&84JH;"Z^G=^8Y1M6?M%V'N;F!?
M'@OP.TDP#JB+<?/\"<HJ\P$A<U-.,>Y(K-J6+WV%Y'[5X9X$><L >\DF":S7
MPI8%GLPXW^]?C;>'AZ\ M@OV2-DSY_U<'MV5='-PMO]-EX3PFTU*4FDFJH'S
M./,B_ $$]O5T +\K^-M^,OMO]$=_J_4'I,Q-A86Q^T9T]JZ&PB8'!<Z9RT<^
M S.&."'MT]+\NA2B1];<F%]XGS3@]W:<XZ710T\_3H@'RCD3Q?3SL;;'$WH4
M?11TCT_DV]CF/#&XB+0TN(&=;K\ "G8E@S%'T<&^3R P-/6#THG%"JY%D,S:
MZ.OQ2S3];(MPP:)U.>.23?[GNGEEXN%=/ZP;$<1![N-3)<FM=![R5N7[;]BZ
MPTA%:EK>FU/R7J1?]EHMP)BKV/_H\"\(O-F@"9)N"  J_H6N-:&BD9ZMVREW
M WP+E@RTOC\L7.OG,.HJ:V$U:E4"*FS&6)\'JK:'<_SY'7\7Q$42$*\_"P$@
MW(5# $+AZ"]P"A=%IS5E/$.BE&5!I6@2G\6QBOIGD*SCY4]3%+CR#WD< Y:6
M<\@5+_HBDNHUV(291/@BOD]2\6"YK^H3Q4O\H27U(G8VD-!OK7%]C^X^5%="
MB!]^@QCE_* 19S7?CL9)W\@HG\Z?X?0Q:4M"%23OYMT>16\ADB?NSH@YF&3R
M=<'FV<QUJ:ZW/5 #R85?FWG+/<?Q!C8$/$)WWWO8I67%ZF;U?Q5WED%U/UF?
MOS@!@KM[<'=WN"'8#>X$MXN[!@(!@EW<W37(Q=T)[DYP=TW0S4S5[O[GF7EV
MIFJK=E_TBW[5Y_?K[G.^=4[WIS-? 71PKP"+JOR>+/+IFR@^U')FV0B?=,_1
M6C!M(^!>Q$7S]A3NPX*]Q*R]I@,MMYRS)$A>)":G(H'B'6/%Y6QGO7^-Y8^.
MYPI/+L-/B/JW>*<M?GT.%R_SZH^AW5J7RTC7%>TT7>0D+5-V8/J9$2!K&WA_
MW"E.'6>]@;?$_J83#558'4NJ]5,4DDE6=J&+5KL03OS)*X FGRPR/Z(417VF
M)?D)8W*3K<*^ROR:3FHLD+LM9L>VW0CY(%W^@>;F%9 =+OZK;,>NDJZS5>&3
ME+/<%A**<+QA B( ;V>'?*H'K-60]*3\84E2H+"CD<.!QY:,7;[#5@#-[C*P
M;V@L%J.9MW^,(A,>8DDR6^7'Q3RKHS'Y)^C0P&-UEU$L>EL^_1Y\6) S3YKM
M5X]Z[_Q^I+IRE,-S2#7X2[R'B-62S5B^GC9OAE[%,G95W26#'!FBP(9'0=,T
M+VHI^95"HL%9G&9CM!V'K%(^QE+KY<V8#_\=>>HK0,SII3[ Y##[>I_B6)NE
M$3]S)L;PV2T@O+Q_TF9,\>*P9H^8+J.!6-_]&@&=: 6FT1B?%M8G@US%^]B7
M\15 I2-^'/[RJ87]1)3[Q7?[V:8?&E69=5[7!4DZDCA6Q$C0"J73RDBZG]XN
MCRED8DOXN-P?P9#7D7 9]*\*/_]-9M$*UH:AJ,DB*E'/%E/"SA)I/E $=<N@
M>:9-0X1S1;<?!M:JCP&.;W/8=$'X\_$O+=YB6_K1(,\']$1;PYJF&(/.^J1+
M!PL@LFVB?8_T@N#M+5FTK#EK.CHAIF0W$M1/!%M]UK"%E ]D-]]ZJ1YG3A,)
MB6D;B_9/G#B'%*P;?-L7#C_7I&M<&I,9'*)3W8T!^6@,<"K*@.[]R<:^D8$?
MAA"$S:7G2,W\W8KS RQM<%J4;$G9QE)4L==JG3$(J^1'??>=Q@QGJ@W7]P03
M8@^<%<Z$7Q*_]7Y4^H$R,?)0 ]57\IK9R:A*_GE__BMS=9B4$UX"H!8Q\;7W
MH3J,)DV/4.OD>\,2/:0A[Q7P,?H7J>8K(-17-*!Z77?"P^ZX:)@HX4=5H8H^
M.H;(+85AXKSD5C7&B,^[$+,( 1.&29[8V._<Y"BEI)$/#Y>&;G8JW^\UMWLV
MBG6OZJP=[$]7/8*?@(5AE6T"R;# DTT%S0TGTI-\))/S9Q\M$,\*7DO:CLY*
M^#Z,>?P(288WSGI;C,%%119.AR9HQKJV@2;A5OIY?C! >KTE"JG_GJ,-_[Y@
M=46A&S]@6TH9,:"-R_OV82&V;+AQK/F&,+(!/:T\Q".JY?P5@+%[3W8 H\X4
M"" $N!?F14Q>_M>5@/P.<E_!B4GKKXB56;XZB[U4$?9C9MSE:&FPB;#P<]M
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M#1^GF7=5?D?OH!'1]Y0X^37ZL=ME'+T8/6ECH!$3<TJJ2I/])@F,/2;\NO"
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MV-BJFI(@FE_&3[1L/+G#E&V09%ANZ@5(B ?28E3J-S:$SK,S(<\+W'/;JPT
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MEDVR0?_-K+M2"1\=^R+@?A/9X1[*T2/,&.!>:Z)7O0-HZ-G'M\YI<%RS^+O
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M,C>MV*_K:]PQ,+JZ#P4AGE;%R^LT4)*!Q>>?MU@T%1T<S01&A%OJZUI;";F
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M8J'$14'#'YP'JJQ#!96O9OD4F$Q+%Q2CB/_!7G=Y0WI2+B?M4,\[VI[;E2:
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MM4+8+S=CD^$>YDB[%F%8[<NXJ6<4PG:B/V&MN!!X@2[1W@."ET"V[-F@*7?
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MQT?++"PNQ"/&Q<O'\Y<0!'0,#&PL;#(<'#*>EU0O>?[3[:D#0(".<(@4@X1
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M(X5K12DGN;X@8UER7(>7[X*O8RUP#Q<+X#N"E.=5]IB:7/#+UY@5&E24+8,
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MT3]\;YMK]E/=KLK86%3*?@KU'(6=@B\UASBJ05*GRK0)#,_I6>TH;M%'4[E
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M?O=M=]Q)'MY1')/L -;Y7: [*2DIR7%"\N\H 3EW]X_62(RI"'&?8<F-LD0
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MV>G+-$KUQJD+]N8R31*+.KW'048"L0B"*&&59H5^\GYRYN3#4M=6R?>Z)"3
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M$3L64+7$%^=9YW?G>/I!:-6=4A/+I R9Z-(^<;61X>]Y>Q:D6C]8+S$G*=O
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M_%S^E.D9_\@5%.K<VW]4.2D:P9^*WT!#LSJ1O9Q2&U2,B+S'U=Z[U5ZD4CO
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MIC1/D/9%O),R]W4?YAVU'4D7\U\/-4O[J'K*SK:R&9HKF% B3#^HJX0"&$O
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M/U*4SS[/D-++MBOB>I-$! JD<<(V[: XE1-D*"#\?=M._VW;:"VP*H=LMG%
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M+4Q)\49/9@1NKV0K'PJ_2EMK]OKZ*AE9Z2L_;5YY%1>6M8C!H-KNL?L4K8[
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MSR%DNJ!B)-Y=M%R K-L7+ PF6 A373[):)ZEJARVK&>$U^M$5:WB5-0EWX7
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M#LN<ZJAN;Y0W'DL6)NJW+^J2A%OVGV>:@2MK"\-RV9-BRG1$U(G (8DU:.,
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M-]I =H4YB"@*TUY525?X1GHX)'W+?[P3CN>6)ELZP$=>Q&^5+&+(>*H89!I
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MXO</0HXC(U["%)B"K!/(CR^8\>SKVN_#T"9>B&5CDC>'.(EG $/C [R=ES7
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M<?TE73B/=#U!0(!'0/Y%%]P3MU\%<! 0J3B0<,55D8T=GE%S^J/@O8[-JNI
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MJM'04H]P('UZ]\VK\XBE2ZE:"_BAB1\Q_I%#C=S8&%MA'4&I-BA;KEH9OY9
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M"8%$2*/%O8Y6<_155VR>L+7/K8];$=ZWNUGEW_+4+ WC9(2S_+L4U'WD._L
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MXLJ>M*K"4I9V"<"./E.":^13X]F(8CF9A/C56AR&I^6,>=EAF$]BHCRA4&+
M((S*%$TI@!UG=%D7N BA3?JY?2[*L]#?07,I[0F;YB&LW>>5I5M/L94\XPE>
M)A%.?J9OD'6C%U%HOPR< I'4)-XD>J>VYEBI;FNA/_G1N"%U?U3&+"ZO*ZR4
M^<O^BRVAVO]5JOL+9D&\&GE0586%UUQTU5Q&\CWP97[B4+'&FG3(]F[A]P>
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M:!88+A@?V=9\$8<4XY/?BLG^_<VOW)Q?97-["#-1'J?K7\K]97/_-RIU>S\
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M(!L>%^9F<P!:QSU:O5<M?U[?JF\YTMU#>&XI5,LG3%*U^0S?)*T-!8\"ICU
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M"7FCCIFWZ35DM]=^H)_466QL6Y0R$]D,_:^F@?4<''5XE&(EY]-RTWWE"%E
M,\/9Q3DP="C[^]BX7;S)7@XCF@U=* ES^0YD97G$TV'U(#]6KO-,D.W _-G?
M=?R;2?*B&-TY=A 7@SG)Y$&_7MA3IN@N]^ZXF2W-@JEO9K4=;L2BB%"!H*1=
M6/QQDO3HW7+DCNH#U;[.5#'@7^7&]$)W8H,O"0>F_1RP:W/?D7N,0JK"2>>_
M1)[]9-G[5YC[3:FQC$)7GMK!:"A<3XA#-BC[BG@/Y1H70VP.<HVG7X!H/ ^W
M_[54\/"@WJIPXTJ)#/+O^0+_!G#0G_\#4$L#!!0    ( 'N*@EJ1;_0T81H
M  H<   ,    ;&]G;U\P,#$N:G!GI7=[.)1KU/>#$"HY)<?9B22A'%(2>V?G
MV.04<IQ*<IC&H4P&PQ0YDRVA",EAA#'.2LS$#(I=<AR'&#,JY\R$\<0<WMG?
MN_?[7=>[WS^^ZWOOYWK^>*Y[/6NMW[U^:]UK\<9YL\!^6TL;2T! 0 "XRG\
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M84OV[%,C[>55DZ4U^^&#0HM4\+@;J_@>T1\VH<ER8JA61](@23!9L^.@T.Q
MBKS%'^->7J!05Y3ET[+ 6)5C$IU'LN;ML4MN'FCF!SC2+,4W\(XR"WI'F;N7
M7RE^YZ3P '\>,.X_J]E%G?1E.3#*YSNI:9C=9KHHU0%[YJ4$.DP&1H7GQWPL
MQOWYOE:WN7KIA/=,R\N*P$8OKUY9"4SYA^H -X9WH$GFQ%6./#]_JF/?\P 9
M'A"(B2=*-E/O,R>#8 <)@FCH$$$;94PR2?B*2R"F'6I,H8\::GM6+R)N^8Z.
M76F:]H1Z+G/,AC8"6TTNY[7@*WO#Y#LQ31D\8'6*[ZDI@TH*F<ATY:2V^^WH
M@294.B3)U(V)I1>3O3%_?E)K&#R.W^A/-M5"1)8M&"LVUV6[C#3;*>EHM5M@
M*H-.%:DV/EJ&#E$=QBJ%%C)!':MNC$)@,3] ]PR)8G#Y(GD8GR8R!!40TDU1
MO#%TX0SC80>M>#^JVOD3852I-[1%,8>5C?58^L-*'3,9=;ICJ-;N"G7:0K-T
MV;PNA"V=Q[IF+O(+__;B ;3,^';[.W2\V )Q3SMT+E,>5=1+YNJ#&<^73%R^
M9Y[K&$(E3NHXDPW@-EBJC;]<351(\1VYLE,G%E^<E9KA,^X2QI<''(P=H3:4
MYY&H\6M^HF18PHP. T^V3S+Q*4>&^,'QWBCGBZ.&8NA3VQESW7[8F9D%C^Z1
MR0NC.R3LJ69_[-22VP%7>7GC%AZ0!VDJ3C-'#$R%]&#J6Y/0CCN"Z"#0O9:]
M#YR;+99'_\I$]F58O)TL2;K">*:J,=)4,(4[>[%A>,/3L<)[V2$;#P?<\>,E
M;2/8M-7;0,Q)?BBV**K]K&A0['F0,:4.U",7-[G>,T56>-B$5M<L>.@EFEJ]
M[&@><2V#1JI4'X9-3>Z=:E:*5GKBMMK2<JN%>#T$@NG\!6V_8PGJ67&RN5)>
M*/\Y7%$6?6=@-RINC39/7I59B8K!)C9+V,O4C['MD6:%RJVQRNW$9M]*K:*U
M56GU$-9KZ8Y&KH3 SFGV57Z2,L[2$K$,JZZ!N8&#; 6P_SGZXBN&#NY#>06.
M?DY\X.)HT_*70?6.5RUQ\X[UK]_4O8XYH^'9CS-?_8 M']TXL!VS5L+]2&RA
MK,HP6^D5\;,097Z&\BN7**/B)1P'K4$[,K_AQ,$(TJ/%-AUNJ6^(4>%\0K@V
M[O=ECXQR0@J<)39I_3UD];M?LF=-^:_FZL39.IB$*9SIS (999@]FQ*%QG1C
M4LAXV_Q<1/R-85QZ6_,,GA%/%R5+'M0HRCAF(YO;-CDUZ45=<-)ZTH]SOS)Q
M7,2N^U4K2S*5VF29M'.%?8F?5PKHB&'I]WJF,*8='<96GT0VJJ<\1ZU9QM.*
MDN8R%$_8/-59:;?!+DF4#_R2L;81:,BQ<?"D>C9R.N?P#S R2#U0F](9DG$@
M=A=3>+X+*L&ZR#2.;\8G2TU:SB@,M[M$TR'*7IZHV!\K?0I([32$9=_E%BE9
MU-HO(0;/)/_4T6-)<LK,Q/@$M3&3!N%O,7M,G6MCWYE)<"K7, &2 B#>KK&E
MH&M&>(B@B8H^G]F]#9TI.?)\>)&)"F1#RE%>@>L]6_*GBB"#R !2/^Z/7\U?
M:BR8Q?]T6X_F<^IV.ZA3SJ52ZWI>[E@L'MBF=GI"A%'?8<GY-[;Y\\OE-Y^H
MSFW6+TP@23JUF]/6>Z]MO,^G\L>*D.F?:THDV1?$LD/O1$?V%6HSAKGBYVAZ
MF:K*G%;B];7):%K$RB93>XZ28"818&:LJCX4J^1A%5U9:.^0O]1'L2OHLYO"
MG<.VCB9LN-T);'#_(%?#J.FZVG</HLC]<\N\42^#.%M%%=J$@)HB]RO19T$X
M;2!)U> UIX36%A/]-A^2VC0_9/3J:N,06W)NVL846F,J'Y67\*+XTO#&[E7$
MYM&--1E/]PE2:9"/FCT>$_3N$_\$;Q%G"VL=W2DTM\SS;XXU5G))X/@)2,!U
M0%U0\I?L[%?9F;-$T=@16$L$6Q;"0G*JV-=VCH'%+"@8N&.*ND,>4ZQXR82X
M#D_U$O<'&T'/DN_F*IJ:0)MKLZH+PHN]]UO(C3W;=BTLA]+MGAJEO<'9]MK:
M!W)*8\79'DPKMEP>2PE\SX=!T!B+E0,E:+WI&P.*(*MK2 MM3,LXOV4)UJO@
MBG"HX=(I:-B1YK(RL2^M3Y 2?NGU-\4%^",*PV%MGR=W&,)PTAOW9^F#*3%5
M_8S#;@QL"E<7U=ME$HR-*9]"D3R&5DVC8X2+\+K%8?"PK[@DTN-!1 BN(LEY
MJ&E-!I6U$?UFK^6FWO/UXDD]5BS([UQW\0 . 3-;%'N6DQ.NP)5;Y'<4[)@J
M]B&P9+8#XD'19>O10_9!:T')W_/MJJ&^3B-']#]/@(O?CS0&>MI"?4FQBA1$
M#6(S3:F@G_J2WQ.50 0P 5!-5A;G*28$,E'P5HN9U$T5.&Z$%P77:<=-,FKS
M:E%Y;[?;X%(%Q?OLPD^&1; DY< W-NUVUFN;GMH%'$F7X0WOFSKFCG4A,BT,
M["J<3U9)3AW&CYA*E>4!-R&RW#X8P /\5**=F)0L)L0M<;['1Y_YK'5;MW%O
M8@'6#KL0598;D9^7T*X)A*R<;L*=M6UD[OW<MOD=BZD(//464EFTCY.%UIA=
MFY3IAC0)8Y.;HPN=R1X9WQO:U,<^Z4UL>EN2O(=K8T>K4Z;7FI(/,<V(1XHK
M++"+ZRG!3=_&-E60Z#.TD:&^[8G?A)[YJS.+YL_Q@&W2)X$+P!WN8<9 $MN[
M)(AP@&F?M&$O@_*'U;\:1E+W@?&V]6/A.KZ7WEBH?$C$E2V=VC*)+?4S];_!
M:OW#;M?+'VTYL]S]L9]@C)#>E5:F$EDQ*94K@MKI,6]T+:TR\/)"P2SKFYD\
M@.09G7+P_;F>+%IAB-.0$4?Z;-R0$#:0H)_V6P-G:#'JP@.I2,F=A1OHNG>T
M.C.7V:O1SA+^"KO#AH\F02[BY;Y_,74D>QEXN/Q0IBKD?"SO: H=U3O?D4.,
M2:BIHL$-F]*K/MU)';QL-PT[U/U9J),=$9\HFH:*UOFX,.1:8NJM<-Q5!7D%
M?5<5Q7_UHS[*UIOUW+T4KJ&A8/6S! SACSP+@0YPP1!^&]F,3V5#:3<B))ZC
M3X*1%2@9EXYT_95 -I0.VX]B38ZZ"]C@5MD&AIEOPB.8JR0N+;8/4D]YFSE.
MHGVA[N4*HQPWO(V=1HH]F>;)R.I%HP%%U(#728GPT787NG;RM7PN''X5$3YU
M\%#3D&&TZZ.]$&A=:N20/=9"*EU8*>K:?M_%'TS0:2VX6/?<*7QMS+G(;4H)
MV2NB^[,+U&' X$\?/3&%X>*1YY6T$Y?""6+V$@]*;>648>T=.-OW4*VC/3:V
M9O*[P'.TUB2D1@I-5:9?OR9\<11KVI];:V 0OJSM\B!L?+(Y:/@!Y<W1P7*+
M_(*<,W:YSLXM\;OC!R]';*BV<]';ZW;W%\ZR5+:Y*(5M%WNC7DN.//OH^@WN
MU@*1!M-8?+&X.(R0'#;'&;*-6LNG6]Y\?GT__:KO</,1D9/W,R^&+;.7L 6:
M6\0+/$#<=,*\8UL/=!!NW^,KI/ID[D=IT/8^D]#3\^8#Q7@CYP_9.]07/"!!
M]5;QS%]&!"> 38#SJ^'5T!,G3/:$K_;2NB__;=CJ'Y5 :W.,Z!>M4!.^2>;
M^OSR9?9_&G'\]IZS-HCINJ?SAZ2#Y(@0!>]QXIRHRNE%%]/_+K *^^WGOI\#
MZ^9/-TN#>$ X<N W"F7Y7W*ZX8LV]Y_-^E.4N<C_V=?YVE]+@^:4W)29]Q]>
MLO]FH_GY6U5D R9Z \8H_><'P//MAG+X;!B%;?\MX.W'4(/EAU&^^$]9&U5%
M?ZOZ&^*O\D>KJK4?"81\BHHY^ER2-_$?4$L#!!0    ( 'N*@EK7I3*1P!,
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MJJ1'A4+B!G%41\J.4;AE02-2)4'HKNMADO'M#<\U@Z']Z"7'4M6:Y!]M@NQ
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MY<5_3NS WI!;)<2_PPI#F]W(BQT_C-/H&,45[ZG<X)?KCF/P39PB6 W#U8Z
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MWO>1!/,#QJ&U]X[.SRG6_IQB+0>9\W.*Y^<4S=QO3'U.\?1E#1$/A=:4L(@
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MXZ^]Z60T[ \'S4&R4Q6Z#-][0;(*\TC_E"=]IRN]_N3F<DAU:#@9-T8DJS:
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MY$F2*VMS][@JXC9Y5RD)B:G5U/A+<+*\TF786:%)('WUJL0@NEX&Y$\/)1L
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M\:GP<I/]B]BX+C-&AZSM\J(Q*(DN2Z+,Y..UU6-^5Q YC)FY]OAIX)ALCS<
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M0R[#"GX_>4_=7CT(S,O-T5]4/7BEAC/&6Z<*,.B+JR!%X_UN:CR)G7)EQC#
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MWROME\JZ99<&;IM3$D% 3%*C4_"GE+RJ_H&H#IHG4$CSH8>I'_R3YH,M:3Z
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MS1&I*""NZ/ I.%.I(*Y3E=3U0YXOQX+BO,JBVE*)J&/:*,%V."/(02*,"IS
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M,6+Y7,RC2>.TFENZ^6WU$I 7.#\4.1U!"3#U*KA6R?'V@H4!G4T&C08@ZEG
M5&TX,$W$5*\05T8-;4_SL_Q8!1"'UV]+O,49/7>PQE^*:_*@WS0S# M=U[,W
M:W.ZDSFC(@@2]D6KFNKEJ-D >J(Y8F43Z!?:"&*MN+Z_?+;99BR1),TF18%)
MUV!)3/+3!CIA5[0S ZYXII8$02PCO"Z39C=W2U1JH(:*CP,)QWM!B&?>%=,L
M2[.;E S?&PU];)3<W\UB,D"\ID6E 8)6UC UE[<(B62(-8..[:!?:$NNG55)
M_KLHV\UDBYJ=WYTF)79AM3(0JQ]!,$2&2)I;2+XX%4*S6S_?>;Z/$L(U75RD
ME'3\[550.RSHBD'B@P*;BAFEN,_8I82B."75^M4Q'61GHAH_0?KLFA-0U:?V
M<.ZI?#2M *0X[")(./[$76B=SUS]#.E3=S"I/G<E-NHGWP;Y$T-[R-\]!\&>
M?W<<%WGUER,!RC_\.LES7.23)WH?T*:[-J@2<D$#/4#*!+F$=S)H80E\8$)
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MJ)WS2%TQ,-118Y.<-RJ3(\LB8:]4V#M=&B7/=%P1Q=S.[^4@VQ/ZM@P8BBB
MB7-U5D$NY^3X^^^__?[[[]_3145.E#^A?_O^^ZOO^?]'.2\P%QR*ES2+_AN'
M?T+O__5?K_[XQ_=7/_S+']C&[OOW?R3_3?[_O_VQ$H_H]5HAW_8]EJ9#08%N
M\0;3HKWHA_=7B'*$"77_^H-WMD["D%4]#^)%$(6SY";81V1<5VV0JZ2=)AWH
M(;=2#N2B8)BLQR>D&]32B!ZT?!<E:,,5O--HB8L@2G X#;*$5@:=;#:'W8$M
MX]_R85SQ!FP479++WI FS\Q:8"AG#562[%()@@G-Q#C3.B#U'>';1?:P)H5*
M?/*YX84D_DISG,W38H4:I*QTPXJ#5 <6XRS1&M<FP">BMZ<]BR";9ZR 8\@B
MW 7.6 5DJSF36MG?5-1DD'IVJM($,Z#V@JN>PY;3E'IZ HR1O #WI)X>6;T,
M4<D? U4&J)G7U0#*. 5,(].$&2](QK$+K/NPK5+PS;0V<!/+N#1HAK4@VK*+
M+Y" 9);ZC@AK+=\<4]P28:D"FFWF>R)4E$O/=$?$Z;R[CTC,&K+RG/P'>G^
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MOU%[1Z\ Q<?U 2N=%9 A-"H5.;4JU7+3Q_O0^H +XY2R(^.T0JH,7JLV:E,
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MWGB,5_J\"$'5.Q45QAB)V-&["!K*,4M(2 5EXW4C2@5(S=K=LPEE96CW>.\
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M<U&-=B@G::W%<_)R\U;RDOSCR$OR'[_>O#WA+"^3*)91_MO'( EX1+ J2$"
MG]\F2?@3/?6=T-L')T]Y06N==%[6:4VY8.T8QE(2G]*.=TZ/ %XH5M%L#M'V
MT+'!*U0U><4H?VP5_5*U>YY1?Q#C68_,<YS?I=F$_F]..NTL)+]$6YIM1-X+
M$R;_7)-G!X6R]/LY'P2@MXSPHBSZT@E/@=[33C>M5S]$]?/8 :/ZB5>H\4S>
M1:O'HO*YZ!?Z9,0>#;&KSA+B7JB/D47L0QN!U,7D!O;I/NT6+J9K2&$/I?VQ
M,?0+;0XVE4\=5J0MP23U20.#I)D+I/=8KKW)<9!.>_T2D9E4D!5OT^29_&V
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MI!$'0R@SQBZEN 8B*D#7(R4FF9R57L4SQ;0N2R</F60FQS5[(/._*5I/_C>
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M<E:*8%C8!ZUQL<T[!V]Q%KV2[O&*#0.XC8+;0[4FX.USM2II,+PR0NR2Z>>
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M8: $M[H7"LK&SC3!_8BS9YPU;F6Z2?,BOX]V$3W;E;+MM1*!;#K12]W9Y'*
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ME'"& 9]>$$5OZF0RWDE3;63.M\;*Q;FJ=+&NR,^([3N-1<=^+:WP=:S&P72
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MW+S0$7263). %KH]?5A0-0AM-- ;WG<0D+?FG?RCF2 <3L"T^CBF5^A&V[*
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M9%*PLC27GA/+RYR#N2UNLN=W%!9!5IPZ$U.5*#G#7$Q=>"&C^0,Y37+.0NH
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M-]^XJ&]%:QTNH_PWZK[O(S*;"Z/B;8V_%->Q+,ZQ5X7UG7KC%N_2.=Y6R%I
MK E$VD!U(^@7V@QB[7CYLG<9&37+DU?T5!:A6!BRPUU5"E]Y<&N1QM%&\YV'
M-@3KJY]HA5!UN=$<^_!5@^W\Q;)-] MO%?GF1)7$]Q$'^2%C"ZA\QS!]HG6+
M>-W4_:%@]?$3NDO'7NB2;N?15=CK((_J>S/>RJBO*E I,N>LCP/&+Q>V"BP\
MIE/NCH^M-F&/#R8Q,WTRJT%Q?#3]3_YL]$0?7L?.;W6 714/]1*#C?Q*;W%9
M@H/*/.[3A.>QT@L;YEN:OJJJ4>8)QU?-[YXOP1GQPR8N=-BSZBT5,I9E1[!5
ME;M\+5T_E6CGV[L#O?:[#CH4H;-9!1;7K/%*UJ<K1?JMN&HS)O,::6?1*S'Y
M%3=61>I>I5QWME.#]?UZ81:CZTJYN9;3/#G@=>N0YU2MJ -AP-8XVPD?328$
MZQ-I$'8_"!=%>2V+2$RP\Q,19+0V%X^Z%]6J-0^QI=,6A2RL3V$&*IM\H'KV
M<5R&YTI^ND4Y_5%]C<[OL+Z ')S0#ZH9GL_W3$:X/<[(_"!AV9UL$>(QQ]M#
M?!]M,:N#H9[)]U&&]84&()?$!JP)/ENO&D&\%42;*>N(^)ZD2Y;5EW7MP%E(
M0$?;B +E=^A4*1QL!>MX'309(W<X+.LK-']H[]38;$2<[^FP2.;#=*MMD6/I
M2!0U8)17D1XS;^@N6#-F"C@6M.%@VK]UMM"\>+./.'O&66-7\2;-Z;VLNXC5
MCVIF* E$[:$+BV;]@7=)PEMH;9'2$J-T'LL:H=6'-\V<+"@[H8.[TP,N%O$A
M[[ZTLWHOQ3-AD<F=P4X\%;W,;4\PB-SV$]4&69(>RF,VBL45B0PLBJ@!"A$N
MET1E*7.?JR4MT+=1OHE3NLJGCFU-"H"_B1JMZ0,=-7T'K<>$@\:.FC%U0I"%
M]97,0'4)%:V-0*_9%?S."55>1?-76.]?!DUUH8;/%WR?!LGD.<-L$T+QFB4R
ML%ZV&J!XI"-(4"WJ]<VO7_ B*'!\%^RB^.W^?J%R.7(Y6%] #U)P-2\8,7'$
MY1%1\/HM)G5AOLDN/21%>RU3\6%LE&!]I1Z(NY_LJ(JX+JJ4RT01K]]OD<9!
M]O$0%]&*1-\%?G[[&.0%SNX.2:C:6#2JP/IV_U]YU[;;.(Y$?X6/TX #;._E
M W+IS :;3H*T&_O0#X%LT8D6BF1(=B[[]<LJDA)EDA*EMLU*]F%F,E95L<A3
MI"BR+L'Z6H>'P,B0\T2S,LG+@#GN(OA:SI_*;2T^JN:OHOOOEV+DH&B);S'L
MIZ<%69BRNWA!CAH&5)'=6K%F%&9,WXE^]3JY#G#0 B=47=L!%OE.D)&UG 0V
MRW>\6I75,]PORV[]^.G[\O>3TD)I4$]KM6L9-$2")>Y4ZDM)L-]P_#$R:0&]
MOPZ-S^! /2)?=MFP[(5CT<(A@/#8'V*,ZY4\?[Q=-0Y$YV61MAYK>5F+<;#,
MZF MT3*V0W?34R!DW3;(L$6/D<D0Y=IH%NPR;US!EKIEY>0GVXZ3D4C.S^WB
M/WRYF9?2:PVZ*Q1JX[3;D34.HUJFLEKQ#!CM96ZOXFD9X4'ZYJGL64L&N%Q;
M2<?"%]E0)Q#>L,:E/ "41FER-PW&27YAC(%1XQ1B-MM:/1C:*;UQ)=&\/.,-
MX;>WG:<A=GBD=FD9Z'$[[4G-KBRP4Z 6(V9;%61XK79R5J3"5A?<9.!O-A$=
MPY;1ZZ>W!>\&L/N_M7K(:9E1D*Z.KRQ,J6!G5""[DS>C /KB[Z<((8;H]!Y,
M2J]FA##$#I$?2#GX.P;0)^-#X!_0@2DI%PFA?YXG=7V[4B4A;JO[[/%I(P?"
MWC+X:6FA.:RH]6H&#L#C5?*PLF(5<"DDXW@7;Q=YMM35.GS'7@XB6FCT:&@=
M=2$IT[11WXQ:B7N>\F>\#[K@];+*UL[\<[W4M/ (4=57,D9\4&DFEK9<<5Y<
MTM< 4M_X8D5M$EI0>/7S^54DZ4N&55EJ>69?0S:>J &02K-3I9BZ2ZA%E_H]
M7+P,)!$:TM:'E^9CFI$)SKC+6K:"_.-/&5]]>^/++83VW:Y60C>?2](@!RW$
M0M6UECB(.8&*5\#)&E:F>*."]IT_;9+U4UEE2[$;K>'B&\\I/(CUD]."*TA7
MV^6^86(M%Q-L03#]1G&5.PR'Y5<%G#;N>O%U=CUNPJ,5,NE5U(A!<U#1,I ^
M%>VH,J1EFCANB'GU/2F>RZ>D0,<P#P).*EH(]*EHQ8M73!,K?[BHIUO+)YYN
M<UE<;9T4[]<\J<TP^($0S9'\M&";IKRUDU%2Q'N0*3D,!3%#DHK5;&1% ?MV
MS2%#8?&(ZD$Z3)F'),F;,KCWB:L>9"@C+7A':KV+:\/.<N2'*P<M@"VT!,CY
M&.ED2G2H?.;SY*V;P:;Y685NGO&"K[*-4043\M5DOB18>Y%*RQ#VV:5=*Y%"
MV"9YVTW:D[5/5- J6\@6.H5$"Z.-*&9TH>Y:Q$#(H+ONO.D[U0YGI640H_6V
MD[ZH^RE 5P4+EMWU(OK!M=5)3]+C850]C,0Q[=<Z!%%_VF8:@%YF;SR5?PZ#
M:! 3!\[6- 2L%7"I_Z$!S[G.$(YN9ES(>1)&:&1C1=-,T0$A ,!1XHA#/*4O
M(4:P;.6"9Q,*QEF;&CEPN2$[MJ48KQJ\@[M=_:QE['N?0?BYR.(^J'(OO&;L
MO;QU+%=L6ZM _5B[[PJ_"V!36:60"J/94-Y5Y4M6NV[!@KAH@3A&9<?N6/+B
MYAB8P>_*V!FOM8 X5S/- 0#X,> (G.9Y^0K.D9=E=<,WULH5?!XR42(M[/?5
MG;XSDT8R:T0S(9L)X:Q9!(1X)N43R7HE%)(I9,&4,1D.]N&."P@*2+)NF<8@
M!RWH0]6UXGPEGY[D><,)3CZ*-<ID_Q/NYR\J_CI8%M5+20NA(35WD4%ZE@H&
M1\E2<IYU-_P5G]3S5[O\3"@C+<!&:CW:<:X0R.+CFFU>X]2AZ743G0*IS?DA
M,/6J/=X9E@"J<*VQW?!*?*/]*%>;5Z&7Y[+.2TD+M2$U'8$)2(_).#7'D6[2
MW>Z-C@O@7<)CWZ0/^6&ZJ&B919^*OIMT$JZ8,L.BV#%#\)CV/X0CS\$,A,&<
MM) :J[8G)27D[\,@N$8$GA:-R^;W&U/\&E(2WJ[.A0+9YD: +#.?NGKL)3W:
M-!]0MDT=Y::C94#]2EHII( :+&6)]*P PY <!S,-,[^5LP==@N.9@4LQ=]XP
M8I [5'/F"DLT$:4MM(JT>1:?TU@*3D9G[M1![\=F;Y)IX;KO;DT(6-*--$&K
M=DWYG*QEZ1B^ YC6!-$?PK:F]VM*,.3'L*Y.;_NV!VXZ6KCW*]G_U@C>'1QT
MGK?USMV3M7U.:^3=RKFG3=6011GG?]W_\^[Z^MSSO=MY2FN,7:KMCC#0,$$4
MZ[MV6Y\\)LGZ03D,V(N)D^#AKP_Y(C_:2'?T5B/<KY>58Q.I9DS111UD_^B2
M&]:!\62_+O@JV>8;=@W<L6S7<'KH,6";BM!P]RAG?R0WI+'MV?#AO2Z+1Z@6
M![Z\KC#80!9"D(1J:A]BMU['R, 4QXRU.YQ(@+D=<-_=V\A@)D*@A>OJCT-
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M2EW+8JPX%VY7WY*J$ L_1!;B1/!O<O8BF)!9[+<_UK>/(9VUXIF6+TN(&RU
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M^Q3X\_L@\K3Z_4DS**-=N-]*Z$/A\YT7_D&WFV2^XQ6_">%^G?BP_@ W+.
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M<VJ8('VAB#58T\82,3A'T,$KTV:C&EC$.#L#CIKB*];T3(I1]4@/.,3.&4K
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MI3\G-+X/#5(/Z ;&H7XGJI''D0TA*+B,":$?:;3=" L, !%M!S 6];L?+;
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ML30"9EQ((R@J>.02C/L_]M<;1F#9 W/Z]W/@KOPES!B11L3B3)Z[)#ZI$5-
MP4.G7SP_X)7"1O21Z660U_A,O++] &:@2"/"4HW#%]>V$_(2K4CX]3Q:IXIV
MJH:,EG?;F,TP+E=W^?G;]]\7]>EA>_8XZ;5&]ZV[QVE_V)M.S]>;*Q4KG\_Y
M^V"Y= *-^KRO#JWI@U/Y>\_Z+HGGU!>IU>UP<>?%?CQ:CG-0ZQ9H-EB5L; T
M:P @IVOP#!I=66Y=\D*":,.OZ._BA%W6^;4]9M,?^']N_07;4&0+L%1>J=O[
MU!N,Q@^]X>S==-;^V&M-^M-_3%OM8;<UZ/_SL=_MSWZKM":3EU4H1/3]A^_>
M"S&=??HX_/WX]1P%<@(T2Y /56FD2@M31<KQLU/I9W7+3%!@,0#6VJK,Z=,5
M9TNN*\MLNEVO/;H;+:?^*A0QF.QD+^TSLJ7V8W&I31\?'MJ3W_AA-^U_'/;O
M^YWV<-9J=SJCQ^&L/_S8&H\&_4Z_=SL#SWG]0H<3X-R#]K^VL\Z.+_@+;W\V
M=Z+U4U9V0;;*2BG?>SVRU1D]W/69?MD?#7'6DX0"MMEQ!Q]#@.UXJ5W=O,9L
MQ\'5/7.S/.)BH6^:^B.ONVJ@*O1.&*_PUV+/HV&T3<0S-M*S[B_%5=AK3X:C
MQUEK^DM[4O$\,^J/)[,"ZXJ*7G7JA2>?@"T"WL_<S0T=4,OWO+X'Y0.^@(]I
MM"$TX8[U'EO$0D4=DD0FZC\717T\&8U[D]EOXLK48S<F<9GZWZUA;X9S[NR)
MX6]*)7F*S$<-H"O.Z:*<F-498S<*\DD#AK%PN%1A%?X*9#HIW9)%[Y4_H4;X
MK7"4/!,Z\-/WON5WK _?EIY\[70FCSVV#O\U[@VGO=2.,9K]TINT!OWV77_0
MGZ'=K\;>CAMR.6V"6B\ 7+"TG9 >=DRO#W$VM?W,R"('EM6RK#P@]@HU UI\
M*O(\UN$OTRYYDIV*']Z7[8IW2,<?G^)Q*N85IFJ/L[A.9P-8/,H.R(M##T-A
M71BHQI?[ ?%B^1%4*JPTZ+6G35UYTFF [SK%YC@B/6+JB,>M3>ET1LL!N_I&
MU$K*;<9PXY8DAZH@]_:LP5\*:12H\ "P\ZL3"4,B"15F\ ^E$,K.Z.&A/^-W
MI%0[ZXR$\;LWQ+-\:TBR.4DLA\%9C:!) E:D[3C(QU$EB NKM1KK\%?L-&'3
M>?=4?*-:MEI+ 1K3V:CSCW=W[$CC*_6!WZH03>K'J8V6>5(F).!![ITH3F)A
M;GK*/;8-N&6=.RZ2K@B==?[I<8@/[.R!L77/6L2DJ*/6PVU'MH/G*& 0Q%VR
M].>^]$I7"A416\$OHT&W-YG^YW_\Y</[G_[&KGGW_4X?Z:;'+5O:*)&L8;$=
MDF,ZQ_9T1L,H(59GKL40R"M0#DW1)6W+$?RU,R3)((KC,:%BJ<O632GN8]B;
MM0:CZ;0U[DU2AQC2<O%HR!26P^0!"T?9 V<)%><#6#*:+MA+Q !'8;$8:<=?
M'/V0_4AFWJO\)EBNSC]D&F6O-6O_"^OB=YBQS35/VPEG84BF!%@;^E[(RP,
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M$UE>4UGA+8-VOK;X$!O:SD3WA="G*"9N!"&U%_^SS8H#'1P%@"NWO-NU!77
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M>)B0@+NG5!9:C1%#-09V1!\8>7O&O DYR-'(B1LM][;B7IBP30]@MB_PSWI
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M,C$M,2YH=&U02P$"% ,4    " ![BH):#)/(MH0"   :#   "@
M    @ $%2   97@R,RTQ+FAT;5!+ 0(4 Q0    ( 'N*@EH/[;J[N@<  #,Q
M   *              "  ;%*  !E>#,Q+3$N:'1M4$L! A0#%     @ >XJ"
M6BMN_IN;!P  @BT   H              ( !DU(  &5X,S$M,BYH=&U02P$"
M% ,4    " ![BH):54\Q%B0$  !3%@  "@              @ %66@  97@S
M,BTQ+FAT;5!+ 0(4 Q0    ( 'N*@EJN4U \(00  * 6   *
M  "  :)>  !E>#,R+3(N:'1M4$L! A0#%     @ >XJ"6FR,*Y9M10  5AD"
M  D              ( !ZV(  &5X-"TS+FAT;5!+ 0(4 Q0    ( 'N*@EHC
M"\$KY*H# (4@'0 ,              "  7^H  !F;W)M,3 M:RYH=&U02P$"
M% ,4    " ![BH):O@ 301+7  !)  $ $               @ &-4P0 9F]R
M;3$P+6M?,# R+FIP9U!+ 0(4 Q0    ( 'N*@EJV!4')6DD  -A.   0
M          "  <TJ!0!F;W)M,3 M:U\P,#,N:G!G4$L! A0#%     @ >XJ"
M6L@I)$ XB   @)(  !               ( !570% &9O<FTQ,"UK7S P-"YJ
M<&=02P$"% ,4    " ![BH):ZE1_Z\"A  "BK   $               @ &[
M_ 4 9F]R;3$P+6M?,# U+FIP9U!+ 0(4 Q0    ( 'N*@EJ+N0RWH L! )]%
M 0 0              "  :F>!@!F;W)M,3 M:U\P,#8N:G!G4$L! A0#%
M  @ >XJ"6M"M=MH:;    '<  !               ( !=ZH' &9O<FTQ,"UK
M7S P-RYJ<&=02P$"% ,4    " ![BH):/H>DBX\C  #M*P  $
M    @ &_%@@ 9F]R;3$P+6M?,# X+FIP9U!+ 0(4 Q0    ( 'N*@EH?$>8F
M?J,  #_<   0              "  7PZ" !F;W)M,3 M:U\P,#DN:G!G4$L!
M A0#%     @ >XJ"6C[V>" A4   #V   !               ( !*-X( &9O
M<FTQ,"UK7S Q,"YJ<&=02P$"% ,4    " ![BH):D6_T-&$:   *'   #
M            @ %W+@D ;&]G;U\P,#$N:G!G4$L! A0#%     @ >XJ"6M>E
M,I' $P  ILT  !$              ( ! DD) '1V9VXM,C R-#$R,S$N>'-D
M4$L! A0#%     @ >XJ"6BQO>L$T&   D"8! !4              ( !\5P)
M '1V9VXM,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( 'N*@EI<R>$?5$0
M %)Y!  5              "  5AU"0!T=F=N+3(P,C0Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    " ![BH):W(BH[E:"  !*60< %0              @ '?N0D
M='9G;BTR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ >XJ"6E.?@;<W8
M:D@& !4              ( !:#P* '1V9VXM,C R-#$R,S%?<')E+GAM;%!+
4!08     &  8 *P%  #2G H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:TVGN="http://tevogen.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tvgn-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:TevogenBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SemperParatusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">TVGN:ProbabilityOfFutureLiquidityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-14_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:TevogenBioCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ComputerAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ComputerAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">TVGN:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">TVGN:AdditionalAmountPurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:PolarMultiStrategyMasterFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">TVGN:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:ServiceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PerformanceBasedRSUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">TVGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-21</startDate>
            <endDate>2024-08-21</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:ThePatelFamilyLLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-21</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">TVGN:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SemperParatusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember69680781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember69680796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">TVGN:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember69680906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">TVGN:SponsorAdvisoryServicesFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">TVGN:WifeOfChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">TVGN:PerformanceBasedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:MehtaphoricConsultingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:DrManmohanPatelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">TVGN:KRHPLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-02-28_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-02_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001860871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Segment">
        <measure>TVGN:Segment</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001860871</dei:EntityCentralIndexKey>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0288"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0310"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0312"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0324"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0326"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0476"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0492"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:CashAcquiredInConnectionWithReverseRecapitalization
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:RepurchaseOfSeriesBPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-02-14_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0974"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0976"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0978"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0980"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0982"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0984"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0986"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0988"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0990"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl0992"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1002"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      id="xdx2ixbrl1004"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1018"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1020"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1030"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1032"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1038"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="xdx2ixbrl1040"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl1176"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockRepurchase
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1179"
      unitRef="USD"
      xsi:nil="true"/>
    <TVGN:StockRepurchase
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl1182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl1185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl1188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      id="xdx2ixbrl1199"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1202"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl1204"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_EarnoutSharesMember"
      id="xdx2ixbrl1208"
      unitRef="Shares"
      xsi:nil="true"/>
    <TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1226"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1239"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1242"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1244"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1247"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1248"
      unitRef="Pure"
      xsi:nil="true"/>
    <TVGN:DeferredTaxAssetsFixedAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1298"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000018">001-39269</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000019">Tevogen Bio Holdings Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">98-1597194</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000022">15     Independence Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000023">Suite #410</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000024">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000025">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">(877)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000028">838-6434</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000029">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember"
      id="Fact000030">Warrants,     each exercisable for one share of Common Stock for $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000031">TVGN</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember"
      id="Fact000032">TVGNW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember"
      id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-12-31" id="Fact000042">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000045">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="-5"
      id="Fact000046"
      unitRef="USD">21400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-21"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">183893433</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000048">Portions
of the registrant&#x2019;s Definitive Proxy Statement relating to the registrant&#x2019;s 2025 Annual Meeting of Stockholders are incorporated
by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the
Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2024.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Program&lt;/b&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
security and availability of our information systems and the protection of the information we collect, create, process, and store are
important to our business. We have implemented a cybersecurity program that is designed to support both the effectiveness of our systems
and our preparedness for information security risks. This program includes a number of safeguards, such as: multi-factor authentication;
monitoring internal and cloud-based systems for threats; email filters; cybersecurity awareness training; limitation on the use of third-party
devices; conditional access rules; and regular evaluations of our cybersecurity program.&lt;/span&gt;&lt;/p&gt;

&#160;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_i01_dbT_c20240101__20241231_zAHdpa5PWZpk"&gt;We
use a risk-based approach with respect to our use and oversight of third-party service providers and vendors, tailoring processes according
to the nature and sensitivity of the data accessed, processed, or stored by such third-party service provider. We use numerous means
to assess cyber risks related to our third-party service providers, including for example use of a managed security service provider
(&#x201c;MSSP&#x201d;) that monitors cybersecurity events for our cloud systems. We also seek to include appropriate security terms in
our contracts where applicable as part of our oversight of third-party service providers.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000060">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Governance&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Management
Oversight&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
controls and processes employed to assess, identify,&#160;and manage material risks from cybersecurity threats are implemented and overseen
by &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_i01_dbT_c20240101__20241231_z2qwTKXXXNql"&gt;our Chief Information Officer (&#x201c;CIO&#x201d;). Our CIO has more than 20 years of information technology experience, including
seven years specializing in cybersecurity. Our CIO is responsible for assessing the impact of cybersecurity threats and incidents, assessing
whether and to what extent they can be contained and mitigated, containing and mitigating them, remediating incidents, and performing
post-incident analysis and program enhancements. In the event of a significant cybersecurity incident, our CIO would engage senior management
to inform them of the incident and related threats and response. We would also likely engage a third-party incident response vendor to
assist us in the event of a significant cybersecurity incident. Our Chief Executive Officer directly oversees our CIO and receives information
on cybersecurity risks from our CIO. Our CIO, in turn, is informed about risks from cybersecurity threats through dashboards, email alerts,
reporting from the MSSP, and regular review of our systems and information technology environment&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Board
Oversight&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Board has overall responsibility for risk oversight, the Board delegated to the audit committee the responsibility for assisting
the Board with oversight and monitoring of matters relating to our risk assessment, risk management, and risk mitigation policies and
programs, including matters related to privacy, information technology,&#160;and cybersecurity, and for reviewing and discussing with
management our risk exposures related to these matters. In its oversight role, the Board is expected to specifically consider risks that
relate to our reputation and the general industry in which we operate, including with respect to privacy, information technology and
cybersecurity,&#160;and threats to technology infrastructure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
CIO may report to and brief the Board and the audit committee on cybersecurity matters, including key risks, the potential impact of
those exposures on our business, financial results, operations, and reputation, as well as the programs and steps implemented by management
to monitor and mitigate risks&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt; The reporting cadence and structure continues to develop.&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-01-01to2024-12-31" id="Fact000061">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000065">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Risks&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cybersecurity risk management processes are integrated into our overall approach to risk management. Given the nature and size of our
Company, we do not have a dedicated enterprise risk function, but our executives regularly consider and evaluate risks to our Company.
As part of that risk management process, members of our executive team identify, assess,&#160;and evaluate risks impacting our operations,
including those risks related to cybersecurity, and raise them for discussion with other executives, and where it is determined to be
appropriate, issues are also raised to the Board for consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.75pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this Annual Report, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_dbT_c20240101__20241231_zgQ8dgrVqXk6"&gt;we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zkXZL3j403Tc"&gt;no&lt;/span&gt;t aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity
incidents, that have materially affected our business strategy, results of operations,&#160;or financial condition or are reasonably
likely to have such a material effect&lt;/span&gt;. While we have implemented a cybersecurity program, the techniques used to infiltrate information
technology systems continue to evolve. Accordingly, we may not be able to timely detect threats or anticipate and implement security
measures adequate to prevent cybersecurity incidents or fully mitigate their impact. For additional information regarding risks relating
to privacy and cybersecurity, see &#x201c;Item 1A&#x2014;Risk Factors&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000066">we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zkXZL3j403Tc"&gt;no&lt;/span&gt;t aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity
incidents, that have materially affected our business strategy, results of operations,&#160;or financial condition or are reasonably
likely to have such a material effect</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000067">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000069">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000071">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000073">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000075">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000076">185</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000077">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of Tevogen Bio Holdings Inc. and subsidiaries (the Company) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#x2019; deficit, and cash flows for the
years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000078">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000079">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">1282995</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">1052397</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">919088</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">670582</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000093"
      unitRef="USD">158819</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">2360902</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">1722979</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">296442</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">458651</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">228490</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">469862</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">2582870</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">575841</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">271141</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">3461675</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">5505503</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">5200245</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">3418378</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">1712396</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">1096450</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">229063</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">252714</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">1651000</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">80712000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000135"
      unitRef="USD">250000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">9042704</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">85479542</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">14220000</us-gaap:ConvertibleLongTermNotesPayable>
    <TVGN:LoanAgreementNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">1000000</TVGN:LoanAgreementNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">5796</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">234858</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">87180</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">10135680</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">99934400</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000170"
      unitRef="USD">2076712</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000159"
      unitRef="USD">2799990</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000175"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">600</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000183"
      unitRef="USD">6082603</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000172"
      unitRef="USD">6000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000185"
      unitRef="USD">6000000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000191"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">119999989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">119999989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">17800</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">97893322</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">5216840</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-113385117</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-99657737</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-6674005</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">3461675</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">5505503</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">31033276</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">4403526</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">22531212</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">4439499</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">53564488</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">8843025</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-53564488</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-8843025</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">184037</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">1206352</us-gaap:InterestExpense>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">7499353</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">58180</us-gaap:FairValueAdjustmentOfWarrants>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">48468678</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">-50428303</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">890000</TVGN:LossOnIssuanceOfCommitmentShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-10273695</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-10273695</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-60477680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-60477680</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000260"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000262"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000264"
      unitRef="USDPShares">-2.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000266"
      unitRef="USDPShares">-2.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">146672534</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">146672534</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">24752000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">24752000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-39180057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-33951217</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000305"
      unitRef="USD">-99657737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">119999989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">5216840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-99657737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-94428897</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">2799990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">2799990</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <TVGN:StockIssuedDuringPeriodSharesNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">600</TVGN:StockIssuedDuringPeriodSharesNewIssuesTwo>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">6000000</TVGN:StockIssuedDuringPeriodValueNewIssuesTwo>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">6000000</TVGN:StockIssuedDuringPeriodValueNewIssuesTwo>
    <TVGN:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">3613</TVGN:StockIssuedDuringPeriodSharesNewIssuesOne>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">10337419</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">1034</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">46621593</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">46622627</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000380"
      unitRef="Shares">14778056</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-1478</TVGN:MergerNetOfRedemptionsAndTransactionCosts>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">2885459</TVGN:MergerNetOfRedemptionsAndTransactionCosts>
    <TVGN:MergerNetOfRedemptionsAndTransactionCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">2883981</TVGN:MergerNetOfRedemptionsAndTransactionCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">19348954</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">1935</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">-1935</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000400"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">676485</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">676500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">1000000</TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithLoanAgreement>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000405"
      unitRef="USD">100</TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">889900</TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement>
    <TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">890000</TVGN:StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithLoanAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000420"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000415"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000416"
      unitRef="USD">-150</us-gaap:StockIssuedDuringPeriodValueOther>
    <TVGN:StockIssuedDuringPeriodSharesContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000430"
      unitRef="Shares">-3613</TVGN:StockIssuedDuringPeriodSharesContributionFromRelatedParty>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">-3613000</TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty>
    <TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueContributionFromRelatedParty>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">3000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">3000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000448"
      unitRef="Shares">10876947</TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000443"
      unitRef="USD">1088</TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits>
    <TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">-1088</TVGN:StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">40764136</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">40764136</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000464"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">2799990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000478"
      unitRef="Shares">600</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000468"
      unitRef="USD">6000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000480"
      unitRef="Shares">177991365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">17800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">97893322</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">-113385117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-6674005</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">2799990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">600</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000484"
      unitRef="USD">6000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000496"
      unitRef="Shares">177991365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">17800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">97893322</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000487"
      unitRef="USD">-113385117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-6674005</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">162209</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">163300</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">40764136</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000513"
      unitRef="USD">187575</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000514"
      unitRef="USD">1206697</us-gaap:PaidInKindInterest>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">7099353</us-gaap:NoncashMergerRelatedCosts>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">48468678</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:ChangeInFairValueOfConvertiblePromissoryNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000520"
      unitRef="USD">-50428303</TVGN:ChangeInFairValueOfConvertiblePromissoryNotes>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">799990</TVGN:LossOnPreferredStockIssuance>
    <TVGN:LossOnIssuanceOfCommitmentShares
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">890000</TVGN:LossOnIssuanceOfCommitmentShares>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">58180</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">241372</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000532"
      unitRef="USD">215057</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">246005</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">317605</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">511011</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">-323742</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">1685692</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">1114261</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">-681450</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">-603832</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">-252713</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">-223361</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">-11998730</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">-8171118</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">133000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <TVGN:CashAcquiredInConnectionWithReverseRecapitalization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">229328</TVGN:CashAcquiredInConnectionWithReverseRecapitalization>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">6000000</TVGN:ProceedsFromIssuanceOfSeriesCPreferredStock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000576"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">3000000</TVGN:NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000583"
      unitRef="USD">127750</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000586"
      unitRef="USD">4000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">12229328</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">3872250</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000591"
      unitRef="USD">230598</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000592"
      unitRef="USD">-4431868</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">1052397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000595"
      unitRef="USD">5484265</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000597"
      unitRef="USD">1282995</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000598"
      unitRef="USD">1052397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000604"
      unitRef="USD">2455120</TVGN:ReverseRecapitalizationTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">46622627</us-gaap:DebtConversionOriginalDebtAmount1>
    <TVGN:RepurchaseOfSeriesBPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000609"
      unitRef="USD">3613000</TVGN:RepurchaseOfSeriesBPreferredStock>
    <us-gaap:StockIssued1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000612"
      unitRef="USD">3113309</us-gaap:StockIssued1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000615">&lt;p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCNaGI6GbMM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82B_zN9tcoyn3jBc"&gt;NATURE OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tevogen
Bio Holdings Inc., a Delaware corporation (the &#x201c;Company&#x201d;), is a clinical-stage specialty immunotherapy company harnessing
the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases,
cancers, and other disorders. The Company&#x2019;s precision T cell technology, ExacTcell, is a set of processes and methodologies to
develop, enrich, and expand single human leukocyte antigen-restricted CTL therapies with proactively selected, precisely defined targets.
The Company has completed a Phase 1 proof-of-concept trial for the first clinical product of ExacTcell, TVGN 489, for the treatment of
ambulatory, high-risk adult COVID-19 patients, and has other product candidates in its pipeline.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024 (the &#x201c;Closing Date&#x201d;), pursuant to the Agreement and Plan of Merger dated June 28, 2023 (the &#x201c;Merger
Agreement&#x201d;) by and among Semper Paratus Acquisition Corporation (&#x201c;Semper Paratus&#x201d;), Semper Merger Sub, Inc., a wholly
owned subsidiary of Semper Paratus (&#x201c;Merger Sub&#x201d;), SSVK Associates, LLC (the &#x201c;Sponsor&#x201d;), Tevogen Bio Inc (n/k/a
Tevogen Bio Inc.) (&#x201c;Tevogen Bio&#x201d;), and Dr. Ryan Saadi, in his capacity as seller representative, Merger Sub merged with and
into Tevogen Bio, with Tevogen Bio being the surviving entity and a wholly owned subsidiary of Semper Paratus (the &#x201c;Merger&#x201d;
and together with the other transactions contemplated by the Merger Agreement, the &#x201c;Business Combination&#x201d;) and Semper Paratus
was renamed Tevogen Bio Holdings Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the closing of the Business Combination (the &#x201c;Closing&#x201d;), the then-outstanding shares of common stock of Tevogen
Bio, were converted into shares of the common stock of the Company at an exchange ratio of approximately&#160;&lt;span id="xdx_909_ecustom--BusinessCombinationSharesExchangeRatio_iI_c20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9kQzOCdLY6" title="Share exchange ratio"&gt;4.85&lt;/span&gt;&#160;shares of Company
common stock for each share of Tevogen Bio common stock (the &#x201c;Exchange Ratio&#x201d;). See Note 4 for more information on the Business
Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 4, the Merger was accounted for as a reverse recapitalization under which the historical financial statements of the
Company prior to the Merger are those of Tevogen Bio. All information related to the common stock of Tevogen Bio prior to the Closing
and presented in the consolidated financial statements and notes thereto has been retroactively adjusted to reflect the Exchange Ratio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Merger, the former equity holders and holders of convertible promissory notes of Tevogen Bio held&#160;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_z8YaQSRt0PL" title="Equity holders percentage"&gt;91.0&lt;/span&gt;% of the outstanding shares
of common stock of the Company and the former shareholders, creditors, and other contractual counterparties of Semper Paratus held&#160;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SemperParatusMember_zS1x4Q5pwyxe" title="Equity ownership percentage"&gt;9.0&lt;/span&gt;%
of the Company.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <TVGN:BusinessCombinationSharesExchangeRatio
      contextRef="AsOf2024-02-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000617"
      unitRef="Pure">4.85</TVGN:BusinessCombinationSharesExchangeRatio>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_TevogenBioMember"
      decimals="INF"
      id="Fact000619"
      unitRef="Pure">0.910</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_SemperParatusMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Pure">0.090</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <TVGN:DevelopmentStageRisksAndLiquidityTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000623">&lt;p id="xdx_80E_ecustom--DevelopmentStageRisksAndLiquidityTextBlock_zSEL1kYFLT55" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_825_zdaGSlgqJht8"&gt;DEVELOPMENT-STAGE RISKS AND LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has generally incurred losses and negative cash flows from operations since inception. The Company anticipates incurring
additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in
development. Management believes that cash of $&lt;span id="xdx_901_eus-gaap--Cash_iI_c20241231_zGHO8recjvFj" title="Cash"&gt;1,282,995&lt;/span&gt;
as of December 31, 2024, the amounts available under the Loan Agreement entered into in June 2024 (as defined in Note 8), and the
commitment for an $&lt;span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zaK1MocjrLd5" title="Grant received"&gt;8,000,000&lt;/span&gt; grant from KRHP LLC, a New Jersey limited liability company (&#x201c;KRHP&#x201d;), will allow the
Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these
consolidated financial statements. Subsequent to December 31, 2024, the Company received a grant of $&lt;span id="xdx_907_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziCgx2cNVqQ6" title="Grant received"&gt;2,000,000&lt;/span&gt;
from KRHP and drew $&lt;span id="xdx_90C_ecustom--GrantDrewFromRelatedParty_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUKBhXmPDXii" title="Grant drew from related party"&gt;1,000,000&lt;/span&gt;
in each of February 2025 and in March 2025 under the Loan Agreement. The grant funding may not be used for repayment of existing
debt obligations and does not include any requirement to repay the investor or to issue equity in consideration of the funding. KRHP
has committed to provide an additional $&lt;span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_ztrY5a1rcjvc" title="Grant received"&gt;8,000,000&lt;/span&gt; of grant funding to the Company to be used towards the Company&#x2019;s ongoing
operational expenses. The grant funding will be used to satisfy the Company&#x2019;s obligations as they come due through March 31,
2026. The Company does not plan to initiate a clinical trial until additional funding is received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly evaluates different strategies to obtain funding for operations for subsequent periods. These strategies may include but are
not limited to private placements of securities, licensing and/or marketing arrangements, partnerships with other pharmaceutical or biotechnology
companies, and public offerings of securities. The Company may not be able to obtain financing on acceptable terms and the Company may
not be able to enter into strategic alliances or other arrangements on favorable terms. The terms of any financing may adversely affect
the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain sufficient funding, the Company could
be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization
efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operations
since inception have consisted primarily of organizing the Company, securing financing, developing licensed technologies, performing
research, conducting pre-clinical studies and a clinical trial, and pursuing and completing the Business Combination. The Company is
subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
The Company&#x2019;s research and development projects may not be successful, products developed may not obtain necessary regulatory approval,
and any approved product may not be commercially viable. In addition, the Company operates in an environment of rapid technological change
and is largely dependent on the services of its employees and consultants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</TVGN:DevelopmentStageRisksAndLiquidityTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000625"
      unitRef="USD">1282995</us-gaap:Cash>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000627"
      unitRef="USD">8000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000629"
      unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <TVGN:GrantDrewFromRelatedParty
      contextRef="From2025-01-012025-03-31_custom_LoanAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">1000000</TVGN:GrantDrewFromRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000633"
      unitRef="USD">8000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000635">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zFtpcnRqHCDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_82D_zIoAw2Lo0PA"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z6zGIDk7hIo2"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z9OsFUUKNFM7"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
areas that require management&#x2019;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjZOTYXrYvW1"&gt;Freestanding
and Embedded Common Stock Purchase Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity-linked
purchase options issued in connection with the Company&#x2019;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;&lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity&#160;&lt;/i&gt;(&#x201c;ASC
815&#x201d;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#x2019;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#x2018;Change in
fair value of written call option derivative liabilities&#x2019; within the consolidated statements of operations and consolidated statements
of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zBYIf29m4TMl"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zqy1DxfGgale"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in &lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zCdpbsx6vrej" title="Number of operating segments"&gt;one&lt;/span&gt; segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zTyoPxhDqOEb"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#x2019;s initial public offering
(the &#x201c;IPO&#x201d;) in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity &lt;/i&gt;(&#x201c;ASC
815&#x201d;) and ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#160;(&#x201c;ASC 480&#x201d;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#x2019;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zPsHFdIWiME8"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unadjusted
    quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s convertible promissory
notes.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zLwMSvweVTPg" style="display: none"&gt;SCHEDULE OF FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"&gt;39,297,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"&gt;4,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"&gt;1,206,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;50,428,303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"&gt;94,932,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"&gt;159,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Derecognition upon conversion of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;(46,622,627&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between levels during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (&lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z545EdZ4cnwb" title="Volatility"&gt;80&lt;/span&gt;%), discount rate (&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zECVEqwfbOp5" title="Volatility"&gt;35&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_zzwuKcFjoQk4" title="Volatility"&gt;36&lt;/span&gt;%), and probability of a future liquidity event (&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zEjMN6sa3IMj" title="Volatility"&gt;85&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_zbUb1Yp6ohjb" title="Convertible promissory notes measurement input"&gt;95&lt;/span&gt;%). The Company
used its stock price on the Closing Date to determine the fair value for the  derecognition of the convertible promissory notes
upon conversion on the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuQ5OVhtN1ue"&gt;58,180&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#x2019;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgANSzrkc1n5"&gt;375,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zKxxJeSEy77b" style="display: none"&gt;SCHEDULE OF FAIR VALUES OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;warrant liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Written call option&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;derivative liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at February 15, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0687"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;375,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;58,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(375,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;87,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zMdNzDoPK375" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets &lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs &lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Unobservable &lt;br/&gt; Inputs (Level 3)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;87,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#x201c;MCS&#x201d;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;&lt;span id="xdx_908_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zo9yBcrmtNi7" title="Stock, measurement input"&gt;75&lt;/span&gt;% to&#160;&lt;span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi" title="Alternative investment, measurement input"&gt;85&lt;/span&gt;%, a holding
period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;&lt;span id="xdx_907_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zNKj7Fj8NTb3" title="Holding period"&gt;0.5&lt;/span&gt;&#160;to&#160;&lt;span id="xdx_905_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_z7eHCVkhCn6" title="Range in years"&gt;10.0&lt;/span&gt;&#160;years,
and a risk-free interest rate between&#160;&lt;span id="xdx_903_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ztGJw2vPfY57" title="Risk-free interest rate percentage"&gt;4.3&lt;/span&gt;% and&#160;&lt;span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z0dBlZtpCM79" title="Stock, measurement input"&gt;5.3&lt;/span&gt;%. The difference between the cash received of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsEMs6S6rOn8" title="Cash received upon issuance of preferred stock"&gt;2,000,000&lt;/span&gt;&#160;upon issuance
of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used a MCS valuation methodology to determine the fair value of the freestanding $&lt;span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zu2sTFTPziLj" title="Free standing purchase options"&gt;14,000,000&lt;/span&gt;&#160;purchase option and remaining
embedded $&lt;span id="xdx_90C_ecustom--EmbeddedOptions_c20240101__20241231_zc8eFNvcHCu5" title="Embedded options"&gt;30,000,000&lt;/span&gt;&#160;purchase option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the
Company&#x2019;s future stock price to estimate if and when the Trailing VWAP (as defined below) will reach $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zV3ZldBNhFwg"&gt;10.00&lt;/span&gt;&#160;per share, and
discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;&lt;span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7"&gt;78.3&lt;/span&gt;% and discount rate of&#160;&lt;span id="xdx_90B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zXlSz5FcJLKh"&gt;4.3&lt;/span&gt;%. At December 31, 2024, the MCS produced
a fair value of $&lt;span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zbJgzA6FSiy6" title="Fair value"&gt;0&lt;/span&gt; relating to these freestanding and embedded options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zfPQfeKGxXZ1"&gt;Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were &lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_ziFSTW2Sk4gi" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zTSLrHP6qI37" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zoqVO2hfbssd"&gt;Property
and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zJYD2SpYrHLa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z4mqZGMPTzPj"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
with an initial term of &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zlzIGLkluEAc" title="Leases initial term"&gt;12 months&lt;/span&gt; or less and without a purchase option that the Company is reasonably certain of exercising are not
included within the lease ROU assets and lease liabilities on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z51STCTlamK2"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#x2019; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zN8KNyRNRiS1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#x2019;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#x2019; &lt;i&gt;Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zldsYnnmPWEb"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC
740&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_znCeJn71YSG1"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#x2019;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOYer4WwVUw5"&gt;Recently
Issued Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity &lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07,&#160;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;&lt;/i&gt;(&#x201c;ASU
2023-07&#x201d;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#x201c;CODM&#x201d;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) &lt;/i&gt;(&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_853_znCRnm9LZro" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000637">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zEjozw92zT9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z6zGIDk7hIo2"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000639">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zh4v7xeUIyE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z9OsFUUKNFM7"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of
expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions
are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
areas that require management&#x2019;s estimates include the fair value of the common stock and convertible promissory notes prior to
the Merger, the fair value of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock, fair value of the
purchase options under the Loan Agreement, stock-based compensation assumptions, and accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <TVGN:FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000641">&lt;p id="xdx_84C_ecustom--FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock_zU1Yg00Ynoqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjZOTYXrYvW1"&gt;Freestanding
and Embedded Common Stock Purchase Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity-linked
purchase options issued in connection with the Company&#x2019;s debt agreements are assessed to determine whether they are freestanding
or embedded with the host instrument under ASC 815,&#160;&lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity&#160;&lt;/i&gt;(&#x201c;ASC
815&#x201d;). Each type of purchase option is then assessed for equity or liability classification under ASC 815. The Company&#x2019;s
embedded and freestanding purchase options were determined to be liability-classified derivative instruments and are measured at fair
value both on the date of issuance and at each subsequent balance sheet date, with changes in fair value recorded to &#x2018;Change in
fair value of written call option derivative liabilities&#x2019; within the consolidated statements of operations and consolidated statements
of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</TVGN:FreestandingAndEmbeddedCommonStockOptionsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000643">&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zaVX69hJqaGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zBYIf29m4TMl"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company
maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced
any losses in such accounts and believes it is not exposed to significant risk on its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000645">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGavjTbsGjld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zqy1DxfGgale"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which discrete financial information is both available and regularly reviewed by
its chief operating decision maker or decision-making group. The Company views its operations and manages its business in &lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zCdpbsx6vrej" title="Number of operating segments"&gt;one&lt;/span&gt; segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000647"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000649">&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zD1xmE1CP1Z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zTyoPxhDqOEb"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the result of the Merger, the Company accounts for its warrants originally sold as part of Semper Paratus&#x2019;s initial public offering
(the &#x201c;IPO&#x201d;) in accordance with ASC 815, &lt;i&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity &lt;/i&gt;(&#x201c;ASC
815&#x201d;) and ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#160;(&#x201c;ASC 480&#x201d;). The assessment considers whether
the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480 and meet all of the conditions
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own shares of common stock,
among other conditions. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance
and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes
in the estimated fair value of the warrants are recognized as a non-cash loss on the consolidated statements of operations. Under these
standards, the Company&#x2019;s private placement warrants sold at the time of the IPO do not meet the criteria for equity classification
and must be recorded as liabilities while the public warrants sold in connection with the IPO do meet the criteria for equity classification
and must be recorded as equity.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000651">&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrhlYragtHG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zPsHFdIWiME8"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or
paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs
and minimize the use of unobservable inputs to the extent possible. When considering market participant assumptions in fair value measurements,
the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following
levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.5in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unadjusted
    quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than Level 1 prices, such as quoted prices for similar, but not identical, assets or liabilities in active markets;
    quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data available and which require the Company to develop its own assumptions that market
    participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments recognized at historical amounts in the balance sheets consist of accounts payable and notes payable. The Company believes
that the carrying value of accounts payable and notes payable approximates their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s recurring fair value measurements consist of the convertible promissory notes prior to the Merger, for which the Company
elected the fair value option to reduce accounting complexity, and private warrants after the Merger. Such fair value measurements are
Level 3 inputs. The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s convertible promissory
notes.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zLwMSvweVTPg" style="display: none"&gt;SCHEDULE OF FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"&gt;39,297,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"&gt;4,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"&gt;1,206,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;50,428,303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"&gt;94,932,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"&gt;159,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Derecognition upon conversion of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;(46,622,627&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqcgjNCAyIG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between levels during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used the probability weighted expected return method valuation methodology to determine the fair value of the convertible promissory
notes prior to the Merger. Significant assumptions and ranges used in determining the fair value of convertible promissory notes prior
to the Merger include volatility (&lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z545EdZ4cnwb" title="Volatility"&gt;80&lt;/span&gt;%), discount rate (&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MinimumMember_zECVEqwfbOp5" title="Volatility"&gt;35&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__srt--RangeAxis__srt--MaximumMember_zzwuKcFjoQk4" title="Volatility"&gt;36&lt;/span&gt;%), and probability of a future liquidity event (&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MinimumMember_zEjMN6sa3IMj" title="Volatility"&gt;85&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__custom--ProbabilityOfFutureLiquidityMember__srt--RangeAxis__srt--MaximumMember_zbUb1Yp6ohjb" title="Convertible promissory notes measurement input"&gt;95&lt;/span&gt;%). The Company
used its stock price on the Closing Date to determine the fair value for the  derecognition of the convertible promissory notes
upon conversion on the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing, the Company acquired private warrants, the fair value of which increased by $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuQ5OVhtN1ue"&gt;58,180&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the Closing Date and December 31, 2024 primarily due to changes in the market value of the Company&#x2019;s common shares. In June 2024,
the Company issued written call options in connection with the Loan Agreement, the fair value of which decreased by $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgANSzrkc1n5"&gt;375,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;between
the issuance and December 31, 2024. Such fair value measurements are Level 3 inputs. The following table provides a roll-forward of the
aggregate fair values of the warrants and the written call option derivative liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zKxxJeSEy77b" style="display: none"&gt;SCHEDULE OF FAIR VALUES OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;warrant liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Written call option&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;derivative liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at February 15, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0687"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;375,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;58,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(375,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;87,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zoiLz4vJKfVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zMdNzDoPK375" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets &lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs &lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Unobservable &lt;br/&gt; Inputs (Level 3)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;87,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zfdgPue2UFzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s nonrecurring fair value measurements consist of Series A Preferred Stock. Such fair value measurements are Level 3 inputs.
The Company determined the fair value of Series A Preferred Stock using a Monte Carlo Simulation (&#x201c;MCS&#x201d;). Key inputs utilized
in the MCS to estimate fair value of Series A Preferred Stock included a range of volatility between&#160;&lt;span id="xdx_908_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zo9yBcrmtNi7" title="Stock, measurement input"&gt;75&lt;/span&gt;% to&#160;&lt;span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zY07bkVh1tTi" title="Alternative investment, measurement input"&gt;85&lt;/span&gt;%, a holding
period to a deemed liquidation event, as defined in the Series A Preferred Stock agreement, ranging from&#160;&lt;span id="xdx_907_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zNKj7Fj8NTb3" title="Holding period"&gt;0.5&lt;/span&gt;&#160;to&#160;&lt;span id="xdx_905_ecustom--EquitySecuritiesTerm_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_z7eHCVkhCn6" title="Range in years"&gt;10.0&lt;/span&gt;&#160;years,
and a risk-free interest rate between&#160;&lt;span id="xdx_903_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_ztGJw2vPfY57" title="Risk-free interest rate percentage"&gt;4.3&lt;/span&gt;% and&#160;&lt;span id="xdx_90E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z0dBlZtpCM79" title="Stock, measurement input"&gt;5.3&lt;/span&gt;%. The difference between the cash received of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsEMs6S6rOn8" title="Cash received upon issuance of preferred stock"&gt;2,000,000&lt;/span&gt;&#160;upon issuance
of the Series A Preferred Stock and its estimated fair value was recognized as general and administrative expense on the consolidated
statements of operations during the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used a MCS valuation methodology to determine the fair value of the freestanding $&lt;span id="xdx_905_ecustom--FreeStandingPurchaseOptions_c20240101__20241231_zu2sTFTPziLj" title="Free standing purchase options"&gt;14,000,000&lt;/span&gt;&#160;purchase option and remaining
embedded $&lt;span id="xdx_90C_ecustom--EmbeddedOptions_c20240101__20241231_zc8eFNvcHCu5" title="Embedded options"&gt;30,000,000&lt;/span&gt;&#160;purchase option associated with the Loan Agreement as of December 31, 2024. The MCS methodology simulates the
Company&#x2019;s future stock price to estimate if and when the Trailing VWAP (as defined below) will reach $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_uUSDPShares_c20241231_zV3ZldBNhFwg"&gt;10.00&lt;/span&gt;&#160;per share, and
discounts the resulting payoff back to each valuation date using a present value factor. Significant assumptions used in determining
the fair value of these options include volatility of&#160;&lt;span id="xdx_905_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zO4ZtR8xaGD7"&gt;78.3&lt;/span&gt;% and discount rate of&#160;&lt;span id="xdx_90B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zXlSz5FcJLKh"&gt;4.3&lt;/span&gt;%. At December 31, 2024, the MCS produced
a fair value of $&lt;span id="xdx_900_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231_zbJgzA6FSiy6" title="Fair value"&gt;0&lt;/span&gt; relating to these freestanding and embedded options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000653">&lt;p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zvQIcfKfBw7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zLwMSvweVTPg" style="display: none"&gt;SCHEDULE OF FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-weight: bold"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmPdTyoWTo8e" style="width: 16%; text-align: right" title="Fair value beginning balance"&gt;39,297,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn2RHV15r6Be" style="text-align: right" title="Initial fair value at issuance"&gt;4,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPFQwSUZCOQj" style="text-align: right" title="Accrued interest expense"&gt;1,206,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNzncNEjVShd" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;50,428,303&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4rCEr5QVgp4" style="text-align: right" title="Fair value beginning balance"&gt;94,932,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zt6aGeiPKPWa" style="text-align: right" title="Accrued interest expense"&gt;159,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyjBGFf91vbi" style="text-align: right" title="Change in fair value"&gt;(48,468,678&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Derecognition upon conversion of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5YwVfhmAdXj" style="border-bottom: Black 1pt solid; text-align: right" title="Derecognition upon conversion of convertible promissory notes"&gt;(46,622,627&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2ME1DbWt72e" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000655"
      unitRef="USD">39297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000657"
      unitRef="USD">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000659"
      unitRef="USD">1206697</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000661"
      unitRef="USD">50428303</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000663"
      unitRef="USD">94932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000665"
      unitRef="USD">159305</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccruedInterest>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000667"
      unitRef="USD">-48468678</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000669"
      unitRef="USD">-46622627</TVGN:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionUponConversionOfNotePayable>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Pure">80</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000675"
      unitRef="Pure">35</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000677"
      unitRef="Pure">36</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000679"
      unitRef="Pure">85</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_ProbabilityOfFutureLiquidityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Pure">95</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000682"
      unitRef="USD">-58180</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000683"
      unitRef="USD">-375000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000685">&lt;p id="xdx_89E_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zVFlWWOtgvBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zKxxJeSEy77b" style="display: none"&gt;SCHEDULE OF FAIR VALUES OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;warrant liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Written call option&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;derivative liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Balance at February 15, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBI9UhFXWzg" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0687"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesNoncurrent_iS_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zNojA057WR65" style="text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Initial fair value at issuance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziWiAcw0clR" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DerivativeLiabilitiesFairValueIssuance_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zh8O4BbAP9Vc" style="width: 16%; text-align: right" title="Initial fair value at issuance"&gt;375,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQUdk6IQWDg1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;58,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zhTcXjj4WLil" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(375,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYQcoChW2m" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;87,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iE_c20240215__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--CallOptionMember_zfSJPgabLkfk" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative warrant liabilities, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <TVGN:DerivativeLiabilitiesFairValueIssuance
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000691"
      unitRef="USD">29000</TVGN:DerivativeLiabilitiesFairValueIssuance>
    <TVGN:DerivativeLiabilitiesFairValueIssuance
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      decimals="0"
      id="Fact000693"
      unitRef="USD">375000</TVGN:DerivativeLiabilitiesFairValueIssuance>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000695"
      unitRef="USD">58180</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-152024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CallOptionMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">-375000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000699"
      unitRef="USD">87180</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000703">&lt;p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zUKPgDAmlig6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zMdNzDoPK375" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets &lt;br/&gt; (Level 1)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs &lt;br/&gt; (Level 2)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Unobservable &lt;br/&gt; Inputs (Level 3)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTFE3aAAK2o2" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zI5XpHzeno74" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zT3vY3M4tuw6" style="width: 10%; text-align: right" title="Derivative warrant liabilities"&gt;87,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000709"
      unitRef="USD">87180</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000711"
      unitRef="Pure">75</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000713"
      unitRef="Pure">85</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <TVGN:EquitySecuritiesTerm
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember"
      id="Fact000715">P0Y6M</TVGN:EquitySecuritiesTerm>
    <TVGN:EquitySecuritiesTerm
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember"
      id="Fact000717">P10Y</TVGN:EquitySecuritiesTerm>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Pure">4.3</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000721"
      unitRef="Pure">5.3</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000723"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:FreeStandingPurchaseOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">14000000</TVGN:FreeStandingPurchaseOptions>
    <TVGN:EmbeddedOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">30000000</TVGN:EmbeddedOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000728"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Pure">78.3</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputDiscountRateMember"
      decimals="INF"
      id="Fact000730"
      unitRef="Pure">4.3</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000732"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000734">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zDD1mMrYTiic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zfPQfeKGxXZ1"&gt;Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid financial instruments with a maturity date of 90 days or less when purchased to be cash equivalents.
There were &lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20241231_ziFSTW2Sk4gi" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_do_c20231231_zTSLrHP6qI37" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2024 and 2023 as all amounts consisted of bank deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000740">&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zdqI5jkunLD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zoqVO2hfbssd"&gt;Property
and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zJYD2SpYrHLa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zl5Ugxi1eSE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the carrying value of property and equipment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its eventual use and disposition. Based on
this assessment, management has determined that there was no impairment during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000742">&lt;p id="xdx_893_ecustom--PropertyAndEquipmentUsefulLifeTableTextBlock_zHN0wr1ikGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment is recorded at cost. Depreciation and amortization is provided using straight-line methods over their respective estimated
useful lives. Repairs and maintenance, which do not extend the useful lives of the related assets, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zJYD2SpYrHLa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT USEFUL LIFE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zSmCnJVquYwk" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zLgmtUmLGPcb" title="Property, plant and equipment, useful life"&gt;3&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_z9cacl6O2Qdk" title="Property, plant and equipment, useful life"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z7NZyDGS80ge" title="Property, plant and equipment, useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmZvLGW66Mf4" title="Property, plant and equipment, useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TVGN:PropertyAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000744">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      id="Fact000746">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      id="Fact000748">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      id="Fact000750">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000752">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000754">&lt;p id="xdx_84A_eus-gaap--LesseeLeasesPolicyTextBlock_zfKTy2QrYHCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_z4mqZGMPTzPj"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases
with a term greater than one year will be recognized on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets, current lease liabilities,
and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably
certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values
of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such,
the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized
basis, over similar terms, amounts equal to the lease payments in a similar economic environment. If significant events, changes in circumstances,
or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure
the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line
basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
with an initial term of &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20241231_zlzIGLkluEAc" title="Leases initial term"&gt;12 months&lt;/span&gt; or less and without a purchase option that the Company is reasonably certain of exercising are not
included within the lease ROU assets and lease liabilities on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2024-12-31" id="Fact000756">P12M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000758">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIdxFuVgTZNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z51STCTlamK2"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development activities are expensed as incurred. Costs for clinical trials and manufacturing activities are recognized based on an
evaluation of our vendors&#x2019; progress towards completion of specific tasks, using data such as participant enrollment, clinical site
activations, or information provided to us by vendors regarding their actual costs incurred. Payments for these activities are based
on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed.
The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers
as to the progress or state of completion of studies, or the services completed. The Company estimates accrued expenses as of each balance
sheet date based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid
expense and amortized over the service period as the services are provided.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000760">&lt;p id="xdx_840_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlWE40LQEnBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zN8KNyRNRiS1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost is measured at the grant date fair value of the award and is recognized over the vesting period of the award. The Company uses the
straight-line method to record compensation expense of awards with service-based vesting conditions. The Company accounts for forfeitures
of awards as they occur rather than applying an estimated forfeiture rate to stock-based compensation expense. The Company recognizes
compensation expense for awards with performance conditions when it is probable that the condition will be met, and the award will vest.
Prior to the Merger, the Company estimated the fair value of the Company&#x2019;s common stock on the date of grant in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#x2019; &lt;i&gt;Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000762">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zoWCJBw0vlYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zldsYnnmPWEb"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC
740&#x201d;), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities
are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted
tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies. At December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary
for its net deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000764">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zPrUSe34nzZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_znCeJn71YSG1"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes basic net loss per share by dividing net loss by the weighted-average common stock outstanding during the period. Given
the Company&#x2019;s net loss, basic and diluted net loss per share for the years ended December 31, 2024 and 2023 are the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000766">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zWIqaAo2igS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOYer4WwVUw5"&gt;Recently
Issued Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815 -40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s
Own Equity &lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for convertible instruments by reducing the number of accounting
models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments and requires the use of the if-converted method. Effective January 1, 2024, the Company adopted
ASU 2020-06 and that adoption did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07,&#160;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#160;&lt;/i&gt;(&#x201c;ASU
2023-07&#x201d;). ASU 2023-07 enhances reportable segment disclosures by requiring disclosures such as significant segment expenses. The
main provisions of this update require companies to disclose, on an annual and interim basis, significant segment expenses, segment profit
and loss, and other segments items that are regularly provided to the chief operating decision maker (&#x201c;CODM&#x201d;). This update
also requires companies to disclose the title and position of the CODM and to explain how the CODM uses the reported segment measures
in assessing segment performance and deciding how to allocate resources. The update also requires companies with a single reportable
segment to provide all required segment reporting disclosures. This new standard is effective for fiscal years beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this standard on January 1,
2024 for annual reporting and interim periods beginning in 2025. See Note 16 for additional disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures,
(Subtopic 220-40) &lt;/i&gt;(&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 improves disclosures regarding the types of expenses included in commonly
presented expense captions, including disaggregating the amounts of employee compensation, depreciation and amortization included within
each income statement expense caption. This standard is effective for fiscal years beginning after December 15, 2026, and interim periods
within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the standard on its consolidated
financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000768">&lt;p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_zqNIOxtWAU41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4.&#160;&lt;span id="xdx_82A_zDbQ2iMDygAd"&gt;BUSINESS COMBINATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company completed the Business Combination described in Note 1. The Merger was accounted for as a reverse recapitalization
under GAAP because Tevogen Bio was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including
that following the Merger, former Tevogen Bio (i) equity holders and holders of convertible promissory notes owned approximately&#160;&lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TevogenBioMember_zjhGpEZDB0vh" title="Ownership percentage"&gt;91.0&lt;/span&gt;%
of the Company, (ii) directors constituted the majority (six of seven) of the directors of the Company, and (iii) management held all
key positions of management of the Company. Accordingly, the Merger was treated as the equivalent of Tevogen Bio issuing stock to acquire
the net assets of Semper Paratus. As a result of the Merger, the net liabilities of Semper Paratus were recorded at their acquisition-date
fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Tevogen Bio.
Immediately after the Merger, there were&#160;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20240214_z753sBkvdcH" title="Common stock, shares outstanding"&gt;164,614,418&lt;/span&gt;&#160;shares of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the net liabilities acquired in the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BF_zCTQj89vyov1" style="display: none"&gt;SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February&#160;14,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;229,328&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from Sponsor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses and other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,269,126&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total net liabilities acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,654,653&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Plus: Merger transaction costs limited to cash acquired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(229,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net liabilities acquired plus transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,883,981&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zqlUY39z45fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
transaction costs of $&lt;span id="xdx_908_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240214__20240214_zP1fDqF5q1kd" title="Transaction costs"&gt;7,728,681&lt;/span&gt;&#160;were incurred in relation to the Business Combination through the Closing Date, of which $&lt;span id="xdx_909_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20240214_zDfqsdo3iXNk" title="Transaction costs charged to equity"&gt;229,328&lt;/span&gt;&#160;were
charged directly to equity to the extent of the cash received from the Business Combination, with the balance of $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_c20240101__20241231_zgddjwounOZ2" title="Merger transaction costs"&gt;7,499,353&lt;/span&gt;&#160;charged
to Merger transaction costs for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Former
holders of Tevogen Bio common stock and the Sponsor are eligible to receive up to an aggregate of&#160;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240214__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zEzmDjBmWlb6" title="Earnout shares issuable"&gt;24,500,000&lt;/span&gt;&#160;shares of common
stock (&#x201c;Earnout Shares&#x201d;) if the volume-weighted average price (the &#x201c;VWAP&#x201d;) of the Company&#x2019;s common stock
reaches specified threshold levels during the three-year period commencing on the Closing Date. Refer to Note 5, Earnout Shares, for
further details of the earnout arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Merger, the Company issued Series B Preferred Stock to the Sponsor in return for the Sponsor assuming $&lt;span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_c20240214__20240214_zjD7fdFKOdr" title="Issuance of Series B preferred stock"&gt;3,613,000&lt;/span&gt;&#160;of
liabilities and obligations (&#x201c;Assumed Liabilities&#x201d;) of Semper Paratus and Tevogen Bio. The issuance date fair value of the
Series B Preferred Stock was recorded to Merger transaction costs within the consolidated statements of operations. All of the issued
Series B Preferred Stock was repurchased by the Company during the three months ended June 30, 2024 in exchange for the Sponsor being
released from their obligation to repay the Assumed Liabilities. See Note 12 for additional information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_TevogenBioMember"
      decimals="INF"
      id="Fact000770"
      unitRef="Pure">0.910</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-02-14"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">164614418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000774">&lt;p id="xdx_892_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zJzX1OzWkW2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the net liabilities acquired in the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BF_zCTQj89vyov1" style="display: none"&gt;SCHEDULE
OF NET LIABILITIES ACQUIRED IN MERGER&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240214_zbcnrScvqKR1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February&#160;14,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_maBCRIAzgn3_z9Io3A3mnHy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;229,328&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_maBCRIAzgn3_z0mQ6Jgtmb0h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from Sponsor&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_maBCRIAzgn3_zl4ektKvznGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses and other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_di_msBCRIAzgn3_zQnadgn4rRHk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,175&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iNI_di_msBCRIAzgn3_zY1HfC6433le" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,269,126&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iNI_di_msBCRIAzgn3_zZRAK9OX6HM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iNI_di_msBCRIAzgn3_zPRMCGucTFN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_mtBCRIAzgn3_maBCRIAzidu_ztgwK4PBMIHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total net liabilities acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,654,653&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--MergerTransactionCostsLimitedToCashAcquired_iI_maBCRIAzidu_z4zGz7PO8Sa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Plus: Merger transaction costs limited to cash acquired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(229,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts_iTI_mtBCRIAzidu_z3Z0rZNtOiEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net liabilities acquired plus transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,883,981&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000776"
      unitRef="USD">229328</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000778"
      unitRef="USD">158819</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000780"
      unitRef="USD">2501</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000782"
      unitRef="USD">96175</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000784"
      unitRef="USD">1269126</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000786"
      unitRef="USD">1651000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000788"
      unitRef="USD">29000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000790"
      unitRef="USD">-2654653</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <TVGN:MergerTransactionCostsLimitedToCashAcquired
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000792"
      unitRef="USD">-229328</TVGN:MergerTransactionCostsLimitedToCashAcquired>
    <TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000794"
      unitRef="USD">-2883981</TVGN:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-02-142024-02-14"
      decimals="0"
      id="Fact000796"
      unitRef="USD">7728681</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="AsOf2024-02-14"
      decimals="0"
      id="Fact000798"
      unitRef="USD">229328</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000800"
      unitRef="USD">7499353</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-02-14_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000802"
      unitRef="Shares">24500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <TVGN:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-02-142024-02-14"
      decimals="0"
      id="Fact000804"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueNewIssuesOne>
    <TVGN:EarnoutSharesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000806">&lt;p id="xdx_806_ecustom--EarnoutSharesDisclosureTextBlock_zagX6b1RQoS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5.&#160;&lt;span id="xdx_82B_znlZKg6laZk7"&gt;EARNOUT SHARES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Closing, former holders of Tevogen Bio common stock may receive up to&#160;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_z844gkSOWlx9" title="Earnout shares"&gt;20,000,000&lt;/span&gt;&#160;Earnout Shares in tranches of&#160;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zuzU6iWvKd8d" title="Earnout shares"&gt;6,666,667&lt;/span&gt;,&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zT17NDLXKdXi" title="Earnout shares"&gt;6,666,667&lt;/span&gt;,
and&#160;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zJTNwFOh7I2l" title="Earnout shares"&gt;6,666,666&lt;/span&gt;&#160;shares of common stock per tranche, respectively. The first, second, and third tranches are issuable if the VWAP
per share of the Company&#x2019;s common stock is greater or equal to $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA1zCKVSTS11" title="Shares issued, price per share"&gt;15.00&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuyvJJIBokQj" title="Shares issued, price per share"&gt;17.50&lt;/span&gt;, and $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--TevogenBioCommonStockMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGw48JnhzVwf" title="Shares issued, price per share"&gt;20.00&lt;/span&gt;, respectively, over any twenty trading
days within any thirty consecutive day trading period during the three-year period after the Closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sponsor received the right to Earnout Shares with the same terms above, except that each of the Sponsor&#x2019;s three earnout tranches
are for&#160;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z4KFltTC2ru6" title="Earnout shares"&gt;1,500,000&lt;/span&gt;&#160;shares of common stock, for an aggregate of&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20241231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--AwardTypeAxis__custom--EarnoutSharesMember_zBKKDaByl4Al" title="Earnout shares"&gt;4,500,000&lt;/span&gt;&#160;shares of common stock across the entire
Sponsor earnout. The Earnout Shares are a form of dividend for holders of Tevogen Bio common stock, and the Earnout Shares earnable by
the Sponsor are treated as contingent consideration in a reverse recapitalization. In accordance with ASC 815, the Earnout Shares were
considered to be indexed to the Company&#x2019;s common stock and are classified within permanent equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</TVGN:EarnoutSharesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000808"
      unitRef="Shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000810"
      unitRef="Shares">6666667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Shares">6666667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">6666666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000816"
      unitRef="USDPShares">15.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000818"
      unitRef="USDPShares">17.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TevogenBioCommonStockMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000820"
      unitRef="USDPShares">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_SponsorMember_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact000824"
      unitRef="Shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000826">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z8VPehfYwEia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_823_zklmFykksWod"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zL4gRjUr8gL8" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;292,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;292,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(425,327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(263,118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;296,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zsRWGRsOH3c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20240101__20241231_ztgdRLVGznQd" title="Depreciation expense"&gt;162,209&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Depreciation_c20230101__20231231_zfXzM9btM0hb" title="Depreciation expense"&gt;163,300&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000828">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyTLeod1iAYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zL4gRjUr8gL8" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_z2fTAjjPcK87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zafoUtjWTt3c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndSoftwareMember_zLcF9UHhLe03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;292,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;292,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWEzRTWh31K3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zOA54W6JoE32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zAxeUorRM0F7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;33,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzFLE_z9CL68pLllfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzFLE_zDXDRLq09mIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(425,327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(263,118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzFLE_zd2iNvK6JHzf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;296,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ComputerAndSoftwareMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">292341</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerAndSoftwareMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">292341</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">263217</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">263217</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">132468</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000837"
      unitRef="USD">132468</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">33743</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">33743</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000842"
      unitRef="USD">721769</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000843"
      unitRef="USD">721769</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000845"
      unitRef="USD">425327</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000846"
      unitRef="USD">263118</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000848"
      unitRef="USD">296442</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000849"
      unitRef="USD">458651</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000851"
      unitRef="USD">162209</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000853"
      unitRef="USD">163300</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000855">&lt;p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z6RfvuWeYq5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_827_zRrSDVU9XqN4"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zB2Az3kYPDPi" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,309,163&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;976,301&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;403,233&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;120,149&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,712,396&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,096,450&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_z7WvcneI6UYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000857">&lt;p id="xdx_892_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zRlUj4VqPk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zB2Az3kYPDPi" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zjOO0oCsnLwg" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z9WXnm6jsJTl" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzC3I_zGgDsihN9oXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 62%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    services&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,309,163&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 16%; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;976,301&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 1%; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzC3I_zrCYjFa3Avbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;403,233&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;120,149&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzC3I_zmG7bIjIJOo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,712,396&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; padding-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,096,450&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-bottom: 0pt; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000859"
      unitRef="USD">1309163</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000860"
      unitRef="USD">976301</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000862"
      unitRef="USD">403233</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000863"
      unitRef="USD">120149</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000865"
      unitRef="USD">1712396</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000866"
      unitRef="USD">1096450</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000868">&lt;p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zw2kLZQBNkj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8.&#160;&lt;span id="xdx_823_zgdJfRsQOU48"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2024, in connection with the consummation of the Business Combination, previously issued promissory notes and accrued interest
were automatically converted into an aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240214__20240214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEK5y4HKzDQk" title="Converted shares"&gt;10,337,419&lt;/span&gt; shares of common stock. These debt obligations were retired upon conversion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Loan
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2024, the Company entered into a Loan Agreement (the &#x201c;Loan Agreement&#x201d;) with The Patel Family, LLP (the &#x201c;Patel Family&#x201d;),
a related party of the Company, providing for an unsecured line of credit facility (the &#x201c;Facility&#x201d;) for term loans of up
to an initial total of $&lt;span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zxsAadBIcza1" title="Line of credit maximum borrowing capacity"&gt;36,000,000&lt;/span&gt;. Under the Facility, the Company may draw up to $&lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z8mf9puuQScj" title="Line of credit borrowing capacity"&gt;1,000,000&lt;/span&gt;&#160;in term loans per calendar month over
a draw period of 36 months. Each term loan draw will have a maturity date of&#160;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtM_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zrryz2lcOsJd" title="Debt maturity date"&gt;48&lt;/span&gt;&#160;months and will accrue interest at the lower
of (i) daily SOFR plus&#160;&lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zuySRYwHK8Ei" title="Debt instrument variable rate"&gt;2.00&lt;/span&gt;% and (ii)&#160;&lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zIvaeYSPmbGa" title="Debt instrument interest rate"&gt;7.00&lt;/span&gt;%. Interest accrues quarterly and is payable on the three-month anniversary of the
draw date. Interest is payable in shares of common stock at an effective price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zM8NfIOFCS2f" title="Share price"&gt;1.50&lt;/span&gt;&#160;per share. Interest payable through December
31, 2024 relating to the first two draws on the Facility were settled in February 2025 through issuance of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_ziYglc8zbDJa" title="Shares issued"&gt;18,847&lt;/span&gt; shares of common stock.
Principal may be prepaid at any time without penalty, and repayments or prepayments may be made in cash or common stock at the Company&#x2019;s
election. Payments of principal in common stock would be made at an effective price of the greater of $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__srt--RangeAxis__srt--MaximumMember_zYzKJtAyeaec" title="Share price"&gt;1.50&lt;/span&gt;&#160;per share and the ten-day
trailing volume weighted average price per share of the common stock (the &#x201c;Trailing VWAP&#x201d;) as of the trading day prior to
payment. As an inducement to enter into the Loan Agreement, the Company issued&#160;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_znCkx6wZyMk3" title="Issuance of shares"&gt;1,000,000&lt;/span&gt;&#160;shares of common stock to the Patel Family
during June 2024. As of December 31, 2024, the Company has drawn $&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zo28h9XX9xBc" title="Line of credit borrowing capacity"&gt;1,000,000&lt;/span&gt;&#160;from the Facility, with maturity dates in July and August 2028, with a remaining $&lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zQJVNySeYQ54" title="Line of credit remaining capacity"&gt;30,000,000&lt;/span&gt;&#160;available
for future financing over the remaining&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z5ChVKGiEFQh" title="Debt maturity date"&gt;30&lt;/span&gt;&#160;months. The Company drew an additional $&lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpE8RJPFn8Pa" title="Line of credit borrowing capacity"&gt;&lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zR7pcG1mWobj" title="Line of credit borrowing capacity"&gt;1,000,000&lt;/span&gt;&lt;/span&gt; in each of February and March 2025, with maturity dates in February and
March 2029, respectively (see Note 17).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement includes a purchase option whereby the Patel Family has the option to purchase up to $&lt;span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJkZ50n7lT18" title="Option to purchase common stock, value"&gt;14,000,000&lt;/span&gt;&#160;of shares of common stock
at a purchase price equal to&#160;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zRuIZHYmEz7a" title="Percentage of price of common stock purchased"&gt;70&lt;/span&gt;% of the Trailing VWAP per share (the &#x201c;$&lt;span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zsFqU9TPVtn2" title="Option to purchase common stock, value"&gt;14&lt;/span&gt;&#160;million Purchase Option&#x201d;). The $&lt;span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zMXzkmwIoSY5" title="Option to purchase common stock, value"&gt;14&lt;/span&gt;&#160;million
Purchase Option only becomes exercisable once Trailing VWAP reaches $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zUNpmbR6fKPh" title="Purchase, price per share"&gt;10.00&lt;/span&gt;&#160;per share. The $&lt;span id="xdx_90D_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zwRode1UFF2g" title="Derivative liability"&gt;14&lt;/span&gt;&#160;million Purchase Option was determined
to be a freestanding derivative liability under ASC 815 and is carried at fair value, with changes in fair value recorded to change in
fair value of written call option derivatives liabilities within the consolidated statements of operations and consolidated statements
of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement also includes a purchase option (the &#x201c;Additional Amount Purchase Option&#x201d;) that is identical to the $&lt;span id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_pn6n6_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_zLeBpQ0QG6vk" title="Option to purchase common stock, value"&gt;14&lt;/span&gt;&#160;million
Purchase Option, except that the option is exercisable for an amount up to the then-remaining undrawn term loan amount under the Loan
Agreement at the time Trailing VWAP reaches $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AdditionalAmountPurchaseOptionMember_ztNbS6XR3JGg" title="Purchase, price per share"&gt;10.00&lt;/span&gt;&#160;per share. The Additional Amount Purchase Option was determined to be an embedded
derivative within the written loan commitment that requires bifurcation under ASC 815, and thus is carried at fair value with changes
in fair value recorded to change in fair value of written call option derivatives liabilities within the consolidated statements of operations
and consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
$&lt;span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630_z1KuAUxd4G0f" title="Derivative liability"&gt;14&lt;/span&gt;&#160;million Purchase Option and the Additional Amount Purchase Option are recorded to written call option derivative liabilities
within the consolidated balance sheet and have a fair value of $&lt;span id="xdx_90F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_zxpXfB9xpIm7" title="Derivative liabilities"&gt;0&lt;/span&gt; as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement is a written loan commitment that is not eligible for the fair value option under ASC 825,&#160;&lt;i&gt;Financial Instruments&lt;/i&gt;.
However, management intends to elect the fair value option for future draws under this commitment, and therefore has expensed all issuance
costs associated with the Loan Agreement, which are comprised of the fair value of the&#160;&lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility_c20240601__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zx9g5g8Kjcrf" title="Issuance of commitment shares in connection with unsecured equity line of credit facility"&gt;1,000,000&lt;/span&gt;&#160;shares of common stock issued
to the Patel Family as well as the issuance date fair value of the $&lt;span id="xdx_900_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zN2WjAXBmPE9" title="Derivative liability"&gt;14&lt;/span&gt;&#160;million Purchase Option and Additional Amount Purchase Option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Notes
Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Merger, the Company assumed notes payable held by Polar Multi-Strategy Master Fund (&#x201c;Polar&#x201d;) for which the
proceeds were to be used for working capital purposes by Semper Paratus with an outstanding balance of $&lt;span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PolarMultiStrategyMasterFundMember_znJ5ftS26bml" title="Notes payable"&gt;1,651,000&lt;/span&gt;&#160;on the Closing
Date and remain outstanding at December 31, 2024. The notes payable do not accrue interest. The outstanding balance of the notes was
required to be repaid in full within five business days of the Merger, and the Company is therefore in default of its obligations at
December 31, 2024. The notes&#x2019; default provisions do not require the Company to transfer any shares or pay any amounts to Polar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-02-142024-02-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">10337419</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">36000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      id="Fact000876">P48M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Pure">0.0200</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Pure">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000882"
      unitRef="USDPShares">1.50</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">18847</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_us-gaap_UnsecuredDebtMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000886"
      unitRef="USDPShares">1.50</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-012024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000890"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">30000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-012024-12-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      id="Fact000894">P30M</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2025-02-28_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="AsOf2025-03-31_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">1000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="0"
      id="Fact000900"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Pure">0.70</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="-6"
      id="Fact000904"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="-6"
      id="Fact000906"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact000908"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember"
      decimals="-6"
      id="Fact000910"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember_custom_AdditionalAmountPurchaseOptionMember"
      decimals="-6"
      id="Fact000912"
      unitRef="USD">14000000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_custom_AdditionalAmountPurchaseOptionMember"
      decimals="INF"
      id="Fact000914"
      unitRef="USDPShares">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30"
      decimals="-6"
      id="Fact000916"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesCurrent>
    <TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility
      contextRef="From2024-06-012024-06-30_custom_ThePatelFamilyLLPMember_custom_LoanAgreementMember"
      decimals="INF"
      id="Fact000920"
      unitRef="Shares">1000000</TVGN:StockIssuedDuringPeriodSharesCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember"
      decimals="-6"
      id="Fact000922"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_custom_PolarMultiStrategyMasterFundMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">1651000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000926">&lt;p id="xdx_80E_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zc3CeCOj6qU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_82C_zArk9wUoyvf7"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022, the Company entered into leases for office and laboratory space in Warren Township, New Jersey and Philadelphia, Pennsylvania under
operating leases expiring in February 2026 and July 2025, respectively. The leases require fixed monthly payments of rent, as well as
a share of operating costs. The leases are classified as operating leases and the lease liabilities were calculated using incremental
borrowing rates ranging from &lt;span id="xdx_90D_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zB8YyCh7E3ma" title="Operating leases incremental borrowing rates"&gt;11.0&lt;/span&gt;% to &lt;span id="xdx_90F_ecustom--OperatingLeasesIncrementalBorrowingRates_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z1hEkSCxIZxi" title="Operating leases incremental borrowing rates"&gt;11.2&lt;/span&gt;%, which was determined using a synthetic credit rating model. Lease expense for the year ended
December 31, 2024 was $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zih4CLa5lv95" title="Operating lease expense"&gt;1,065,784&lt;/span&gt;, which consisted of $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zgoV4EtlJzzj" title="Operating lease expense"&gt;897,958&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zx7xhLtqdISl" title="Operating lease expense"&gt;167,826&lt;/span&gt; recognized as a component of research and development expense
and general and administrative expense, respectively. This amount included $&lt;span id="xdx_90E_eus-gaap--ShortTermLeasePayments_c20240101__20241231_zvXFayMDshW2" title="Short term lease"&gt;785,424&lt;/span&gt; of expense under short-term leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining lease term for the Company&#x2019;s operating leases as of December 31, 2024 was &lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zXQ2DP3bHQk6" title="Operating leases weighted average remaining lease term"&gt;0.93&lt;/span&gt; years. The weighted average
discount rate for the Company&#x2019;s operating leases for the year ended December 31, 2024 was &lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z209KcV9MlL8" title="Operating leases weighted average discount rate"&gt;11.1&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z56qhGR4fHig" style="display: none"&gt;SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES&lt;/span&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Years Ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;230,471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,975&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;244,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,587&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;234,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zNODONkrSBx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash payments related to leases for the years ended December 31, 2024 and 2023 were $&lt;span id="xdx_900_eus-gaap--OperatingLeasePayments_c20240101__20241231_z3eSn06J9Nq" title="Cash payments"&gt;1,077,127&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20230101__20231231_zP05UIXT7Qpb" title="Cash payments"&gt;1,058,754&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <TVGN:OperatingLeasesIncrementalBorrowingRates
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000928"
      unitRef="Pure">0.110</TVGN:OperatingLeasesIncrementalBorrowingRates>
    <TVGN:OperatingLeasesIncrementalBorrowingRates
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Pure">0.112</TVGN:OperatingLeasesIncrementalBorrowingRates>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000932"
      unitRef="USD">1065784</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentArrangementMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">897958</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">167826</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000938"
      unitRef="USD">785424</us-gaap:ShortTermLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact000940">P0Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000942"
      unitRef="Pure">0.111</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000944">&lt;p id="xdx_895_ecustom--ScheduleOfCompanyLeaseLiabilitiesTableTextBlock_z5Amd0mc7FH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
aggregate minimum rental payments under the operating leases as of December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z56qhGR4fHig" style="display: none"&gt;SCHEDULE
OF MINIMUM RENTAL PAYMENTS UNDER THE OPERATING LEASES&lt;/span&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Years Ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_ziRvYQE54ivl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOLLzALR_zmGsqaMQdUM" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;230,471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOLLzALR_zGr95ElDsClh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,975&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLLzALR_zrMvbdd8G9Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;244,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zS0rZ8shQAB6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,587&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_zj9oIpfMdBmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;234,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TVGN:ScheduleOfCompanyLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000946"
      unitRef="USD">230471</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000948"
      unitRef="USD">13975</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000950"
      unitRef="USD">244446</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000952"
      unitRef="USD">9587</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000954"
      unitRef="USD">234859</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000956"
      unitRef="USD">1077127</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000958"
      unitRef="USD">1058754</us-gaap:OperatingLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000960">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHq3GNNa6Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_821_zsWcklDknXOc"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employment
contracts&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into employment contracts with its officers and certain employees that provide for severance and continuation of
benefits in the event of termination of employment either by the Company without cause or by the employee for good reason, both as defined
in the applicable agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000962">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyMCODyWWnya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_827_z4dAxgKik4m6"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Closing, the Company adopted the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (the &#x201c;2024 Plan&#x201d;)
and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). Each RSU award granted under the
2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024
Plan with respect to the common stock of the Company (the &#x201c;Rollover RSUs&#x201d;). Such Rollover RSUs remain subject to the same
terms and conditions as set forth under the applicable award agreement prior to the Closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to covering the Rollover RSUs, under the 2024 Plan, the Company is authorized to grant awards up to an aggregate&#160;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zHzCwRN2s0nk"&gt;40,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
of common stock. The 2024 Plan provides for the grant of options, stock appreciation rights, Restricted Stock, RSUs, and other
equity-based awards. As of December 31, 2024, awards for &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember_zp4OZxGfChc2"&gt;10,670,118 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
remained available to be granted under the 2024 Plan.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions.
Compensation expense for service-based RSUs are recognized on a straight-line basis over the vesting period of the award. Compensation
expense for service-based and performance-based RSUs (&#x201c;Performance-Based RSUs&#x201d;) are recognized when the performance condition,
which is based on a liquidity event condition being satisfied, is deemed probable of achievement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date, the Company issued an aggregate of&#160;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zozYmExqOUAe" title="Number of shares issued for RSUs"&gt;19,348,954&lt;/span&gt;&#160;RSUs under the 2024 Plan to the Company&#x2019;s Chief Executive
Officer, Dr. Ryan Saadi (the &#x201c;Special RSU Award&#x201d;). Such RSUs immediately converted into shares of Restricted Stock, the restrictions
on which lapse in four equal annual installments beginning on February 14, 2031 (&#x201c;Vesting Period&#x201d;). Pursuant to the terms
of the Special RSU Award, Dr. Saadi will be entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred,
pledged, hypothecated, or otherwise encumbered, subject to forfeit. Dr. Saadi will automatically forfeit all unvested Restricted Stock
in the event he departs the Company. The fair value per share for the Special RSU Award was determined to be $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdXnDus2lokl" title="Fair value per share for award"&gt;4.51&lt;/span&gt;&#160;per share, equivalent
to the Company&#x2019;s stock price on the Closing Date, resulting in a total grant date fair value of $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20240214__20240214__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourPlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLG0Lg6jZtLa" title="Grant date fair value of shares"&gt;87,263,783&lt;/span&gt;. In accordance with
ASC 718,&#160;&lt;i&gt;Compensation - Stock Compensation&#160;&lt;/i&gt;(&#x201c;ASC 718&#x201d;), the Company will recognize compensation expense
on a straight-line basis from the Closing Date until the completion of the Vesting Period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
Stock and RSU activity was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zKiyxUa8Uqya" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Service-Based Restricted Stock and RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested as of January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0986"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted"&gt;29,329,882&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;3.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested"&gt;(2,639,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;26,690,254&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;3.54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Performance-Based RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Nonvested as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning"&gt;9,894,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;2.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted"&gt;1,027,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;4.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;(22,626&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;4.39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning"&gt;10,900,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;2.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested"&gt;(9,610,540&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;2.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1040"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;1,289,578&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;3.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z4eThjaJVWS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Merger, the liquidity event performance condition was achieved and therefore compensation cost of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4Ufve4JqSjb" title="Compensation cost recognized"&gt;25,233,487&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;for
the year ended December 31, 2024 was recognized for the Performance-Based RSUs, of which&#160;&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zlIzAuY2Njn8" title="Number of shares issued and outstading RSU"&gt;8,237,319&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
shares were issued and outstanding as of December 31, 2024, and&#160;&lt;span id="xdx_902_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z40DPp8wElZb" title="Number of shares issuable"&gt;1,373,221&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;shares
will be issued subsequent to December 31, 2024. There was $&lt;span id="xdx_902_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrEwkew1oNWi" title="Compensation cost"&gt;11,410,921&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;compensation
cost related to Service-Based Restricted Stock and RSUs, for the year ended December 31, 2024, and &lt;span id="xdx_90E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20250101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zzgMC1eBnPy9" title="Number of shares issuable"&gt;2,639,628&lt;/span&gt; &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
were issued and outstanding. There was $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zms2tZhdeNc5" title="Unrecognized compensation cost"&gt;85,601,786&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
unrecognized compensation cost related to Service-Based Restricted Stock and RSUs as of December 31, 2024, which will be expensed
over a weighted average period of&#160;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zclEMmCJ3Dz9" title="Weighted average period"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;years.
There was $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zIrQ7oNuc7Uc" title="Unrecognized compensation cost"&gt;2,984,909&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;of
unrecognized compensation cost related to Performance-Based RSUs as of December 31, 2024, which will be expensed over a weighted
average period of&#160;&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zY1GdZYbLZc4" title="Weighted average period for recognition"&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B4_z0T6x9S9R0nc" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;27,019,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,744,355&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,764,136&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zolbzGpD9Gyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_do_c20230101__20231231_ze91l903pZjd" title="Stock-based compensation expense recognized"&gt;No&lt;/span&gt;
stock-based compensation expense was recognized in 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember"
      decimals="INF"
      id="Fact000963"
      unitRef="Shares">40000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourPlanMember"
      decimals="INF"
      id="Fact000964"
      unitRef="Shares">10670118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">19348954</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000968"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2024-02-142024-02-14_custom_TwoThousandTwentyFourPlanMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">87263783</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000972">&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zg71PxSY1j3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
Stock and RSU activity was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zKiyxUa8Uqya" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK AND RSU ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Service-Based Restricted Stock and RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested as of January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYkbcEwtskV6" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zTw0SUr5swm" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zSMKKQsYVatk" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zfQCmYSGg127" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zYGORBC0qyr8" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zgzleRueiFa5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_z0nVoVud6em5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0986"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zxUFVKPP1Mf5" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zl7TdslQqUz7" style="text-align: right" title="Nonvested Shares, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVjv6BEq74j5" style="text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zmhyAJn6R25k" style="width: 16%; text-align: right" title="Nonvested Shares, Granted"&gt;29,329,882&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zIVhFVfiUd26" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;3.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zb4N3FdAt0F4" style="text-align: right" title="Nonvested Shares, Vested"&gt;(2,639,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zjmY3Ryy46re" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zOT6oxpXsWYh" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zVr3GW8f4fFg" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zAbeEL3jQWA2" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;26,690,254&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockMember_zpPP7ynEpTU" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;3.54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Performance-Based RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average grant-date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Nonvested as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z1rlz6ZIH2E1" style="width: 16%; text-align: right" title="Nonvested Shares, Beginning"&gt;9,894,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zYEBRUUa4fS6" style="width: 16%; text-align: right" title="Nonvested weighted average grant-date fair value, Beginning"&gt;2.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zXzXs5LuVewk" style="text-align: right" title="Nonvested Shares, Granted"&gt;1,027,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zU5QwhOVtKKh" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;4.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zNihbNDgoJlj" style="text-align: right" title="Nonvested Shares, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zRtEuhMXxxY2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4WNux4psgFf" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;(22,626&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zCwJ89xod5X9" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;4.39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zVTTQ5j3Vxe1" style="text-align: right" title="Nonvested Shares, Beginning"&gt;10,900,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z4tOtcsDbQrk" style="text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;2.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zmsRkYvAG8l3" style="text-align: right" title="Nonvested Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zf55dHhm3mC2" style="text-align: right" title="Nonvested weighted average grant-date fair value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zaPBEe7jGmH7" style="text-align: right" title="Nonvested Shares, Vested"&gt;(9,610,540&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z3qi8eJlnIoj" style="text-align: right" title="Nonvested weighted average grant-date fair value, Vested"&gt;2.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zDVaCo8Kj5x6" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested Shares, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_zZJSQQVnys22" style="border-bottom: Black 1pt solid; text-align: right" title="Nonvested weighted average grant-date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1040"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_z6DRsiRRodBh" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested Shares, Beginning"&gt;1,289,578&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember_znTBbMTO9Iii" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested weighted average grant-date fair value, Ending"&gt;3.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000994"
      unitRef="Shares">29329882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000996"
      unitRef="USDPShares">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Shares">2639628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001000"
      unitRef="USDPShares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">26690254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001010"
      unitRef="Shares">9894958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001012"
      unitRef="USDPShares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">1027796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001016"
      unitRef="USDPShares">4.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">22626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001024"
      unitRef="USDPShares">4.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001026"
      unitRef="Shares">10900128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001028"
      unitRef="USDPShares">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">9610540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001036"
      unitRef="USDPShares">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">1289578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001044"
      unitRef="USDPShares">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">25233487</us-gaap:ShareBasedCompensation>
    <TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001048"
      unitRef="Shares">8237319</TVGN:StockIssuedDuringPeriodSharesSettlementOfVestedRestrictedStockUnits>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_PerformanceBasedRSUsMember"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">1373221</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">11410921</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2025-01-01_us-gaap_SubsequentEventMember_custom_ServiceBasedRestrictedStockMember"
      decimals="INF"
      id="Fact001054"
      unitRef="Shares">2639628</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_custom_ServiceBasedRestrictedStockMember"
      decimals="0"
      id="Fact001056"
      unitRef="USD">85601786</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      id="Fact001058">P7Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_custom_PerformanceBasedRSUsMember"
      decimals="0"
      id="Fact001060"
      unitRef="USD">2984909</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_custom_PerformanceBasedRSUsMember"
      id="Fact001062">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001064">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqQ6C3RkJXLh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of
operations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B4_z0T6x9S9R0nc" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zDU36E9nUsml" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYTqU2Y6qIUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;27,019,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2XZFhW9Nmak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,744,355&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zwdTtZqbiUNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,764,136&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001066"
      unitRef="USD">27019781</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">13744355</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001070"
      unitRef="USD">40764136</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001072"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001074">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z39WwpxsIVGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12.&#160;&lt;span id="xdx_823_zPEUk6aDyaG5"&gt;STOCKHOLDERS&#x2019; DEFICIT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of February 15, 2024, the Company&#x2019;s common stock and warrants began trading on The Nasdaq Stock Market LLC under the symbols &#x201c;TVGN&#x201d;
and &#x201c;TVGNW&#x201d;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had&#160;&lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_znAw7bEFMQ5h" title="Common shares, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zk1HMAnH51cj" title="Common shares, shares outstanding"&gt;177,991,365&lt;/span&gt;&lt;/span&gt;&#160;shares of common stock issued and outstanding. For accounting purposes related
to earnings per share, only shares that are fully vested are considered issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is a reconciliation of shares of common stock issued and outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BF_zBobVkOAVlrc" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total shares of common stock issued and outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_zTz0o6SVpLl3" title="Total shares of common stock legally issued"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zub7NIVcS1ji" title="Total shares of common stock legally outstanding"&gt;177,991,365&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Plus: shares to be issued:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Vested RSUs not yet legally settled into common stock (a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"&gt;1,373,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Shares subject to future vesting:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Issuance of restricted common stock subject to forfeiture (b)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"&gt;(19,348,954&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total shares, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"&gt;160,015,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zFXyPlOcKyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Merger, Tevogen Bio had outstanding shares of voting and non-voting common stock. Upon the Closing, Tevogen Bio&#x2019;s common
stockholders received shares of the Company&#x2019;s common stock in an amount determined by application of the Exchange Ratio, as discussed
in Note 1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue up to&#160;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zawzrFyiUhW8" title="Preferred shares, shares authorized"&gt;20,000,000&lt;/span&gt;&#160;shares of preferred stock, par value $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zQGkdUfNumd3" title="Preferred shares, par value"&gt;0.0001&lt;/span&gt;&#160;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
A Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, the Company authorized and issued&#160;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUfWFBKOpx95" title="Preferred stock, shares authorized"&gt;2,000&lt;/span&gt;&#160;and&#160;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z4r56mILnzl" title="Preferred stock, shares issued"&gt;500&lt;/span&gt;&#160;shares, respectively, of Series A Preferred Stock (the
&#x201c;Series A&#x201d;) to the Patel Family at a price of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQfbWQrcOZi3" title="Original issue price per share"&gt;4,000&lt;/span&gt;&#160;per share (the &#x201c;Series A Original Issue Price&#x201d;), for gross
proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zxixjJLqeg62" title="Proceeds from issuance of preferred stock"&gt;2,000,000&lt;/span&gt;. The Company recorded an expense of $&lt;span id="xdx_909_ecustom--LossOnPreferredStockIssuance_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQxnGU5zd5Tb" title="Loss on preferred stock issuance"&gt;799,990&lt;/span&gt;&#160;in its consolidated statements of operations related to issuance
of the Series A equal to the fair value of the Series A when issued of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhHdHpBEqGkj" title="Price per share"&gt;5,600&lt;/span&gt;&#160;per share less the purchase price of $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zAqqP6PNvXv7" title="Share price"&gt;4,000&lt;/span&gt;&#160;per
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of Series A are entitled to receive dividends accruing daily on a cumulative basis payable at a fixed rate of&#160;&lt;span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztYDttjnovo9" title="Dividend rate, percentage"&gt;5&lt;/span&gt;% per annum per share
on&#160;&lt;span id="xdx_90D_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zF61u4UZsN72" title="Dividend variable rate, description"&gt;the Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding
(the &#x201c;Series A Accruing Dividends&#x201d;). These dividends become payable when and if declared by the Company. The Series A Preferred
Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common stock&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A ranks senior to common stock and Series C Preferred Stock in liquidation priority. In the event of a liquidation of the Company,
or certain deemed liquidation events, the Series A is redeemable for a price equal to the greater of the Series A Original Issue Price
plus all Series A Accruing Dividends that are unpaid through the redemption date, or such amount that would have been payable had the
Series A converted into shares of common stock immediately before the liquidation or deemed liquidation event.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A does not have any voting rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Redemption&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem the Series A at a price equal to the Series A Original Issue Price plus any Series A Accruing
Dividends accrued but unpaid thereon, if the VWAP of the Company&#x2019;s common stock exceeds $&lt;span id="xdx_909_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwbfq8s8aZ8a" title="Redemption price per share"&gt;5.00&lt;/span&gt;&#160;per share for&#160;&lt;span id="xdx_907_eus-gaap--PreferredStockRedemptionTerms_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOlzljlEejp8" title="Redemption term"&gt;the twenty
days immediately prior to the Company&#x2019;s call election&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series A have the option to convert the Series A into shares of common stock at a ratio equal to the Series A Original Issue
Price divided by the Series A Conversion Price, which is initially $&lt;span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAhs7sA9a3Hg" title="Conversion price per share"&gt;4.00&lt;/span&gt;&#160;per share and is subject to standard antidilution adjustments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-decoration: underline"&gt;Series
A-1 Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 27, 2024, the Company entered into an Amended and Restated Securities Purchase Agreement with the Patel Family covering the
issuance of&#160;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zyjFwzKjShS9" title="Stock issuance"&gt;600&lt;/span&gt;&#160;shares of Series A-1 Preferred Stock for a gross purchase price of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSYuOdfosOrl" title="Stock issuance, value"&gt;6,000,000&lt;/span&gt;.&#160;&lt;span id="xdx_907_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240326__20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zwimI6SmD7Wc" title="Dividend variable rate, description"&gt;The terms of the Series
A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum, and the Series A-1
Issuance Price is defined as $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20240327__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zpRWlyP2lmhc" title="Share price"&gt;10,000&lt;/span&gt;&#160;per share&lt;/span&gt;. As of December 31, 2024, the investor had paid a non-refundable deposit of $&lt;span id="xdx_907_eus-gaap--Deposits_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z0L4O5xe3d58" title="Non refundable deposist paid"&gt;3,000,000&lt;/span&gt;&#160;towards
the Series A-1 purchase price, and no shares of Series A-1 Preferred Stock were issued or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
B Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Closing, the Company entered into an agreement to issue shares of Series B to the Sponsor in return for the Sponsor
assuming certain liabilities and obligations of Semper Paratus and Tevogen Bio. In March 2024,&#160;&lt;span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztKdBv7rrvtf" title="Conversion of certain liabilities into Series B preferred stock, shares"&gt;3,613&lt;/span&gt;&#160;shares of Series B were
issued in return for the assumption of the Assumed Liabilities. The issuance date fair value of the Series B was determined to be $&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodValueConversionOfLiabilities_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjWUK6RK25vf" title="Conversion of certain liabilities into Series B preferred stock"&gt;3,613,000&lt;/span&gt;&#160;and
was recorded within Merger transaction costs in the consolidated statements of operations. The Series B was classified as permanent equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 15, 2024, the Company and the Sponsor entered into the Preferred Stock Repurchase Agreement, pursuant to which the Company repurchased
all outstanding Series B in exchange for the release of the Sponsor from its obligations related to the Assumed Liabilities, but no cash
consideration. The repurchase was recorded as a deemed contribution from a related party and recorded to additional paid-in capital.
As of June 30, 2024, there were&#160;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8b7tstNVUK" title="Preferred stock shares outstanding"&gt;no&lt;/span&gt;&#160;shares of Series B outstanding, and on August 9, 2024, the Company filed a Certificate of
Elimination to eliminate the Series B. Although the Company was not legally released by the creditors, the Company has made payments
towards the Assumed Liabilities and approximately $&lt;span id="xdx_904_eus-gaap--LiabilitiesAssumed1_pn5n6_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z49kJiiE3Ygk" title="Liabilities assumed"&gt;2.6&lt;/span&gt;&#160;million remains on the Company&#x2019;s balance sheet at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-decoration: underline"&gt;Series
C Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 21, 2024, the Company entered into a securities purchase agreement (the &#x201c;Series C Agreement&#x201d;) with an investor, pursuant
to which the Patel Family purchased&#160;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zSPnuzVFW8I3" title="Stock issuance"&gt;600&lt;/span&gt;&#160;shares of Series C Preferred Stock (the &#x201c;Series C&#x201d;) of the Company at a price
of $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_z54wxKCwg1gb" title="Share price"&gt;10,000&lt;/span&gt;&#160;per share (the &#x201c;Series C Original Issue Price&#x201d;), for gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20240821__20240821__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember_zWevHguMjFh8" title="Gross proceeds"&gt;6,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C is subject to a call right providing the Company the right to call the stock at any time after the fifth anniversary of the
date of issuance. The Company also agreed that so long as the Series C is outstanding, the Company will not, without the written consent
of the holders of 50.1% of the Series C, amend, alter, or repeal any provision of the Company&#x2019;s certificate of incorporation or
bylaws in a manner adverse to the Series C. Assessed under accounting guidance within ASC 480 and ASC 815, as the Series C is unregistered
and without mandatory redemption features, the Series C is classified within equity at issued face value as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C carries an annual&#160;&lt;span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znIWnoIckvq7" title="Dividend rate, percentage"&gt;7.5&lt;/span&gt;% cumulative dividend, compounded annually, beginning on the later of (1) September 30, 2024 and (2)&#160;the
date on which the investor has paid the entirety of the purchase price under the Series C Agreement and ending on the last business day
of the calendar quarter ending September 30, 2034 (the &#x201c;Series C Accruing Dividends&#x201d;). Dividends will be payable in shares
of Series C or, at the election of the Company, in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C ranks subordinate to the Series A and Series A-1 Preferred Stock and ranks senior to common stock in liquidation priority. In
&lt;span id="xdx_90C_eus-gaap--PreferredStockDividendPaymentRateVariable_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9gScDguhoh2" title="Dividend variable rate, description"&gt;the event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the
greater of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such
asset amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or
deemed liquidation event&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Voting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series C does not have any voting rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Redemption&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
holders of Series C are not entitled to redeem their shares outside of the liquidation of the Company or the occurrence of a deemed liquidation
event. The Company is entitled to redeem that Series C at a price equal to the Series C Original Issue Price plus any Series C Accruing
Dividends accrued but unpaid thereon, subject to the conversion right described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of Series C will be convertible at the election of the holder, beginning six months after the date of issuance, into shares of
common stock at a conversion price equal to the volume-weighted average price of the Common Stock for the 30 trading days immediately
prior to the exercise of the holder&#x2019;s conversion option, subject to a floor price of $&lt;span id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_uUSDPShares_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7dM0Y1ql89b" title="Floor price"&gt;0.6172&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Closing,&#160;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember_zIGtQfTezVW6" title="Number of warrants issued"&gt;17,975,000&lt;/span&gt;&#160;warrants initially issued by Semper Paratus in November 2021, comprising&#160;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zn3BV62feMah" title="Number of warrants issued"&gt;17,250,000&lt;/span&gt;&#160;public
warrants sold in the IPO and&#160;&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRightIssued_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVzxWQkVh4vf" title="Number of warrants issued"&gt;725,000&lt;/span&gt;&#160;warrants issued in a concurrent private placement, were assumed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Public
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
public warrants have an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zIbJmxaroH8f" title="Exercise price"&gt;11.50&lt;/span&gt;&#160;per share, became exercisable on&#160;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zmhBTSemoD57" title="Exercisable date"&gt;March 15, 2024&lt;/span&gt;, and will expire at 5:00 p.m.,
New York City time, on February 14, 2029, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is
an effective registration statement and during any period when the Company has failed to maintain an effective registration statement
covering the shares of the Company&#x2019;s common stock issuable upon exercise of the warrants, exercise warrants on a &#x201c;cashless
basis&#x201d; in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, or another exception.&#160;&lt;span id="xdx_909_ecustom--WarrantsRedemptionDescription_c20211101__20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zCHigflJdi3f" title="Warrants redemption description"&gt;The Company may
redeem the public warrants if the Company&#x2019;s common stock equals or exceeds $18.00 per share for 20 trading days within a 30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of public
warrants&lt;/span&gt;.&#160;As of December 31, 2024, there are&#160;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zp8Nj2uoLvG3" title="Number of warrants outstanding"&gt;17,386,580&lt;/span&gt;&#160;public warrants outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;i&gt;Private
Placement Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
private placement warrant is identical to the public warrants, except that the private placement warrants, so long as they are held by
the initial purchasers or their permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders
on a cashless basis. As of December 31, 2024, there are&#160;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SemperParatusMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z69tfKiXr8nj" title="Number of warrants outstanding"&gt;588,398&lt;/span&gt; private placement warrants outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 3 for additional information on the Company&#x2019;s warrant accounting policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001076"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001078"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001080">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zSOL5mLD6Ex8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is a reconciliation of shares of common stock issued and outstanding:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BF_zBobVkOAVlrc" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total shares of common stock issued and outstanding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20241231_zTz0o6SVpLl3" title="Total shares of common stock legally issued"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zub7NIVcS1ji" title="Total shares of common stock legally outstanding"&gt;177,991,365&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Plus: shares to be issued:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Vested RSUs not yet legally settled into common stock (a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing_iI_c20241231_fKGEp_zCbHItSD0oN5" style="text-align: right" title="Vested Performance-Based RSUs from satisfaction of liquidity condition upon the Closing"&gt;1,373,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Shares subject to future vesting:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Issuance of restricted common stock subject to forfeiture (b)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture_iI_c20241231_fKGIp_zAWe8GbZVlj2" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance of restricted common stock subject to forfeiture"&gt;(19,348,954&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total shares, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture_iI_c20241231_zTEH5atUDVxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares issued and outstanding"&gt;160,015,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 24px; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F0C_zk3ugD4zYWK3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F1B_z37YHzlQJlp4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F03_zRtXAoAo4a1b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F1E_zYoDAP8O7hp2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001082"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001084"
      unitRef="Shares">177991365</us-gaap:CommonStockSharesOutstanding>
    <TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001086"
      unitRef="Shares">1373221</TVGN:VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing>
    <TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001088"
      unitRef="Shares">-19348954</TVGN:SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture>
    <TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001090"
      unitRef="Shares">160015632</TVGN:CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001094"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001098"
      unitRef="Shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Shares">500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001102"
      unitRef="USDPShares">4000</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001104"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <TVGN:LossOnPreferredStockIssuance
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001106"
      unitRef="USD">799990</TVGN:LossOnPreferredStockIssuance>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001108"
      unitRef="USDPShares">5600</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_SeriesAPreferredStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">4000</us-gaap:SharePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001114">the Series A Original Issue Price, which rate will automatically increase by 2% every year that the Series A remains outstanding
(the &#x201c;Series A Accruing Dividends&#x201d;). These dividends become payable when and if declared by the Company. The Series A Preferred
Stock will also participate on an as-converted basis in any regular or special dividends paid to holders of the common stock</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001116"
      unitRef="USDPShares">5.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionTerms
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="Fact001118">the twenty
days immediately prior to the Company&#x2019;s call election</us-gaap:PreferredStockRedemptionTerms>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001120"
      unitRef="USDPShares">4.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Shares">600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">6000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-03-262024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      id="Fact001126">The terms of the Series
A-1 Preferred Stock are identical to the Series A, except that the cumulative dividends are capped at 15% per annum, and the Series A-1
Issuance Price is defined as $10,000&#160;per share</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-27_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001128"
      unitRef="USDPShares">10000</us-gaap:SharePrice>
    <us-gaap:Deposits
      contextRef="AsOf2024-12-31_custom_SeriesAOnePreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">3000000</us-gaap:Deposits>
    <TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001132"
      unitRef="Shares">3613</TVGN:StockIssuedDuringPeriodSharesConversionOfLiabilities>
    <TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities
      contextRef="From2024-03-012024-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">3613000</TVGN:StockIssuedDuringPeriodValueConversionOfLiabilities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001136"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      id="Fact001138"
      unitRef="USD">2600000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001140"
      unitRef="Shares">600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="INF"
      id="Fact001142"
      unitRef="USDPShares">10000</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-08-212024-08-21_us-gaap_SeriesCPreferredStockMember_custom_ThePatelFamilyLLPMember"
      decimals="0"
      id="Fact001144"
      unitRef="USD">6000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Pure">0.075</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendPaymentRateVariable
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      id="Fact001148">the event of a liquidation of the Company, or certain deemed liquidation events, the Series C is redeemable for a price equal to the
greater of the Series C Original Issue Price plus all Series C Accruing Dividends that are unpaid through the redemption date, or such
asset amount as would have been payable had the Series C converted into shares of common stock immediately before the liquidation or
deemed liquidation event</us-gaap:PreferredStockDividendPaymentRateVariable>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001150"
      unitRef="USDPShares">0.6172</us-gaap:PreferredStockConvertibleConversionPrice>
    <TVGN:ClassOfWarrantOrRightIssued
      contextRef="AsOf2021-11-30_custom_SemperParatusMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">17975000</TVGN:ClassOfWarrantOrRightIssued>
    <TVGN:ClassOfWarrantOrRightIssued
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">17250000</TVGN:ClassOfWarrantOrRightIssued>
    <TVGN:ClassOfWarrantOrRightIssued
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">725000</TVGN:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001158"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      id="Fact001160">2024-03-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <TVGN:WarrantsRedemptionDescription
      contextRef="From2021-11-012021-11-30_custom_SemperParatusMember_custom_PublicWarrantsMember"
      id="Fact001162">The Company may
redeem the public warrants if the Company&#x2019;s common stock equals or exceeds $18.00 per share for 20 trading days within a 30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of public
warrants</TVGN:WarrantsRedemptionDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SemperParatusMember_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">17386580</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SemperParatusMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">588398</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001168">&lt;p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zlDNnfZH9OPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13.&#160;&lt;span id="xdx_825_zqPN9q60Q2sd"&gt;NET LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
below table is a reconciliation of net loss to net loss attributable to common stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zqvjlw0tPPPc" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF NET LOSS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(13,727,380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(60,477,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series A cumulative preferred stock dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76,712&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series B stock repurchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,613,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock repurchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,613,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series C cumulative preferred stock dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(82,603&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cumulative preferred stock dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(82,603&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(10,273,695&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(60,477,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zG3z9K9LYeO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company excluded the following potential shares from the computation of diluted net loss per share because including them would have
had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKc0WDQkU0cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zdSENhIO9rV3" style="display: none"&gt;SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F44_zmfQq5K6hhX9" style="width: 60%; text-align: left"&gt;Outstanding RSUs (a)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,623,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,900,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,348,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,974,978&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4C_zJyDr0riXTXa" style="text-align: left"&gt;Convertible promissory notes (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;891,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Earnout Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1208"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;70,447,157&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,791,426&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F0C_zykjScqdVvK1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F11_zmclaahZPjfi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024 there were an additional&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85" title="Stock option vested"&gt;1,373,221&lt;/span&gt;&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F0A_zTdx4tJUoNKl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F10_z19ovviNsVu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common
    stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_ztzzjDJRdhf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
above table excludes any potentially anti-dilutive shares as a result of the $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_pn6n6_c20241231_zD8TY04o0C1c" title="Derivative liability"&gt;14&lt;/span&gt;&#160;million Purchase Option and the Additional Amount
Purchase Option (see Note 8). These are excluded as the number of shares issuable cannot be determined until the conditions for issuance
are met and the share prices are known upon exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001170">&lt;p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zrMhznhcADK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
below table is a reconciliation of net loss to net loss attributable to common stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zqvjlw0tPPPc" style="display: none"&gt;SCHEDULE OF RECONCILIATION OF NET LOSS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zewavYKYmcO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z5LV02lxoR03" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_maNILATzLnk_z0EjB95kvWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(13,727,380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(60,477,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_msNILATzLnk_ziuy4AAZlZpa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series A cumulative preferred stock dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76,712&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_msNILATzLnk_zMbcnuDaiYHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series B stock repurchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,613,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockRepurchase_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsFxVRhsUdRd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock repurchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,613,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_msNILATzLnk_zXXqhExT8Qp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series C cumulative preferred stock dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(82,603&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYSKuDF6E6f7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cumulative preferred stock dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(82,603&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzLnk_zCi7OAkiAonl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(10,273,695&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(60,477,680&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001172"
      unitRef="USD">-13727380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001173"
      unitRef="USD">-60477680</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001175"
      unitRef="USD">76712</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <TVGN:StockRepurchase
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001178"
      unitRef="USD">3613000</TVGN:StockRepurchase>
    <TVGN:StockRepurchase
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001181"
      unitRef="USD">3613000</TVGN:StockRepurchase>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001184"
      unitRef="USD">82603</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001187"
      unitRef="USD">82603</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001190"
      unitRef="USD">-10273695</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001191"
      unitRef="USD">-60477680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001193">&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKc0WDQkU0cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zdSENhIO9rV3" style="display: none"&gt;SCHEDULE OF ANTI-DILUTIVE NET LOSS PER SHARE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zsfIgTckdztj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_z3pWLbJFR0Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zF2EpHKswSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F44_zmfQq5K6hhX9" style="width: 60%; text-align: left"&gt;Outstanding RSUs (a)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,623,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,900,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z059N4sxVyL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,348,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs04JFRW2k1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,974,978&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zvxNYvig3f4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4C_zJyDr0riXTXa" style="text-align: left"&gt;Convertible promissory notes (b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;891,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zQdxAkjI4TOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Earnout Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1208"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zQ4P6OqK2bi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;70,447,157&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,791,426&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 0.25in; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F0C_zykjScqdVvK1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F11_zmclaahZPjfi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024 there were an additional&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85" title="Stock option vested"&gt;1,373,221&lt;/span&gt;&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F0A_zTdx4tJUoNKl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; text-align: justify; padding-right: 0pt; padding-bottom: 0pt"&gt;&lt;span id="xdx_F10_z19ovviNsVu5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common
    stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001195"
      unitRef="Shares">8623225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">10900128</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember69680781"
      decimals="INF"
      id="Fact001198"
      unitRef="Shares">19348954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember69680796"
      decimals="INF"
      id="Fact001201"
      unitRef="Shares">17974978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact001205"
      unitRef="Shares">891298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_EarnoutSharesMember"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">24500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001210"
      unitRef="Shares">70447157</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">11791426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember69680906"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">1373221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-6"
      id="Fact001217"
      unitRef="USD">14000000</us-gaap:DerivativeLiabilities>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001219">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zOH3qqx6CUEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14. &lt;span id="xdx_82E_zVru2JBQBEJ"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the Company&#x2019;s net losses for 2024 and 2023, as well as the full valuation allowance on its net deferred tax assets as discussed
below, the Company did not record any income tax expense or benefit for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#x2019;s effective
income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zfqHypT5TS0f" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Federal benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible note interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(66.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1242"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1244"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income Tax Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zI1V4O0T35ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Realization of net deferred tax assets is dependent upon future earnings, if any,
the timing and amount of which are uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following items comprise the Company&#x2019;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zDJj32uxJhO7" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,808,826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,755,008&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued expenses and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,110,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;718,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Capitalized research and development expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,944,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,589,105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Research and development credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;234,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;317,455&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,610,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,549,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,551,169&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,426,952&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;59,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;122,798&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(59,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(122,798&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(59,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(122,798&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zlBeaG0lqf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company continually evaluates the likelihood of the realization of deferred tax assets and adjusts the carrying amount of the deferred
tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is more likely than not. The Company
considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative
earnings experience by taxing jurisdiction, expectation of future taxable income or loss, the carryforward periods available to the Company
for tax reporting purposes, and other relevant factors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, based on the Company&#x2019;s history of earnings and its assessment of future earnings, management believes that
it is more likely than not that future taxable income will not be sufficient to realize the deferred tax assets. Therefore, a valuation
allowance has been applied to deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the year ended December 31, 2024, the Company has federal and state net operating loss carryforwards of approximately $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zKvRHdzwguA" title="Federal  net operating loss carryforwards"&gt;25.6&lt;/span&gt; million
and $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zneQ6a3fQVda" title="State net operating loss carryforwards"&gt;27.8&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
net operating loss (&#x201c;NOL&#x201d;) carryforwards in the amount of $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20241231_zUCHXrTKyWh3" title="Federal  net operating loss carryforwards"&gt;25.6&lt;/span&gt; million have an indefinite life. Federal NOL carryforwards
generated after tax year 2017 are subject to an &lt;span id="xdx_90B_ecustom--TaxableIncomeLimitationPercentage_dp_uPure_c20240101__20241231_zRxLMcaLeQXd" title="Taxable income percentage"&gt;80&lt;/span&gt;% limitation on taxable income, do not expire and will carryforward indefinitely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
net operating loss carryforwards in the amount of $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20241231_zJC8GpWitUF5" title="State net operating loss carryforwards"&gt;27.8&lt;/span&gt; million begin expiring in 2040.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
utilization of the Company&#x2019;s net operating losses may be subject to a U.S. federal limitation due to the &#x201c;change in ownership
provisions&#x201d; under Section 382 of the Internal Revenue Code and other similar limitations in various state jurisdictions. Such limitations
may result in a reduction of the amount of net operating loss carryforwards in future years and possibly the expiration of certain net
operating loss carryforwards before their utilization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions
in which it operates. In the normal course of business, the Company is subject to examinations by federal, state and local jurisdictions,
where applicable. There are currently no pending tax examinations. The Company&#x2019;s tax years are still open under statute from 2021
to the present in the United States. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was
generated may still be adjusted upon examination by the Internal Revenue Service and state and local tax authorities to the extent utilized
in a future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As required by the uncertain tax position guidance in ASC No. 740, Income
Tax, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would
more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount
recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement
with the relevant tax authority. The Company applied the uncertain tax position guidance in ASC No. 740 to all tax positions for which
the statute of limitations remained open. Any estimates of tax contingencies contain assumptions and judgments about potential actions
by taxing jurisdictions. Any interest and penalties related to uncertain tax positions would be included as part of the income tax provision.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zf0aPlttrYT4" style="display: none"&gt;SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,426,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,175,241&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Increases recorded to income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,124,217&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,251,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,551,169&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,426,952&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zp0wzhbf7Lr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company
to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of
any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely
than not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater
than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. There were no material uncertain
tax positions as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes interest and penalties related to uncertain tax positions in income tax expense when in a taxable income position.
As of December 31, 2024, the Company had &lt;span id="xdx_901_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_zuOXGDUSWMy1" title="Income tax penalties and interest accrued"&gt;no&lt;/span&gt; accrued interest or penalties related to uncertain tax positions and no amounts have been
recognized in the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001221">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzuUunQjL2f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income tax benefit at the federal statutory income tax rate to the income tax expense at the Company&#x2019;s effective
income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zfqHypT5TS0f" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF INCOME TAX BENEFIT AT THE FEDERAL STATUTORY INCOME TAX RATE&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zFaKKRbw9Jgg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zNiY81lgme86" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_ma123_zUDNJ7EwY67a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Federal benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest_dp_uPure_ma123_zW5cTaPDNid4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible note interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPure_ma123_z5fy4lkgWl6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_ma123_z93Oyuc8PpGh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_ma123_z8l8k4IRndd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(66.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_dp_uPure_ma123_zdjWGnsqB8jb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_iN_dpi_uPure_ms123_zV87CPJluAad" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1242"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_dp_ms123_zZEC2coYO4Ze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1244"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp_uPure_mt123_zpKTAJJeo2Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income Tax Expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001223"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001224"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001227"
      unitRef="Pure">-0.004</TVGN:IncomeTaxReconciliationIncomeTaxExpenseBenefitConvertibleNoteinterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001229"
      unitRef="Pure">0.292</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001230"
      unitRef="Pure">-0.174</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001232"
      unitRef="Pure">0.123</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001233"
      unitRef="Pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001235"
      unitRef="Pure">-0.665</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001236"
      unitRef="Pure">-0.054</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001238"
      unitRef="Pure">0.046</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001241"
      unitRef="Pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001245"
      unitRef="Pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001250">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVwD84JmqhR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following items comprise the Company&#x2019;s net deferred tax assets and liabilities as of December&#160;31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zDJj32uxJhO7" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zGc3SqzUGCkk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zhmEz9hnVLok" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_z6v0y1kTSMR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJ64_zOmUptAXUjeg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,808,826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,755,008&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAccruedExpensesAndOther_iI_maDTAGzJ64_zbnWptSsezM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued expenses and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_maDTAGzJ64_zbPtKvCafCgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzJ64_z4vJKSUIuMtd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,110,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;718,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsFixedAssets_iI_maDTAGzJ64_z9o5LRtyj6Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJ64_zRoN4unq5yVf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_maDTAGzJ64_zzXlwd8COPvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Capitalized research and development expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,944,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,589,105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzJ64_zTLvRLdgkjH8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Research and development credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;234,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;317,455&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJ64_maDTANz2Fd_zCuir0pCfzL2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 20pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,610,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,549,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz2Fd_zxaKCulwpvQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,551,169&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,426,952&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz2Fd_maDTALNz6fV_zBQC16G4WuN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;59,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;122,798&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zwH9JPsFaUL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzmly_zrkAHcCoXP54" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(59,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(122,798&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzmly_msDTALNz6fV_zHWdAIwKT5s5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(59,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(122,798&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz6fV_zsuFt7LrE58b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001255"
      unitRef="USD">6808826</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001256"
      unitRef="USD">3755008</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <TVGN:DeferredTaxAssetsAccruedExpensesAndOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001258"
      unitRef="USD">385801</TVGN:DeferredTaxAssetsAccruedExpensesAndOther>
    <TVGN:DeferredTaxAssetsAccruedExpensesAndOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001259"
      unitRef="USD">42330</TVGN:DeferredTaxAssetsAccruedExpensesAndOther>
    <TVGN:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001261"
      unitRef="USD">61380</TVGN:DeferredTaxAssetsOperatingLeaseLiabilities>
    <TVGN:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001262"
      unitRef="USD">127427</TVGN:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001264"
      unitRef="USD">6110942</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001265"
      unitRef="USD">718425</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <TVGN:DeferredTaxAssetsFixedAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001267"
      unitRef="USD">33834</TVGN:DeferredTaxAssetsFixedAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001270"
      unitRef="USD">30823</us-gaap:DeferredTaxAssetsOther>
    <TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">2944801</TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures>
    <TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001274"
      unitRef="USD">2589105</TVGN:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001276"
      unitRef="USD">234478</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001277"
      unitRef="USD">317455</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">16610885</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001280"
      unitRef="USD">7549750</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001282"
      unitRef="USD">16551169</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001283"
      unitRef="USD">7426952</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">59716</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001286"
      unitRef="USD">122798</us-gaap:DeferredTaxAssetsNet>
    <TVGN:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001291"
      unitRef="USD">59716</TVGN:DeferredTaxLiabilitiesRightOfUseAsset>
    <TVGN:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001292"
      unitRef="USD">122798</TVGN:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">59716</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001295"
      unitRef="USD">122798</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001300"
      unitRef="USD">25600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001302"
      unitRef="USD">27800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001304"
      unitRef="USD">25600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <TVGN:TaxableIncomeLimitationPercentage
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001306"
      unitRef="Pure">0.80</TVGN:TaxableIncomeLimitationPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001308"
      unitRef="USD">27800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001310">&lt;p id="xdx_89A_ecustom--ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock_zWnNsTHpLs3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of changes in the valuation allowance for net deferred tax assets during the year ended December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zf0aPlttrYT4" style="display: none"&gt;SCHEDULE
OF VALUATION ALLOWANCE FOR NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_z9U4XQUAmYQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zSNRXftI7Xx" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_zdHNImCfERul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,426,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,175,241&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--IncreasesRecordedToIncomeTaxProvision_zSpem9g5uypc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Increases recorded to income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,124,217&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,251,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_z3yEnVjWbsEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,551,169&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,426,952&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</TVGN:ScheduleOfValuationAllowanceForNetDeferredTaxAssetsTableTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001312"
      unitRef="USD">7426952</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001313"
      unitRef="USD">4175241</us-gaap:DeferredTaxAssetsValuationAllowance>
    <TVGN:IncreasesRecordedToIncomeTaxProvision
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001315"
      unitRef="USD">9124217</TVGN:IncreasesRecordedToIncomeTaxProvision>
    <TVGN:IncreasesRecordedToIncomeTaxProvision
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001316"
      unitRef="USD">3251711</TVGN:IncreasesRecordedToIncomeTaxProvision>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001318"
      unitRef="USD">16551169</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001319"
      unitRef="USD">7426952</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001321"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001323">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrerlloKSUG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15. &lt;span id="xdx_826_zuwxRamozzMf"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transactions
with Sponsor&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Merger Agreement, the Company incurred $&lt;span id="xdx_905_eus-gaap--SponsorFees_c20240101__20241231_zTy8sC0UubZ8" title="Sponsor advisory service fee"&gt;2,000,000&lt;/span&gt;&#160;in fees to the Sponsor for advisory services (the &#x201c;Sponsor Advisory
Service Fee&#x201d;). In connection with the Merger and thereafter, the Company and Sponsor agreed that $&lt;span id="xdx_906_ecustom--SponsorFeesPayable_iI_c20241231_zkE0us8TZD65" title="Sponsor advisory services fee payable"&gt;250,000&lt;/span&gt;&#160;of the Sponsor Advisory
Service Fee is payable in cash, $&lt;span id="xdx_901_eus-gaap--OtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zbPCTNfYXcbh" title="Sponsor fee payable offset"&gt;250,000&lt;/span&gt;&#160;would be offset against amounts due from the Sponsor, and the remainder of the Sponsor
Advisory Service Fee was paid with the issuance of&#160;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsorAdvisoryServicesFeeMember_zhcrPARWOjwj" title="Number of shares issued for sponsor fees"&gt;150,000&lt;/span&gt;&#160;shares of the Company&#x2019;s common stock at Closing. The Sponsor
Advisory Service Fee payable in cash is presented on the consolidated balance sheets under the line item &#x201c;Due to related party.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Sponsor owes the Company $&lt;span id="xdx_904_eus-gaap--OtherReceivables_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z4vWtjG20yL" title="Due from related party"&gt;158,819&lt;/span&gt;&#160;to cover working capital expenses, which is presented on the consolidated
balance sheets under the line item &#x201c;Due from related party.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 12 for additional information on the Series B issued to the Sponsor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company issued&#160;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--AwardTypeAxis__custom--PerformanceBasedRSUsMember__srt--TitleOfIndividualAxis__custom--WifeOfChiefExecutiveOfficerMember_zTnpqXQArEhh" title="Isssued shares to related party"&gt;40,000&lt;/span&gt;&#160;Performance-Based RSUs to the wife of the Company&#x2019;s chair and chief executive
officer for advisory services provided to the Company, and&#160;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MehtaphoricConsultingIncMember_zrYzQdMpRkNh" title="Shares issued to related party"&gt;20,000&lt;/span&gt;&#160;Performance-Based RSUs to Mehtaphoric Consulting Inc, a company
controlled by the daughter of the Company&#x2019;s chief financial officer, for information technology services provided to the Company.
In connection with the Closing, the performance condition was achieved and therefore compensation cost of $&lt;span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPCompensationExpense_c20240101__20241231_zOUwKIHuqzk" title="Compensation cost recognized"&gt;800,396&lt;/span&gt;&#160;has been recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loan
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 8 for additional information on the Loan Agreement with the Patel Family, which provides for an unsecured line of credit facility for term loans of
up to an initial amount of $&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_zLKScQ5vkAk3" title="Line of credit maximum borrowing capacity"&gt;36,000,000&lt;/span&gt;
in the aggregate. As of December 31, 2024, the facility has remaining available capacity of $&lt;span id="xdx_904_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThePatelFamilyLLPMember__us-gaap--LongtermDebtTypeAxis__us-gaap--UnsecuredDebtMember_z9y8tO1wTFIj" title="Line of credit remaining borrowing capacity"&gt;30,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 12 for additional information on the Series A, Series A-1, and Series C Preferred Stock, which were purchased by the Patel Family.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;TEVOGEN BIO HOLDINGS INC.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Consulting
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2024, the Company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services to the Company in
support of the Company&#x2019;s manufacturing development, including but not limited to identifying and developing real estate, establishing
quality management processes, attracting and hiring an executive to lead operations, providing medical advice, and addressing government
affairs and regulatory matters. In exchange for his consultation services, Dr. Patel was granted &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zfQ0S0ve5fg7" title="Granted, shares"&gt;6,000,000&lt;/span&gt; RSUs, of which &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember_zh6uXjAWemfi" title="Vested shares"&gt;2,000,000&lt;/span&gt; immediately
vested, and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQvaOG3s7d5h" title="Vested shares"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManmohanPatelMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0Juwz4Y4g4" title="Vested shares"&gt;2,000,000&lt;/span&gt;&lt;/span&gt; RSUs vested in both January  2025 and February  2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SponsorFees
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001325"
      unitRef="USD">2000000</us-gaap:SponsorFees>
    <TVGN:SponsorFeesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001327"
      unitRef="USD">250000</TVGN:SponsorFeesPayable>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact001329"
      unitRef="USD">250000</us-gaap:OtherLiabilities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_SponsorAdvisoryServicesFeeMember"
      decimals="INF"
      id="Fact001331"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31_custom_SponsorMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">158819</us-gaap:OtherReceivables>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_PerformanceBasedRSUsMember_custom_WifeOfChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">40000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-01-31_custom_MehtaphoricConsultingIncMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001339"
      unitRef="USD">800396</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">36000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ThePatelFamilyLLPMember_us-gaap_UnsecuredDebtMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">30000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember"
      decimals="INF"
      id="Fact001345"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember"
      decimals="INF"
      id="Fact001347"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-01-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_DrManmohanPatelMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001351"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001353">&lt;p id="xdx_805_eus-gaap--SegmentReportingDisclosureTextBlock_zjViOtEdXFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
16. &lt;span id="xdx_824_zz8eWF3pcbLk"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in one operating segment, and therefore one reportable segment, and is focused on the global discovery, development
and commercialization of proprietary therapeutics. The Company&#x2019;s business activities are managed on a consolidated basis through
the development and potential commercialization of pharmaceutical products, which are aimed at the global market in the event that products
are successful in receiving regulatory approvals. Our determination that we operate as a single operating segment is consistent with
the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating
resources, setting incentive compensation targets, and planning and forecasting for future periods. Our chief operating decision maker
is the Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies for our single operating segment are the same as those described in the summary of significant accounting policies.
Our single operating segment incurs expenses from the development of TVGN 489, which is developed by our research and development department,
designed to target various disease indications. The Company has not yet generated revenue in its operating history.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the segment, the chief operating decision maker uses net loss, which is reported on the consolidated statements of operations as consolidated
net income (loss), to allocate resources (including employees, property, and financial resources), predominantly during the annual budget
and forecasting process. The chief operating decision maker also uses consolidated net loss, along with non-financial inputs and qualitative
information, to evaluate our performance, establish compensation, monitor budget versus actual results, and decide the level of investment
in our various research activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001355">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zcq2drwDeQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
17. &lt;span id="xdx_823_zySUOK5HYSp2"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated subsequent events and transactions for potential recognition or disclosure from the balance sheet date through
April 2, 2025, the issuance date of these the consolidated financial statements, and has not identified any additional items requiring
disclosure except as noted below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company executed an agreement with KRHP to receive a grant for $&lt;span id="xdx_901_eus-gaap--OtherReceivablesNetCurrent_iI_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHPLLCMember_zTmBGFqf4706" title="Grant"&gt;2,000,000&lt;/span&gt;.
KRHP is affiliated with the Patel Family. The grant is specified for use toward the Company&#x2019;s ongoing operational expenses,
may not be used for repayment of existing debt obligations, and does not include any requirement to repay the investor or to issue
equity in response. Cash payment was received by the Company in January 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February  2025, the Company executed a draw on the Loan Agreement for an additional $&lt;span id="xdx_902_eus-gaap--LineOfCredit_iI_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzvyNsOHXNv8" title="Line of credit Facility additional"&gt;1,000,000&lt;/span&gt; to be utilized for operational
expenses. An additional draw of $&lt;span id="xdx_908_eus-gaap--LineOfCredit_iI_c20250331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9Pe2aZwH1z9" title="Line of credit Facility additional"&gt;1,000,000&lt;/span&gt; was completed in March  2025. As of the date of filing, the facility has a remaining
capacity of $&lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20250402__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z33Qh5rDOJ1l" title="Line of credit Facility remaining capacity"&gt;26,000,000&lt;/span&gt; and remains effective for the next 26 months.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-01-31_us-gaap_SubsequentEventMember_custom_KRHPLLCMember"
      decimals="0"
      id="Fact001357"
      unitRef="USD">2000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-02-28_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001359"
      unitRef="USD">1000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-03-31_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">1000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="AsOf2025-04-02_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001363"
      unitRef="USD">26000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001086"
          xlink:label="Fact001086"
          xlink:type="locator"/>
        <link:footnote id="Footnote001091" xlink:label="Footnote001091" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    of December 31, 2024, there were RSUs that had vested but had not been legally settled into common stock. See Note 11 for additional
    information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001086"
          xlink:to="Footnote001091"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001088"
          xlink:label="Fact001088"
          xlink:type="locator"/>
        <link:footnote id="Footnote001092" xlink:label="Footnote001092" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Dr.
    Saadi will automatically forfeit all unvested Restricted Stock granted pursuant to the Special RSU Award in the event he departs
    the Company. See Note 11 for additional information on the Special RSU Award.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001088"
          xlink:to="Footnote001092"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001195"
          xlink:label="Fact001195"
          xlink:type="locator"/>
        <link:footnote id="Footnote001212" xlink:label="Footnote001212" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    of December 31, 2024 there were an additional&#160;<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVEktRElMVVRJVkUgTkVUIExPU1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9VjNaGsMz85"
  title="Stock option vested">1,373,221</xhtml:span>&#160;RSUs that had vested but had not been legally settled into common
    stock and therefore were included in the basic net income per share. See Note 11 for additional information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001195"
          xlink:to="Footnote001212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001196"
          xlink:label="Fact001196"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001196"
          xlink:to="Footnote001212"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1204"
          xlink:label="xdx2ixbrl1204"
          xlink:type="locator"/>
        <link:footnote id="Footnote001215" xlink:label="Footnote001215" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    numbers of shares were determined based on the conversion upon maturity provisions in the convertible promissory note agreements,
    dividing the conversion amount (principal plus accrued interest) by three times the estimated fair value of the Company&#x2019;s common
    stock derived from the Company&#x2019;s most recently completed convertible promissory notes valuation as of the balance sheet date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1204"
          xlink:to="Footnote001215"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001205"
          xlink:label="Fact001205"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001205"
          xlink:to="Footnote001215"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
